{"PMC7397243": [["IntroductionWith the beginning of the COVID-19 pandemic, fundamental changes have taken place in medical care in Germany and globally.", [["the COVID", "TREATMENT", 34, 43]]], ["The preventive, containment, and medical requirements are fundamentally the same, but are being implemented to varying degrees due to different resources of individual countries.", [["containment", "OBSERVATION_MODIFIER", 16, 27]]], ["Since the outbreak of the pandemic in November 2019 in China, the understanding of preventive measures has been steadily growing.", [["preventive measures", "TREATMENT", 83, 102]]], ["The German healthcare system has had time to draw conclusions from the findings in China, but also elsewhere in Europe, especially Italy and Spain.IntroductionThere were two central factors in the German hospital landscape that led to the restrictions described below: First, the call by the German Federal Ministry of Health to substantially increase the number of intensive care beds which would allow invasive ventilation of patients by temporarily postponing elective procedures; and second, the shortage of personal protective equipment (PPE), which is mainly produced in China, that accompanied the beginning of the pandemic.IntroductionWhile the problem of PPE procurement was centrally organized by the federal and state governments, each hospital had to secure intensive care resources by reassigning or recruiting personnel to adequately staff isolation areas and ICUs.", [["patients", "ORGANISM", 428, 436], ["patients", "SPECIES", 428, 436], ["intensive care beds", "TREATMENT", 366, 385], ["invasive ventilation", "TREATMENT", 404, 424], ["elective procedures", "TREATMENT", 463, 482], ["personal protective equipment", "TREATMENT", 512, 541], ["PPE procurement", "TREATMENT", 664, 679], ["central", "OBSERVATION_MODIFIER", 174, 181]]], ["Part of the new intensive care personnel to be recruited came from the surgical staff, which consequently immediately reduced daily operating-theater capacity.", [["new", "OBSERVATION_MODIFIER", 12, 15]]], ["In addition, inpatient capacities had to be reallocated to create COVID-19 isolation and pre-isolation areas to protect the wards.IntroductionFor the surgical department, this meant the immediate suspension of elective surgical procedures.", [["COVID-19 isolation", "TREATMENT", 66, 84], ["pre-isolation areas", "TREATMENT", 89, 108], ["elective surgical procedures", "TREATMENT", 210, 238]]], ["In the recommendations of 24 April 2020, the DGAV (German Society of General and Visceral Surgery) compiled a list of diseases that could be considered as indications for urgent surgery [1].", [["General and Visceral Surgery", "TREATMENT", 69, 97], ["diseases", "PROBLEM", 118, 126], ["urgent surgery", "TREATMENT", 171, 185], ["Visceral", "ANATOMY", 81, 89]]], ["The Federal Ministry of Health has not yet issued a uniform, binding and nationwide guideline for the surgical departments.IntroductionSince then, the following needs have arisen for the surgical clinics:IntroductionDefinition of the range of surgical procedures to be continuedCreation and management of patient waiting listsSurgical patient care with reduced intensive care and inpatient bed capacityEstablishment of care structures for COVID-19 patients (including suspected cases) in the operating theaterMaintaining training and education in the pandemic situationIntroductionThe definition of the range of interventions to be continued has recently been amended.", [["patient", "ORGANISM", 305, 312], ["patient", "ORGANISM", 335, 342], ["patients", "ORGANISM", 448, 456], ["patient", "SPECIES", 305, 312], ["patient", "SPECIES", 335, 342], ["patients", "SPECIES", 448, 456], ["surgical procedures", "TREATMENT", 243, 262], ["reduced intensive care", "TREATMENT", 353, 375], ["interventions", "TREATMENT", 612, 625]]], ["The Federal Minister of Health, with his publication of the fact paper on the New Daily Routine for Hospitals of 27 April 2020 [2], cleared the way for the resumption elective surgery (see no. 1, above).", [["the resumption elective surgery", "TREATMENT", 152, 183]]], ["The administration of patient lists generated to date will thus be highly influenced by the regional implementation of this regulation by the states, as well as by the expected renewed increase in the number of newly infected and sick patients after the relaxation of protective measures (see no. 2, above).IntroductionA bottleneck in the near future will be the intensive care capacity for elective surgery patients.", [["patient", "ORGANISM", 22, 29], ["patients", "ORGANISM", 235, 243], ["patients", "ORGANISM", 408, 416], ["patient", "SPECIES", 22, 29], ["patients", "SPECIES", 235, 243], ["patients", "SPECIES", 408, 416], ["the relaxation of protective measures", "TREATMENT", 250, 287], ["elective surgery", "TREATMENT", 391, 407], ["increase", "OBSERVATION_MODIFIER", 185, 193], ["newly", "OBSERVATION_MODIFIER", 211, 216], ["infected", "OBSERVATION", 217, 225]]], ["The newly created intensive care capacities will be generated in particular by the nursing staff reassigned from peripheral care areas, which will be able to help out in the intensive care area if necessary after intensive training in recent weeks.", [["peripheral care areas", "TREATMENT", 113, 134], ["intensive training", "TREATMENT", 213, 231]]], ["This does not increase planning security for patients who require intensive medical monitoring and care in the early post-operative phase (see no. 3, above).IntroductionIf the establishment of a care structure for COVID-19 patients (Pa-COV19) is successful, it would facilitate the rapid return to a well-organized operative care.", [["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 223, 231], ["intensive medical monitoring", "TEST", 66, 94], ["COVID", "TEST", 214, 219], ["a well-organized operative care", "TREATMENT", 298, 329], ["operative", "OBSERVATION", 315, 324]]], ["Comparable to the establishment of isolation and pre-isolation areas in the ward block, this requires parallel structures in the operating theater in order to safely care for Pa-COV19 and guarantee human and material resources for the duration of the pandemic.Room requirements in the operating areaThe spatial and building technology situation is usually set.", [["human", "ORGANISM", 198, 203], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 198, 203], ["isolation", "TREATMENT", 35, 44], ["pre-isolation areas", "TREATMENT", 49, 68], ["the ward block", "PROBLEM", 72, 86], ["Pa-COV19 and guarantee human and material resources", "TREATMENT", 175, 226], ["the pandemic", "PROBLEM", 247, 259], ["isolation", "OBSERVATION", 35, 44], ["ward block", "OBSERVATION", 76, 86], ["spatial", "OBSERVATION_MODIFIER", 303, 310]]], ["Because very few clinics have spatially separate surgical units for Pa-COV19 and non-Pa-COV19, the analysis below begins with the inward transfer into the operating theatre and ends with the outward transfer.Room requirements in the operating areaThe hygiene requirements of the pandemic regulation in Germany mean that central areas of the OR tract, such as induction areas and recovery rooms, must not be used simultaneously by Pa-COV19 and non-Pa-COV19.", [["pandemic", "DISEASE", 279, 287], ["tract", "ORGANISM_SUBDIVISION", 344, 349], ["Pa-COV19", "GENE_OR_GENE_PRODUCT", 430, 438], ["Pa-COV19", "DNA", 68, 76], ["non-Pa-COV19", "DNA", 81, 93], ["Pa-COV19", "PROTEIN", 430, 438], ["non-Pa-COV19", "PROTEIN", 443, 455], ["Pa-COV19", "TREATMENT", 68, 76], ["the analysis", "TEST", 95, 107], ["the pandemic regulation", "TREATMENT", 275, 298], ["central", "OBSERVATION_MODIFIER", 320, 327], ["areas", "OBSERVATION_MODIFIER", 328, 333], ["tract", "OBSERVATION", 344, 349]]], ["As a result, in addition to its primary function, the operating theatre should also be used for the induction of surgery and for the phase of early post-operative monitoring.", [["surgery", "TREATMENT", 113, 120], ["early post-operative monitoring", "TEST", 142, 173]]], ["The path of Pa-COV19 in the OR tract is thus reduced to the operating room with direct insertion.", [["OR tract", "ANATOMY", 28, 36], ["Pa-COV19", "CHEMICAL", 12, 20], ["Pa-COV19", "GENE_OR_GENE_PRODUCT", 12, 20], ["tract", "ORGANISM_SUBDIVISION", 31, 36], ["Pa-COV19", "DNA", 12, 20], ["direct insertion", "TREATMENT", 80, 96], ["reduced", "OBSERVATION_MODIFIER", 45, 52]]], ["Anaesthesia preparation, induction and discharge are performed in the closed OR.", [["Anaesthesia preparation", "TREATMENT", 0, 23]]], ["The operating room functions as a recovery room for the patient.", [["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63]]], ["Postoperatively, the Pa-COV19 is transferred to the isolation area of the intensive care unit or directly to the pre-ISO ward in suspected cases or to the isolation ward if SARS-CoV-2 is detected.Surgical hygiene and ventilationSARS-CoV-2 is transmitted by droplet infection.", [["SARS", "DISEASE", 173, 177], ["infection", "DISEASE", 265, 274], ["ventilationSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 217, 238], ["Pa-COV19", "DNA", 21, 29], ["SARS", "PROBLEM", 173, 177], ["Surgical hygiene", "TREATMENT", 196, 212], ["ventilationSARS", "TEST", 217, 232], ["droplet infection", "PROBLEM", 257, 274], ["droplet infection", "OBSERVATION", 257, 274]]], ["Aerosols from infected carriers pose a particular risk.", [["Aerosols", "CHEMICAL", 0, 8], ["Aerosols", "TREATMENT", 0, 8], ["infected", "OBSERVATION", 14, 22]]], ["However, aerogenic spread also takes place.", [["aerogenic spread", "PROBLEM", 9, 25], ["aerogenic", "OBSERVATION_MODIFIER", 9, 18], ["spread", "OBSERVATION", 19, 25]]], ["The problem is that testing by deep throat swabbing during the incubation period (2\u201314 days) [3] may be negative, although the carrier is already infectious.", [["throat", "ANATOMY", 36, 42], ["throat", "ORGANISM_SUBDIVISION", 36, 42], ["deep throat swabbing", "PROBLEM", 31, 51], ["infectious", "PROBLEM", 146, 156], ["negative", "OBSERVATION", 104, 112], ["infectious", "OBSERVATION", 146, 156]]], ["As a result of replication in the throat area, the virus thus also reaches the upper and lower gastrointestinal tract, which means that fluids from these areas can also be considered infectious during surgery.", [["throat area", "ANATOMY", 34, 45], ["upper", "ANATOMY", 79, 84], ["lower gastrointestinal tract", "ANATOMY", 89, 117], ["throat area", "MULTI-TISSUE_STRUCTURE", 34, 45], ["upper", "ORGANISM_SUBDIVISION", 79, 84], ["lower gastrointestinal", "ORGANISM_SUBDIVISION", 89, 111], ["tract", "ORGANISM_SUBDIVISION", 112, 117], ["replication in the throat area", "PROBLEM", 15, 45], ["the virus", "PROBLEM", 47, 56], ["surgery", "TREATMENT", 201, 208], ["replication", "OBSERVATION", 15, 26], ["throat", "ANATOMY", 34, 40], ["virus", "OBSERVATION", 51, 56], ["upper", "ANATOMY_MODIFIER", 79, 84], ["lower", "ANATOMY_MODIFIER", 89, 94], ["gastrointestinal tract", "ANATOMY", 95, 117], ["fluids", "OBSERVATION", 136, 142], ["can also be considered", "UNCERTAINTY", 160, 182], ["infectious", "OBSERVATION_MODIFIER", 183, 193]]], ["Suspected cases of COVID-19 and confirmed positive patients must be treated equally in the operating theatre.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["COVID", "TEST", 19, 24]]], ["The hazard for the staff in the OR is defined by contact with patient-related aerosols.Surgical hygiene and ventilationIn accordance with the regulations of DIN 1946-4:2018-09 (Room Air Technology \u2013 Part 4 [4], Tab.", [["DIN 1946-4:2018-09", "CHEMICAL", 157, 175], ["DIN 1946-4:2018-09", "CHEMICAL", 157, 175], ["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["Surgical hygiene", "TREATMENT", 87, 103], ["ventilation", "TREATMENT", 108, 119], ["ventilation", "OBSERVATION", 108, 119]]], ["1 Item 5.1: Infectious patients), the following ventilation requirements exist for the space in the intensive care unit: staff and third parties must be protected from infectious patients (e.g., patients with multi-resistant tuberculosis).", [["tuberculosis", "DISEASE", 225, 237], ["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 179, 187], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 179, 187], ["patients", "SPECIES", 195, 203], ["the following ventilation requirements", "TREATMENT", 34, 72], ["multi-resistant tuberculosis", "PROBLEM", 209, 237], ["tuberculosis", "OBSERVATION", 225, 237]]], ["Here, the technical requirements for room air requirements apply: patient rooms with supply and exhaust air and negative air balance to the airlock; airlock with negative air balance to adjacent corridors.", [["airlock", "ANATOMY", 140, 147], ["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["room air requirements", "TREATMENT", 37, 58], ["air balance", "OBSERVATION", 121, 132], ["air balance", "OBSERVATION", 171, 182]]], ["As a result, these ventilation requirements must be implemented in the pre-, peri-, intra- and post-operative treatment process for infectious patients in whom aerosol formation is to be expected during treatment.Surgical hygiene and ventilationIdeally, the room air-conditioning system (RATS) in the operating theater can be switched to negative pressure.", [["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["these ventilation requirements", "TREATMENT", 13, 43], ["intra- and post-operative treatment process", "TREATMENT", 84, 127], ["Surgical hygiene", "TREATMENT", 213, 229], ["ventilationIdeally", "TREATMENT", 234, 252], ["pressure", "OBSERVATION_MODIFIER", 347, 355]]], ["This ensures that no viruses from the OR are able to escape into neighboring rooms.", [["viruses", "PROBLEM", 21, 28], ["no", "UNCERTAINTY", 18, 20], ["viruses", "OBSERVATION", 21, 28]]], ["Since opened doors immediately interrupt the negative pressure, air is exchanged with the environment during door opening.", [["pressure", "OBSERVATION_MODIFIER", 54, 62], ["air", "OBSERVATION", 64, 67]]], ["Therefore, the doors must be kept closed during surgery.", [["surgery", "TREATMENT", 48, 55]]], ["When switching to negative pressure, it is recommended that the surgical field be flushed antiseptically before the surgical suture is applied, in order to kill pathogens originating from the room air and entering the surgical field, due to potential turbulence.", [["the surgical field", "TREATMENT", 60, 78], ["the surgical suture", "TREATMENT", 112, 131], ["pathogens", "PROBLEM", 161, 170], ["potential turbulence", "PROBLEM", 241, 261], ["surgical suture", "OBSERVATION", 116, 131], ["air", "OBSERVATION", 197, 200], ["surgical", "ANATOMY", 218, 226], ["turbulence", "OBSERVATION", 251, 261]]], ["With antiseptic irrigation, a reduction of postoperative wound infections can be achieved even without this additional risk factor [5].Surgical hygiene and ventilationIn ORs that do not allow negative pressure maintenance, the overflow technique contaminates neighbouring rooms.", [["wound", "ANATOMY", 57, 62], ["postoperative wound infections", "DISEASE", 43, 73], ["wound", "PATHOLOGICAL_FORMATION", 57, 62], ["antiseptic irrigation", "TREATMENT", 5, 26], ["postoperative wound infections", "PROBLEM", 43, 73], ["Surgical hygiene", "TREATMENT", 135, 151], ["ventilationIn ORs", "TREATMENT", 156, 173], ["negative pressure maintenance", "TREATMENT", 192, 221], ["antiseptic irrigation", "OBSERVATION", 5, 26], ["reduction", "OBSERVATION_MODIFIER", 30, 39], ["postoperative", "OBSERVATION_MODIFIER", 43, 56], ["wound", "OBSERVATION_MODIFIER", 57, 62], ["infections", "OBSERVATION", 63, 73]]], ["Although contamination is lower due to the considerably higher ventilation flow in class 1a (LAF, laminar air flow) operating theaters than in air from mixed-ventilation operating theaters (class 1b).", [["contamination", "PROBLEM", 9, 22], ["laminar air flow)", "TREATMENT", 98, 115], ["contamination", "OBSERVATION", 9, 22], ["higher", "OBSERVATION_MODIFIER", 56, 62], ["ventilation flow", "OBSERVATION", 63, 79], ["laminar", "OBSERVATION_MODIFIER", 98, 105], ["air flow", "OBSERVATION", 106, 114]]], ["However, since SARS-CoV-2 can survive in room air as an aerosol for 16 hours [6], there is a risk of infection during this period.", [["infection", "DISEASE", 101, 110], ["SARS-CoV-2", "ORGANISM", 15, 25], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "PROBLEM", 15, 19], ["an aerosol", "TREATMENT", 53, 63], ["infection", "PROBLEM", 101, 110], ["infection", "OBSERVATION", 101, 110]]], ["Operating theaters with LAF have a considerably larger ventilation volume flow than operating theaters with mixed ventilation (1b), which means that the aerosol dilution in the operating theatre with LAF is considerably faster.", [["LAF", "PROTEIN", 200, 203], ["LAF", "PROBLEM", 24, 27], ["mixed ventilation", "TREATMENT", 108, 125], ["the aerosol dilution", "TREATMENT", 149, 169], ["considerably", "OBSERVATION_MODIFIER", 35, 47], ["larger", "OBSERVATION_MODIFIER", 48, 54], ["ventilation volume flow", "OBSERVATION", 55, 78], ["mixed ventilation", "OBSERVATION", 108, 125], ["aerosol dilution", "OBSERVATION", 153, 169], ["considerably", "OBSERVATION_MODIFIER", 207, 219], ["faster", "OBSERVATION_MODIFIER", 220, 226]]], ["In operating theatres with LAF, the directional rather than merely mixing ventilation in the OR area also ensures additional protection for the surgical team and the patient.", [["patient", "ORGANISM", 166, 173], ["patient", "SPECIES", 166, 173], ["LAF", "TREATMENT", 27, 30], ["merely mixing ventilation", "TREATMENT", 60, 85], ["mixing ventilation", "OBSERVATION", 67, 85]]], ["Due to the characteristics described above, operating theaters of room class Ib are associated with a higher risk of contamination for the OR team.", [["Ib", "GENE_OR_GENE_PRODUCT", 77, 79], ["contamination", "OBSERVATION", 117, 130]]], ["It is questionable whether the FFP3 mask guarantees such a tight seal that the team is not endangered.", [["the FFP3 mask", "TREATMENT", 27, 40], ["questionable whether", "UNCERTAINTY", 6, 26]]], ["In this case, secure protection of the surgical team can be achieved with overpressure body-exhaust suits [7].", [["body", "ANATOMY", 87, 91], ["body", "ORGANISM_SUBDIVISION", 87, 91], ["the surgical team", "TREATMENT", 35, 52]]], ["With LAF, the surgical team is protected; however, due to the approximately 80-fold air change/h, adjacent rooms are contaminated with overflow technology.", [["overflow technology", "TREATMENT", 135, 154], ["LAF", "OBSERVATION_MODIFIER", 5, 8], ["surgical", "OBSERVATION", 14, 22], ["air", "OBSERVATION", 84, 87], ["contaminated", "OBSERVATION", 117, 129]]], ["If, however, the air should flow directly out of the operating room, the operating theater can be used.", [["air", "OBSERVATION", 17, 20]]], ["The PPE described would be sufficient.Surgical hygiene and ventilationWe have created a simple control protocol for ventilation evaluation and validated it in the flue gas video test.", [["The PPE", "TREATMENT", 0, 7], ["Surgical hygiene", "TREATMENT", 38, 54], ["ventilationWe", "TREATMENT", 59, 72], ["a simple control protocol", "TREATMENT", 86, 111], ["ventilation evaluation", "TEST", 116, 138], ["the flue gas video test", "TEST", 159, 182]]], ["Compared to the OR standard ventilation, the RATS protocol for the OR is adapted as follows:Surgical hygiene and ventilationSupply air is reduced from 360 Pa 200 Pa.Exhaust air is increased from 180 Pa 300 Pa.A negative flow of 100 Pa results when the Laminar Flow Ceiling remains active.Surgical hygiene and ventilationOperating theaters or ORs of room class II with RATS without sterile filters are not appropriate, for the same reason as operating theaters with turbulent mixed flow.Surgical hygiene and ventilationOperating theaters without an HVAC are also out of the question, since there is no dilution of aerosols released and the highest aerosol concentration occurs after opening the door at the end of the operating theater.PPE in the OR procedures ::: Protective materials and personnelDue to the transmission of SARS-CoV-2 by aerosols from the respiratory tract, respiratory and other surgery-related aerosols must be avoided or protective measures taken to prevent their transmission to staff and patients.", [["respiratory tract", "ANATOMY", 857, 874], ["SARS", "DISEASE", 825, 829], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 825, 835], ["respiratory tract", "ORGANISM_SUBDIVISION", 857, 874], ["patients", "ORGANISM", 1011, 1019], ["patients", "SPECIES", 1011, 1019], ["SARS-CoV", "SPECIES", 825, 833], ["standard ventilation", "TREATMENT", 19, 39], ["the RATS protocol", "TREATMENT", 41, 58], ["Surgical hygiene", "TREATMENT", 92, 108], ["ventilationSupply air", "TREATMENT", 113, 134], ["Exhaust air", "PROBLEM", 165, 176], ["Surgical hygiene", "TREATMENT", 288, 304], ["ventilation", "TREATMENT", 309, 320], ["sterile filters", "TREATMENT", 381, 396], ["turbulent mixed flow", "PROBLEM", 465, 485], ["Surgical hygiene", "TREATMENT", 486, 502], ["ventilation", "TREATMENT", 507, 518], ["dilution of aerosols", "PROBLEM", 601, 621], ["SARS", "PROBLEM", 825, 829], ["CoV", "TEST", 830, 833], ["other surgery", "TREATMENT", 892, 905], ["aerosols", "TREATMENT", 914, 922], ["protective measures", "TREATMENT", 942, 961], ["air", "OBSERVATION", 173, 176], ["increased", "OBSERVATION_MODIFIER", 180, 189], ["negative", "OBSERVATION", 211, 219], ["Laminar Flow", "OBSERVATION", 252, 264], ["active", "OBSERVATION", 281, 287], ["turbulent", "OBSERVATION_MODIFIER", 465, 474], ["mixed flow", "OBSERVATION", 475, 485], ["no", "UNCERTAINTY", 598, 600], ["highest", "OBSERVATION_MODIFIER", 639, 646], ["aerosol concentration", "OBSERVATION", 647, 668], ["respiratory tract", "ANATOMY", 857, 874]]], ["According to the recommendations of the RKI [8], at least one FFP2 mask should be worn in direct patient contact in the case of justified suspicion and confirmed infection with COVID-19.", [["infection", "DISEASE", 162, 171], ["COVID-19", "CHEMICAL", 177, 185], ["COVID-19", "CHEMICAL", 177, 185], ["patient", "ORGANISM", 97, 104], ["patient", "SPECIES", 97, 104], ["one FFP2 mask", "TREATMENT", 58, 71], ["infection", "PROBLEM", 162, 171], ["COVID", "TEST", 177, 182], ["infection", "OBSERVATION", 162, 171]]], ["Depending on material availability, this means one FFP3 mask for daily routine in the anesthesia/high risk/intubation department, and for all others in the operating theater at least one FFP2 mask.", [["one FFP3 mask", "TREATMENT", 47, 60], ["the anesthesia", "TREATMENT", 82, 96], ["FFP2 mask", "TREATMENT", 187, 196]]], ["The recommendations of the DGAV from 24 April 2020 [1] suggest a mouth and nose protective mask for the rest of the OR team and an FFP2 mask for the anesthesia team, which in the authors\u2019 view does not correspond to the strict interpretation of the current RKI recommendations.PPE in the OR procedures ::: Protective materials and personnelUncertainty exists with regard to the surgically produced aerosols from mono- and bipolar cutting of tissue [11] as well as the aerosol generation during minimally invasive surgery, which are generated in the course of insufflation.", [["mouth", "ANATOMY", 65, 70], ["nose", "ANATOMY", 75, 79], ["tissue", "ANATOMY", 441, 447], ["bipolar", "DISEASE", 422, 429], ["mouth", "ORGANISM_SUBDIVISION", 65, 70], ["nose", "ORGANISM_SUBDIVISION", 75, 79], ["tissue", "TISSUE", 441, 447], ["the DGAV", "TREATMENT", 23, 31], ["a mouth and nose protective mask", "TREATMENT", 63, 95], ["an FFP2 mask", "TREATMENT", 128, 140], ["the surgically produced aerosols", "PROBLEM", 374, 406], ["mono- and bipolar cutting of tissue", "TREATMENT", 412, 447], ["the aerosol generation", "TREATMENT", 464, 486], ["minimally invasive surgery", "TREATMENT", 494, 520], ["insufflation", "TREATMENT", 559, 571], ["aerosols", "OBSERVATION", 398, 406], ["invasive", "OBSERVATION_MODIFIER", 504, 512], ["surgery", "OBSERVATION", 513, 520]]], ["No information is currently available on the infectivity of aerosol from pleural and/or peritoneal fluid.", [["pleural", "ANATOMY", 73, 80], ["peritoneal fluid", "ANATOMY", 88, 104], ["pleural", "MULTI-TISSUE_STRUCTURE", 73, 80], ["peritoneal fluid", "MULTI-TISSUE_STRUCTURE", 88, 104], ["aerosol", "TREATMENT", 60, 67], ["pleural and/or peritoneal fluid", "PROBLEM", 73, 104], ["pleural", "ANATOMY", 73, 80], ["peritoneal", "ANATOMY", 88, 98], ["fluid", "OBSERVATION", 99, 104]]], ["However, it is certain that viruses are detectable in the lungs and upper and lower gastrointestinal tract [12].", [["lungs", "ANATOMY", 58, 63], ["upper", "ANATOMY", 68, 73], ["lower gastrointestinal tract", "ANATOMY", 78, 106], ["lungs", "ORGAN", 58, 63], ["upper", "ORGANISM_SUBDIVISION", 68, 73], ["lower gastrointestinal", "ORGANISM_SUBDIVISION", 78, 100], ["tract", "ORGANISM_SUBDIVISION", 101, 106], ["viruses", "PROBLEM", 28, 35], ["viruses", "OBSERVATION", 28, 35], ["lungs", "ANATOMY", 58, 63], ["upper", "ANATOMY_MODIFIER", 68, 73], ["lower", "ANATOMY_MODIFIER", 78, 83], ["gastrointestinal tract", "ANATOMY", 84, 106]]], ["Fecal or oral transmission is therefore not excluded, but has not yet been proven [13].", [["Fecal", "ANATOMY", 0, 5], ["oral", "ANATOMY", 9, 13], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["oral", "ORGANISM_SUBDIVISION", 9, 13], ["Fecal or oral transmission", "PROBLEM", 0, 26], ["not excluded", "UNCERTAINTY", 40, 52]]], ["For laparoscopy and pleural minimally invasive procedures, there is at least a theoretical risk of infectious aerosols in dissecting and resecting procedures on the lungs as well as the gastrointestinal tract.", [["pleural", "ANATOMY", 20, 27], ["lungs", "ANATOMY", 165, 170], ["gastrointestinal tract", "ANATOMY", 186, 208], ["lungs", "ORGAN", 165, 170], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 186, 208], ["laparoscopy", "TEST", 4, 15], ["pleural minimally invasive procedures", "TREATMENT", 20, 57], ["infectious aerosols", "PROBLEM", 99, 118], ["dissecting and resecting procedures", "TREATMENT", 122, 157], ["laparoscopy", "OBSERVATION", 4, 15], ["pleural", "ANATOMY", 20, 27], ["minimally", "OBSERVATION_MODIFIER", 28, 37], ["invasive", "OBSERVATION", 38, 46], ["infectious", "OBSERVATION_MODIFIER", 99, 109], ["aerosols", "OBSERVATION", 110, 118], ["resecting", "OBSERVATION_MODIFIER", 137, 146], ["lungs", "ANATOMY", 165, 170], ["gastrointestinal tract", "ANATOMY", 186, 208]]], ["In addition, SARS-CoV2 is detectable in the blood at a frequency of 15%, which must be taken into account when bloody aerosols are formed (e.g., in vascular corrosion or orthopedic/accident surgery).", [["blood", "ANATOMY", 44, 49], ["vascular", "ANATOMY", 148, 156], ["SARS", "DISEASE", 13, 17], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 13, 22], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["vascular", "MULTI-TISSUE_STRUCTURE", 148, 156], ["CoV2", "DNA", 18, 22], ["SARS-CoV2", "TEST", 13, 22], ["bloody aerosols", "PROBLEM", 111, 126], ["orthopedic/accident surgery", "TREATMENT", 170, 197], ["SARS", "OBSERVATION", 13, 17], ["vascular", "ANATOMY", 148, 156]]], ["As the role of the vapors from electric cautery has not yet been clarified, this should either be avoided or an additional smoke extraction system should be used.PPE in the OR procedures ::: Protective materials and personnelThe choice of surgical procedure should continue to be based on the principle of \u201cprimum nihil nocere\u201d.", [["electric cautery", "TREATMENT", 31, 47], ["an additional smoke extraction system", "TREATMENT", 109, 146], ["surgical procedure", "TREATMENT", 239, 257]]], ["Thus, the best possible procedure currently clinically established for the treatment of a disease with the least invasiveness for the patient should be chosen.Personnel ::: Protective materials and personnelThe personnel in the OR is to be reduced to the necessary minimum, optimally to:Personnel ::: Protective materials and personnelsurgeon + 1 assistantanaesthesiologist + 1 anaesthesia nurse; the work of the circulating nurse in the OR is delegated to the anaesthesia nurse; the circulating nurse communicates by telephone with the room team for any additional material requirementsOTA (physician\u2018s assistant)Personnel ::: Protective materials and personnelSince the risk of exposure to patient-related aerosols is considered to be highest during in- and extubation, but also during surgery directly on the patient, \u201ckeep your distance\u201d is to be taken as given, even during the ongoing surgical procedure for everyone who is able to do so, i.e., operate at a distance.InsufflationIn accordance with physiological specifications in the pressure structure of the venous vascular system, insufflation pressures of 12\u201315 mmHg have been established as the standard in laparoscopy [14], [15], [16].", [["venous vascular system", "ANATOMY", 1066, 1088], ["patient", "ORGANISM", 134, 141], ["patient", "ORGANISM", 692, 699], ["patient", "ORGANISM", 812, 819], ["venous vascular", "MULTI-TISSUE_STRUCTURE", 1066, 1081], ["patient", "SPECIES", 134, 141], ["patient", "SPECIES", 692, 699], ["patient", "SPECIES", 812, 819], ["procedure", "TREATMENT", 24, 33], ["a disease", "PROBLEM", 88, 97], ["related aerosols", "PROBLEM", 700, 716], ["surgery", "TREATMENT", 788, 795], ["the ongoing surgical procedure", "TREATMENT", 879, 909], ["Insufflation", "TREATMENT", 973, 985], ["insufflation pressures", "TEST", 1090, 1112], ["laparoscopy", "TEST", 1168, 1179], ["disease", "OBSERVATION", 90, 97], ["venous", "ANATOMY_MODIFIER", 1066, 1072], ["vascular system", "ANATOMY", 1073, 1088]]], ["Lower pressures of 8\u201310 mmHg are recommended in children and patients with premature cardiopulmonary disease and, in some studies, have been found to be superior to mechanical retraction systems [17], [18], [19].", [["cardiopulmonary", "ANATOMY", 85, 100], ["premature cardiopulmonary disease", "DISEASE", 75, 108], ["children", "ORGANISM", 48, 56], ["patients", "ORGANISM", 61, 69], ["children", "SPECIES", 48, 56], ["patients", "SPECIES", 61, 69], ["Lower pressures", "TEST", 0, 15], ["premature cardiopulmonary disease", "PROBLEM", 75, 108], ["some studies", "TEST", 117, 129], ["mechanical retraction systems", "TEST", 165, 194], ["pressures", "OBSERVATION_MODIFIER", 6, 15], ["cardiopulmonary", "ANATOMY", 85, 100], ["disease", "OBSERVATION", 101, 108], ["mechanical retraction", "OBSERVATION", 165, 186]]], ["Insufflators of the current generation can produce these low intracavitary target pressures with good intraoperative performance.", [["Insufflators", "TREATMENT", 0, 12], ["these low intracavitary target pressures", "TREATMENT", 51, 91]]], ["Trocar sites should be kept tight by using assisting sutures or suitable trocar systems [20], [21], [22].InsufflationModern two-lumen insufflation systems with \u201csmoke evacuation\u201d function and dissipative smoke filtration are preferable to others.", [["Trocar sites", "ANATOMY", 0, 12], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 128, 133], ["Trocar sites", "TREATMENT", 0, 12], ["assisting sutures", "TREATMENT", 43, 60], ["Insufflation", "TREATMENT", 105, 117], ["two-lumen insufflation systems", "TREATMENT", 124, 154], ["smoke evacuation", "TREATMENT", 161, 177], ["dissipative smoke filtration", "TREATMENT", 192, 220], ["lumen insufflation", "OBSERVATION", 128, 146]]], ["Alternatively, older generations of insufflators with an established disposable smoke evacuation filter (according to DIN EN1822-1:2019) [23], [24] with a Luer-Lock connection can be used to render filtered smoke evacuation.InsufflationBefore intubation, as a pre-exposure prophylaxis, it is recommended that the oral cavity be irrigated with 1.25% aqueous PVP-iodine solution, if possible in combination with gargling.", [["oral cavity", "ANATOMY", 313, 324], ["PVP-iodine", "CHEMICAL", 357, 367], ["PVP", "CHEMICAL", 357, 360], ["iodine", "CHEMICAL", 361, 367], ["oral cavity", "ORGANISM_SUBDIVISION", 313, 324], ["aqueous PVP-iodine", "SIMPLE_CHEMICAL", 349, 367], ["insufflators", "TREATMENT", 36, 48], ["an established disposable smoke evacuation filter", "TREATMENT", 54, 103], ["a Luer-Lock connection", "TREATMENT", 153, 175], ["evacuation", "TREATMENT", 213, 223], ["Insufflation", "TREATMENT", 224, 236], ["intubation", "TREATMENT", 243, 253], ["a pre-exposure prophylaxis", "TREATMENT", 258, 284], ["the oral cavity", "TREATMENT", 309, 324], ["1.25% aqueous PVP-iodine solution", "TREATMENT", 343, 376], ["smoke", "OBSERVATION", 207, 212]]], ["The patient is asked to rinse the oral cavity thoroughly, spit out the solution, and then gargle with fresh solution.", [["oral", "ANATOMY", 34, 38], ["patient", "ORGANISM", 4, 11], ["oral cavity", "ORGANISM_SUBDIVISION", 34, 45], ["patient", "SPECIES", 4, 11], ["fresh solution", "TREATMENT", 102, 116], ["oral cavity", "ANATOMY", 34, 45]]], ["Contraindications are hyperthyroidism, autonomous adenoma of the thyroid gland, and very rarelyOpen surgery ::: Surgery procedureThere are voices \u2013 unfortunately without citable references \u2013 which proclaim the return to open surgery under COVID-19 circumstances with the argumentation of less aerosol production and quicker surgery.", [["adenoma", "ANATOMY", 50, 57], ["thyroid gland", "ANATOMY", 65, 78], ["hyperthyroidism", "DISEASE", 22, 37], ["adenoma of the thyroid gland", "DISEASE", 50, 78], ["adenoma", "CANCER", 50, 57], ["thyroid gland", "ORGAN", 65, 78], ["hyperthyroidism", "PROBLEM", 22, 37], ["autonomous adenoma of the thyroid gland", "PROBLEM", 39, 78], ["Open surgery", "TREATMENT", 95, 107], ["Surgery procedure", "TREATMENT", 112, 129], ["open surgery", "TREATMENT", 220, 232], ["less aerosol production", "TREATMENT", 288, 311], ["quicker surgery", "TREATMENT", 316, 331], ["hyperthyroidism", "OBSERVATION", 22, 37], ["autonomous adenoma", "OBSERVATION", 39, 57], ["thyroid gland", "ANATOMY", 65, 78], ["surgery", "OBSERVATION", 100, 107], ["less", "OBSERVATION_MODIFIER", 288, 292], ["aerosol production", "OBSERVATION", 293, 311]]], ["Open surgery is more personnel-intensive and requires 2 to 3, occasionally even 4 medical colleagues plus instrumental OTA over the patient for the duration of surgery.", [["patient", "ORGANISM", 132, 139], ["patient", "SPECIES", 132, 139], ["Open surgery", "TREATMENT", 0, 12], ["instrumental OTA", "TREATMENT", 106, 122], ["surgery", "TREATMENT", 160, 167], ["surgery", "OBSERVATION", 5, 12]]], ["The advantage is the isobaric setting in the operating field, although tissue-specific aerosols can also be generated in the operating field during electrocoagulation.Conventional laparoscopy ::: Surgery procedureIn the opinion of the DGAV, there is nothing fundamentally wrong with performing laparoscopy in accordance with the published recommendations of 24 April 2020, provided that the protective measures mentioned above are implemented.", [["tissue", "ANATOMY", 71, 77], ["tissue", "TISSUE", 71, 77], ["electrocoagulation", "TREATMENT", 148, 166], ["Conventional laparoscopy", "TEST", 167, 191], ["Surgery", "TREATMENT", 196, 203], ["laparoscopy", "TREATMENT", 294, 305], ["the protective measures", "TREATMENT", 387, 410], ["laparoscopy", "OBSERVATION", 180, 191]]], ["One advantage may be the reduced number of surgeons, which is limited to the surgeon and camera assistant in the vast majority of laparoscopic procedures.", [["laparoscopic procedures", "TREATMENT", 130, 153], ["laparoscopic", "OBSERVATION", 130, 142]]], ["Also, the involvement of the OTA is usually less than in open surgery.Robot-assisted surgery ::: Surgery procedureIn the past 5 years, robot-assisted surgery has established itself worldwide as a special form of laparoscopy, also in visceral surgery.", [["visceral", "ANATOMY", 233, 241], ["OTA", "CHEMICAL", 29, 32], ["OTA", "SIMPLE_CHEMICAL", 29, 32], ["visceral", "TISSUE", 233, 241], ["the involvement of the OTA", "PROBLEM", 6, 32], ["open surgery", "TREATMENT", 57, 69], ["Surgery procedure", "TREATMENT", 97, 114], ["robot-assisted surgery", "TREATMENT", 135, 157], ["laparoscopy", "TREATMENT", 212, 223], ["visceral surgery", "TREATMENT", 233, 249], ["OTA", "OBSERVATION", 29, 32], ["less", "OBSERVATION_MODIFIER", 44, 48], ["surgery", "OBSERVATION", 62, 69], ["laparoscopy", "OBSERVATION", 212, 223], ["visceral", "ANATOMY", 233, 241], ["surgery", "OBSERVATION", 242, 249]]], ["Currently still far from being considered a \u201cgold standard\u201d, the evaluation is undergoing a change based on the first randomized studies of this technique comparing laparoscopy vs. robotics [25] in terms of oncological precision, reduced intraoperative blood loss, shortened inpatient intensive care stay and shortened hospital stay in various indications.", [["blood", "ANATOMY", 253, 258], ["intraoperative blood loss", "DISEASE", 238, 263], ["blood", "ORGANISM_SUBSTANCE", 253, 258], ["the evaluation", "TEST", 61, 75], ["this technique", "TEST", 140, 154], ["laparoscopy", "TEST", 165, 176], ["reduced intraoperative blood loss", "PROBLEM", 230, 263]]], ["While the previous path of robot-assisted surgery was often rocky, not least from an economic point of view, robot-assisted surgery obviously conforms to \u201ckeeping your distance\u201d from the pandemic perspective.", [["robot-assisted surgery", "TREATMENT", 27, 49], ["robot-assisted surgery", "TREATMENT", 109, 131]]], ["No other surgical technique in visceral and thoracic surgery is able to reduce the number of high-risk surgeons on patients in a comparable way.Robot-assisted surgery ::: Surgery procedureThis applies to simple operations such as hernias on the groin or diaphragm, up to complex operations on the pancreas, stomach, esophagus and the colorectum.", [["visceral", "ANATOMY", 31, 39], ["thoracic", "ANATOMY", 44, 52], ["groin", "ANATOMY", 245, 250], ["diaphragm", "ANATOMY", 254, 263], ["pancreas", "ANATOMY", 297, 305], ["stomach", "ANATOMY", 307, 314], ["esophagus", "ANATOMY", 316, 325], ["colorectum", "ANATOMY", 334, 344], ["hernias", "DISEASE", 230, 237], ["visceral", "TISSUE", 31, 39], ["thoracic", "ORGAN", 44, 52], ["patients", "ORGANISM", 115, 123], ["groin", "ORGANISM_SUBDIVISION", 245, 250], ["diaphragm", "ORGAN", 254, 263], ["pancreas", "ORGAN", 297, 305], ["stomach", "ORGAN", 307, 314], ["esophagus", "ORGAN", 316, 325], ["colorectum", "ORGAN", 334, 344], ["patients", "SPECIES", 115, 123], ["thoracic surgery", "TREATMENT", 44, 60], ["Surgery procedure", "TREATMENT", 171, 188], ["simple operations", "TREATMENT", 204, 221], ["hernias on the groin or diaphragm", "PROBLEM", 230, 263], ["complex operations on the pancreas, stomach, esophagus and the colorectum", "PROBLEM", 271, 344], ["surgical", "OBSERVATION", 9, 17], ["visceral", "ANATOMY", 31, 39], ["thoracic", "ANATOMY", 44, 52], ["surgery", "OBSERVATION", 53, 60], ["simple", "OBSERVATION_MODIFIER", 204, 210], ["operations", "OBSERVATION", 211, 221], ["hernias", "OBSERVATION", 230, 237], ["groin", "ANATOMY", 245, 250], ["diaphragm", "ANATOMY", 254, 263], ["complex", "OBSERVATION_MODIFIER", 271, 278], ["operations", "OBSERVATION", 279, 289], ["pancreas", "ANATOMY", 297, 305], ["stomach", "ANATOMY", 307, 314], ["esophagus", "ANATOMY", 316, 325], ["colorectum", "ANATOMY", 334, 344]]], ["The \u201cfirst assistant\u201d in the operating field is occasionally needed to change instruments, to apply a suture or a compress at the situs.", [["situs", "ANATOMY", 130, 135], ["instruments", "TREATMENT", 78, 89], ["a suture", "TREATMENT", 100, 108], ["a compress at the situs", "TREATMENT", 112, 135], ["situs", "ANATOMY", 130, 135]]], ["As a rule, the surgeon can perform the operation alone from the console, which can be placed at any distance.", [["the operation", "TREATMENT", 35, 48]]], ["Thus, in the discussion about acute and elective surgical interventions in the pandemic situation because of COVID-19, robot-assisted surgery can demonstrate its importance in a way not previously shown.", [["acute and elective surgical interventions", "TREATMENT", 30, 71], ["COVID", "TEST", 109, 114], ["robot-assisted surgery", "TREATMENT", 119, 141]]], ["In that, even complex and intricate oncological surgical interventions can continue to be offered and performed with the highest possible safety for the patient and the surgical team, with the best possible quality.ConclusionSurgery must be able to be offered continuously without loss of quality for both infected and non-infected patients, even in the pandemic situation.", [["patient", "ORGANISM", 153, 160], ["patients", "ORGANISM", 332, 340], ["patient", "SPECIES", 153, 160], ["patients", "SPECIES", 332, 340], ["intricate oncological surgical interventions", "TREATMENT", 26, 70], ["loss of quality", "PROBLEM", 281, 296], ["both infected and non-infected patients", "PROBLEM", 301, 340], ["infected", "OBSERVATION", 306, 314]]], ["The requirements for protective measures no longer only concern the protection of the patient, but increasingly the protection of the staff against infection by aerosols from the patient.", [["infection", "DISEASE", 148, 157], ["patient", "ORGANISM", 86, 93], ["patient", "ORGANISM", 179, 186], ["patient", "SPECIES", 86, 93], ["patient", "SPECIES", 179, 186], ["protective measures", "TREATMENT", 21, 40], ["infection", "PROBLEM", 148, 157]]], ["Distance to the patient and reduction of the acting persons are current imperatives.", [["patient", "ORGANISM", 16, 23], ["persons", "ORGANISM", 52, 59], ["patient", "SPECIES", 16, 23], ["persons", "SPECIES", 52, 59]]], ["In addition, building technology adjustments must be made in the operating theater.ConclusionThe conversion of operating theater ventilation to negative pressure operation in accordance with the specifications for isolation rooms with air-lock operation in intensive care units must be implemented.ConclusionThe choice of the technical operating procedure is not influenced by the COVID-19 situation and should continue to be based on the medical requirements of the illness and the respective expertise of the surgeon.ConclusionLaparoscopic techniques produce aerosols from the capnoperitoneum.", [["capnoperitoneum", "ANATOMY", 579, 594], ["illness", "DISEASE", 467, 474], ["capnoperitoneum", "DISEASE", 579, 594], ["capnoperitoneum", "CANCER", 579, 594], ["building technology adjustments", "TREATMENT", 13, 44], ["operating theater ventilation", "TREATMENT", 111, 140], ["negative pressure operation", "TREATMENT", 144, 171], ["isolation rooms", "TREATMENT", 214, 229], ["air-lock operation", "TREATMENT", 235, 253], ["intensive care units", "TREATMENT", 257, 277], ["the technical operating procedure", "TREATMENT", 322, 355], ["ConclusionLaparoscopic techniques", "TREATMENT", 519, 552], ["aerosols from the capnoperitoneum", "PROBLEM", 561, 594], ["pressure operation", "OBSERVATION", 153, 171], ["aerosols", "OBSERVATION", 561, 569], ["capnoperitoneum", "ANATOMY", 579, 594]]], ["Insufflation systems with smoke evacuation and defined CO2 supply and removal are preferred.ConclusionRobot-assisted surgery increases the safety aspect for the surgical team, as the decentralized position of the surgeon reduces the number of people needed in the direct surgical field to one.", [["CO2", "CHEMICAL", 55, 58], ["CO2", "CHEMICAL", 55, 58], ["CO2", "SIMPLE_CHEMICAL", 55, 58], ["people", "ORGANISM", 243, 249], ["people", "SPECIES", 243, 249], ["Insufflation systems", "TREATMENT", 0, 20], ["smoke evacuation", "TREATMENT", 26, 42], ["defined CO2 supply", "TREATMENT", 47, 65], ["removal", "TREATMENT", 70, 77], ["ConclusionRobot-assisted surgery", "TREATMENT", 92, 124], ["CO2 supply", "OBSERVATION", 55, 65]]], ["In addition, the globally standardized robotic system available can help to quickly share surgical experience with the system in all regions affected by the pandemic and thus make the virus easy to trace, for the protection of patients and staff alike.Key messagesSurgery under COVID-19 conditions is the new daily routine.The change of surgical procedures is necessary to protect patients and staff in the long term.Minimally invasive procedures, especially robotics, can be performed with fewer staff in high-risk areas.The risk of aerosol entrainment in minimal invasive surgery can be minimized by insufflation systems with flue gas disposal.Negative pressure ventilation in the OR tract while maintaining the directional ceiling to floor ventilation (with or without laminar air flow) can be easily and safely produced technically and supports the prompt, routine treatment of COVID-19-affected patients in the OR.Competing interests ::: NotesKr\u00fcger CM has a consulting mandate with W.O.M. WORLD OF MEDICINE GmbH.", [["tract", "ANATOMY", 686, 691], ["floor", "ANATOMY", 737, 742], ["CM", "DISEASE", 955, 957], ["patients", "ORGANISM", 227, 235], ["patients", "ORGANISM", 381, 389], ["tract", "ORGANISM_SUBDIVISION", 686, 691], ["COVID-19", "SIMPLE_CHEMICAL", 882, 890], ["patients", "ORGANISM", 900, 908], ["patients", "SPECIES", 227, 235], ["patients", "SPECIES", 381, 389], ["patients", "SPECIES", 900, 908], ["the pandemic", "PROBLEM", 153, 165], ["the virus", "PROBLEM", 180, 189], ["surgical procedures", "TREATMENT", 337, 356], ["Minimally invasive procedures", "TREATMENT", 417, 446], ["robotics", "TREATMENT", 459, 467], ["aerosol entrainment", "TREATMENT", 534, 553], ["minimal invasive surgery", "TREATMENT", 557, 581], ["insufflation systems", "TREATMENT", 602, 622], ["flue gas disposal", "TREATMENT", 628, 645], ["pressure ventilation", "TREATMENT", 655, 675], ["ventilation", "TREATMENT", 743, 754], ["laminar air flow", "TREATMENT", 772, 788], ["COVID", "TEST", 882, 887], ["surgical procedures", "OBSERVATION", 337, 356], ["invasive", "OBSERVATION_MODIFIER", 427, 435], ["procedures", "OBSERVATION", 436, 446], ["aerosol entrainment", "OBSERVATION", 534, 553], ["pressure ventilation", "OBSERVATION", 655, 675]]]], "PMC4755156": [["IntroductionPlaque formation in the CNS of multiple sclerosis (MS) patients has been appreciated for over a century; however, how discrete plaques are restrained is poorly understood.", [["CNS", "ANATOMY", 36, 39], ["plaques", "ANATOMY", 139, 146], ["multiple sclerosis", "DISEASE", 43, 61], ["MS", "DISEASE", 63, 65], ["CNS", "ANATOMICAL_SYSTEM", 36, 39], ["patients", "ORGANISM", 67, 75], ["plaques", "MULTI-TISSUE_STRUCTURE", 139, 146], ["patients", "SPECIES", 67, 75], ["IntroductionPlaque formation", "PROBLEM", 0, 28], ["multiple sclerosis (MS)", "PROBLEM", 43, 66], ["CNS", "ANATOMY", 36, 39], ["multiple", "OBSERVATION_MODIFIER", 43, 51], ["sclerosis", "OBSERVATION", 52, 61], ["discrete", "OBSERVATION_MODIFIER", 130, 138], ["plaques", "OBSERVATION", 139, 146]]], ["Demyelination with no evidence of T cells as an early event in MS (Barnett and Prineas, 2004) and expanding lesions with little or no T cells in autologous bone marrow recipients (Metz et al., 1994) both suggest expansion may be regulated by intrinsic pathological processes.", [["T cells", "ANATOMY", 34, 41], ["lesions", "ANATOMY", 108, 115], ["T cells", "ANATOMY", 134, 141], ["bone marrow", "ANATOMY", 156, 167], ["Demyelination", "DISEASE", 0, 13], ["MS", "DISEASE", 63, 65], ["T cells", "CELL", 34, 41], ["lesions", "CANCER", 108, 115], ["T cells", "CELL", 134, 141], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 156, 167], ["T cells", "CELL_TYPE", 34, 41], ["T cells", "CELL_TYPE", 134, 141], ["Demyelination", "PROBLEM", 0, 13], ["T cells", "PROBLEM", 34, 41], ["MS", "PROBLEM", 63, 65], ["expanding lesions", "PROBLEM", 98, 115], ["T cells", "PROBLEM", 134, 141], ["autologous bone marrow recipients", "TREATMENT", 145, 178], ["intrinsic pathological processes", "PROBLEM", 242, 274], ["no evidence of", "UNCERTAINTY", 19, 33], ["expanding", "OBSERVATION_MODIFIER", 98, 107], ["lesions", "OBSERVATION", 108, 115], ["autologous bone marrow recipients", "OBSERVATION", 145, 178], ["expansion", "OBSERVATION", 212, 221], ["may be", "UNCERTAINTY", 222, 228]]], ["The focal nature of white matter lesions in MS patients is also observed in rodents with experimental autoimmune encephalomyelitis (EAE), spinal cord injury, and demyelination induced by gliatropic coronavirus infection (Bender and Weiss, 2010; Bergmann et al., 2006; Liedtke et al., 1998; Okada et al., 2006; Voskuhl et al., 2009), supporting a conserved regulatory mechanism that restrains lesion expansion.", [["white matter lesions", "ANATOMY", 20, 40], ["spinal cord", "ANATOMY", 138, 149], ["lesion", "ANATOMY", 392, 398], ["white matter lesions", "DISEASE", 20, 40], ["MS", "DISEASE", 44, 46], ["autoimmune encephalomyelitis", "DISEASE", 102, 130], ["EAE", "DISEASE", 132, 135], ["cord injury", "DISEASE", 145, 156], ["demyelination", "DISEASE", 162, 175], ["gliatropic coronavirus infection", "DISEASE", 187, 219], ["white matter lesions", "PATHOLOGICAL_FORMATION", 20, 40], ["patients", "ORGANISM", 47, 55], ["spinal cord", "MULTI-TISSUE_STRUCTURE", 138, 149], ["gliatropic coronavirus", "ORGANISM", 187, 209], ["lesion", "PATHOLOGICAL_FORMATION", 392, 398], ["patients", "SPECIES", 47, 55], ["gliatropic coronavirus", "SPECIES", 187, 209], ["white matter lesions", "PROBLEM", 20, 40], ["experimental autoimmune encephalomyelitis", "PROBLEM", 89, 130], ["spinal cord injury", "PROBLEM", 138, 156], ["demyelination", "PROBLEM", 162, 175], ["gliatropic coronavirus infection", "PROBLEM", 187, 219], ["restrains lesion expansion", "PROBLEM", 382, 408], ["focal", "OBSERVATION_MODIFIER", 4, 9], ["white matter", "OBSERVATION_MODIFIER", 20, 32], ["lesions", "OBSERVATION", 33, 40], ["autoimmune encephalomyelitis", "OBSERVATION", 102, 130], ["spinal cord", "ANATOMY", 138, 149], ["injury", "OBSERVATION", 150, 156], ["demyelination", "OBSERVATION", 162, 175], ["coronavirus", "OBSERVATION_MODIFIER", 198, 209], ["infection", "OBSERVATION", 210, 219], ["lesion", "OBSERVATION", 392, 398]]], ["Astrocytes are implicated as a critical component, as glial scars formed by reactive astrocytes demarcate injured areas following trauma, spinal cord injury, neurodegenerative disease, and autoimmune disease, thus shielding adjacent healthy tissue from bystander damage (Cregg et al., 2014; Sofroniew and Vinters, 2010).", [["Astrocytes", "ANATOMY", 0, 10], ["glial scars", "ANATOMY", 54, 65], ["astrocytes", "ANATOMY", 85, 95], ["spinal cord", "ANATOMY", 138, 149], ["tissue", "ANATOMY", 241, 247], ["trauma", "DISEASE", 130, 136], ["cord injury", "DISEASE", 145, 156], ["neurodegenerative disease", "DISEASE", 158, 183], ["autoimmune disease", "DISEASE", 189, 207], ["bystander damage", "DISEASE", 253, 269], ["Astrocytes", "CELL", 0, 10], ["glial scars", "TISSUE", 54, 65], ["astrocytes", "CELL", 85, 95], ["spinal cord", "MULTI-TISSUE_STRUCTURE", 138, 149], ["tissue", "TISSUE", 241, 247], ["Astrocytes", "CELL_TYPE", 0, 10], ["reactive astrocytes", "CELL_TYPE", 76, 95], ["glial scars", "PROBLEM", 54, 65], ["reactive astrocytes demarcate injured areas", "PROBLEM", 76, 119], ["trauma", "PROBLEM", 130, 136], ["spinal cord injury", "PROBLEM", 138, 156], ["neurodegenerative disease", "PROBLEM", 158, 183], ["autoimmune disease", "PROBLEM", 189, 207], ["shielding adjacent healthy tissue", "PROBLEM", 214, 247], ["bystander damage", "PROBLEM", 253, 269], ["glial scars", "OBSERVATION", 54, 65], ["reactive astrocytes", "OBSERVATION", 76, 95], ["demarcate", "OBSERVATION_MODIFIER", 96, 105], ["injured", "OBSERVATION_MODIFIER", 106, 113], ["areas", "OBSERVATION_MODIFIER", 114, 119], ["spinal cord", "ANATOMY", 138, 149], ["injury", "OBSERVATION", 150, 156], ["neurodegenerative disease", "OBSERVATION", 158, 183], ["autoimmune disease", "OBSERVATION", 189, 207], ["healthy tissue", "OBSERVATION_MODIFIER", 233, 247]]], ["Ablating astrocyte intermediate filaments or inducing apoptosis of dividing astrocytes attenuates gliosis as well as formation of discrete demyelination foci (Liedtke et al., 1998; Toft\u2010Hansen et al., 2011).", [["astrocyte intermediate filaments", "ANATOMY", 9, 41], ["astrocytes", "ANATOMY", 76, 86], ["gliosis", "DISEASE", 98, 105], ["demyelination", "DISEASE", 139, 152], ["astrocyte intermediate filaments", "CELLULAR_COMPONENT", 9, 41], ["astrocytes", "CELL", 76, 86], ["dividing astrocytes", "CELL_TYPE", 67, 86], ["Ablating astrocyte intermediate filaments", "PROBLEM", 0, 41], ["dividing astrocytes attenuates gliosis", "PROBLEM", 67, 105], ["discrete demyelination foci", "PROBLEM", 130, 157], ["astrocyte", "OBSERVATION", 9, 18], ["intermediate filaments", "OBSERVATION", 19, 41], ["dividing astrocytes", "OBSERVATION", 67, 86], ["attenuates", "OBSERVATION_MODIFIER", 87, 97], ["gliosis", "OBSERVATION", 98, 105], ["discrete", "OBSERVATION_MODIFIER", 130, 138], ["demyelination", "OBSERVATION_MODIFIER", 139, 152], ["foci", "OBSERVATION", 153, 157]]], ["Similarly, elimination of Signal Transducer and Activator of Transcription (STAT)\u20103, required for signaling via interleukin (IL)\u20106, IL\u201010, leukemia inhibitory factor (LIF), and ciliary neurotropic factor (CNTF), specifically in astrocytes inhibits scar formation (Herrmann et al., 2008; Wanner et al., 2013).", [["astrocytes", "ANATOMY", 228, 238], ["scar", "ANATOMY", 248, 252], ["Signal Transducer and Activator of Transcription (STAT)\u20103", "GENE_OR_GENE_PRODUCT", 26, 83], ["interleukin (IL)\u20106", "GENE_OR_GENE_PRODUCT", 112, 130], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 132, 137], ["leukemia inhibitory factor", "GENE_OR_GENE_PRODUCT", 139, 165], ["LIF", "GENE_OR_GENE_PRODUCT", 167, 170], ["ciliary neurotropic factor", "GENE_OR_GENE_PRODUCT", 177, 203], ["CNTF", "GENE_OR_GENE_PRODUCT", 205, 209], ["astrocytes", "CELL", 228, 238], ["scar", "PATHOLOGICAL_FORMATION", 248, 252], ["Signal Transducer and Activator of Transcription (STAT)\u20103", "PROTEIN", 26, 83], ["interleukin (IL)\u20106", "PROTEIN", 112, 130], ["IL\u201010", "PROTEIN", 132, 137], ["leukemia inhibitory factor", "PROTEIN", 139, 165], ["LIF", "PROTEIN", 167, 170], ["ciliary neurotropic factor", "PROTEIN", 177, 203], ["CNTF", "PROTEIN", 205, 209], ["astrocytes", "CELL_TYPE", 228, 238], ["Signal Transducer", "TREATMENT", 26, 43], ["Transcription (STAT)", "TEST", 61, 81], ["signaling via interleukin (IL)", "TREATMENT", 98, 128], ["leukemia inhibitory factor", "PROBLEM", 139, 165], ["ciliary neurotropic factor (CNTF)", "PROBLEM", 177, 210], ["scar formation", "PROBLEM", 248, 262], ["ciliary neurotropic", "ANATOMY", 177, 196], ["astrocytes", "ANATOMY", 228, 238], ["scar", "OBSERVATION", 248, 252]]], ["By contrast, abrogation of Suppressor of Cytokine Signaling (SOCS)\u20103 in astrocytes, thereby increasing STAT3 phosphorylation, limits lesion area, enhances astrocyte migration, and improves functional recovery (Okada et al., 2006).IntroductionThe anti\u2010inflammatory cytokine IL\u201010 also provides neuroprotection by ameliorating demyelination caused by neurotropic coronavirus (Trandem et al., 2011) and reducing encephalomyelitis caused by Sindbis virus infection (Kulcsar et al., 2014).", [["astrocytes", "ANATOMY", 72, 82], ["lesion area", "ANATOMY", 133, 144], ["astrocyte", "ANATOMY", 155, 164], ["demyelination", "DISEASE", 325, 338], ["neurotropic coronavirus", "DISEASE", 349, 372], ["encephalomyelitis", "DISEASE", 409, 426], ["Sindbis virus infection", "DISEASE", 437, 460], ["Suppressor of Cytokine Signaling (SOCS)\u20103", "GENE_OR_GENE_PRODUCT", 27, 68], ["astrocytes", "CELL", 72, 82], ["STAT3", "GENE_OR_GENE_PRODUCT", 103, 108], ["astrocyte", "CELL", 155, 164], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 273, 278], ["neurotropic coronavirus", "ORGANISM", 349, 372], ["Sindbis virus", "ORGANISM", 437, 450], ["Suppressor of Cytokine Signaling (SOCS)\u20103", "PROTEIN", 27, 68], ["astrocytes", "CELL_TYPE", 72, 82], ["STAT3", "PROTEIN", 103, 108], ["anti\u2010inflammatory cytokine IL\u201010", "PROTEIN", 246, 278], ["Sindbis virus", "SPECIES", 437, 450], ["neurotropic coronavirus", "SPECIES", 349, 372], ["Sindbis virus", "SPECIES", 437, 450], ["increasing STAT3 phosphorylation", "TREATMENT", 92, 124], ["limits lesion area", "PROBLEM", 126, 144], ["enhances astrocyte migration", "PROBLEM", 146, 174], ["The anti\u2010inflammatory cytokine IL\u2010", "TREATMENT", 242, 276], ["neuroprotection", "TREATMENT", 293, 308], ["ameliorating demyelination", "PROBLEM", 312, 338], ["neurotropic coronavirus", "PROBLEM", 349, 372], ["reducing encephalomyelitis", "PROBLEM", 400, 426], ["Sindbis virus infection", "PROBLEM", 437, 460], ["astrocytes", "ANATOMY", 72, 82], ["increasing", "OBSERVATION_MODIFIER", 92, 102], ["STAT3 phosphorylation", "OBSERVATION", 103, 124], ["lesion", "OBSERVATION_MODIFIER", 133, 139], ["astrocyte migration", "OBSERVATION", 155, 174], ["encephalomyelitis", "OBSERVATION", 409, 426], ["Sindbis virus", "OBSERVATION", 437, 450]]], ["Although IL\u201010 decreases tissue damage at the cost of limiting pathogen control (Chen et al., 2012; Couper et al., 2008b; Holscher et al., 2000; Kullberg et al., 2002), the contribution and mechanisms by which of IL\u201010 ameliorates pathology varies dramatically with the type of infection, the target tissue and source of IL\u201010 (Couper et al., 2008a, 2008b; Kullberg et al., 2002; Lund et al., 2008; Sun et al., 2011, 2009).", [["tissue", "ANATOMY", 25, 31], ["tissue", "ANATOMY", 300, 306], ["infection", "DISEASE", 278, 287], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 9, 14], ["tissue", "TISSUE", 25, 31], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 213, 218], ["tissue", "TISSUE", 300, 306], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 321, 326], ["IL\u201010", "PROTEIN", 9, 14], ["IL\u201010", "PROTEIN", 213, 218], ["IL\u2010", "TREATMENT", 9, 12], ["tissue damage", "PROBLEM", 25, 38], ["limiting pathogen control", "TREATMENT", 54, 79], ["ameliorates pathology", "PROBLEM", 219, 240], ["infection", "PROBLEM", 278, 287], ["decreases tissue", "OBSERVATION_MODIFIER", 15, 31], ["damage", "OBSERVATION", 32, 38], ["infection", "OBSERVATION", 278, 287]]], ["IL\u201010 production at sites of inflammation commonly limits macrophage and dendritic cell maturation, resulting in suppression of T cell function (Couper et al., 2008a; Fahey and Brooks, 2010).", [["sites", "ANATOMY", 20, 25], ["macrophage", "ANATOMY", 58, 68], ["dendritic cell", "ANATOMY", 73, 87], ["T cell", "ANATOMY", 128, 134], ["inflammation", "DISEASE", 29, 41], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 0, 5], ["macrophage", "CELL", 58, 68], ["dendritic cell", "CELL", 73, 87], ["T cell", "CELL", 128, 134], ["IL\u201010", "PROTEIN", 0, 5], ["IL\u2010", "TREATMENT", 0, 3], ["inflammation", "PROBLEM", 29, 41], ["dendritic cell maturation", "PROBLEM", 73, 98], ["inflammation", "OBSERVATION", 29, 41], ["macrophage", "OBSERVATION_MODIFIER", 58, 68], ["dendritic cell maturation", "OBSERVATION", 73, 98]]], ["However, during encephalomyelitis caused by glia tropic coronavirus designated JHMV, IL\u201010 deficiency increases demyelination and lethality, despite accelerated virus control in the CNS and quiescence of antiviral T cell function (Lin et al., 1998; Trandem et al., 2011).", [["CNS", "ANATOMY", 182, 185], ["T cell", "ANATOMY", 214, 220], ["encephalomyelitis", "DISEASE", 16, 33], ["demyelination", "DISEASE", 112, 125], ["glia tropic coronavirus", "ORGANISM", 44, 67], ["JHMV", "GENE_OR_GENE_PRODUCT", 79, 83], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 85, 90], ["CNS", "ANATOMICAL_SYSTEM", 182, 185], ["T cell", "CELL", 214, 220], ["IL\u201010", "PROTEIN", 85, 90], ["encephalomyelitis", "PROBLEM", 16, 33], ["glia tropic coronavirus designated JHMV", "PROBLEM", 44, 83], ["IL\u201010 deficiency", "PROBLEM", 85, 101], ["demyelination", "PROBLEM", 112, 125], ["lethality", "PROBLEM", 130, 139], ["accelerated virus control", "TREATMENT", 149, 174], ["encephalomyelitis", "OBSERVATION", 16, 33], ["demyelination", "OBSERVATION", 112, 125], ["virus", "OBSERVATION", 161, 166], ["CNS", "ANATOMY", 182, 185], ["antiviral T cell", "OBSERVATION", 204, 220]]], ["These outcomes represented an intriguing conflict, as delayed viral control generally correlates with enhanced demyelination in this model (Lin et al., 1999; Ramakrishna et al., 2002).", [["demyelination", "DISEASE", 111, 124], ["delayed viral control", "PROBLEM", 54, 75], ["enhanced demyelination", "PROBLEM", 102, 124], ["conflict", "OBSERVATION", 41, 49], ["enhanced", "OBSERVATION_MODIFIER", 102, 110], ["demyelination", "OBSERVATION", 111, 124]]], ["Demyelination induced by sublethal neurotropic mouse hepatitis virus strains, including JHMV, require both oligodendroglia infection and adaptive immunity (Bender and Weiss, 2010; Bergmann et al., 2006, 2004; Wu et al., 2000).", [["oligodendroglia", "ANATOMY", 107, 122], ["Demyelination", "DISEASE", 0, 13], ["hepatitis", "DISEASE", 53, 62], ["oligodendroglia infection", "DISEASE", 107, 132], ["neurotropic", "ORGANISM", 35, 46], ["mouse hepatitis virus", "ORGANISM", 47, 68], ["oligodendroglia", "CELL", 107, 122], ["mouse", "SPECIES", 47, 52], ["hepatitis virus", "SPECIES", 53, 68], ["mouse hepatitis virus", "SPECIES", 47, 68], ["JHMV", "SPECIES", 88, 92], ["Demyelination", "PROBLEM", 0, 13], ["sublethal neurotropic mouse hepatitis virus strains", "PROBLEM", 25, 76], ["JHMV", "PROBLEM", 88, 92], ["both oligodendroglia infection", "PROBLEM", 102, 132], ["sublethal", "OBSERVATION_MODIFIER", 25, 34], ["neurotropic mouse hepatitis", "OBSERVATION", 35, 62], ["oligodendroglia infection", "OBSERVATION", 107, 132]]], ["Lesions containing macrophages and microglia develop prominently after virus control (Bergmann et al., 2006; Templeton et al., 2008), but lesion formation is independent of both IL\u201017 and infiltrating monocytes, distinct from EAE (Kapil et al., 2009; Savarin et al., 2010; Xue et al., 1999).", [["macrophages", "ANATOMY", 19, 30], ["microglia", "ANATOMY", 35, 44], ["lesion", "ANATOMY", 138, 144], ["infiltrating monocytes", "ANATOMY", 188, 210], ["EAE", "DISEASE", 226, 229], ["macrophages", "CELL", 19, 30], ["microglia", "CELL", 35, 44], ["lesion", "PATHOLOGICAL_FORMATION", 138, 144], ["IL\u201017", "GENE_OR_GENE_PRODUCT", 178, 183], ["monocytes", "CELL", 201, 210], ["macrophages", "CELL_TYPE", 19, 30], ["microglia", "CELL_TYPE", 35, 44], ["IL\u201017", "PROTEIN", 178, 183], ["infiltrating monocytes", "CELL_TYPE", 188, 210], ["Lesions containing macrophages", "PROBLEM", 0, 30], ["virus control", "TREATMENT", 71, 84], ["lesion formation", "PROBLEM", 138, 154], ["infiltrating monocytes", "PROBLEM", 188, 210], ["macrophages", "OBSERVATION", 19, 30], ["microglia", "OBSERVATION_MODIFIER", 35, 44], ["lesion", "OBSERVATION", 138, 144], ["infiltrating monocytes", "OBSERVATION", 188, 210]]], ["Furthermore, IL\u201010 is primarily secreted by CD4+ T cells within the JHMV infected CNS (Puntambekar et al., 2011), although IL\u201010 may be secreted by numerous cell types in other models (Couper et al., 2008a; Saraiva and O'Garra, 2010).IntroductionTo better understand the cellular events underlying the protective effects of IL\u201010 on demyelination we performed a detailed kinetic analysis of viral control, persisting virus, and lesion formation in JHMV infected WT and IL\u201010\u2212/\u2212 mice.", [["CD4+ T cells", "ANATOMY", 44, 56], ["JHMV", "ANATOMY", 68, 72], ["CNS", "ANATOMY", 82, 85], ["cell", "ANATOMY", 157, 161], ["cellular", "ANATOMY", 271, 279], ["lesion", "ANATOMY", 428, 434], ["demyelination", "DISEASE", 333, 346], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 13, 18], ["CD4", "GENE_OR_GENE_PRODUCT", 44, 47], ["CNS", "ANATOMICAL_SYSTEM", 82, 85], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 123, 128], ["cell", "CELL", 157, 161], ["cellular", "CELL", 271, 279], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 324, 329], ["lesion", "PATHOLOGICAL_FORMATION", 428, 434], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 469, 474], ["IL\u201010", "PROTEIN", 13, 18], ["CD4", "PROTEIN", 44, 47], ["T cells", "CELL_TYPE", 49, 56], ["IL\u201010", "PROTEIN", 123, 128], ["IL\u201010", "PROTEIN", 324, 329], ["mice", "SPECIES", 478, 482], ["JHMV", "SPECIES", 448, 452], ["mice", "SPECIES", 478, 482], ["the cellular events", "PROBLEM", 267, 286], ["IL\u2010", "TREATMENT", 324, 327], ["demyelination", "PROBLEM", 333, 346], ["a detailed kinetic analysis", "TEST", 360, 387], ["viral control", "TREATMENT", 391, 404], ["persisting virus", "PROBLEM", 406, 422], ["lesion formation", "PROBLEM", 428, 444], ["infected CNS", "ANATOMY", 73, 85], ["numerous cell types", "OBSERVATION", 148, 167], ["lesion", "OBSERVATION", 428, 434]]], ["Accelerated viral control in the absence of IL\u201010 initially resulted in limited demyelination.", [["demyelination", "DISEASE", 80, 93], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 44, 49], ["IL\u201010", "PROTEIN", 44, 49], ["Accelerated viral control", "TREATMENT", 0, 25], ["limited demyelination", "PROBLEM", 72, 93], ["viral control", "OBSERVATION", 12, 25], ["demyelination", "OBSERVATION", 80, 93]]], ["However, in contrast to relatively stable lesions with well demarcated borders in WT mice, lesion areas increased in the absence of IL\u201010 without evidence of viral recrudescence or altered cellular immunity.", [["lesions", "ANATOMY", 42, 49], ["lesion areas", "ANATOMY", 91, 103], ["cellular", "ANATOMY", 189, 197], ["lesions", "PATHOLOGICAL_FORMATION", 42, 49], ["mice", "ORGANISM", 85, 89], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 132, 137], ["cellular", "CELL", 189, 197], ["IL\u201010", "PROTEIN", 132, 137], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["relatively stable lesions", "PROBLEM", 24, 49], ["lesion areas", "PROBLEM", 91, 103], ["viral recrudescence", "PROBLEM", 158, 177], ["altered cellular immunity", "PROBLEM", 181, 206], ["stable", "OBSERVATION_MODIFIER", 35, 41], ["lesions", "OBSERVATION", 42, 49], ["well demarcated", "OBSERVATION_MODIFIER", 55, 70], ["borders", "OBSERVATION_MODIFIER", 71, 78], ["WT mice", "OBSERVATION_MODIFIER", 82, 89], ["lesion", "OBSERVATION_MODIFIER", 91, 97], ["areas", "OBSERVATION_MODIFIER", 98, 103], ["increased", "OBSERVATION_MODIFIER", 104, 113], ["without evidence of", "UNCERTAINTY", 138, 157], ["viral", "OBSERVATION_MODIFIER", 158, 163], ["recrudescence", "OBSERVATION", 164, 177], ["altered", "OBSERVATION_MODIFIER", 181, 188], ["cellular immunity", "OBSERVATION", 189, 206]]], ["The expanding lesions exhibited ill\u2010defined borders and lacked elongated interdigitating processes associated with scar formation in WT mice, despite the presence of hypertropic astrocytes.", [["lesions", "ANATOMY", 14, 21], ["scar", "ANATOMY", 115, 119], ["hypertropic astrocytes", "ANATOMY", 166, 188], ["lesions", "PATHOLOGICAL_FORMATION", 14, 21], ["scar", "PATHOLOGICAL_FORMATION", 115, 119], ["mice", "ORGANISM", 136, 140], ["astrocytes", "CELL", 178, 188], ["hypertropic astrocytes", "CELL_TYPE", 166, 188], ["mice", "SPECIES", 136, 140], ["mice", "SPECIES", 136, 140], ["The expanding lesions", "PROBLEM", 0, 21], ["ill\u2010defined borders", "PROBLEM", 32, 51], ["elongated interdigitating processes", "PROBLEM", 63, 98], ["scar formation", "PROBLEM", 115, 129], ["hypertropic astrocytes", "PROBLEM", 166, 188], ["expanding", "OBSERVATION_MODIFIER", 4, 13], ["lesions", "OBSERVATION", 14, 21], ["ill\u2010defined", "OBSERVATION_MODIFIER", 32, 43], ["borders", "OBSERVATION_MODIFIER", 44, 51], ["elongated", "OBSERVATION_MODIFIER", 63, 72], ["interdigitating processes", "OBSERVATION", 73, 98], ["scar", "OBSERVATION", 115, 119], ["WT mice", "OBSERVATION_MODIFIER", 133, 140], ["hypertropic astrocytes", "OBSERVATION", 166, 188]]], ["In the absence of IL\u201010, lesions were also characterized by large foamy cells, axonal sparing, and a partial loss of macrophage/microglia exhibiting an acquired deactivation phenotype.", [["lesions", "ANATOMY", 25, 32], ["foamy cells", "ANATOMY", 66, 77], ["axonal", "ANATOMY", 79, 85], ["macrophage", "ANATOMY", 117, 127], ["microglia", "ANATOMY", 128, 137], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 18, 23], ["lesions", "PATHOLOGICAL_FORMATION", 25, 32], ["foamy cells", "CELL", 66, 77], ["axonal", "TISSUE", 79, 85], ["macrophage", "CELL", 117, 127], ["microglia", "CELL", 128, 137], ["IL", "PROTEIN", 18, 20], ["foamy cells", "CELL_TYPE", 66, 77], ["macrophage", "CELL_TYPE", 117, 127], ["microglia", "CELL_TYPE", 128, 137], ["lesions", "PROBLEM", 25, 32], ["large foamy cells", "PROBLEM", 60, 77], ["axonal sparing", "PROBLEM", 79, 93], ["a partial loss of macrophage/microglia", "PROBLEM", 99, 137], ["an acquired deactivation phenotype", "PROBLEM", 149, 183], ["lesions", "OBSERVATION", 25, 32], ["large", "OBSERVATION_MODIFIER", 60, 65], ["foamy cells", "OBSERVATION", 66, 77], ["axonal", "OBSERVATION_MODIFIER", 79, 85], ["sparing", "OBSERVATION_MODIFIER", 86, 93], ["partial", "OBSERVATION_MODIFIER", 101, 108], ["loss", "OBSERVATION_MODIFIER", 109, 113], ["macrophage", "OBSERVATION_MODIFIER", 117, 127], ["microglia", "OBSERVATION", 128, 137], ["deactivation phenotype", "OBSERVATION", 161, 183]]], ["Expanding lesion formation, temporally remote from the viral insult, is thus reminiscent of the epidemiological association of MS with an early insult, possibly an infection.", [["lesion", "ANATOMY", 10, 16], ["viral insult", "DISEASE", 55, 67], ["MS", "DISEASE", 127, 129], ["infection", "DISEASE", 164, 173], ["lesion", "PATHOLOGICAL_FORMATION", 10, 16], ["Expanding lesion formation", "PROBLEM", 0, 26], ["the viral insult", "PROBLEM", 51, 67], ["MS", "PROBLEM", 127, 129], ["an early insult", "PROBLEM", 135, 150], ["an infection", "PROBLEM", 161, 173], ["lesion", "OBSERVATION", 10, 16], ["temporally", "OBSERVATION_MODIFIER", 28, 38], ["remote", "OBSERVATION_MODIFIER", 39, 45], ["viral insult", "OBSERVATION", 55, 67], ["early", "OBSERVATION_MODIFIER", 138, 143], ["insult", "OBSERVATION", 144, 150], ["possibly", "UNCERTAINTY", 152, 160], ["infection", "OBSERVATION", 164, 173]]], ["Moreover, the data suggest a novel astrocyte dependent mechanism by which IL\u201010 contributes to stemming pathology within the CNS.Mice and Virus Infection ::: Materials and MethodsC57BL/6 WT mice were purchased from the National Cancer Institute (Frederick, MD).", [["astrocyte", "ANATOMY", 35, 44], ["CNS", "ANATOMY", 125, 128], ["Cancer", "DISEASE", 228, 234], ["astrocyte", "CELL", 35, 44], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 74, 79], ["CNS", "ANATOMICAL_SYSTEM", 125, 128], ["Mice", "ORGANISM", 129, 133], ["Virus", "ORGANISM", 138, 143], ["MethodsC57BL/6 WT mice", "ORGANISM", 172, 194], ["IL\u201010", "PROTEIN", 74, 79], ["Mice", "SPECIES", 129, 133], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 190, 194], ["the data", "TEST", 10, 18], ["a novel astrocyte dependent mechanism", "PROBLEM", 27, 64], ["stemming pathology within the CNS", "PROBLEM", 95, 128], ["MethodsC57BL/6 WT mice", "TREATMENT", 172, 194], ["CNS", "ANATOMY", 125, 128], ["Virus Infection", "OBSERVATION", 138, 153]]], ["IL\u201010 deficient mice on a C57BL/6 background (IL\u201010\u2212/\u2212), purchased from The Jackson Laboratory (Bar Harbor, MA), were housed and maintained locally under pathogen free conditions.", [["IL\u201010", "GENE_OR_GENE_PRODUCT", 0, 5], ["mice", "ORGANISM", 16, 20], ["C57BL/6 background", "ORGANISM", 26, 44], ["IL", "GENE_OR_GENE_PRODUCT", 46, 48], ["IL\u201010", "PROTEIN", 0, 5], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["a C57BL/6 background", "TREATMENT", 24, 44]]], ["Mice were infected at 6 to 7 weeks of age by intracranial injection of 250 plaque forming units of the glia tropic mAb derived escape mutant of mouse hepatitis virus strain JHM (JHMV), designated V2.2\u20101 (Fleming et al., 1986).", [["intracranial", "ANATOMY", 45, 57], ["plaque", "ANATOMY", 75, 81], ["glia", "ANATOMY", 103, 107], ["hepatitis virus", "DISEASE", 150, 165], ["Mice", "ORGANISM", 0, 4], ["glia", "CELL", 103, 107], ["mAb", "GENE_OR_GENE_PRODUCT", 115, 118], ["mouse hepatitis virus strain JHM", "ORGANISM", 144, 176], ["glia tropic mAb", "PROTEIN", 103, 118], ["Mice", "SPECIES", 0, 4], ["mouse", "SPECIES", 144, 149], ["hepatitis virus", "SPECIES", 150, 165], ["mouse hepatitis virus", "SPECIES", 144, 165], ["JHMV", "SPECIES", 178, 182], ["the glia tropic mAb", "TREATMENT", 99, 118], ["mouse hepatitis virus strain JHM", "PROBLEM", 144, 176], ["glia", "ANATOMY", 103, 107], ["mouse hepatitis", "OBSERVATION", 144, 159]]], ["Infectious virus was determined in clarified supernatants of homogenized brains by plaque assay as described (Fleming et al., 1986).", [["supernatants", "ANATOMY", 45, 57], ["brains", "ANATOMY", 73, 79], ["plaque", "ANATOMY", 83, 89], ["brains", "ORGAN", 73, 79], ["Infectious virus", "SPECIES", 0, 16], ["Infectious virus", "PROBLEM", 0, 16], ["brains", "ANATOMY", 73, 79], ["plaque", "OBSERVATION", 83, 89]]], ["Plaques were counted after 48 h incubation at 37\u00b0C. All procedures were conducted under protocols approved by the Institutional Animal Care and Use Committee.Isolation of CNS Cells and Enzyme Linked Immunosorbent Assay (ELISA) ::: Materials and MethodsCells from the CNS were isolated by nonenzymatic homogenization and using 30%/70% Percoll (Pharmacia, Piscataway, NJ) step gradients as described (Bergmann et al., 1999; Kapil et al., 2009).", [["Plaques", "ANATOMY", 0, 7], ["CNS Cells", "ANATOMY", 171, 180], ["CNS", "ANATOMY", 267, 270], ["CNS Cells", "CELL", 171, 180], ["CNS", "ANATOMICAL_SYSTEM", 267, 270], ["Plaques", "PROBLEM", 0, 7], ["All procedures", "TREATMENT", 52, 66], ["CNS Cells", "TEST", 171, 180], ["Enzyme", "TEST", 185, 191], ["MethodsCells", "TREATMENT", 245, 257], ["nonenzymatic homogenization", "TREATMENT", 288, 315], ["Percoll (Pharmacia", "TREATMENT", 334, 352], ["CNS Cells", "OBSERVATION", 171, 180], ["CNS", "ANATOMY", 267, 270]]], ["Supernatants from the homogenates were stored at \u221280\u00b0C for virus titer determination and ELISA.", [["Supernatants", "ANATOMY", 0, 12], ["homogenates", "ANATOMY", 22, 33], ["C", "GENE_OR_GENE_PRODUCT", 53, 54], ["the homogenates", "TEST", 18, 33], ["virus titer determination", "TEST", 59, 84], ["ELISA", "TEST", 89, 94]]], ["Cells recovered from the Percoll interphase were washed with RPMI containing 25 mM HEPES and resuspended in FACS buffer (PBS containing 0.5% BSA).", [["Cells", "ANATOMY", 0, 5], ["Percoll interphase", "ANATOMY", 25, 43], ["HEPES", "CHEMICAL", 83, 88], ["Cells", "CELL", 0, 5], ["BSA", "SIMPLE_CHEMICAL", 141, 144], ["the Percoll interphase", "TREATMENT", 21, 43], ["RPMI", "TREATMENT", 61, 65], ["25 mM HEPES", "TREATMENT", 77, 88], ["FACS buffer (PBS", "TREATMENT", 108, 124], ["Percoll interphase", "OBSERVATION", 25, 43]]], ["Cervical lymph nodes (CLN) were collected in cold RPMI supplemented with 25 mM HEPES, dissociated by passage through 70 \u00b5m cell strainers and washed as above.", [["Cervical lymph nodes", "ANATOMY", 0, 20], ["CLN", "ANATOMY", 22, 25], ["cell", "ANATOMY", 123, 127], ["HEPES", "CHEMICAL", 79, 84], ["Cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 0, 20], ["CLN", "MULTI-TISSUE_STRUCTURE", 22, 25], ["cell", "CELL", 123, 127], ["Cervical lymph nodes", "PROBLEM", 0, 20], ["25 mM HEPES", "TREATMENT", 73, 84], ["70 \u00b5m cell strainers", "TREATMENT", 117, 137], ["lymph nodes", "OBSERVATION", 9, 20], ["25 mM", "OBSERVATION_MODIFIER", 73, 78]]], ["Viable cells were determined by Trypan blue exclusion and a minimum of 5 \u00d7 105 cells used for flow cytometric analysis.Isolation of CNS Cells and Enzyme Linked Immunosorbent Assay (ELISA) ::: Materials and MethodsIFN\u2010\u03b3 in clarified brain supernatants was determined by ELISA as described (Kapil et al., 2009).", [["cells", "ANATOMY", 7, 12], ["cells", "ANATOMY", 79, 84], ["CNS Cells", "ANATOMY", 132, 141], ["brain supernatants", "ANATOMY", 232, 250], ["Trypan blue", "CHEMICAL", 32, 43], ["Trypan blue", "CHEMICAL", 32, 43], ["cells", "CELL", 7, 12], ["Trypan blue", "SIMPLE_CHEMICAL", 32, 43], ["cells", "CELL", 79, 84], ["CNS Cells", "CELL", 132, 141], ["MethodsIFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 206, 218], ["brain", "ORGAN", 232, 237], ["MethodsIFN\u2010\u03b3", "PROTEIN", 206, 218], ["Viable cells", "PROBLEM", 0, 12], ["Trypan blue exclusion", "TEST", 32, 53], ["flow cytometric analysis", "TEST", 94, 118], ["CNS Cells", "TEST", 132, 141], ["Enzyme", "TEST", 146, 152], ["MethodsIFN\u2010\u03b3", "TREATMENT", 206, 218], ["CNS Cells", "OBSERVATION", 132, 141], ["brain", "ANATOMY", 232, 237]]], ["Briefly, supernatants were added in triplicate to 96 well plates (Fischer Scientific) precoated with mouse antiIFN\u2010\u03b3 mAb (1 \u00b5g/ml; R4\u20106A2; BD Biosciences) and blocked with 10% FBS in PBS.", [["supernatants", "ANATOMY", 9, 21], ["FBS", "ANATOMY", 176, 179], ["mouse", "ORGANISM", 101, 106], ["antiIFN", "GENE_OR_GENE_PRODUCT", 107, 114], ["FBS", "ORGANISM_SUBSTANCE", 176, 179], ["antiIFN", "PROTEIN", 107, 114], ["\u03b3 mAb", "PROTEIN", 115, 120], ["mouse", "SPECIES", 101, 106], ["mouse", "SPECIES", 101, 106], ["mouse antiIFN\u2010\u03b3 mAb", "TREATMENT", 101, 120], ["10% FBS in PBS", "TREATMENT", 172, 186]]], ["Following incubation overnight at 4\u00b0C, IFN\u2010\u03b3 was detected using biotinylated anti\u2010IFN\u2010\u03b3 mAb (1 \u00b5g/ml; XMG1.2; BD Biosciences), avidin\u2010horseradish peroxidase and 3,3\u2032,5,5\u2032\u2010TMB substrate reagent set (BD Biosciences).", [["3,3\u2032,5,5\u2032\u2010", "CHEMICAL", 161, 171], ["avidin\u2010horseradish", "CHEMICAL", 127, 145], ["3,3\u2032,5,5\u2032\u2010", "CHEMICAL", 161, 171], ["TMB", "CHEMICAL", 171, 174], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 39, 44], ["anti\u2010IFN", "GENE_OR_GENE_PRODUCT", 77, 85], ["avidin\u2010horseradish peroxidase", "SIMPLE_CHEMICAL", 127, 156], ["3,3\u2032,5,5\u2032\u2010", "SIMPLE_CHEMICAL", 161, 171], ["TMB", "SIMPLE_CHEMICAL", 171, 174], ["IFN\u2010\u03b3", "PROTEIN", 39, 44], ["anti\u2010IFN", "PROTEIN", 77, 85], ["\u03b3 mAb", "PROTEIN", 86, 91], ["XMG1", "PROTEIN", 102, 106], ["BD Biosciences", "PROTEIN", 110, 124], ["avidin\u2010horseradish peroxidase", "PROTEIN", 127, 156], ["biotinylated anti\u2010IFN\u2010\u03b3 mAb", "TREATMENT", 64, 91], ["XMG1", "TEST", 102, 106]]], ["Optical density was measured at 450 nm with a microplate reader (Bio\u2010Rad Laboratories, Hercules, CA) and analyzed with SoftMax Pro software (Molecular Devices, Sunnyvale, CA).Flow Cytometric Analysis ::: Materials and MethodsCells were incubated with mouse serum and rat anti\u2010mouse Fc\u03b3III/II mAb (2.4G2) (BD Biosciences, San Diego, CA) for 20 min on ice to minimize nonspecific binding.", [["serum", "ANATOMY", 257, 262], ["mouse", "ORGANISM", 251, 256], ["serum", "ORGANISM_SUBSTANCE", 257, 262], ["rat", "ORGANISM", 267, 270], ["rat anti\u2010mouse Fc\u03b3III", "PROTEIN", 267, 288], ["II mAb", "PROTEIN", 289, 295], ["mouse", "SPECIES", 251, 256], ["rat", "SPECIES", 267, 270], ["mouse", "SPECIES", 251, 256], ["rat", "SPECIES", 267, 270], ["a microplate", "TEST", 44, 56], ["Bio\u2010Rad Laboratories", "TEST", 65, 85], ["Hercules", "TEST", 87, 95], ["MethodsCells", "TREATMENT", 218, 230], ["mouse serum", "TEST", 251, 262], ["III/II mAb", "TREATMENT", 285, 295], ["ice", "TREATMENT", 350, 353], ["nonspecific binding", "PROBLEM", 366, 385], ["density", "OBSERVATION", 8, 15]]], ["Cell type specific expression of surface antigens (Ag) was determined by incubation with either phycoerythrin (PE)\u2010, fluorescein isothiocyanate (FITC)\u2010, phycoerythrinperidinin chlorophyll protein (PerCP)\u2010, or allophycocyanin (APC)\u2010conjugated mAb specific for CD45 (30\u2010F11), CD11b (M1/20), major histocompatibility complex (MHC) class II (IA/IE, 2G9), CD4 (RM4\u20105), and CD8 (53\u20136.7) (all from BD Biosciences, San Jose, CA) for 30 min on ice.Flow Cytometric Analysis ::: Materials and MethodsCNS derived T cells were analyzed for virus specific IFN\u2010\u03b3 production by viral peptide stimulation (Kapil et al., 2009).", [["Cell", "ANATOMY", 0, 4], ["surface", "ANATOMY", 33, 40], ["T cells", "ANATOMY", 501, 508], ["PE", "CHEMICAL", 111, 113], ["fluorescein isothiocyanate", "CHEMICAL", 117, 143], ["Ag", "CHEMICAL", 51, 53], ["fluorescein isothiocyanate", "CHEMICAL", 117, 143], ["FITC", "CHEMICAL", 145, 149], ["phycoerythrinperidinin chlorophyll", "CHEMICAL", 153, 187], ["APC", "CHEMICAL", 226, 229], ["Cell", "CELL", 0, 4], ["surface antigens", "GENE_OR_GENE_PRODUCT", 33, 49], ["Ag", "GENE_OR_GENE_PRODUCT", 51, 53], ["phycoerythrin", "SIMPLE_CHEMICAL", 96, 109], ["PE", "SIMPLE_CHEMICAL", 111, 113], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 117, 143], ["FITC)\u2010", "SIMPLE_CHEMICAL", 145, 151], ["phycoerythrinperidinin chlorophyll protein", "SIMPLE_CHEMICAL", 153, 195], ["PerCP)\u2010", "SIMPLE_CHEMICAL", 197, 204], ["allophycocyanin", "SIMPLE_CHEMICAL", 209, 224], ["APC", "GENE_OR_GENE_PRODUCT", 226, 229], ["CD45", "GENE_OR_GENE_PRODUCT", 259, 263], ["CD11b", "GENE_OR_GENE_PRODUCT", 274, 279], ["CD4", "GENE_OR_GENE_PRODUCT", 351, 354], ["CD8", "GENE_OR_GENE_PRODUCT", 368, 371], ["MethodsCNS derived T cells", "CELL", 482, 508], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 542, 547], ["surface antigens", "PROTEIN", 33, 49], ["Ag", "PROTEIN", 51, 53], ["phycoerythrin (PE)\u2010", "PROTEIN", 96, 115], ["fluorescein isothiocyanate (FITC)\u2010, phycoerythrinperidinin chlorophyll protein", "PROTEIN", 117, 195], ["PerCP", "PROTEIN", 197, 202], ["allophycocyanin (APC)\u2010conjugated mAb", "PROTEIN", 209, 245], ["CD45", "PROTEIN", 259, 263], ["F11", "PROTEIN", 268, 271], ["CD11b", "PROTEIN", 274, 279], ["M1", "PROTEIN", 281, 283], ["major histocompatibility complex", "PROTEIN", 289, 321], ["MHC", "PROTEIN", 323, 326], ["IA", "PROTEIN", 338, 340], ["IE", "PROTEIN", 341, 343], ["2G9", "PROTEIN", 345, 348], ["CD4", "PROTEIN", 351, 354], ["RM4", "PROTEIN", 356, 359], ["CD8", "PROTEIN", 368, 371], ["MethodsCNS derived T cells", "CELL_LINE", 482, 508], ["IFN\u2010\u03b3", "PROTEIN", 542, 547], ["phycoerythrin (PE)", "TREATMENT", 96, 114], ["fluorescein isothiocyanate (FITC)", "TREATMENT", 117, 150], ["phycoerythrinperidinin chlorophyll protein (PerCP)", "TREATMENT", 153, 203], ["allophycocyanin (APC)", "TREATMENT", 209, 230], ["conjugated mAb", "TREATMENT", 231, 245], ["CD45", "TEST", 259, 263], ["CD11b", "TEST", 274, 279], ["CD4", "TEST", 351, 354], ["CD8", "TEST", 368, 371], ["Materials", "TREATMENT", 468, 477], ["MethodsCNS derived T cells", "TREATMENT", 482, 508], ["virus", "PROBLEM", 527, 532], ["viral peptide stimulation", "TREATMENT", 562, 587], ["PE", "OBSERVATION", 111, 113]]], ["CNS cells (\u223c5 \u00d7 105) were incubated with 2 \u00d7 105 H\u20102b EL4 cells with or without 0.5 \u00b5M S510 peptide for CD8+ T cells, or with I\u2010Ab expressing CHB3 cells with or without 5 \u00b5M M133 peptide for CD4+ T cells.", [["CNS cells", "ANATOMY", 0, 9], ["EL4 cells", "ANATOMY", 54, 63], ["CD8+ T cells", "ANATOMY", 104, 116], ["CHB3 cells", "ANATOMY", 142, 152], ["CD4+ T cells", "ANATOMY", 191, 203], ["CNS cells", "CELL", 0, 9], ["H\u20102b EL4 cells", "CELL", 49, 63], ["CD8", "GENE_OR_GENE_PRODUCT", 104, 107], ["CHB3 cells", "CELL", 142, 152], ["CD4", "GENE_OR_GENE_PRODUCT", 191, 194], ["CNS cells", "CELL_TYPE", 0, 9], ["H\u20102b EL4 cells", "CELL_LINE", 49, 63], ["CD8", "PROTEIN", 104, 107], ["T cells", "CELL_TYPE", 109, 116], ["I\u2010Ab expressing CHB3 cells", "CELL_LINE", 126, 152], ["CD4", "PROTEIN", 191, 194], ["T cells", "CELL_TYPE", 196, 203], ["CNS cells", "TEST", 0, 9], ["H\u20102b EL4 cells", "TEST", 49, 63], ["CD8+ T cells", "PROBLEM", 104, 116], ["CD4+ T cells", "PROBLEM", 191, 203]]], ["After 6 h stimulation at 37\u00b0C in RPMI supplemented with 10% FBS and 1 \u00b5l/ml golgi stop (BD Biosciences, San Jose, CA), cells were centrifuged, resuspended in FACS buffer, and stained for surface expression of CD4, CD8, and CD45.", [["FBS", "ANATOMY", 60, 63], ["cells", "ANATOMY", 119, 124], ["surface", "ANATOMY", 187, 194], ["FBS", "ORGANISM_SUBSTANCE", 60, 63], ["cells", "CELL", 119, 124], ["CD4", "GENE_OR_GENE_PRODUCT", 209, 212], ["CD8", "GENE_OR_GENE_PRODUCT", 214, 217], ["CD45", "GENE_OR_GENE_PRODUCT", 223, 227], ["CD4", "PROTEIN", 209, 212], ["CD8", "PROTEIN", 214, 217], ["CD45", "PROTEIN", 223, 227], ["10% FBS", "TREATMENT", 56, 63], ["CD4", "TEST", 209, 212], ["CD8", "TEST", 214, 217], ["CD45", "TEST", 223, 227]]], ["Cells were fixed and permeabilized using Cytofix/Cytoperm reagent (BD Biosciences, San Jose, CA) and intracellular IFN\u2010\u03b3 detected by incubation with FITC\u2010labeled anti\u2010IFN\u2010\u03b3 mAb (XMG1.2).", [["Cells", "ANATOMY", 0, 5], ["intracellular", "ANATOMY", 101, 114], ["FITC", "CHEMICAL", 149, 153], ["Cells", "CELL", 0, 5], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 101, 114], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 115, 120], ["FITC\u2010", "SIMPLE_CHEMICAL", 149, 154], ["anti\u2010IFN\u2010\u03b3 mAb", "SIMPLE_CHEMICAL", 162, 176], ["XMG1.2", "SIMPLE_CHEMICAL", 178, 184], ["intracellular IFN\u2010\u03b3", "PROTEIN", 101, 120], ["FITC\u2010labeled anti\u2010IFN", "PROTEIN", 149, 170], ["\u03b3 mAb", "PROTEIN", 171, 176], ["XMG1.2", "PROTEIN", 178, 184], ["Cells", "TEST", 0, 5], ["Cytofix", "TREATMENT", 41, 48], ["Cytoperm reagent", "TREATMENT", 49, 65], ["FITC", "TEST", 149, 153]]], ["Data were collected using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) and analyzed using FlowJo (7.6.1) software (Tree Star, Ashland, OR).Cytotoxic T Lymphocyte Assay ::: Materials and MethodsCytolysis by virus specific CD8+ T cells was analyzed using EL4 cells pulsed with H\u20102Db restricted S510 peptide (de Aquino et al., 2014).", [["CD8+ T cells", "ANATOMY", 236, 248], ["EL4 cells", "ANATOMY", 268, 277], ["Cytotoxic T Lymphocyte", "CELL", 154, 176], ["CD8", "GENE_OR_GENE_PRODUCT", 236, 239], ["EL4 cells", "CELL", 268, 277], ["virus specific CD8+ T cells", "CELL_TYPE", 221, 248], ["EL4 cells", "CELL_LINE", 268, 277], ["a FACSCalibur flow cytometer", "TREATMENT", 26, 54], ["FlowJo", "TEST", 105, 111], ["Cytotoxic T Lymphocyte Assay", "TEST", 154, 182], ["MethodsCytolysis", "TREATMENT", 201, 217], ["EL4 cells pulsed", "TREATMENT", 268, 284]]], ["Target cells were incubated with 0.5 \u00b5M S510 peptide for 2 h at 37\u00b0C, washed, and labeled with 2.5 \u00b5M carboxyflourescein succinimidyl ester (CFSE; Molecular Probes, Eugene, OR).", [["cells", "ANATOMY", 7, 12], ["carboxyflourescein succinimidyl ester", "CHEMICAL", 102, 139], ["CFSE", "CHEMICAL", 141, 145], ["carboxyflourescein succinimidyl ester", "CHEMICAL", 102, 139], ["CFSE", "CHEMICAL", 141, 145], ["cells", "CELL", 7, 12], ["carboxyflourescein succinimidyl ester", "SIMPLE_CHEMICAL", 102, 139], ["CFSE", "SIMPLE_CHEMICAL", 141, 145], ["Molecular Probes", "SIMPLE_CHEMICAL", 147, 163], ["Eugene", "SIMPLE_CHEMICAL", 165, 171], ["Target cells", "PROBLEM", 0, 12], ["2.5 \u00b5M carboxyflourescein succinimidyl ester", "TREATMENT", 95, 139]]], ["Non\u2010peptide treated control EL4 cells were labeled with 0.125 \u00b5M CFSE.", [["EL4 cells", "ANATOMY", 28, 37], ["Non\u2010peptide", "CHEMICAL", 0, 11], ["CFSE", "CHEMICAL", 65, 69], ["Non\u2010peptide", "CHEMICAL", 0, 11], ["CFSE", "CHEMICAL", 65, 69], ["Non\u2010peptide", "SIMPLE_CHEMICAL", 0, 11], ["EL4 cells", "CELL", 28, 37], ["CFSE", "SIMPLE_CHEMICAL", 65, 69], ["Non\u2010peptide treated control EL4 cells", "CELL_LINE", 0, 37], ["Non\u2010peptide treated control EL4 cells", "TREATMENT", 0, 37], ["EL4 cells", "OBSERVATION", 28, 37]]], ["Control and peptide pulsed targets were mixed at a 1:1 ratio, added to 96 well plates and incubated with CNS derived cells at various effector:target (E:T) ratios based on virus specific CD8+ T cells measured using Db/S510 MHC class I tetramers (Beckman Coulter, Fullerton, CA).", [["CNS derived cells", "ANATOMY", 105, 122], ["CD8+ T cells", "ANATOMY", 187, 199], ["CNS derived cells", "CELL", 105, 122], ["CD8", "GENE_OR_GENE_PRODUCT", 187, 190], ["CNS derived cells", "CELL_TYPE", 105, 122], ["virus specific CD8+ T cells", "CELL_TYPE", 172, 199], ["Db", "PROTEIN", 215, 217], ["S510 MHC class I tetramers", "PROTEIN", 218, 244], ["peptide pulsed targets", "TREATMENT", 12, 34], ["ratios", "TEST", 156, 162], ["virus", "TEST", 172, 177], ["Db/S510 MHC class I tetramers (Beckman Coulter", "TREATMENT", 215, 261]]], ["After 6 h incubation at 37\u00b0C, the loss of CSFE labeled cells was determined using a FACSCalibur flow cytometer (BD Biosciences).", [["cells", "ANATOMY", 55, 60], ["CSFE", "SIMPLE_CHEMICAL", 42, 46], ["cells", "CELL", 55, 60], ["CSFE labeled cells", "CELL_LINE", 42, 60], ["the loss of CSFE labeled cells", "PROBLEM", 30, 60], ["a FACSCalibur flow cytometer", "TREATMENT", 82, 110]]], ["Data were analyzed using FlowJo (7.6.1) software.", [["FlowJo", "TEST", 25, 31]]], ["Specific lysis of peptide pulsed target cells was calculated based on the following formula: [1\u2010(ratio of targets only/ratio of target + T cells)] \u00d7 100.Histopathological Analysis ::: Materials and MethodsSpinal cords were fixed in 10% Zinc formalin, divided into six sections corresponding to cervical, thoracic and lumbar regions and embedded in paraffin as described (de Aquino et al., 2014; Puntambekar et al., 2011).", [["cells", "ANATOMY", 40, 45], ["target + T cells", "ANATOMY", 128, 144], ["cords", "ANATOMY", 212, 217], ["sections", "ANATOMY", 268, 276], ["cervical", "ANATOMY", 294, 302], ["thoracic", "ANATOMY", 304, 312], ["lumbar regions", "ANATOMY", 317, 331], ["Zinc formalin", "CHEMICAL", 236, 249], ["paraffin", "CHEMICAL", 348, 356], ["cells", "CELL", 40, 45], ["Zinc formalin", "SIMPLE_CHEMICAL", 236, 249], ["cervical", "MULTI-TISSUE_STRUCTURE", 294, 302], ["thoracic", "MULTI-TISSUE_STRUCTURE", 304, 312], ["lumbar regions", "MULTI-TISSUE_STRUCTURE", 317, 331], ["peptide pulsed target cells", "CELL_LINE", 18, 45], ["T cells", "CELL_TYPE", 137, 144], ["Specific lysis of peptide pulsed target cells", "TREATMENT", 0, 45], ["ratio", "TEST", 97, 102], ["targets", "TEST", 106, 113], ["Histopathological Analysis", "TEST", 153, 179], ["Materials and MethodsSpinal cords", "TREATMENT", 184, 217], ["10% Zinc formalin", "TREATMENT", 232, 249], ["cervical, thoracic and lumbar regions", "TREATMENT", 294, 331], ["cords", "ANATOMY", 212, 217], ["cervical", "ANATOMY", 294, 302], ["thoracic", "ANATOMY", 304, 312], ["lumbar", "ANATOMY", 317, 323], ["regions", "ANATOMY_MODIFIER", 324, 331]]], ["Sections were stained with hematoxylin and eosin (H&E) to visualize inflammation or Luxol Fast Blue (LFB) to visualize myelin.", [["myelin", "ANATOMY", 119, 125], ["inflammation", "DISEASE", 68, 80], ["hematoxylin", "CHEMICAL", 27, 38], ["eosin", "CHEMICAL", 43, 48], ["hematoxylin", "SIMPLE_CHEMICAL", 27, 38], ["eosin", "SIMPLE_CHEMICAL", 43, 48], ["myelin", "CELLULAR_COMPONENT", 119, 125], ["hematoxylin", "TREATMENT", 27, 38], ["eosin", "TREATMENT", 43, 48], ["inflammation", "PROBLEM", 68, 80], ["Luxol Fast Blue (LFB)", "PROBLEM", 84, 105], ["myelin", "PROBLEM", 119, 125]]], ["Viral Ag was detected by anti\u2010JHMV mAb J.3.3 specific for the viral nucleocapsid (N) protein and visualized using immunoperoxidase labeled antimouse mAb (Vectastain\u2010ABC kit, Vector Laboratories, Burlingame, CA) and 3,3\u2010DAB (Sigma, St. Louis, MO) as chromogen.", [["3,3\u2010DAB", "CHEMICAL", 215, 222], ["Ag", "CHEMICAL", 6, 8], ["3,3\u2010DAB", "CHEMICAL", 215, 222], ["Viral", "ORGANISM", 0, 5], ["Ag", "GENE_OR_GENE_PRODUCT", 6, 8], ["immunoperoxidase", "GENE_OR_GENE_PRODUCT", 114, 130], ["Burlingame", "GENE_OR_GENE_PRODUCT", 195, 205], ["3,3\u2010DAB", "SIMPLE_CHEMICAL", 215, 222], ["Sigma", "SIMPLE_CHEMICAL", 224, 229], ["St. Louis", "ORGANISM", 231, 240], ["MO", "ORGANISM", 242, 244], ["chromogen", "SIMPLE_CHEMICAL", 249, 258], ["Viral Ag", "PROTEIN", 0, 8], ["anti\u2010JHMV mAb", "PROTEIN", 25, 38], ["J.3.3", "PROTEIN", 39, 44], ["viral nucleocapsid (N) protein", "PROTEIN", 62, 92], ["immunoperoxidase labeled antimouse mAb", "PROTEIN", 114, 152], ["Vectastain\u2010ABC kit", "PROTEIN", 154, 172], ["anti\u2010JHMV", "SPECIES", 25, 34], ["Viral Ag", "TEST", 0, 8], ["anti\u2010JHMV mAb", "TEST", 25, 38], ["the viral nucleocapsid", "TEST", 58, 80], ["protein", "TEST", 85, 92], ["immunoperoxidase labeled antimouse mAb", "TREATMENT", 114, 152], ["Vectastain", "TEST", 154, 164], ["Burlingame", "TEST", 195, 205], ["CA", "TEST", 207, 209]]], ["Sections from 6 levels per mouse were scanned with an AperioScanScope (Vista, CA) at 40\u00d7, digitally imaged at high resolution, and scored in a blind manner for inflammation, demyelination, and viral Ag.", [["inflammation", "DISEASE", 160, 172], ["demyelination", "DISEASE", 174, 187], ["mouse", "ORGANISM", 27, 32], ["mouse", "SPECIES", 27, 32], ["mouse", "SPECIES", 27, 32], ["inflammation", "PROBLEM", 160, 172], ["demyelination", "PROBLEM", 174, 187], ["viral Ag.", "PROBLEM", 193, 202], ["high resolution", "OBSERVATION_MODIFIER", 110, 125], ["inflammation", "OBSERVATION", 160, 172], ["demyelination", "OBSERVATION", 174, 187]]], ["In addition, demyelination within the white matter was quantified using Aperio software (Vista, CA).", [["white matter", "ANATOMY", 38, 50], ["demyelination", "DISEASE", 13, 26], ["demyelination within the white matter", "PROBLEM", 13, 50], ["demyelination", "OBSERVATION", 13, 26], ["white matter", "OBSERVATION_MODIFIER", 38, 50]]], ["Representative fields for photomicroscopy were identified based on average score of all sections in each experimental group.Histopathological Analysis ::: Materials and MethodsFor confocal microscopy spinal cords from PBS perfused animals were embedded in Tissue\u2010Tek OCT compound (Sakura Finetek, Torrance, CA) and snap frozen in liquid nitrogen.", [["sections", "ANATOMY", 88, 96], ["spinal cords", "ANATOMY", 200, 212], ["Tissue", "ANATOMY", 256, 262], ["nitrogen", "CHEMICAL", 337, 345], ["spinal cords", "MULTI-TISSUE_STRUCTURE", 200, 212], ["Tissue", "TISSUE", 256, 262], ["photomicroscopy", "TEST", 26, 41], ["confocal microscopy spinal cords", "TEST", 180, 212], ["snap frozen in liquid nitrogen", "TREATMENT", 315, 345], ["spinal cords", "ANATOMY", 200, 212]]], ["Tissues were sectioned onto Microfrost slides (Fisher Scientific, Florence, KY) at 10 \u00b5m and stored at \u221280\u00b0C. Prior to staining, slides were subjected to heat mediated Ag retrieval using 0.01M citrate buffer, pH 6.0, fixed with 4% paraformaldehyde for 20 min at room temperature, permeabilized with 0.1% Triton X 100 for 30 min at room temperature and blocked for 30 min at room temperature with a mixture of 10% normal goat serum (Atlanta Biologicals, Lawrenceville, GA) and 1% BSA (Sigma Aldrich, St. Louis, MO) in PBS.", [["Tissues", "ANATOMY", 0, 7], ["serum", "ANATOMY", 425, 430], ["Ag", "CHEMICAL", 168, 170], ["0.01M citrate", "CHEMICAL", 187, 200], ["Triton X 100", "CHEMICAL", 304, 316], ["BSA", "CHEMICAL", 479, 482], ["Ag", "CHEMICAL", 168, 170], ["0.01M citrate", "CHEMICAL", 187, 200], ["paraformaldehyde", "CHEMICAL", 231, 247], ["Tissues", "TISSUE", 0, 7], ["citrate", "SIMPLE_CHEMICAL", 193, 200], ["paraformaldehyde", "SIMPLE_CHEMICAL", 231, 247], ["Triton X 100", "SIMPLE_CHEMICAL", 304, 316], ["goat", "ORGANISM", 420, 424], ["serum", "ORGANISM_SUBSTANCE", 425, 430], ["Lawrenceville", "SIMPLE_CHEMICAL", 453, 466], ["BSA", "SIMPLE_CHEMICAL", 479, 482], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 484, 497], ["St. Louis", "ORGANISM", 499, 508], ["Ag", "PROTEIN", 168, 170], ["goat", "SPECIES", 420, 424], ["goat", "SPECIES", 420, 424], ["heat mediated Ag retrieval", "TREATMENT", 154, 180], ["0.01M citrate buffer", "TREATMENT", 187, 207], ["pH", "TEST", 209, 211], ["4% paraformaldehyde", "TREATMENT", 228, 247], ["0.1% Triton", "TREATMENT", 299, 310]]], ["Primary Ab were applied in blocking solution overnight at 4\u00b0C. Areas of demyelination were identified using mouse anti\u2010myelin proteolipid protein (PLP) mAb (Millipore, PLPC1,1:500).", [["demyelination", "DISEASE", 72, 85], ["Ab", "GENE_OR_GENE_PRODUCT", 8, 10], ["mouse", "ORGANISM", 108, 113], ["anti\u2010myelin proteolipid protein (PLP) mAb", "GENE_OR_GENE_PRODUCT", 114, 155], ["Primary Ab", "PROTEIN", 0, 10], ["mouse anti\u2010myelin proteolipid protein (PLP) mAb", "PROTEIN", 108, 155], ["Millipore", "PROTEIN", 157, 166], ["PLPC1", "PROTEIN", 168, 173], ["1:500", "PROTEIN", 174, 179], ["mouse", "SPECIES", 108, 113], ["mouse", "SPECIES", 108, 113], ["Primary Ab", "TREATMENT", 0, 10], ["blocking solution", "TREATMENT", 27, 44], ["demyelination", "PROBLEM", 72, 85], ["mouse anti\u2010myelin proteolipid protein", "TREATMENT", 108, 145], ["demyelination", "OBSERVATION", 72, 85]]], ["Microglia/macrophages were detected using rabbit anti\u2010Iba1 polyclonal Ab (Wako, 019\u201019741, 1:300).", [["Microglia", "ANATOMY", 0, 9], ["macrophages", "ANATOMY", 10, 21], ["Microglia", "CELL", 0, 9], ["macrophages", "CELL", 10, 21], ["rabbit", "ORGANISM", 42, 48], ["Iba1", "GENE_OR_GENE_PRODUCT", 54, 58], ["Microglia", "CELL_TYPE", 0, 9], ["macrophages", "CELL_TYPE", 10, 21], ["rabbit anti\u2010Iba1 polyclonal Ab", "PROTEIN", 42, 72], ["Wako, 019\u201019741, 1:300", "PROTEIN", 74, 96], ["rabbit", "SPECIES", 42, 48], ["rabbit", "SPECIES", 42, 48], ["Microglia/macrophages", "TEST", 0, 21], ["macrophages", "OBSERVATION", 10, 21]]], ["Microglia/macrophage phenotypes were identified using rat anti\u2010MHC class II mAb (Abcam, M5/114, 1:600), mouse anti\u2010inducible nitric oxide synthase (iNOS) mAb (BD biosciences, 610330, 1:100) and rabbit anti\u2010mannose receptor Ab (Abcam,1:600).", [["Microglia", "ANATOMY", 0, 9], ["macrophage", "ANATOMY", 10, 20], ["nitric oxide", "CHEMICAL", 125, 137], ["nitric oxide", "CHEMICAL", 125, 137], ["Microglia", "CELL", 0, 9], ["macrophage", "CELL", 10, 20], ["rat", "ORGANISM", 54, 57], ["Abcam", "GENE_OR_GENE_PRODUCT", 81, 86], ["mouse", "ORGANISM", 104, 109], ["anti\u2010inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 110, 146], ["iNOS", "GENE_OR_GENE_PRODUCT", 148, 152], ["rabbit", "ORGANISM", 194, 200], ["anti\u2010mannose receptor Ab", "GENE_OR_GENE_PRODUCT", 201, 225], ["Abcam", "GENE_OR_GENE_PRODUCT", 227, 232], ["Microglia", "CELL_TYPE", 0, 9], ["rat anti\u2010MHC class II mAb", "PROTEIN", 54, 79], ["Abcam", "PROTEIN", 81, 86], ["M5", "PROTEIN", 88, 90], ["1:600", "PROTEIN", 96, 101], ["mouse anti\u2010inducible nitric oxide synthase (iNOS) mAb", "PROTEIN", 104, 157], ["BD biosciences, 610330, 1:100", "PROTEIN", 159, 188], ["rabbit anti\u2010mannose receptor Ab", "PROTEIN", 194, 225], ["Abcam,1:600", "PROTEIN", 227, 238], ["rat", "SPECIES", 54, 57], ["mouse", "SPECIES", 104, 109], ["rabbit", "SPECIES", 194, 200], ["mouse", "SPECIES", 104, 109], ["rabbit", "SPECIES", 194, 200], ["Microglia/macrophage phenotypes", "PROBLEM", 0, 31], ["Abcam", "TEST", 81, 86], ["mouse anti\u2010inducible nitric oxide synthase", "TREATMENT", 104, 146], ["BD biosciences", "TEST", 159, 173], ["macrophage phenotypes", "OBSERVATION", 10, 31]]], ["Astrocytes were identified using rat anti\u2010GFAP mAb (Invitrogen, 2.2B10, 1:300).", [["Astrocytes", "ANATOMY", 0, 10], ["Astrocytes", "CELL", 0, 10], ["rat", "ORGANISM", 33, 36], ["GFAP mAb", "GENE_OR_GENE_PRODUCT", 42, 50], ["Astrocytes", "CELL_TYPE", 0, 10], ["GFAP mAb", "PROTEIN", 42, 50], ["rat", "SPECIES", 33, 36], ["Astrocytes", "TEST", 0, 10], ["GFAP mAb", "TEST", 42, 50], ["Invitrogen", "TEST", 52, 62]]], ["IL\u201010R expression was detected using rabbit anti\u2010IL\u201010R\u03b1 Ab (SantaCruz, C\u201020, 1:300).", [["IL\u201010R", "GENE_OR_GENE_PRODUCT", 0, 6], ["rabbit", "ORGANISM", 37, 43], ["anti\u2010IL", "GENE_OR_GENE_PRODUCT", 44, 51], ["10R", "PROTEIN", 3, 6], ["rabbit anti\u2010IL\u201010R\u03b1 Ab", "PROTEIN", 37, 59], ["SantaCruz", "PROTEIN", 61, 70], ["C\u201020", "PROTEIN", 72, 76], ["rabbit", "SPECIES", 37, 43], ["rabbit", "SPECIES", 37, 43]]], ["Tissues were incubated for 1 h at room temperature with alexa fluor goat anti\u2010rabbit 488, alexa fluor goat anti\u2010mouse 594 or alexa fluor goat antirat 594 (all from Invitrogen, 1:1000).", [["Tissues", "ANATOMY", 0, 7], ["anti\u2010mouse 594", "CHEMICAL", 107, 121], ["anti\u2010rabbit 488", "CHEMICAL", 73, 88], ["anti\u2010mouse 594", "CHEMICAL", 107, 121], ["antirat 594", "CHEMICAL", 142, 153], ["Tissues", "CANCER", 0, 7], ["anti\u2010rabbit 488", "SIMPLE_CHEMICAL", 73, 88], ["alexa fluor goat anti\u2010mouse 594", "SIMPLE_CHEMICAL", 90, 121], ["alexa fluor", "SIMPLE_CHEMICAL", 125, 136], ["goat antirat 594", "SIMPLE_CHEMICAL", 137, 153], ["goat", "SPECIES", 68, 72], ["goat", "SPECIES", 102, 106], ["goat", "SPECIES", 137, 141], ["goat", "SPECIES", 102, 106], ["alexa fluor goat anti\u2010rabbit", "TREATMENT", 56, 84], ["alexa fluor goat anti\u2010mouse", "TREATMENT", 90, 117]]], ["Slides were mounted with Prolong Gold antifade reagent with DAPI (Invitrogen) and analyzed on a Leica TCS confocal microscope and Leica DM4000B fluorescence microscope.Histopathological Analysis ::: Materials and MethodsFor epon embedded sections animals were perfused with 4% paraformaldehyde and 2.5% glutaraldehyde in Sorensons phosphate buffer.", [["sections", "ANATOMY", 238, 246], ["glutaraldehyde", "CHEMICAL", 303, 317], ["Sorensons phosphate", "CHEMICAL", 321, 340], ["DAPI", "CHEMICAL", 60, 64], ["TCS", "CHEMICAL", 102, 105], ["paraformaldehyde", "CHEMICAL", 277, 293], ["glutaraldehyde", "CHEMICAL", 303, 317], ["Sorensons phosphate", "CHEMICAL", 321, 340], ["DAPI", "SIMPLE_CHEMICAL", 60, 64], ["paraformaldehyde", "SIMPLE_CHEMICAL", 277, 293], ["glutaraldehyde", "SIMPLE_CHEMICAL", 303, 317], ["Sorensons phosphate buffer", "SIMPLE_CHEMICAL", 321, 347], ["Prolong Gold antifade reagent", "TREATMENT", 25, 54], ["DAPI (Invitrogen)", "TREATMENT", 60, 77], ["Histopathological Analysis", "TEST", 168, 194], ["Methods", "TREATMENT", 213, 220], ["epon embedded sections animals", "TREATMENT", 224, 254], ["4% paraformaldehyde", "TREATMENT", 274, 293], ["2.5% glutaraldehyde in Sorensons phosphate buffer", "TREATMENT", 298, 347]]], ["Spinal cord segments were placed in fixative overnight, post fixed in Osmium tetroxide, and processed to Epon by standard procedures.", [["Spinal cord", "ANATOMY", 0, 11], ["Osmium tetroxide", "CHEMICAL", 70, 86], ["Osmium tetroxide", "CHEMICAL", 70, 86], ["Spinal cord segments", "MULTI-TISSUE_STRUCTURE", 0, 20], ["Osmium tetroxide", "SIMPLE_CHEMICAL", 70, 86], ["Spinal cord segments", "TREATMENT", 0, 20], ["fixed in Osmium tetroxide", "TREATMENT", 61, 86], ["cord segments", "ANATOMY", 7, 20]]], ["Cross\u2010sections of cervical, thoracic, and lumbar cord segments were cut on an ultramicrotome at a thickness of 1 micron and stained with toluidine blue.Gene Expression ::: Materials and MethodsSpinal cords were homogenized in Trizol (Invitrogen) using a TissueLyzer and stainless steel beads (Qiagen, Valencia CA) and RNA isolated as described (de Aquino et al., 2014).", [["cervical", "ANATOMY", 18, 26], ["thoracic", "ANATOMY", 28, 36], ["lumbar cord", "ANATOMY", 42, 53], ["MethodsSpinal cords", "ANATOMY", 186, 205], ["toluidine blue", "CHEMICAL", 137, 151], ["toluidine blue", "CHEMICAL", 137, 151], ["cervical", "ORGAN", 18, 26], ["thoracic", "ORGAN", 28, 36], ["lumbar cord segments", "MULTI-TISSUE_STRUCTURE", 42, 62], ["toluidine blue", "SIMPLE_CHEMICAL", 137, 151], ["MethodsSpinal cords", "MULTI-TISSUE_STRUCTURE", 186, 205], ["Cross\u2010sections of cervical, thoracic, and lumbar cord segments", "PROBLEM", 0, 62], ["toluidine blue", "TREATMENT", 137, 151], ["MethodsSpinal cords", "TREATMENT", 186, 205], ["Trizol (Invitrogen", "TREATMENT", 226, 244], ["a TissueLyzer and stainless steel beads", "TREATMENT", 252, 291], ["Qiagen, Valencia CA)", "TREATMENT", 293, 313], ["cervical", "ANATOMY", 18, 26], ["thoracic", "ANATOMY", 28, 36], ["lumbar cord", "ANATOMY", 42, 53], ["segments", "ANATOMY_MODIFIER", 54, 62], ["MethodsSpinal cords", "ANATOMY", 186, 205]]], ["Following DNase I treatment (DNA\u2010free kit; Ambion, Austin, TX), cDNA was synthesized using Moloney murine leukemia virus (M\u2010MLV) reverse transcriptase (Invitrogen) with oligo(dT) and random primers (Promega, Madison, WI).", [["Moloney murine leukemia", "DISEASE", 91, 114], ["DNase I", "GENE_OR_GENE_PRODUCT", 10, 17], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["TX", "GENE_OR_GENE_PRODUCT", 59, 61], ["Moloney murine leukemia virus", "ORGANISM", 91, 120], ["M\u2010MLV", "ORGANISM", 122, 127], ["DNase I", "PROTEIN", 10, 17], ["cDNA", "DNA", 64, 68], ["reverse transcriptase", "PROTEIN", 129, 150], ["murine", "SPECIES", 99, 105], ["leukemia virus", "SPECIES", 106, 120], ["Moloney murine leukemia virus", "SPECIES", 91, 120], ["MLV", "SPECIES", 124, 127], ["DNase I treatment", "TREATMENT", 10, 27], ["DNA\u2010free kit", "TREATMENT", 29, 41], ["Ambion", "TREATMENT", 43, 49], ["Austin, TX)", "TREATMENT", 51, 62], ["cDNA", "TREATMENT", 64, 68], ["Moloney murine leukemia virus (M\u2010MLV", "TREATMENT", 91, 127], ["transcriptase (Invitrogen", "TREATMENT", 137, 162], ["oligo(dT)", "TREATMENT", 169, 178], ["random primers", "TREATMENT", 183, 197], ["leukemia virus", "OBSERVATION", 106, 120]]], ["Quantitative real\u2010time PCR (qRT\u2010PCR) was performed using SYBR green master mix (Applied Biosystems, Foster City, CA) in triplicate on a 7500 Fast real\u2010time PCR system (Applied Biosystems).", [["Quantitative real\u2010time PCR", "TEST", 0, 26], ["PCR", "TEST", 32, 35]]], ["PCR conditions were 10 min at 95\u00b0C followed by 40 cycles of 95\u00b0C for 15 s, 60\u00b0C for 30 s, and 72\u00b0C for 30 s.", [["PCR conditions", "TEST", 0, 14]]], ["Real\u2010time primer sequences were as follows: GAPDH sense, 5\u2032\u2010CATGGCCTTCCGTGTTCCTA\u20103\u2032; GAPDH antisense, 5\u2032\u2010ATGCCTGCTTCACCACCTTCT\u20103\u2032, JHMV N gene sense, 5\u2032\u2010CGCAGAGTATGGCGACGAT\u20103\u2032; JHMV(N) antisense, 5\u2032\u2010GAGGTCCTAGTCTCGGCCTGTT\u20103\u2032; Arginase\u20101 (Arg\u20101) sense, 5\u2032\u2010TGGGTGGATGCTCACACTGA\u20103\u2032, Arg\u20101 antisense, 5\u2032\u2010 CAGGTTGCCCATGCAGATT\u20103\u2032; IL\u20101 receptor antagonist (IL\u20101Ran) sense, 5\u2032\u2010AGATAGACATGGTGCCTATTGACCTT\u20103\u2032, IL\u20101Ran antisense, 5\u2032\u2010CATCTCCAGACTTGGCACAAGA\u20103\u2032.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 44, 49], ["GAPDH", "GENE_OR_GENE_PRODUCT", 85, 90], ["JHMV N", "GENE_OR_GENE_PRODUCT", 131, 137], ["IL\u20101 receptor", "GENE_OR_GENE_PRODUCT", 325, 338], ["IL\u20101Ran", "GENE_OR_GENE_PRODUCT", 351, 358], ["IL", "GENE_OR_GENE_PRODUCT", 401, 403], ["Real\u2010time primer sequences", "DNA", 0, 26], ["GAPDH antisense", "DNA", 85, 100], ["Arginase\u20101", "DNA", 226, 236], ["Arg\u20101 antisense", "DNA", 280, 295], ["IL\u20101Ran", "DNA", 351, 358], ["Real\u2010time primer sequences", "TEST", 0, 26], ["GAPDH", "TEST", 44, 49], ["sense", "TEST", 50, 55], ["CATGGCCTTCCGTGTTCCTA", "TEST", 60, 80], ["\u2010", "TEST", 80, 81], ["antisense", "TEST", 91, 100], ["ATGCCTGCTTCACCACCTTCT", "TEST", 105, 126], ["\u2010", "TEST", 126, 127], ["JHMV", "TEST", 131, 135], ["sense", "TEST", 143, 148], ["CGCAGAGTATGGCGACGAT", "TEST", 153, 172], ["\u2010", "TEST", 172, 173], ["JHMV", "TEST", 177, 181], ["antisense", "TEST", 185, 194], ["GAGGTCCTAGTCTCGGCCTGTT", "TEST", 199, 221], ["\u2010", "TEST", 221, 222], ["\u2032", "TEST", 223, 224], ["Arginase\u20101", "TEST", 226, 236], ["Arg", "TEST", 238, 241], ["sense", "TEST", 245, 250], ["TGGGTGGATGCTCACACTGA", "TEST", 255, 275], ["\u2010", "TEST", 275, 276], ["antisense", "TEST", 286, 295], ["CAGGTTGCCCATGCAGATT", "TEST", 301, 320], ["\u2010", "TEST", 320, 321], ["\u2032", "TEST", 322, 323], ["IL", "TEST", 325, 327], ["antagonist", "TEST", 339, 349], ["IL", "TEST", 351, 353], ["sense", "TEST", 360, 365], ["AGATAGACATGGTGCCTATTGACCTT", "TEST", 370, 396], ["\u2010", "TEST", 396, 397], ["\u2032", "TEST", 398, 399], ["IL", "TEST", 401, 403], ["antisense", "TEST", 409, 418], ["CATCTCCAGACTTGGCACAAGA", "TEST", 423, 445]]], ["For IFN\u2010\u03b3 (Mm01168134_m1) and GAPDH (Mm99999915_g1) expression levels were determined using Applied Biosystems gene expression arrays with Universal TaqMan Fast master mix (Applied Biosystems).", [["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 4, 9], ["GAPDH (Mm99999915_g1", "GENE_OR_GENE_PRODUCT", 30, 50], ["IFN\u2010\u03b3", "PROTEIN", 4, 9], ["Mm01168134_m1", "PROTEIN", 11, 24], ["Mm99999915_g1", "PROTEIN", 37, 50], ["GAPDH (Mm", "TEST", 30, 39], ["expression levels", "TEST", 52, 69], ["Applied Biosystems gene expression arrays", "TREATMENT", 92, 133], ["Universal TaqMan Fast master mix", "TREATMENT", 139, 171]]], ["PCR conditions were 20s at 95\u00b0C followed by 40 cycles of 95\u00b0C for 3 s and 60\u00b0C for 30 s.", [["PCR conditions", "TEST", 0, 14]]], ["Transcript levels were calculated relative to the levels of the housekeeping gene GAPDH using the formula 2[CT(GAPDH) \u2013CT(target gene)] \u00d7 1,000 where CT is determined as the threshold cycle at which the fluorescent signal becomes significantly higher than that of the background.Quantification and Statistical Analysis ::: Materials and MethodsLesion area and total cell numbers were quantified using images acquired with a Leica DM4000B fluorescence microscope at 10\u00d7 magnification.", [["cell", "ANATOMY", 366, 370], ["GAPDH", "GENE_OR_GENE_PRODUCT", 82, 87], ["cell", "CELL", 366, 370], ["housekeeping gene", "DNA", 64, 81], ["GAPDH", "DNA", 82, 87], ["formula 2[CT(GAPDH) \u2013CT", "DNA", 98, 121], ["target gene", "DNA", 122, 133], ["Transcript levels", "TEST", 0, 17], ["the formula", "TREATMENT", 94, 105], ["CT(GAPDH) \u2013CT", "TEST", 108, 121], ["CT", "TEST", 150, 152], ["the fluorescent signal", "TEST", 199, 221], ["total cell numbers", "TEST", 360, 378], ["images", "TEST", 401, 407], ["a Leica DM4000B fluorescence microscope", "TREATMENT", 422, 461], ["significantly", "OBSERVATION_MODIFIER", 230, 243], ["higher", "OBSERVATION_MODIFIER", 244, 250], ["total cell", "OBSERVATION", 360, 370]]], ["PLP stained lesions were outlined and the selected area quantified using the ImageJ/Fiji processing software.", [["lesions", "ANATOMY", 12, 19], ["PLP", "CHEMICAL", 0, 3], ["PLP", "GENE_OR_GENE_PRODUCT", 0, 3], ["lesions", "PATHOLOGICAL_FORMATION", 12, 19], ["PLP stained lesions", "PROBLEM", 0, 19], ["stained", "OBSERVATION_MODIFIER", 4, 11], ["lesions", "OBSERVATION", 12, 19]]], ["Cells of interest within the area were counted manually.", [["Cells", "ANATOMY", 0, 5], ["area", "ANATOMY", 29, 33], ["Cells", "CELL", 0, 5]]], ["The total number of cells normalized to 1 mm2 lesion area was calculated using the formula [(number of cells in lesion/total area of lesion)] \u00d7 105.", [["cells", "ANATOMY", 20, 25], ["lesion area", "ANATOMY", 46, 57], ["cells", "ANATOMY", 103, 108], ["lesion", "ANATOMY", 112, 118], ["area", "ANATOMY", 125, 129], ["lesion", "ANATOMY", 133, 139], ["cells", "CELL", 20, 25], ["cells", "CELL", 103, 108], ["1 mm2 lesion area", "PROBLEM", 40, 57], ["the formula [(number of cells in lesion/total area of lesion", "TREATMENT", 79, 139], ["total", "OBSERVATION_MODIFIER", 4, 9], ["total", "OBSERVATION_MODIFIER", 119, 124], ["lesion", "OBSERVATION", 133, 139]]], ["Statistical analysis was performed using Microsoft excel and GraphPad Prism 5 Software.", [["Statistical analysis", "TEST", 0, 20]]], ["A value of P <0.05 was considered statistically significant.IL\u201010 Limits Viral Clearance ::: ResultsTo resolve the discrepancy between IL\u201010 mediated control of tissue damage coupled with delayed virus control, pathogenesis was monitored longitudinally in WT and IL\u201010\u2212/\u2212 mice infected with sublethal JHMV.", [["tissue", "ANATOMY", 161, 167], ["tissue damage", "DISEASE", 161, 174], ["JHMV", "CHEMICAL", 301, 305], ["IL", "GENE_OR_GENE_PRODUCT", 60, 62], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 135, 140], ["tissue", "TISSUE", 161, 167], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 263, 268], ["IL\u201010", "PROTEIN", 135, 140], ["mice", "SPECIES", 272, 276], ["mice", "SPECIES", 272, 276], ["JHMV", "SPECIES", 301, 305], ["A value", "TEST", 0, 7], ["the discrepancy", "PROBLEM", 111, 126], ["IL\u2010", "TREATMENT", 135, 138], ["tissue damage", "PROBLEM", 161, 174], ["delayed virus control", "TREATMENT", 188, 209], ["pathogenesis", "PROBLEM", 211, 223], ["sublethal JHMV", "TREATMENT", 291, 305]]], ["CNS viral loads were initially similar in both groups, but were reduced more efficiently in IL\u201010\u2212/\u2212 mice at days 7 and 10 post infection (p.i.) as the host exerts T cell mediated control (Fig. 1A).", [["CNS", "ANATOMY", 0, 3], ["T cell", "ANATOMY", 164, 170], ["infection", "DISEASE", 128, 137], ["CNS", "ANATOMICAL_SYSTEM", 0, 3], ["IL\u201010\u2212", "GENE_OR_GENE_PRODUCT", 92, 98], ["T cell", "CELL", 164, 170], ["IL", "PROTEIN", 92, 94], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["CNS viral loads", "PROBLEM", 0, 15], ["infection", "PROBLEM", 128, 137], ["T cell mediated control", "TREATMENT", 164, 187], ["viral loads", "OBSERVATION", 4, 15]]], ["By day 14 p.i. infectious virus was still detectable in the CNS of some WT mice, but cleared from IL\u201010\u2212/\u2212 mice (Fig. 1A), consistent with less than 10% mortality in both groups.", [["CNS", "ANATOMY", 60, 63], ["CNS", "ANATOMICAL_SYSTEM", 60, 63], ["mice", "ORGANISM", 75, 79], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 98, 103], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 107, 111], ["p.i. infectious virus", "PROBLEM", 10, 31]]], ["These data confirm that the anti\u2010inflammatory cytokine IL\u201010 delays viral control within the CNS (Lin et al., 1998; Trandem et al., 2011).IL\u201010 Limits Viral Clearance ::: ResultsJHMV initially replicates in brain, but rapidly spreads into the spinal cord where it preferentially infects and persists within oligodendrocytes (Kapil et al., 2012; Phares et al., 2014; Wang et al., 1992).", [["CNS", "ANATOMY", 93, 96], ["brain", "ANATOMY", 207, 212], ["spinal cord", "ANATOMY", 243, 254], ["oligodendrocytes", "ANATOMY", 307, 323], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 55, 60], ["CNS", "ANATOMICAL_SYSTEM", 93, 96], ["IL", "GENE_OR_GENE_PRODUCT", 138, 140], ["ResultsJHMV", "GENE_OR_GENE_PRODUCT", 171, 182], ["brain", "ORGAN", 207, 212], ["spinal cord", "ORGAN", 243, 254], ["oligodendrocytes", "CELL", 307, 323], ["anti\u2010inflammatory cytokine IL\u201010", "PROTEIN", 28, 60], ["ResultsJHMV", "PROTEIN", 171, 182], ["oligodendrocytes", "CELL_TYPE", 307, 323], ["ResultsJHMV", "SPECIES", 171, 182], ["These data", "TEST", 0, 10], ["the anti\u2010inflammatory cytokine IL\u2010", "TREATMENT", 24, 58], ["delays viral control", "TREATMENT", 61, 81], ["ResultsJHMV", "TEST", 171, 182], ["CNS", "ANATOMY", 93, 96], ["brain", "ANATOMY", 207, 212], ["spinal cord", "ANATOMY", 243, 254], ["preferentially", "OBSERVATION_MODIFIER", 264, 278], ["infects", "OBSERVATION", 279, 286]]], ["Consistent with more efficient virus control in brain in the absence of IL\u201010, virus infected cells in spinal cord also appeared to be reduced (Fig. 1B,C).", [["brain", "ANATOMY", 48, 53], ["cells", "ANATOMY", 94, 99], ["spinal cord", "ANATOMY", 103, 114], ["brain", "ORGAN", 48, 53], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 72, 77], ["cells", "CELL", 94, 99], ["spinal cord", "ORGAN", 103, 114], ["IL\u201010", "PROTEIN", 72, 77], ["virus infected cells", "CELL_TYPE", 79, 99], ["more efficient virus control in brain", "PROBLEM", 16, 53], ["virus infected cells in spinal cord", "PROBLEM", 79, 114], ["more efficient", "OBSERVATION_MODIFIER", 16, 30], ["virus", "OBSERVATION", 31, 36], ["brain", "ANATOMY", 48, 53], ["infected cells", "OBSERVATION", 85, 99], ["spinal cord", "ANATOMY", 103, 114], ["reduced", "OBSERVATION_MODIFIER", 135, 142]]], ["Moreover, similar morphology and distribution of virus infected cells indicated that viral tropism was not altered.", [["cells", "ANATOMY", 64, 69], ["cells", "CELL", 64, 69], ["virus infected cells", "CELL_TYPE", 49, 69], ["virus infected cells", "PROBLEM", 49, 69], ["viral tropism", "PROBLEM", 85, 98], ["distribution", "OBSERVATION_MODIFIER", 33, 45], ["virus infected cells", "OBSERVATION", 49, 69], ["viral tropism", "OBSERVATION", 85, 98]]], ["Accelerated control of infectious virus in the absence of IL\u201010 suggested that viral persistence may also be reduced.", [["IL\u201010", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL\u201010", "PROTEIN", 58, 63], ["infectious virus", "PROBLEM", 23, 39], ["viral persistence", "PROBLEM", 79, 96], ["infectious virus", "OBSERVATION", 23, 39], ["viral persistence", "OBSERVATION", 79, 96], ["may also be", "UNCERTAINTY", 97, 108], ["reduced", "OBSERVATION_MODIFIER", 109, 116]]], ["However, although levels of the abundant viral mRNA encoding the N protein were reduced in IL\u201010\u2212/\u2212 relative to WT spinal cords at day 10 p.i., they were similar in both groups thereafter (Fig. 1F).", [["spinal cords", "ANATOMY", 115, 127], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 91, 96], ["\u2212", "GENE_OR_GENE_PRODUCT", 98, 99], ["spinal cords", "MULTI-TISSUE_STRUCTURE", 115, 127], ["viral mRNA", "RNA", 41, 51], ["N protein", "PROTEIN", 65, 74], ["IL", "PROTEIN", 91, 93], ["the abundant viral mRNA", "PROBLEM", 28, 51], ["the N protein", "TEST", 61, 74], ["abundant", "OBSERVATION_MODIFIER", 32, 40], ["viral mRNA", "OBSERVATION", 41, 51], ["spinal cords", "ANATOMY", 115, 127]]], ["IL\u201010 deficiency also did not alter the extent or distribution of inflammatory foci in spinal cords (Fig. 1D,E).", [["foci", "ANATOMY", 79, 83], ["spinal cords", "ANATOMY", 87, 99], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 0, 5], ["spinal cords", "TISSUE", 87, 99], ["IL\u201010", "PROTEIN", 0, 5], ["deficiency", "PROBLEM", 6, 16], ["inflammatory foci in spinal cords", "PROBLEM", 66, 99], ["deficiency", "OBSERVATION", 6, 16], ["distribution", "OBSERVATION_MODIFIER", 50, 62], ["inflammatory", "OBSERVATION_MODIFIER", 66, 78], ["foci", "OBSERVATION", 79, 83], ["spinal cords", "ANATOMY", 87, 99]]], ["CNS recruitment of CD45hi inflammatory cells was examined to support the notion that the anti\u2010inflammatory properties of IL\u201010 (Couper et al., 2008a) did not alter cellular infiltrates.", [["CNS", "ANATOMY", 0, 3], ["CD45hi inflammatory cells", "ANATOMY", 19, 44], ["cellular", "ANATOMY", 164, 172], ["CNS", "ANATOMICAL_SYSTEM", 0, 3], ["CD45hi inflammatory cells", "CELL", 19, 44], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 121, 126], ["cellular", "CELL", 164, 172], ["CD45hi inflammatory cells", "CELL_TYPE", 19, 44], ["CD45hi inflammatory cells", "PROBLEM", 19, 44], ["the anti\u2010inflammatory properties of IL\u2010", "TREATMENT", 85, 124], ["cellular infiltrates", "PROBLEM", 164, 184], ["inflammatory cells", "OBSERVATION", 26, 44], ["infiltrates", "OBSERVATION", 173, 184]]], ["Indeed, IL\u201010 deficiency did not affect the accumulation of inflammatory cells at any time p.i.", [["inflammatory cells", "ANATOMY", 60, 78], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 8, 13], ["cells", "CELL", 73, 78], ["IL\u201010", "PROTEIN", 8, 13], ["inflammatory cells", "CELL_TYPE", 60, 78], ["inflammatory cells", "PROBLEM", 60, 78], ["inflammatory cells", "OBSERVATION", 60, 78]]], ["Thus, despite an IL\u201010 dependent delay in clearance of infectious virus, IL\u201010 did not affect overall inflammation, viral tropism, or persistence.IL\u201010 Preferentially Influences Virus Specific CD4+ T Cells ::: ResultsTo assess whether enhanced viral control correlated with increased T cell effector activity we measured IFN\u2010\u03b3 as the primary T cell derived mediator of viral control (Bergmann et al., 2004; Parra et al., 1999; Stohlman et al., 2008).", [["CD4+ T Cells", "ANATOMY", 193, 205], ["T cell", "ANATOMY", 284, 290], ["T cell", "ANATOMY", 342, 348], ["inflammation", "DISEASE", 102, 114], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 17, 22], ["infectious virus", "ORGANISM", 55, 71], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 73, 78], ["IL", "GENE_OR_GENE_PRODUCT", 146, 148], ["Virus", "ORGANISM", 178, 183], ["CD4", "GENE_OR_GENE_PRODUCT", 193, 196], ["T cell", "CELL", 284, 290], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 321, 326], ["T cell", "CELL", 342, 348], ["CD4", "PROTEIN", 193, 196], ["IFN\u2010\u03b3", "PROTEIN", 321, 326], ["an IL\u2010", "TREATMENT", 14, 20], ["dependent delay", "PROBLEM", 23, 38], ["infectious virus", "PROBLEM", 55, 71], ["overall inflammation", "PROBLEM", 94, 114], ["viral tropism", "PROBLEM", 116, 129], ["enhanced viral control", "PROBLEM", 235, 257], ["increased T cell effector activity", "PROBLEM", 274, 308], ["infectious virus", "OBSERVATION", 55, 71], ["inflammation", "OBSERVATION", 102, 114], ["viral tropism", "OBSERVATION", 116, 129]]], ["Indeed, IFN\u2010\u03b3 levels within the CNS were elevated in the absence of IL\u201010 (Fig. 2A).", [["CNS", "ANATOMY", 32, 35], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 8, 13], ["CNS", "ANATOMICAL_SYSTEM", 32, 35], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 68, 73], ["IFN", "PROTEIN", 8, 11], ["\u2010\u03b3", "PROTEIN", 11, 13], ["IFN\u2010\u03b3 levels", "TEST", 8, 20], ["elevated", "PROBLEM", 41, 49], ["elevated", "OBSERVATION", 41, 49]]], ["Virus specific CD4+ T cells within the CNS produce higher levels of IFN\u2010\u03b3 as compared to CD8+ T cells (Phares et al., 2010), although CD8+ T cells are essential to control JHMV infection (Bergmann et al., 1999, 2004).", [["CD4+ T cells", "ANATOMY", 15, 27], ["CNS", "ANATOMY", 39, 42], ["CD8+ T cells", "ANATOMY", 89, 101], ["CD8+ T cells", "ANATOMY", 134, 146], ["infection", "DISEASE", 177, 186], ["Virus", "ORGANISM", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 15, 18], ["CNS", "ANATOMICAL_SYSTEM", 39, 42], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 68, 73], ["CD8", "GENE_OR_GENE_PRODUCT", 89, 92], ["CD8", "GENE_OR_GENE_PRODUCT", 134, 137], ["JHMV", "ORGANISM", 172, 176], ["Virus specific CD4+ T cells", "CELL_TYPE", 0, 27], ["IFN\u2010\u03b3", "PROTEIN", 68, 73], ["CD8+ T cells", "CELL_TYPE", 89, 101], ["CD8+ T cells", "CELL_TYPE", 134, 146], ["JHMV", "SPECIES", 172, 176], ["Virus specific CD4", "TEST", 0, 18], ["T cells", "PROBLEM", 20, 27], ["the CNS", "TEST", 35, 42], ["IFN\u2010\u03b3", "TEST", 68, 73], ["CD8", "TEST", 89, 92], ["Phares", "TEST", 103, 109], ["et al.", "TEST", 110, 116], ["CD8", "TEST", 134, 137], ["T cells", "PROBLEM", 139, 146], ["JHMV infection", "PROBLEM", 172, 186], ["CNS", "ANATOMY", 39, 42], ["higher", "OBSERVATION_MODIFIER", 51, 57], ["infection", "OBSERVATION", 177, 186]]], ["To assess which T cell subset is responsible for enhanced IFN\u2010\u03b3 levels in the absence of IL\u201010, numbers and function of virus specific T cells within the CNS were analyzed.", [["T cell", "ANATOMY", 16, 22], ["T cells", "ANATOMY", 135, 142], ["CNS", "ANATOMY", 154, 157], ["T cell", "CELL", 16, 22], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 89, 94], ["T cells", "CELL", 135, 142], ["CNS", "ANATOMICAL_SYSTEM", 154, 157], ["T cell subset", "CELL_TYPE", 16, 29], ["IFN\u2010\u03b3", "PROTEIN", 58, 63], ["IL\u201010", "PROTEIN", 89, 94], ["virus specific T cells", "CELL_TYPE", 120, 142], ["enhanced IFN\u2010\u03b3 levels", "TEST", 49, 70], ["CNS", "ANATOMY", 154, 157]]], ["Although total CD4+ T cell numbers were similar in both groups at all times p.i., virus specific IFN\u2010\u03b3+CD4+ T cells were more abundant in the absence of IL\u201010 at day 7 p.i.", [["CD4+ T cell", "ANATOMY", 15, 26], ["IFN\u2010\u03b3+CD4+ T cells", "ANATOMY", 97, 115], ["CD4", "GENE_OR_GENE_PRODUCT", 15, 18], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 97, 102], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 153, 158], ["CD4", "PROTEIN", 15, 18], ["IFN\u2010\u03b3", "PROTEIN", 97, 102], ["CD4", "PROTEIN", 103, 106], ["T cells", "CELL_TYPE", 108, 115], ["IL", "PROTEIN", 153, 155], ["total CD4", "TEST", 9, 18], ["T cell numbers", "TEST", 20, 34], ["virus specific IFN\u2010\u03b3", "TEST", 82, 102], ["CD4", "PROBLEM", 103, 106], ["T cells", "PROBLEM", 108, 115]]], ["(Fig. 2A), when virus control was initially apparent.", [["virus control", "TREATMENT", 16, 29]]], ["In addition, mean fluorescent intensity (MFI) of the IFN\u2010\u03b3 producing populations indicated CD4+ T cells from the CNS of IL\u201010\u2212/\u2212 mice produced more IFN\u2010\u03b3 at the cellular level (Fig. 2B).", [["CD4+ T cells", "ANATOMY", 91, 103], ["CNS", "ANATOMY", 113, 116], ["cellular", "ANATOMY", 161, 169], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 53, 58], ["CD4", "GENE_OR_GENE_PRODUCT", 91, 94], ["CNS", "ANATOMICAL_SYSTEM", 113, 116], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 120, 125], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 148, 153], ["cellular", "CELL", 161, 169], ["IFN\u2010\u03b3", "PROTEIN", 53, 58], ["CD4", "PROTEIN", 91, 94], ["T cells", "CELL_TYPE", 96, 103], ["IFN\u2010\u03b3", "PROTEIN", 148, 153], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["mean fluorescent intensity", "TEST", 13, 39], ["the IFN", "TEST", 49, 56], ["CD4+ T cells", "PROBLEM", 91, 103], ["CNS", "ANATOMY", 113, 116]]], ["To confirm that increased IFN\u2010\u03b3 was mainly attributable to CD4+ T cells, CD8+ T cells were also analyzed.", [["CD4+ T cells", "ANATOMY", 59, 71], ["CD8+ T cells", "ANATOMY", 73, 85], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 26, 31], ["CD4", "GENE_OR_GENE_PRODUCT", 59, 62], ["CD8", "GENE_OR_GENE_PRODUCT", 73, 76], ["IFN\u2010\u03b3", "PROTEIN", 26, 31], ["CD4", "PROTEIN", 59, 62], ["T cells", "CELL_TYPE", 64, 71], ["CD8+ T cells", "CELL_TYPE", 73, 85], ["increased IFN\u2010\u03b3", "PROBLEM", 16, 31], ["CD4+ T cells", "PROBLEM", 59, 71], ["CD8+ T cells", "PROBLEM", 73, 85], ["increased", "OBSERVATION_MODIFIER", 16, 25]]], ["Neither the number of virus specific CD8+ T cells detected by S510/H\u20102Db tetramer staining (Fig. 2C), the percentage of virus specific CD8+ T cells secreting IFN\u2010\u03b3, nor their relative MFI (data not shown) were altered in the absence of IL\u201010.", [["CD8+ T cells", "ANATOMY", 37, 49], ["CD8+ T cells", "ANATOMY", 135, 147], ["CD8", "GENE_OR_GENE_PRODUCT", 37, 40], ["H\u20102Db tetramer", "GENE_OR_GENE_PRODUCT", 67, 81], ["CD8", "GENE_OR_GENE_PRODUCT", 135, 138], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 158, 163], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 236, 241], ["virus specific CD8+ T cells", "CELL_TYPE", 22, 49], ["S510", "PROTEIN", 62, 66], ["virus specific CD8+ T cells", "CELL_TYPE", 120, 147], ["IFN\u2010\u03b3", "PROTEIN", 158, 163], ["MFI", "PROTEIN", 184, 187], ["IL\u201010", "PROTEIN", 236, 241], ["S510", "TEST", 62, 66], ["tetramer staining", "TEST", 73, 90], ["virus", "PROBLEM", 120, 125]]], ["Similarly, CD8+ T cell cytolytic activity, also contributing to virus control (Bergmann et al., 2004), was similar (Fig. 2D).", [["CD8+ T cell", "ANATOMY", 11, 22], ["CD8", "GENE_OR_GENE_PRODUCT", 11, 14], ["CD8", "PROTEIN", 11, 14], ["CD8", "TEST", 11, 14], ["T cell cytolytic activity", "PROBLEM", 16, 41], ["virus control", "TREATMENT", 64, 77], ["T cell cytolytic activity", "OBSERVATION", 16, 41]]], ["Overall, these data support the notion that IL\u201010 primarily inhibits control of infectious virus within the CNS by suppressing IFN\u2010\u03b3 secretion specifically by CD4+ T cells, albeit without affecting the level of viral persistence or CD8+ T cell function.IL\u201010 Limits Lesion Area ::: ResultsTo determine how the accelerated virus reduction influenced tissue damage, the extent of demyelination in spinal cords was quantified.", [["CNS", "ANATOMY", 108, 111], ["CD4+ T cells", "ANATOMY", 159, 171], ["T cell", "ANATOMY", 237, 243], ["tissue", "ANATOMY", 349, 355], ["spinal cords", "ANATOMY", 395, 407], ["demyelination", "DISEASE", 378, 391], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 44, 49], ["infectious virus", "ORGANISM", 80, 96], ["CNS", "ANATOMICAL_SYSTEM", 108, 111], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 127, 132], ["CD4", "GENE_OR_GENE_PRODUCT", 159, 162], ["CD8", "GENE_OR_GENE_PRODUCT", 232, 235], ["T cell", "CELL", 237, 243], ["IL", "GENE_OR_GENE_PRODUCT", 253, 255], ["tissue", "TISSUE", 349, 355], ["spinal cords", "ORGAN", 395, 407], ["IL\u201010", "PROTEIN", 44, 49], ["IFN", "PROTEIN", 127, 130], ["CD4", "PROTEIN", 159, 162], ["T cells", "CELL_TYPE", 164, 171], ["CD8", "PROTEIN", 232, 235], ["IL\u2010", "TREATMENT", 44, 47], ["infectious virus", "PROBLEM", 80, 96], ["suppressing IFN\u2010\u03b3 secretion", "PROBLEM", 115, 142], ["CD4+ T cells", "PROBLEM", 159, 171], ["viral persistence", "PROBLEM", 211, 228], ["the accelerated virus reduction", "TREATMENT", 306, 337], ["tissue damage", "PROBLEM", 349, 362], ["demyelination in spinal cords", "PROBLEM", 378, 407], ["infectious virus", "OBSERVATION", 80, 96], ["cell function", "OBSERVATION", 239, 252], ["virus", "OBSERVATION", 322, 327], ["extent", "OBSERVATION_MODIFIER", 368, 374], ["demyelination", "OBSERVATION", 378, 391], ["spinal cords", "ANATOMY", 395, 407]]], ["Because of the random distribution of focal lesions along the neuroaxis following JHMV infection, areas of demyelination were quantified in individual spinal cord sections representing six levels.", [["focal lesions", "ANATOMY", 38, 51], ["neuroaxis", "ANATOMY", 62, 71], ["spinal cord sections", "ANATOMY", 151, 171], ["infection", "DISEASE", 87, 96], ["demyelination", "DISEASE", 107, 120], ["focal lesions", "PATHOLOGICAL_FORMATION", 38, 51], ["neuroaxis", "CANCER", 62, 71], ["spinal cord sections", "MULTI-TISSUE_STRUCTURE", 151, 171], ["JHMV", "SPECIES", 82, 86], ["focal lesions", "PROBLEM", 38, 51], ["JHMV infection", "PROBLEM", 82, 96], ["demyelination", "PROBLEM", 107, 120], ["focal", "OBSERVATION_MODIFIER", 38, 43], ["lesions", "OBSERVATION", 44, 51], ["infection", "OBSERVATION", 87, 96], ["areas", "OBSERVATION_MODIFIER", 98, 103], ["demyelination", "OBSERVATION", 107, 120], ["spinal cord", "ANATOMY", 151, 162], ["six", "OBSERVATION_MODIFIER", 185, 188], ["levels", "OBSERVATION_MODIFIER", 189, 195]]], ["In WT mice demyelination affected \u223c8% of white matter by day 10 p.i. and then remained relatively constant (Fig. 3A).", [["white matter", "ANATOMY", 41, 53], ["demyelination", "DISEASE", 11, 24], ["WT mice", "ORGANISM", 3, 10], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["WT mice demyelination", "PROBLEM", 3, 24], ["demyelination", "OBSERVATION", 11, 24]]], ["By contrast, demyelination was reduced by \u223c50% at days 10 and 14 p.i. in IL\u201010\u2212/\u2212 relative to WT mice.", [["demyelination", "DISEASE", 13, 26], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 73, 78], ["\u2212", "GENE_OR_GENE_PRODUCT", 78, 79], ["\u2212", "GENE_OR_GENE_PRODUCT", 80, 81], ["WT mice", "ORGANISM", 94, 101], ["IL", "PROTEIN", 73, 75], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 97, 101], ["demyelination", "PROBLEM", 13, 26], ["demyelination", "OBSERVATION", 13, 26]]], ["However, by day 31 p.i. demyelination had increased to \u223c35% in the absence of IL\u201010 (Fig. 3A), representing a 3.5\u2010fold increase relative to WT mice.", [["demyelination", "DISEASE", 24, 37], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 78, 83], ["Fig. 3A", "GENE_OR_GENE_PRODUCT", 85, 92], ["mice", "ORGANISM", 143, 147], ["IL\u201010", "PROTEIN", 78, 83], ["mice", "SPECIES", 143, 147], ["mice", "SPECIES", 143, 147], ["p.i. demyelination", "TEST", 19, 37], ["a 3.5\u2010fold increase", "PROBLEM", 108, 127]]], ["Thus, despite ongoing viral control in the 2 week interval, damage to the white matter tracks could not be contained in the absence of IL\u201010.IL\u201010 Limits Lesion Area ::: ResultsThe absence of viral recrudescence in infected IL\u201010\u2212/\u2212 mice (Fig. 1) suggested that increased demyelination is independent of new foci initiated by sustained viral replication.", [["white matter", "ANATOMY", 74, 86], ["foci", "ANATOMY", 308, 312], ["viral recrudescence", "DISEASE", 192, 211], ["demyelination", "DISEASE", 272, 285], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 135, 140], ["IL", "GENE_OR_GENE_PRODUCT", 141, 143], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 224, 229], ["IL", "PROTEIN", 135, 137], ["mice", "SPECIES", 233, 237], ["mice", "SPECIES", 233, 237], ["ongoing viral control", "TREATMENT", 14, 35], ["damage to the white matter", "PROBLEM", 60, 86], ["viral recrudescence", "PROBLEM", 192, 211], ["infected IL\u2010", "TREATMENT", 215, 227], ["increased demyelination", "PROBLEM", 262, 285], ["new foci", "PROBLEM", 304, 312], ["sustained viral replication", "TREATMENT", 326, 353], ["increased", "OBSERVATION_MODIFIER", 262, 271], ["demyelination", "OBSERVATION", 272, 285], ["new", "OBSERVATION_MODIFIER", 304, 307], ["foci", "OBSERVATION", 308, 312], ["viral replication", "OBSERVATION", 336, 353]]], ["Therefore, lesion area was measured to distinguish increased numbers of foci from increased size of individual lesions.", [["lesion area", "ANATOMY", 11, 22], ["foci", "ANATOMY", 72, 76], ["lesions", "ANATOMY", 111, 118], ["lesion area", "CANCER", 11, 22], ["lesions", "PATHOLOGICAL_FORMATION", 111, 118], ["lesion area", "PROBLEM", 11, 22], ["increased numbers of foci", "PROBLEM", 51, 76], ["individual lesions", "PROBLEM", 100, 118], ["lesion", "OBSERVATION", 11, 17], ["increased", "OBSERVATION_MODIFIER", 51, 60], ["numbers", "OBSERVATION_MODIFIER", 61, 68], ["foci", "OBSERVATION", 72, 76], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["size", "OBSERVATION_MODIFIER", 92, 96], ["individual", "OBSERVATION_MODIFIER", 100, 110], ["lesions", "OBSERVATION", 111, 118]]], ["Lesion area within spinal cords of infected WT mice increased \u223c2\u2010fold between days 14 and 21 p.i. and then remained relatively stable (Fig. 3B).", [["Lesion area", "ANATOMY", 0, 11], ["spinal cords", "ANATOMY", 19, 31], ["Lesion area", "TISSUE", 0, 11], ["spinal cords", "ORGAN", 19, 31], ["WT mice", "ORGANISM", 44, 51], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51], ["Lesion area", "PROBLEM", 0, 11], ["spinal cords", "ANATOMY", 19, 31], ["infected", "OBSERVATION_MODIFIER", 35, 43], ["mice", "OBSERVATION_MODIFIER", 47, 51], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["relatively", "OBSERVATION_MODIFIER", 116, 126], ["stable", "OBSERVATION", 127, 133]]], ["Although lesion area in IL\u201010\u2212/\u2212 spinal cords was initially decreased relative to WT controls, it progressively increased in the absence of IL\u201010 (Fig. 3B).", [["lesion area", "ANATOMY", 9, 20], ["IL\u201010\u2212/\u2212 spinal cords", "ANATOMY", 24, 45], ["lesion area", "CANCER", 9, 20], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 24, 29], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 140, 145], ["IL", "PROTEIN", 140, 142], ["lesion area", "PROBLEM", 9, 20], ["IL", "TEST", 24, 26], ["lesion", "OBSERVATION", 9, 15], ["IL", "ANATOMY_MODIFIER", 24, 26], ["spinal cords", "ANATOMY", 33, 45], ["decreased", "OBSERVATION", 60, 69], ["progressively", "OBSERVATION_MODIFIER", 98, 111], ["increased", "OBSERVATION_MODIFIER", 112, 121]]], ["These data contrast with the focal demarcated and relatively stable lesion area in WT mice between days 21 and 31 p.i.", [["lesion area", "ANATOMY", 68, 79], ["lesion area", "TISSUE", 68, 79], ["mice", "ORGANISM", 86, 90], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["These data contrast", "TEST", 0, 19], ["the focal demarcated and relatively stable lesion area", "PROBLEM", 25, 79], ["focal", "OBSERVATION_MODIFIER", 29, 34], ["demarcated", "OBSERVATION_MODIFIER", 35, 45], ["relatively", "OBSERVATION_MODIFIER", 50, 60], ["stable", "OBSERVATION_MODIFIER", 61, 67], ["lesion", "OBSERVATION", 68, 74]]], ["Kinetic analysis of lesion area and percentage demyelination thus both revealed that increased demyelination in infected IL\u201010\u2212/\u2212 mice is initially preceded by less demyelination.", [["lesion area", "ANATOMY", 20, 31], ["demyelination", "DISEASE", 47, 60], ["demyelination", "DISEASE", 95, 108], ["demyelination", "DISEASE", 165, 178], ["lesion area", "CANCER", 20, 31], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 121, 126], ["mice", "SPECIES", 130, 134], ["Kinetic analysis", "TEST", 0, 16], ["lesion area", "PROBLEM", 20, 31], ["percentage demyelination", "PROBLEM", 36, 60], ["increased demyelination", "PROBLEM", 85, 108], ["infected IL\u2010", "TREATMENT", 112, 124], ["less demyelination", "PROBLEM", 160, 178], ["lesion", "OBSERVATION", 20, 26], ["percentage", "OBSERVATION_MODIFIER", 36, 46], ["demyelination", "OBSERVATION", 47, 60], ["increased", "OBSERVATION_MODIFIER", 85, 94], ["demyelination", "OBSERVATION", 95, 108], ["infected", "OBSERVATION_MODIFIER", 112, 120], ["IL", "OBSERVATION_MODIFIER", 121, 123], ["less", "OBSERVATION_MODIFIER", 160, 164], ["demyelination", "OBSERVATION", 165, 178]]], ["Progressively expanding demyelination in the absence of IL\u201010 demonstrates a critical role of IL\u201010 in constraining lesion area.IL\u201010 Limits Lesion Area ::: ResultsMorphological differences in focal versus expanding lesions were examined in Epon embedded sections at day 31 p.i.", [["lesion area", "ANATOMY", 116, 127], ["focal", "ANATOMY", 193, 198], ["lesions", "ANATOMY", 216, 223], ["sections", "ANATOMY", 255, 263], ["demyelination", "DISEASE", 24, 37], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 56, 61], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 94, 99], ["lesion area", "CANCER", 116, 127], ["IL", "GENE_OR_GENE_PRODUCT", 128, 130], ["lesions", "CANCER", 216, 223], ["IL\u201010", "PROTEIN", 56, 61], ["IL\u201010", "PROTEIN", 94, 99], ["Progressively expanding demyelination", "PROBLEM", 0, 37], ["ResultsMorphological differences in focal versus expanding lesions", "PROBLEM", 157, 223], ["expanding", "OBSERVATION_MODIFIER", 14, 23], ["demyelination", "OBSERVATION", 24, 37], ["lesion", "OBSERVATION", 116, 122], ["focal", "OBSERVATION_MODIFIER", 193, 198], ["expanding", "OBSERVATION_MODIFIER", 206, 215], ["lesions", "OBSERVATION", 216, 223]]], ["Demyelination was confined to relatively small areas at the outer perimeter of the WT spinal cord (Fig. 3C).", [["outer perimeter", "ANATOMY", 60, 75], ["WT spinal cord", "ANATOMY", 83, 97], ["Demyelination", "DISEASE", 0, 13], ["spinal cord", "ORGAN", 86, 97], ["Demyelination", "PROBLEM", 0, 13], ["relatively", "OBSERVATION_MODIFIER", 30, 40], ["small", "OBSERVATION_MODIFIER", 41, 46], ["areas", "OBSERVATION", 47, 52], ["outer", "ANATOMY_MODIFIER", 60, 65], ["perimeter", "ANATOMY_MODIFIER", 66, 75], ["WT", "ANATOMY_MODIFIER", 83, 85], ["spinal cord", "ANATOMY", 86, 97]]], ["Debris filled macrophage/microglia were not prominent in these areas, indicating sparse active demyelination.", [["macrophage", "ANATOMY", 14, 24], ["microglia", "ANATOMY", 25, 34], ["demyelination", "DISEASE", 95, 108], ["macrophage", "CELL", 14, 24], ["microglia", "CELL", 25, 34], ["macrophage", "CELL_TYPE", 14, 24], ["microglia", "CELL_TYPE", 25, 34], ["Debris filled macrophage/microglia", "PROBLEM", 0, 34], ["sparse active demyelination", "PROBLEM", 81, 108], ["filled macrophage", "OBSERVATION", 7, 24], ["microglia", "ANATOMY", 25, 34], ["not", "UNCERTAINTY", 40, 43], ["prominent", "OBSERVATION_MODIFIER", 44, 53], ["indicating", "UNCERTAINTY", 70, 80], ["sparse", "OBSERVATION_MODIFIER", 81, 87], ["active", "OBSERVATION_MODIFIER", 88, 94], ["demyelination", "OBSERVATION", 95, 108]]], ["Consistent with the lesion area determinations, demyelinated lesions were significantly larger in spinal cords from infected IL\u201010\u2212/\u2212 mice (Fig. 3D).", [["lesion area", "ANATOMY", 20, 31], ["demyelinated lesions", "ANATOMY", 48, 68], ["spinal cords", "ANATOMY", 98, 110], ["demyelinated lesions", "PATHOLOGICAL_FORMATION", 48, 68], ["spinal cords", "ORGAN", 98, 110], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 125, 130], ["mice", "SPECIES", 134, 138], ["the lesion area determinations", "PROBLEM", 16, 46], ["demyelinated lesions", "PROBLEM", 48, 68], ["significantly larger in spinal cords", "PROBLEM", 74, 110], ["infected IL\u2010", "TREATMENT", 116, 128], ["lesion", "OBSERVATION", 20, 26], ["demyelinated", "OBSERVATION_MODIFIER", 48, 60], ["lesions", "OBSERVATION", 61, 68], ["significantly", "OBSERVATION_MODIFIER", 74, 87], ["larger", "OBSERVATION_MODIFIER", 88, 94], ["spinal cords", "ANATOMY", 98, 110], ["infected", "OBSERVATION_MODIFIER", 116, 124], ["IL", "OBSERVATION_MODIFIER", 125, 127]]], ["Moreover, the presence of phagocytic macrophage/microglia at the outer perimeter of the lesions (Fig. 3D, arrowheads) supported ongoing active demyelination, spreading from the perimeter toward the center of the spinal cord.", [["phagocytic macrophage", "ANATOMY", 26, 47], ["microglia", "ANATOMY", 48, 57], ["outer perimeter", "ANATOMY", 65, 80], ["lesions", "ANATOMY", 88, 95], ["spinal cord", "ANATOMY", 212, 223], ["demyelination", "DISEASE", 143, 156], ["phagocytic macrophage", "CELL", 26, 47], ["microglia", "CELL", 48, 57], ["lesions", "PATHOLOGICAL_FORMATION", 88, 95], ["spinal cord", "ORGAN", 212, 223], ["phagocytic macrophage", "CELL_TYPE", 26, 47], ["microglia", "CELL_TYPE", 48, 57], ["phagocytic macrophage/microglia", "PROBLEM", 26, 57], ["the lesions", "PROBLEM", 84, 95], ["ongoing active demyelination", "PROBLEM", 128, 156], ["phagocytic macrophage", "OBSERVATION", 26, 47], ["microglia", "OBSERVATION", 48, 57], ["outer", "OBSERVATION_MODIFIER", 65, 70], ["perimeter", "OBSERVATION_MODIFIER", 71, 80], ["lesions", "OBSERVATION", 88, 95], ["active", "OBSERVATION_MODIFIER", 136, 142], ["demyelination", "OBSERVATION", 143, 156], ["perimeter", "OBSERVATION_MODIFIER", 177, 186], ["center", "ANATOMY_MODIFIER", 198, 204], ["spinal cord", "ANATOMY", 212, 223]]], ["In addition, the numbers of demyelinated axons were significantly increased in the IL\u201010\u2212/\u2212 spinal cords.Demyelination is Independent of Sustained T Cell Activation ::: ResultsBystander damage due to uncontrolled and/or sustained T cell activation can contribute to pathology during viral infections of lung, mucosal sites as well as the CNS (Lund et al., 2008; Phares et al., 2010; Richards et al., 2011; Sun et al., 2011, 2009).", [["demyelinated axons", "ANATOMY", 28, 46], ["IL\u201010\u2212/\u2212 spinal cords", "ANATOMY", 83, 104], ["Cell", "ANATOMY", 149, 153], ["T cell", "ANATOMY", 230, 236], ["lung", "ANATOMY", 303, 307], ["mucosal sites", "ANATOMY", 309, 322], ["CNS", "ANATOMY", 338, 341], ["Demyelination", "DISEASE", 105, 118], ["ResultsBystander damage", "DISEASE", 169, 192], ["viral infections", "DISEASE", 283, 299], ["axons", "MULTI-TISSUE_STRUCTURE", 41, 46], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 83, 88], ["T Cell", "CELL", 147, 153], ["T cell", "CELL", 230, 236], ["lung", "ORGAN", 303, 307], ["mucosal sites", "MULTI-TISSUE_STRUCTURE", 309, 322], ["CNS", "ANATOMICAL_SYSTEM", 338, 341], ["demyelinated axons", "PROBLEM", 28, 46], ["Demyelination", "PROBLEM", 105, 118], ["ResultsBystander damage", "PROBLEM", 169, 192], ["sustained T cell activation", "PROBLEM", 220, 247], ["pathology during viral infections of lung, mucosal sites", "PROBLEM", 266, 322], ["demyelinated", "OBSERVATION_MODIFIER", 28, 40], ["axons", "OBSERVATION_MODIFIER", 41, 46], ["significantly", "OBSERVATION_MODIFIER", 52, 65], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["spinal cords", "ANATOMY", 92, 104], ["viral", "OBSERVATION_MODIFIER", 283, 288], ["infections", "OBSERVATION", 289, 299], ["lung", "ANATOMY", 303, 307], ["mucosal", "ANATOMY", 309, 316], ["CNS", "ANATOMY", 338, 341]]], ["However, there was no evidence for either altered recruitment of inflammatory cells into the brain (Fig. 1G) or mononuclear cells adjacent to, or within, demyelinating lesions in WT or IL\u201010\u2212/\u2212 mice by histological examination (Fig. 1D,E).", [["inflammatory cells", "ANATOMY", 65, 83], ["brain", "ANATOMY", 93, 98], ["mononuclear cells", "ANATOMY", 112, 129], ["lesions", "ANATOMY", 168, 175], ["demyelinating lesions", "DISEASE", 154, 175], ["inflammatory cells", "CELL", 65, 83], ["brain", "ORGAN", 93, 98], ["1G", "CELL", 105, 107], ["mononuclear cells", "CELL", 112, 129], ["demyelinating lesions", "CANCER", 154, 175], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 185, 190], ["inflammatory cells", "CELL_TYPE", 65, 83], ["mononuclear cells", "CELL_TYPE", 112, 129], ["mice", "SPECIES", 194, 198], ["mice", "SPECIES", 194, 198], ["inflammatory cells into the brain", "PROBLEM", 65, 98], ["mononuclear cells", "PROBLEM", 112, 129], ["demyelinating lesions", "PROBLEM", 154, 175], ["histological examination", "TEST", 202, 226], ["no evidence for", "UNCERTAINTY", 19, 34], ["altered", "OBSERVATION_MODIFIER", 42, 49], ["recruitment", "OBSERVATION", 50, 61], ["inflammatory cells", "OBSERVATION", 65, 83], ["brain", "ANATOMY", 93, 98], ["Fig", "OBSERVATION_MODIFIER", 100, 103], ["mononuclear cells", "OBSERVATION", 112, 129], ["demyelinating", "OBSERVATION_MODIFIER", 154, 167], ["lesions", "OBSERVATION", 168, 175]]], ["Irrespective of similar T cell recruitment into the brain (Fig. 2), we also compared the composition and frequency of T cells within spinal cords of infected WT and IL\u201010\u2212/\u2212 mice to exclude the possibility that sustained inflammation contributed to increasing lesion area.", [["T cell", "ANATOMY", 24, 30], ["brain", "ANATOMY", 52, 57], ["T cells", "ANATOMY", 118, 125], ["spinal cords", "ANATOMY", 133, 145], ["lesion area", "ANATOMY", 260, 271], ["inflammation", "DISEASE", 221, 233], ["T cell", "CELL", 24, 30], ["brain", "ORGAN", 52, 57], ["T cells", "CELL", 118, 125], ["spinal cords", "ORGAN", 133, 145], ["IL", "GENE_OR_GENE_PRODUCT", 165, 167], ["10\u2212", "GENE_OR_GENE_PRODUCT", 168, 171], ["T cells", "CELL_TYPE", 118, 125], ["mice", "SPECIES", 174, 178], ["mice", "SPECIES", 174, 178], ["similar T cell recruitment", "TREATMENT", 16, 42], ["T cells", "PROBLEM", 118, 125], ["sustained inflammation", "PROBLEM", 211, 233], ["increasing lesion area", "PROBLEM", 249, 271], ["similar", "OBSERVATION_MODIFIER", 16, 23], ["T cell recruitment", "OBSERVATION", 24, 42], ["brain", "ANATOMY", 52, 57], ["spinal cords", "ANATOMY", 133, 145], ["sustained", "OBSERVATION_MODIFIER", 211, 220], ["inflammation", "OBSERVATION", 221, 233], ["increasing", "OBSERVATION_MODIFIER", 249, 259], ["lesion", "OBSERVATION", 260, 266]]], ["CD4+ T cells accumulated to similar maximal numbers between days 10 and 14 p.i.", [["CD4+ T cells", "ANATOMY", 0, 12], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 5, 12], ["CD4", "TEST", 0, 3], ["T cells", "PROBLEM", 5, 12], ["T cells", "OBSERVATION", 5, 12], ["similar", "OBSERVATION_MODIFIER", 28, 35], ["maximal", "OBSERVATION_MODIFIER", 36, 43], ["numbers", "OBSERVATION_MODIFIER", 44, 51]]], ["Virus specific CD8+ T cells in spinal cords accumulated between days 14 and 21 p.i.", [["T cells", "ANATOMY", 20, 27], ["spinal cords", "ANATOMY", 31, 43], ["Virus", "ORGANISM", 0, 5], ["CD8", "GENE_OR_GENE_PRODUCT", 15, 18], ["T cells", "CELL", 20, 27], ["spinal cords", "ORGAN", 31, 43], ["CD8", "PROTEIN", 15, 18], ["T cells", "CELL_TYPE", 20, 27], ["T cells in spinal cords", "PROBLEM", 20, 43], ["CD8", "OBSERVATION", 15, 18], ["spinal cords", "ANATOMY", 31, 43]]], ["(Fig. 4B) reflecting similar, but preferential recruitment/retention at the site of viral persistence relative to brain.", [["brain", "ANATOMY", 114, 119], ["brain", "ORGAN", 114, 119], ["preferential recruitment/retention", "PROBLEM", 34, 68], ["viral persistence", "PROBLEM", 84, 101], ["similar", "OBSERVATION_MODIFIER", 21, 28], ["preferential", "OBSERVATION_MODIFIER", 34, 46], ["recruitment", "OBSERVATION", 47, 58], ["retention", "OBSERVATION_MODIFIER", 59, 68], ["viral persistence", "OBSERVATION", 84, 101], ["brain", "ANATOMY", 114, 119]]], ["Similar to CD4+ T cells there was no evidence of sustained CD8+ T cell activation in spinal cords.", [["CD4+", "ANATOMY", 11, 15], ["T cells", "ANATOMY", 16, 23], ["T cell", "ANATOMY", 64, 70], ["spinal cords", "ANATOMY", 85, 97], ["CD4", "GENE_OR_GENE_PRODUCT", 11, 14], ["T cells", "CELL", 16, 23], ["CD8", "GENE_OR_GENE_PRODUCT", 59, 62], ["T cell", "CELL", 64, 70], ["spinal cords", "ORGAN", 85, 97], ["CD4", "PROTEIN", 11, 14], ["T cells", "CELL_TYPE", 16, 23], ["CD8", "PROTEIN", 59, 62], ["T cells", "TEST", 16, 23], ["T cell activation in spinal cords", "PROBLEM", 64, 97], ["CD4", "OBSERVATION", 11, 14], ["no evidence of", "UNCERTAINTY", 34, 48], ["sustained", "OBSERVATION_MODIFIER", 49, 58], ["CD8", "OBSERVATION", 59, 62], ["cell activation", "OBSERVATION", 66, 81], ["spinal cords", "ANATOMY", 85, 97]]], ["IFN\u2010\u03b3 mRNA expression was maximal at day 7 p.i. and \u223c5\u2010fold higher in the absence of IL\u201010 (Fig. 4C), but declined to minimal detectable levels by day 21 p.i. in both groups.", [["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 85, 90], ["IFN\u2010\u03b3 mRNA", "RNA", 0, 10]]], ["These data indicated that lesion expansion in the absence of IL\u201010 is independent of persisting virus levels or sustained T cell activity.IL\u201010 Regulates Microglia/Macrophage Phenotype ::: ResultsLesions in both WT and IL\u201010\u2212/\u2212 groups were surrounded by microglia/macrophages with rounded cell bodies and withdrawn processes (Fig. 6), indicative of sustained activation.", [["lesion", "ANATOMY", 26, 32], ["T cell", "ANATOMY", 122, 128], ["Microglia", "ANATOMY", 154, 163], ["Macrophage", "ANATOMY", 164, 174], ["microglia", "ANATOMY", 254, 263], ["macrophages", "ANATOMY", 264, 275], ["cell bodies", "ANATOMY", 289, 300], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 61, 66], ["T cell", "CELL", 122, 128], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 138, 143], ["Microglia", "CELL", 154, 163], ["Macrophage", "CELL", 164, 174], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 219, 224], ["microglia", "CELL", 254, 263], ["macrophages", "CELL", 264, 275], ["cell bodies", "CELL", 289, 300], ["IL\u201010", "PROTEIN", 61, 66], ["IL\u201010", "PROTEIN", 138, 143], ["Microglia", "CELL_TYPE", 154, 163], ["microglia", "CELL_TYPE", 254, 263], ["macrophages", "CELL_TYPE", 264, 275], ["These data", "TEST", 0, 10], ["lesion expansion", "PROBLEM", 26, 42], ["persisting virus levels", "PROBLEM", 85, 108], ["sustained T cell activity", "PROBLEM", 112, 137], ["Microglia", "TEST", 154, 163], ["Phenotype", "TEST", 175, 184], ["ResultsLesions", "TEST", 189, 203], ["WT", "TEST", 212, 214], ["IL", "TEST", 219, 221], ["microglia/macrophages", "TEST", 254, 275], ["rounded cell bodies", "PROBLEM", 281, 300], ["sustained activation", "PROBLEM", 349, 369], ["lesion", "OBSERVATION", 26, 32], ["expansion", "OBSERVATION_MODIFIER", 33, 42], ["T cell activity", "OBSERVATION", 122, 137], ["macrophages", "ANATOMY", 264, 275], ["rounded cell bodies", "OBSERVATION", 281, 300], ["indicative of", "UNCERTAINTY", 335, 348], ["sustained activation", "OBSERVATION", 349, 369]]], ["Although IL\u201010 is associated with an acquired deactivation phenotype (Mosser and Edwards, 2008), neither the relative expression of genes associated with repair following viral induced demyelination, nor the influence of IL\u201010 on these genes are well defined.", [["demyelination", "DISEASE", 185, 198], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 9, 14], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 221, 226], ["IL\u201010", "PROTEIN", 9, 14], ["IL\u201010", "PROTEIN", 221, 226], ["an acquired deactivation phenotype", "PROBLEM", 34, 68], ["repair", "TREATMENT", 154, 160], ["viral induced demyelination", "PROBLEM", 171, 198], ["deactivation phenotype", "OBSERVATION", 46, 68], ["viral induced", "OBSERVATION_MODIFIER", 171, 184], ["demyelination", "OBSERVATION", 185, 198]]], ["To examine the influence of IL\u201010 on promoting a deactivation phenotype, we compared expression of CD206/mannose receptor associated with induction of deactivated macrophages (Martinez\u2010Pomares, 2012).", [["macrophages", "ANATOMY", 163, 174], ["mannose", "CHEMICAL", 105, 112], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 28, 33], ["CD206", "GENE_OR_GENE_PRODUCT", 99, 104], ["mannose receptor", "GENE_OR_GENE_PRODUCT", 105, 121], ["macrophages", "CELL", 163, 174], ["IL\u201010", "PROTEIN", 28, 33], ["CD206", "PROTEIN", 99, 104], ["mannose receptor", "PROTEIN", 105, 121], ["deactivated macrophages", "CELL_TYPE", 151, 174], ["a deactivation phenotype", "PROBLEM", 47, 71], ["CD206/mannose receptor", "TREATMENT", 99, 121], ["deactivated macrophages", "PROBLEM", 151, 174]]], ["CD206 expressing cells were initially present in the lesions of WT mice; however, their number declined as inflammation declined and lesion size stabilized.", [["cells", "ANATOMY", 17, 22], ["lesions", "ANATOMY", 53, 60], ["lesion", "ANATOMY", 133, 139], ["inflammation", "DISEASE", 107, 119], ["CD206", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 17, 22], ["lesions", "PATHOLOGICAL_FORMATION", 53, 60], ["mice", "ORGANISM", 67, 71], ["CD206 expressing cells", "CELL_LINE", 0, 22], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 67, 71], ["CD206 expressing cells", "PROBLEM", 0, 22], ["inflammation", "PROBLEM", 107, 119], ["lesion size", "PROBLEM", 133, 144], ["lesions", "OBSERVATION", 53, 60], ["inflammation", "OBSERVATION", 107, 119], ["lesion", "OBSERVATION_MODIFIER", 133, 139], ["size", "OBSERVATION_MODIFIER", 140, 144]]], ["Interestingly, CD206+ cell numbers associated with lesions were increased in IL\u201010\u2212/\u2212 relative to WT mice at day 14 p.i.", [["CD206+ cell", "ANATOMY", 15, 26], ["lesions", "ANATOMY", 51, 58], ["CD206+ cell", "CELL", 15, 26], ["lesions", "PATHOLOGICAL_FORMATION", 51, 58], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 77, 82], ["\u2212", "GENE_OR_GENE_PRODUCT", 84, 85], ["mice", "ORGANISM", 101, 105], ["CD206", "PROTEIN", 15, 20], ["IL", "PROTEIN", 77, 79], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["cell numbers", "TEST", 22, 34], ["lesions", "PROBLEM", 51, 58], ["cell numbers", "OBSERVATION", 22, 34], ["lesions", "OBSERVATION", 51, 58], ["increased", "OBSERVATION_MODIFIER", 64, 73]]], ["(Fig. 5A\u2013C), suggesting IL\u201010 independent CD206 induction.", [["IL\u201010", "GENE_OR_GENE_PRODUCT", 24, 29], ["CD206", "GENE_OR_GENE_PRODUCT", 42, 47], ["CD206", "PROTEIN", 42, 47]]], ["Subsequently however, CD206+ cells declined in both groups to below the level of detection (Fig. 5C).", [["CD206+ cells", "ANATOMY", 22, 34], ["CD206+ cells", "CELL", 22, 34], ["CD206", "PROTEIN", 22, 27], ["CD206+ cells", "PROBLEM", 22, 34]]], ["Loss of the CD206+ deactivation phenotype was thus not a marker for exacerbated tissue destruction in the absence of IL\u201010.", [["tissue", "ANATOMY", 80, 86], ["CD206", "GENE_OR_GENE_PRODUCT", 12, 17], ["tissue", "TISSUE", 80, 86], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 117, 122], ["CD206", "PROTEIN", 12, 17], ["IL\u201010", "PROTEIN", 117, 122], ["deactivation phenotype", "PROBLEM", 19, 41], ["exacerbated tissue destruction", "PROBLEM", 68, 98], ["destruction", "OBSERVATION", 87, 98]]], ["Analysis of additional genes associated with the transitional decrease in activation showed that IL\u20101Ran mRNA expression in spinal cords was initially higher in IL10\u2212/\u2212 as compared to WT mice but subsequently declined in both groups (Fig. 5D) with a more pronounced drop apparent in IL\u201010\u2212/\u2212 mice.", [["spinal cords", "ANATOMY", 124, 136], ["IL\u20101Ran", "GENE_OR_GENE_PRODUCT", 97, 104], ["spinal cords", "ORGAN", 124, 136], ["IL10", "GENE_OR_GENE_PRODUCT", 161, 165], ["WT mice", "ORGANISM", 184, 191], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 283, 288], ["IL\u20101Ran mRNA", "RNA", 97, 109], ["IL10", "PROTEIN", 161, 165], ["IL", "PROTEIN", 283, 285], ["mice", "SPECIES", 187, 191], ["mice", "SPECIES", 292, 296], ["mice", "SPECIES", 187, 191], ["additional genes", "PROBLEM", 12, 28], ["the transitional decrease in activation", "PROBLEM", 45, 84], ["IL\u2010", "TREATMENT", 97, 100], ["mRNA expression in spinal cords", "PROBLEM", 105, 136], ["a more pronounced drop", "PROBLEM", 248, 270], ["spinal cords", "ANATOMY", 124, 136], ["higher", "OBSERVATION_MODIFIER", 151, 157]]], ["Arg\u20101 mRNA expression, initially reduced in the absence of IL\u201010, declined similarly with time p.i., approaching na\u00efve levels by day 31 p.i.", [["Arg\u20101", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 59, 64], ["IL\u201010", "PROTEIN", 59, 64], ["mRNA expression", "OBSERVATION", 6, 21], ["reduced", "OBSERVATION_MODIFIER", 33, 40]]], ["Additional markers of anti\u2010inflammatory activation, i.e., Fizz1 and Ym1/2, were expressed at similar levels in the spinal cords of IL\u201010\u2212/\u2212 and WT mice (data not shown).", [["spinal cords", "ANATOMY", 115, 127], ["Fizz1", "GENE_OR_GENE_PRODUCT", 58, 63], ["Ym1/2", "GENE_OR_GENE_PRODUCT", 68, 73], ["spinal cords", "ORGAN", 115, 127], ["IL", "GENE_OR_GENE_PRODUCT", 131, 133], ["10", "GENE_OR_GENE_PRODUCT", 134, 136], ["\u2212", "GENE_OR_GENE_PRODUCT", 138, 139], ["Fizz1", "PROTEIN", 58, 63], ["Ym1", "PROTEIN", 68, 71], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 147, 151], ["anti\u2010inflammatory activation", "PROBLEM", 22, 50], ["anti\u2010inflammatory activation", "OBSERVATION", 22, 50], ["spinal cords", "ANATOMY", 115, 127]]], ["Despite similar inflammation and morphological evidence of microglia/macrophage activation (Fig. 1 and 2), initially reduced demyelination in IL\u201010\u2212/\u2212 mice thus correlated with microglia/macrophages expressing an acquired deactivation phenotype, which was progressively lost, irrespective of lesion stability.IL\u201010 Regulates Microglia/Macrophage Phenotype ::: ResultsExpression of iNOS and MHC class II were examined to determine if increasing demyelination in the absence of IL\u201010 was associated with sustained microglial/macrophage activation.", [["microglia", "ANATOMY", 59, 68], ["macrophage", "ANATOMY", 69, 79], ["microglia", "ANATOMY", 177, 186], ["macrophages", "ANATOMY", 187, 198], ["lesion", "ANATOMY", 292, 298], ["Microglia", "ANATOMY", 325, 334], ["Macrophage", "ANATOMY", 335, 345], ["microglial", "ANATOMY", 512, 522], ["macrophage", "ANATOMY", 523, 533], ["inflammation", "DISEASE", 16, 28], ["demyelination", "DISEASE", 125, 138], ["demyelination", "DISEASE", 444, 457], ["microglia", "CELL", 59, 68], ["macrophage", "CELL", 69, 79], ["IL\u201010\u2212", "GENE_OR_GENE_PRODUCT", 142, 148], ["microglia", "CELL", 177, 186], ["macrophages", "CELL", 187, 198], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 309, 314], ["Microglia", "CELL", 325, 334], ["Macrophage", "CELL", 335, 345], ["iNOS", "GENE_OR_GENE_PRODUCT", 381, 385], ["MHC class II", "GENE_OR_GENE_PRODUCT", 390, 402], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 476, 481], ["microglial", "CELL", 512, 522], ["macrophage", "CELL", 523, 533], ["microglia", "CELL_TYPE", 59, 68], ["microglia", "CELL_TYPE", 177, 186], ["macrophages", "CELL_TYPE", 187, 198], ["IL\u201010", "PROTEIN", 309, 314], ["Microglia", "CELL_TYPE", 325, 334], ["iNOS", "PROTEIN", 381, 385], ["MHC class II", "PROTEIN", 390, 402], ["IL\u201010", "PROTEIN", 476, 481], ["mice", "SPECIES", 151, 155], ["mice", "SPECIES", 151, 155], ["similar inflammation", "PROBLEM", 8, 28], ["microglia/macrophage activation", "PROBLEM", 59, 90], ["reduced demyelination", "PROBLEM", 117, 138], ["microglia/macrophages", "PROBLEM", 177, 198], ["an acquired deactivation phenotype", "PROBLEM", 210, 244], ["lesion stability", "PROBLEM", 292, 308], ["iNOS", "PROBLEM", 381, 385], ["increasing demyelination", "PROBLEM", 433, 457], ["sustained microglial/macrophage activation", "PROBLEM", 502, 544], ["inflammation", "OBSERVATION", 16, 28], ["evidence of", "UNCERTAINTY", 47, 58], ["microglia", "OBSERVATION", 59, 68], ["macrophage activation", "OBSERVATION", 69, 90], ["reduced", "OBSERVATION_MODIFIER", 117, 124], ["demyelination", "OBSERVATION", 125, 138], ["deactivation phenotype", "OBSERVATION", 222, 244], ["lesion", "OBSERVATION", 292, 298], ["stability", "OBSERVATION_MODIFIER", 299, 308], ["increasing", "OBSERVATION_MODIFIER", 433, 443], ["demyelination", "OBSERVATION", 444, 457], ["macrophage activation", "OBSERVATION", 523, 544]]], ["Consistent with stable foci of demyelination, few microglia/macrophages and <10% of astrocytes in the lesions of WT mice expressed iNOS (Fig. 6A\u2013C, G) By contrast, \u223c40% of Iba1+cells associated with lesions in IL\u201010\u2212/\u2212 mice expressed iNOS (Fig. 6D\u2013F, G), while iNOS+ astrocytes were similar to WT mice.", [["foci", "ANATOMY", 23, 27], ["microglia", "ANATOMY", 50, 59], ["macrophages", "ANATOMY", 60, 71], ["astrocytes", "ANATOMY", 84, 94], ["lesions", "ANATOMY", 102, 109], ["Iba1+cells", "ANATOMY", 172, 182], ["lesions", "ANATOMY", 199, 206], ["iNOS+ astrocytes", "ANATOMY", 261, 277], ["demyelination", "DISEASE", 31, 44], ["microglia", "CELL", 50, 59], ["macrophages", "CELL", 60, 71], ["astrocytes", "CELL", 84, 94], ["lesions", "PATHOLOGICAL_FORMATION", 102, 109], ["mice", "ORGANISM", 116, 120], ["iNOS", "GENE_OR_GENE_PRODUCT", 131, 135], ["Iba1", "GENE_OR_GENE_PRODUCT", 172, 176], ["lesions", "PATHOLOGICAL_FORMATION", 199, 206], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 210, 215], ["iNOS", "GENE_OR_GENE_PRODUCT", 234, 238], ["Fig. 6D\u2013F, G)", "GENE_OR_GENE_PRODUCT", 240, 253], ["iNOS", "GENE_OR_GENE_PRODUCT", 261, 265], ["astrocytes", "CELL", 267, 277], ["mice", "ORGANISM", 297, 301], ["microglia", "CELL_TYPE", 50, 59], ["macrophages", "CELL_TYPE", 60, 71], ["astrocytes", "CELL_TYPE", 84, 94], ["iNOS", "PROTEIN", 131, 135], ["Iba1", "PROTEIN", 172, 176], ["iNOS", "PROTEIN", 234, 238], ["Fig. 6D\u2013F, G)", "PROTEIN", 240, 253], ["iNOS", "PROTEIN", 261, 265], ["astrocytes", "CELL_TYPE", 267, 277], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 219, 223], ["mice", "SPECIES", 297, 301], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 219, 223], ["mice", "SPECIES", 297, 301], ["demyelination", "PROBLEM", 31, 44], ["few microglia/macrophages", "PROBLEM", 46, 71], ["Iba1+cells", "PROBLEM", 172, 182], ["lesions", "PROBLEM", 199, 206], ["IL", "TEST", 210, 212], ["iNOS", "TEST", 234, 238], ["astrocytes", "PROBLEM", 267, 277], ["stable", "OBSERVATION_MODIFIER", 16, 22], ["foci", "OBSERVATION", 23, 27], ["demyelination", "OBSERVATION", 31, 44], ["few", "OBSERVATION_MODIFIER", 46, 49], ["microglia", "OBSERVATION_MODIFIER", 50, 59], ["macrophages", "ANATOMY", 60, 71], ["lesions", "OBSERVATION", 102, 109], ["iNOS", "OBSERVATION_MODIFIER", 131, 135], ["lesions", "OBSERVATION", 199, 206]]], ["These data are consistent with retention of activated Iba1+ cells during lesion expansion.", [["Iba1+ cells", "ANATOMY", 54, 65], ["lesion", "ANATOMY", 73, 79], ["Iba1", "GENE_OR_GENE_PRODUCT", 54, 58], ["Iba1", "PROTEIN", 54, 58], ["These data", "TEST", 0, 10], ["activated Iba1+ cells", "PROBLEM", 44, 65], ["lesion expansion", "PROBLEM", 73, 89], ["consistent with", "UNCERTAINTY", 15, 30], ["Iba1+ cells", "OBSERVATION", 54, 65], ["lesion", "OBSERVATION_MODIFIER", 73, 79], ["expansion", "OBSERVATION_MODIFIER", 80, 89]]], ["Iba1+ cells distal to the lesions did not express iNOS in either WT or IL\u201010\u2212/\u2212 mice (data not shown).", [["Iba1+ cells", "ANATOMY", 0, 11], ["lesions", "ANATOMY", 26, 33], ["Iba1", "GENE_OR_GENE_PRODUCT", 0, 4], ["lesions", "PATHOLOGICAL_FORMATION", 26, 33], ["iNOS", "GENE_OR_GENE_PRODUCT", 50, 54], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 71, 76], ["Iba1", "PROTEIN", 0, 4], ["iNOS", "PROTEIN", 50, 54], ["mice", "SPECIES", 80, 84], ["the lesions", "PROBLEM", 22, 33], ["cells", "OBSERVATION_MODIFIER", 6, 11], ["distal", "OBSERVATION_MODIFIER", 12, 18], ["lesions", "OBSERVATION", 26, 33], ["iNOS", "OBSERVATION", 50, 54]]], ["Similarly, while few MHC class II+Iba1+ cells were associated with focal lesions in WT mice (Fig. 6H\u2013J, N), the majority of lesion associated Iba1+ cells in IL\u201010\u2212/\u2212 mice expressed MHC class II (Fig. 6K\u2013M, N).", [["MHC class II+Iba1+ cells", "ANATOMY", 21, 45], ["focal lesions", "ANATOMY", 67, 80], ["lesion", "ANATOMY", 124, 130], ["Iba1+ cells", "ANATOMY", 142, 153], ["Iba1", "GENE_OR_GENE_PRODUCT", 34, 38], ["focal lesions", "PATHOLOGICAL_FORMATION", 67, 80], ["mice", "ORGANISM", 87, 91], ["Iba1", "GENE_OR_GENE_PRODUCT", 142, 146], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 157, 162], ["MHC class II", "GENE_OR_GENE_PRODUCT", 181, 193], ["MHC class II", "PROTEIN", 21, 33], ["Iba1", "PROTEIN", 34, 38], ["Iba1", "PROTEIN", 142, 146], ["MHC class II", "PROTEIN", 181, 193], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 166, 170], ["Iba1+ cells", "PROBLEM", 34, 45], ["focal lesions", "PROBLEM", 67, 80], ["lesion", "PROBLEM", 124, 130], ["IL", "TEST", 157, 159], ["Iba1+ cells", "OBSERVATION", 34, 45], ["focal", "OBSERVATION_MODIFIER", 67, 72], ["lesions", "OBSERVATION", 73, 80], ["WT mice", "OBSERVATION_MODIFIER", 84, 91], ["lesion", "OBSERVATION", 124, 130], ["Iba1+ cells", "OBSERVATION", 142, 153]]], ["By contrast, MHC class II+Iba1+ cells were not present in areas of normal white matter or within the adjoining gray matter in either group (data not shown).", [["MHC class II+Iba1+ cells", "ANATOMY", 13, 37], ["white matter", "ANATOMY", 74, 86], ["gray matter", "ANATOMY", 111, 122], ["Iba1", "GENE_OR_GENE_PRODUCT", 26, 30], ["MHC class II", "PROTEIN", 13, 25], ["Iba1", "PROTEIN", 26, 30], ["Iba1+ cells", "PROBLEM", 26, 37], ["Iba1+ cells", "OBSERVATION", 26, 37], ["normal", "OBSERVATION", 67, 73], ["white matter", "OBSERVATION_MODIFIER", 74, 86], ["gray matter", "OBSERVATION", 111, 122]]], ["Demyelination in the absence of IL\u201010 was thus associated with microglia/macrophages expressing a sustained pro\u2010inflammatory phenotype in contrast to the few pro\u2010inflammatory microglia/macrophages associated with the stable focal lesions in WT mice.IL\u201010 Regulates Microglia/Macrophage Phenotype ::: ResultsInfluences of IL\u201010 deficiency on macrophages versus microglia in spinal cords were assessed by flow cytometry based on differential CD45 expression (Ford et al., 1995).", [["microglia", "ANATOMY", 63, 72], ["macrophages", "ANATOMY", 73, 84], ["pro\u2010inflammatory microglia", "ANATOMY", 158, 184], ["macrophages", "ANATOMY", 185, 196], ["focal lesions", "ANATOMY", 224, 237], ["Microglia", "ANATOMY", 265, 274], ["Macrophage", "ANATOMY", 275, 285], ["macrophages", "ANATOMY", 341, 352], ["microglia", "ANATOMY", 360, 369], ["spinal cords", "ANATOMY", 373, 385], ["Demyelination", "DISEASE", 0, 13], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 32, 37], ["microglia", "CELL", 63, 72], ["macrophages", "CELL", 73, 84], ["microglia", "CELL", 175, 184], ["macrophages", "CELL", 185, 196], ["focal lesions", "PATHOLOGICAL_FORMATION", 224, 237], ["mice", "ORGANISM", 244, 248], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 249, 254], ["Microglia", "CELL", 265, 274], ["Macrophage", "CELL", 275, 285], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 321, 326], ["macrophages", "CELL", 341, 352], ["microglia", "CELL", 360, 369], ["spinal cords", "ORGAN", 373, 385], ["CD45", "GENE_OR_GENE_PRODUCT", 440, 444], ["IL\u201010", "PROTEIN", 32, 37], ["microglia", "CELL_TYPE", 63, 72], ["macrophages", "CELL_TYPE", 73, 84], ["pro\u2010inflammatory microglia", "CELL_TYPE", 158, 184], ["macrophages", "CELL_TYPE", 185, 196], ["IL\u201010", "PROTEIN", 249, 254], ["Microglia", "CELL_TYPE", 265, 274], ["IL\u201010", "PROTEIN", 321, 326], ["macrophages", "CELL_TYPE", 341, 352], ["microglia", "CELL_TYPE", 360, 369], ["CD45", "PROTEIN", 440, 444], ["mice", "SPECIES", 244, 248], ["mice", "SPECIES", 244, 248], ["Demyelination", "PROBLEM", 0, 13], ["microglia/macrophages", "PROBLEM", 63, 84], ["a sustained pro\u2010inflammatory phenotype in contrast", "PROBLEM", 96, 146], ["the few pro\u2010inflammatory microglia/macrophages", "PROBLEM", 150, 196], ["the stable focal lesions", "PROBLEM", 213, 237], ["IL\u2010", "TEST", 321, 324], ["deficiency on macrophages", "PROBLEM", 327, 352], ["microglia in spinal cords", "PROBLEM", 360, 385], ["flow cytometry", "TEST", 403, 417], ["few", "OBSERVATION_MODIFIER", 154, 157], ["pro\u2010inflammatory microglia", "OBSERVATION", 158, 184], ["macrophages", "OBSERVATION", 185, 196], ["stable", "OBSERVATION_MODIFIER", 217, 223], ["focal", "OBSERVATION_MODIFIER", 224, 229], ["lesions", "OBSERVATION", 230, 237], ["macrophages", "OBSERVATION", 341, 352], ["spinal cords", "ANATOMY", 373, 385]]], ["Macrophages (CD45hiCD11b+) were initially increased at day 14 p.i. in IL\u201010\u2212/\u2212 mice, but declined to similar numbers in both groups thereafter (Fig. 7A).", [["Macrophages", "ANATOMY", 0, 11], ["CD45hiCD11b+", "ANATOMY", 13, 25], ["Macrophages", "CELL", 0, 11], ["CD45hiCD11b+", "GENE_OR_GENE_PRODUCT", 13, 25], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 70, 75], ["Macrophages", "CELL_TYPE", 0, 11], ["CD45hiCD11b+", "PROTEIN", 13, 25], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 79, 83], ["Macrophages (CD45hiCD11b+", "TREATMENT", 0, 25]]], ["The number of activated MHC class II+ macrophages was similar at day 14 p.i. and decreased in both groups with a more pronounced drop in the absence of IL\u201010 (Fig. 7B,C).", [["MHC class II+ macrophages", "ANATOMY", 24, 49], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 152, 157], ["C", "GENE_OR_GENE_PRODUCT", 167, 168], ["MHC class II", "PROTEIN", 24, 36], ["macrophages", "CELL_TYPE", 38, 49], ["IL\u201010", "PROTEIN", 152, 157], ["a more pronounced drop", "PROBLEM", 111, 133], ["macrophages", "OBSERVATION", 38, 49], ["decreased", "OBSERVATION_MODIFIER", 81, 90]]], ["The number of microglia (CD45lowCD11b+) remained relatively stable, independent of IL\u201010 (Fig. 7D).", [["microglia", "ANATOMY", 14, 23], ["microglia", "CELL", 14, 23], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 83, 88], ["microglia", "CELL_TYPE", 14, 23], ["CD45lowCD11b", "PROTEIN", 25, 37], ["IL\u201010", "PROTEIN", 83, 88], ["microglia (CD45lowCD11b", "TEST", 14, 37], ["number", "OBSERVATION_MODIFIER", 4, 10], ["microglia", "OBSERVATION", 14, 23], ["stable", "OBSERVATION_MODIFIER", 60, 66]]], ["However, while the number of MHC class II+ microglia declined by \u223c50% in WT mice, microglia remained MHC class II+ in the absence of IL\u201010 as lesion area increased (Fig. 7E,F), implicating microglia as the activated population of Iba1+ cells associated with increasing lesion area (Fig. 6H\u2013N).Impaired Glial Scar Formation in the Absence of IL\u201010 ::: ResultsThe progressive expansion of demyelination in the absence of IL\u201010 is reminiscent of expanding lesions in the absence of astroglial scar formation following spinal cord injury and autoimmune mediated demyelination (Faulkner et al., 2004; Toft\u2010Hansen et al., 2011; Voskuhl et al., 2009).", [["MHC class II+ microglia", "ANATOMY", 29, 52], ["microglia", "ANATOMY", 82, 91], ["lesion area", "ANATOMY", 142, 153], ["microglia", "ANATOMY", 189, 198], ["Iba1+ cells", "ANATOMY", 230, 241], ["lesion area", "ANATOMY", 269, 280], ["Glial Scar", "ANATOMY", 302, 312], ["lesions", "ANATOMY", 453, 460], ["astroglial scar", "ANATOMY", 479, 494], ["spinal cord", "ANATOMY", 515, 526], ["demyelination", "DISEASE", 387, 400], ["cord injury", "DISEASE", 522, 533], ["demyelination", "DISEASE", 558, 571], ["MHC class II", "GENE_OR_GENE_PRODUCT", 29, 41], ["WT mice", "ORGANISM", 73, 80], ["microglia", "CELL", 82, 91], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 133, 138], ["microglia", "CELL", 189, 198], ["Iba1", "GENE_OR_GENE_PRODUCT", 230, 234], ["Glial Scar", "TISSUE", 302, 312], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 419, 424], ["lesions", "PATHOLOGICAL_FORMATION", 453, 460], ["astroglial scar", "TISSUE", 479, 494], ["spinal cord", "ORGAN", 515, 526], ["MHC class II", "PROTEIN", 29, 41], ["microglia", "CELL_TYPE", 43, 52], ["microglia", "CELL_TYPE", 82, 91], ["MHC class II", "PROTEIN", 101, 113], ["IL\u201010", "PROTEIN", 133, 138], ["microglia", "CELL_TYPE", 189, 198], ["Iba1", "PROTEIN", 230, 234], ["IL\u201010", "PROTEIN", 419, 424], ["mice", "SPECIES", 76, 80], ["mice", "SPECIES", 76, 80], ["microglia", "PROBLEM", 43, 52], ["lesion area", "PROBLEM", 142, 153], ["microglia", "PROBLEM", 189, 198], ["Iba1+ cells", "PROBLEM", 230, 241], ["increasing lesion area", "PROBLEM", 258, 280], ["Impaired Glial Scar Formation", "PROBLEM", 293, 322], ["demyelination", "PROBLEM", 387, 400], ["expanding lesions", "PROBLEM", 443, 460], ["astroglial scar formation", "PROBLEM", 479, 504], ["spinal cord injury", "PROBLEM", 515, 533], ["autoimmune mediated demyelination", "PROBLEM", 538, 571], ["lesion", "OBSERVATION", 142, 148], ["microglia", "ANATOMY", 189, 198], ["Iba1+ cells", "OBSERVATION", 230, 241], ["increasing", "OBSERVATION_MODIFIER", 258, 268], ["lesion", "OBSERVATION", 269, 275], ["Glial", "OBSERVATION_MODIFIER", 302, 307], ["Scar", "OBSERVATION", 308, 312], ["progressive", "OBSERVATION_MODIFIER", 362, 373], ["expansion", "OBSERVATION_MODIFIER", 374, 383], ["demyelination", "OBSERVATION", 387, 400], ["expanding", "OBSERVATION_MODIFIER", 443, 452], ["lesions", "OBSERVATION", 453, 460], ["astroglial", "OBSERVATION_MODIFIER", 479, 489], ["scar", "OBSERVATION", 490, 494], ["spinal cord", "ANATOMY", 515, 526], ["injury", "OBSERVATION", 527, 533], ["demyelination", "OBSERVATION", 558, 571]]], ["Astrogliosis was thus analyzed by comparing the number and distribution of astrocytes associated with focal relative to expanding lesions.", [["astrocytes", "ANATOMY", 75, 85], ["lesions", "ANATOMY", 130, 137], ["Astrogliosis", "DISEASE", 0, 12], ["astrocytes", "CELL", 75, 85], ["lesions", "PATHOLOGICAL_FORMATION", 130, 137], ["astrocytes", "CELL_TYPE", 75, 85], ["Astrogliosis", "PROBLEM", 0, 12], ["astrocytes", "PROBLEM", 75, 85], ["focal relative to expanding lesions", "PROBLEM", 102, 137], ["astrocytes", "OBSERVATION", 75, 85], ["focal", "OBSERVATION_MODIFIER", 102, 107], ["expanding", "OBSERVATION_MODIFIER", 120, 129], ["lesions", "OBSERVATION", 130, 137]]], ["GFAP+ astrocytes were present both at the edges and within lesions of WT mice (Fig. 8A\u2013C,8G).", [["GFAP+ astrocytes", "ANATOMY", 0, 16], ["lesions", "ANATOMY", 59, 66], ["GFAP", "GENE_OR_GENE_PRODUCT", 0, 4], ["lesions", "PATHOLOGICAL_FORMATION", 59, 66], ["mice", "ORGANISM", 73, 77], ["8A\u2013C", "SIMPLE_CHEMICAL", 84, 88], ["GFAP", "PROTEIN", 0, 4], ["astrocytes", "CELL_TYPE", 6, 16], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 73, 77], ["GFAP", "TEST", 0, 4], ["astrocytes", "PROBLEM", 6, 16], ["astrocytes", "OBSERVATION", 6, 16], ["edges", "OBSERVATION_MODIFIER", 42, 47], ["lesions", "OBSERVATION", 59, 66]]], ["Unlike the stellate morphology characteristic of resting astrocytes in uninvolved white matter (Fig. 8L), areas of myelin loss in WT mice exhibited increased GFAP expression and an organizational pattern consistent with scar\u2010like structures (Fig. 8A\u2013C).", [["stellate", "ANATOMY", 11, 19], ["astrocytes", "ANATOMY", 57, 67], ["uninvolved white matter", "ANATOMY", 71, 94], ["myelin", "ANATOMY", 115, 121], ["scar\u2010like structures", "ANATOMY", 220, 240], ["myelin loss", "DISEASE", 115, 126], ["astrocytes", "CELL", 57, 67], ["white matter", "TISSUE", 82, 94], ["myelin", "GENE_OR_GENE_PRODUCT", 115, 121], ["WT mice", "ORGANISM", 130, 137], ["GFAP", "GENE_OR_GENE_PRODUCT", 158, 162], ["resting astrocytes", "CELL_TYPE", 49, 67], ["GFAP", "PROTEIN", 158, 162], ["mice", "SPECIES", 133, 137], ["resting astrocytes in uninvolved white matter", "PROBLEM", 49, 94], ["myelin loss in WT mice", "PROBLEM", 115, 137], ["increased GFAP expression", "PROBLEM", 148, 173], ["scar\u2010like structures", "PROBLEM", 220, 240], ["stellate", "OBSERVATION_MODIFIER", 11, 19], ["resting astrocytes", "OBSERVATION", 49, 67], ["uninvolved", "OBSERVATION_MODIFIER", 71, 81], ["white matter", "OBSERVATION_MODIFIER", 82, 94], ["myelin loss", "OBSERVATION", 115, 126], ["increased", "OBSERVATION_MODIFIER", 148, 157], ["GFAP expression", "OBSERVATION", 158, 173], ["organizational pattern", "OBSERVATION", 181, 203], ["consistent with", "UNCERTAINTY", 204, 219], ["scar\u2010like structures", "OBSERVATION", 220, 240]]], ["Furthermore, increasing astrocyte numbers per lesion area in WT mice from day 21 to 31 p.i. suggested an active repair response (Fig. 8G).", [["astrocyte", "ANATOMY", 24, 33], ["lesion area", "ANATOMY", 46, 57], ["astrocyte", "CELL", 24, 33], ["mice", "ORGANISM", 64, 68], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["increasing astrocyte numbers", "PROBLEM", 13, 41], ["an active repair response", "TREATMENT", 102, 127], ["increasing", "OBSERVATION_MODIFIER", 13, 23], ["astrocyte numbers", "OBSERVATION", 24, 41], ["lesion", "OBSERVATION_MODIFIER", 46, 52], ["area", "OBSERVATION_MODIFIER", 53, 57], ["active", "OBSERVATION_MODIFIER", 105, 111], ["repair", "OBSERVATION", 112, 118]]], ["By contrast, diffuse lesions in the absence of IL\u201010 were devoid of organized astrocyte formations at the lesion edges and the numbers of activated astrocytes were decreased (Fig. 8D\u2013F, G).", [["diffuse lesions", "ANATOMY", 13, 28], ["astrocyte", "ANATOMY", 78, 87], ["lesion edges", "ANATOMY", 106, 118], ["astrocytes", "ANATOMY", 148, 158], ["diffuse lesions", "PATHOLOGICAL_FORMATION", 13, 28], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 47, 52], ["astrocyte", "CELL", 78, 87], ["lesion edges", "MULTI-TISSUE_STRUCTURE", 106, 118], ["astrocytes", "CELL", 148, 158], ["IL\u201010", "PROTEIN", 47, 52], ["activated astrocytes", "CELL_TYPE", 138, 158], ["diffuse lesions", "PROBLEM", 13, 28], ["organized astrocyte formations at the lesion edges", "PROBLEM", 68, 118], ["activated astrocytes", "PROBLEM", 138, 158], ["diffuse", "OBSERVATION_MODIFIER", 13, 20], ["lesions", "OBSERVATION", 21, 28], ["organized", "OBSERVATION_MODIFIER", 68, 77], ["astrocyte formations", "OBSERVATION", 78, 98], ["lesion", "OBSERVATION_MODIFIER", 106, 112], ["edges", "OBSERVATION_MODIFIER", 113, 118], ["numbers", "OBSERVATION_MODIFIER", 127, 134], ["activated astrocytes", "OBSERVATION", 138, 158], ["decreased", "OBSERVATION_MODIFIER", 164, 173]]], ["Stable astrocyte numbers per lesion area in IL\u201010\u2212/\u2212 mice supported a lack of proliferation due to the absence of IL\u201010 mediated STAT\u20103 signaling.", [["astrocyte", "ANATOMY", 7, 16], ["lesion area", "ANATOMY", 29, 40], ["astrocyte", "CELL", 7, 16], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 44, 49], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 114, 119], ["STAT\u20103", "GENE_OR_GENE_PRODUCT", 129, 135], ["IL\u201010", "PROTEIN", 114, 119], ["STAT\u20103", "PROTEIN", 129, 135], ["mice", "SPECIES", 53, 57], ["astrocyte numbers", "OBSERVATION", 7, 24], ["lesion", "OBSERVATION_MODIFIER", 29, 35], ["area", "OBSERVATION_MODIFIER", 36, 40]]], ["This notion was supported by IL\u201010R induction on activated astrocytes associated with lesions (Fig. 8H\u2013K), but not on astrocytes in surrounding uninvolved white matter (Fig. 8H, L\u2013N).", [["astrocytes", "ANATOMY", 59, 69], ["lesions", "ANATOMY", 86, 93], ["astrocytes", "ANATOMY", 118, 128], ["uninvolved white matter", "ANATOMY", 144, 167], ["IL\u201010R", "GENE_OR_GENE_PRODUCT", 29, 35], ["astrocytes", "CELL", 59, 69], ["lesions", "PATHOLOGICAL_FORMATION", 86, 93], ["astrocytes", "CELL", 118, 128], ["uninvolved white matter", "TISSUE", 144, 167], ["L\u2013N", "SIMPLE_CHEMICAL", 178, 181], ["IL", "PROTEIN", 29, 31], ["10R", "PROTEIN", 32, 35], ["activated astrocytes", "CELL_TYPE", 49, 69], ["astrocytes", "CELL_TYPE", 118, 128], ["activated astrocytes", "PROBLEM", 49, 69], ["lesions", "PROBLEM", 86, 93], ["lesions", "OBSERVATION", 86, 93], ["white matter", "OBSERVATION_MODIFIER", 155, 167]]], ["Indeed, no other cell type associated with the lesions including Iba1+ macrophage/microglia or CD3+ T cells expressed the IL\u201010R.", [["cell", "ANATOMY", 17, 21], ["lesions", "ANATOMY", 47, 54], ["Iba1+ macrophage", "ANATOMY", 65, 81], ["microglia", "ANATOMY", 82, 91], ["CD3+ T cells", "ANATOMY", 95, 107], ["cell type", "CELL", 17, 26], ["lesions", "PATHOLOGICAL_FORMATION", 47, 54], ["Iba1", "GENE_OR_GENE_PRODUCT", 65, 69], ["microglia", "CELL", 82, 91], ["CD3", "GENE_OR_GENE_PRODUCT", 95, 98], ["IL\u201010R", "GENE_OR_GENE_PRODUCT", 122, 128], ["Iba1", "PROTEIN", 65, 69], ["microglia", "CELL_TYPE", 82, 91], ["CD3+ T cells", "CELL_TYPE", 95, 107], ["IL\u201010R", "PROTEIN", 122, 128], ["the lesions", "PROBLEM", 43, 54], ["Iba1", "TEST", 65, 69], ["macrophage", "PROBLEM", 71, 81], ["microglia", "PROBLEM", 82, 91], ["T cells", "PROBLEM", 100, 107], ["no other", "UNCERTAINTY", 8, 16], ["cell type", "OBSERVATION", 17, 26], ["lesions", "OBSERVATION", 47, 54], ["macrophage", "OBSERVATION_MODIFIER", 71, 81]]], ["Impaired astrocyte scar formation in the absence of IL\u201010 indicated that IL\u201010 confines focal lesions following viral induced demyelination via altering astrogliosis.DiscussionThe anti\u2010inflammatory properties of IL\u201010 are known to dampen T cell effector function (Couper et al., 2008a; Fahey and Brooks, 2010).", [["astrocyte scar", "ANATOMY", 9, 23], ["focal lesions", "ANATOMY", 88, 101], ["T cell", "ANATOMY", 238, 244], ["demyelination", "DISEASE", 126, 139], ["astrogliosis", "DISEASE", 153, 165], ["astrocyte scar", "PATHOLOGICAL_FORMATION", 9, 23], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 52, 57], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 73, 78], ["focal lesions", "PATHOLOGICAL_FORMATION", 88, 101], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 212, 217], ["T cell", "CELL", 238, 244], ["IL\u201010", "PROTEIN", 52, 57], ["IL\u201010", "PROTEIN", 73, 78], ["IL\u201010", "PROTEIN", 212, 217], ["Impaired astrocyte scar formation", "PROBLEM", 0, 33], ["focal lesions", "PROBLEM", 88, 101], ["viral induced demyelination", "PROBLEM", 112, 139], ["altering astrogliosis", "PROBLEM", 144, 165], ["The anti\u2010inflammatory properties of IL\u2010", "TREATMENT", 176, 215], ["astrocyte scar", "OBSERVATION", 9, 23], ["focal", "OBSERVATION_MODIFIER", 88, 93], ["lesions", "OBSERVATION", 94, 101], ["viral induced demyelination", "OBSERVATION", 112, 139], ["astrogliosis", "OBSERVATION", 153, 165]]], ["However, the relative contribution of reduced T cell activity versus additional IL\u201010 mediated regulation of tissue resident cells to CNS pathology is less well explored.", [["T cell", "ANATOMY", 46, 52], ["tissue resident cells", "ANATOMY", 109, 130], ["CNS", "ANATOMY", 134, 137], ["T cell", "CELL", 46, 52], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 80, 85], ["tissue resident cells", "CELL", 109, 130], ["CNS", "ANATOMICAL_SYSTEM", 134, 137], ["IL\u201010", "PROTEIN", 80, 85], ["tissue resident cells", "CELL_TYPE", 109, 130], ["reduced T cell activity", "PROBLEM", 38, 61], ["additional IL\u2010", "TREATMENT", 69, 83], ["CNS pathology", "TEST", 134, 147], ["reduced", "OBSERVATION_MODIFIER", 38, 45], ["T cell activity", "OBSERVATION", 46, 61], ["CNS", "ANATOMY", 134, 137]]], ["The data herein support the concept that IL\u201010 plays three distinct, yet overlapping roles in the JHMV model of viral induced demyelination.", [["demyelination", "DISEASE", 126, 139], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 41, 46], ["JHMV", "CANCER", 98, 102], ["IL\u201010", "PROTEIN", 41, 46], ["IL\u2010", "TREATMENT", 41, 44], ["viral induced demyelination", "PROBLEM", 112, 139], ["viral induced demyelination", "OBSERVATION", 112, 139]]], ["First, it selectively dampens CD4+ T cell IFN\u2010\u03b3 production, thereby delaying viral control and enhancing initial demyelination.", [["CD4+ T cell", "ANATOMY", 30, 41], ["demyelination", "DISEASE", 113, 126], ["CD4", "GENE_OR_GENE_PRODUCT", 30, 33], ["T cell IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 35, 47], ["CD4", "PROTEIN", 30, 33], ["IFN", "PROTEIN", 42, 45], ["T cell IFN\u2010\u03b3 production", "PROBLEM", 35, 58], ["viral control", "TREATMENT", 77, 90], ["enhancing initial demyelination", "PROBLEM", 95, 126], ["selectively", "OBSERVATION_MODIFIER", 10, 21], ["dampens", "OBSERVATION_MODIFIER", 22, 29], ["CD4", "OBSERVATION", 30, 33], ["T cell", "OBSERVATION", 35, 41], ["enhancing", "OBSERVATION_MODIFIER", 95, 104], ["initial", "OBSERVATION_MODIFIER", 105, 112], ["demyelination", "OBSERVATION", 113, 126]]], ["Second, by limiting IFN\u2010\u03b3, IL\u201010 not only deactivates microglia/macrophages but also dampens their pro\u2010inflammatory responses.", [["microglia", "ANATOMY", 54, 63], ["macrophages", "ANATOMY", 64, 75], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 20, 25], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 27, 32], ["microglia", "CELL", 54, 63], ["macrophages", "CELL", 64, 75], ["IFN\u2010\u03b3", "PROTEIN", 20, 25], ["IL\u201010", "PROTEIN", 27, 32], ["microglia", "CELL_TYPE", 54, 63], ["macrophages", "CELL_TYPE", 64, 75], ["macrophages", "OBSERVATION", 64, 75]]], ["Third, IL\u201010 signaling facilitates glial scar formation by astrocytes thus containing lesion size.", [["glial scar", "ANATOMY", 35, 45], ["astrocytes", "ANATOMY", 59, 69], ["lesion", "ANATOMY", 86, 92], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 7, 12], ["glial scar", "PATHOLOGICAL_FORMATION", 35, 45], ["astrocytes", "CELL", 59, 69], ["IL\u201010", "PROTEIN", 7, 12], ["astrocytes", "CELL_TYPE", 59, 69], ["Third, IL\u2010", "TREATMENT", 0, 10], ["glial scar formation", "PROBLEM", 35, 55], ["lesion size", "PROBLEM", 86, 97], ["glial scar", "OBSERVATION", 35, 45], ["astrocytes", "ANATOMY", 59, 69], ["lesion", "OBSERVATION", 86, 92], ["size", "OBSERVATION_MODIFIER", 93, 97]]], ["The anti\u2010inflammatory consequences of IL\u201010 signaling in initially increasing demyelination are thus counterbalanced by a repair promoting activity apparent in microglia/macrophages as well as astrocytes.", [["microglia", "ANATOMY", 160, 169], ["macrophages", "ANATOMY", 170, 181], ["astrocytes", "ANATOMY", 193, 203], ["demyelination", "DISEASE", 78, 91], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 38, 43], ["microglia", "CELL", 160, 169], ["macrophages", "CELL", 170, 181], ["astrocytes", "CELL", 193, 203], ["IL\u201010", "PROTEIN", 38, 43], ["microglia", "CELL_TYPE", 160, 169], ["macrophages", "CELL_TYPE", 170, 181], ["astrocytes", "CELL_TYPE", 193, 203], ["IL\u2010", "TREATMENT", 38, 41], ["increasing demyelination", "PROBLEM", 67, 91], ["a repair", "TREATMENT", 120, 128], ["microglia/macrophages", "PROBLEM", 160, 181], ["increasing", "OBSERVATION_MODIFIER", 67, 77], ["demyelination", "OBSERVATION", 78, 91]]], ["This in turn prevents lesion spread independent of residual persisting virus and sustained T cell mediated inflammation.DiscussionCD4+ T cells are the major source of IL\u201010 within the CNS during JHMV induced encephalomyelitis (Puntambekar et al., 2011), implicating either Foxp3+ regulatory T cells (Treg) or IL\u201027 induced Type 1 regulatory (Tr1) T cells as the IL\u201010 producing populations, which suppress IFN\u2010\u03b3 production.", [["lesion", "ANATOMY", 22, 28], ["T cell", "ANATOMY", 91, 97], ["DiscussionCD4+ T cells", "ANATOMY", 120, 142], ["CNS", "ANATOMY", 184, 187], ["Foxp3+ regulatory T cells", "ANATOMY", 273, 298], ["Treg", "ANATOMY", 300, 304], ["Type 1 regulatory (Tr1) T cells", "ANATOMY", 323, 354], ["inflammation", "DISEASE", 107, 119], ["encephalomyelitis", "DISEASE", 208, 225], ["lesion", "CANCER", 22, 28], ["T cell", "CELL", 91, 97], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 167, 172], ["CNS", "ANATOMICAL_SYSTEM", 184, 187], ["Foxp3", "GENE_OR_GENE_PRODUCT", 273, 278], ["Treg", "CELL", 300, 304], ["IL\u201027", "GENE_OR_GENE_PRODUCT", 309, 314], ["Type 1", "GENE_OR_GENE_PRODUCT", 323, 329], ["Tr1) T cells", "CELL", 342, 354], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 362, 367], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 406, 411], ["DiscussionCD4", "PROTEIN", 120, 133], ["T cells", "CELL_TYPE", 135, 142], ["IL\u201010", "PROTEIN", 167, 172], ["Foxp3", "PROTEIN", 273, 278], ["regulatory T cells", "CELL_TYPE", 280, 298], ["Treg", "CELL_TYPE", 300, 304], ["IL\u201027", "PROTEIN", 309, 314], ["Type 1 regulatory (Tr1) T cells", "CELL_TYPE", 323, 354], ["IFN", "PROTEIN", 406, 409], ["\u2010\u03b3", "PROTEIN", 409, 411], ["JHMV", "SPECIES", 195, 199], ["lesion spread", "PROBLEM", 22, 35], ["residual persisting virus", "PROBLEM", 51, 76], ["sustained T cell mediated inflammation", "PROBLEM", 81, 119], ["T cells", "PROBLEM", 135, 142], ["JHMV induced encephalomyelitis", "PROBLEM", 195, 225], ["Foxp3+ regulatory T cells", "PROBLEM", 273, 298], ["IL\u2010", "TEST", 309, 312], ["the IL\u2010", "TREATMENT", 358, 365], ["lesion", "OBSERVATION", 22, 28], ["residual", "OBSERVATION_MODIFIER", 51, 59], ["persisting", "OBSERVATION_MODIFIER", 60, 70], ["virus", "OBSERVATION", 71, 76], ["sustained", "OBSERVATION_MODIFIER", 81, 90], ["T cell mediated", "OBSERVATION_MODIFIER", 91, 106], ["inflammation", "OBSERVATION", 107, 119], ["CNS", "ANATOMY", 184, 187], ["encephalomyelitis", "OBSERVATION", 208, 225]]], ["Moreover, IL\u201010 selectively suppressed effector CD4+ T cells, as neither CD8+ T cell IFN\u2010\u03b3 production nor cytolytic activity was altered in the absence of IL\u201010.", [["effector CD4+ T cells", "ANATOMY", 39, 60], ["CD8+ T cell", "ANATOMY", 73, 84], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 10, 15], ["CD4", "GENE_OR_GENE_PRODUCT", 48, 51], ["CD8+ T cell IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 73, 90], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 155, 160], ["IL\u201010", "PROTEIN", 10, 15], ["CD4", "PROTEIN", 48, 51], ["T cells", "CELL_TYPE", 53, 60], ["CD8", "PROTEIN", 73, 76], ["IFN", "PROTEIN", 85, 88], ["IL\u201010", "PROTEIN", 155, 160], ["T cells", "PROBLEM", 53, 60], ["CD8", "TEST", 73, 76], ["T cell IFN\u2010\u03b3 production", "PROBLEM", 78, 101], ["cytolytic activity", "PROBLEM", 106, 124]]], ["The absence of an effect on cytolysis is distinct from increased cytolytic activity associated with a subpopulation of IL\u201010 expressing virus specific CD8+ T cells (Trandem et al., 2011).", [["CD8+ T cells", "ANATOMY", 151, 163], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 119, 124], ["CD8", "GENE_OR_GENE_PRODUCT", 151, 154], ["IL\u201010 expressing virus specific CD8+ T cells", "CELL_TYPE", 119, 163], ["an effect on cytolysis", "PROBLEM", 15, 37], ["increased cytolytic activity", "PROBLEM", 55, 83], ["a subpopulation of IL\u2010", "TREATMENT", 100, 122], ["effect", "OBSERVATION_MODIFIER", 18, 24], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["cytolytic activity", "OBSERVATION", 65, 83], ["subpopulation", "OBSERVATION_MODIFIER", 102, 115]]], ["Both IL\u201010 producing Treg and Tr1 cells are rapidly recruited into the CNS following JHMV infection, do not alter CNS inflammation, and decline but are sustained throughout persistence (Anghelina et al., 2009; de Aquino et al., 2014, 2013).", [["Treg", "ANATOMY", 21, 25], ["Tr1 cells", "ANATOMY", 30, 39], ["CNS", "ANATOMY", 71, 74], ["CNS", "ANATOMY", 114, 117], ["infection", "DISEASE", 90, 99], ["inflammation", "DISEASE", 118, 130], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 5, 10], ["Treg", "CELL", 21, 25], ["Tr1 cells", "CELL", 30, 39], ["CNS", "ANATOMICAL_SYSTEM", 71, 74], ["JHMV", "GENE_OR_GENE_PRODUCT", 85, 89], ["CNS", "ANATOMICAL_SYSTEM", 114, 117], ["IL\u201010 producing Treg and Tr1 cells", "CELL_LINE", 5, 39], ["JHMV", "SPECIES", 85, 89], ["Both IL\u2010", "TREATMENT", 0, 8], ["Treg and Tr1 cells", "TREATMENT", 21, 39], ["JHMV infection", "PROBLEM", 85, 99], ["CNS inflammation", "PROBLEM", 114, 130], ["CNS", "ANATOMY", 71, 74], ["infection", "OBSERVATION", 90, 99], ["inflammation", "OBSERVATION", 118, 130]]], ["Adoptive transfer and depletion studies suggest distinct roles of Treg and Tr1 cells in suppressing antiviral activity versus demyelination.", [["Treg", "ANATOMY", 66, 70], ["Tr1 cells", "ANATOMY", 75, 84], ["demyelination", "DISEASE", 126, 139], ["Treg", "CELL", 66, 70], ["Tr1 cells", "CELL", 75, 84], ["Treg", "CELL_TYPE", 66, 70], ["Tr1 cells", "CELL_TYPE", 75, 84], ["depletion studies", "TEST", 22, 39], ["Treg and Tr1 cells", "TREATMENT", 66, 84], ["suppressing antiviral activity", "PROBLEM", 88, 118], ["demyelination", "PROBLEM", 126, 139], ["Treg", "ANATOMY", 66, 70], ["antiviral activity", "OBSERVATION", 100, 118], ["demyelination", "OBSERVATION", 126, 139]]], ["Treg transfer during acute JHMV infection ameliorated clinical disease and immunopathology without altering viral clearance (Trandem et al., 2010).", [["Treg", "ANATOMY", 0, 4], ["infection", "DISEASE", 32, 41], ["immunopathology", "DISEASE", 75, 90], ["Treg", "CELL", 0, 4], ["JHMV", "SPECIES", 27, 31], ["Treg transfer", "TREATMENT", 0, 13], ["acute JHMV infection", "PROBLEM", 21, 41], ["clinical disease", "PROBLEM", 54, 70], ["immunopathology", "PROBLEM", 75, 90], ["altering viral clearance", "PROBLEM", 99, 123], ["without", "UNCERTAINTY", 91, 98]]], ["Similarly, Treg depletion during acute infection only transiently impaired infectious virus control coincident with a minimal increase in demyelination (de Aquino et al., 2013).", [["Treg", "ANATOMY", 11, 15], ["infection", "DISEASE", 39, 48], ["impaired infectious virus control", "DISEASE", 66, 99], ["demyelination", "DISEASE", 138, 151], ["Treg", "CELL", 11, 15], ["Treg depletion", "PROBLEM", 11, 25], ["acute infection", "PROBLEM", 33, 48], ["transiently impaired infectious virus control", "PROBLEM", 54, 99], ["a minimal increase in demyelination", "PROBLEM", 116, 151], ["Treg depletion", "OBSERVATION", 11, 25], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["infection", "OBSERVATION", 39, 48], ["transiently", "OBSERVATION_MODIFIER", 54, 65], ["impaired", "OBSERVATION_MODIFIER", 66, 74], ["infectious", "OBSERVATION_MODIFIER", 75, 85], ["minimal", "OBSERVATION_MODIFIER", 118, 125], ["increase", "OBSERVATION_MODIFIER", 126, 134], ["demyelination", "OBSERVATION", 138, 151]]], ["By contrast, elimination of Tr1 cells during JHMV infection accelerated viral clearance and reduced demyelination (de Aquino et al., 2014).", [["Tr1 cells", "ANATOMY", 28, 37], ["infection", "DISEASE", 50, 59], ["demyelination", "DISEASE", 100, 113], ["Tr1 cells", "CELL", 28, 37], ["JHMV", "ORGANISM", 45, 49], ["Tr1 cells", "CELL_TYPE", 28, 37], ["JHMV", "SPECIES", 45, 49], ["Tr1 cells", "PROBLEM", 28, 37], ["JHMV infection", "PROBLEM", 45, 59], ["accelerated viral clearance", "PROBLEM", 60, 87], ["reduced demyelination", "PROBLEM", 92, 113], ["Tr1 cells", "OBSERVATION", 28, 37], ["viral clearance", "OBSERVATION", 72, 87], ["reduced", "OBSERVATION_MODIFIER", 92, 99], ["demyelination", "OBSERVATION", 100, 113]]], ["These data suggested that Tr1 cells are not the IL\u201010 source during chronic infection preventing sustained demyelination, contrasting with the results of CNS pathology mediated by parasites and autoimmune disease (Butler et al., 2013; Pot et al., 2011).", [["Tr1 cells", "ANATOMY", 26, 35], ["CNS", "ANATOMY", 154, 157], ["chronic infection", "DISEASE", 68, 85], ["demyelination", "DISEASE", 107, 120], ["autoimmune disease", "DISEASE", 194, 212], ["Tr1 cells", "CELL", 26, 35], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 48, 53], ["CNS", "ANATOMICAL_SYSTEM", 154, 157], ["Tr1 cells", "CELL_TYPE", 26, 35], ["Tr1 cells", "PROBLEM", 26, 35], ["chronic infection", "PROBLEM", 68, 85], ["sustained demyelination", "PROBLEM", 97, 120], ["CNS pathology", "PROBLEM", 154, 167], ["autoimmune disease", "PROBLEM", 194, 212], ["Tr1 cells", "OBSERVATION", 26, 35], ["chronic", "OBSERVATION_MODIFIER", 68, 75], ["infection", "OBSERVATION", 76, 85], ["demyelination", "OBSERVATION", 107, 120]]], ["Our data cannot rule out the possibility that the early increase in IFN\u2010\u03b3 inflicts increased and irreversible oxidative damage in the absence of IL\u201010 (Molina\u2010Holgado et al., 2001), which is progressively manifested at later time points.", [["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 68, 73], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 145, 150], ["IFN\u2010\u03b3", "PROTEIN", 68, 73], ["Our data", "TEST", 0, 8], ["the early increase in IFN\u2010\u03b3 inflicts", "PROBLEM", 46, 82], ["irreversible oxidative damage", "PROBLEM", 97, 126], ["early", "OBSERVATION_MODIFIER", 50, 55], ["increase", "OBSERVATION_MODIFIER", 56, 64], ["irreversible", "OBSERVATION_MODIFIER", 97, 109], ["oxidative damage", "OBSERVATION", 110, 126]]], ["However, the similar increase in IFN\u2010\u03b3 coupled with reduced demyelination in the absence of Tr1 cells (de Aquino et al., 2014) supports to the concept that Tr1 cells are not the source of IL\u201010 preventing sustained demyelination.DiscussionJHMV induced demyelination requires both infection of oligodendroglia and antiviral cell mediated immunity (Bergmann et al., 2004; Wu et al., 2000).", [["Tr1 cells", "ANATOMY", 92, 101], ["Tr1 cells", "ANATOMY", 156, 165], ["oligodendroglia", "ANATOMY", 293, 308], ["cell", "ANATOMY", 323, 327], ["demyelination", "DISEASE", 60, 73], ["demyelination", "DISEASE", 215, 228], ["demyelination", "DISEASE", 252, 265], ["infection", "DISEASE", 280, 289], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 33, 38], ["Tr1 cells", "CELL", 92, 101], ["Tr1 cells", "CELL", 156, 165], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 188, 193], ["oligodendroglia", "CELL", 293, 308], ["antiviral cell", "CELL", 313, 327], ["IFN\u2010\u03b3", "PROTEIN", 33, 38], ["Tr1 cells", "CELL_TYPE", 92, 101], ["Tr1 cells", "CELL_TYPE", 156, 165], ["IL\u201010", "PROTEIN", 188, 193], ["the similar increase in IFN\u2010\u03b3", "PROBLEM", 9, 38], ["reduced demyelination", "PROBLEM", 52, 73], ["Tr1 cells", "PROBLEM", 92, 101], ["Tr1 cells", "PROBLEM", 156, 165], ["sustained demyelination", "PROBLEM", 205, 228], ["demyelination", "PROBLEM", 252, 265], ["both infection of oligodendroglia", "PROBLEM", 275, 308], ["antiviral cell mediated immunity", "TREATMENT", 313, 345], ["similar", "OBSERVATION_MODIFIER", 13, 20], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["reduced", "OBSERVATION_MODIFIER", 52, 59], ["demyelination", "OBSERVATION", 60, 73], ["Tr1 cells", "OBSERVATION", 156, 165], ["demyelination", "OBSERVATION", 215, 228], ["demyelination", "OBSERVATION", 252, 265], ["both", "OBSERVATION_MODIFIER", 275, 279], ["infection", "OBSERVATION", 280, 289], ["antiviral cell", "OBSERVATION", 313, 327]]], ["The lesions are defined by a mixed population of macrophages and microglia expressing both pro\u2010inflammatory and repair promoting genes, similar to lesion formation after spinal cord injury (Kigerl et al., 2009).", [["lesions", "ANATOMY", 4, 11], ["macrophages", "ANATOMY", 49, 60], ["microglia", "ANATOMY", 65, 74], ["lesion", "ANATOMY", 147, 153], ["spinal cord", "ANATOMY", 170, 181], ["cord injury", "DISEASE", 177, 188], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["macrophages", "CELL", 49, 60], ["microglia", "CELL", 65, 74], ["lesion", "PATHOLOGICAL_FORMATION", 147, 153], ["cord", "ORGAN", 177, 181], ["macrophages", "CELL_TYPE", 49, 60], ["microglia", "CELL_TYPE", 65, 74], ["pro\u2010inflammatory and repair promoting genes", "DNA", 91, 134], ["The lesions", "PROBLEM", 0, 11], ["a mixed population of macrophages", "PROBLEM", 27, 60], ["repair promoting genes", "TREATMENT", 112, 134], ["lesion formation", "PROBLEM", 147, 163], ["spinal cord injury", "PROBLEM", 170, 188], ["lesions", "OBSERVATION", 4, 11], ["mixed", "OBSERVATION_MODIFIER", 29, 34], ["population", "OBSERVATION_MODIFIER", 35, 45], ["macrophages", "OBSERVATION", 49, 60], ["microglia", "OBSERVATION_MODIFIER", 65, 74], ["pro\u2010inflammatory", "OBSERVATION_MODIFIER", 91, 107], ["repair", "OBSERVATION_MODIFIER", 112, 118], ["promoting genes", "OBSERVATION", 119, 134], ["lesion", "OBSERVATION", 147, 153], ["spinal cord", "ANATOMY", 170, 181], ["injury", "OBSERVATION", 182, 188]]], ["However, the highly polarized Th1 immune response to JHMV coincides with only sparse IL\u20104 and IL\u201013 expression, preempting the transition to, or replacement of pro\u2010inflammatory macrophages by an IL\u20104/IL\u201013 dependent repair\u2010promoting phenotype evident following peripheral injury (Chen et al., 2012; Shirey et al., 2010).", [["pro\u2010inflammatory macrophages", "ANATOMY", 160, 188], ["peripheral injury", "DISEASE", 261, 278], ["Th1", "CELL", 30, 33], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 85, 89], ["IL\u201013", "GENE_OR_GENE_PRODUCT", 94, 99], ["pro\u2010inflammatory macrophages", "CELL", 160, 188], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 195, 199], ["IL\u201013", "GENE_OR_GENE_PRODUCT", 200, 205], ["peripheral", "TISSUE", 261, 271], ["pro\u2010inflammatory macrophages", "CELL_TYPE", 160, 188], ["JHMV", "SPECIES", 53, 57], ["JHMV", "TEST", 53, 57], ["replacement of pro\u2010inflammatory macrophages", "TREATMENT", 145, 188], ["an IL\u20104/IL\u2010", "TREATMENT", 192, 203], ["dependent repair\u2010promoting phenotype", "PROBLEM", 206, 242], ["peripheral injury", "PROBLEM", 261, 278], ["sparse", "OBSERVATION_MODIFIER", 78, 84], ["IL", "OBSERVATION", 85, 87], ["peripheral", "ANATOMY_MODIFIER", 261, 271], ["injury", "OBSERVATION", 272, 278]]], ["The limited induction of IL\u20104/IL\u201013 dependent populations nevertheless appears to be compensated by transition to an IL\u201010 dependent anti\u2010inflammatory microglia/macrophage phenotype, which augments remyelination through enhanced phagocytosis/clearance of myelin debris and/or oligodendrogenesis (Butovsky et al., 2006; Miron et al., 2013).", [["microglia", "ANATOMY", 151, 160], ["macrophage", "ANATOMY", 161, 171], ["myelin debris", "ANATOMY", 255, 268], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 25, 29], ["IL\u201013", "GENE_OR_GENE_PRODUCT", 30, 35], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 117, 122], ["microglia", "CELL", 151, 160], ["macrophage", "CELL", 161, 171], ["myelin debris", "CELLULAR_COMPONENT", 255, 268], ["IL\u20104", "PROTEIN", 25, 29], ["IL\u20104/IL", "TREATMENT", 25, 32], ["dependent populations", "PROBLEM", 36, 57], ["an IL\u2010", "TREATMENT", 114, 120], ["macrophage phenotype", "PROBLEM", 161, 181], ["enhanced phagocytosis", "PROBLEM", 220, 241], ["myelin debris", "PROBLEM", 255, 268], ["oligodendrogenesis", "PROBLEM", 276, 294], ["appears to be", "UNCERTAINTY", 71, 84], ["compensated", "OBSERVATION", 85, 96], ["macrophage phenotype", "OBSERVATION", 161, 181], ["myelin debris", "OBSERVATION", 255, 268]]], ["The CNS lesion micro\u2010environment associated with IL\u201010 thus appears to ellicit a unique repair promoting microglia/macrophage phenotype, which restrains by\u2010stander immune pathology.", [["CNS lesion", "ANATOMY", 4, 14], ["microglia", "ANATOMY", 105, 114], ["macrophage", "ANATOMY", 115, 125], ["CNS lesion", "PATHOLOGICAL_FORMATION", 4, 14], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 49, 54], ["microglia", "CELL", 105, 114], ["macrophage", "CELL", 115, 125], ["IL\u201010", "PROTEIN", 49, 54], ["microglia", "CELL_TYPE", 105, 114], ["The CNS lesion micro\u2010environment", "PROBLEM", 0, 32], ["a unique repair", "TREATMENT", 79, 94], ["macrophage phenotype", "PROBLEM", 115, 135], ["CNS", "ANATOMY", 4, 7], ["lesion", "OBSERVATION", 8, 14], ["repair", "OBSERVATION", 88, 94], ["macrophage phenotype", "OBSERVATION", 115, 135]]], ["Our data indicate that impaired activation of cells that support tissue repair in the absence of IL\u201010, combined with persistent pro\u2010inflammatory activation and the lack of a clear transition to an anti\u2010inflammatory phenotype contributes to progressive myelin loss.", [["cells", "ANATOMY", 46, 51], ["tissue", "ANATOMY", 65, 71], ["myelin", "ANATOMY", 253, 259], ["myelin loss", "DISEASE", 253, 264], ["cells", "CELL", 46, 51], ["tissue", "TISSUE", 65, 71], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 97, 102], ["myelin", "GENE_OR_GENE_PRODUCT", 253, 259], ["IL\u201010", "PROTEIN", 97, 102], ["Our data", "TEST", 0, 8], ["impaired activation of cells", "PROBLEM", 23, 51], ["tissue repair", "TREATMENT", 65, 78], ["persistent pro\u2010inflammatory activation", "PROBLEM", 118, 156], ["an anti\u2010inflammatory phenotype", "PROBLEM", 195, 225], ["progressive myelin loss", "PROBLEM", 241, 264], ["impaired", "OBSERVATION_MODIFIER", 23, 31], ["activation of cells", "OBSERVATION", 32, 51], ["tissue repair", "OBSERVATION", 65, 78], ["persistent", "OBSERVATION_MODIFIER", 118, 128], ["pro\u2010inflammatory activation", "OBSERVATION", 129, 156], ["progressive", "OBSERVATION_MODIFIER", 241, 252], ["myelin loss", "OBSERVATION", 253, 264]]], ["JHMV induced demyelination shares a variety of pathophysiological features with MS and EAE, but differs in two important aspects.", [["JHMV", "CHEMICAL", 0, 4], ["demyelination", "DISEASE", 13, 26], ["MS", "DISEASE", 80, 82], ["EAE", "DISEASE", 87, 90], ["JHMV", "SPECIES", 0, 4], ["JHMV induced demyelination", "PROBLEM", 0, 26], ["MS", "PROBLEM", 80, 82], ["EAE", "PROBLEM", 87, 90], ["demyelination", "OBSERVATION", 13, 26]]], ["First, the highly polarized Th1 response excludes T cells secreting IL\u201017 (Kapil et al., 2009; Savarin et al., 2012).", [["T cells", "ANATOMY", 50, 57], ["Th1", "CELL", 28, 31], ["T cells", "CELL", 50, 57], ["IL\u201017", "GENE_OR_GENE_PRODUCT", 68, 73], ["T cells", "CELL_TYPE", 50, 57]]], ["Second, viral induced demyelination is independent of bone marrow derived macrophages (Savarin et al., 2010; Xue et al., 1999).", [["bone marrow", "ANATOMY", 54, 65], ["macrophages", "ANATOMY", 74, 85], ["demyelination", "DISEASE", 22, 35], ["bone marrow derived macrophages", "CELL", 54, 85], ["bone marrow derived macrophages", "CELL_TYPE", 54, 85], ["viral induced demyelination", "PROBLEM", 8, 35], ["viral induced", "OBSERVATION_MODIFIER", 8, 21], ["demyelination", "OBSERVATION", 22, 35], ["bone marrow", "ANATOMY", 54, 65]]], ["This is supported by the continuous decline in activated macrophages within spinal cords in both infected WT and IL\u201010\u2212/\u2212 mice as well as sustained microglial, but not macrophage activation associated with the expanding lesions in the absence of IL\u201010.", [["macrophages", "ANATOMY", 57, 68], ["spinal cords", "ANATOMY", 76, 88], ["microglial", "ANATOMY", 148, 158], ["macrophage", "ANATOMY", 168, 178], ["lesions", "ANATOMY", 220, 227], ["macrophages", "CELL", 57, 68], ["spinal cords", "ORGAN", 76, 88], ["IL", "GENE_OR_GENE_PRODUCT", 113, 115], ["10\u2212", "GENE_OR_GENE_PRODUCT", 116, 119], ["microglial", "CELL", 148, 158], ["macrophage", "CELL", 168, 178], ["lesions", "PATHOLOGICAL_FORMATION", 220, 227], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 246, 251], ["activated macrophages", "CELL_TYPE", 47, 68], ["IL\u201010", "PROTEIN", 246, 251], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 122, 126], ["the continuous decline in activated macrophages within spinal cords", "PROBLEM", 21, 88], ["macrophage activation", "PROBLEM", 168, 189], ["the expanding lesions", "PROBLEM", 206, 227], ["macrophages", "OBSERVATION", 57, 68], ["spinal cords", "ANATOMY", 76, 88], ["infected", "OBSERVATION_MODIFIER", 97, 105], ["microglial", "OBSERVATION", 148, 158], ["not", "UNCERTAINTY", 164, 167], ["macrophage", "OBSERVATION", 168, 178], ["expanding", "OBSERVATION_MODIFIER", 210, 219], ["lesions", "OBSERVATION", 220, 227]]], ["This contrasts the concerted effort of macrophages stripping myelin with microglia phagocytizing myelin debris during EAE (Yamasaki et al., 2014).", [["macrophages", "ANATOMY", 39, 50], ["myelin", "ANATOMY", 61, 67], ["microglia", "ANATOMY", 73, 82], ["EAE", "DISEASE", 118, 121], ["macrophages", "CELL", 39, 50], ["myelin", "CELLULAR_COMPONENT", 61, 67], ["microglia", "CELL", 73, 82], ["myelin debris", "CELLULAR_COMPONENT", 97, 110], ["macrophages", "CELL_TYPE", 39, 50], ["microglia", "CELL_TYPE", 73, 82], ["macrophages stripping myelin", "TREATMENT", 39, 67], ["microglia phagocytizing myelin debris", "PROBLEM", 73, 110], ["macrophages stripping", "OBSERVATION", 39, 60], ["microglia phagocytizing myelin debris", "OBSERVATION", 73, 110]]], ["Pathologically similar tissue damage, i.e., demyelination, can thus be affected by distinct mechanisms during viral and autoimmune induced lesion formation.", [["tissue", "ANATOMY", 23, 29], ["lesion", "ANATOMY", 139, 145], ["tissue damage", "DISEASE", 23, 36], ["demyelination", "DISEASE", 44, 57], ["tissue", "TISSUE", 23, 29], ["lesion", "PATHOLOGICAL_FORMATION", 139, 145], ["Pathologically similar tissue damage", "PROBLEM", 0, 36], ["demyelination", "PROBLEM", 44, 57], ["viral and autoimmune induced lesion formation", "PROBLEM", 110, 155], ["similar tissue", "OBSERVATION_MODIFIER", 15, 29], ["damage", "OBSERVATION", 30, 36], ["demyelination", "OBSERVATION", 44, 57], ["lesion", "OBSERVATION", 139, 145]]], ["Irrespectively, the focal nature of demyelination following distinct CNS insults, many of which are associated with increased IL\u201010 (Weiner and Selkoe, 2002), support a conserved mechanism that involves astrocyte activation and glial scar formation to limit CNS damage (Cregg et al., 2014; Sofroniew and Vinters, 2010).", [["CNS", "ANATOMY", 69, 72], ["astrocyte", "ANATOMY", 203, 212], ["glial scar", "ANATOMY", 228, 238], ["CNS", "ANATOMY", 258, 261], ["demyelination", "DISEASE", 36, 49], ["CNS", "ANATOMICAL_SYSTEM", 69, 72], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 126, 131], ["astrocyte", "CELL", 203, 212], ["glial scar", "TISSUE", 228, 238], ["CNS", "ANATOMICAL_SYSTEM", 258, 261], ["demyelination", "PROBLEM", 36, 49], ["distinct CNS insults", "PROBLEM", 60, 80], ["increased IL\u2010", "TREATMENT", 116, 129], ["astrocyte activation", "PROBLEM", 203, 223], ["glial scar formation", "PROBLEM", 228, 248], ["CNS damage", "PROBLEM", 258, 268], ["focal", "OBSERVATION_MODIFIER", 20, 25], ["demyelination", "OBSERVATION", 36, 49], ["distinct", "OBSERVATION_MODIFIER", 60, 68], ["CNS insults", "OBSERVATION", 69, 80], ["astrocyte activation", "OBSERVATION", 203, 223], ["glial scar", "OBSERVATION", 228, 238]]], ["Focal demyelinated lesions are characterized by increased expression of GFAP indicative of an astrogliotic scar (Silver and Miller, 2004).", [["Focal demyelinated lesions", "ANATOMY", 0, 26], ["astrogliotic scar", "ANATOMY", 94, 111], ["Focal demyelinated lesions", "PATHOLOGICAL_FORMATION", 0, 26], ["GFAP", "GENE_OR_GENE_PRODUCT", 72, 76], ["scar", "PATHOLOGICAL_FORMATION", 107, 111], ["GFAP", "PROTEIN", 72, 76], ["Focal demyelinated lesions", "PROBLEM", 0, 26], ["increased expression of GFAP", "PROBLEM", 48, 76], ["an astrogliotic scar", "PROBLEM", 91, 111], ["demyelinated", "OBSERVATION_MODIFIER", 6, 18], ["lesions", "OBSERVATION", 19, 26], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["expression", "OBSERVATION_MODIFIER", 58, 68], ["indicative of", "UNCERTAINTY", 77, 90], ["astrogliotic", "OBSERVATION_MODIFIER", 94, 106], ["scar", "OBSERVATION", 107, 111], ["Silver", "OBSERVATION_MODIFIER", 113, 119]]], ["Induction of EAE in GFAP\u2212/\u2212 mice (Liedtke et al., 1998) or ablation of proliferating astrocytes supports the critical role of astrogliosis in the formation of discrete white matter lesions and the concept that astrocytes not only regulate glial scar formation, but also limit inflammatory cell invasion into the CNS parenchyma (Toft\u2010Hansen et al., 2011; Voskuhl et al., 2009).DiscussionA universal role of IL\u201010 in white matter lesion formation is supported by focal IL\u201010R expression by activated astrocytes, coincident with suppressed microglia activation in rodent models of both MS and CNS injury (Hulshof et al., 2002; Ledeboer et al., 2003; Starossom et al., 2012; Xin et al., 2011).", [["astrocytes", "ANATOMY", 85, 95], ["white matter lesions", "ANATOMY", 168, 188], ["astrocytes", "ANATOMY", 210, 220], ["glial scar", "ANATOMY", 239, 249], ["cell", "ANATOMY", 289, 293], ["CNS parenchyma", "ANATOMY", 312, 326], ["white matter lesion", "ANATOMY", 415, 434], ["astrocytes", "ANATOMY", 498, 508], ["microglia", "ANATOMY", 537, 546], ["CNS", "ANATOMY", 590, 593], ["EAE", "DISEASE", 13, 16], ["astrogliosis", "DISEASE", 126, 138], ["white matter lesion", "DISEASE", 415, 434], ["MS", "DISEASE", 583, 585], ["CNS injury", "DISEASE", 590, 600], ["GFAP\u2212", "GENE_OR_GENE_PRODUCT", 20, 25], ["astrocytes", "CELL", 85, 95], ["white matter lesions", "PATHOLOGICAL_FORMATION", 168, 188], ["astrocytes", "CELL", 210, 220], ["glial scar", "TISSUE", 239, 249], ["cell", "CELL", 289, 293], ["CNS parenchyma", "TISSUE", 312, 326], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 406, 411], ["white matter lesion", "PATHOLOGICAL_FORMATION", 415, 434], ["IL\u201010R", "GENE_OR_GENE_PRODUCT", 467, 473], ["astrocytes", "CELL", 498, 508], ["microglia", "CELL", 537, 546], ["CNS", "ANATOMICAL_SYSTEM", 590, 593], ["proliferating astrocytes", "CELL_TYPE", 71, 95], ["astrocytes", "CELL_TYPE", 210, 220], ["IL\u201010", "PROTEIN", 406, 411], ["IL", "PROTEIN", 467, 469], ["10R", "PROTEIN", 470, 473], ["activated astrocytes", "CELL_TYPE", 488, 508], ["microglia", "CELL_TYPE", 537, 546], ["mice", "SPECIES", 28, 32], ["EAE", "PROBLEM", 13, 16], ["ablation", "TREATMENT", 59, 67], ["proliferating astrocytes", "PROBLEM", 71, 95], ["astrogliosis", "PROBLEM", 126, 138], ["discrete white matter lesions", "PROBLEM", 159, 188], ["glial scar formation", "PROBLEM", 239, 259], ["inflammatory cell invasion into the CNS parenchyma", "PROBLEM", 276, 326], ["white matter lesion formation", "PROBLEM", 415, 444], ["activated astrocytes", "PROBLEM", 488, 508], ["suppressed microglia activation", "PROBLEM", 526, 557], ["both MS", "PROBLEM", 578, 585], ["CNS injury", "PROBLEM", 590, 600], ["proliferating astrocytes", "OBSERVATION", 71, 95], ["astrogliosis", "OBSERVATION", 126, 138], ["discrete", "OBSERVATION_MODIFIER", 159, 167], ["white matter", "OBSERVATION_MODIFIER", 168, 180], ["lesions", "OBSERVATION", 181, 188], ["glial", "OBSERVATION_MODIFIER", 239, 244], ["scar", "OBSERVATION", 245, 249], ["inflammatory cell invasion", "OBSERVATION", 276, 302], ["CNS", "ANATOMY", 312, 315], ["parenchyma", "ANATOMY_MODIFIER", 316, 326], ["focal", "OBSERVATION_MODIFIER", 461, 466], ["CNS", "ANATOMY", 590, 593], ["injury", "OBSERVATION", 594, 600]]], ["Moreover, by binding their respective receptors, IL\u201010, IL\u20106, LIF, and CNTF all activate STAT3 (Schindler et al., 2007), supporting a contribution of IL\u201010 induced STAT3 activation to the formation of focal lesions following viral induced demyelination.", [["focal lesions", "ANATOMY", 201, 214], ["demyelination", "DISEASE", 239, 252], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 49, 54], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 56, 60], ["LIF", "GENE_OR_GENE_PRODUCT", 62, 65], ["CNTF", "GENE_OR_GENE_PRODUCT", 71, 75], ["STAT3", "GENE_OR_GENE_PRODUCT", 89, 94], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 150, 155], ["STAT3", "GENE_OR_GENE_PRODUCT", 164, 169], ["focal lesions", "PATHOLOGICAL_FORMATION", 201, 214], ["IL\u201010", "PROTEIN", 49, 54], ["IL\u20106", "PROTEIN", 56, 60], ["LIF", "PROTEIN", 62, 65], ["CNTF", "PROTEIN", 71, 75], ["STAT3", "PROTEIN", 89, 94], ["IL\u201010", "PROTEIN", 150, 155], ["STAT3", "PROTEIN", 164, 169], ["IL\u2010", "TREATMENT", 56, 59], ["IL\u2010", "TREATMENT", 150, 153], ["STAT3 activation", "PROBLEM", 164, 180], ["focal lesions", "PROBLEM", 201, 214], ["viral induced demyelination", "PROBLEM", 225, 252], ["focal", "OBSERVATION_MODIFIER", 201, 206], ["lesions", "OBSERVATION", 207, 214], ["viral induced demyelination", "OBSERVATION", 225, 252]]], ["Indeed, in a spinal cord injury model, STAT3 ablation specifically in astrocytes resulted in lesion expansion, coincident with inhibited astrocyte migration and formation of a distinct lesion border, as well as increased macrophage infiltration (Wanner et al., 2013).", [["spinal cord", "ANATOMY", 13, 24], ["astrocytes", "ANATOMY", 70, 80], ["lesion", "ANATOMY", 93, 99], ["astrocyte", "ANATOMY", 137, 146], ["lesion border", "ANATOMY", 185, 198], ["macrophage", "ANATOMY", 221, 231], ["cord injury", "DISEASE", 20, 31], ["spinal cord", "ORGAN", 13, 24], ["STAT3", "GENE_OR_GENE_PRODUCT", 39, 44], ["astrocytes", "CELL", 70, 80], ["lesion", "PATHOLOGICAL_FORMATION", 93, 99], ["astrocyte", "CELL", 137, 146], ["macrophage", "CELL", 221, 231], ["STAT3", "PROTEIN", 39, 44], ["astrocytes", "CELL_TYPE", 70, 80], ["a spinal cord injury model", "PROBLEM", 11, 37], ["STAT3 ablation", "TREATMENT", 39, 53], ["lesion expansion", "PROBLEM", 93, 109], ["inhibited astrocyte migration", "PROBLEM", 127, 156], ["a distinct lesion border", "PROBLEM", 174, 198], ["increased macrophage infiltration", "PROBLEM", 211, 244], ["spinal cord", "ANATOMY", 13, 24], ["injury", "OBSERVATION", 25, 31], ["lesion", "OBSERVATION", 93, 99], ["inhibited", "OBSERVATION_MODIFIER", 127, 136], ["astrocyte migration", "OBSERVATION", 137, 156], ["distinct", "OBSERVATION_MODIFIER", 176, 184], ["lesion", "OBSERVATION", 185, 191], ["increased", "OBSERVATION_MODIFIER", 211, 220], ["macrophage infiltration", "OBSERVATION", 221, 244]]], ["A critical role of STAT3 signaling in regulating astrocyte function is also supported by spinal cord injury in mice in which SOCS3, which inhibits STAT3 signaling, was specifically ablated in astrocytes.", [["astrocyte", "ANATOMY", 49, 58], ["spinal cord", "ANATOMY", 89, 100], ["astrocytes", "ANATOMY", 192, 202], ["cord injury", "DISEASE", 96, 107], ["STAT3", "GENE_OR_GENE_PRODUCT", 19, 24], ["astrocyte", "CELL", 49, 58], ["spinal cord", "ORGAN", 89, 100], ["mice", "ORGANISM", 111, 115], ["SOCS3", "GENE_OR_GENE_PRODUCT", 125, 130], ["STAT3", "GENE_OR_GENE_PRODUCT", 147, 152], ["astrocytes", "CELL", 192, 202], ["STAT3", "PROTEIN", 19, 24], ["SOCS3", "PROTEIN", 125, 130], ["STAT3", "PROTEIN", 147, 152], ["astrocytes", "CELL_TYPE", 192, 202], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["STAT3 signaling", "PROBLEM", 19, 34], ["spinal cord injury", "PROBLEM", 89, 107], ["STAT3 signaling", "PROBLEM", 147, 162], ["STAT3 signaling", "OBSERVATION", 19, 34], ["astrocyte function", "OBSERVATION", 49, 67], ["spinal cord", "ANATOMY", 89, 100], ["injury", "OBSERVATION", 101, 107]]], ["Conditional disruption of SOCS3 signaling increased astrocyte migration, lesion confinement and functional recovery (Okada et al., 2006).", [["astrocyte", "ANATOMY", 52, 61], ["lesion", "ANATOMY", 73, 79], ["SOCS3", "GENE_OR_GENE_PRODUCT", 26, 31], ["astrocyte", "CELL", 52, 61], ["SOCS3", "PROTEIN", 26, 31], ["SOCS3 signaling increased astrocyte migration", "PROBLEM", 26, 71], ["lesion confinement", "PROBLEM", 73, 91], ["SOCS3", "OBSERVATION", 26, 31], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["astrocyte migration", "OBSERVATION", 52, 71]]], ["The present data thus expand the regulation of autoimmune mediated demyelination and spinal cord injury by restricted expression of IL\u201010R and potential STAT3 signaling in astrocytes, to include viral induced demyelination.", [["spinal cord", "ANATOMY", 85, 96], ["astrocytes", "ANATOMY", 172, 182], ["demyelination", "DISEASE", 67, 80], ["cord injury", "DISEASE", 92, 103], ["demyelination", "DISEASE", 209, 222], ["spinal cord", "ORGAN", 85, 96], ["IL\u201010R", "GENE_OR_GENE_PRODUCT", 132, 138], ["STAT3", "GENE_OR_GENE_PRODUCT", 153, 158], ["astrocytes", "CELL", 172, 182], ["IL\u201010R", "PROTEIN", 132, 138], ["STAT3", "PROTEIN", 153, 158], ["astrocytes", "CELL_TYPE", 172, 182], ["autoimmune mediated demyelination", "PROBLEM", 47, 80], ["spinal cord injury", "PROBLEM", 85, 103], ["potential STAT3 signaling in astrocytes", "PROBLEM", 143, 182], ["viral induced demyelination", "PROBLEM", 195, 222], ["autoimmune", "OBSERVATION", 47, 57], ["demyelination", "OBSERVATION", 67, 80], ["spinal cord", "ANATOMY", 85, 96], ["injury", "OBSERVATION", 97, 103], ["astrocytes", "ANATOMY", 172, 182], ["demyelination", "OBSERVATION", 209, 222]]], ["Lesion expansion, despite accelerated clearance of a subacute viral infection, is further reminiscent of epidemiological data implicating an elusive environmental agent in the pathophysiology of MS (Fujinami et al., 2006).", [["Lesion", "ANATOMY", 0, 6], ["viral infection", "DISEASE", 62, 77], ["MS", "DISEASE", 195, 197], ["Lesion expansion", "PROBLEM", 0, 16], ["a subacute viral infection", "PROBLEM", 51, 77], ["accelerated", "OBSERVATION_MODIFIER", 26, 37], ["clearance", "OBSERVATION_MODIFIER", 38, 47], ["subacute", "OBSERVATION_MODIFIER", 53, 61], ["viral", "OBSERVATION_MODIFIER", 62, 67], ["infection", "OBSERVATION", 68, 77]]], ["Overall this model defines multifactorial events by which IL\u201010 limits CNS damage subsequent to viral control and supports the concept that IL\u201010 signaling to astrocytes regulates the formation of the glial scar surrounding and limiting areas of demyelination.", [["CNS", "ANATOMY", 71, 74], ["astrocytes", "ANATOMY", 159, 169], ["glial scar", "ANATOMY", 201, 211], ["demyelination", "DISEASE", 246, 259], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 58, 63], ["CNS", "ANATOMICAL_SYSTEM", 71, 74], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 140, 145], ["astrocytes", "CELL", 159, 169], ["glial scar", "TISSUE", 201, 211], ["IL\u201010", "PROTEIN", 58, 63], ["IL\u201010", "PROTEIN", 140, 145], ["astrocytes", "CELL_TYPE", 159, 169], ["multifactorial events", "PROBLEM", 27, 48], ["CNS damage", "PROBLEM", 71, 81], ["viral control", "TREATMENT", 96, 109], ["IL\u2010", "TREATMENT", 140, 143], ["the glial scar", "PROBLEM", 197, 211], ["demyelination", "PROBLEM", 246, 259], ["multifactorial", "OBSERVATION_MODIFIER", 27, 41], ["glial", "ANATOMY", 201, 206], ["scar", "OBSERVATION", 207, 211], ["demyelination", "OBSERVATION", 246, 259]]]], "PMC7197364": [["IntroductionA novel coronavirus newly named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO) [1] is responsible for the recent pneumonia outbreak that started in December 2019 in Wuhan City, China.", [["coronavirus disease", "DISEASE", 44, 63], ["COVID-19", "CHEMICAL", 70, 78], ["pneumonia", "DISEASE", 153, 162], ["coronavirus", "ORGANISM", 20, 31], ["coronavirus", "ORGANISM", 44, 55], ["coronavirus", "SPECIES", 44, 55], ["coronavirus disease 2019 (COVID-19", "SPECIES", 44, 78], ["IntroductionA novel coronavirus newly named coronavirus disease", "PROBLEM", 0, 63], ["COVID", "TEST", 70, 75], ["the recent pneumonia", "PROBLEM", 142, 162], ["coronavirus disease", "OBSERVATION", 44, 63], ["pneumonia", "OBSERVATION", 153, 162]]], ["Different from both the Middle East respiratory syndrome (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV), COVID-19 is a brand new member of enveloped RNA coronaviruses (subgenus Sarbecovirus, Orthocoronavirinae subfamily) infecting humans [2].", [["Middle East respiratory syndrome (MERS-CoV)", "DISEASE", 24, 67], ["acute respiratory syndrome coronavirus", "DISEASE", 79, 117], ["SARS", "DISEASE", 119, 123], ["Middle East respiratory", "ORGANISM", 24, 47], ["MERS-CoV", "ORGANISM", 58, 66], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 72, 117], ["SARS-CoV", "ORGANISM", 119, 127], ["enveloped RNA coronaviruses", "ORGANISM", 164, 191], ["subgenus Sarbecovirus", "ORGANISM", 193, 214], ["Orthocoronavirinae subfamily", "ORGANISM", 216, 244], ["humans", "ORGANISM", 256, 262], ["humans", "SPECIES", 256, 262], ["Middle East respiratory syndrome (MERS-CoV", "SPECIES", 24, 66], ["severe acute respiratory syndrome coronavirus", "SPECIES", 72, 117], ["SARS-CoV", "SPECIES", 119, 127], ["COVID-19", "SPECIES", 130, 138], ["humans", "SPECIES", 256, 262], ["the Middle East respiratory syndrome", "PROBLEM", 20, 56], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 72, 117], ["COVID", "TEST", 130, 135], ["enveloped RNA coronaviruses", "PROBLEM", 164, 191], ["Middle", "ANATOMY_MODIFIER", 24, 30], ["respiratory syndrome", "OBSERVATION", 36, 56], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["respiratory syndrome coronavirus", "OBSERVATION", 85, 117]]], ["Although the majority of cases were reported to be related to the Huanan Seafood Market, the source of the virus is still unclear [3].", [["the virus", "PROBLEM", 103, 112], ["virus", "OBSERVATION", 107, 112]]], ["As of 11 p.m. on February 15, 2020, Chinese authorities have reported 56,563 confirmed cases and 8969 suspected cases, including 1524 deaths in mainland China.", [["deaths", "DISEASE", 134, 140]]], ["Among them, Wuhan City has the largest number of 34,256 confirmed cases with 1123 deaths [4].", [["deaths", "DISEASE", 82, 88]]], ["There is increasing evidence of human-to-human transmission in hospitals and among family members; the rate of severe cases was reported to have reached 26%, and the mortality rate has reached 4.3% by the latest study [5].", [["human", "ORGANISM", 32, 37], ["human", "ORGANISM", 41, 46], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 41, 46], ["severe cases", "PROBLEM", 111, 123], ["the mortality rate", "TEST", 162, 180], ["the latest study", "TEST", 201, 217], ["increasing", "OBSERVATION_MODIFIER", 9, 19]]], ["Asymptomatic infectious individuals can also be a source of infection according to the latest version of the guidelines [6].", [["infection", "DISEASE", 60, 69], ["individuals", "ORGANISM", 24, 35], ["Asymptomatic infectious individuals", "PROBLEM", 0, 35], ["infection", "PROBLEM", 60, 69], ["infectious", "OBSERVATION", 13, 23], ["infection", "OBSERVATION", 60, 69]]], ["A previous study [7] indicated CT has a higher sensitivity (97%) than RT-PCR results (30\u201360%) for COVID-19 pneumonia.", [["pneumonia", "DISEASE", 107, 116], ["COVID-19", "SPECIES", 98, 106], ["A previous study", "TEST", 0, 16], ["CT", "TEST", 31, 33], ["RT-PCR", "TEST", 70, 76], ["COVID", "TEST", 98, 103], ["pneumonia", "PROBLEM", 107, 116], ["pneumonia", "OBSERVATION", 107, 116]]], ["With the rapid spread of COVID-19, CT is especially important for the diagnosis of COVID-19 pneumonia and the judgment of the degree of disease.", [["pneumonia", "DISEASE", 92, 101], ["COVID", "TEST", 25, 30], ["CT", "TEST", 35, 37], ["COVID-19 pneumonia", "PROBLEM", 83, 101], ["disease", "PROBLEM", 136, 143], ["rapid", "OBSERVATION_MODIFIER", 9, 14], ["spread", "OBSERVATION_MODIFIER", 15, 21], ["pneumonia", "OBSERVATION", 92, 101], ["degree", "OBSERVATION_MODIFIER", 126, 132], ["disease", "OBSERVATION", 136, 143]]], ["Although several studies have described the CT imaging features of COVID-19 pneumonia [8\u201310], so far, there is still a lack of large-sample CT imaging studies and follow-up observation.", [["pneumonia", "DISEASE", 76, 85], ["several studies", "TEST", 9, 24], ["the CT imaging", "TEST", 40, 54], ["COVID", "TEST", 67, 72], ["pneumonia", "PROBLEM", 76, 85], ["large-sample CT imaging studies", "TEST", 127, 158], ["follow-up observation", "TEST", 163, 184], ["pneumonia", "OBSERVATION", 76, 85]]], ["In this study, we collected 100 cases of laboratory-confirmed COVID-19 pneumonia patients, including 84 cases with CT follow-up scan, to describe the CT imaging features and evolution of this disease.CT scanning protocol ::: Materials and methodsUCT 780 (United Imaging), GE optima 660 (GE Healthcare), or Siemens SOMATOM Definition AS+ (Siemens Healthcare) spiral CT scanners were used.", [["pneumonia", "DISEASE", 71, 80], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["this study", "TEST", 3, 13], ["COVID", "TEST", 62, 67], ["pneumonia", "PROBLEM", 71, 80], ["CT follow-up scan", "TEST", 115, 132], ["the CT imaging", "TEST", 146, 160], ["this disease", "PROBLEM", 187, 199], ["CT scanning protocol", "TEST", 200, 220], ["spiral CT scanners", "TREATMENT", 358, 376], ["pneumonia", "OBSERVATION", 71, 80], ["disease", "OBSERVATION", 192, 199]]], ["The patients were scanned in the supine position and with breath holding at end of inspiration.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["breath holding", "TREATMENT", 58, 72]]], ["The scanning range is from the apex to the bottom of the lung.", [["lung", "ANATOMY", 57, 61], ["lung", "ORGAN", 57, 61], ["The scanning range", "TEST", 0, 18], ["apex", "ANATOMY_MODIFIER", 31, 35], ["bottom", "ANATOMY_MODIFIER", 43, 49], ["lung", "ANATOMY", 57, 61]]], ["The scanning parameters were tube voltage, 120 kV; tube current, 200\u2013300 mAs; pitch, 0.99\u20131.22 mm; matrix, 512 \u00d7 512; layer thickness, 5 mm; field, 350 mm \u00d7 350 mm; and reconstruction section thickness, 0.625 or 1.25 mm.", [["matrix", "ANATOMY", 99, 105], ["tube", "TISSUE", 29, 33], ["tube", "TISSUE", 51, 55], ["The scanning parameters", "TEST", 0, 23], ["tube voltage", "TEST", 29, 41], ["tube current", "TEST", 51, 63], ["mAs", "TEST", 73, 76], ["pitch", "TEST", 78, 83], ["matrix", "TEST", 99, 105], ["layer thickness", "TEST", 118, 133], ["reconstruction section thickness", "TEST", 169, 201], ["5 mm", "OBSERVATION_MODIFIER", 135, 139]]], ["All of the patients underwent unenhanced CT scan without contrast agent administration.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["unenhanced CT scan", "TEST", 30, 48], ["contrast agent administration", "TREATMENT", 57, 86]]], ["Fifteen cases had only one CT scan, 30 cases underwent two CT scans, 30 cases had three CT scans, 18 cases underwent four CT scans, and 17 cases had five CT examinations for follow-up observation.", [["one CT scan", "TEST", 23, 34], ["two CT scans", "TEST", 55, 67], ["three CT scans", "TEST", 82, 96], ["four CT scans", "TEST", 117, 130], ["five CT examinations", "TEST", 149, 169], ["follow-up observation", "TEST", 174, 195]]], ["A total of 272 CT examinations of all the 100 patients were reviewed and evaluated.CT image viewing and estimation ::: Materials and methodsThe CT images were reviewed by three experienced thoracic radiologists (Z.S., W.Y., and Z.T. with 13, 9, and 9 years of experience, respectively) on a console (Synapses; Fujifilm) with multiplanar reconstruction tool kit independently; when there was a discrepancy, the final result was made by consensus.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["CT examinations", "TEST", 15, 30], ["CT image viewing", "TEST", 83, 99], ["The CT images", "TEST", 140, 153], ["Z.T.", "TEST", 228, 232], ["thoracic", "ANATOMY", 189, 197]]], ["The lung and mediastinal windows were set as follows: window width, 1000\u20131500 HU; window level, \u2212 700 HU to \u2013 550 HU; and window width, 300\u2013350 HU; window level, 30\u201340 HU, respectively.CT image viewing and estimation ::: Materials and methodsThe location of lung abnormalities was divided into peripheral distribution (mainly involving the peripheral one third of the lung) and peripheral plus center distribution (including both peripheral and central regions); the number of lung lobes affected was also recorded.", [["lung", "ANATOMY", 4, 8], ["mediastinal", "ANATOMY", 13, 24], ["lung", "ANATOMY", 258, 262], ["lung", "ANATOMY", 368, 372], ["lung lobes", "ANATOMY", 477, 487], ["lung abnormalities", "DISEASE", 258, 276], ["lung", "ORGAN", 4, 8], ["lung", "ORGAN", 258, 262], ["lung", "ORGAN", 368, 372], ["peripheral", "TISSUE", 430, 440], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 477, 487], ["CT image viewing", "TEST", 185, 201], ["lung abnormalities", "PROBLEM", 258, 276], ["lung", "ANATOMY", 4, 8], ["mediastinal", "ANATOMY", 13, 24], ["700 HU", "OBSERVATION_MODIFIER", 98, 104], ["550 HU", "OBSERVATION_MODIFIER", 110, 116], ["350 HU", "OBSERVATION_MODIFIER", 140, 146], ["lung", "ANATOMY", 258, 262], ["abnormalities", "OBSERVATION", 263, 276], ["peripheral", "ANATOMY_MODIFIER", 294, 304], ["distribution", "OBSERVATION_MODIFIER", 305, 317], ["peripheral", "ANATOMY_MODIFIER", 340, 350], ["one third", "ANATOMY_MODIFIER", 351, 360], ["lung", "ANATOMY", 368, 372], ["peripheral", "ANATOMY_MODIFIER", 378, 388], ["center", "OBSERVATION_MODIFIER", 394, 400], ["distribution", "OBSERVATION_MODIFIER", 401, 413], ["both", "ANATOMY_MODIFIER", 425, 429], ["peripheral", "ANATOMY_MODIFIER", 430, 440], ["central", "ANATOMY_MODIFIER", 445, 452], ["regions", "ANATOMY_MODIFIER", 453, 460], ["number", "OBSERVATION_MODIFIER", 467, 473], ["lung", "ANATOMY", 477, 481], ["lobes", "ANATOMY_MODIFIER", 482, 487]]], ["The number of lung abnormalities was recorded as single and multiple.", [["lung", "ANATOMY", 14, 18], ["lung abnormalities", "DISEASE", 14, 32], ["lung", "ORGAN", 14, 18], ["lung abnormalities", "PROBLEM", 14, 32], ["number", "OBSERVATION_MODIFIER", 4, 10], ["lung", "ANATOMY", 14, 18], ["abnormalities", "OBSERVATION", 19, 32], ["multiple", "OBSERVATION_MODIFIER", 60, 68]]], ["The main CT signs included 13 items divided into 3 categories as follows: primary sign: (1) ground glass opacity (GGO, irregular hazy increased attenuation, with visible lung markings), (2) consolidation (homogeneous increase intensity with obscuring lung markings), (3) GGO plus consolidation (consolidation superimposed on a background of GGO), and (4) GGO plus reticular pattern (thickened interlobular and intralobular septum on the basis of GGO, showing crazy-paving sign); secondary sign: (1) vacuolar sign (low-density area of vacuole < 5 mm), (2) microvascular dilation (small vessels dilate in the focus), (3) air bronchogram (air-filled bronchi on a basis of opaque airless lung), (4) subpleural transparent line (thin transparent line lying between the focus and pleura), (5) thickening of the pleura, (6) pleural retraction (lesions located under the pleura and pull pleura), and (7) pleural effusion; and repairing sign: (1) subpleural line (arc-like dense shadow less than 1 cm away from the pleura and parallel to the pleura), (1) bronchus distortion (tortuosity of branches of small bronchus), and (1) fibrotic strips (irregular fibrotic streak shadow); lymphadenopathy, pneumothorax, and pneumomediastinum were also recorded.CT image viewing and estimation ::: Materials and methodsA CT scoring method was used to evaluate the extent of lung involvement according to a previous study related to SARS and MERS CT imaging [12\u201315].", [["lung", "ANATOMY", 170, 174], ["lung", "ANATOMY", 251, 255], ["reticular", "ANATOMY", 364, 373], ["interlobular", "ANATOMY", 393, 405], ["intralobular septum", "ANATOMY", 410, 429], ["vacuolar", "ANATOMY", 499, 507], ["vacuole", "ANATOMY", 534, 541], ["microvascular", "ANATOMY", 555, 568], ["vessels", "ANATOMY", 585, 592], ["focus", "ANATOMY", 607, 612], ["bronchi", "ANATOMY", 647, 654], ["lung", "ANATOMY", 684, 688], ["focus", "ANATOMY", 764, 769], ["pleura", "ANATOMY", 774, 780], ["pleura", "ANATOMY", 805, 811], ["pleural", "ANATOMY", 817, 824], ["lesions", "ANATOMY", 837, 844], ["pleura", "ANATOMY", 863, 869], ["pleura", "ANATOMY", 879, 885], ["pleural", "ANATOMY", 896, 903], ["subpleural line", "ANATOMY", 938, 953], ["pleura", "ANATOMY", 1006, 1012], ["pleura", "ANATOMY", 1033, 1039], ["bronchus", "ANATOMY", 1046, 1054], ["branches", "ANATOMY", 1081, 1089], ["bronchus", "ANATOMY", 1099, 1107], ["streak", "ANATOMY", 1154, 1160], ["lung", "ANATOMY", 1354, 1358], ["GGO", "DISEASE", 114, 117], ["pleural effusion", "DISEASE", 896, 912], ["lymphadenopathy", "DISEASE", 1170, 1185], ["pneumothorax", "DISEASE", 1187, 1199], ["pneumomediastinum", "DISEASE", 1205, 1222], ["SARS", "DISEASE", 1412, 1416], ["lung", "ORGAN", 170, 174], ["lung", "ORGAN", 251, 255], ["interlobular", "MULTI-TISSUE_STRUCTURE", 393, 405], ["intralobular septum", "MULTI-TISSUE_STRUCTURE", 410, 429], ["vacuole", "CELLULAR_COMPONENT", 534, 541], ["microvascular", "TISSUE", 555, 568], ["vessels", "MULTI-TISSUE_STRUCTURE", 585, 592], ["bronchi", "MULTI-TISSUE_STRUCTURE", 647, 654], ["lung", "ORGAN", 684, 688], ["pleura", "ORGAN", 774, 780], ["pleura", "ORGAN", 805, 811], ["pleural", "ORGAN", 817, 824], ["lesions", "CANCER", 837, 844], ["pleura", "ORGAN", 863, 869], ["pleura", "ORGAN", 879, 885], ["pleural", "ORGAN", 896, 903], ["pleura", "ORGAN", 1006, 1012], ["pleura", "ORGAN", 1033, 1039], ["bronchus", "MULTI-TISSUE_STRUCTURE", 1046, 1054], ["bronchus", "MULTI-TISSUE_STRUCTURE", 1099, 1107], ["lung", "ORGAN", 1354, 1358], ["The main CT signs", "TEST", 0, 17], ["ground glass opacity (GGO", "PROBLEM", 92, 117], ["irregular hazy increased attenuation", "PROBLEM", 119, 155], ["visible lung markings)", "PROBLEM", 162, 184], ["(2) consolidation (homogeneous increase intensity", "PROBLEM", 186, 235], ["obscuring lung markings)", "PROBLEM", 241, 265], ["GGO plus consolidation (consolidation", "PROBLEM", 271, 308], ["GGO", "PROBLEM", 341, 344], ["GGO plus reticular pattern (thickened interlobular and intralobular septum", "PROBLEM", 355, 429], ["GGO", "PROBLEM", 446, 449], ["vacuolar sign", "TEST", 499, 512], ["(2) microvascular dilation (small vessels dilate in the focus), (3) air bronchogram (air-filled bronchi", "PROBLEM", 551, 654], ["opaque airless lung)", "PROBLEM", 669, 689], ["subpleural transparent line (thin transparent line", "TREATMENT", 695, 745], ["thickening of the pleura", "PROBLEM", 787, 811], ["pleural retraction (lesions", "PROBLEM", 817, 844], ["pleural effusion", "PROBLEM", 896, 912], ["subpleural line (arc-like dense shadow", "PROBLEM", 938, 976], ["bronchus distortion (tortuosity of branches of small bronchus), and (1) fibrotic strips (irregular fibrotic streak shadow", "PROBLEM", 1046, 1167], ["lymphadenopathy", "PROBLEM", 1170, 1185], ["pneumothorax", "PROBLEM", 1187, 1199], ["pneumomediastinum", "PROBLEM", 1205, 1222], ["CT image viewing", "TEST", 1242, 1258], ["methodsA CT scoring method", "TEST", 1292, 1318], ["lung involvement", "PROBLEM", 1354, 1370], ["a previous study", "TEST", 1384, 1400], ["SARS", "PROBLEM", 1412, 1416], ["MERS CT imaging", "TEST", 1421, 1436], ["main", "OBSERVATION_MODIFIER", 4, 8], ["ground glass opacity", "OBSERVATION", 92, 112], ["GGO", "OBSERVATION_MODIFIER", 114, 117], ["irregular", "OBSERVATION_MODIFIER", 119, 128], ["hazy", "OBSERVATION_MODIFIER", 129, 133], ["increased", "OBSERVATION_MODIFIER", 134, 143], ["attenuation", "OBSERVATION_MODIFIER", 144, 155], ["visible", "OBSERVATION_MODIFIER", 162, 169], ["lung", "ANATOMY", 170, 174], ["markings", "ANATOMY_MODIFIER", 175, 183], ["consolidation", "OBSERVATION", 190, 203], ["homogeneous", "OBSERVATION_MODIFIER", 205, 216], ["increase", "OBSERVATION_MODIFIER", 217, 225], ["intensity", "OBSERVATION_MODIFIER", 226, 235], ["obscuring", "OBSERVATION_MODIFIER", 241, 250], ["lung", "ANATOMY", 251, 255], ["markings", "OBSERVATION", 256, 264], ["consolidation", "OBSERVATION", 280, 293], ["consolidation", "OBSERVATION", 295, 308], ["GGO", "OBSERVATION", 341, 344], ["reticular", "ANATOMY_MODIFIER", 364, 373], ["thickened", "OBSERVATION_MODIFIER", 383, 392], ["interlobular", "ANATOMY_MODIFIER", 393, 405], ["intralobular septum", "ANATOMY", 410, 429], ["GGO", "OBSERVATION", 446, 449], ["low-density", "OBSERVATION_MODIFIER", 514, 525], ["vacuole", "ANATOMY_MODIFIER", 534, 541], ["< 5 mm", "OBSERVATION_MODIFIER", 542, 548], ["microvascular", "ANATOMY_MODIFIER", 555, 568], ["dilation", "OBSERVATION", 569, 577], ["small", "OBSERVATION_MODIFIER", 579, 584], ["vessels", "ANATOMY", 585, 592], ["dilate", "OBSERVATION_MODIFIER", 593, 599], ["air bronchogram", "OBSERVATION", 619, 634], ["air-", "ANATOMY_MODIFIER", 636, 640], ["filled", "OBSERVATION", 640, 646], ["bronchi", "ANATOMY", 647, 654], ["opaque", "OBSERVATION_MODIFIER", 669, 675], ["airless", "OBSERVATION", 676, 683], ["lung", "ANATOMY", 684, 688], ["subpleural", "ANATOMY_MODIFIER", 695, 705], ["transparent line", "OBSERVATION", 706, 722], ["thin", "OBSERVATION_MODIFIER", 724, 728], ["transparent", "OBSERVATION_MODIFIER", 729, 740], ["line", "OBSERVATION_MODIFIER", 741, 745], ["pleura", "ANATOMY", 774, 780], ["thickening", "OBSERVATION", 787, 797], ["pleura", "ANATOMY", 805, 811], ["pleural", "ANATOMY", 817, 824], ["retraction", "OBSERVATION", 825, 835], ["lesions", "OBSERVATION", 837, 844], ["pleura", "ANATOMY", 863, 869], ["pull", "ANATOMY_MODIFIER", 874, 878], ["pleura", "ANATOMY", 879, 885], ["pleural", "ANATOMY", 896, 903], ["effusion", "OBSERVATION", 904, 912], ["subpleural", "ANATOMY", 938, 948], ["line", "OBSERVATION", 949, 953], ["arc", "OBSERVATION_MODIFIER", 955, 958], ["dense", "OBSERVATION_MODIFIER", 964, 969], ["shadow", "OBSERVATION_MODIFIER", 970, 976], ["less than 1 cm", "OBSERVATION_MODIFIER", 977, 991], ["pleura", "ANATOMY", 1006, 1012], ["pleura", "ANATOMY", 1033, 1039], ["bronchus", "ANATOMY", 1046, 1054], ["tortuosity", "OBSERVATION_MODIFIER", 1067, 1077], ["branches", "ANATOMY_MODIFIER", 1081, 1089], ["small", "OBSERVATION_MODIFIER", 1093, 1098], ["bronchus", "ANATOMY", 1099, 1107], ["fibrotic", "OBSERVATION_MODIFIER", 1118, 1126], ["strips", "OBSERVATION_MODIFIER", 1127, 1133], ["irregular", "OBSERVATION_MODIFIER", 1135, 1144], ["fibrotic", "OBSERVATION_MODIFIER", 1145, 1153], ["streak", "OBSERVATION_MODIFIER", 1154, 1160], ["shadow", "OBSERVATION_MODIFIER", 1161, 1167], ["lymphadenopathy", "OBSERVATION", 1170, 1185], ["pneumothorax", "OBSERVATION", 1187, 1199], ["pneumomediastinum", "OBSERVATION", 1205, 1222], ["lung", "ANATOMY", 1354, 1358], ["involvement", "OBSERVATION", 1359, 1370]]], ["Both lungs were divided into the upper zone (from the apex to above the carina level), middle zone (from the carina to the inferior pulmonary vein), and the lower zone (below the inferior pulmonary vein); then, a vertical line crossing the midpoint of the diaphragm in sagittal position was used to divide each lung into two parts: anterior and posterior parts.", [["lungs", "ANATOMY", 5, 10], ["upper zone", "ANATOMY", 33, 43], ["carina", "ANATOMY", 72, 78], ["middle zone", "ANATOMY", 87, 98], ["carina", "ANATOMY", 109, 115], ["inferior pulmonary vein", "ANATOMY", 123, 146], ["lower zone", "ANATOMY", 157, 167], ["inferior pulmonary vein", "ANATOMY", 179, 202], ["diaphragm", "ANATOMY", 256, 265], ["lung", "ANATOMY", 311, 315], ["anterior", "ANATOMY", 332, 340], ["posterior parts", "ANATOMY", 345, 360], ["lungs", "ORGAN", 5, 10], ["upper zone", "MULTI-TISSUE_STRUCTURE", 33, 43], ["carina", "MULTI-TISSUE_STRUCTURE", 72, 78], ["carina", "MULTI-TISSUE_STRUCTURE", 109, 115], ["inferior pulmonary vein", "MULTI-TISSUE_STRUCTURE", 123, 146], ["inferior pulmonary vein", "MULTI-TISSUE_STRUCTURE", 179, 202], ["diaphragm", "ORGAN", 256, 265], ["lung", "ORGAN", 311, 315], ["anterior", "MULTI-TISSUE_STRUCTURE", 332, 340], ["a vertical line", "TREATMENT", 211, 226], ["lungs", "ANATOMY", 5, 10], ["divided", "OBSERVATION", 16, 23], ["upper", "ANATOMY_MODIFIER", 33, 38], ["zone", "ANATOMY_MODIFIER", 39, 43], ["apex", "ANATOMY_MODIFIER", 54, 58], ["carina", "ANATOMY", 72, 78], ["middle", "ANATOMY_MODIFIER", 87, 93], ["zone", "ANATOMY_MODIFIER", 94, 98], ["carina", "ANATOMY", 109, 115], ["inferior pulmonary vein", "ANATOMY", 123, 146], ["lower", "ANATOMY_MODIFIER", 157, 162], ["zone", "ANATOMY_MODIFIER", 163, 167], ["inferior pulmonary vein", "ANATOMY", 179, 202], ["vertical line", "OBSERVATION", 213, 226], ["midpoint", "ANATOMY_MODIFIER", 240, 248], ["diaphragm", "ANATOMY", 256, 265], ["lung", "ANATOMY", 311, 315], ["two parts", "ANATOMY_MODIFIER", 321, 330], ["anterior", "ANATOMY_MODIFIER", 332, 340], ["posterior", "ANATOMY_MODIFIER", 345, 354], ["parts", "ANATOMY_MODIFIER", 355, 360]]], ["Finally, each lung was divided into 6 zones altogether, namely the upper anterior zone, the upper posterior zone, the middle anterior zone, the middle posterior zone, the lower anterior zone, and the lower posterior zone.", [["lung", "ANATOMY", 14, 18], ["upper anterior zone", "ANATOMY", 67, 86], ["upper posterior zone", "ANATOMY", 92, 112], ["middle anterior zone", "ANATOMY", 118, 138], ["middle posterior zone", "ANATOMY", 144, 165], ["lower anterior zone", "ANATOMY", 171, 190], ["lower posterior zone", "ANATOMY", 200, 220], ["lung", "ORGAN", 14, 18], ["anterior zone", "MULTI-TISSUE_STRUCTURE", 73, 86], ["posterior zone", "MULTI-TISSUE_STRUCTURE", 98, 112], ["anterior zone", "MULTI-TISSUE_STRUCTURE", 125, 138], ["posterior zone", "MULTI-TISSUE_STRUCTURE", 151, 165], ["anterior zone", "MULTI-TISSUE_STRUCTURE", 177, 190], ["lung", "ANATOMY", 14, 18], ["6 zones", "ANATOMY_MODIFIER", 36, 43], ["upper", "ANATOMY_MODIFIER", 67, 72], ["anterior", "ANATOMY_MODIFIER", 73, 81], ["zone", "ANATOMY_MODIFIER", 82, 86], ["upper", "ANATOMY_MODIFIER", 92, 97], ["posterior", "ANATOMY_MODIFIER", 98, 107], ["zone", "ANATOMY_MODIFIER", 108, 112], ["middle", "ANATOMY_MODIFIER", 118, 124], ["anterior", "ANATOMY_MODIFIER", 125, 133], ["zone", "ANATOMY_MODIFIER", 134, 138], ["middle", "ANATOMY_MODIFIER", 144, 150], ["posterior", "ANATOMY_MODIFIER", 151, 160], ["zone", "ANATOMY_MODIFIER", 161, 165], ["lower", "ANATOMY_MODIFIER", 171, 176], ["anterior", "ANATOMY_MODIFIER", 177, 185], ["zone", "ANATOMY_MODIFIER", 186, 190], ["lower", "ANATOMY_MODIFIER", 200, 205], ["posterior", "ANATOMY_MODIFIER", 206, 215], ["zone", "ANATOMY_MODIFIER", 216, 220]]], ["The involvement scale in each lung zone was scored based on the following criteria: score 0 (no involvement), score 1 (< 25% involvement), score 2 (25% to less than 50% involvement), score 3 (50% to less than 75% involvement), and score 4 (> 75% involvement).", [["lung zone", "ANATOMY", 30, 39], ["lung", "ORGAN", 30, 34], ["The involvement scale in each lung zone", "PROBLEM", 0, 39], ["score", "TEST", 110, 115], ["score", "TEST", 139, 144], ["score", "TEST", 183, 188], ["score", "TEST", 231, 236], ["scale", "OBSERVATION_MODIFIER", 16, 21], ["lung", "ANATOMY", 30, 34], ["zone", "ANATOMY_MODIFIER", 35, 39]]], ["The CT scores were also assessed by the three radiologists mentioned before by consensus.", [["The CT scores", "TEST", 0, 13]]], ["The scores were recorded and summed for different lung regions (such as the left and right lung; bilateral upper, middle, and lower zone; bilateral anterior and posterior zones), with a maximum score of 48.Statistical analysis ::: Materials and methodsData were analyzed using SPSS, version 22.0 (IBM Statistics).", [["lung", "ANATOMY", 50, 54], ["left", "ANATOMY", 76, 80], ["right lung", "ANATOMY", 85, 95], ["lower zone", "ANATOMY", 126, 136], ["anterior", "ANATOMY", 148, 156], ["posterior zones", "ANATOMY", 161, 176], ["lung", "ORGAN", 50, 54], ["lung", "ORGAN", 91, 95], ["upper", "ORGANISM_SUBDIVISION", 107, 112], ["anterior", "MULTI-TISSUE_STRUCTURE", 148, 156], ["The scores", "TEST", 0, 10], ["different lung regions (such as the left and right lung; bilateral upper, middle, and lower zone; bilateral anterior and posterior zones", "PROBLEM", 40, 176], ["a maximum score", "TEST", 184, 199], ["methodsData", "TEST", 245, 256], ["SPSS", "TEST", 277, 281], ["version", "TEST", 283, 290], ["lung", "ANATOMY", 50, 54], ["regions", "ANATOMY_MODIFIER", 55, 62], ["left", "ANATOMY_MODIFIER", 76, 80], ["right", "ANATOMY_MODIFIER", 85, 90], ["lung", "ANATOMY", 91, 95], ["bilateral", "ANATOMY_MODIFIER", 97, 106], ["upper", "ANATOMY_MODIFIER", 107, 112], ["middle", "ANATOMY_MODIFIER", 114, 120], ["lower", "ANATOMY_MODIFIER", 126, 131], ["zone", "ANATOMY_MODIFIER", 132, 136], ["bilateral", "ANATOMY_MODIFIER", 138, 147], ["anterior", "ANATOMY_MODIFIER", 148, 156], ["posterior", "ANATOMY_MODIFIER", 161, 170], ["zones", "ANATOMY_MODIFIER", 171, 176], ["maximum", "OBSERVATION_MODIFIER", 186, 193]]], ["Continuous variables were expressed as means \u00b1 standard deviations, the Kolmogorov-Smirnov test was used for the normal distribution test, and continuous variables were compared with the Mann-Whitney U test.", [["the Kolmogorov-Smirnov test", "TEST", 68, 95], ["the Mann-Whitney U test", "TEST", 183, 206]]], ["The incidence of CT signs was expressed as number (%) and compared by \u03c72 test between the early rapid progressive stage, advanced stage, and absorption stage.", [["CT signs", "TEST", 17, 25], ["the early rapid progressive stage", "PROBLEM", 86, 119], ["advanced stage", "PROBLEM", 121, 135], ["absorption stage", "PROBLEM", 141, 157], ["rapid", "OBSERVATION_MODIFIER", 96, 101], ["progressive", "OBSERVATION_MODIFIER", 102, 113], ["stage", "OBSERVATION_MODIFIER", 114, 119], ["advanced stage", "OBSERVATION_MODIFIER", 121, 135], ["absorption stage", "OBSERVATION_MODIFIER", 141, 157]]], ["Bonferroni correction was used for pairwise comparisons among the three groups.", [["Bonferroni correction", "TREATMENT", 0, 21], ["pairwise comparisons", "TEST", 35, 55]]], ["A p value of less than 0.05 was considered statistically significant difference.Symptoms ::: Clinical features ::: ResultsA total of 100 patients (mean age, 52.3 years \u00b1 13.1; age range, 27\u201380 years) with COVID-19 pneumonia without ARDS were included.", [["pneumonia", "DISEASE", 214, 223], ["ARDS", "DISEASE", 232, 236], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["A p value", "TEST", 0, 9], ["Symptoms", "PROBLEM", 80, 88], ["COVID", "TEST", 205, 210], ["pneumonia", "PROBLEM", 214, 223], ["ARDS", "PROBLEM", 232, 236], ["significant", "OBSERVATION_MODIFIER", 57, 68], ["difference", "OBSERVATION", 69, 79], ["pneumonia", "OBSERVATION", 214, 223], ["without", "UNCERTAINTY", 224, 231], ["ARDS", "OBSERVATION", 232, 236]]], ["Fifty-four (54%) patients were men (mean age, 52.4 years \u00b1 12.5; age range, 30\u201377 years), and 46 (46%) were women (mean age, 52.3 years \u00b1 14.0; age range, 27\u201380 years).", [["patients", "ORGANISM", 17, 25], ["men", "ORGANISM", 31, 34], ["women", "ORGANISM", 108, 113], ["patients", "SPECIES", 17, 25], ["men", "SPECIES", 31, 34], ["women", "SPECIES", 108, 113]]], ["The initial symptoms included fever in 87 patients (87.0%), coughing in 56 patients (56%), fatigue in 17 patients (17%), shortness of breath in 27 patients (27%), muscle pain in 26 patients (26%), and diarrhea in 22 patients (22%).", [["muscle", "ANATOMY", 163, 169], ["fever", "DISEASE", 30, 35], ["coughing", "DISEASE", 60, 68], ["fatigue", "DISEASE", 91, 98], ["shortness of breath", "DISEASE", 121, 140], ["muscle pain", "DISEASE", 163, 174], ["diarrhea", "DISEASE", 201, 209], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 105, 113], ["patients", "ORGANISM", 147, 155], ["muscle", "ORGAN", 163, 169], ["patients", "ORGANISM", 181, 189], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 147, 155], ["patients", "SPECIES", 181, 189], ["patients", "SPECIES", 216, 224], ["The initial symptoms", "PROBLEM", 0, 20], ["fever", "PROBLEM", 30, 35], ["coughing", "PROBLEM", 60, 68], ["fatigue", "PROBLEM", 91, 98], ["shortness of breath", "PROBLEM", 121, 140], ["muscle pain", "PROBLEM", 163, 174], ["diarrhea", "PROBLEM", 201, 209], ["muscle", "ANATOMY", 163, 169], ["diarrhea", "OBSERVATION", 201, 209]]], ["Four patients first showed negative results from RT-PCR test of COVID-19 nucleic acid; 1 patient\u2019s result turned positive on day 14 from the symptom onset, 1 patient\u2019s result turned positive on day 17, 1 patient\u2019s result turned positive on day 20, and 1 patient\u2019s result turned positive on day 27.", [["COVID-19 nucleic acid", "CHEMICAL", 64, 85], ["patients", "ORGANISM", 5, 13], ["patient", "ORGANISM", 89, 96], ["patient", "ORGANISM", 158, 165], ["patient", "ORGANISM", 204, 211], ["patient", "ORGANISM", 254, 261], ["patients", "SPECIES", 5, 13], ["patient", "SPECIES", 89, 96], ["patient", "SPECIES", 158, 165], ["patient", "SPECIES", 204, 211], ["patient", "SPECIES", 254, 261], ["RT", "TEST", 49, 51], ["PCR test", "TEST", 52, 60], ["COVID", "TEST", 64, 69], ["nucleic acid", "TEST", 73, 85]]], ["Majority of the laboratory test results were in the normal range, and the most common abnormalities included decreased lymphocyte count, elevated lactate dehydrogenase (LDH) and erythrocyte sedimentation rate (ESR), and high sensitive C-reactive protein (hs-CRP) (see Table 1 for details).", [["lymphocyte", "ANATOMY", 119, 129], ["erythrocyte", "ANATOMY", 178, 189], ["lactate", "CHEMICAL", 146, 153], ["lactate", "CHEMICAL", 146, 153], ["lymphocyte", "CELL", 119, 129], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 146, 167], ["LDH", "SIMPLE_CHEMICAL", 169, 172], ["erythrocyte", "CELL", 178, 189], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 235, 253], ["hs-CRP", "GENE_OR_GENE_PRODUCT", 255, 261], ["lactate dehydrogenase", "PROTEIN", 146, 167], ["LDH", "PROTEIN", 169, 172], ["C-reactive protein", "PROTEIN", 235, 253], ["hs", "PROTEIN", 255, 257], ["CRP", "PROTEIN", 258, 261], ["the laboratory test", "TEST", 12, 31], ["the most common abnormalities", "PROBLEM", 70, 99], ["decreased lymphocyte count", "PROBLEM", 109, 135], ["elevated lactate dehydrogenase (LDH)", "PROBLEM", 137, 173], ["erythrocyte sedimentation rate", "TEST", 178, 208], ["ESR", "TEST", 210, 213], ["high sensitive C-reactive protein", "PROBLEM", 220, 253], ["CRP", "TEST", 258, 261], ["normal range", "OBSERVATION_MODIFIER", 52, 64], ["decreased", "OBSERVATION_MODIFIER", 109, 118], ["lymphocyte count", "OBSERVATION", 119, 135], ["erythrocyte", "ANATOMY", 178, 189]]], ["In addition, in our cohort, 2 patients processed to severe condition; each of these 2 patients underwent 2 CT scans (all within 14 days after symptom onset) before their condition became severe; after that, X-ray was used to monitor their condition.Distribution of lung abnormalities ::: Clinical features ::: ResultsOf all 272 CT scans, 169 (62.1%) showed predominantly peripheral distribution, 103 (37.9%) showed peripheral plus central distribution, 22 (8.1%) showed single lung abnormality, and 250 (91.9%) showed multiple lung abnormalities.", [["lung", "ANATOMY", 265, 269], ["lung", "ANATOMY", 477, 481], ["lung", "ANATOMY", 527, 531], ["lung abnormalities", "DISEASE", 265, 283], ["lung abnormality", "DISEASE", 477, 493], ["lung abnormalities", "DISEASE", 527, 545], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 86, 94], ["lung", "ORGAN", 265, 269], ["lung", "ORGAN", 477, 481], ["lung", "ORGAN", 527, 531], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 86, 94], ["severe condition", "PROBLEM", 52, 68], ["2 CT scans", "TEST", 105, 115], ["severe", "PROBLEM", 187, 193], ["lung abnormalities", "PROBLEM", 265, 283], ["CT scans", "TEST", 328, 336], ["predominantly peripheral distribution", "PROBLEM", 357, 394], ["peripheral plus central distribution", "PROBLEM", 415, 451], ["single lung abnormality", "PROBLEM", 470, 493], ["multiple lung abnormalities", "PROBLEM", 518, 545], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["lung", "ANATOMY", 265, 269], ["abnormalities", "OBSERVATION", 270, 283], ["predominantly", "OBSERVATION_MODIFIER", 357, 370], ["peripheral", "ANATOMY_MODIFIER", 371, 381], ["peripheral", "ANATOMY_MODIFIER", 415, 425], ["central", "ANATOMY_MODIFIER", 431, 438], ["lung", "ANATOMY", 477, 481], ["abnormality", "OBSERVATION", 482, 493], ["multiple", "OBSERVATION_MODIFIER", 518, 526], ["lung", "ANATOMY", 527, 531], ["abnormalities", "OBSERVATION", 532, 545]]], ["We compared the CT scores of different regions of the lungs of all the 272 CT scans.", [["lungs", "ANATOMY", 54, 59], ["lungs", "ORGAN", 54, 59], ["the CT scores", "TEST", 12, 25], ["CT scans", "TEST", 75, 83], ["lungs", "ANATOMY", 54, 59]]], ["No significant difference was found between the left (6.6 \u00b1 5.4) and right (6.8 \u00b1 5.4) lung (p = 0.556).", [["left", "ANATOMY", 48, 52], ["lung", "ANATOMY", 87, 91], ["lung", "ORGAN", 87, 91], ["right", "TEST", 69, 74], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25], ["left", "ANATOMY_MODIFIER", 48, 52], ["right", "ANATOMY_MODIFIER", 69, 74], ["lung", "ANATOMY", 87, 91]]], ["The CT scores of the upper zone (3.4 \u00b1 3.6) were significantly lower than those of the middle (5.0 \u00b1 3.9) and lower (4.8 \u00b1 3.6) zones (p < 0.001).", [["upper zone", "ANATOMY", 21, 31], ["upper", "ORGANISM_SUBDIVISION", 21, 26], ["The CT scores of the upper zone", "TEST", 0, 31], ["upper", "ANATOMY_MODIFIER", 21, 26], ["zone", "ANATOMY_MODIFIER", 27, 31], ["significantly", "OBSERVATION_MODIFIER", 49, 62], ["lower", "OBSERVATION_MODIFIER", 63, 68], ["middle", "ANATOMY_MODIFIER", 87, 93], ["lower", "ANATOMY_MODIFIER", 110, 115]]], ["No significant difference was found between the middle and lower zones (p = 1.0).", [["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25], ["middle", "ANATOMY_MODIFIER", 48, 54], ["lower", "ANATOMY_MODIFIER", 59, 64], ["zones", "ANATOMY_MODIFIER", 65, 70]]], ["The CT scores of the anterior zones (4.9 \u00b1 4.7) were significantly lower than those of the posterior zones (8.4 \u00b1 6.2) (p < 0.001).Disease course ::: Clinical features ::: ResultsAs this is a brand new disease with less than 1 month\u2019s observation since initial onset, we drew a picture of the extent of lung abnormality involvement on CT (evaluated by the sum of scores for all zones of both lungs) according to the course of disease to speculate the general course of the disease.", [["anterior zones", "ANATOMY", 21, 35], ["posterior zones", "ANATOMY", 91, 106], ["lung", "ANATOMY", 303, 307], ["lungs", "ANATOMY", 392, 397], ["lung abnormality", "DISEASE", 303, 319], ["anterior zones", "MULTI-TISSUE_STRUCTURE", 21, 35], ["lung", "ORGAN", 303, 307], ["lungs", "ORGAN", 392, 397], ["The CT scores of the anterior zones", "TEST", 0, 35], ["a brand new disease", "PROBLEM", 190, 209], ["lung abnormality involvement", "PROBLEM", 303, 331], ["CT", "TEST", 335, 337], ["disease", "PROBLEM", 426, 433], ["the disease", "PROBLEM", 469, 480], ["anterior", "ANATOMY_MODIFIER", 21, 29], ["zones", "ANATOMY_MODIFIER", 30, 35], ["significantly", "OBSERVATION_MODIFIER", 53, 66], ["lower", "OBSERVATION_MODIFIER", 67, 72], ["posterior", "ANATOMY_MODIFIER", 91, 100], ["zones", "ANATOMY_MODIFIER", 101, 106], ["new", "OBSERVATION_MODIFIER", 198, 201], ["disease", "OBSERVATION", 202, 209], ["lung", "ANATOMY", 303, 307], ["abnormality", "OBSERVATION", 308, 319], ["zones", "ANATOMY_MODIFIER", 378, 383], ["both", "ANATOMY_MODIFIER", 387, 391], ["lungs", "ANATOMY", 392, 397], ["disease", "OBSERVATION", 426, 433], ["disease", "OBSERVATION", 473, 480]]], ["Figure 1 approximately shows that 1\u20137 days after symptom onset is the early rapid progressive period, 8\u201314 days is the advanced period with the most severe lung involvement, and after 14 days, the extent of involvement was shown as starting to decrease; particularly, after 21 days, the absorption is more obvious.CT imaging features ::: Clinical features ::: ResultsFrom the above course analysis and a preliminary COVID-19 pneumonia image diagnostic guide in China [6], we divided the CT images into an early rapid progressive stage (\u2264 7 days), an advanced stage (8~14 days), and an absorption stage (> 14 days) according to the course.", [["lung", "ANATOMY", 156, 160], ["pneumonia", "DISEASE", 425, 434], ["lung", "ORGAN", 156, 160], ["symptom", "PROBLEM", 49, 56], ["the most severe lung involvement", "PROBLEM", 140, 172], ["CT imaging features", "TEST", 314, 333], ["the above course analysis", "TEST", 372, 397], ["a preliminary COVID", "TEST", 402, 421], ["the CT images", "TEST", 483, 496], ["an early rapid progressive stage", "PROBLEM", 502, 534], ["an absorption stage", "PROBLEM", 582, 601], ["rapid", "OBSERVATION_MODIFIER", 76, 81], ["progressive", "OBSERVATION_MODIFIER", 82, 93], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["lung", "ANATOMY", 156, 160], ["involvement", "OBSERVATION", 161, 172], ["more obvious", "OBSERVATION_MODIFIER", 301, 313], ["early", "OBSERVATION_MODIFIER", 505, 510], ["rapid", "OBSERVATION_MODIFIER", 511, 516], ["progressive", "OBSERVATION_MODIFIER", 517, 528], ["stage", "OBSERVATION_MODIFIER", 529, 534], ["advanced", "OBSERVATION_MODIFIER", 550, 558], ["absorption stage", "OBSERVATION_MODIFIER", 585, 601]]], ["A total of 272 CT examinations of all the 100 patients were stratified into the above three groups and evaluated.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["CT examinations", "TEST", 15, 30]]], ["Table 2 indicates that in the early rapid progressive stage, GGO (41.9%), GGO plus consolidation (43.0%), and GGO plus reticular pattern (58.1%) were all common; consolidation was relatively rare (11.6%).", [["reticular", "ANATOMY", 119, 128], ["GGO", "DISEASE", 61, 64], ["GGO", "DISEASE", 74, 77], ["GGO", "TEST", 61, 64], ["GGO plus consolidation", "PROBLEM", 74, 96], ["GGO plus reticular pattern", "TEST", 110, 136], ["consolidation", "PROBLEM", 162, 175], ["early", "OBSERVATION_MODIFIER", 30, 35], ["rapid", "OBSERVATION_MODIFIER", 36, 41], ["progressive", "OBSERVATION_MODIFIER", 42, 53], ["consolidation", "OBSERVATION", 83, 96], ["reticular", "ANATOMY_MODIFIER", 119, 128], ["consolidation", "OBSERVATION", 162, 175]]], ["In the advanced stage, GGO showed a significant decrease (p < 0.05), GGO plus reticular pattern showed a significant increase (p < 0.05), GGO plus consolidation (30.1%) showed a decreasing trend, and pleural effusion (12.8%) significantly developed compared with the early rapid progressive stage (2.3%) (p < 0.05).", [["reticular", "ANATOMY", 78, 87], ["pleural effusion", "ANATOMY", 200, 216], ["GGO", "DISEASE", 23, 26], ["pleural effusion", "DISEASE", 200, 216], ["pleural", "ORGAN", 200, 207], ["GGO", "TEST", 23, 26], ["a significant decrease", "PROBLEM", 34, 56], ["GGO plus reticular pattern", "TEST", 69, 95], ["GGO plus consolidation", "PROBLEM", 138, 160], ["a decreasing trend", "PROBLEM", 176, 194], ["pleural effusion", "PROBLEM", 200, 216], ["the early rapid progressive stage", "PROBLEM", 263, 296], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["decrease", "OBSERVATION_MODIFIER", 48, 56], ["reticular", "ANATOMY_MODIFIER", 78, 87], ["significant", "OBSERVATION_MODIFIER", 105, 116], ["increase", "OBSERVATION_MODIFIER", 117, 125], ["consolidation", "OBSERVATION", 147, 160], ["decreasing", "OBSERVATION_MODIFIER", 178, 188], ["trend", "OBSERVATION_MODIFIER", 189, 194], ["pleural", "ANATOMY", 200, 207], ["effusion", "OBSERVATION", 208, 216], ["rapid", "OBSERVATION_MODIFIER", 273, 278], ["progressive", "OBSERVATION_MODIFIER", 279, 290], ["stage", "OBSERVATION_MODIFIER", 291, 296]]], ["In the absorption stage, GGO plus consolidation (9.1%) showed a sharp decrease (p < 0.05), consolidation (9.1%) and GGO plus reticular pattern (66.2%) showed a decreasing trend compared with the first two stages, and GGO (22.1%) kept the same level as that of the advanced stage.", [["reticular", "ANATOMY", 125, 134], ["GGO", "DISEASE", 217, 220], ["the absorption stage", "TEST", 3, 23], ["GGO plus consolidation", "PROBLEM", 25, 47], ["a sharp decrease", "PROBLEM", 62, 78], ["consolidation", "PROBLEM", 91, 104], ["GGO", "TEST", 116, 119], ["reticular pattern", "TEST", 125, 142], ["a decreasing trend", "PROBLEM", 158, 176], ["GGO", "TEST", 217, 220], ["the advanced stage", "PROBLEM", 260, 278], ["absorption stage", "OBSERVATION_MODIFIER", 7, 23], ["GGO", "OBSERVATION", 25, 28], ["consolidation", "OBSERVATION", 34, 47], ["sharp", "OBSERVATION_MODIFIER", 64, 69], ["decrease", "OBSERVATION_MODIFIER", 70, 78], ["consolidation", "OBSERVATION", 91, 104], ["reticular", "ANATOMY_MODIFIER", 125, 134], ["decreasing", "OBSERVATION_MODIFIER", 160, 170], ["trend", "OBSERVATION_MODIFIER", 171, 176], ["GGO", "OBSERVATION", 217, 220]]], ["The repairing signs significantly increased in the advanced stage (p < 0.05) and kept increasing in the absorption stage.", [["The repairing signs", "TEST", 0, 19], ["the absorption stage", "PROBLEM", 100, 120], ["signs", "OBSERVATION_MODIFIER", 14, 19], ["significantly", "OBSERVATION_MODIFIER", 20, 33], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["advanced", "OBSERVATION_MODIFIER", 51, 59], ["stage", "OBSERVATION_MODIFIER", 60, 65], ["increasing", "OBSERVATION_MODIFIER", 86, 96], ["absorption stage", "OBSERVATION_MODIFIER", 104, 120]]], ["Figure 2 displays that the 7 CT signs (GGO, GGO + consolidation, microvascular dilation, air bronchogram, subpleural transparent line, thickening of the pleura, and pleural retraction) showed a downward trend with the course of the disease, 4 CT signs (consolidation, GGO + reticular, vacuolar sign, and pleural effusion) showed a trend of first ascending then descending, and 3 CT signs (subpleural line, bronchus distortion, and fibrotic strips) showed an upward trend.", [["microvascular", "ANATOMY", 65, 78], ["air bronchogram", "ANATOMY", 89, 104], ["subpleural transparent line", "ANATOMY", 106, 133], ["pleura", "ANATOMY", 153, 159], ["pleural", "ANATOMY", 165, 172], ["reticular", "ANATOMY", 274, 283], ["vacuolar", "ANATOMY", 285, 293], ["pleural effusion", "ANATOMY", 304, 320], ["subpleural line", "ANATOMY", 389, 404], ["bronchus", "ANATOMY", 406, 414], ["GGO", "DISEASE", 39, 42], ["pleural effusion", "DISEASE", 304, 320], ["microvascular", "TISSUE", 65, 78], ["pleura", "MULTI-TISSUE_STRUCTURE", 153, 159], ["pleural", "ORGAN", 165, 172], ["vacuolar", "CELLULAR_COMPONENT", 285, 293], ["pleural", "ORGAN", 304, 311], ["bronchus", "MULTI-TISSUE_STRUCTURE", 406, 414], ["the 7 CT signs", "TEST", 23, 37], ["GGO", "PROBLEM", 39, 42], ["GGO", "PROBLEM", 44, 47], ["consolidation", "PROBLEM", 50, 63], ["microvascular dilation", "PROBLEM", 65, 87], ["air bronchogram", "PROBLEM", 89, 104], ["subpleural transparent line", "TREATMENT", 106, 133], ["thickening of the pleura", "PROBLEM", 135, 159], ["pleural retraction", "PROBLEM", 165, 183], ["a downward trend", "PROBLEM", 192, 208], ["the disease", "PROBLEM", 228, 239], ["4 CT signs", "TEST", 241, 251], ["consolidation", "PROBLEM", 253, 266], ["GGO", "PROBLEM", 268, 271], ["reticular, vacuolar sign", "PROBLEM", 274, 298], ["pleural effusion", "PROBLEM", 304, 320], ["3 CT signs", "TEST", 377, 387], ["subpleural line, bronchus distortion", "PROBLEM", 389, 425], ["fibrotic strips", "TEST", 431, 446], ["an upward trend", "PROBLEM", 455, 470], ["GGO", "OBSERVATION", 39, 42], ["consolidation", "OBSERVATION", 50, 63], ["microvascular", "OBSERVATION_MODIFIER", 65, 78], ["dilation", "OBSERVATION", 79, 87], ["air bronchogram", "OBSERVATION", 89, 104], ["subpleural", "ANATOMY_MODIFIER", 106, 116], ["transparent line", "OBSERVATION", 117, 133], ["thickening", "OBSERVATION_MODIFIER", 135, 145], ["pleura", "ANATOMY", 153, 159], ["pleural", "ANATOMY", 165, 172], ["retraction", "OBSERVATION", 173, 183], ["downward", "OBSERVATION_MODIFIER", 194, 202], ["trend", "OBSERVATION_MODIFIER", 203, 208], ["disease", "OBSERVATION", 232, 239], ["consolidation", "OBSERVATION", 253, 266], ["GGO", "OBSERVATION", 268, 271], ["reticular", "ANATOMY_MODIFIER", 274, 283], ["vacuolar sign", "OBSERVATION", 285, 298], ["pleural", "ANATOMY", 304, 311], ["effusion", "OBSERVATION", 312, 320], ["ascending", "ANATOMY_MODIFIER", 346, 355], ["descending", "ANATOMY_MODIFIER", 361, 371], ["subpleural line", "OBSERVATION", 389, 404], ["bronchus", "ANATOMY", 406, 414], ["fibrotic", "OBSERVATION_MODIFIER", 431, 439], ["upward", "OBSERVATION_MODIFIER", 458, 464], ["trend", "OBSERVATION_MODIFIER", 465, 470]]], ["In addition, the pneumothorax and pneumomediastinum occurred in two patients.DiscussionWe investigated the CT imaging features of COVID-19 pneumonia and CT changes according to the disease course of a large sample of 100 patients with 272 CT scans in this study.", [["pneumothorax", "DISEASE", 17, 29], ["pneumomediastinum", "DISEASE", 34, 51], ["pneumonia", "DISEASE", 139, 148], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 221, 229], ["the pneumothorax", "PROBLEM", 13, 29], ["pneumomediastinum", "PROBLEM", 34, 51], ["the CT imaging", "TEST", 103, 117], ["COVID", "TEST", 130, 135], ["pneumonia", "PROBLEM", 139, 148], ["CT changes", "PROBLEM", 153, 163], ["CT scans", "TEST", 239, 247], ["this study", "TEST", 251, 261], ["pneumothorax", "OBSERVATION", 17, 29], ["pneumomediastinum", "OBSERVATION", 34, 51], ["pneumonia", "OBSERVATION", 139, 148], ["large", "OBSERVATION_MODIFIER", 201, 206]]], ["Several previous studies [8, 10, 15\u201317] have described the main CT signs of COVID-19, summarized as GGO, crazy-paving pattern, and consolidation.", [["Several previous studies", "TEST", 0, 24], ["COVID", "TEST", 76, 81], ["GGO", "TEST", 100, 103], ["consolidation", "PROBLEM", 131, 144], ["main", "OBSERVATION_MODIFIER", 59, 63], ["GGO", "OBSERVATION", 100, 103], ["crazy", "OBSERVATION_MODIFIER", 105, 110], ["paving pattern", "OBSERVATION", 111, 125], ["consolidation", "OBSERVATION", 131, 144]]], ["We found 13 signs on CT imaging altogether, which were partially similar to the previous study but more comprehensive and detailed, including GGO, consolidation, GGO plus consolidation, GGO plus reticular pattern, vacuolar sign, microvascular dilation, air bronchogram, subpleural transparent line, thickening of the pleura, pleural retraction, pleural effusion, subpleural line, bronchus distortion, and fibrotic strips, taking into account the signs inside the lesions (vacuole sign, microvascular dilation, air bronchogram) and the sign of pleural involvement.", [["reticular", "ANATOMY", 195, 204], ["vacuolar", "ANATOMY", 214, 222], ["microvascular", "ANATOMY", 229, 242], ["subpleural transparent line", "ANATOMY", 270, 297], ["pleura", "ANATOMY", 317, 323], ["pleural", "ANATOMY", 325, 332], ["pleural", "ANATOMY", 345, 352], ["subpleural line", "ANATOMY", 363, 378], ["bronchus", "ANATOMY", 380, 388], ["lesions", "ANATOMY", 463, 470], ["vacuole", "ANATOMY", 472, 479], ["microvascular", "ANATOMY", 486, 499], ["pleural", "ANATOMY", 543, 550], ["GGO", "DISEASE", 162, 165], ["pleural retraction", "DISEASE", 325, 343], ["pleural effusion", "DISEASE", 345, 361], ["vacuolar", "CELLULAR_COMPONENT", 214, 222], ["microvascular", "TISSUE", 229, 242], ["pleura", "MULTI-TISSUE_STRUCTURE", 317, 323], ["pleural", "MULTI-TISSUE_STRUCTURE", 325, 332], ["pleural", "PATHOLOGICAL_FORMATION", 345, 352], ["bronchus", "MULTI-TISSUE_STRUCTURE", 380, 388], ["lesions", "PATHOLOGICAL_FORMATION", 463, 470], ["microvascular", "TISSUE", 486, 499], ["pleural", "ORGAN", 543, 550], ["CT imaging", "TEST", 21, 31], ["the previous study", "TEST", 76, 94], ["GGO", "PROBLEM", 142, 145], ["consolidation", "PROBLEM", 147, 160], ["GGO", "PROBLEM", 162, 165], ["consolidation", "PROBLEM", 171, 184], ["GGO plus reticular pattern", "PROBLEM", 186, 212], ["vacuolar sign", "TEST", 214, 227], ["microvascular dilation", "PROBLEM", 229, 251], ["air bronchogram", "PROBLEM", 253, 268], ["subpleural transparent line", "PROBLEM", 270, 297], ["thickening of the pleura", "PROBLEM", 299, 323], ["pleural retraction", "PROBLEM", 325, 343], ["pleural effusion", "PROBLEM", 345, 361], ["subpleural line", "PROBLEM", 363, 378], ["bronchus distortion", "PROBLEM", 380, 399], ["fibrotic strips", "TREATMENT", 405, 420], ["the lesions", "PROBLEM", 459, 470], ["vacuole sign", "TEST", 472, 484], ["microvascular dilation", "PROBLEM", 486, 508], ["air bronchogram", "TEST", 510, 525], ["pleural involvement", "PROBLEM", 543, 562], ["13 signs", "OBSERVATION_MODIFIER", 9, 17], ["GGO", "OBSERVATION", 142, 145], ["consolidation", "OBSERVATION", 147, 160], ["GGO", "OBSERVATION", 162, 165], ["consolidation", "OBSERVATION", 171, 184], ["GGO", "OBSERVATION", 186, 189], ["reticular pattern", "OBSERVATION", 195, 212], ["vacuolar sign", "OBSERVATION", 214, 227], ["microvascular", "OBSERVATION_MODIFIER", 229, 242], ["dilation", "OBSERVATION", 243, 251], ["air bronchogram", "OBSERVATION", 253, 268], ["subpleural", "ANATOMY_MODIFIER", 270, 280], ["transparent line", "OBSERVATION", 281, 297], ["thickening", "OBSERVATION", 299, 309], ["pleura", "ANATOMY", 317, 323], ["pleural", "ANATOMY", 325, 332], ["retraction", "OBSERVATION", 333, 343], ["pleural", "ANATOMY", 345, 352], ["effusion", "OBSERVATION", 353, 361], ["subpleural line", "OBSERVATION", 363, 378], ["bronchus distortion", "OBSERVATION", 380, 399], ["fibrotic", "OBSERVATION_MODIFIER", 405, 413], ["strips", "OBSERVATION_MODIFIER", 414, 420], ["lesions", "OBSERVATION", 463, 470], ["vacuole sign", "OBSERVATION", 472, 484], ["microvascular", "OBSERVATION_MODIFIER", 486, 499], ["dilation", "OBSERVATION", 500, 508], ["air bronchogram", "OBSERVATION", 510, 525], ["pleural", "ANATOMY", 543, 550], ["involvement", "OBSERVATION", 551, 562]]], ["Also, we found that the lung abnormalities tended to be predominantly distributed in the peripheral zone, middle and lower zone, and posterior zone in bilateral lungs.", [["lung", "ANATOMY", 24, 28], ["peripheral zone", "ANATOMY", 89, 104], ["lower zone", "ANATOMY", 117, 127], ["posterior zone", "ANATOMY", 133, 147], ["lungs", "ANATOMY", 161, 166], ["lung abnormalities", "DISEASE", 24, 42], ["lung", "ORGAN", 24, 28], ["peripheral zone", "MULTI-TISSUE_STRUCTURE", 89, 104], ["lower zone", "TISSUE", 117, 127], ["posterior zone", "TISSUE", 133, 147], ["lungs", "ORGAN", 161, 166], ["the lung abnormalities", "PROBLEM", 20, 42], ["lung", "ANATOMY", 24, 28], ["abnormalities", "OBSERVATION", 29, 42], ["predominantly", "OBSERVATION_MODIFIER", 56, 69], ["peripheral", "ANATOMY_MODIFIER", 89, 99], ["zone", "ANATOMY_MODIFIER", 100, 104], ["middle", "ANATOMY_MODIFIER", 106, 112], ["lower", "ANATOMY_MODIFIER", 117, 122], ["zone", "ANATOMY_MODIFIER", 123, 127], ["posterior", "ANATOMY_MODIFIER", 133, 142], ["zone", "ANATOMY_MODIFIER", 143, 147], ["bilateral", "ANATOMY_MODIFIER", 151, 160], ["lungs", "ANATOMY", 161, 166]]], ["The peripheral distribution may be due to the fact that the virus is more likely to invade bronchioles and alveoli, causing inflammatory reactions which need the participation of immune cells; the distribution of blood vessels and lymphatics rich in immune cells is more abundant in the peripheral and lower areas, so the lesions tended to distribute in the peripheral and lower area of the lungs.DiscussionAccording to the degree of lung involvement evaluated by CT scoring summation of all the zones of both lungs, we defined pneumonia into three stages in CT imaging, 1~7 days after symptom onset is the early rapid progressive stage with involving extent fast progressing, 8~14 days is the advanced stage with the involving extent maintaining a peak plateau level, and after 14 days, the involving extent started to decrease.", [["bronchioles", "ANATOMY", 91, 102], ["alveoli", "ANATOMY", 107, 114], ["immune cells", "ANATOMY", 179, 191], ["blood vessels", "ANATOMY", 213, 226], ["lymphatics", "ANATOMY", 231, 241], ["immune cells", "ANATOMY", 250, 262], ["peripheral", "ANATOMY", 287, 297], ["lower areas", "ANATOMY", 302, 313], ["lesions", "ANATOMY", 322, 329], ["peripheral", "ANATOMY", 358, 368], ["lower area", "ANATOMY", 373, 383], ["lungs", "ANATOMY", 391, 396], ["lung", "ANATOMY", 434, 438], ["lungs", "ANATOMY", 510, 515], ["pneumonia", "DISEASE", 528, 537], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 91, 102], ["alveoli", "MULTI-TISSUE_STRUCTURE", 107, 114], ["immune cells", "CELL", 179, 191], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 213, 226], ["lymphatics", "MULTI-TISSUE_STRUCTURE", 231, 241], ["immune cells", "CELL", 250, 262], ["peripheral", "TISSUE", 287, 297], ["lesions", "PATHOLOGICAL_FORMATION", 322, 329], ["peripheral", "TISSUE", 358, 368], ["lungs", "ORGAN", 391, 396], ["lung", "ORGAN", 434, 438], ["lungs", "ORGAN", 510, 515], ["immune cells", "CELL_TYPE", 179, 191], ["immune cells", "CELL_TYPE", 250, 262], ["the virus", "PROBLEM", 56, 65], ["alveoli", "PROBLEM", 107, 114], ["inflammatory reactions", "PROBLEM", 124, 146], ["immune cells", "PROBLEM", 179, 191], ["blood vessels and lymphatics rich in immune cells", "PROBLEM", 213, 262], ["the lesions", "PROBLEM", 318, 329], ["lung involvement", "PROBLEM", 434, 450], ["CT scoring summation", "TEST", 464, 484], ["pneumonia", "PROBLEM", 528, 537], ["CT imaging", "TEST", 559, 569], ["symptom", "PROBLEM", 586, 593], ["a peak plateau level", "TEST", 747, 767], ["peripheral", "ANATOMY_MODIFIER", 4, 14], ["may be due to", "UNCERTAINTY", 28, 41], ["virus", "OBSERVATION", 60, 65], ["more likely to", "UNCERTAINTY", 69, 83], ["alveoli", "ANATOMY", 107, 114], ["inflammatory", "OBSERVATION_MODIFIER", 124, 136], ["immune cells", "OBSERVATION", 179, 191], ["blood vessels", "ANATOMY", 213, 226], ["lymphatics", "ANATOMY", 231, 241], ["immune cells", "OBSERVATION", 250, 262], ["more", "OBSERVATION_MODIFIER", 266, 270], ["abundant", "OBSERVATION_MODIFIER", 271, 279], ["peripheral", "ANATOMY_MODIFIER", 287, 297], ["lower", "ANATOMY_MODIFIER", 302, 307], ["lesions", "OBSERVATION", 322, 329], ["peripheral", "ANATOMY_MODIFIER", 358, 368], ["lower", "ANATOMY_MODIFIER", 373, 378], ["area", "ANATOMY_MODIFIER", 379, 383], ["lungs", "ANATOMY", 391, 396], ["lung", "ANATOMY", 434, 438], ["involvement", "OBSERVATION", 439, 450], ["zones", "ANATOMY_MODIFIER", 496, 501], ["both", "ANATOMY_MODIFIER", 505, 509], ["lungs", "ANATOMY", 510, 515], ["pneumonia", "OBSERVATION", 528, 537], ["rapid", "OBSERVATION_MODIFIER", 613, 618], ["progressive", "OBSERVATION_MODIFIER", 619, 630], ["peak plateau", "OBSERVATION", 749, 761], ["decrease", "OBSERVATION_MODIFIER", 820, 828]]], ["This course was partially similar to a previous study [10].", [["a previous study", "TEST", 37, 53]]], ["Representative cases are shown in Fig. 3.DiscussionWe compared the incidence of various CT signs in different stages of the disease, drew a CT sign change trend chart, and found that in the early rapid progressive stage, the CT imaging showed diversified primary signs including GGO plus reticular pattern, GGO plus consolidation, and GGO; consolidation was relatively rare.", [["reticular", "ANATOMY", 288, 297], ["GGO", "DISEASE", 307, 310], ["GGO", "DISEASE", 335, 338], ["various CT signs", "TEST", 80, 96], ["the disease", "PROBLEM", 120, 131], ["a CT sign", "TEST", 138, 147], ["the early rapid progressive stage", "PROBLEM", 186, 219], ["the CT imaging", "TEST", 221, 235], ["diversified primary signs", "PROBLEM", 243, 268], ["GGO plus reticular pattern", "PROBLEM", 279, 305], ["GGO", "PROBLEM", 307, 310], ["consolidation", "PROBLEM", 316, 329], ["GGO", "PROBLEM", 335, 338], ["consolidation", "PROBLEM", 340, 353], ["disease", "OBSERVATION", 124, 131], ["rapid", "OBSERVATION_MODIFIER", 196, 201], ["progressive", "OBSERVATION_MODIFIER", 202, 213], ["diversified", "OBSERVATION_MODIFIER", 243, 254], ["primary signs", "OBSERVATION", 255, 268], ["GGO", "OBSERVATION", 279, 282], ["reticular pattern", "OBSERVATION", 288, 305], ["GGO", "OBSERVATION", 307, 310], ["consolidation", "OBSERVATION", 316, 329], ["GGO", "OBSERVATION", 335, 338], ["consolidation", "OBSERVATION", 340, 353]]], ["In the advanced stage, GGO plus reticular pattern sharply increased and was the most prominent sign, GGO and GGO plus consolidation decreased, consolidation showed an increase, and all the repairing signs (subpleural line, bronchus distortion, and fibrotic strips) significantly increased.", [["reticular", "ANATOMY", 32, 41], ["subpleural line", "ANATOMY", 206, 221], ["bronchus", "ANATOMY", 223, 231], ["GGO", "DISEASE", 23, 26], ["GGO", "DISEASE", 101, 104], ["GGO", "DISEASE", 109, 112], ["bronchus", "MULTI-TISSUE_STRUCTURE", 223, 231], ["GGO plus reticular pattern", "PROBLEM", 23, 49], ["GGO", "PROBLEM", 101, 104], ["GGO", "PROBLEM", 109, 112], ["consolidation", "PROBLEM", 118, 131], ["consolidation", "PROBLEM", 143, 156], ["subpleural line, bronchus distortion", "PROBLEM", 206, 242], ["fibrotic strips", "TREATMENT", 248, 263], ["advanced", "OBSERVATION_MODIFIER", 7, 15], ["GGO", "OBSERVATION", 23, 26], ["reticular", "OBSERVATION_MODIFIER", 32, 41], ["pattern", "OBSERVATION_MODIFIER", 42, 49], ["sharply", "OBSERVATION_MODIFIER", 50, 57], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["most prominent", "OBSERVATION_MODIFIER", 80, 94], ["GGO", "OBSERVATION", 101, 104], ["GGO", "OBSERVATION_MODIFIER", 109, 112], ["consolidation", "OBSERVATION_MODIFIER", 118, 131], ["decreased", "OBSERVATION_MODIFIER", 132, 141], ["consolidation", "OBSERVATION", 143, 156], ["increase", "OBSERVATION_MODIFIER", 167, 175], ["repairing", "OBSERVATION_MODIFIER", 189, 198], ["signs", "OBSERVATION_MODIFIER", 199, 204], ["subpleural line", "OBSERVATION", 206, 221], ["bronchus", "ANATOMY", 223, 231], ["fibrotic", "OBSERVATION_MODIFIER", 248, 256], ["strips", "OBSERVATION_MODIFIER", 257, 263], ["significantly", "OBSERVATION_MODIFIER", 265, 278], ["increased", "OBSERVATION_MODIFIER", 279, 288]]], ["In the absorption stage, GGO plus consolidation sharply decreased, consolidation and GGO plus reticular pattern decreased, GGO and all the repairing signs remained with repairing signs continued increasing.", [["reticular", "ANATOMY", 94, 103], ["GGO", "DISEASE", 123, 126], ["GGO plus consolidation", "PROBLEM", 25, 47], ["consolidation", "PROBLEM", 67, 80], ["GGO", "PROBLEM", 85, 88], ["reticular pattern", "PROBLEM", 94, 111], ["GGO", "PROBLEM", 123, 126], ["repairing signs", "PROBLEM", 169, 184], ["absorption stage", "OBSERVATION_MODIFIER", 7, 23], ["GGO", "OBSERVATION", 25, 28], ["consolidation", "OBSERVATION", 34, 47], ["sharply", "OBSERVATION_MODIFIER", 48, 55], ["decreased", "OBSERVATION_MODIFIER", 56, 65], ["consolidation", "OBSERVATION", 67, 80], ["GGO", "OBSERVATION_MODIFIER", 85, 88], ["reticular", "OBSERVATION_MODIFIER", 94, 103], ["pattern", "OBSERVATION_MODIFIER", 104, 111], ["decreased", "OBSERVATION_MODIFIER", 112, 121], ["GGO", "OBSERVATION", 123, 126], ["increasing", "OBSERVATION_MODIFIER", 195, 205]]], ["This change course indicated that in the advanced stage, signs of progression and absorption coexisted; lung abnormalities showed an asynchronous process with parts absorption and parts progressing or involvement expanding.", [["lung", "ANATOMY", 104, 108], ["lung abnormalities", "DISEASE", 104, 122], ["lung", "ORGAN", 104, 108], ["progression and absorption", "PROBLEM", 66, 92], ["lung abnormalities", "PROBLEM", 104, 122], ["an asynchronous process", "PROBLEM", 130, 153], ["parts absorption", "PROBLEM", 159, 175], ["progression", "OBSERVATION_MODIFIER", 66, 77], ["lung", "ANATOMY", 104, 108], ["abnormalities", "OBSERVATION", 109, 122], ["asynchronous process", "OBSERVATION", 133, 153]]], ["Representative cases are shown in Fig. 5.DiscussionFrom the change of CT signs with the course of the disease, we inferred that COVID-19 initially involves both lung parenchyma and lung interstitium (manifested as GGO, GGO plus consolidation, or GGO plus reticular pattern), and causes single or multiple abnormalities simultaneously; some abnormalities were located under the pleura and involved the pleura, resulting in pleural thickening and retraction.", [["lung parenchyma", "ANATOMY", 161, 176], ["lung interstitium", "ANATOMY", 181, 198], ["reticular", "ANATOMY", 255, 264], ["pleura", "ANATOMY", 377, 383], ["pleura", "ANATOMY", 401, 407], ["pleural", "ANATOMY", 422, 429], ["GGO", "DISEASE", 214, 217], ["GGO", "DISEASE", 219, 222], ["lung parenchyma", "TISSUE", 161, 176], ["lung interstitium", "MULTI-TISSUE_STRUCTURE", 181, 198], ["pleura", "ORGAN", 377, 383], ["pleura", "ORGAN", 401, 407], ["pleural", "MULTI-TISSUE_STRUCTURE", 422, 429], ["COVID-19", "DNA", 128, 136], ["CT signs", "TEST", 70, 78], ["the disease", "PROBLEM", 98, 109], ["COVID", "TEST", 128, 133], ["GGO", "PROBLEM", 214, 217], ["GGO", "PROBLEM", 219, 222], ["consolidation", "PROBLEM", 228, 241], ["GGO", "PROBLEM", 246, 249], ["multiple abnormalities", "PROBLEM", 296, 318], ["some abnormalities", "PROBLEM", 335, 353], ["pleural thickening", "PROBLEM", 422, 440], ["retraction", "PROBLEM", 445, 455], ["disease", "OBSERVATION", 102, 109], ["both", "ANATOMY_MODIFIER", 156, 160], ["lung", "ANATOMY", 161, 165], ["parenchyma", "ANATOMY_MODIFIER", 166, 176], ["lung", "ANATOMY", 181, 185], ["interstitium", "ANATOMY_MODIFIER", 186, 198], ["GGO", "OBSERVATION", 214, 217], ["consolidation", "OBSERVATION", 228, 241], ["reticular pattern", "OBSERVATION", 255, 272], ["multiple", "OBSERVATION_MODIFIER", 296, 304], ["abnormalities", "OBSERVATION", 305, 318], ["pleura", "ANATOMY", 377, 383], ["pleura", "ANATOMY", 401, 407], ["pleural", "ANATOMY", 422, 429], ["thickening", "OBSERVATION", 430, 440], ["retraction", "OBSERVATION_MODIFIER", 445, 455]]], ["As the disease progressed, both the parenchyma and interstitium involvement evolved, manifested as the intensity of the previous abnormalities increasing, GGO turned into GGO plus reticular pattern, and GGO plus reticular pattern turned into consolidation, so the vacuolar sign was the most prominent in this advanced stage; also, pleural effusion developed in a small proportion of the cases.", [["parenchyma", "ANATOMY", 36, 46], ["interstitium", "ANATOMY", 51, 63], ["reticular", "ANATOMY", 180, 189], ["reticular", "ANATOMY", 212, 221], ["vacuolar", "ANATOMY", 264, 272], ["pleural effusion", "ANATOMY", 331, 347], ["GGO", "DISEASE", 155, 158], ["pleural effusion", "DISEASE", 331, 347], ["parenchyma", "TISSUE", 36, 46], ["interstitium", "MULTI-TISSUE_STRUCTURE", 51, 63], ["vacuolar", "CELLULAR_COMPONENT", 264, 272], ["pleural", "PATHOLOGICAL_FORMATION", 331, 338], ["the disease", "PROBLEM", 3, 14], ["interstitium involvement", "PROBLEM", 51, 75], ["the previous abnormalities", "PROBLEM", 116, 142], ["GGO", "PROBLEM", 155, 158], ["GGO plus reticular pattern", "PROBLEM", 171, 197], ["GGO", "PROBLEM", 203, 206], ["consolidation", "PROBLEM", 242, 255], ["the vacuolar sign", "TEST", 260, 277], ["pleural effusion", "PROBLEM", 331, 347], ["disease", "OBSERVATION", 7, 14], ["parenchyma", "ANATOMY_MODIFIER", 36, 46], ["interstitium", "ANATOMY_MODIFIER", 51, 63], ["intensity", "OBSERVATION_MODIFIER", 103, 112], ["abnormalities", "OBSERVATION", 129, 142], ["increasing", "OBSERVATION_MODIFIER", 143, 153], ["reticular pattern", "OBSERVATION", 180, 197], ["GGO", "OBSERVATION_MODIFIER", 203, 206], ["reticular", "OBSERVATION_MODIFIER", 212, 221], ["pattern", "OBSERVATION_MODIFIER", 222, 229], ["consolidation", "OBSERVATION", 242, 255], ["vacuolar sign", "OBSERVATION", 264, 277], ["most prominent", "OBSERVATION_MODIFIER", 286, 300], ["pleural", "ANATOMY", 331, 338], ["effusion", "OBSERVATION", 339, 347], ["small", "OBSERVATION_MODIFIER", 363, 368]]], ["The vacuolar sign may be due to the inhomogeneous involvement and incomplete filling of alveoli, it was characteristic especially during the advanced stage.", [["vacuolar", "ANATOMY", 4, 12], ["alveoli", "ANATOMY", 88, 95], ["vacuolar", "CELLULAR_COMPONENT", 4, 12], ["alveoli", "MULTI-TISSUE_STRUCTURE", 88, 95], ["the inhomogeneous involvement", "PROBLEM", 32, 61], ["incomplete filling of alveoli", "PROBLEM", 66, 95], ["vacuolar sign", "OBSERVATION", 4, 17], ["may be due to", "UNCERTAINTY", 18, 31], ["inhomogeneous", "OBSERVATION_MODIFIER", 36, 49], ["involvement", "OBSERVATION", 50, 61], ["alveoli", "ANATOMY", 88, 95]]], ["Meanwhile, some lesions began to absorb.", [["lesions", "ANATOMY", 16, 23], ["lesions", "PATHOLOGICAL_FORMATION", 16, 23], ["some lesions", "PROBLEM", 11, 23], ["some", "OBSERVATION_MODIFIER", 11, 15], ["lesions", "OBSERVATION", 16, 23]]], ["The intensity of the previous abnormalities decreased; GGO plus consolidation, consolidation, and GGO plus reticular pattern all decreased, and the repairing signs continued increasing, including the subpleural line, bronchus distortion, and fibrotic strips.", [["reticular", "ANATOMY", 107, 116], ["subpleural line", "ANATOMY", 200, 215], ["bronchus", "ANATOMY", 217, 225], ["GGO", "DISEASE", 55, 58], ["bronchus", "MULTI-TISSUE_STRUCTURE", 217, 225], ["the previous abnormalities", "PROBLEM", 17, 43], ["GGO", "PROBLEM", 55, 58], ["consolidation", "PROBLEM", 64, 77], ["consolidation", "PROBLEM", 79, 92], ["GGO plus reticular pattern", "PROBLEM", 98, 124], ["the repairing signs", "PROBLEM", 144, 163], ["the subpleural line", "PROBLEM", 196, 215], ["bronchus distortion", "PROBLEM", 217, 236], ["fibrotic strips", "TREATMENT", 242, 257], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["abnormalities", "OBSERVATION", 30, 43], ["decreased", "OBSERVATION_MODIFIER", 44, 53], ["GGO", "OBSERVATION_MODIFIER", 55, 58], ["consolidation", "OBSERVATION", 64, 77], ["consolidation", "OBSERVATION", 79, 92], ["GGO", "OBSERVATION_MODIFIER", 98, 101], ["reticular", "OBSERVATION_MODIFIER", 107, 116], ["pattern", "OBSERVATION_MODIFIER", 117, 124], ["all", "OBSERVATION_MODIFIER", 125, 128], ["decreased", "OBSERVATION_MODIFIER", 129, 138], ["repairing", "OBSERVATION_MODIFIER", 148, 157], ["signs", "OBSERVATION_MODIFIER", 158, 163], ["continued", "OBSERVATION_MODIFIER", 164, 173], ["increasing", "OBSERVATION_MODIFIER", 174, 184], ["subpleural line", "OBSERVATION", 200, 215], ["bronchus distortion", "OBSERVATION", 217, 236], ["fibrotic", "OBSERVATION_MODIFIER", 242, 250], ["strips", "OBSERVATION_MODIFIER", 251, 257]]], ["Each lung abnormality had its own course of change, so some patients showed an asynchronous change of lung abnormality during the course, with part of the abnormality absorption and part of abnormality progressed.DiscussionIn addition, in this cohort, we found 4 cases showed a negative result of the RT-PCR test for COVID-19 nucleic acid at the first CT scan; after several repeated RT-PCR tests, the result finally turned positive (12~18 days after the first CT scan with lung abnormality, 13~26 days after initial symptom onset).", [["lung", "ANATOMY", 5, 9], ["lung", "ANATOMY", 102, 106], ["lung", "ANATOMY", 474, 478], ["lung abnormality", "DISEASE", 5, 21], ["lung abnormality", "DISEASE", 102, 118], ["COVID-19 nucleic acid", "CHEMICAL", 317, 338], ["lung abnormality", "DISEASE", 474, 490], ["lung", "ORGAN", 5, 9], ["patients", "ORGANISM", 60, 68], ["lung", "ORGAN", 102, 106], ["lung", "ORGAN", 474, 478], ["patients", "SPECIES", 60, 68], ["Each lung abnormality", "PROBLEM", 0, 21], ["an asynchronous change of lung abnormality", "PROBLEM", 76, 118], ["the abnormality absorption", "PROBLEM", 151, 177], ["abnormality", "PROBLEM", 190, 201], ["the RT-PCR test", "TEST", 297, 312], ["COVID", "TEST", 317, 322], ["nucleic acid", "TEST", 326, 338], ["the first CT scan", "TEST", 342, 359], ["several repeated RT-PCR tests", "TEST", 367, 396], ["the first CT scan", "TEST", 451, 468], ["lung abnormality", "PROBLEM", 474, 490], ["lung", "ANATOMY", 5, 9], ["abnormality", "OBSERVATION", 10, 21], ["asynchronous", "OBSERVATION", 79, 91], ["lung", "ANATOMY", 102, 106], ["abnormality", "OBSERVATION", 107, 118], ["abnormality", "OBSERVATION", 155, 166], ["lung", "ANATOMY", 474, 478], ["abnormality", "OBSERVATION", 479, 490]]], ["We found the CT findings of these 4 patients were similar to the other cases, indicating that CT scan was more sensitive than RT-PCR results; this finding was consistent with some previous reports [7].", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["the CT findings", "TEST", 9, 24], ["CT scan", "TEST", 94, 101], ["RT-PCR", "TEST", 126, 132], ["consistent with", "UNCERTAINTY", 159, 174]]], ["This may be related to the viral load of the lower respiratory tract secretion in patients with a different course of disease, or nonstandard sampling operation for pharyngeal swab, or it may be related to the existence of a certain degree of false-negative rate of the RT-PCR test.", [["lower respiratory tract", "ANATOMY", 45, 68], ["pharyngeal swab", "ANATOMY", 165, 180], ["lower", "ORGANISM_SUBDIVISION", 45, 50], ["respiratory tract", "ORGANISM_SUBDIVISION", 51, 68], ["patients", "ORGANISM", 82, 90], ["pharyngeal swab", "MULTI-TISSUE_STRUCTURE", 165, 180], ["patients", "SPECIES", 82, 90], ["the viral load", "PROBLEM", 23, 37], ["the lower respiratory tract secretion", "PROBLEM", 41, 78], ["disease", "PROBLEM", 118, 125], ["nonstandard sampling operation", "TREATMENT", 130, 160], ["pharyngeal swab", "PROBLEM", 165, 180], ["PCR test", "TEST", 273, 281], ["may be related to", "UNCERTAINTY", 5, 22], ["viral load", "OBSERVATION", 27, 37], ["lower", "ANATOMY_MODIFIER", 45, 50], ["respiratory tract", "ANATOMY", 51, 68], ["disease", "OBSERVATION", 118, 125], ["pharyngeal swab", "ANATOMY", 165, 180], ["false", "OBSERVATION", 243, 248]]], ["This suggested that CT may be more sensitive and detect lesions earlier than the present RT-PCR test for COVID-19 nucleic acid.", [["lesions", "ANATOMY", 56, 63], ["COVID-19 nucleic acid", "CHEMICAL", 105, 126], ["lesions", "PATHOLOGICAL_FORMATION", 56, 63], ["COVID-19 nucleic acid", "SIMPLE_CHEMICAL", 105, 126], ["CT", "TEST", 20, 22], ["lesions", "PROBLEM", 56, 63], ["PCR test", "TEST", 92, 100], ["COVID", "TEST", 105, 110], ["nucleic acid", "TEST", 114, 126], ["lesions", "OBSERVATION", 56, 63]]], ["This also suggested that there may be a proportion of COVID-19 pneumonia patients with negative COVID-19 nucleic acid result when lung abnormalities already existed on CT imaging; the establishment of diagnostic criteria should take these patients into account.DiscussionThere are still some limitations in this study.", [["lung", "ANATOMY", 130, 134], ["pneumonia", "DISEASE", 63, 72], ["COVID-19 nucleic acid", "CHEMICAL", 96, 117], ["lung abnormalities", "DISEASE", 130, 148], ["COVID-19", "ORGANISM", 54, 62], ["patients", "ORGANISM", 73, 81], ["lung", "ORGAN", 130, 134], ["patients", "ORGANISM", 239, 247], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 239, 247], ["COVID", "TEST", 54, 59], ["pneumonia", "PROBLEM", 63, 72], ["COVID", "TEST", 96, 101], ["nucleic acid", "TEST", 105, 117], ["lung abnormalities", "PROBLEM", 130, 148], ["CT imaging", "TEST", 168, 178], ["this study", "TEST", 307, 317], ["pneumonia", "OBSERVATION", 63, 72], ["lung", "ANATOMY", 130, 134], ["abnormalities", "OBSERVATION", 135, 148]]], ["First, the time for CT reexamination of each patient is not standardized.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["CT reexamination", "TEST", 20, 36]]], ["Second, there were only 2 cases of severe COVID-19 pneumonia patients hospitalized in ICU because their condition did not permit CT scan.DiscussionIn conclusion, the main CT signs of COVID-19 pneumonia mainly included GGO, GGO plus consolidation, and GGO plus reticular pattern, single or multiple focus onset, distributed predominantly in the peripheral, middle, and lower zones, and the posterior zone in bilateral lungs.", [["reticular", "ANATOMY", 260, 269], ["peripheral", "ANATOMY", 344, 354], ["lower zones", "ANATOMY", 368, 379], ["posterior zone", "ANATOMY", 389, 403], ["lungs", "ANATOMY", 417, 422], ["COVID", "DISEASE", 42, 47], ["pneumonia", "DISEASE", 51, 60], ["COVID", "DISEASE", 183, 188], ["pneumonia", "DISEASE", 192, 201], ["GGO", "DISEASE", 218, 221], ["GGO", "DISEASE", 223, 226], ["patients", "ORGANISM", 61, 69], ["peripheral", "TISSUE", 344, 354], ["posterior zone", "MULTI-TISSUE_STRUCTURE", 389, 403], ["lungs", "ORGAN", 417, 422], ["patients", "SPECIES", 61, 69], ["severe COVID", "PROBLEM", 35, 47], ["pneumonia", "PROBLEM", 51, 60], ["CT scan", "TEST", 129, 136], ["the main CT signs", "TEST", 162, 179], ["COVID", "TEST", 183, 188], ["pneumonia", "PROBLEM", 192, 201], ["GGO", "PROBLEM", 218, 221], ["GGO", "PROBLEM", 223, 226], ["consolidation", "PROBLEM", 232, 245], ["GGO plus reticular pattern", "PROBLEM", 251, 277], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["pneumonia", "OBSERVATION", 51, 60], ["pneumonia", "OBSERVATION", 192, 201], ["GGO", "OBSERVATION", 218, 221], ["GGO", "OBSERVATION_MODIFIER", 223, 226], ["consolidation", "OBSERVATION", 232, 245], ["GGO", "OBSERVATION_MODIFIER", 251, 254], ["reticular", "OBSERVATION_MODIFIER", 260, 269], ["pattern", "OBSERVATION_MODIFIER", 270, 277], ["single", "OBSERVATION_MODIFIER", 279, 285], ["multiple", "OBSERVATION_MODIFIER", 289, 297], ["focus", "OBSERVATION_MODIFIER", 298, 303], ["onset", "OBSERVATION_MODIFIER", 304, 309], ["peripheral", "ANATOMY_MODIFIER", 344, 354], ["middle", "ANATOMY_MODIFIER", 356, 362], ["lower", "ANATOMY_MODIFIER", 368, 373], ["zones", "ANATOMY_MODIFIER", 374, 379], ["posterior", "ANATOMY_MODIFIER", 389, 398], ["zone", "ANATOMY_MODIFIER", 399, 403], ["bilateral", "ANATOMY_MODIFIER", 407, 416], ["lungs", "ANATOMY", 417, 422]]], ["One to seven days from symptom onset is the early rapid progressive stage, 8\u201314 days is the advanced stage with peak levels of abnormalities on CT, and after 14 days, the abnormalities started to improve.", [["symptom", "PROBLEM", 23, 30], ["peak levels of abnormalities", "PROBLEM", 112, 140], ["CT", "TEST", 144, 146], ["the abnormalities", "PROBLEM", 167, 184], ["early", "OBSERVATION_MODIFIER", 44, 49], ["rapid", "OBSERVATION_MODIFIER", 50, 55], ["progressive", "OBSERVATION_MODIFIER", 56, 67]]], ["It should be noted that there are patients with negative nucleic acid test but positive CT result.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["nucleic acid test", "TEST", 57, 74]]]], "70bbeba9609b9feba19c1cf5a5c6e694c0de570b": [["A widely studied class of binary balanced words are the Christoffel words, whose interest arises from their strong connections with geometry, algebra, and number theory (see [2] for the definitions, first properties and extensive bibliography).", [["widely", "OBSERVATION_MODIFIER", 2, 8]]], ["Such standard factorization allows us to arrange all the Christoffel words in a binary tree structure, called Christoffel tree, whose root is the word w = 01 = (0, 1).", [["root", "ANATOMY", 134, 138], ["root", "ORGAN", 134, 138], ["Christoffel words", "DNA", 57, 74]]], ["The notion of balancedness allows us to define, for each binary word w, a balance matrix B w whose maximal element provides its order of balancedness, noted by \u03b4(w).", [["\u03b4(w)", "PROTEIN", 160, 164], ["a balance matrix B w whose maximal element", "TREATMENT", 72, 114]]], ["The present study focuses on Christoffel words that are balanced words, i.e. whose order of balancedness is 1.", [["The present study", "TEST", 0, 17]]], ["In this case, each row of the balance matrix is again a binary word, whose order of balancedness can be computed again, obtaining a second order balance matrix U w whose maximal element is defined as the second order balance value \u03b4 2 (w).", [["matrix", "CELLULAR_COMPONENT", 38, 44], ["a second order balance matrix U w whose maximal element", "TREATMENT", 130, 185]]], ["This value can also be obtained using the link between the abelian complexity and balanced words represented by Zamboni ( [6] , Section 4), using the Parikh vectors.IntroductionThe matrix U w has several properties that allow a recursive construction by referring to three U w matrices, of some specific ancestors w of w in the Christoffel tree [12] .", [["U w matrices", "DNA", 273, 285], ["the Parikh vectors", "TREATMENT", 146, 164], ["a recursive construction", "TREATMENT", 226, 250]]], ["The authors used this notion to study the distribution of 1 s in Christoffel words and relate it to the longstanding problem of their synchronization [7, 8] .IntroductionThe correspondence between Christoffel word and continued fraction representation of its rational slope allows us to transfer the notion of balancedness to the Stern-Brocot tree.", [["Stern-Brocot tree", "DNA", 330, 347], ["Christoffel word", "TREATMENT", 197, 213]]], ["In our study, we first establish a connection between the second order balance value of a Christoffel word and the form of the continued fraction representation of the slope of the related discrete segment.", [["our study", "TEST", 3, 12], ["a Christoffel word", "PROBLEM", 88, 106], ["slope", "OBSERVATION_MODIFIER", 168, 173], ["discrete", "OBSERVATION_MODIFIER", 189, 197], ["segment", "OBSERVATION_MODIFIER", 198, 205]]], ["Then, we present the sequence of the ratios of consecutive Fibonacci numbers constitutes, in the SB-tree, as being an example of a path which minimizes the growth of the second order balancedness parameter of the related Christoffel words.", [["Christoffel words", "PROTEIN", 221, 238], ["consecutive Fibonacci numbers", "TEST", 47, 76], ["tree", "ANATOMY_MODIFIER", 100, 104], ["growth", "OBSERVATION_MODIFIER", 156, 162]]], ["Finally, relying on this result, we characterize the minimal paths (w.r.t the second order balance value) by mixing algebraic and arithmetic techniques on the continued fraction representations.", [["the continued fraction representations", "TREATMENT", 155, 193], ["minimal", "OBSERVATION_MODIFIER", 53, 60]]], ["2, we recall the definitions of Christoffel words, Christoffel tree and the Stern-Brocot tree.", [["Stern", "ANATOMY", 76, 81], ["Brocot", "ANATOMY", 82, 88], ["tree", "ANATOMY_MODIFIER", 89, 93]]], ["2.4, we introduce the notion of balancedness and we define the balance matrix of a binary word.", [["balancedness", "PROBLEM", 32, 44]]], ["Then we generalize the notion to the second order balance matrix.", [["matrix", "CELLULAR_COMPONENT", 58, 64]]], ["3, we show how the second order balancedness parameter is spread on the SB-tree, providing the example of the Fibonacci sequence.", [["Fibonacci sequence", "DNA", 110, 128], ["the Fibonacci sequence", "TEST", 106, 128]]], ["Here we provide our main result: the characterization of the minimal paths in the SB-tree according to the \u03b4 2 parameter.", [["minimal", "OBSERVATION_MODIFIER", 61, 68], ["paths", "OBSERVATION", 69, 74], ["tree", "ANATOMY_MODIFIER", 85, 89]]], ["We prove that a rational number on the SB-tree belongs to a minimal path, according to the growth of a second order balancedness, if the elements of its continued fractions start by 0, 1 and end by 2, while the middle terms are only made of blocks of (1, 1, 1); (2, 1); (1, 2) or (3).Definitions and Previous ResultsWe refer to the book [5] for the standard terminology in combinatorics of words: alphabet, word, length of a word, occurrence of a letter, factor, prefix, suffix, period, conjugate, primitive, reversal, palindrome etc. The related notation will be recalled when used.Definitions and Previous ResultsChristoffel Paths and Christoffel Words.", [["palindrome etc", "TREATMENT", 519, 533], ["middle", "ANATOMY_MODIFIER", 211, 217]]], ["In discrete geometry, the theory of Christoffel words has been considered during this last few decades and has acquired a prominent role in the study of the discretization of segments and shapes.", [["the study", "TEST", 140, 149], ["discrete", "OBSERVATION_MODIFIER", 3, 11], ["geometry", "OBSERVATION_MODIFIER", 12, 20], ["prominent", "OBSERVATION_MODIFIER", 122, 131], ["segments", "ANATOMY_MODIFIER", 175, 183], ["shapes", "OBSERVATION_MODIFIER", 188, 194]]], ["Concerning the former, let a, b be two co-prime numbers; the Christoffel path of slope a b is defined as the connected path joining the origin O(0, 0) to the point (b, a) in the integer lattice Z \u00d7 Z; such that it is the nearest path below the Euclidean line segment joining these two points, as shown in Fig. 1 .", [["origin", "ANATOMY_MODIFIER", 136, 142], ["Euclidean line", "OBSERVATION", 244, 258], ["segment", "ANATOMY_MODIFIER", 259, 266]]], ["So, there are no points of the discrete plane between the path and the line segment.Definitions and Previous ResultsStill in Fig. 1 , we can see the coding of a Christoffel path by a binary word, say Christoffel word, whose letters 0 and 1 represent a horizontal and a vertical step in the path, respectively.Definitions and Previous ResultsThe Christoffel word related to the path reaching the point (b, a) is indicated by C( a b ), and its slope is a b = |w|1 |w|0 , where the notation |w| x stands for the number of occurrences of the letter x in w.", [["Christoffel path", "DNA", 161, 177], ["Christoffel word", "DNA", 200, 216], ["no", "UNCERTAINTY", 14, 16], ["discrete", "OBSERVATION_MODIFIER", 31, 39], ["plane", "OBSERVATION_MODIFIER", 40, 45], ["path", "OBSERVATION_MODIFIER", 58, 62], ["line", "OBSERVATION_MODIFIER", 71, 75], ["segment", "OBSERVATION_MODIFIER", 76, 83]]], ["A binary word w is k-balanced, with k > 0, if, for any two factors u and v of its conjugates such that |u| = |v|, it follows that ||u| 1 \u2212 |v| 1 | \u2264 k.", [["k", "TEST", 36, 37], ["v", "TEST", 140, 141]]], ["The root of the Christoffel tree is labeled by the pair (0, 1), representing the Christoffel word 01 of slope 1 1 .", [["root", "ANATOMY", 4, 8], ["root", "ORGAN", 4, 8], ["Christoffel tree", "MULTI-TISSUE_STRUCTURE", 16, 32], ["root", "ANATOMY_MODIFIER", 4, 8], ["Christoffel", "ANATOMY", 16, 27], ["tree", "ANATOMY_MODIFIER", 28, 32]]], ["Each node (u, v) generates two children according to two functions \u03c6 0 and \u03c6 1 such that: \u03c6 0 (u, v) = (u, uv) produces the left-child, and \u03c6 1 (u, v) = (uv, v) produces the right-child.", [["node", "ANATOMY", 5, 9], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39], ["node", "OBSERVATION", 5, 9], ["left", "ANATOMY_MODIFIER", 124, 128], ["right", "ANATOMY_MODIFIER", 174, 179]]], ["Each node (u, v) corresponds to the Christoffel word uv and represents its standard factorization form [5] .", [["node", "ANATOMY", 5, 9], ["node", "OBSERVATION", 5, 9]]], ["Figure 2 shows the first levels of the Christoffel tree.", [["Christoffel tree", "MULTI-TISSUE_STRUCTURE", 39, 55], ["Christoffel", "ANATOMY", 39, 50], ["tree", "ANATOMY_MODIFIER", 51, 55]]], ["Let w = C( a b ) be a Christoffel word lying at level k of the tree.", [["a Christoffel word", "PROBLEM", 20, 38], ["tree", "ANATOMY_MODIFIER", 63, 67]]], ["The directive sequence of w is the wordChristoffel TreeAccording to the definition of \u03c6 0 and \u03c6 1 , the elements of \u0394( a b ) also show, step by step, the directions to reach the word w in the tree starting from its root at level 1.", [["root", "ANATOMY", 215, 219], ["root", "TISSUE", 215, 219], ["\u03c6 0 and \u03c6 1", "DNA", 86, 97], ["tree", "ANATOMY_MODIFIER", 192, 196], ["root", "ANATOMY", 215, 219]]], ["If i n = 0, we must move to the left, otherwise, to the right.Christoffel TreeAs an example, the directive sequence of the Christoffel word C( 4 3 ) = 0101011 at level 4 of the Christoffel tree is \u0394( 4 3 ) = 100: according to the definition it holdsStern-Brocot TreeThe Christoffel tree is known to be isomorphic to the SB-tree, that was introduced by M. Stern [11] and A. Brocot [4] as a binary-tree arrangement of the irreducible fractions.", [["the Christoffel word C", "TEST", 119, 141], ["the irreducible fractions", "PROBLEM", 416, 441], ["left", "ANATOMY_MODIFIER", 32, 36], ["right", "ANATOMY_MODIFIER", 56, 61], ["tree", "ANATOMY_MODIFIER", 323, 327], ["irreducible fractions", "OBSERVATION", 420, 441]]], ["Such arrangement relies on the Farey sum operator, indicated by \u2295, and defined on two generic rational numbers as a b \u2295 c d = a+c b+d .", [["Farey sum operator", "DNA", 31, 49], ["+c b+d", "PROTEIN", 127, 133]]], ["The root of the SB-tree is labeled with the fraction 1 1 and each node at level n > 1 is labeled with the Farey sum of its nearest left and right ancestors, i.e., the nodes lying on the greatest level of the tree and having k in its left and right subtree, respectively.", [["root", "ANATOMY", 4, 8], ["node", "ANATOMY", 66, 70], ["left", "ANATOMY", 131, 135], ["nodes", "ANATOMY", 167, 172], ["left", "ANATOMY", 233, 237], ["right subtree", "ANATOMY", 242, 255], ["root", "ORGAN", 4, 8], ["the nodes", "PROBLEM", 163, 172], ["root", "ANATOMY_MODIFIER", 4, 8], ["SB", "ANATOMY", 16, 18], ["tree", "ANATOMY_MODIFIER", 19, 23], ["node", "OBSERVATION", 66, 70], ["left", "ANATOMY_MODIFIER", 131, 135], ["right", "ANATOMY_MODIFIER", 140, 145], ["ancestors", "ANATOMY_MODIFIER", 146, 155], ["nodes", "OBSERVATION", 167, 172], ["greatest", "OBSERVATION_MODIFIER", 186, 194], ["tree", "ANATOMY_MODIFIER", 208, 212], ["left", "ANATOMY_MODIFIER", 233, 237], ["right", "ANATOMY_MODIFIER", 242, 247], ["subtree", "ANATOMY_MODIFIER", 248, 255]]], ["The left and right ancestors of the root are considered to be the fractions 0 1 and 1 0 , even if not present in the tree.", [["left", "ANATOMY", 4, 8], ["root", "ANATOMY", 36, 40], ["root", "ORGAN", 36, 40], ["left", "ANATOMY_MODIFIER", 4, 8], ["right", "ANATOMY_MODIFIER", 13, 18], ["ancestors", "ANATOMY_MODIFIER", 19, 28], ["root", "ANATOMY", 36, 40], ["tree", "ANATOMY_MODIFIER", 117, 121]]], ["The first levels of the SB-tree are depicted in Fig. 3 .", [["SB", "ANATOMY", 24, 26], ["tree", "ANATOMY_MODIFIER", 27, 31], ["Fig", "OBSERVATION_MODIFIER", 48, 51]]], ["As an example, we compute the left-child and right-child of the node 3 4 by Farey summing it with its left-ancestor 2 3 and with its right-ancestor 1 1 , and obtaining 5 7 and 4 5 , respectively.", [["node", "ANATOMY", 64, 68], ["left", "ANATOMY_MODIFIER", 30, 34], ["right", "ANATOMY_MODIFIER", 45, 50], ["node", "OBSERVATION", 64, 68], ["left", "ANATOMY_MODIFIER", 102, 106], ["ancestor", "ANATOMY_MODIFIER", 107, 115], ["2 3", "ANATOMY_MODIFIER", 116, 119], ["right", "ANATOMY_MODIFIER", 133, 138], ["ancestor", "ANATOMY_MODIFIER", 139, 147]]], ["The SB-tree contains once each irreducible fraction and over the years has attracted researchers for its many interesting properties.Stern-Brocot TreeRemark 1.", [["each irreducible fraction", "PROBLEM", 26, 51], ["tree", "ANATOMY_MODIFIER", 7, 11], ["irreducible", "OBSERVATION_MODIFIER", 31, 42], ["fraction", "OBSERVATION_MODIFIER", 43, 51], ["Brocot TreeRemark", "ANATOMY", 139, 156]]], ["By the construction of the SB-tree, the following hold i) The tree is divided into two symmetric parts.", [["symmetric", "OBSERVATION_MODIFIER", 87, 96]]], ["The left part contains all the reduced fractions less than 1, while the right part contains the reduced fractions bigger than 1. ii) For each level k of the SB tree, the rational numbers appear in increasing order from left to right, and their values are bounded by 1 k and k 1 .Stern-Brocot TreeFrom our perspective, the SB-tree's appeal reveals in its close relationship with the Christoffel tree: in fact, we can note that if we replace the label of each node (u, v) of this last with the rational number |uv|1 |uv|0 representing the slope of the corresponding Christoffel word, we obtain the SB-tree.", [["left part", "ANATOMY", 4, 13], ["right part", "ANATOMY", 72, 82], ["Christoffel word", "DNA", 564, 580], ["all the reduced fractions", "PROBLEM", 23, 48], ["the reduced fractions", "PROBLEM", 92, 113], ["the rational numbers", "TEST", 166, 186], ["the SB", "TEST", 318, 324], ["left", "ANATOMY_MODIFIER", 4, 8], ["all", "OBSERVATION_MODIFIER", 23, 26], ["reduced", "OBSERVATION_MODIFIER", 31, 38], ["fractions", "OBSERVATION_MODIFIER", 39, 48], ["right", "ANATOMY_MODIFIER", 72, 77], ["reduced", "OBSERVATION_MODIFIER", 96, 103], ["fractions", "OBSERVATION_MODIFIER", 104, 113], ["bigger", "OBSERVATION_MODIFIER", 114, 120], ["increasing", "OBSERVATION_MODIFIER", 197, 207], ["left", "ANATOMY_MODIFIER", 219, 223], ["right", "ANATOMY_MODIFIER", 227, 232], ["node", "OBSERVATION", 458, 462], ["tree", "ANATOMY_MODIFIER", 599, 603]]], ["For instance, take the rational number 3 5 on the SB-tree, it is at the same position of the Christoffel word 00100101 of slope 3 5 on the Christoffel tree.Continued Fraction RepresentationOur study requires to recall a final notion to identify the nodes of the SB-tree.", [["nodes", "OBSERVATION", 249, 254], ["SB", "ANATOMY", 262, 264], ["tree", "ANATOMY_MODIFIER", 265, 269]]], ["Let a b be a positive fraction, we define its continued fraction representation as the sequence of integers [a 0 , . . . , a z ], with a 0 \u2265 0, represented below, and such that for each 1 \u2264 i \u2264 z, a i \u2265 1:Continued Fraction RepresentationIn order to obtain a unique continued fraction representation of each rational number, it is also commonly required that if z \u2265 2, then a z \u2265 2.", [["Let a b", "GENE_OR_GENE_PRODUCT", 0, 7], ["a positive fraction", "PROBLEM", 11, 30], ["z", "TEST", 194, 195]]], ["Otherwise, with a simple calculation, we can remark that if a z = 1, it is sufficient to reduc ethe sequence to a z\u22121 and add +1, for example:Continued Fraction RepresentationThe continued fraction representation of a rational number is always finite while the representation is infinite in the case of an irrational number (among the vast literature on continued fraction representation, we refer the reader to [10] for the main properties).Continued Fraction RepresentationEquivalently to the Christoffel tree, the directive sequence of the Christoffel word of slope a b can be read in the SB-tree by using the terms of the continued fraction representation of a b .", [["z\u22121", "DNA", 114, 117], ["Christoffel tree", "DNA", 495, 511], ["a simple calculation", "TEST", 16, 36], ["Fraction", "OBSERVATION", 452, 460]]], ["Referring again to the continued fraction representation [0, 1, 2, 2] of 5 7 , the directive sequence \u0394( 5 7 ) is exactly 1 0 0 1 1 2 0 1 .The Second Order Balance MatrixThe second order of balancedness of a Christoffel word w, denoted \u03b4 2 (w), provides an idea of how uniformly the factors of each abelian class, as defined in [6] , are distributed in w.", [["the continued fraction representation", "TEST", 19, 56], ["the directive sequence \u0394", "TEST", 79, 103]]], ["It is the maximal value of the second order balance matrix, denoted U w , introduced in [12] .", [["matrix", "CELLULAR_COMPONENT", 52, 58], ["U w", "GENE_OR_GENE_PRODUCT", 68, 71], ["U w", "CELL_LINE", 68, 71]]], ["In order to construct this matrix, the author had to define the balance matrix B w , of a binary word w.", [["matrix", "CELLULAR_COMPONENT", 27, 33]]], ["This matrix calculates the order of balancedness, that is usually obtained by computing ||u| 1 \u2212 |v| 1 | \u2264 k for any factors u and v of same length, of any binary word w = w 1 w 2 . . . w n in an explicit way.", [["matrix", "CELLULAR_COMPONENT", 5, 11], ["k", "TEST", 107, 108], ["any factors u", "TEST", 113, 126], ["v", "TEST", 131, 132], ["same length", "TEST", 136, 147], ["any binary word w", "TEST", 152, 169]]], ["We provide the matrices S w and B w :The Second Order Balance MatrixSince each Christoffel word w is 1-balanced, then the rows of its balance matrix B w are binary words too.", [["The Second Order Balance MatrixSince", "TREATMENT", 37, 73]]], ["Let us define the second order balance matrix U w of dimension (n \u2212 1) \u00d7 (n \u2212 1), with n = |w|, asThe Second Order Balance Matrix).", [["dimension", "TEST", 53, 62]]], ["More details and properties about this matrix can be found in [12] .Example 2.Let us consider the 1-balanced word w of Example 1.", [["matrix", "CELLULAR_COMPONENT", 39, 45]]], ["We explicitly determine the element U w [4, 3] : the eight factors of the conjugates of B w [4] of length 3 are (001, 010, 101, 011, 110, 101, 101, 100) , and the maximum difference of the number of elements 1 between any two of them is 1, so U w [4, 3] = 1.", [["length", "TEST", 99, 105], ["U w [4", "TEST", 243, 249]]], ["Doing an analogous computation for all the lengths from 1 to 7, we obtain U w [4] = (1, 2, 1, 2, 1, 2, 1) .Example 2.So, the second order of balancedness of a Christoffel word w provides an idea of how uniformly the factors of each abelian class, as defined in [6] , are distributed in w.Path Minimality in SB-TreeIn this section, we prove some new properties of the second order balance parameter for Christoffel words and we show how it is distributed on the Christoffel tree.", [["Christoffel tree", "MULTI-TISSUE_STRUCTURE", 461, 477], ["U w", "TEST", 74, 77]]], ["Finally, we characterize the paths of the tree where the parameter's growth is minimal.", [["the parameter's growth", "TEST", 53, 75], ["tree", "ANATOMY_MODIFIER", 42, 46], ["minimal", "OBSERVATION_MODIFIER", 79, 86]]], ["So, let us consider the following two ancestors of a b = [a 0 , . . . , a z ] in the SB-tree: In [12] , Section 6.1, the authors proved that the matrix U w , with w = C( a b ), can be decomposed into blocks belonging either to U w1 or to U w2 + 1, with w 1 = C( u v ) and w 2 = C( \u03c1 \u03b8 ).", [["C", "CHEMICAL", 278, 279], ["U w1", "CELL_LINE", 227, 231], ["u v", "TEST", 262, 265]]], ["The second order balance value of C( a b ) is:Path Minimality in SB-TreeUsing the previous result, we set a lower bound to the growth of the second order balanced value inside the Christoffel tree.", [["Christoffel", "ANATOMY", 180, 191], ["tree", "ANATOMY_MODIFIER", 192, 196]]], ["The next lemma states that \u03b4 2 (C( a b )) increases according to the distance between a b and u v in the SB-tree.", [["u v", "GENE_OR_GENE_PRODUCT", 94, 97], ["SB", "ANATOMY", 105, 107], ["tree", "ANATOMY_MODIFIER", 108, 112]]], ["Let a b = [a 0 , . . . , a z ] and belongs to the level k on the SB-tree, where \u03b4 2 (C( u v )) = t and \u03b4 2 (C( \u03c1 \u03b8 )) = n. i) If a z = 2, then \u03b4 2 (C( a b )) \u2208 {t; t + 1}. ii) If a z > 2, then \u03b4 2 (C( a b )) = n + 1, i.e it is increased by one value each 2 levels after u v .", [["tree", "TEST", 68, 72], ["increased", "OBSERVATION_MODIFIER", 227, 236]]], ["Let us consider these two rational numbers a b = [a 0 , . . . , a z ] and u/v = [a 0 , . . . , a z\u22121 + 1], where \u03b4 2 (C( u v )) = t.", [["z", "TEST", 66, 67], ["u/v", "TEST", 74, 77], ["a z\u22121", "TEST", 95, 100], ["\u03b4", "TEST", 113, 114]]], ["If a z = 2, then \u03c1 \u03b8 = [a 0 , . . . , a z\u22122 ], in this case, its second order value is equal to n \u2264 t.", [["a z\u22122", "TEST", 38, 43], ["its", "TEST", 61, 64]]], ["In all the cases, from Theorem 1, \u03b4 2 (C( a b )) = max(\u03b4 2 (C( u v )), \u03b4 2 (C( \u03c1 \u03b8 ))+1) that can be either t or t + 1.", [["Theorem", "TEST", 23, 30], ["max", "TEST", 51, 54], ["\u03b4", "TEST", 71, 72]]], ["If a z \u2265 3, then we must consider two cases for the rational number \u03c1 \u03b8 .Path Minimality in SB-Tree-If a z = 3, in this case \u03c1 \u03b8 = u v and n = t, then: \u03b4 2 (C( a b )) = max(\u03b4 2 (C( u v )), \u03b4 2 (C( \u03c1 \u03b8 ) + 1) = n + 1. -If a z \u2265 4, in this case \u03c1 \u03b8 = [a 0 , a 1 , \u00b7 \u00b7 \u00b7 , a z \u2212 2], and n \u2265 t then: \u03b4 2 (C( a b )) = \u03b4 2 (C( \u03c1 \u03b8 )) + 1 = n + 1.Path Minimality in SB-TreeFinally, we provide a lower bound, denoted by \u03b4 2 k , for the second order balance value of any element at level k in the Christoffel tree.Theorem 2.For each level k in the SB tree, we have:Theorem 2.Proof.", [["the rational number", "TEST", 48, 67], ["Minimality", "TEST", 78, 88], ["SB", "TEST", 92, 94], ["Tree", "TEST", 95, 99], ["v", "TEST", 133, 134], ["t", "TEST", 143, 144], ["max", "TEST", 169, 172], ["u v", "TEST", 181, 184], ["\u03b4", "TEST", 189, 190], ["C", "TEST", 194, 195], ["a z \u2265", "TEST", 221, 226], ["C", "TEST", 301, 302], ["b", "TEST", 306, 307], ["any element", "PROBLEM", 458, 469], ["SB", "ANATOMY", 359, 361], ["Tree", "ANATOMY_MODIFIER", 362, 366], ["Christoffel", "ANATOMY", 488, 499], ["tree", "ANATOMY_MODIFIER", 500, 504]]], ["Hence the minimal value of \u03b4 2 3 (denoted min \u03b4 2 3 ) is equal to 1 and min \u03b4 2 4 = 2.", [["the minimal value", "TEST", 6, 23], ["minimal", "OBSERVATION_MODIFIER", 10, 17]]], ["Suppose that it is true for all the levels till k = 3k ; i.e min \u03b4 2 k = min \u03b4 2 k\u22121 = min \u03b4 2 k\u22122 = k .", [["k", "TEST", 48, 49]]], ["We prove that \u03b4 2 k+1 \u2265 k+1 3 = k + 1.", [["k", "TEST", 18, 19], ["k", "TEST", 24, 25], ["k", "TEST", 32, 33]]], ["All the children of the fractions on level k, with \u03b4 2 > k , have \u03b4 2 \u2265 k + 1.", [["children", "ORGANISM", 8, 16], ["children", "SPECIES", 8, 16], ["level k", "TEST", 37, 44]]], ["For that, we let u v be a fraction at level k with \u03b4 2 (C( u v )) = k .", [["a fraction", "TEST", 24, 34], ["\u03b4", "TEST", 51, 52]]], ["By contradiction, we let c d be the fraction at level k + 1 with \u03b4 2 (C( c d )) = k .", [["the fraction", "TEST", 32, 44], ["k", "TEST", 54, 55], ["\u03b4", "TEST", 65, 66]]], ["This fraction is either in the same, or opposite direction of u v .", [["u v", "GENE_OR_GENE_PRODUCT", 62, 65], ["This fraction", "TEST", 0, 13], ["u v", "OBSERVATION", 62, 65]]], ["If c d is in the same direction of u v , then by Lemma 3, we get \u03b4 2 (C( a b )) = k \u2212 1, where a b is the fraction at level k \u2212 1.", [["k \u2212", "TEST", 82, 85]]], ["In this case, we let m n be the fraction at level (k \u2212 2) and we have:Theorem 2., \u03b4 2 (C( m n )) + 1) = k .", [["Theorem", "TEST", 70, 77]]], ["If \u03b4 2 (C( m n )) = k then \u03b4 2 (C( c d )) = k + 1; and if \u03b4 2 (C( m n )) = k \u2212 1 we get a contradiction sinceTheorem 2.Therefore \u03b4 2 \u2265 k + 1 for all the fractions on the level k + 1 thusTheorem 2.The remaining part of the section, is devoted to the study of the paths of the SB-tree whose related Christoffel words realize the lower bound.", [["Christoffel words", "PROTEIN", 297, 314], ["\u03b4", "TEST", 3, 4], ["k", "TEST", 20, 21], ["k", "TEST", 44, 45], ["\u03b4", "TEST", 58, 59], ["k \u2212", "TEST", 75, 78], ["the level k", "TEST", 166, 177], ["the study", "TEST", 245, 254], ["the lower bound", "PROBLEM", 323, 338], ["lower", "ANATOMY_MODIFIER", 327, 332]]], ["The symmetry of the tree allows us to consider, without loss of generality, its left part only, i.e., those fractions less than or equal to 1 and whose continued fractions have a 0 = 0.", [["loss of generality", "PROBLEM", 56, 74], ["those fractions", "TEST", 102, 117], ["symmetry", "OBSERVATION_MODIFIER", 4, 12], ["tree", "ANATOMY_MODIFIER", 20, 24], ["left", "ANATOMY_MODIFIER", 80, 84]]], ["We denote the subtree SB L .Minimal Paths in the SB-TreeLet us assign to each fraction of SB L the \u03b4 2 value of its related Christoffel word starting from the root 1 1 : Fig. 4 shows the computation till the fifth level of the tree.", [["the computation", "TEST", 183, 198], ["Minimal", "OBSERVATION_MODIFIER", 28, 35], ["Christoffel word", "OBSERVATION", 124, 140], ["root", "ANATOMY", 159, 163], ["tree", "ANATOMY_MODIFIER", 227, 231]]], ["Let us indicate by P ( a b ) the sequence of all the fractions in the path from the root of SB L to the element a b , and by P \u03b4 2 ( a b ) the sequence of the related \u03b4 2 values.", [["root", "ANATOMY", 84, 88], ["\u03b4 2", "GENE_OR_GENE_PRODUCT", 167, 170], ["\u03b4 2", "PROTEIN", 167, 170], ["root", "ANATOMY_MODIFIER", 84, 88]]], ["From Lemma 3, it follows that P \u03b4 2 ( a b ) is a weakly increasing integer sequence.Minimal Paths in the SB-TreeAs an example, let us consider the fraction 7 12 , lying in the sixth level of SB L .", [["a weakly increasing integer sequence", "PROBLEM", 47, 83], ["the fraction", "TEST", 143, 155], ["Paths", "OBSERVATION_MODIFIER", 92, 97], ["SB", "ANATOMY", 191, 193], ["L", "ANATOMY_MODIFIER", 194, 195]]], ["We have P ( 7 12 ) = ( 1 1 , 1 2 , 2 3 , 3 5 , 4 7 , 7 12 ), and the related \u03b4 2 sequence is P \u03b4 2 ( 7 12 ) = (1, 1, 1, 2, 2, 2).Minimal Paths in the SB-TreeWe give now the definition of a minimal path at a certain level k of SB L .Definition 1.For each level k of the SB L , the minimal path MP k is given by: (1, 1, 1, 2, 2, 2, 3 , . . . , k 3 ).", [["1, 1, 1, 2, 2, 2", "SIMPLE_CHEMICAL", 111, 127], ["\u03b4 2 sequence", "DNA", 77, 89], ["the related \u03b4 2 sequence", "TEST", 65, 89], ["Minimal Paths", "PROBLEM", 129, 142], ["a minimal path", "PROBLEM", 187, 201], ["each level k", "TEST", 249, 261], ["the SB L", "TEST", 265, 273], ["the minimal path MP k", "TEST", 276, 297], ["Paths", "OBSERVATION_MODIFIER", 137, 142], ["SB", "ANATOMY", 150, 152], ["minimal", "OBSERVATION_MODIFIER", 189, 196], ["path", "OBSERVATION_MODIFIER", 197, 201], ["minimal", "OBSERVATION_MODIFIER", 280, 287]]], ["In order to give an example, we consider the Fibonacci sequence {f k } \u221e k=0 = 1, 1, 2, 3, 5, 8, 13, . . ., and define the zig-zag path to be the sequence of rational numbers obtained by the ratio of two consecutive elements.", [["the Fibonacci sequence", "TEST", 41, 63], ["k", "TEST", 67, 68], ["k", "TEST", 73, 74], ["the zig-zag path", "PROBLEM", 119, 135], ["rational numbers", "TEST", 158, 174]]], ["It is well known that the golden number is the limit of the sequence of the rational numbers f k f k+1 , with k \u2265 0.", [["k", "TEST", 99, 100], ["k", "TEST", 110, 111]]], ["The continued fraction representations of these rational numbers are of the form [0, 1, 1 . . . , 1, 2], and they constitute a (infinite) path in SB L .", [["SB", "ANATOMY", 146, 148], ["L", "ANATOMY_MODIFIER", 149, 150]]], ["This path realizes the lower bound stated in Theorem 2 assuring that, for each k, P \u03b4 2 ( f k f k+1 ) is minimal, and it equals MP k .", [["MP k", "GENE_OR_GENE_PRODUCT", 128, 132], ["the lower bound", "PROBLEM", 19, 34], ["P \u03b4 2 ( f k f k", "TEST", 82, 97]]], ["Now we focus our study on the questions: For each level k, is the zig-zag path the only minimal one?", [["each level k", "TEST", 45, 57], ["the zig-zag path", "TREATMENT", 62, 78], ["minimal", "OBSERVATION_MODIFIER", 88, 95]]], ["If no, can we characterize all the minimal paths in SB L ?A Connection Between \u03b4 2 Value and the Continued Fraction RepresentationLet us consider the following continued fraction representations: a b = [a 0 , a 1 , \u00b7 \u00b7 \u00b7 , a z ]; u v = [a 0 , a 1 , \u00b7 \u00b7 \u00b7 , a z\u22121 + 1]; p q = [a 0 , \u00b7 \u00b7 \u00b7 , a z\u22122 + 1]; s t = [a 0 , \u00b7 \u00b7 \u00b7 , a z\u22122 ]; and \u03c1 \u03b8 =A Connection Between \u03b4 2 Value and the Continued Fraction Representation[a 0 , a 1 , \u00b7 \u00b7 \u00b7 , a z\u22121 + 1] if a z = 3A Connection Between \u03b4 2 Value and the Continued Fraction Representation[a 0 , a 1 , \u00b7 \u00b7 \u00b7 , a z\u22122 ] if a z = 2.A Connection Between \u03b4 2 Value and the Continued Fraction RepresentationFrom Lemma 3, we know that \u03b4 2 C a b is related to \u03b4 2 C u v and \u03b4 2 C \u03c1 \u03b8 .", [["z", "TEST", 225, 226], ["v", "TEST", 232, 233], ["\u00b7", "TEST", 249, 250], ["\u00b7", "TEST", 251, 252], ["\u00b7", "TEST", 253, 254], ["z\u22122", "TEST", 292, 295], ["\u00b7", "TEST", 315, 316], ["\u00b7", "TEST", 319, 320], ["z\u22122", "TEST", 325, 328], ["\u03c1", "TEST", 336, 337], ["\u03b8", "TEST", 338, 339], ["A Connection", "TEST", 341, 353], ["\u03b4", "TEST", 362, 363], ["Value", "TEST", 366, 371], ["the Continued Fraction Representation", "TEST", 376, 413], ["\u00b7", "TEST", 430, 431], ["z", "TEST", 436, 437], ["a z", "TEST", 448, 451], ["Connection", "TEST", 457, 467], ["Value", "TEST", 480, 485], ["the Continued Fraction Representation", "TEST", 490, 527], ["\u00b7", "TEST", 544, 545], ["a z\u22122", "TEST", 548, 553], ["a z", "TEST", 559, 562], ["A Connection", "TEST", 567, 579], ["\u03b4", "TEST", 690, 691], ["u v", "TEST", 696, 699], ["\u03b4", "TEST", 704, 705], ["\u03b8", "TEST", 712, 713], ["minimal", "OBSERVATION_MODIFIER", 35, 42]]], ["Let a b = [a 0 , a 1 , \u00b7 \u00b7 \u00b7 , a z ], we have:A Connection Between \u03b4 2 Value and the Continued Fraction RepresentationProof.", [["a z", "TEST", 31, 34], ["A Connection", "TEST", 46, 58]]], ["Without loss of generality and in order to enlighten the notation, we denoteA Connection Between \u03b4 2 Value and the Continued Fraction Representationand \u03b4 2 C s t = D s .", [["loss of generality", "PROBLEM", 8, 26], ["the Continued Fraction", "TEST", 111, 133]]], ["We start by considering separately the cases a z \u2265 4 and a z = 3, then we discuss the case a z = 2.General Form of a Minimal PathIn this section we give the final result of the paper, by providing a characterization on the elements of the continued fraction of a b in order to consider P \u03b4 2 ( a b ) as a minimal path in SB L .General Form of a Minimal PathAt level 4 of the SB L , only two rational numbers out of 4 belong to a minimal path as we can see in Table 1 .", [["minimal", "OBSERVATION_MODIFIER", 305, 312]]], ["We have P \u03b4 2 ( 3 5 ) = P \u03b4 2 ( 3 4 ) = (1, 1, 1, 2), where 3 5 = [0, 1, 1, 2] and 3 4 = [0, 1, 3] .", [["\u03b4 2 ( 3 4 ) = (1, 1, 1, 2)", "SIMPLE_CHEMICAL", 26, 52], ["5 = [0, 1, 1, 2]", "SIMPLE_CHEMICAL", 62, 78], ["3 4 = [0, 1, 3]", "SIMPLE_CHEMICAL", 83, 98], ["P", "TEST", 8, 9], ["where", "TEST", 54, 59]]], ["At level 5, we note that these two rational numbers generate 4 rational numbers that belong to a minimal path.", [["minimal", "OBSERVATION_MODIFIER", 97, 104]]], ["Hence, all the children of the rational numbers of SB L belonging to MP 6 maintain the minimality at levels 7 and 8.", [["children", "ORGANISM", 15, 23], ["children", "SPECIES", 15, 23], ["MP", "TEST", 69, 71]]], ["While at level 9, there exist only 16 (= 4 2 ) fractions that belong to MP 9 and are represented in Table 2 .General Form of a Minimal PathConsidering these first levels, we note that the continued fraction representations of the elements of MP 9 must start with 0, 1 and end with 2.", [["MP", "TEST", 72, 74]]], ["On the other hand, all the remaining \u03b4 2 values of each element of MP 9 can be grouped into the blocks (1, 1, 1); (1, 2); (2, 1) or 3 as the red and blue colored sequences in Table 2 witness.", [["MP 9", "CHEMICAL", 67, 71], ["red and blue colored sequences", "DNA", 141, 171], ["blue colored sequences", "TEST", 149, 171]]], ["Aware of this, we can characterize the elements of SB L that belongs to a minimal path.", [["SB L", "GENE_OR_GENE_PRODUCT", 51, 55], ["minimal", "OBSERVATION_MODIFIER", 74, 81]]], ["The rational numbers a b at level 4 of SBL with their continued fraction representation, P ( a b ) and P \u03b4 2 ( a b ).", [["SBL", "PROTEIN", 39, 42]]], ["The four rational numbers at level 6 that belong to a minimal path with their continued fraction representation, and sequences P and P \u03b4 2 .", [["P", "DNA", 127, 128], ["P \u03b4 2", "DNA", 133, 138]]], ["Let a b be an element of SB L at a certain level k \u2265 6 and whose continued fraction representation is [a 0 , a 1 , . . . , a z ].", [["Let a b", "GENE_OR_GENE_PRODUCT", 0, 7], ["SB L", "PROBLEM", 25, 29]]], ["If the a i 's respect the following conditions: a 0 = 0, a 1 = 1, a z = 2 and the elements a 2 , . . . , a z\u22121 are obtained by the concatenation of the blocks (1, 1, 1), (2, 1) (1, 2) and (3), then a b \u2208 MP k .Level FractionProof.", [["Level FractionProof", "PROTEIN", 210, 229], ["a b \u2208 MP k", "TEST", 198, 208], ["Level FractionProof", "TEST", 210, 229]]], ["From Lemma 3, we know that a z must be equal to 2 in order to realize the minimal growth.", [["a z", "TREATMENT", 27, 30], ["minimal", "OBSERVATION_MODIFIER", 74, 81], ["growth", "OBSERVATION", 82, 88]]], ["Relying on that, we consider all the possible ways to pass from a level t to a level t + 3 in SB L keeping the minimal growth of one, and we easily realize that these elements can only have one the following forms: (1, 1, 1), (2, 1) (1, 2) or (3), i.e. all the possible integer decompositions of the number three.", [["minimal", "OBSERVATION_MODIFIER", 111, 118], ["growth", "OBSERVATION_MODIFIER", 119, 125]]], ["Note that the first case, is equivalent to the zig-zag path, while the other cases are obtained by Theorem 3 and Lemma 3.Level FractionFinally, some simple computations lead to the following:", [["the zig-zag path", "TREATMENT", 43, 59], ["some simple computations", "PROBLEM", 144, 168]]]], "PMC7094409": [["Rhinoviruses and enteroviruses ::: Detection of Microbes ::: MethodsA multiplex reverse-transcription PCR-hybridization assay for rhinovirus and enterovirus was carried out in 96-well plates as described previously.10, 11, 12 The primers targeted highly conserved sequences in the 5\u2032 noncoding region shared by rhinoviruses and enteroviruses.10 Extracted RNA was reverse-transcribed into cDNA by incubating 5 \u03bcL in a total volume of 40 \u03bcL with the antisense primer.", [["enteroviruses", "DISEASE", 17, 30], ["enteroviruses", "DISEASE", 328, 341], ["enteroviruses", "ORGANISM", 17, 30], ["rhinovirus", "ORGANISM", 130, 140], ["enterovirus", "ORGANISM", 145, 156], ["rhinoviruses", "ORGANISM", 311, 323], ["5\u2032 noncoding region", "DNA", 281, 300], ["cDNA", "DNA", 388, 392], ["antisense primer", "DNA", 448, 464], ["Rhinoviruses", "PROBLEM", 0, 12], ["MethodsA", "TEST", 61, 69], ["transcription PCR", "TEST", 88, 105], ["hybridization assay", "TEST", 106, 125], ["rhinovirus", "PROBLEM", 130, 140], ["enterovirus", "PROBLEM", 145, 156], ["The primers", "TEST", 226, 237], ["rhinoviruses", "PROBLEM", 311, 323], ["enteroviruses", "PROBLEM", 328, 341], ["a total volume", "TREATMENT", 415, 429], ["the antisense primer", "TREATMENT", 444, 464], ["enteroviruses", "OBSERVATION", 17, 30], ["rhinoviruses", "OBSERVATION", 311, 323], ["enteroviruses", "OBSERVATION", 328, 341]]], ["After RT reaction the cDNA 5 \u03bcL was subjected to PCR in 96-well plates with the antisense primer and biotinylated sense primer.Rhinoviruses and enteroviruses ::: Detection of Microbes ::: MethodsLiquid-phase hybridization assay with lanthanide labeled oligonucleotide probes was done as described previously11 by applying 10 \u03bcL of amplified PCR products to the wells of streptavidin-coated microtiter plates and denaturing in 50 mmol/L NaOH.", [["enteroviruses", "DISEASE", 144, 157], ["lanthanide", "CHEMICAL", 233, 243], ["NaOH", "CHEMICAL", 436, 440], ["lanthanide", "CHEMICAL", 233, 243], ["NaOH", "CHEMICAL", 436, 440], ["enteroviruses", "ORGANISM", 144, 157], ["lanthanide", "SIMPLE_CHEMICAL", 233, 243], ["streptavidin", "SIMPLE_CHEMICAL", 370, 382], ["cDNA 5 \u03bcL", "DNA", 22, 31], ["antisense primer", "DNA", 80, 96], ["biotinylated sense primer", "DNA", 101, 126], ["streptavidin", "PROTEIN", 370, 382], ["RT reaction", "PROBLEM", 6, 17], ["the cDNA 5 \u03bcL", "TREATMENT", 18, 31], ["PCR", "TEST", 49, 52], ["the antisense primer", "TREATMENT", 76, 96], ["biotinylated sense primer", "TREATMENT", 101, 126], ["Rhinoviruses", "PROBLEM", 127, 139], ["MethodsLiquid-phase hybridization assay", "TREATMENT", 188, 227], ["lanthanide labeled oligonucleotide probes", "TREATMENT", 233, 274], ["amplified PCR products", "TREATMENT", 331, 353], ["streptavidin-coated microtiter plates", "TREATMENT", 370, 407], ["denaturing", "TREATMENT", 412, 422], ["enteroviruses", "OBSERVATION", 144, 157]]], ["After washing away the detached DNA strand, hybridization with 2 lanthanide probes (Europium for rhinoviruses, Samarium for enteroviruses, Wallac Oy, Turku, Finland), was allowed to take place at 37\u00b0C for 30 minutes in Tris-HCl (pH 7.5) 40 mmol/L supplemented with 10 mmol/L ethylenediamine tetraacetic acid in NaCl 1.5 mol/L. Quantification of lanthanide fluorescence was done in a time-resolved manner.", [["Europium", "CHEMICAL", 84, 92], ["Tris-HCl", "CHEMICAL", 219, 227], ["ethylenediamine tetraacetic acid", "CHEMICAL", 275, 307], ["NaCl", "CHEMICAL", 311, 315], ["lanthanide", "CHEMICAL", 65, 75], ["Tris-HCl", "CHEMICAL", 219, 227], ["ethylenediamine tetraacetic acid", "CHEMICAL", 275, 307], ["NaCl", "CHEMICAL", 311, 315], ["lanthanide", "CHEMICAL", 345, 355], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["Tris-HCl", "SIMPLE_CHEMICAL", 219, 227], ["ethylenediamine tetraacetic acid", "SIMPLE_CHEMICAL", 275, 307], ["lanthanide", "SIMPLE_CHEMICAL", 345, 355], ["detached DNA strand", "DNA", 23, 42], ["the detached DNA strand", "TREATMENT", 19, 42], ["2 lanthanide probes (Europium", "TREATMENT", 63, 92], ["rhinoviruses", "PROBLEM", 97, 109], ["Samarium", "TREATMENT", 111, 119], ["enteroviruses", "PROBLEM", 124, 137], ["pH", "TEST", 229, 231], ["L ethylenediamine tetraacetic acid in NaCl", "TREATMENT", 273, 315], ["lanthanide fluorescence", "TEST", 345, 368]]], ["Previous work with prototype strains of human rhinoviruses and human enteroviruses11 revealed that although use of these 2 probes provides optimal capture of the vast number of serotypes in both genera of viruses, it is not always possible to permit unequivocal separation of the 2 groups.", [["human rhinoviruses", "DISEASE", 40, 58], ["enteroviruses", "DISEASE", 69, 82], ["human", "ORGANISM", 40, 45], ["rhinoviruses", "ORGANISM", 46, 58], ["human", "ORGANISM", 63, 68], ["enteroviruses", "ORGANISM", 69, 82], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 63, 68], ["human rhinoviruses", "SPECIES", 40, 58], ["human", "SPECIES", 63, 68], ["human rhinoviruses", "PROBLEM", 40, 58], ["human enteroviruses", "PROBLEM", 63, 82], ["these 2 probes", "TREATMENT", 115, 129], ["serotypes", "PROBLEM", 177, 186], ["viruses", "PROBLEM", 205, 212], ["enteroviruses", "OBSERVATION", 69, 82], ["viruses", "OBSERVATION", 205, 212], ["not always possible", "UNCERTAINTY", 220, 239]]], ["Therefore, in the following text, positive hybridization result with both probes is referred to as the presence of rhinovirus.Coronaviruses ::: Detection of Microbes ::: MethodsRT-PCR was performed with a primer pair that amplifies a 251 bp fragment of the polymerase gene that is well conserved between coronavirus 229E, coronavirus OC43, coronavirus NL-63, and the SARS-coronavirus.13 The amplified product was detected by electrophoresis in 2% agarose gels after ethidium bromide staining.", [["SARS-coronavirus", "DISEASE", 367, 383], ["ethidium bromide", "CHEMICAL", 466, 482], ["ethidium bromide", "CHEMICAL", 466, 482], ["rhinovirus", "ORGANISM", 115, 125], ["coronavirus 229E", "ORGANISM", 304, 320], ["coronavirus OC43", "ORGANISM", 322, 338], ["coronavirus NL-63", "ORGANISM", 340, 357], ["SARS-coronavirus", "ORGANISM", 367, 383], ["agarose", "SIMPLE_CHEMICAL", 447, 454], ["ethidium bromide", "SIMPLE_CHEMICAL", 466, 482], ["primer pair", "DNA", 205, 216], ["251 bp fragment", "DNA", 234, 249], ["polymerase gene", "DNA", 257, 272], ["coronavirus", "SPECIES", 304, 315], ["coronavirus", "SPECIES", 322, 333], ["coronavirus", "SPECIES", 340, 351], ["coronavirus 229E", "SPECIES", 304, 320], ["coronavirus NL-63", "SPECIES", 340, 357], ["SARS-coronavirus", "SPECIES", 367, 383], ["positive hybridization result", "PROBLEM", 34, 63], ["rhinovirus", "PROBLEM", 115, 125], ["MethodsRT-PCR", "TEST", 170, 183], ["a primer pair", "PROBLEM", 203, 216], ["a 251 bp fragment of the polymerase gene", "TREATMENT", 232, 272], ["coronavirus", "TEST", 304, 315], ["coronavirus OC43", "TEST", 322, 338], ["coronavirus NL", "TEST", 340, 354], ["the SARS-coronavirus", "PROBLEM", 363, 383], ["electrophoresis", "TEST", 425, 440], ["2% agarose gels", "TREATMENT", 444, 459], ["ethidium bromide staining", "TREATMENT", 466, 491], ["rhinovirus", "OBSERVATION", 115, 125], ["coronavirus", "OBSERVATION", 372, 383]]], ["SARS-coronavirus RNA (Frankfurt-1 strain) was included as a positive control in each run.", [["SARS", "DISEASE", 0, 4], ["SARS-coronavirus", "ORGANISM", 0, 16], ["SARS-coronavirus", "SPECIES", 0, 16], ["SARS-coronavirus RNA", "PROBLEM", 0, 20], ["coronavirus RNA", "OBSERVATION", 5, 20]]], ["Only samples showing a distinct band of the expected size without any other fragments occurring in the lane were considered positive.Influenza viruses, RSV, and parainfluenza viruses ::: Detection of Microbes ::: MethodsViral RNA was reverse transcribed into cDNA with random hexamer primers (Roche, Mannheim, Germany) and Superscript III reverse transcriptase enzyme (Invitrogen, Carlsbad, Calif) following the manufacturer's procedures.", [["samples", "ANATOMY", 5, 12], ["fragments", "ANATOMY", 76, 85], ["Influenza viruses", "DISEASE", 133, 150], ["RSV", "DISEASE", 152, 155], ["parainfluenza viruses", "DISEASE", 161, 182], ["samples", "CANCER", 5, 12], ["Influenza viruses", "ORGANISM", 133, 150], ["RSV", "ORGANISM", 152, 155], ["parainfluenza viruses", "ORGANISM", 161, 182], ["Superscript III reverse transcriptase enzyme", "GENE_OR_GENE_PRODUCT", 323, 367], ["MethodsViral RNA", "RNA", 213, 229], ["cDNA", "DNA", 259, 263], ["Superscript III reverse transcriptase enzyme", "PROTEIN", 323, 367], ["Influenza", "SPECIES", 133, 142], ["RSV", "SPECIES", 152, 155], ["parainfluenza", "SPECIES", 161, 174], ["Influenza viruses", "SPECIES", 133, 150], ["RSV", "SPECIES", 152, 155], ["a distinct band of the expected size", "PROBLEM", 21, 57], ["any other fragments", "PROBLEM", 66, 85], ["Influenza viruses", "PROBLEM", 133, 150], ["RSV", "PROBLEM", 152, 155], ["MethodsViral RNA", "TREATMENT", 213, 229], ["random hexamer primers", "TREATMENT", 269, 291], ["transcriptase enzyme", "TEST", 347, 367], ["the manufacturer's procedures", "TREATMENT", 408, 437], ["distinct", "OBSERVATION_MODIFIER", 23, 31], ["band", "OBSERVATION_MODIFIER", 32, 36], ["size", "OBSERVATION_MODIFIER", 53, 57], ["fragments", "OBSERVATION", 76, 85], ["viruses", "OBSERVATION", 143, 150], ["parainfluenza viruses", "OBSERVATION", 161, 182]]], ["For the detection of influenza A and B viruses and RSV, cDNA was amplified in a real-time multiplex PCR9 with minor modifications.", [["influenza A", "ORGANISM", 21, 32], ["B viruses", "ORGANISM", 37, 46], ["RSV", "ORGANISM", 51, 54], ["cDNA", "DNA", 56, 60], ["influenza A", "SPECIES", 21, 32], ["B viruses", "SPECIES", 37, 46], ["RSV", "SPECIES", 51, 54], ["the detection", "TEST", 4, 17], ["influenza", "PROBLEM", 21, 30], ["B viruses", "PROBLEM", 37, 46], ["RSV", "PROBLEM", 51, 54], ["minor modifications", "TREATMENT", 110, 129], ["influenza", "OBSERVATION", 21, 30]]], ["In the case of PIV 1, 2, and 3, cDNA was also amplified in a real-time multiplex PCR.9", [["PIV 1", "GENE_OR_GENE_PRODUCT", 15, 20], ["3", "GENE_OR_GENE_PRODUCT", 29, 30], ["PIV 1, 2, and 3, cDNA", "DNA", 15, 36], ["PIV", "TEST", 15, 18], ["cDNA", "TEST", 32, 36]]]], "PMC5322638": [["BackgroundThe conceptual model under which physicians train affects the way they approach patient care.", [["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97]]], ["Changing patterns in diseases on a global scale suggest a need for new conceptual models for medical education.", [["diseases", "PROBLEM", 21, 29], ["a global scale", "TREATMENT", 33, 47], ["medical education", "TREATMENT", 93, 110], ["diseases", "OBSERVATION", 21, 29]]], ["Rapid global population growth and mobility, agricultural intensification, and the effects of accelerating climate change are impacting biodiversity and ecosystems challenging planetary boundaries for sustainability and creating new environmental health threats at the community and individual level [1].", [["Rapid global population growth", "PROBLEM", 0, 30], ["agricultural intensification", "TREATMENT", 45, 73], ["accelerating climate change", "PROBLEM", 94, 121], ["global", "OBSERVATION_MODIFIER", 6, 12], ["population", "OBSERVATION_MODIFIER", 13, 23], ["growth", "OBSERVATION_MODIFIER", 24, 30], ["mobility", "OBSERVATION_MODIFIER", 35, 43], ["new", "OBSERVATION_MODIFIER", 229, 232]]], ["Emerging infectious diseases in recent decades, driven in large part by such environmental developments, are mostly zoonotic (transmitted between animals and humans) in origin.", [["infectious diseases", "DISEASE", 9, 28], ["humans", "ORGANISM", 158, 164], ["humans", "SPECIES", 158, 164], ["humans", "SPECIES", 158, 164], ["Emerging infectious diseases", "PROBLEM", 0, 28], ["infectious", "OBSERVATION", 9, 19], ["large", "OBSERVATION_MODIFIER", 58, 63], ["mostly", "OBSERVATION_MODIFIER", 109, 115], ["zoonotic", "OBSERVATION_MODIFIER", 116, 124], ["origin", "ANATOMY_MODIFIER", 169, 175]]], ["Zoonotic disease outbreaks and pandemics including Severe Acute Respiratory Syndrome (SARS), avian influenza, pandemic 2009 H1N1 influenza, West Nile virus, Middle East Respiratory Syndrome (MERS), and Ebola, are occurring with increasing frequency and threaten global health security and economic stability [2, 3].", [["Zoonotic disease", "DISEASE", 0, 16], ["pandemics", "DISEASE", 31, 40], ["Acute Respiratory Syndrome", "DISEASE", 58, 84], ["SARS", "DISEASE", 86, 90], ["avian influenza", "DISEASE", 93, 108], ["H1N1 influenza", "DISEASE", 124, 138], ["West Nile virus", "DISEASE", 140, 155], ["Middle East Respiratory Syndrome", "DISEASE", 157, 189], ["MERS", "DISEASE", 191, 195], ["Ebola", "DISEASE", 202, 207], ["avian influenza", "ORGANISM", 93, 108], ["pandemic 2009 H1N1 influenza", "ORGANISM", 110, 138], ["West Nile virus", "ORGANISM", 140, 155], ["Ebola", "ORGANISM", 202, 207], ["avian influenza", "SPECIES", 93, 108], ["H1N1 influenza", "SPECIES", 124, 138], ["West Nile virus", "SPECIES", 140, 155], ["Ebola", "SPECIES", 202, 207], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 51, 91], ["West Nile virus", "SPECIES", 140, 155], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 157, 196], ["Zoonotic disease outbreaks", "PROBLEM", 0, 26], ["pandemics", "PROBLEM", 31, 40], ["Severe Acute Respiratory Syndrome", "PROBLEM", 51, 84], ["SARS)", "PROBLEM", 86, 91], ["avian influenza", "PROBLEM", 93, 108], ["pandemic", "PROBLEM", 110, 118], ["H1N1 influenza", "PROBLEM", 124, 138], ["West Nile virus", "PROBLEM", 140, 155], ["Middle East Respiratory Syndrome", "PROBLEM", 157, 189], ["Ebola", "PROBLEM", 202, 207], ["Severe", "OBSERVATION_MODIFIER", 51, 57], ["Acute", "OBSERVATION_MODIFIER", 58, 63], ["Respiratory Syndrome", "OBSERVATION", 64, 84], ["Middle", "ANATOMY_MODIFIER", 157, 163], ["Respiratory Syndrome", "OBSERVATION", 169, 189], ["Ebola", "OBSERVATION", 202, 207]]], ["There is increasing evidence for the changing relationship with our environment leading to many chronic and emerging challenges such as malnutrition associated with food systems leading to both under- and over nutrition, and diseases relating to declining quality of the environment in particular the air, water, soils and access to space and nature.", [["malnutrition", "DISEASE", 136, 148], ["malnutrition", "PROBLEM", 136, 148], ["food systems", "TREATMENT", 165, 177], ["diseases", "PROBLEM", 225, 233], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["diseases", "OBSERVATION", 225, 233], ["air", "OBSERVATION", 301, 304]]], ["Antibiotic resistant bacteria are emerging in both humans and animals related to widespread use of antibiotics across species including in animal agriculture [4].", [["humans", "ORGANISM", 51, 57], ["humans", "SPECIES", 51, 57], ["humans", "SPECIES", 51, 57], ["Antibiotic resistant bacteria", "PROBLEM", 0, 29], ["antibiotics across species", "TREATMENT", 99, 125], ["resistant", "OBSERVATION_MODIFIER", 11, 20], ["bacteria", "OBSERVATION", 21, 29], ["widespread", "OBSERVATION_MODIFIER", 81, 91]]], ["At the same time, studies of physicians reveal limited awareness of the environmental health aspects of medical problems in the patient care setting [5], as well as low levels of awareness about prevention or treatment of zoonotic diseases [6].", [["zoonotic diseases", "DISEASE", 222, 239], ["patient", "ORGANISM", 128, 135], ["patient", "SPECIES", 128, 135], ["zoonotic diseases", "PROBLEM", 222, 239]]], ["Therefore, there have been calls for training health professionals in \u201csystems thinking\u201d to better prepare them to face these emerging disease issues [7].BackgroundA precedent for teaching systems approaches in medical education can be found in the development of Engel\u2019s biopsychosocial model.", [["teaching systems", "TREATMENT", 180, 196]]], ["In 1980, Engel presented a case of a patient with chest pain to demonstrate how a reductionist \u201cbiomedical\u201d model (that breaks down biological processes into discrete pathways and considers each separately [8] could miss important elements of the social and psychological aspects of care.", [["chest", "ANATOMY", 50, 55], ["chest pain", "DISEASE", 50, 60], ["patient", "ORGANISM", 37, 44], ["chest", "ORGANISM_SUBDIVISION", 50, 55], ["patient", "SPECIES", 37, 44], ["chest pain", "PROBLEM", 50, 60], ["chest", "ANATOMY", 50, 55]]], ["The \u201cbiopsychosocial\u201d model for medical care that he proposed as an alternative approach to a clinical situation was a systems approach that considers the patient as part of a larger system with hierarchical levels of increasing complexity, from the molecular to the cellular to the organ, individual, community, and society (Fig. 1) [9, 10].", [["cellular", "ANATOMY", 267, 275], ["organ", "ANATOMY", 283, 288], ["patient", "ORGANISM", 155, 162], ["cellular", "CELL", 267, 275], ["organ", "ORGAN", 283, 288], ["patient", "SPECIES", 155, 162], ["medical care", "TREATMENT", 32, 44], ["increasing complexity", "PROBLEM", 218, 239], ["increasing", "OBSERVATION_MODIFIER", 218, 228], ["complexity", "OBSERVATION_MODIFIER", 229, 239], ["organ", "ANATOMY", 283, 288]]], ["The concepts of patient-centered care and consideration of social determinants of health can be seen as the most recent efforts to incorporate biopsychosocial approaches into the patient-provider encounter [11, 12].", [["patient", "ORGANISM", 16, 23], ["patient", "ORGANISM", 179, 186], ["patient", "SPECIES", 16, 23], ["patient", "SPECIES", 179, 186], ["patient-centered care", "TREATMENT", 16, 37]]]], "16e918d0a2f2dacb1901178d6316f4850d8da9ef": [["Regardless of the transmission capacity of contemporary vaccines, genome engineering has expanded the capacity to create new vaccines far more prone to transmission [1, 3, [7] [8] [9] .", [["contemporary vaccines", "TREATMENT", 43, 64], ["new vaccines", "TREATMENT", 121, 133]]], ["In some wildlife applications, transmission is even a goal [10] [11] [12] [13] [14] [15] .", [["[10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 59, 88]]], ["In this treatise, we bring together results from genome engineering, evolutionary biology, and mathematical epidemiology to discuss the problems and unknowns facing the design, implementation, and outcomes of transmissible vaccines.", [["transmissible vaccines", "TREATMENT", 209, 231]]], ["Our understanding is yet rudimentary, so this document is both a review and a recommendation for new studies.", [["new studies", "TEST", 97, 108]]], ["The technology of genome engineering has advanced by leaps, enabling many new transmissible vaccine designs.", [["new transmissible vaccine designs", "TREATMENT", 74, 107]]], ["Transmissible vaccines are but one set of strategies of transmissible interventions (Box 1), and the general topic offers many exciting opportunities for research and possible implementation.Attenuated VaccinesLive, attenuated viruses have provided one of the two pillars of vaccine design, the other being inactivated (killed) viruses [3, 4] .", [["Transmissible vaccines", "TREATMENT", 0, 22], ["transmissible interventions", "TREATMENT", 56, 83], ["Attenuated VaccinesLive", "TREATMENT", 191, 214], ["attenuated viruses", "PROBLEM", 216, 234], ["vaccine design", "TREATMENT", 275, 289], ["attenuated", "OBSERVATION_MODIFIER", 216, 226], ["viruses", "OBSERVATION", 227, 234]]], ["Recombinant vector vaccines, another form of live vaccines, Trends Two types of live viral vaccine are amenable to transmission: attenuated and recombinant vector vaccines.Attenuated VaccinesThe epidemiological consequences of vaccine transmission vary with vaccine design and are often case-specific.Attenuated VaccinesRecombinant vector vaccines offer the greatest and least appreciated potential for transmission.Attenuated VaccinesVaccine evolution is a major issue that stems from transmission and can undermine vaccine utility.Attenuated VaccinesAttenuated vaccines can now be designed that largely suppress evolution; recombinant vectors are prone to evolution. appear to be a rapidly ascending third pillar (addressed below).", [["VaccinesVaccine", "CHEMICAL", 427, 442], ["Recombinant vector vaccines", "TREATMENT", 0, 27], ["live vaccines", "TREATMENT", 45, 58], ["live viral vaccine", "TREATMENT", 80, 98], ["recombinant vector vaccines", "TREATMENT", 144, 171], ["Attenuated Vaccines", "TREATMENT", 172, 191], ["vaccine transmission", "TREATMENT", 227, 247], ["vaccine design", "TREATMENT", 258, 272], ["Attenuated VaccinesRecombinant vector vaccines", "TREATMENT", 301, 347], ["Attenuated VaccinesVaccine evolution", "PROBLEM", 416, 452], ["Attenuated Vaccines", "TREATMENT", 533, 552], ["Attenuated vaccines", "TREATMENT", 552, 571], ["a rapidly ascending third pillar", "PROBLEM", 682, 714], ["rapidly", "OBSERVATION_MODIFIER", 684, 691], ["ascending", "OBSERVATION_MODIFIER", 692, 701], ["third", "OBSERVATION_MODIFIER", 702, 707], ["pillar", "OBSERVATION_MODIFIER", 708, 714]]], ["They have a medicinal advantage over killed vaccines in generating an appropriate immune response because they infect cells, and hence can elicit both humoral and cell-mediated defenses.", [["cells", "ANATOMY", 118, 123], ["cell", "ANATOMY", 163, 167], ["cells", "CELL", 118, 123], ["cell", "CELL", 163, 167], ["a medicinal advantage over killed vaccines", "TREATMENT", 10, 52]]], ["They also infect the same tissues as does the pathogenic wild type.Attenuated VaccinesHistorically, a serious drawback of attenuated vaccines has been that haphazard methods were used to create them [4, 16] .", [["tissues", "ANATOMY", 26, 33], ["tissues", "TISSUE", 26, 33], ["Attenuated VaccinesHistorically", "PROBLEM", 67, 98], ["attenuated vaccines", "TREATMENT", 122, 141], ["haphazard methods", "TREATMENT", 156, 173]]], ["The virus was grown in unnatural conditions, perhaps novel temperatures, novel hosts, or novel host cells.", [["cells", "ANATOMY", 100, 105], ["host cells", "CELL", 95, 105], ["novel host cells", "CELL_TYPE", 89, 105], ["The virus", "PROBLEM", 0, 9], ["novel temperatures, novel hosts", "PROBLEM", 53, 84], ["novel host cells", "PROBLEM", 89, 105], ["virus", "OBSERVATION", 4, 9], ["unnatural conditions", "OBSERVATION", 23, 43], ["host cells", "OBSERVATION", 95, 105]]], ["Adaptation to the new conditions compromised viral growth ability in the natural hostresulting in a viral growth rate reduction that subdued the infection enough to avoid disease.", [["infection", "DISEASE", 145, 154], ["viral growth ability", "PROBLEM", 45, 65], ["a viral growth rate reduction", "TREATMENT", 98, 127], ["the infection", "PROBLEM", 141, 154], ["disease", "PROBLEM", 171, 178], ["infection", "OBSERVATION", 145, 154]]], ["The endpoint of the adaptation was chosen by trial and error, with little insight to the vaccine properties until tested in an actual host.", [["the vaccine properties", "TREATMENT", 85, 107]]], ["It was thus not feasible to knowingly generate a variety of vaccine candidates differing in the degree of attenuation.", [["a variety of vaccine", "TREATMENT", 47, 67], ["attenuation", "OBSERVATION", 106, 117]]], ["Consequently, the range of attenuation compatible with avirulence and immunogenicity was never worked out.", [["avirulence", "PROBLEM", 55, 65], ["attenuation", "OBSERVATION_MODIFIER", 27, 38], ["compatible with", "UNCERTAINTY", 39, 54], ["avirulence", "OBSERVATION", 55, 65]]], ["But the fact that adequate immunity and avirulence were often achieved by such an imprecise method suggests that the acceptable range of attenuation levels is broad.", [["avirulence", "PROBLEM", 40, 50], ["adequate", "OBSERVATION_MODIFIER", 18, 26], ["immunity", "OBSERVATION", 27, 35], ["attenuation", "OBSERVATION", 137, 148], ["broad", "OBSERVATION_MODIFIER", 159, 164]]], ["(Of course, the inoculum dose could always be adjusted to compensate for different levels of attenuation.)Attenuated VaccinesGenetic engineering now affords 'tunable' attenuation, enabling the construction of an almost limitless range of intermediates across the spectrum from wild-type growth to zero growth, although the challenge remains to find the right balance between attenuation and immunogenicity [8] .", [["the inoculum dose", "TREATMENT", 12, 29], ["Attenuated VaccinesGenetic engineering", "TREATMENT", 106, 144], ["'tunable' attenuation", "TREATMENT", 157, 178], ["type growth", "PROBLEM", 282, 293], ["zero growth", "PROBLEM", 297, 308], ["right", "ANATOMY_MODIFIER", 353, 358], ["attenuation", "OBSERVATION_MODIFIER", 375, 386]]], ["Three promising methods (that do not yield chimeric genomes of different viruses) include synonymous codon replacement, genome rearrangement, and introduction of nonlethal deletions; these methods are considered below.Box 1.", [["Box 1", "GENE_OR_GENE_PRODUCT", 218, 223], ["chimeric genomes", "DNA", 43, 59], ["different viruses", "PROBLEM", 63, 80], ["synonymous codon replacement", "TREATMENT", 90, 118], ["nonlethal deletions", "PROBLEM", 162, 181], ["synonymous codon replacement", "OBSERVATION", 90, 118]]], ["Other Forms of Transmissible DefenseAdvances in genome engineering have created opportunities for other forms of transmissible defenses.", [["transmissible defenses", "PROBLEM", 113, 135]]], ["Here, we briefly discuss two prominent alternatives.Viral Defective Interfering ParticlesDefective interfering particles (DIPs) are subgenomic derivatives of a fully competent virus and act as parasites of the competent virus.", [["DIPs", "GENE_OR_GENE_PRODUCT", 122, 126], ["Viral Defective Interfering Particles", "TREATMENT", 52, 89], ["Defective interfering particles", "PROBLEM", 89, 120], ["subgenomic derivatives", "TREATMENT", 132, 154], ["a fully competent virus", "PROBLEM", 158, 181], ["the competent virus", "PROBLEM", 206, 225], ["Defective", "OBSERVATION_MODIFIER", 58, 67], ["Interfering", "OBSERVATION_MODIFIER", 68, 79], ["ParticlesDefective", "OBSERVATION", 80, 98], ["interfering", "OBSERVATION_MODIFIER", 99, 110], ["particles", "OBSERVATION_MODIFIER", 111, 120], ["subgenomic derivatives", "OBSERVATION", 132, 154], ["competent virus", "OBSERVATION", 210, 225]]], ["Cells coinfected with the DIP and standard virus vastly overproduce the DIP, and the asymmetry in output leads to an overall reduction in standard viral load [44, 45] .", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["DIP", "GENE_OR_GENE_PRODUCT", 26, 29], ["the DIP", "TREATMENT", 22, 29], ["standard virus", "TREATMENT", 34, 48], ["the DIP", "PROBLEM", 68, 75], ["the asymmetry in output", "PROBLEM", 81, 104], ["an overall reduction", "TREATMENT", 114, 134], ["standard viral load", "TEST", 138, 157], ["DIP", "OBSERVATION_MODIFIER", 72, 75], ["asymmetry", "OBSERVATION_MODIFIER", 85, 94], ["reduction", "OBSERVATION_MODIFIER", 125, 134]]], ["Because DIPs suppress viral load, they have long been entertained as therapies for viral diseases [46, 47] .", [["viral diseases", "DISEASE", 83, 97], ["DIPs", "GENE_OR_GENE_PRODUCT", 8, 12], ["DIPs", "PROTEIN", 8, 12], ["DIPs suppress viral load", "PROBLEM", 8, 32], ["viral diseases", "PROBLEM", 83, 97], ["viral load", "OBSERVATION", 22, 32]]], ["A more recent proposal is to engineer DIPs as therapeutic interfering particles (TIPs); any TIP transmission among hosts is a strong potential benefit [48, 49] .", [["DIPs", "CHEMICAL", 38, 42], ["DIPs", "SIMPLE_CHEMICAL", 38, 42], ["therapeutic interfering particles (TIPs", "TREATMENT", 46, 85]]], ["Thus, TIPs that protect against HIV would not only suppress the disease but would also spread and automatically target superspreaders [7] .", [["TIPs", "CHEMICAL", 6, 10], ["TIPs", "SIMPLE_CHEMICAL", 6, 10], ["HIV", "ORGANISM", 32, 35], ["HIV", "SPECIES", 32, 35], ["HIV", "SPECIES", 32, 35], ["TIPs", "TREATMENT", 6, 10], ["HIV", "PROBLEM", 32, 35], ["the disease", "PROBLEM", 60, 71], ["disease", "OBSERVATION", 64, 71]]], ["Despite the promise of this approach, challenges await.", [["this approach", "TREATMENT", 23, 36]]], ["For instance, because DIPs and TIPs require a high density of the competent virus for effective replication, an interfering virus that profoundly suppresses the pathogenic virusotherwise a good propertywill ultimately suppress its own replication, with poor transmission to other hosts.Gene DrivesGene drive systems are elements of a genome and thus not 'infectious'.", [["DIPs", "GENE_OR_GENE_PRODUCT", 22, 26], ["TIPs", "GENE_OR_GENE_PRODUCT", 31, 35], ["DIPs", "PROTEIN", 22, 26], ["TIPs", "PROTEIN", 31, 35], ["DIPs", "PROBLEM", 22, 26], ["TIPs", "TREATMENT", 31, 35], ["a high density of the competent virus", "PROBLEM", 44, 81], ["effective replication", "TREATMENT", 86, 107], ["an interfering virus", "PROBLEM", 109, 129], ["TIPs", "OBSERVATION_MODIFIER", 31, 35], ["high density", "OBSERVATION_MODIFIER", 46, 58]]], ["They nonetheless spread through populations by biasing transmission during sexual reproductionthe classic 'selfish gene'.", [["selfish gene", "DNA", 107, 119], ["spread", "OBSERVATION_MODIFIER", 17, 23]]], ["Because gene drive systems transmit only vertically from parent to offspring, they spread through a population more slowly than infectious agents.", [["infectious agents", "TREATMENT", 128, 145]]], ["Even so, for short-lived organisms, gene drives provide a powerful mechanism for spreading a particular gene through a population, such as a gene for resistance to malaria in Anopheles mosquitoes [50] [51] [52] .", [["malaria", "DISEASE", 164, 171], ["Anopheles mosquitoes", "ORGANISM", 175, 195], ["Anopheles mosquitoes", "SPECIES", 175, 195], ["short-lived organisms", "PROBLEM", 13, 34], ["malaria", "PROBLEM", 164, 171]]], ["Conceptually similar approaches use vertically transmitted bacterial symbionts (genus Wolbachia) that reduce or block transmission of virus from mosquitoes carrying the symbiont [53, 54] .Gene DrivesGene drive (and symbiont based) approaches offer powerful and exciting opportunities for controlling infectious diseases that rely on short-lived vector organisms, or for eliminating infectious disease from animal reservoir populations with short generation times (e.g., hantavirus in deer mice).", [["infectious diseases", "DISEASE", 300, 319], ["infectious disease", "DISEASE", 382, 400], ["deer mice", "ORGANISM", 484, 493], ["deer", "SPECIES", 484, 488], ["mice", "SPECIES", 489, 493], ["mice", "SPECIES", 489, 493], ["vertically transmitted bacterial symbionts (genus Wolbachia", "PROBLEM", 36, 95], ["block transmission of virus", "PROBLEM", 112, 139], ["controlling infectious diseases", "PROBLEM", 288, 319], ["infectious disease", "PROBLEM", 382, 400], ["animal reservoir populations", "TREATMENT", 406, 434], ["bacterial symbionts", "OBSERVATION", 59, 78], ["infectious", "OBSERVATION", 382, 392]]], ["Compared to transmissible vaccines, gene drive systems have restricted utility: they require sexual reproduction and short generation time and cannot be used in humans.Synonymous Codon ReplacementPerhaps the most exciting new design is to engineer many synonymous codon changes into viral protein coding sequences; in some cases, the existing codons for each amino acid are merely exchanged with each other, creating new codon pairs but not changing the numbers of each codon [17] [18] [19] [20] .", [["amino acid", "CHEMICAL", 359, 369], ["amino acid", "CHEMICAL", 359, 369], ["humans", "ORGANISM", 161, 167], ["amino acid", "AMINO_ACID", 359, 369], ["viral protein coding sequences", "DNA", 283, 313], ["codon pairs", "DNA", 421, 432], ["humans", "SPECIES", 161, 167], ["humans", "SPECIES", 161, 167], ["transmissible vaccines", "TREATMENT", 12, 34], ["sexual reproduction", "TREATMENT", 93, 112], ["Synonymous Codon ReplacementPerhaps", "TREATMENT", 168, 203], ["viral protein coding sequences", "TREATMENT", 283, 313], ["the existing codons", "TREATMENT", 330, 349], ["each amino acid", "TREATMENT", 354, 369], ["new codon pairs", "PROBLEM", 417, 432], ["synonymous codon", "OBSERVATION", 253, 269]]], ["The protein sequences are unaltered from the wild type, but protein expression and intracellular growth are reduced (by mechanisms not fully understood but likely involving reduced translation).", [["intracellular", "ANATOMY", 83, 96], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 83, 96], ["The protein sequences", "TEST", 0, 21], ["protein expression", "PROBLEM", 60, 78], ["intracellular growth", "PROBLEM", 83, 103], ["growth", "OBSERVATION_MODIFIER", 97, 103]]], ["Greater attenuation is achieved with larger numbers of synonymous codon changes, allowing a very precise tunability.", [["synonymous codon changes", "PROBLEM", 55, 79], ["attenuation", "OBSERVATION_MODIFIER", 8, 19], ["larger", "OBSERVATION_MODIFIER", 37, 43], ["numbers", "OBSERVATION_MODIFIER", 44, 51], ["synonymous codon changes", "OBSERVATION", 55, 79]]], ["This method can be applied to parts or the whole of any viral genome.", [["viral genome", "DNA", 56, 68], ["This method", "TREATMENT", 0, 11], ["viral genome", "OBSERVATION", 56, 68]]], ["This type of attenuation is very slow to recover high fitness.Genome RearrangementA seemingly simple approach is to reorder the genes in a genome; the main effect is likely in gene regulation [21] [22] [23] .", [["attenuation", "OBSERVATION", 13, 24], ["very", "OBSERVATION_MODIFIER", 28, 32], ["slow", "OBSERVATION_MODIFIER", 33, 37]]], ["Tunability is afforded by different rearrangements, but not with the flexibility of codon replacement.", [["codon replacement", "TREATMENT", 84, 101]]], ["Experiments with virus grown in culture suggest that the rearrangements are stable and that seemingly permanent attenuation can be achieved despite ongoing viral growth.", [["virus", "PROBLEM", 17, 22], ["culture", "TEST", 32, 39], ["seemingly permanent attenuation", "PROBLEM", 92, 123], ["ongoing viral growth", "PROBLEM", 148, 168], ["stable", "OBSERVATION_MODIFIER", 76, 82]]], ["This method may be difficult to implement in small genomes and in those expressed as polyproteins.DeletionsNonessential genes, or portions of genes, may be removed from the genome to reduce viral growth rate [9, 24, 25] .", [["This method", "TREATMENT", 0, 11], ["DeletionsNonessential genes", "PROBLEM", 98, 125], ["viral growth rate", "TEST", 190, 207], ["small genomes", "OBSERVATION_MODIFIER", 45, 58], ["polyproteins", "OBSERVATION", 85, 97]]], ["Experiments with virus grown in culture suggest that fitness effects of the deletions can be at least partly recovered by evolution, and RNA viruses with deletions have sometimes evolved to restore the lost sequences.DeletionsTransmission of attenuated vaccines has not typically been considered in their developmentimmunogenicity and avirulence were the important concerns and were difficult enough to balance without considering a third variable.", [["virus", "PROBLEM", 17, 22], ["culture", "TEST", 32, 39], ["the deletions", "PROBLEM", 72, 85], ["RNA viruses with deletions", "PROBLEM", 137, 163], ["attenuated vaccines", "TREATMENT", 242, 261], ["avirulence", "PROBLEM", 335, 345]]], ["The only existing attenuated human vaccine known to be frequently transmitted is the oral polio vaccine, although there are isolated reports of transmission by other attenuated vaccines [6, [26] [27] [28] [29] ; transmission of vaccines intended for wildlife is well documented in a few cases [15] .", [["oral", "ANATOMY", 85, 89], ["[6, [26] [27] [28] [29", "CHEMICAL", 186, 208], ["human", "ORGANISM", 29, 34], ["oral", "ORGANISM_SUBDIVISION", 85, 89], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["existing attenuated human vaccine", "TREATMENT", 9, 42], ["the oral polio vaccine", "TREATMENT", 81, 103], ["other attenuated vaccines", "TREATMENT", 160, 185], ["transmission of vaccines", "TREATMENT", 212, 236]]], ["The tunability now enabled by genetic engineering may finally allow the deliberate creation of attenuated vaccines that are avirulent and also transmit.", [["attenuated vaccines", "TREATMENT", 95, 114], ["avirulent", "PROBLEM", 124, 133]]], ["Furthermore, if the viral genome carries nonessential genes that effect virulence, deletions may achieve avirulence while allowing transmission.", [["viral genome", "DNA", 20, 32], ["nonessential genes", "DNA", 41, 59], ["the viral genome", "PROBLEM", 16, 32], ["virulence", "PROBLEM", 72, 81], ["avirulence", "PROBLEM", 105, 115]]], ["And radically new approaches to attenuation may become feasible that greatly increase transmission above standard methods (Box 2).Recombinant Vector VaccinesA somewhat new vaccine design is the live recombinant vector vaccine (RVV), a chimera of two viral genomes.", [["Vector", "GENE_OR_GENE_PRODUCT", 142, 148], ["viral genomes", "DNA", 250, 263], ["RVV", "SPECIES", 227, 230], ["Recombinant Vector VaccinesA", "TREATMENT", 130, 158], ["new vaccine design", "TREATMENT", 168, 186], ["the live recombinant vector vaccine", "TREATMENT", 190, 225], ["two viral genomes", "PROBLEM", 246, 263], ["increase", "OBSERVATION_MODIFIER", 77, 85], ["viral genomes", "OBSERVATION", 250, 263]]], ["There are many flavors of these, and our focus is live, self-replicating vaccines in which the vector is a harmless virus whose genome is left largely intact except for inserts of foreign genes [12, 10, [30] [31] [32] [33] [34] [35] [36] [37] [38] .", [["[30] [31] [32] [33] [34] [35] [36] [37] [38]", "SIMPLE_CHEMICAL", 203, 247], ["foreign genes", "DNA", 180, 193], ["self-replicating vaccines", "TREATMENT", 56, 81], ["foreign genes", "TEST", 180, 193], ["many", "OBSERVATION_MODIFIER", 10, 14], ["flavors", "OBSERVATION", 15, 22], ["left", "ANATOMY_MODIFIER", 138, 142], ["intact", "OBSERVATION", 151, 157]]], ["Its genome is engineered to carry one or a few antigenic genes from a pathogen.", [["antigenic genes", "DNA", 47, 62], ["a pathogen", "PROBLEM", 68, 78], ["few", "OBSERVATION_MODIFIER", 43, 46], ["antigenic genes", "OBSERVATION", 47, 62]]], ["The goal is to elicit immunity against the pathogen's antigens, and the vector merely provides the means to amplify those antigens within the host.", [["antigens", "PROTEIN", 54, 62], ["antigens", "PROTEIN", 122, 130], ["the pathogen's antigens", "PROBLEM", 39, 62]]], ["In contrast to an attenuated vaccine, a 'recombinant vector' of this type is intrinsically safe because it carries only a small part of the pathogen's genome.", [["pathogen's genome", "DNA", 140, 157], ["an attenuated vaccine", "TREATMENT", 15, 36], ["small", "OBSERVATION_MODIFIER", 122, 127], ["pathogen", "OBSERVATION_MODIFIER", 140, 148], ["'s genome", "OBSERVATION", 148, 157]]], ["However, even supposedly benign vectors may be pathogenic in individuals with compromised immune systems, so an RVV may be safe only in some individuals.", [["RVV", "SPECIES", 112, 115], ["benign vectors", "PROBLEM", 25, 39], ["pathogenic", "PROBLEM", 47, 57], ["compromised immune systems", "PROBLEM", 78, 104], ["an RVV", "TREATMENT", 109, 115]]], ["RVVs have long been used in wildlife applications (e.g., some rabies vaccines), some have entered human trials, and a great many others are being considered.", [["RVVs", "CHEMICAL", 0, 4], ["RVVs", "SIMPLE_CHEMICAL", 0, 4], ["human", "ORGANISM", 98, 103], ["human", "SPECIES", 98, 103], ["RVVs", "SPECIES", 0, 4], ["human", "SPECIES", 98, 103], ["wildlife applications", "TREATMENT", 28, 49], ["some rabies vaccines", "TREATMENT", 57, 77]]], ["A comprehensive listing of RVVs has been compiled. iRecombinant Vector VaccinesThe RVV design is versatile.", [["RVVs", "CANCER", 27, 31], ["RVVs", "DNA", 27, 31], ["iRecombinant Vector Vaccines", "TREATMENT", 51, 79], ["RVV", "OBSERVATION", 83, 86]]], ["For any set of pathogen genes, the vector can be chosen from many candidates to be avirulent; methods to engineer reduced virulence while maintaining transmission are unnecessary.", [["pathogen genes", "DNA", 15, 29], ["the vector", "TREATMENT", 31, 41], ["avirulent", "PROBLEM", 83, 92], ["reduced virulence", "PROBLEM", 114, 131]]], ["Yet because only one or a few genes from the pathogen are engineered into the vector, and the tissues of vaccine infection may differ from those of the pathogen, RVVs risk eliciting only weak immunity.", [["tissues", "ANATOMY", 94, 101], ["infection", "DISEASE", 113, 122], ["tissues", "TISSUE", 94, 101], ["RVVs", "CANCER", 162, 166], ["the pathogen", "PROBLEM", 41, 53], ["vaccine infection", "PROBLEM", 105, 122], ["the pathogen", "PROBLEM", 148, 160], ["pathogen", "OBSERVATION", 45, 53]]], ["The fact that the pathogen's genes are not only nonessential to the vector but potentially detrimental to it may allow their rapid evolutionary loss.Recombinant Vector VaccinesTransmissibility may be a common property of live RVVs, whether desired or not.", [["RVVs", "ANATOMY", 226, 230], ["Transmissibility", "DISEASE", 176, 192], ["RVVs", "CANCER", 226, 230], ["pathogen's genes", "DNA", 18, 34], ["the pathogen's genes", "PROBLEM", 14, 34], ["their rapid evolutionary loss", "PROBLEM", 119, 148], ["Recombinant Vector Vaccines", "TREATMENT", 149, 176]]], ["If the vector is capable of autonomous spread, the vaccine is likely to be transmissible as well.", [["autonomous spread", "PROBLEM", 28, 45], ["the vaccine", "TREATMENT", 47, 58]]], ["The possibility of vector virulence in some classes of individuals becomes a problem because transmission cannot be limited to appropriate recipients the way that direct vaccination can.", [["vector virulence", "PROBLEM", 19, 35], ["direct vaccination", "TREATMENT", 163, 181], ["possibility of", "UNCERTAINTY", 4, 18], ["vector virulence", "OBSERVATION", 19, 35]]], ["However, vectors that require an intermediate host for transmission (such as arboviruses) will not transmit if the intermediate host is absent.Properties of Transmissible Vaccines, and ChallengesThe two flavors of transmissible vaccines, RVVs and attenuated vaccines, have different epidemiological and evolutionary properties and consequences.", [["arboviruses", "PROBLEM", 77, 88], ["Transmissible Vaccines", "TREATMENT", 157, 179], ["transmissible vaccines", "TREATMENT", 214, 236], ["RVVs", "TREATMENT", 238, 242], ["attenuated vaccines", "TREATMENT", 247, 266], ["absent", "OBSERVATION", 136, 142], ["Transmissible Vaccines", "OBSERVATION", 157, 179]]], ["In the four sections below, we explain those properties and the challenges we face in correcting the problems stemming from the consequences.Viral Genome Engineering Can Influence TransmissionAttenuated vaccines and RVVs present somewhat opposing challenges for the goal of transmission.", [["sections", "ANATOMY", 12, 20], ["the problems", "PROBLEM", 97, 109], ["Viral Genome Engineering", "TREATMENT", 141, 165], ["TransmissionAttenuated vaccines", "TREATMENT", 180, 211], ["RVVs", "TREATMENT", 216, 220]]], ["Attenuated vaccines will be prone to transmit poorlythe reduced growth rate will limit viral titers within the host and thereby limit the dissemination of virions to new hosts (Figure 1 , Key Figure) .", [["Attenuated vaccines", "TREATMENT", 0, 19], ["transmit poorlythe reduced growth rate", "PROBLEM", 37, 75], ["viral titers", "TEST", 87, 99]]], ["If transmission is desired, it may be necessary to test a range of attenuations to find one that is safe but also transmits, or to use designs that suppress pathogenesis but enable BoxVirus Attenuation by Changing Tissue TropismEngineering viruses to infect tissues required for transmission, but avoiding tissues involved in virulence, offers a possible viral attenuation design that may enable levels of transmission near wild-type levels.", [["tissues", "ANATOMY", 258, 265], ["tissues", "ANATOMY", 306, 313], ["tissues", "TISSUE", 258, 265], ["tissues", "TISSUE", 306, 313], ["pathogenesis", "PROBLEM", 157, 169], ["BoxVirus Attenuation", "TREATMENT", 181, 201], ["Changing Tissue TropismEngineering viruses", "TREATMENT", 205, 247], ["infect tissues", "PROBLEM", 251, 265], ["virulence", "PROBLEM", 326, 335], ["viral attenuation design", "PROBLEM", 355, 379], ["possible", "UNCERTAINTY", 346, 354], ["viral attenuation", "OBSERVATION", 355, 372]]], ["Traditional methods of attenuation have aimed at reducing the within-host viral growth rate, invariably reducing transmission as a by-product.", [["attenuation", "OBSERVATION_MODIFIER", 23, 34]]], ["Direct measures of oral polio virus transmission are available [55] , but the apparent absence of transmission by many other live vaccines suggests that standard methods of attenuation suppress transmission.", [["oral", "ANATOMY", 19, 23], ["oral polio virus", "ORGANISM", 19, 35], ["polio virus", "SPECIES", 24, 35], ["oral polio virus transmission", "TEST", 19, 48], ["many other live vaccines", "TREATMENT", 114, 138], ["attenuation", "OBSERVATION_MODIFIER", 173, 184]]], ["Yet, if virulence is due to infection of a secondary tissueone not essential for transmissionengineering might eliminate virulence (attenuate) by blocking that tropism without harming transmission and thus yield an avirulent but highly transmissible vaccine.Virus Attenuation by Changing Tissue TropismOne apparently general method of tissue-specific attenuation is to engineer microRNA response elements (MREs) into the vaccine strain; MREs are sites targeted by host-cell microRNAs that downregulate expression of the targeted gene.", [["tissueone", "ANATOMY", 53, 62], ["tissue", "ANATOMY", 335, 341], ["cell", "ANATOMY", 469, 473], ["infection", "DISEASE", 28, 37], ["Tissue", "TISSUE", 288, 294], ["tissue", "TISSUE", 335, 341], ["MREs", "GENE_OR_GENE_PRODUCT", 437, 441], ["host-cell", "CELL", 464, 473], ["microRNA response elements", "DNA", 378, 404], ["MREs", "DNA", 406, 410], ["MREs", "DNA", 437, 441], ["targeted gene", "DNA", 520, 533], ["virulence", "PROBLEM", 8, 17], ["infection", "PROBLEM", 28, 37], ["a secondary tissueone", "PROBLEM", 41, 62], ["transmissionengineering", "TREATMENT", 81, 104], ["virulence", "PROBLEM", 121, 130], ["harming transmission", "PROBLEM", 176, 196], ["an avirulent", "PROBLEM", 212, 224], ["Virus Attenuation", "TREATMENT", 258, 275], ["Changing Tissue TropismOne", "TREATMENT", 279, 305], ["the vaccine strain", "TREATMENT", 417, 435], ["infection", "OBSERVATION", 28, 37], ["Attenuation", "OBSERVATION_MODIFIER", 264, 275], ["Changing Tissue", "OBSERVATION_MODIFIER", 279, 294], ["cell microRNAs", "OBSERVATION", 469, 483]]], ["If the MREs are targeted only in tissues contributing to virulence, but not other tissues of viral replication, disease phenotypes can be attenuated while vaccine replication is maintained in other tissues [56] [57] [58] .", [["tissues", "ANATOMY", 33, 40], ["tissues", "ANATOMY", 82, 89], ["tissues", "ANATOMY", 198, 205], ["MREs", "GENE_OR_GENE_PRODUCT", 7, 11], ["tissues", "TISSUE", 33, 40], ["tissues", "TISSUE", 82, 89], ["tissues", "TISSUE", 198, 205], ["MREs", "DNA", 7, 11], ["the MREs", "TEST", 3, 11], ["virulence", "PROBLEM", 57, 66], ["viral replication", "PROBLEM", 93, 110], ["disease phenotypes", "PROBLEM", 112, 130], ["vaccine replication", "TREATMENT", 155, 174], ["viral replication", "OBSERVATION", 93, 110]]], ["The engineered MREs may be prone to evolutionary loss within the host, but some designs can reduce this loss [59] , and if the tissues contributing to virulence are not important to transmission (as with the neurotropism of poliovirus [64] ), the MREs may even be maintained as the vaccine spreads across hosts.Virus Attenuation by Changing Tissue TropismA conceptually similar approach to MRE engineering is to change other regulatory elements in the viral genome.", [["tissues", "ANATOMY", 127, 134], ["MREs", "GENE_OR_GENE_PRODUCT", 15, 19], ["tissues", "TISSUE", 127, 134], ["poliovirus", "ORGANISM", 224, 234], ["MREs", "GENE_OR_GENE_PRODUCT", 247, 251], ["Tissue", "TISSUE", 341, 347], ["MRE", "DNA", 390, 393], ["regulatory elements", "DNA", 425, 444], ["viral genome", "DNA", 452, 464], ["evolutionary loss within the host", "PROBLEM", 36, 69], ["this loss", "PROBLEM", 99, 108], ["virulence", "PROBLEM", 151, 160], ["poliovirus", "PROBLEM", 224, 234], ["the MREs", "TEST", 243, 251], ["Virus Attenuation", "TREATMENT", 311, 328], ["Changing Tissue TropismA", "TREATMENT", 332, 356], ["MRE engineering", "TREATMENT", 390, 405], ["Attenuation", "OBSERVATION_MODIFIER", 317, 328], ["regulatory elements", "OBSERVATION", 425, 444], ["viral genome", "OBSERVATION", 452, 464]]], ["For example, replacement of the poliovirus internal ribosomal entry site (IRES) by an IRES from rhinoviruses can eliminate CNS tropism [60] .", [["ribosomal", "ANATOMY", 52, 61], ["CNS", "ANATOMY", 123, 126], ["ribosomal", "CELLULAR_COMPONENT", 52, 61], ["rhinoviruses", "ORGANISM", 96, 108], ["poliovirus internal ribosomal entry site", "DNA", 32, 72], ["IRES", "DNA", 74, 78], ["IRES", "DNA", 86, 90], ["replacement", "TREATMENT", 13, 24], ["the poliovirus internal ribosomal entry site", "PROBLEM", 28, 72], ["rhinoviruses", "PROBLEM", 96, 108], ["CNS tropism", "PROBLEM", 123, 134], ["replacement", "OBSERVATION", 13, 24], ["poliovirus", "OBSERVATION_MODIFIER", 32, 42], ["internal", "OBSERVATION_MODIFIER", 43, 51], ["ribosomal", "OBSERVATION_MODIFIER", 52, 61], ["entry site", "OBSERVATION", 62, 72]]], ["It is likely that the higher frequency of CNS infections by type 1, compared to type 2 and 3, strains is related to different degrees of attenuation at the IRES locus [5] .Virus Attenuation by Changing Tissue TropismObservations of natural evolution also support the possibility of attenuation through changes in tissue tropism while maintaining transmission.", [["CNS", "ANATOMY", 42, 45], ["tissue", "ANATOMY", 313, 319], ["infections", "DISEASE", 46, 56], ["CNS", "ANATOMICAL_SYSTEM", 42, 45], ["tissue", "TISSUE", 313, 319], ["IRES locus", "DNA", 156, 166], ["CNS infections", "PROBLEM", 42, 56], ["strains", "PROBLEM", 94, 101], ["attenuation at the IRES locus", "PROBLEM", 137, 166], ["Virus Attenuation", "TREATMENT", 172, 189], ["Changing Tissue TropismObservations", "TREATMENT", 193, 228], ["attenuation through changes in tissue tropism", "PROBLEM", 282, 327], ["is likely", "UNCERTAINTY", 3, 12], ["higher", "OBSERVATION_MODIFIER", 22, 28], ["CNS", "ANATOMY", 42, 45], ["infections", "OBSERVATION", 46, 56], ["different degrees", "OBSERVATION_MODIFIER", 116, 133], ["attenuation", "OBSERVATION_MODIFIER", 137, 148], ["Attenuation", "OBSERVATION_MODIFIER", 178, 189], ["Changing Tissue", "OBSERVATION_MODIFIER", 193, 208], ["TropismObservations", "OBSERVATION_MODIFIER", 209, 228], ["natural evolution", "OBSERVATION", 232, 249], ["support the possibility of", "UNCERTAINTY", 255, 281], ["attenuation", "OBSERVATION", 282, 293], ["tissue tropism", "OBSERVATION", 313, 327]]], ["In pigs, the corona viruses TGEV (transmissible gastroenteritis virus) and PRCV (porcine respiratory corona virus) infect different tissues (the gut and respiratory tract, respectively) despite few genetic differences.", [["tissues", "ANATOMY", 132, 139], ["gut", "ANATOMY", 145, 148], ["respiratory tract", "ANATOMY", 153, 170], ["transmissible gastroenteritis virus", "DISEASE", 34, 69], ["pigs", "ORGANISM", 3, 7], ["corona viruses TGEV", "ORGANISM", 13, 32], ["transmissible gastroenteritis virus", "ORGANISM", 34, 69], ["PRCV", "ORGANISM", 75, 79], ["porcine respiratory corona virus", "ORGANISM", 81, 113], ["tissues", "TISSUE", 132, 139], ["gut", "ORGANISM_SUBDIVISION", 145, 148], ["respiratory tract", "ORGANISM_SUBDIVISION", 153, 170], ["pigs", "SPECIES", 3, 7], ["TGEV", "SPECIES", 28, 32], ["transmissible gastroenteritis virus", "SPECIES", 34, 69], ["PRCV", "SPECIES", 75, 79], ["porcine respiratory corona virus", "SPECIES", 81, 113], ["pigs", "SPECIES", 3, 7], ["corona viruses TGEV", "SPECIES", 13, 32], ["transmissible gastroenteritis virus", "SPECIES", 34, 69], ["PRCV", "SPECIES", 75, 79], ["porcine respiratory corona virus", "SPECIES", 81, 113], ["the corona viruses TGEV (transmissible gastroenteritis virus", "PROBLEM", 9, 69], ["PRCV (porcine respiratory corona virus", "TREATMENT", 75, 113], ["corona viruses", "ANATOMY", 13, 27], ["corona virus", "OBSERVATION", 101, 113], ["respiratory tract", "ANATOMY", 153, 170]]], ["This tissue tropism is caused by just two amino acid substitutions in the S spike gene that encodes a glycoprotein essential for attachment to host cells [61] .", [["tissue", "ANATOMY", 5, 11], ["cells", "ANATOMY", 148, 153], ["amino acid", "CHEMICAL", 42, 52], ["amino acid", "CHEMICAL", 42, 52], ["tissue", "TISSUE", 5, 11], ["amino acid", "AMINO_ACID", 42, 52], ["host cells", "CELL", 143, 153], ["S spike gene", "DNA", 74, 86], ["glycoprotein", "PROTEIN", 102, 114], ["host cells", "CELL_TYPE", 143, 153], ["This tissue tropism", "PROBLEM", 0, 19], ["two amino acid substitutions", "PROBLEM", 38, 66], ["a glycoprotein", "TREATMENT", 100, 114], ["tropism", "OBSERVATION", 12, 19], ["acid substitutions", "OBSERVATION", 48, 66]]], ["Although TGEV is more fatal than PRCV, infection by the genetically similar PRCV can provide some protection from TGEV [62, 63] .", [["infection", "DISEASE", 39, 48], ["TGEV", "ORGANISM", 9, 13], ["PRCV", "ORGANISM", 76, 80], ["TGEV", "ORGANISM", 114, 118], ["TGEV", "SPECIES", 9, 13], ["PRCV", "SPECIES", 33, 37], ["PRCV", "SPECIES", 76, 80], ["TGEV", "SPECIES", 114, 118], ["TGEV", "PROBLEM", 9, 13], ["infection", "PROBLEM", 39, 48], ["more", "OBSERVATION_MODIFIER", 17, 21], ["fatal", "OBSERVATION_MODIFIER", 22, 27], ["infection", "OBSERVATION", 39, 48]]], ["In this case, there seems to be little possibility of the 'vaccine' strain (PRCV) evolving back to high virulence.", [["PRCV", "SPECIES", 76, 80], ["the 'vaccine' strain", "PROBLEM", 54, 74], ["high virulence", "PROBLEM", 99, 113], ["high virulence", "OBSERVATION", 99, 113]]], ["Studying the genetic basis of naturally occurring tissue tropism should inform blueprints for the genetic engineering of vaccines that maintain transmissibility despite low virulence. transmission (e.g., Box 2).", [["tissue", "ANATOMY", 50, 56], ["tissue", "TISSUE", 50, 56], ["the genetic engineering of vaccines", "TREATMENT", 94, 129], ["low virulence", "PROBLEM", 169, 182], ["low virulence", "OBSERVATION_MODIFIER", 169, 182]]], ["By contrast, live RVVs may unavoidably transmit because they have the (largely) complete genome of the vector.", [["RVVs", "ANATOMY", 18, 22], ["RVVs", "GENE_OR_GENE_PRODUCT", 18, 22]]], ["Engineering may be used to partly disable the vector, thereby limiting transmission, and the use of heterospecific vectors may also effectively block transmission (e.g., a nonhuman vector virus for a human vaccine).Basic Epidemiological Properties of Transmissible VaccinesTransmissible Attenuated Vaccines Do Not Persist Indefinitely Transmission means that a vaccine will sometimes spread to contacts of the vaccinated individuals.", [["human", "ORGANISM", 200, 205], ["human", "SPECIES", 200, 205], ["human", "SPECIES", 200, 205], ["heterospecific vectors", "TREATMENT", 100, 122], ["a nonhuman vector virus", "TREATMENT", 170, 193], ["a human vaccine", "TREATMENT", 198, 213], ["Transmissible Vaccines", "TREATMENT", 251, 273], ["Attenuated Vaccines", "TREATMENT", 287, 306], ["a vaccine", "TREATMENT", 359, 368]]], ["Most transmissible vaccines will simply die out unless continually introduced (Figure 1) .", [["Most transmissible vaccines", "TREATMENT", 0, 27]]], ["If the vaccine R 0 is less than 1such that the average vaccine-infected person transmits the vaccine to less than one new individual in a naive populationthe vaccine is guaranteed to become extinct whenever supplementation stops.Basic Epidemiological Properties of Transmissible VaccinesAt first glance, this epidemiological result seems to imply that a transmissible vaccine must have R 0 > 1 to be an effective tool.", [["person", "ORGANISM", 72, 78], ["person", "SPECIES", 72, 78], ["the vaccine R 0", "TREATMENT", 3, 18], ["the average vaccine", "TREATMENT", 43, 62], ["the vaccine", "TREATMENT", 89, 100], ["a naive populationthe vaccine", "TREATMENT", 136, 165], ["Transmissible Vaccines", "TREATMENT", 265, 287], ["a transmissible vaccine", "TREATMENT", 352, 375]]], ["First, the transmission from weakly transmissible vaccines (those with R 0 < 1) reduces the direct vaccination effort required to eradicate a disease [40] , so even weak transmission has a measurable benefit.", [["weakly transmissible vaccines", "TREATMENT", 29, 58], ["the direct vaccination effort", "TREATMENT", 88, 117], ["a disease", "PROBLEM", 140, 149]]], ["Second, R 0 > 1 is not an assurance of utility: the vaccine may still die out without supplementation.", [["the vaccine", "TREATMENT", 48, 59], ["supplementation", "TREATMENT", 86, 101]]], ["These outcomes can be understood from standard epidemiological models of infectious agents [40] .Basic Epidemiological Properties of Transmissible VaccinesTo address the first point, if the wild-type pathogen's R 0 is denoted R 0 , W and the transmissible vaccine's R 0 is denoted R 0,V , the rate at which individuals must be directly vaccinated to eradicate the disease is reduced to a fractionBasic Epidemiological Properties of Transmissible Vaccinesof vaccinations needed in the absence of transmissionup to R 0,V = R 0,W [40] .", [["R 0", "GENE_OR_GENE_PRODUCT", 211, 214], ["individuals", "ORGANISM", 307, 318], ["infectious agents", "TREATMENT", 73, 90], ["Transmissible Vaccines", "TREATMENT", 133, 155], ["the transmissible vaccine", "TEST", 238, 263], ["the disease", "PROBLEM", 360, 371], ["Transmissible Vaccinesof vaccinations", "TREATMENT", 432, 469], ["transmissionup", "TEST", 495, 509], ["disease", "OBSERVATION", 364, 371]]], ["For example, if R 0, V = 0.5 R 0,W , then half as many vaccinations are required for a transmissible vaccine as for a nontransmissible vaccine.", [["R", "TEST", 16, 17], ["V", "TEST", 21, 22], ["a transmissible vaccine", "TREATMENT", 85, 108], ["a nontransmissible vaccine", "TREATMENT", 116, 142]]], ["Any vaccine transmission helpsthe ratio is fully indifferent to whether R 0,V is greater or less than 1.", [["Any vaccine transmission helpsthe ratio", "TEST", 0, 39], ["greater", "OBSERVATION_MODIFIER", 81, 88]]], ["The impact of vaccine transmission is merely measured relative to that of the pathogen, and the same R 0,V will have a larger impact for a poorly transmitted pathogen than for a highly transmitted pathogen.", [["vaccine transmission", "TREATMENT", 14, 34], ["a poorly transmitted pathogen", "PROBLEM", 137, 166], ["a highly transmitted pathogen", "PROBLEM", 176, 205], ["pathogen", "OBSERVATION", 78, 86], ["pathogen", "OBSERVATION", 197, 205]]], ["The amount of direct vaccination required goes to 0 as the R 0 of the vaccine approaches that of the pathogen.", [["direct vaccination", "TREATMENT", 14, 32], ["the vaccine", "TREATMENT", 66, 77], ["the pathogen", "PROBLEM", 97, 109], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["pathogen", "OBSERVATION", 101, 109]]], ["As is well known from classical theory, the agent with largest R 0 will prevail in the long term [41] , so were the vaccine R 0 to exceed that of the disease agent, the disease agent would disappear without any intervention beyond the initial introduction of the vaccine (the expression in Equation 1 becomes negative).", [["the disease agent", "TREATMENT", 146, 163], ["the disease agent", "PROBLEM", 165, 182], ["any intervention", "TREATMENT", 207, 223], ["the vaccine", "TREATMENT", 259, 270], ["disease", "OBSERVATION", 150, 157]]], ["And this realization also leads to the second point above: whenever the vaccine R 0 is less than that of the pathogen's R 0even if the vaccine is capable of maintaining itself in a na\u00efve populationthe vaccine will die out in the absence of continual supplementation until the pathogen is eradicated.Basic Epidemiological Properties of Transmissible VaccinesThe pros and cons of transmission go beyond these simple considerations.", [["the vaccine", "TREATMENT", 68, 79], ["the vaccine", "TREATMENT", 131, 142], ["a na\u00efve populationthe vaccine", "TREATMENT", 179, 208], ["continual supplementation", "TREATMENT", 240, 265], ["the pathogen", "PROBLEM", 272, 284], ["Transmissible Vaccines", "TREATMENT", 335, 357]]], ["Aside from the relative biological ease of engineering the combination of avirulence and weak transmission (R 0 < 1), weakly transmissible vaccines have the advantage that they do not transmit far beyond the directly vaccinated individuals, so they are less likely to evolve ( [42] , and see under the heading 'Vaccine Evolution', below).", [["avirulence", "PROBLEM", 74, 84], ["weakly transmissible vaccines", "TREATMENT", 118, 147]]], ["On the downside, weakly transmissible vaccines may have such short chains of transmission that they fail to reach isolated or sequestered host individuals and subpopulations any better than a traditional vaccine.", [["weakly transmissible vaccines", "TREATMENT", 17, 46], ["a traditional vaccine", "TREATMENT", 190, 211]]], ["Models evaluating the efficacy of such weakly transmissible vaccines in structured host populations will help to determine their useful scope.Basic Epidemiological Properties of Transmissible VaccinesRVVs Have a Transmission Advantage over Attenuated Vaccines, but Their Epidemiology Is Complicated RVVs have one intrinsic advantage over attenuated vaccinesin transmission.", [["vaccinesin", "CHEMICAL", 349, 359], ["RVVs", "PATHOLOGICAL_FORMATION", 299, 303], ["vaccinesin", "SIMPLE_CHEMICAL", 349, 359], ["such weakly transmissible vaccines", "TREATMENT", 34, 68], ["Transmissible VaccinesRVVs", "TREATMENT", 178, 204], ["Attenuated Vaccines", "TREATMENT", 240, 259], ["attenuated vaccinesin transmission", "TREATMENT", 338, 372]]], ["Whereas, the transmission (or R 0 ) of an attenuated vaccine will almost assuredly be lower than that of the pathogen, the intrinsic transmission of an RVV may exceed that of the pathogen.", [["RVV", "CANCER", 152, 155], ["RVV", "SPECIES", 152, 155], ["an attenuated vaccine", "TREATMENT", 39, 60], ["the pathogen", "PROBLEM", 105, 117], ["an RVV", "TREATMENT", 149, 155], ["the pathogen", "PROBLEM", 175, 187], ["pathogen", "OBSERVATION", 109, 117], ["RVV", "OBSERVATION", 152, 155], ["pathogen", "OBSERVATION", 179, 187]]], ["An attenuated vaccine and pathogen are essentially the same virus, so the attenuation is likely to suppress transmission.", [["An attenuated vaccine", "TREATMENT", 0, 21], ["pathogen", "PROBLEM", 26, 34], ["the same virus", "PROBLEM", 51, 65], ["attenuated", "OBSERVATION_MODIFIER", 3, 13], ["vaccine", "OBSERVATION", 14, 21], ["pathogen", "OBSERVATION", 26, 34], ["attenuation", "OBSERVATION_MODIFIER", 74, 85], ["is likely to", "UNCERTAINTY", 86, 98]]], ["The vector of the RVV and pathogen are different, so there is no constraint on vector transmission.", [["RVV", "CANCER", 18, 21], ["RVV", "SPECIES", 18, 21], ["RVV", "OBSERVATION", 18, 21], ["pathogen", "OBSERVATION", 26, 34], ["different", "OBSERVATION_MODIFIER", 39, 48], ["no", "UNCERTAINTY", 62, 64]]], ["In principle, a vector can even be chosen based on its having a suitably high R 0 .Basic Epidemiological Properties of Transmissible VaccinesAlthough some epidemiological conclusions described in the previous section apply here, the epidemiology is more complicated for an RVV than for an attenuated vaccine.", [["RVV", "SPECIES", 273, 276], ["a vector", "TREATMENT", 14, 22], ["Transmissible Vaccines", "TREATMENT", 119, 141], ["an RVV", "PROBLEM", 270, 276], ["an attenuated vaccine", "TREATMENT", 286, 307]]], ["The challenge for an RVV lies in the presence of two wild-type viruses that will interfere with RVV spread: the pathogen and the vector.", [["RVV", "ANATOMY", 21, 24], ["RVV", "ANATOMY", 96, 99], ["RVV", "CANCER", 21, 24], ["RVV", "SPECIES", 96, 99], ["The challenge", "TREATMENT", 0, 13], ["an RVV lies", "PROBLEM", 18, 29], ["two wild-type viruses", "PROBLEM", 49, 70], ["RVV spread", "PROBLEM", 96, 106], ["RVV", "OBSERVATION", 21, 24], ["type viruses", "OBSERVATION", 58, 70]]], ["The dynamics of a transmissible attenuated vaccine are simple because the vaccine and its pathogen are in direct competition for susceptible hosts: a host previously infected by either the pathogen or vaccine is immune to both.", [["a transmissible attenuated vaccine", "TREATMENT", 16, 50], ["the vaccine", "TREATMENT", 70, 81], ["susceptible hosts", "PROBLEM", 129, 146], ["the pathogen", "PROBLEM", 185, 197], ["vaccine", "TREATMENT", 201, 208]]], ["But the competition is limited to the two viruses.", [["the two viruses", "PROBLEM", 34, 49], ["viruses", "OBSERVATION", 42, 49]]], ["With an RVV, there is a three-way interaction because the RVV faces competition from the pathogen and vector.", [["RVV", "CANCER", 8, 11], ["RVV", "OBSERVATION", 8, 11]]], ["If immunity to the vector is widespread, vaccine transmission may be limited even when the intrinsic vaccine transmission rate is high.", [["vaccine transmission", "TREATMENT", 41, 61], ["the intrinsic vaccine transmission rate", "TEST", 87, 126]]], ["RVVs whose vectors have low levels of cross-immunity in the host population will thus benefit the most from transmission.Basic Epidemiological Properties of Transmissible VaccinesChoice of the vector will influence several of these critical properties, and indeed may have a profound effect on vaccine success, on vaccine evolution, and on side-effects.", [["RVVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["Transmissible Vaccines", "TREATMENT", 157, 179], ["the vector", "TREATMENT", 189, 199], ["vaccine success", "TREATMENT", 294, 309], ["vaccine", "TREATMENT", 314, 321]]], ["In the extreme case of a vector that is not found in the host population (e.g., is from a different species) preexisting immunity will be absenta benefit.", [["a different species", "PROBLEM", 88, 107]]], ["Transmission may even be avoided by use of a vector from a different species.", [["a vector", "TREATMENT", 43, 51], ["a different species", "PROBLEM", 57, 76]]], ["But use of a vector that already exists in the population has the advantage of a priori known transmission (known R 0 ) and known avirulence.", [["a vector", "TREATMENT", 11, 19], ["known avirulence", "PROBLEM", 124, 140], ["avirulence", "OBSERVATION", 130, 140]]], ["Of course, vector choice will also likely be important to whether the vaccine retains its engineered properties amid within-host evolution and important to the very immunogenicity of the vaccine.Vaccine EvolutionRelease of a transmissible vaccine capable of long-term persistence virtually guarantees that evolution will occur, although that evolution may or may not have important consequences.", [["vector choice", "TREATMENT", 11, 24], ["the vaccine", "TREATMENT", 66, 77], ["the vaccine", "TREATMENT", 183, 194], ["Vaccine", "TREATMENT", 195, 202], ["a transmissible vaccine", "TREATMENT", 223, 246], ["long-term persistence", "OBSERVATION_MODIFIER", 258, 279]]], ["The poster child for vaccine evolution is the Sabin oral polio vaccine: much of the present-day, disease-causing virus has evolved directly from the vaccine [2, 6] .", [["oral", "ANATOMY", 52, 56], ["Sabin", "ORGANISM", 46, 51], ["oral", "ORGANISM_SUBDIVISION", 52, 56], ["polio", "ORGANISM", 57, 62], ["vaccine evolution", "TREATMENT", 21, 38], ["the Sabin oral polio vaccine", "TREATMENT", 42, 70], ["disease", "PROBLEM", 97, 104], ["virus", "PROBLEM", 113, 118], ["disease", "OBSERVATION", 97, 104]]], ["Predicting evolution in detail is problematic, but some evolutionary patterns are expected.", [["problematic", "OBSERVATION_MODIFIER", 34, 45]]], ["First, the virulence of a vaccine is unlikely to evolve above that of its wild-type counterpart.", [["a vaccine", "TREATMENT", 24, 33]]], ["Second, a transmissible vaccine that dies out quickly (e.g., whose R 0 < 1) is less likely to evolve than is one that persists long term [42] .", [["a transmissible vaccine", "TREATMENT", 8, 31], ["less likely", "UNCERTAINTY", 79, 90]]], ["This conclusion applies both to viral persistence in populations and in individuals: immune compromised hosts may allow a long-standing infection that leads to evolution within one host [6] .Vaccine EvolutionAlthough the undesirable consequences of evolution differ for attenuated and recombinant vector vaccines (Figure 2 ), we expect evolution to drive the vaccine back closer to its wild-type phenotype in both cases.", [["infection", "DISEASE", 136, 145], ["immune compromised hosts", "PROBLEM", 85, 109], ["a long-standing infection", "PROBLEM", 120, 145], ["Vaccine", "TREATMENT", 191, 198], ["attenuated and recombinant vector vaccines", "TREATMENT", 270, 312], ["the vaccine", "TREATMENT", 355, 366]]], ["Evolution of an attenuated vaccine is thus likely to be toward the higher transmission and virulence of the ancestral, wild-type state.", [["an attenuated vaccine", "TREATMENT", 13, 34], ["attenuated", "OBSERVATION_MODIFIER", 16, 26], ["vaccine", "OBSERVATION", 27, 34], ["thus likely to be", "UNCERTAINTY", 38, 55], ["higher", "OBSERVATION_MODIFIER", 67, 73], ["virulence", "OBSERVATION_MODIFIER", 91, 100], ["ancestral", "OBSERVATION_MODIFIER", 108, 117]]], ["Modest levels of vaccine reversion are not a serious setback to eradication when the wild type remains abundant because revertants will be a minor contribution to all infections.", [["infections", "DISEASE", 167, 177], ["Modest levels of vaccine reversion", "PROBLEM", 0, 34], ["all infections", "PROBLEM", 163, 177], ["infections", "OBSERVATION", 167, 177]]], ["By contrast, evenVaccine EvolutionWeakly tr ted vaccine (R 0,v < 1)Vaccine EvolutionStrongly tra recombinant vector vaccine (R 0,v > 1)Vaccine Evolutiont Vaccine-infected host Pathogen-infected host Reversion t Vaccine-infected host Vector-infected host Reversion attenuated vaccine that reverts.", [["Pathogen-infected", "DISEASE", 176, 193], ["Vaccine", "ORGANISM", 135, 142], ["evenVaccine", "TEST", 13, 24], ["tr ted vaccine (R 0,v < 1)Vaccine", "TREATMENT", 41, 74], ["EvolutionStrongly tra recombinant vector vaccine", "TREATMENT", 75, 123], ["v > 1)Vaccine", "TREATMENT", 129, 142], ["Evolutiont Vaccine", "TREATMENT", 143, 161], ["infected host Pathogen", "PROBLEM", 162, 184], ["infected host Reversion t Vaccine", "TREATMENT", 185, 218], ["infected host Vector", "TREATMENT", 219, 239], ["infected host Reversion attenuated vaccine", "TREATMENT", 240, 282]]], ["The revertants (red) have high transmissibility, but are suppressed by ongoing vaccination.", [["high transmissibility", "PROBLEM", 26, 47], ["high transmissibility", "OBSERVATION_MODIFIER", 26, 47]]], ["(B) A highly transmissible recombinant vector vaccine that revertsloses its antigenic insert (blue).", [["A highly transmissible recombinant vector vaccine", "TREATMENT", 4, 53], ["antigenic insert", "OBSERVATION", 76, 92]]], ["Revertants are also blocked by ongoing vaccination, provided the complete vaccine elicits immunity against both the pathogen and vector. infrequent reversion of an attenuated vaccine will preclude its use against a not-yet-present infectious disease where it would have the undesirable consequence of introducing the disease it was designed to block.", [["ongoing vaccination", "TREATMENT", 31, 50], ["the complete vaccine", "TREATMENT", 61, 81], ["an attenuated vaccine", "TREATMENT", 161, 182], ["present infectious disease", "PROBLEM", 223, 249], ["the disease", "PROBLEM", 313, 324], ["infectious", "OBSERVATION", 231, 241]]], ["And reversion thwarts the final steps of eradication [43] .Vaccine EvolutionEvolution of recombinant vector vaccines will also likely favor reversion toward the wild-type phenotype.", [["Vaccine", "TREATMENT", 59, 66], ["recombinant vector vaccines", "TREATMENT", 89, 116], ["type phenotype", "PROBLEM", 166, 180]]], ["Rather than increasing virulence, this evolution is likely to introduce ineffective but harmless strains that have ejected or downregulated the antigenic insert (revertants will experience less within-host and herd immunity than the vaccine).", [["increasing virulence", "PROBLEM", 12, 32], ["harmless strains", "PROBLEM", 88, 104], ["the vaccine", "TREATMENT", 229, 240], ["increasing", "OBSERVATION_MODIFIER", 12, 22], ["virulence", "OBSERVATION", 23, 32]]], ["When revertant, 'empty' vectors circulate within the population they will compete with the vaccine and inhibit its spread through the host population.Concluding RemarksViral genome engineering has opened the door to a new property of live vaccines: transmission among hosts.", [["'empty' vectors", "TREATMENT", 16, 31], ["the vaccine", "TREATMENT", 87, 98]]], ["The vaccine may be for humans or wildlife, and transmission may be intentional or accidental.", [["humans", "ORGANISM", 23, 29], ["humans", "SPECIES", 23, 29], ["humans", "SPECIES", 23, 29], ["The vaccine", "TREATMENT", 0, 11]]], ["In addition to possible social objections to human vaccine transmission, there are several biological issues that may lead to unintended consequences or vaccine inefficacy.", [["human", "ORGANISM", 45, 50], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["human vaccine transmission", "TREATMENT", 45, 71], ["several biological issues", "PROBLEM", 83, 108], ["vaccine inefficacy", "TREATMENT", 153, 171]]], ["Exploiting the possible benefits of transmissible vaccines will require a collaboration between epidemiologists, evolutionary biologists, and genome engineers.", [["transmissible vaccines", "TREATMENT", 36, 58], ["possible", "UNCERTAINTY", 15, 23]]], ["Outstanding Questions Current evidence suggests that attenuation is minimally compatible with transmission.", [["attenuation", "OBSERVATION", 53, 64]]], ["Can new engineering methods ensure avirulence (attenuation) but enable more than sporadic transmission?Concluding RemarksTransmission of attenuated vaccines may establish subclinical infections and thus weaker immunity and shorter durations of immunity than direct vaccination.", [["infections", "DISEASE", 183, 193], ["avirulence", "PROBLEM", 35, 45], ["attenuated vaccines", "TREATMENT", 137, 156], ["subclinical infections", "PROBLEM", 171, 193], ["direct vaccination", "TREATMENT", 258, 276]]], ["How will these different levels of immunity affect the spread of the wild-type pathogen?Concluding RemarksWill it be possible to engineer vaccines that can transmit only once (or a finite number of times) but cannot transmit indefinitely?Concluding RemarksDoes the benefit of transmission depend on whether the vaccine confers immunity versus merely blocking transmission and reducing symptoms of the wild-type virus?Concluding RemarksIs it possible to engineer evolutionarily stable recombinant vector vaccines?Concluding RemarksCross-immunity between recombinant vector vaccines and a circulating vector has a large effect on dissemination of the vaccine, and even small levels can be inhibitory.", [["wild-type virus", "ORGANISM", 401, 416], ["type pathogen", "PROBLEM", 74, 87], ["the vaccine", "TREATMENT", 307, 318], ["merely blocking transmission", "PROBLEM", 343, 371], ["reducing symptoms", "PROBLEM", 376, 393], ["the wild-type virus", "PROBLEM", 397, 416], ["recombinant vector vaccines", "TREATMENT", 484, 511], ["recombinant vector vaccines", "TREATMENT", 553, 580], ["a circulating vector", "TREATMENT", 585, 605], ["dissemination of the vaccine", "TREATMENT", 628, 656], ["stable", "OBSERVATION_MODIFIER", 477, 483], ["large", "OBSERVATION_MODIFIER", 612, 617], ["effect", "OBSERVATION_MODIFIER", 618, 624]]], ["Can we measure small levels of cross immunity?", [["small", "OBSERVATION_MODIFIER", 15, 20]]]], "045934a50a9be0653387842a01db9349e1d799bb": [["19Application of immunofluorescence technique to clinical virology Virologists for many years have striven to achieve the goal of rapid virus diagnosis.", [["immunofluorescence technique", "TREATMENT", 17, 45], ["rapid virus diagnosis", "PROBLEM", 130, 151]]], ["The achievement of success in a method of rapid virus diagnosis cannot, in itself, be a final aim, otherwise the method would degenerate solely into a rapid routine method for identifying virus agents and the virologist would become a biological philatelist.", [["philatelist", "CANCER", 246, 257], ["rapid virus diagnosis", "TEST", 42, 63], ["a rapid routine method", "TREATMENT", 149, 171], ["virus agents", "TREATMENT", 188, 200]]], ["An applied science, to justify itself, must bring benefit to the main clientele, which is in this case the physicians and the patients.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134]]], ["In this chapter it is intended to evaluate the applications of rapid immunofluorescence diagnosis in clinical medicine.MANAGEMENT OF PATIENTS AND RATIONAL USE OF ANTIBIOTICSThere are a number of cardinal features of acute virus infections which need to be emphasized.", [["acute virus infections", "DISEASE", 216, 238], ["ANTIBIOTICSThere", "TREATMENT", 162, 178], ["acute virus infections", "PROBLEM", 216, 238], ["acute", "OBSERVATION_MODIFIER", 216, 221], ["virus infections", "OBSERVATION", 222, 238]]], ["The presence of viruses at the site of illness usually means that the virus is associated with that illness and is almost certainly causal.", [["illness", "DISEASE", 100, 107], ["viruses", "PROBLEM", 16, 23], ["illness", "PROBLEM", 39, 46], ["the virus", "PROBLEM", 66, 75], ["viruses", "OBSERVATION", 16, 23], ["illness", "OBSERVATION", 39, 46], ["virus", "OBSERVATION", 70, 75], ["illness", "OBSERVATION", 100, 107]]], ["There are exceptions to this, such as enteroviruses in stools and adenoviruses both in stools and the respiratory tract, but even here they have caused infection and, because they have the property of being excreted for a long time, may be found at the site after the acute phase has passed.", [["stools", "ANATOMY", 87, 93], ["respiratory tract", "ANATOMY", 102, 119], ["enteroviruses", "DISEASE", 38, 51], ["infection", "DISEASE", 152, 161], ["enteroviruses", "ORGANISM", 38, 51], ["adenoviruses", "ORGANISM", 66, 78], ["stools", "ORGANISM_SUBDIVISION", 87, 93], ["respiratory tract", "ORGANISM_SUBDIVISION", 102, 119], ["enteroviruses in stools", "PROBLEM", 38, 61], ["adenoviruses", "PROBLEM", 66, 78], ["stools and the respiratory tract", "PROBLEM", 87, 119], ["infection", "PROBLEM", 152, 161], ["enteroviruses", "OBSERVATION", 38, 51], ["stools", "OBSERVATION", 87, 93], ["respiratory tract", "ANATOMY", 102, 119], ["infection", "OBSERVATION", 152, 161]]], ["However, in lesions of the skin, central nervous system and respiratory tract, viruses found in the presence of symptoms should be taken as causal.", [["lesions", "ANATOMY", 12, 19], ["skin", "ANATOMY", 27, 31], ["central nervous system", "ANATOMY", 33, 55], ["respiratory tract", "ANATOMY", 60, 77], ["lesions", "PATHOLOGICAL_FORMATION", 12, 19], ["skin", "ORGAN", 27, 31], ["central nervous system", "ANATOMICAL_SYSTEM", 33, 55], ["respiratory tract", "ORGANISM_SUBDIVISION", 60, 77], ["lesions of the skin, central nervous system and respiratory tract", "PROBLEM", 12, 77], ["viruses", "PROBLEM", 79, 86], ["symptoms", "PROBLEM", 112, 120], ["lesions", "OBSERVATION", 12, 19], ["skin", "ANATOMY", 27, 31], ["central", "ANATOMY_MODIFIER", 33, 40], ["nervous system", "ANATOMY", 41, 55], ["respiratory tract", "ANATOMY", 60, 77], ["viruses", "OBSERVATION", 79, 86]]], ["In the respiratory tract, influenza virus, respiratory syncytial virus and the parainfluenza viruses are seldom if ever found without illness.", [["respiratory tract", "ANATOMY", 7, 24], ["respiratory tract", "DISEASE", 7, 24], ["influenza virus", "DISEASE", 26, 41], ["respiratory syncytial virus", "DISEASE", 43, 70], ["parainfluenza viruses", "DISEASE", 79, 100], ["respiratory tract", "ORGANISM_SUBDIVISION", 7, 24], ["influenza virus", "ORGANISM", 26, 41], ["respiratory syncytial virus", "ORGANISM", 43, 70], ["parainfluenza viruses", "ORGANISM", 79, 100], ["influenza virus", "SPECIES", 26, 41], ["respiratory syncytial virus", "SPECIES", 43, 70], ["parainfluenza", "SPECIES", 79, 92], ["influenza virus", "SPECIES", 26, 41], ["respiratory syncytial virus", "SPECIES", 43, 70], ["the respiratory tract", "PROBLEM", 3, 24], ["influenza virus", "PROBLEM", 26, 41], ["respiratory syncytial virus", "PROBLEM", 43, 70], ["the parainfluenza viruses", "PROBLEM", 75, 100], ["illness", "PROBLEM", 134, 141], ["respiratory tract", "ANATOMY", 7, 24], ["influenza virus", "OBSERVATION", 26, 41], ["syncytial virus", "OBSERVATION", 55, 70], ["parainfluenza viruses", "OBSERVATION", 79, 100]]], ["The rapid diagnosis of a virus infection in 2-3 hours after admission to hospital revolutionizes the attitude of physicians.", [["infection", "DISEASE", 31, 40], ["a virus infection", "PROBLEM", 23, 40], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["virus", "OBSERVATION_MODIFIER", 25, 30], ["infection", "OBSERVATION", 31, 40]]], ["They are no longer dealing with a disease of unknown aetiology for most, if not all, of the patient's stay in hospital but with one which is a precise entity immediately known.MANAGEMENT OF PATIENTS AND RATIONAL USE OF ANTIBIOTICSA basic tenet in virology is that a virus is completely insensitive to antibiotics and that virus-infected patients, particularly children, do not as The use of antiviral drugs 289 a rule acquire secondary bacterial infections.", [["virus-infected", "DISEASE", 322, 336], ["bacterial infections", "DISEASE", 436, 456], ["patient", "ORGANISM", 92, 99], ["patients", "ORGANISM", 337, 345], ["children", "ORGANISM", 360, 368], ["patient", "SPECIES", 92, 99], ["patients", "SPECIES", 337, 345], ["children", "SPECIES", 360, 368], ["a disease", "PROBLEM", 32, 41], ["a virus", "PROBLEM", 264, 271], ["antibiotics", "TREATMENT", 301, 312], ["antiviral drugs", "TREATMENT", 391, 406], ["secondary bacterial infections", "PROBLEM", 426, 456], ["no longer", "UNCERTAINTY", 9, 18], ["bacterial", "OBSERVATION_MODIFIER", 436, 445], ["infections", "OBSERVATION", 446, 456]]], ["The main exception to this rule is influenza infections in a previously damaged lung.", [["lung", "ANATOMY", 80, 84], ["influenza infections", "DISEASE", 35, 55], ["influenza", "ORGANISM", 35, 44], ["lung", "ORGAN", 80, 84], ["influenza infections", "PROBLEM", 35, 55], ["a previously damaged lung", "PROBLEM", 59, 84], ["main", "OBSERVATION_MODIFIER", 4, 8], ["influenza", "OBSERVATION_MODIFIER", 35, 44], ["infections", "OBSERVATION", 45, 55], ["lung", "ANATOMY", 80, 84]]], ["This knowledge and confidence has been acquired over a number of years of investigation in joint virological and clinical studies (Elderkin et al., 1965; Holdaway, Romer and Gardner, 1967; Gardners al. t 1967; Aherne^a/., 1970) .MANAGEMENT OF PATIENTS AND RATIONAL USE OF ANTIBIOTICSA physician can now manage his patients with, in most cases, sure knowledge of the aetiology.", [["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 314, 322], ["investigation in joint virological", "TEST", 74, 108], ["clinical studies", "TEST", 113, 129], ["joint", "ANATOMY", 91, 96]]], ["This should give him confidence that in respiratory viral infections antibiotics will not benefit the patient, and that nursing and general support therapy should form the treatment.", [["respiratory viral infections", "DISEASE", 40, 68], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["respiratory viral infections antibiotics", "TREATMENT", 40, 80], ["general support therapy", "TREATMENT", 132, 155], ["the treatment", "TREATMENT", 168, 181], ["respiratory", "ANATOMY", 40, 51], ["viral infections", "OBSERVATION", 52, 68]]], ["In other infections antiviral agents are now becoming available and even in respiratory infections the future holds promise as will be seen presently.", [["respiratory", "ANATOMY", 76, 87], ["infections", "DISEASE", 9, 19], ["respiratory infections", "DISEASE", 76, 98], ["antiviral agents", "TREATMENT", 20, 36], ["respiratory infections", "PROBLEM", 76, 98], ["infections", "OBSERVATION", 9, 19]]], ["The clinician should be well satisfied with this rapid progress which will at worst at least satisfy his curiosity during the acute phase of illness and not retrospectively, and at best indicate a line of specific therapy to pursue.THE USE OF ANTIVIRAL DRUGSThere is now a vast literature on the use of antiviral drugs; amongst recent books is Gallasso, Merigan and Buchanan (1979) .", [["specific therapy", "TREATMENT", 205, 221], ["ANTIVIRAL DRUGSThere", "TREATMENT", 243, 263], ["antiviral drugs", "TREATMENT", 303, 318]]], ["Drugs may be used in two ways: prophylactically or therapeutically.", [["Drugs", "TREATMENT", 0, 5]]], ["Rapid virus diagnosis may determine quickly the presence of a virus in a community, for instance a school, factory, family, etc. Should a drug be available for prophylactic use then treatment of the uninfected members of the community may prevent the development and spread of an outbreak.", [["Rapid virus diagnosis", "PROBLEM", 0, 21], ["prophylactic use", "TREATMENT", 160, 176], ["treatment", "TREATMENT", 182, 191], ["virus", "OBSERVATION", 6, 11], ["virus", "OBSERVATION", 62, 67]]], ["One such drug is amantadine hydrochloride which has been used effectively in the prevention of influenza A.THE USE OF ANTIVIRAL DRUGSInfections with the herpesvirus group are those which have, at this time, been the most effectively treated with antiviral drugs.", [["amantadine hydrochloride", "CHEMICAL", 17, 41], ["influenza", "DISEASE", 95, 104], ["amantadine hydrochloride", "CHEMICAL", 17, 41], ["amantadine", "SIMPLE_CHEMICAL", 17, 27], ["herpesvirus", "ORGANISM", 153, 164], ["amantadine hydrochloride", "TREATMENT", 17, 41], ["influenza", "PROBLEM", 95, 104], ["ANTIVIRAL DRUGSInfections", "TREATMENT", 118, 143], ["the herpesvirus group", "TREATMENT", 149, 170], ["antiviral drugs", "TREATMENT", 246, 261], ["influenza", "OBSERVATION", 95, 104], ["most effectively", "OBSERVATION_MODIFIER", 216, 232]]], ["Most studies have been undertaken with herpesvirus hominis, which more often than not, causes just minor skin lesions such as 'cold' sores.", [["skin lesions", "ANATOMY", 105, 117], ["herpesvirus hominis", "DISEASE", 39, 58], ["herpesvirus hominis", "ORGANISM", 39, 58], ["skin lesions", "PATHOLOGICAL_FORMATION", 105, 117], ["herpesvirus hominis", "SPECIES", 39, 58], ["herpesvirus hominis", "SPECIES", 39, 58], ["Most studies", "TEST", 0, 12], ["herpesvirus hominis", "PROBLEM", 39, 58], ["minor skin lesions", "PROBLEM", 99, 117], ["'cold' sores", "PROBLEM", 126, 138], ["minor", "OBSERVATION_MODIFIER", 99, 104], ["skin", "ANATOMY", 105, 109], ["lesions", "OBSERVATION", 110, 117]]], ["However, herpesvirus hominis eye infections are not infrequent and those of the brain, though rare, are often fatal.", [["eye", "ANATOMY", 29, 32], ["brain", "ANATOMY", 80, 85], ["herpesvirus hominis eye infections", "DISEASE", 9, 43], ["herpesvirus hominis", "ORGANISM", 9, 28], ["eye", "ORGAN", 29, 32], ["brain", "ORGAN", 80, 85], ["herpesvirus hominis", "SPECIES", 9, 28], ["herpesvirus hominis", "SPECIES", 9, 28], ["herpesvirus hominis eye infections", "PROBLEM", 9, 43], ["eye", "ANATOMY", 29, 32], ["infections", "OBSERVATION", 33, 43], ["brain", "ANATOMY", 80, 85]]], ["Both these conditions need immediate diagnosis and treatment with one of the antiherpetic drugs now available.", [["treatment", "TREATMENT", 51, 60], ["the antiherpetic drugs", "TREATMENT", 73, 95]]], ["Amongst these drugs with antiherpetic action are idoxuridine, cytarabine, vidarabine and acycloguanosine (Collins and Bauer, 1977) .", [["idoxuridine", "CHEMICAL", 49, 60], ["cytarabine", "CHEMICAL", 62, 72], ["vidarabine", "CHEMICAL", 74, 84], ["acycloguanosine", "CHEMICAL", 89, 104], ["idoxuridine", "CHEMICAL", 49, 60], ["cytarabine", "CHEMICAL", 62, 72], ["vidarabine", "CHEMICAL", 74, 84], ["acycloguanosine", "CHEMICAL", 89, 104], ["idoxuridine", "SIMPLE_CHEMICAL", 49, 60], ["cytarabine", "SIMPLE_CHEMICAL", 62, 72], ["vidarabine", "SIMPLE_CHEMICAL", 74, 84], ["acycloguanosine", "SIMPLE_CHEMICAL", 89, 104], ["these drugs", "TREATMENT", 8, 19], ["antiherpetic action", "TREATMENT", 25, 44], ["idoxuridine", "TREATMENT", 49, 60], ["cytarabine", "TREATMENT", 62, 72], ["vidarabine", "TREATMENT", 74, 84], ["acycloguanosine", "TREATMENT", 89, 104]]], ["The first has been effective when locally applied but is toxic when administered systemically ; cytarabine and vidarabine are less toxic but trial evidence of their effectiveness in herpes encephalitis is still equivocal.", [["cytarabine", "CHEMICAL", 96, 106], ["vidarabine", "CHEMICAL", 111, 121], ["herpes encephalitis", "DISEASE", 182, 201], ["cytarabine", "CHEMICAL", 96, 106], ["vidarabine", "CHEMICAL", 111, 121], ["cytarabine", "SIMPLE_CHEMICAL", 96, 106], ["vidarabine", "SIMPLE_CHEMICAL", 111, 121], ["herpes encephalitis", "ORGANISM", 182, 201], ["cytarabine", "TREATMENT", 96, 106], ["vidarabine", "TREATMENT", 111, 121], ["less toxic", "PROBLEM", 126, 136], ["herpes encephalitis", "PROBLEM", 182, 201], ["effective", "OBSERVATION_MODIFIER", 19, 28]]], ["Acycloguanosine is reputed to be non-toxic and with a very powerful antiherpetic action; its action is directed against viral enzyme only.", [["Acycloguanosine", "CHEMICAL", 0, 15], ["Acycloguanosine", "CHEMICAL", 0, 15], ["Acycloguanosine", "SIMPLE_CHEMICAL", 0, 15], ["viral enzyme", "PROTEIN", 120, 132], ["Acycloguanosine", "TREATMENT", 0, 15], ["a very powerful antiherpetic action", "TREATMENT", 52, 87], ["viral enzyme", "TEST", 120, 132]]], ["It could indicate the lines along which certain antiviral drugs may develop.", [["the lines", "PROBLEM", 18, 27], ["antiviral drugs", "TREATMENT", 48, 63], ["lines", "OBSERVATION", 22, 27]]], ["The results of the clinical trials which are proceeding at 290 Application ofimmunofluorescence technique to clinical virology the moment must be awaited with reasonable optimism (Schaeffer et al, 1978) .THE USE OF ANTIVIRAL DRUGSA naturally occurring substance which has wide application as an antiviral agent in vitro is interferon.", [["interferon", "GENE_OR_GENE_PRODUCT", 323, 333], ["interferon", "PROTEIN", 323, 333], ["the clinical trials", "TEST", 15, 34], ["ANTIVIRAL DRUGSA", "TREATMENT", 215, 231], ["an antiviral agent", "TREATMENT", 292, 310], ["vitro is interferon", "TREATMENT", 314, 333]]], ["Difficulties in manufacture and standardization have prevented early practical use but successes have now been claimed for clinical use especially in eye infections with herpes zoster (Merigan et al., 1978) .", [["eye", "ANATOMY", 150, 153], ["eye infections", "DISEASE", 150, 164], ["herpes zoster", "DISEASE", 170, 183], ["eye", "ORGAN", 150, 153], ["herpes zoster", "ORGANISM", 170, 183], ["herpes zoster", "SPECIES", 170, 183], ["eye infections", "PROBLEM", 150, 164], ["herpes zoster", "PROBLEM", 170, 183], ["eye", "ANATOMY", 150, 153]]], ["Its use in the immunosuppressed patient is discussed on page 292.THE USE OF ANTIVIRAL DRUGSBy the time a patient manifests the signs and symptoms of illness, virus infection of cells at the site of infection is widespread.", [["cells", "ANATOMY", 177, 182], ["infection", "DISEASE", 164, 173], ["infection", "DISEASE", 198, 207], ["patient", "ORGANISM", 32, 39], ["patient", "ORGANISM", 105, 112], ["cells", "CELL", 177, 182], ["patient", "SPECIES", 32, 39], ["patient", "SPECIES", 105, 112], ["ANTIVIRAL DRUGSBy", "TREATMENT", 76, 93], ["the signs and symptoms", "PROBLEM", 123, 145], ["illness", "PROBLEM", 149, 156], ["virus infection of cells", "PROBLEM", 158, 182], ["infection", "PROBLEM", 198, 207], ["infection", "OBSERVATION", 198, 207], ["widespread", "OBSERVATION_MODIFIER", 211, 221]]], ["Therefore, if antiviral therapy is to stand any chance of success a diagnosis must be made as near to the time of onset of symptoms as possible.", [["antiviral therapy", "TREATMENT", 14, 31], ["symptoms", "PROBLEM", 123, 131]]], ["It is only at this stage that antiviral drugs can do good by preventing the infection of further cells and thus further replication of virus.", [["cells", "ANATOMY", 97, 102], ["infection", "DISEASE", 76, 85], ["cells", "CELL", 97, 102], ["antiviral drugs", "TREATMENT", 30, 45], ["the infection of further cells", "PROBLEM", 72, 102], ["further replication of virus", "PROBLEM", 112, 140], ["infection", "OBSERVATION", 76, 85]]], ["This delaying process will allow the normal immunological defences of the body to respond fully and thus terminate what might be an overwhelming virus infection.", [["body", "ANATOMY", 74, 78], ["infection", "DISEASE", 151, 160], ["body", "ORGANISM_SUBDIVISION", 74, 78], ["an overwhelming virus infection", "PROBLEM", 129, 160], ["overwhelming", "OBSERVATION_MODIFIER", 132, 144], ["virus", "OBSERVATION", 145, 150]]], ["The most vulnerable groups are therefore the young, perhaps the very old and those who are immunosuppressed.", [["most vulnerable", "OBSERVATION_MODIFIER", 4, 19], ["immunosuppressed", "OBSERVATION", 91, 107]]], ["Even when efficient antiviral agents become available their use will still be dependent on accurate rapid virus diagnosis in order to start treatment sufficiently early to contain the infection.VIRUS INFECTION OUTSIDE ACUTE STAGE OF ILLNESSSome patients do not come into hospital at the onset of their virus illness but may have been ineffectively treated at home with antibiotics.", [["infection", "DISEASE", 184, 193], ["patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 245, 253], ["efficient antiviral agents", "TREATMENT", 10, 36], ["treatment", "TREATMENT", 140, 149], ["the infection", "PROBLEM", 180, 193], ["VIRUS INFECTION", "PROBLEM", 194, 209], ["their virus illness", "PROBLEM", 296, 315], ["antibiotics", "TREATMENT", 369, 380], ["infection", "OBSERVATION", 184, 193], ["ACUTE", "OBSERVATION_MODIFIER", 218, 223]]], ["These patients can still be diagnosed rapidly on admission to hospital by immunofluorescence.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["It has already been pointed out in Chapter 6 that respiratory syncytial virus may be identified in many patients late in their illness, frequently as late as the seventh day and occasionally as late as the fourteenth day.", [["respiratory syncytial virus", "DISEASE", 50, 77], ["respiratory syncytial virus", "ORGANISM", 50, 77], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["respiratory syncytial virus", "SPECIES", 50, 77], ["respiratory syncytial virus", "PROBLEM", 50, 77], ["syncytial virus", "OBSERVATION", 62, 77]]], ["In the later stages of the illness infected cells have an altered appearance which was illustrated in Figure 41 {see page 115), the fluorescent green colour being dull and the outline of the cell hazy.", [["cells", "ANATOMY", 44, 49], ["cell", "ANATOMY", 191, 195], ["illness", "DISEASE", 27, 34], ["cells", "CELL", 44, 49], ["cell", "CELL", 191, 195], ["the illness infected cells", "PROBLEM", 23, 49], ["an altered appearance", "PROBLEM", 55, 76], ["the fluorescent green colour", "PROBLEM", 128, 156], ["dull", "PROBLEM", 163, 167], ["the cell hazy", "PROBLEM", 187, 200], ["altered", "OBSERVATION_MODIFIER", 58, 65], ["green colour", "OBSERVATION", 144, 156], ["dull", "OBSERVATION_MODIFIER", 163, 167], ["cell hazy", "OBSERVATION", 191, 200]]], ["This is due to a coating of local antibody acquired by infected cells in the respiratory tract during the course of the illness .", [["cells", "ANATOMY", 64, 69], ["respiratory tract", "ANATOMY", 77, 94], ["cells", "CELL", 64, 69], ["respiratory tract", "ORGANISM_SUBDIVISION", 77, 94], ["local antibody", "PROTEIN", 28, 42], ["infected cells", "CELL_TYPE", 55, 69], ["local antibody", "PROBLEM", 28, 42], ["infected cells in the respiratory tract", "PROBLEM", 55, 94], ["the illness", "PROBLEM", 116, 127], ["infected cells", "OBSERVATION", 55, 69], ["respiratory tract", "ANATOMY", 77, 94]]], ["The number of infected cells in the secretions is also greatly reduced as the patient progresses to convalescence.VIRUS INFECTION OUTSIDE ACUTE STAGE OF ILLNESSAt this stage of illness virus is difficult to isolate and in the majority of cases the diagnosis can only be made by immunofluorescence.", [["cells", "ANATOMY", 23, 28], ["secretions", "ANATOMY", 36, 46], ["illness", "DISEASE", 177, 184], ["cells", "CELL", 23, 28], ["secretions", "ORGANISM_SUBSTANCE", 36, 46], ["patient", "ORGANISM", 78, 85], ["infected cells", "CELL_TYPE", 14, 28], ["patient", "SPECIES", 78, 85], ["infected cells in the secretions", "PROBLEM", 14, 46], ["VIRUS INFECTION", "PROBLEM", 114, 129], ["illness virus", "PROBLEM", 177, 190], ["number", "OBSERVATION_MODIFIER", 4, 10], ["infected cells", "OBSERVATION", 14, 28], ["secretions", "OBSERVATION", 36, 46], ["greatly", "OBSERVATION_MODIFIER", 55, 62], ["reduced", "OBSERVATION_MODIFIER", 63, 70], ["ACUTE STAGE", "OBSERVATION_MODIFIER", 138, 149], ["illness", "OBSERVATION", 177, 184], ["difficult to isolate", "OBSERVATION_MODIFIER", 194, 214]]], ["Table 2 in Chapter 6 (page 115) illustrates clearly the difficulty of isolating virus after the early days of the illness have passed.", [["isolating virus", "PROBLEM", 70, 85], ["the illness", "PROBLEM", 110, 121]]], ["The coating of cells by antibody, with the subsequent difficulty of virus isolation, does not occur solely with respiratory syncytial virus but with many other respiratory viruses: the parainfluenza viruses and probably influenza A and B viruses.", [["cells", "ANATOMY", 15, 20], ["respiratory syncytial virus", "DISEASE", 112, 139], ["respiratory viruses", "DISEASE", 160, 179], ["parainfluenza viruses", "DISEASE", 185, 206], ["influenza A and B viruses", "DISEASE", 220, 245], ["cells", "CELL", 15, 20], ["respiratory syncytial virus", "ORGANISM", 112, 139], ["parainfluenza viruses", "ORGANISM", 185, 206], ["influenza A and B viruses", "ORGANISM", 220, 245], ["parainfluenza", "SPECIES", 185, 198], ["respiratory syncytial virus", "SPECIES", 112, 139], ["virus isolation", "TREATMENT", 68, 83], ["respiratory syncytial virus", "PROBLEM", 112, 139], ["many other respiratory viruses", "PROBLEM", 149, 179], ["the parainfluenza viruses", "PROBLEM", 181, 206], ["influenza A and B viruses", "PROBLEM", 220, 245], ["cells", "OBSERVATION", 15, 20], ["syncytial virus", "OBSERVATION", 124, 139], ["respiratory viruses", "OBSERVATION", 160, 179], ["parainfluenza viruses", "OBSERVATION", 185, 206], ["probably", "UNCERTAINTY", 211, 219], ["influenza", "OBSERVATION", 220, 229]]], ["Armed with Rapid diagnostic techniques in fatal infections 291 a knowledge of this phenomenon and with a developing experience of the appearance of these coated cells, all these respiratory virus infections can be rapidly diagnosed, in many cases late in the illness.THE USE OF RAPID DIAGNOSTIC TECHNIQUES IN FATAL INFECTIONSIn the UK there are still approximately 2500 deaths per year from respiratory infections, mainly in those under 1 year of age.", [["cells", "ANATOMY", 161, 166], ["respiratory", "ANATOMY", 391, 402], ["infections", "DISEASE", 48, 58], ["respiratory virus infections", "DISEASE", 178, 206], ["deaths", "DISEASE", 370, 376], ["respiratory infections", "DISEASE", 391, 413], ["cells", "CELL", 161, 166], ["coated cells", "CELL_TYPE", 154, 166], ["fatal infections", "PROBLEM", 42, 58], ["this phenomenon", "PROBLEM", 78, 93], ["these coated cells", "PROBLEM", 148, 166], ["all these respiratory virus infections", "PROBLEM", 168, 206], ["respiratory infections", "PROBLEM", 391, 413], ["fatal", "OBSERVATION_MODIFIER", 42, 47], ["infections", "OBSERVATION", 48, 58], ["coated cells", "OBSERVATION", 154, 166], ["respiratory virus", "OBSERVATION", 178, 195], ["respiratory", "ANATOMY", 391, 402], ["infections", "OBSERVATION", 403, 413]]], ["It would appear from various studies that the majority of these are of viral aetiology Aherne et al., 1970; Scott et al., 1978) .", [["various studies", "TEST", 21, 36]]], ["The viruses most frequently associated with infant deaths are respiratory syncytial virus, influenza A virus, parainfluenza virus type 3 and various adenoviruses, but recently others such as parainfluenza virus type 1, 4a and 4b have also been incriminated.", [["deaths", "DISEASE", 51, 57], ["respiratory syncytial virus", "DISEASE", 62, 89], ["influenza A virus", "DISEASE", 91, 108], ["parainfluenza virus", "DISEASE", 110, 129], ["parainfluenza virus type 1, 4a and 4b", "CHEMICAL", 191, 228], ["respiratory syncytial virus", "ORGANISM", 62, 89], ["influenza A virus", "ORGANISM", 91, 108], ["parainfluenza virus type 3", "ORGANISM", 110, 136], ["adenoviruses", "ORGANISM", 149, 161], ["parainfluenza virus type 1", "ORGANISM", 191, 217], ["4a", "GENE_OR_GENE_PRODUCT", 219, 221], ["4b", "GENE_OR_GENE_PRODUCT", 226, 228], ["infant", "SPECIES", 44, 50], ["respiratory syncytial virus", "SPECIES", 62, 89], ["influenza A virus", "SPECIES", 91, 108], ["parainfluenza virus", "SPECIES", 110, 129], ["parainfluenza virus type 1", "SPECIES", 191, 217], ["respiratory syncytial virus", "SPECIES", 62, 89], ["influenza A virus", "SPECIES", 91, 108], ["parainfluenza virus type 1", "SPECIES", 191, 217], ["The viruses", "PROBLEM", 0, 11], ["infant deaths", "PROBLEM", 44, 57], ["respiratory syncytial virus", "PROBLEM", 62, 89], ["influenza A virus", "PROBLEM", 91, 108], ["parainfluenza virus type 3", "PROBLEM", 110, 136], ["various adenoviruses", "PROBLEM", 141, 161], ["parainfluenza virus type", "PROBLEM", 191, 215], ["viruses", "OBSERVATION", 4, 11], ["respiratory", "ANATOMY", 62, 73], ["syncytial virus", "OBSERVATION", 74, 89], ["parainfluenza virus", "OBSERVATION", 110, 129]]], ["Measles, too, occasionally causes death in the normal child but is a major cause of death in the immunosuppressed child, who is usually undergoing antitumour therapy (see page 292).", [["Measles", "DISEASE", 0, 7], ["death", "DISEASE", 34, 39], ["death", "DISEASE", 84, 89], ["child", "ORGANISM", 114, 119], ["antitumour", "CANCER", 147, 157], ["Measles", "PROBLEM", 0, 7], ["death", "PROBLEM", 34, 39], ["death", "PROBLEM", 84, 89], ["antitumour therapy", "TREATMENT", 147, 165], ["immunosuppressed", "OBSERVATION", 97, 113]]], ["The majority of respiratory viruses are labile and by necessity most autopsies need to be delayed at least 18 hours, often much longer, in order to obtain the consent of relatives.", [["respiratory viruses", "DISEASE", 16, 35], ["respiratory viruses", "PROBLEM", 16, 35], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["respiratory viruses", "OBSERVATION", 16, 35], ["labile", "OBSERVATION_MODIFIER", 40, 46]]], ["It has already been pointed out that the ability to demonstrate the presence of virus antigen persists for longer than the ability to detect virus infectivity.", [["virus antigen", "PROTEIN", 80, 93], ["virus antigen", "PROBLEM", 80, 93], ["virus infectivity", "PROBLEM", 141, 158], ["virus", "OBSERVATION", 80, 85], ["virus", "OBSERVATION", 141, 146]]], ["Immunofluorescence has therefore become a key tool in the examination of autopsy material for the demonstration of viruses.THE USE OF RAPID DIAGNOSTIC TECHNIQUES IN FATAL INFECTIONSVirus deaths in infancy are usually due to bronchiolitis or pneumonia, the latter often being associated with a congenital abnormality.", [["deaths", "DISEASE", 187, 193], ["bronchiolitis", "DISEASE", 224, 237], ["pneumonia", "DISEASE", 241, 250], ["congenital abnormality", "DISEASE", 293, 315], ["Immunofluorescence", "TEST", 0, 18], ["the examination", "TEST", 54, 69], ["autopsy material", "TEST", 73, 89], ["viruses", "PROBLEM", 115, 122], ["bronchiolitis", "PROBLEM", 224, 237], ["pneumonia", "PROBLEM", 241, 250], ["a congenital abnormality", "PROBLEM", 291, 315], ["viruses", "OBSERVATION", 115, 122], ["FATAL", "OBSERVATION_MODIFIER", 165, 170], ["usually due to", "UNCERTAINTY", 209, 223], ["bronchiolitis", "OBSERVATION", 224, 237], ["pneumonia", "OBSERVATION", 241, 250], ["congenital", "OBSERVATION_MODIFIER", 293, 303], ["abnormality", "OBSERVATION", 304, 315]]], ["Recently, the presence of viruses has been clearly demonstrated in about 20-25 per cent of'cot deaths' or the sudden infant death syndrome (SIDS) (Ferris et al., 1973; Scott et al., 1978) .", [["deaths", "DISEASE", 95, 101], ["sudden infant death", "DISEASE", 110, 129], ["SIDS", "DISEASE", 140, 144], ["viruses", "PROBLEM", 26, 33], ["the sudden infant death syndrome", "PROBLEM", 106, 138], ["viruses", "OBSERVATION", 26, 33], ["death syndrome", "OBSERVATION", 124, 138]]], ["In adults influenza A is still the main virus pathogen but, here, especially in those with previously damaged lungs, bacteria may be associated.THE USE OF RAPID DIAGNOSTIC TECHNIQUES IN FATAL INFECTIONSThe presence of a virus in the lungs at autopsy does not necessarily mean that the virus was the cause of death.", [["lungs", "ANATOMY", 110, 115], ["lungs", "ANATOMY", 233, 238], ["influenza A", "DISEASE", 10, 21], ["death", "DISEASE", 308, 313], ["adults influenza A", "ORGANISM", 3, 21], ["lungs", "ORGAN", 110, 115], ["lungs", "ORGAN", 233, 238], ["adults influenza A", "PROBLEM", 3, 21], ["the main virus pathogen", "PROBLEM", 31, 54], ["previously damaged lungs", "PROBLEM", 91, 115], ["bacteria", "PROBLEM", 117, 125], ["FATAL INFECTIONS", "PROBLEM", 186, 202], ["a virus in the lungs", "PROBLEM", 218, 238], ["the virus", "PROBLEM", 281, 290], ["death", "PROBLEM", 308, 313], ["influenza", "OBSERVATION", 10, 19], ["lungs", "ANATOMY", 110, 115], ["bacteria", "OBSERVATION", 117, 125], ["FATAL", "OBSERVATION_MODIFIER", 186, 191], ["INFECTIONS", "OBSERVATION", 192, 202], ["virus", "OBSERVATION", 220, 225], ["lungs", "ANATOMY", 233, 238], ["virus", "OBSERVATION", 285, 290]]], ["It could be present because of contamination from an unrelated infection of the upper respiratory tract.", [["upper respiratory tract", "ANATOMY", 80, 103], ["infection of the upper respiratory tract", "DISEASE", 63, 103], ["upper respiratory", "ORGANISM_SUBDIVISION", 80, 97], ["tract", "ORGANISM_SUBDIVISION", 98, 103], ["contamination", "PROBLEM", 31, 44], ["an unrelated infection of the upper respiratory tract", "PROBLEM", 50, 103], ["contamination", "OBSERVATION", 31, 44], ["unrelated", "OBSERVATION_MODIFIER", 53, 62], ["infection", "OBSERVATION", 63, 72], ["upper", "ANATOMY_MODIFIER", 80, 85], ["respiratory tract", "ANATOMY", 86, 103]]], ["It is therefore essential for all deaths to be investigated by methods other than the isolation of virus in order to substantiate the aetiological role of any virus found.", [["deaths", "DISEASE", 34, 40], ["all deaths", "PROBLEM", 30, 40], ["the isolation of virus", "TREATMENT", 82, 104], ["any virus", "PROBLEM", 155, 164]]], ["In the studies already quoted pains were taken to use conventional histological investigations of the respiratory tract and supporting evidence was looked for and found in all those autopsies in which virus was identified.", [["respiratory tract", "ANATOMY", 102, 119], ["pains", "DISEASE", 30, 35], ["respiratory tract", "ORGANISM_SUBDIVISION", 102, 119], ["quoted pains", "PROBLEM", 23, 35], ["conventional histological investigations", "TEST", 54, 94], ["the respiratory tract", "PROBLEM", 98, 119], ["virus", "PROBLEM", 201, 206], ["respiratory tract", "ANATOMY", 102, 119]]], ["Immunofluorescence, too, supplies a second confirmatory tool, for by its use virus antigen can be actually seen in the alveolar and bronchiolar epithelial cells.THE USE OF RAPID DIAGNOSTIC TECHNIQUES IN FATAL INFECTIONSImmunofluorescence can therefore be used to investigate all respiratory deaths where the prospect of virus isolation is small.", [["alveolar", "ANATOMY", 119, 127], ["bronchiolar epithelial cells", "ANATOMY", 132, 160], ["respiratory deaths", "DISEASE", 279, 297], ["alveolar", "CELL", 119, 127], ["bronchiolar epithelial cells", "CELL", 132, 160], ["alveolar and bronchiolar epithelial cells", "CELL_TYPE", 119, 160], ["Immunofluorescence", "TEST", 0, 18], ["a second confirmatory tool", "TEST", 34, 60], ["virus antigen", "PROBLEM", 77, 90], ["all respiratory deaths", "PROBLEM", 275, 297], ["virus isolation", "TREATMENT", 320, 335], ["alveolar", "ANATOMY_MODIFIER", 119, 127], ["bronchiolar epithelial cells", "OBSERVATION", 132, 160], ["respiratory deaths", "OBSERVATION", 279, 297], ["virus", "OBSERVATION", 320, 325], ["small", "OBSERVATION_MODIFIER", 339, 344]]], ["Respiratory deaths in infancy and occasionally in adults can be sudden and here too immunofluorescence has an important role to play.", [["Respiratory deaths", "DISEASE", 0, 18], ["Respiratory deaths", "PROBLEM", 0, 18]]], ["Many a coroner, faced with unexpected deaths, is grateful for a report within 3-4 hours of autopsy so that other more sinister causes can be quickly eliminated, while the parents of an SIDS may be relieved of the inevitable feeling of guilt that they have experienced.VIRUS INFECTION IN THE IMMUNOSUPPRESSED PATIENT AND ITS MANAGEMENTThe immunosuppression of children and adults as part of specific therapy is now commonplace and on occasions it may be produced as an unwanted side-effect of many current drug regimens.", [["deaths", "DISEASE", 38, 44], ["SIDS", "DISEASE", 185, 189], ["children", "ORGANISM", 359, 367], ["children", "SPECIES", 359, 367], ["VIRUS INFECTION", "PROBLEM", 268, 283], ["ITS MANAGEMENT", "TREATMENT", 320, 334], ["specific therapy", "TREATMENT", 390, 406], ["many current drug regimens", "TREATMENT", 492, 518], ["INFECTION", "OBSERVATION", 274, 283], ["IMMUNOSUPPRESSED", "OBSERVATION_MODIFIER", 291, 307]]], ["Included among the drugs frequently used are vincristine, cyclophosphamide, methotrexate, 6-mercaptopurine, prednisone and azothioprine.VIRUS INFECTION IN THE IMMUNOSUPPRESSED PATIENT AND ITS MANAGEMENTIn adults these immunosuppressive measures often lead to greater risk of reinfection or reactivation with the herpes group of viruses.", [["vincristine", "CHEMICAL", 45, 56], ["cyclophosphamide", "CHEMICAL", 58, 74], ["methotrexate", "CHEMICAL", 76, 88], ["6-mercaptopurine", "CHEMICAL", 90, 106], ["prednisone", "CHEMICAL", 108, 118], ["azothioprine", "CHEMICAL", 123, 135], ["reinfection", "DISEASE", 275, 286], ["vincristine", "CHEMICAL", 45, 56], ["cyclophosphamide", "CHEMICAL", 58, 74], ["methotrexate", "CHEMICAL", 76, 88], ["6-mercaptopurine", "CHEMICAL", 90, 106], ["prednisone", "CHEMICAL", 108, 118], ["azothioprine", "CHEMICAL", 123, 135], ["vincristine", "SIMPLE_CHEMICAL", 45, 56], ["cyclophosphamide", "SIMPLE_CHEMICAL", 58, 74], ["methotrexate", "SIMPLE_CHEMICAL", 76, 88], ["6-mercaptopurine", "SIMPLE_CHEMICAL", 90, 106], ["prednisone", "SIMPLE_CHEMICAL", 108, 118], ["azothioprine", "SIMPLE_CHEMICAL", 123, 135], ["herpes", "ORGANISM", 312, 318], ["the drugs", "TREATMENT", 15, 24], ["vincristine", "TREATMENT", 45, 56], ["cyclophosphamide", "TREATMENT", 58, 74], ["methotrexate", "TREATMENT", 76, 88], ["mercaptopurine", "TREATMENT", 92, 106], ["prednisone", "TREATMENT", 108, 118], ["azothioprine", "TREATMENT", 123, 135], ["VIRUS INFECTION", "PROBLEM", 136, 151], ["ITS MANAGEMENTIn adults", "TREATMENT", 188, 211], ["these immunosuppressive measures", "TREATMENT", 212, 244], ["reinfection", "PROBLEM", 275, 286], ["reactivation", "PROBLEM", 290, 302], ["the herpes group of viruses", "PROBLEM", 308, 335], ["INFECTION", "OBSERVATION", 142, 151], ["IMMUNOSUPPRESSED", "OBSERVATION_MODIFIER", 159, 175], ["reinfection", "OBSERVATION", 275, 286]]], ["They cause a wide variety of bizarre clinical conditions ranging from ocular complications to death (Porter et al, 1972) .", [["ocular", "ANATOMY", 70, 76], ["ocular complications", "DISEASE", 70, 90], ["death", "DISEASE", 94, 99], ["ocular", "ORGAN", 70, 76], ["bizarre clinical conditions", "PROBLEM", 29, 56], ["ocular complications", "PROBLEM", 70, 90], ["wide", "OBSERVATION_MODIFIER", 13, 17]]], ["Cytomegalo virus is the principal culprit but herpesvirus hominis and varicella-zoster are also frequently involved.", [["herpesvirus hominis", "DISEASE", 46, 65], ["varicella-zoster", "DISEASE", 70, 86], ["Cytomegalo virus", "ORGANISM", 0, 16], ["herpesvirus hominis", "ORGANISM", 46, 65], ["varicella-zoster", "ORGANISM", 70, 86], ["herpesvirus hominis", "SPECIES", 46, 65], ["varicella-zoster", "SPECIES", 70, 86], ["Cytomegalo virus", "SPECIES", 0, 16], ["herpesvirus hominis", "SPECIES", 46, 65], ["Cytomegalo virus", "PROBLEM", 0, 16], ["herpesvirus hominis", "PROBLEM", 46, 65], ["varicella", "PROBLEM", 70, 79], ["zoster", "PROBLEM", 80, 86], ["herpesvirus hominis", "OBSERVATION", 46, 65], ["varicella", "OBSERVATION_MODIFIER", 70, 79], ["zoster", "OBSERVATION", 80, 86]]], ["A rapid diagnosis is urgently required as survival of graft, retina or life itself depends on achieving a fine balance between the treatment and the virus infection.", [["graft", "ANATOMY", 54, 59], ["retina", "ANATOMY", 61, 67], ["infection", "DISEASE", 155, 164], ["graft", "TISSUE", 54, 59], ["retina", "MULTI-TISSUE_STRUCTURE", 61, 67], ["graft", "TREATMENT", 54, 59], ["the treatment", "TREATMENT", 127, 140], ["the virus infection", "PROBLEM", 145, 164], ["graft", "OBSERVATION", 54, 59]]], ["Moreover the increasing efficiency of the antiherpes drugs and the possible availability of interferon for clinical use in the future makes early diagnosis essential.VIRUS INFECTION IN THE IMMUNOSUPPRESSED PATIENT AND ITS MANAGEMENTThe major reason for children becoming immunosuppressed is the intensive and prolonged therapy required for the treatment of acute lymphatic leukaemia.", [["lymphatic leukaemia", "ANATOMY", 363, 382], ["acute lymphatic leukaemia", "DISEASE", 357, 382], ["interferon", "GENE_OR_GENE_PRODUCT", 92, 102], ["children", "ORGANISM", 253, 261], ["acute lymphatic leukaemia", "CANCER", 357, 382], ["interferon", "PROTEIN", 92, 102], ["children", "SPECIES", 253, 261], ["the antiherpes drugs", "TREATMENT", 38, 58], ["interferon", "TREATMENT", 92, 102], ["VIRUS INFECTION", "PROBLEM", 166, 181], ["ITS MANAGEMENT", "TREATMENT", 218, 232], ["immunosuppressed", "PROBLEM", 271, 287], ["prolonged therapy", "TREATMENT", 309, 326], ["acute lymphatic leukaemia", "PROBLEM", 357, 382], ["increasing", "OBSERVATION_MODIFIER", 13, 23], ["efficiency", "OBSERVATION_MODIFIER", 24, 34], ["INFECTION", "OBSERVATION", 172, 181], ["IMMUNOSUPPRESSED", "OBSERVATION_MODIFIER", 189, 205], ["immunosuppressed", "OBSERVATION", 271, 287], ["acute", "OBSERVATION_MODIFIER", 357, 362], ["lymphatic leukaemia", "OBSERVATION", 363, 382]]], ["Therapy not only includes the above-mentioned drugs but also radiation.", [["Therapy", "TREATMENT", 0, 7], ["drugs", "TREATMENT", 46, 51]]], ["Recent months have seen the development of techniques for the grafting of bone marrow transplants after whole-body irradiation.", [["bone marrow", "ANATOMY", 74, 85], ["body", "ANATOMY", 110, 114], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 74, 85], ["body", "ORGANISM_SUBDIVISION", 110, 114], ["the grafting", "TREATMENT", 58, 70], ["bone marrow transplants", "TREATMENT", 74, 97], ["whole-body irradiation", "TREATMENT", 104, 126], ["grafting", "OBSERVATION", 62, 70], ["bone", "ANATOMY", 74, 78], ["marrow transplants", "OBSERVATION", 79, 97]]], ["However, during the treatment the child is left highly vulnerable and susceptible to infection.", [["infection", "DISEASE", 85, 94], ["child", "ORGANISM", 34, 39], ["infection", "PROBLEM", 85, 94], ["left", "ANATOMY_MODIFIER", 43, 47], ["vulnerable", "OBSERVATION", 55, 65], ["infection", "OBSERVATION", 85, 94]]], ["Infection has therefore become the major cause of death in acute lymphatic leukaemia, the majority of these infections being associated with viruses.", [["lymphatic leukaemia", "ANATOMY", 65, 84], ["Infection", "DISEASE", 0, 9], ["death", "DISEASE", 50, 55], ["acute lymphatic leukaemia", "DISEASE", 59, 84], ["infections", "DISEASE", 108, 118], ["acute lymphatic leukaemia", "CANCER", 59, 84], ["Infection", "PROBLEM", 0, 9], ["death", "PROBLEM", 50, 55], ["acute lymphatic leukaemia", "PROBLEM", 59, 84], ["these infections", "PROBLEM", 102, 118], ["viruses", "PROBLEM", 141, 148], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["lymphatic leukaemia", "OBSERVATION", 65, 84], ["majority", "OBSERVATION_MODIFIER", 90, 98], ["infections", "OBSERVATION", 108, 118], ["viruses", "OBSERVATION", 141, 148]]], ["The viruses involved are rhinoviruses, measles, mumps, influenza, respiratory syncytial virus and the other everyday viruses which normal children easily combat.", [["measles", "DISEASE", 39, 46], ["mumps", "DISEASE", 48, 53], ["influenza", "DISEASE", 55, 64], ["respiratory syncytial virus", "DISEASE", 66, 93], ["rhinoviruses", "ORGANISM", 25, 37], ["respiratory syncytial virus", "ORGANISM", 66, 93], ["children", "ORGANISM", 138, 146], ["respiratory syncytial virus", "SPECIES", 66, 93], ["children", "SPECIES", 138, 146], ["respiratory syncytial virus", "SPECIES", 66, 93], ["rhinoviruses", "PROBLEM", 25, 37], ["measles", "PROBLEM", 39, 46], ["mumps", "PROBLEM", 48, 53], ["influenza", "PROBLEM", 55, 64], ["respiratory syncytial virus", "PROBLEM", 66, 93], ["viruses", "OBSERVATION", 4, 11], ["rhinoviruses", "OBSERVATION", 25, 37], ["respiratory syncytial virus", "OBSERVATION", 66, 93]]], ["However, children with leukaemia and under therapy can die of rhinovirus pneumonia, and most children who are infected with measles during the course of their leukaemia also die.", [["leukaemia", "ANATOMY", 23, 32], ["leukaemia", "ANATOMY", 159, 168], ["leukaemia", "DISEASE", 23, 32], ["rhinovirus pneumonia", "DISEASE", 62, 82], ["measles", "DISEASE", 124, 131], ["leukaemia", "DISEASE", 159, 168], ["children", "ORGANISM", 9, 17], ["leukaemia", "CANCER", 23, 32], ["rhinovirus", "ORGANISM", 62, 72], ["children", "ORGANISM", 93, 101], ["leukaemia", "CANCER", 159, 168], ["children", "SPECIES", 9, 17], ["children", "SPECIES", 93, 101], ["leukaemia", "PROBLEM", 23, 32], ["therapy", "TREATMENT", 43, 50], ["rhinovirus pneumonia", "PROBLEM", 62, 82], ["leukaemia", "OBSERVATION", 23, 32], ["rhinovirus", "OBSERVATION", 62, 72]]], ["In a defined study of virus infections in childhood leukaemias, their importance in morbidity and mortality has been clearly demonstrated (Craft et al., 1977 (Craft et al., , 1978 (Craft et al., , 1979 .", [["childhood leukaemias", "ANATOMY", 42, 62], ["infections", "DISEASE", 28, 38], ["leukaemias", "DISEASE", 52, 62], ["childhood leukaemias", "CANCER", 42, 62], ["virus infections", "PROBLEM", 22, 38], ["childhood leukaemias", "PROBLEM", 42, 62], ["virus infections", "OBSERVATION", 22, 38], ["leukaemias", "OBSERVATION", 52, 62]]], ["The numbers of patients both in remission and relapse in whom viruses were associated with death are indicated in Table 15 .", [["death", "DISEASE", 91, 96], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["death", "PROBLEM", 91, 96], ["numbers", "OBSERVATION_MODIFIER", 4, 11]]], ["A distinct feature of infectious illness in the immunosuppressed child is its unusual symptomology.", [["infectious illness", "DISEASE", 22, 40], ["child", "ORGANISM", 65, 70], ["infectious illness", "PROBLEM", 22, 40], ["distinct feature of", "UNCERTAINTY", 2, 21], ["infectious", "OBSERVATION_MODIFIER", 22, 32], ["illness", "OBSERVATION", 33, 40], ["immunosuppressed", "OBSERVATION", 48, 64]]], ["Measles is especially severe, often fatal, but seldom has a rash; respiratory syncytial virus, less often seen in childhood after 1-2 years of age, causes severe and prolonged symptoms in the older immunosuppressed child.", [["Measles", "DISEASE", 0, 7], ["rash", "DISEASE", 60, 64], ["respiratory syncytial virus", "DISEASE", 66, 93], ["respiratory syncytial virus", "ORGANISM", 66, 93], ["child", "ORGANISM", 215, 220], ["respiratory syncytial virus", "SPECIES", 66, 93], ["respiratory syncytial virus", "SPECIES", 66, 93], ["Measles", "PROBLEM", 0, 7], ["a rash", "PROBLEM", 58, 64], ["respiratory syncytial virus", "PROBLEM", 66, 93], ["severe and prolonged symptoms", "PROBLEM", 155, 184], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["fatal", "OBSERVATION_MODIFIER", 36, 41], ["rash", "OBSERVATION", 60, 64], ["respiratory", "ANATOMY", 66, 77], ["syncytial virus", "OBSERVATION", 78, 93], ["severe", "OBSERVATION_MODIFIER", 155, 161], ["prolonged", "OBSERVATION_MODIFIER", 166, 175]]], ["On many occasions, onset of a virus infection can be sudden and severe, with death rapidly intervening.", [["infection", "DISEASE", 36, 45], ["death", "DISEASE", 77, 82], ["a virus infection", "PROBLEM", 28, 45], ["death", "PROBLEM", 77, 82], ["virus", "OBSERVATION", 30, 35], ["severe", "OBSERVATION_MODIFIER", 64, 70]]], ["Rapid diagnosis in these circumstances has become a vital procedure; it is a guide both to the amount of immunosuppressive therapy which should be given at this time and to specific antiviral treatment needed.", [["a vital procedure", "TREATMENT", 50, 67], ["immunosuppressive therapy", "TREATMENT", 105, 130], ["antiviral treatment", "TREATMENT", 182, 201], ["immunosuppressive therapy", "OBSERVATION", 105, 130]]], ["The coating of infected epithelial cells by locally produced antibody in the normal infected child has already been discussed but the position is often very different in the immunosuppressed child.", [["epithelial cells", "ANATOMY", 24, 40], ["epithelial cells", "CELL", 24, 40], ["child", "ORGANISM", 93, 98], ["child", "ORGANISM", 191, 196], ["infected epithelial cells", "CELL_TYPE", 15, 40], ["child", "SPECIES", 93, 98], ["infected epithelial cells", "PROBLEM", 15, 40], ["coating", "OBSERVATION_MODIFIER", 4, 11], ["infected epithelial cells", "OBSERVATION", 15, 40], ["antibody", "OBSERVATION_MODIFIER", 61, 69], ["normal", "OBSERVATION_MODIFIER", 77, 83], ["infected", "OBSERVATION", 84, 92], ["immunosuppressed", "OBSERVATION", 174, 190]]], ["Depending on the stage of the illness and the treatment regimen, many of these children are incapable of producing an antibody response either locally in the respiratory tract or humorally.", [["respiratory tract", "ANATOMY", 158, 175], ["children", "ORGANISM", 79, 87], ["respiratory tract", "ORGANISM_SUBDIVISION", 158, 175], ["children", "SPECIES", 79, 87], ["the illness", "PROBLEM", 26, 37], ["the treatment regimen", "TREATMENT", 42, 63], ["an antibody response", "PROBLEM", 115, 135], ["illness", "OBSERVATION", 30, 37], ["respiratory tract", "ANATOMY", 158, 175]]], ["Infected cells therefore continue to be excreted for long periods of time and their appearance, when stained by immunofluorescence, is indistinguishable from that of a normal child's cells in the first day or two of an acute illness.", [["cells", "ANATOMY", 9, 14], ["cells", "ANATOMY", 183, 188], ["cells", "CELL", 9, 14], ["cells", "CELL", 183, 188], ["normal child's cells", "CELL_TYPE", 168, 188], ["Infected cells", "PROBLEM", 0, 14], ["immunofluorescence", "TEST", 112, 130], ["an acute illness", "PROBLEM", 216, 232], ["acute", "OBSERVATION_MODIFIER", 219, 224], ["illness", "OBSERVATION", 225, 232]]], ["Figure 77 illustrates respiratory syncytial virus-infected cells in the secretions of a child aged 4 years with acute lymphatic leukaemia and a severe bronchitis which lasted for 64 days.", [["cells", "ANATOMY", 59, 64], ["secretions", "ANATOMY", 72, 82], ["lymphatic leukaemia", "ANATOMY", 118, 137], ["respiratory syncytial virus-infected", "DISEASE", 22, 58], ["acute lymphatic leukaemia", "DISEASE", 112, 137], ["bronchitis", "DISEASE", 151, 161], ["respiratory syncytial virus", "ORGANISM", 22, 49], ["cells", "CELL", 59, 64], ["lymphatic leukaemia", "CANCER", 118, 137], ["infected cells", "CELL_TYPE", 50, 64], ["child", "SPECIES", 88, 93], ["respiratory syncytial virus", "SPECIES", 22, 49], ["Figure", "TEST", 0, 6], ["respiratory syncytial virus", "PROBLEM", 22, 49], ["infected cells", "PROBLEM", 50, 64], ["acute lymphatic leukaemia", "PROBLEM", 112, 137], ["a severe bronchitis", "PROBLEM", 142, 161], ["respiratory syncytial virus", "OBSERVATION", 22, 49], ["infected cells", "OBSERVATION", 50, 64], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["lymphatic leukaemia", "OBSERVATION", 118, 137], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["bronchitis", "OBSERVATION", 151, 161]]], ["It shows the number and brightness of respiratory syncytial virus-infected cells at the thirty-fifth day of illness-there is no evidence whatsoever of coating.VIRUS INFECTION IN THE IMMUNOSUPPRESSED PATIENT AND ITS MANAGEMENTImmunofluorescence has also become an essential tool for diagnosing an infection which is not resolving, for controlling chemotherapy and for determining prognosis.", [["cells", "ANATOMY", 75, 80], ["respiratory syncytial virus-infected", "DISEASE", 38, 74], ["infection", "DISEASE", 296, 305], ["respiratory syncytial virus", "ORGANISM", 38, 65], ["cells", "CELL", 75, 80], ["infected cells", "CELL_TYPE", 66, 80], ["respiratory syncytial virus", "SPECIES", 38, 65], ["respiratory syncytial virus", "PROBLEM", 38, 65], ["infected cells", "PROBLEM", 66, 80], ["illness", "PROBLEM", 108, 115], ["VIRUS INFECTION", "PROBLEM", 159, 174], ["an infection", "PROBLEM", 293, 305], ["chemotherapy", "TREATMENT", 346, 358], ["respiratory syncytial virus", "OBSERVATION", 38, 65], ["infected cells", "OBSERVATION", 66, 80], ["no evidence whatsoever", "UNCERTAINTY", 125, 147], ["coating", "OBSERVATION", 151, 158], ["INFECTION", "OBSERVATION", 165, 174], ["IMMUNOSUPPRESSED", "OBSERVATION_MODIFIER", 182, 198], ["infection", "OBSERVATION", 296, 305]]], ["Measles is particularly difficult to diagnose in the immunosuppressed child because of its very varied picture.", [["Measles", "DISEASE", 0, 7], ["Measles", "PROBLEM", 0, 7], ["immunosuppressed", "OBSERVATION", 53, 69]]], ["It is possible that early treatment with interferon might alter what has, up till now, been a very gloomy prognosis; the use of rapid diagnosis and interferon therapy in measles is currently being investigated in a multicentred study.", [["measles", "DISEASE", 170, 177], ["interferon", "GENE_OR_GENE_PRODUCT", 41, 51], ["interferon", "PROTEIN", 41, 51], ["interferon", "PROTEIN", 148, 158], ["interferon", "TREATMENT", 41, 51], ["rapid diagnosis", "TREATMENT", 128, 143], ["interferon therapy", "TREATMENT", 148, 166], ["a multicentred study", "TEST", 213, 233]]], ["However, the key to any successful chemotherapy must lie in early diagnosis, and the screening of secretions for respiratory viruses even in mild infections should include a test for measles.", [["secretions", "ANATOMY", 98, 108], ["respiratory", "ANATOMY", 113, 124], ["respiratory viruses", "DISEASE", 113, 132], ["infections", "DISEASE", 146, 156], ["measles", "DISEASE", 183, 190], ["secretions", "ORGANISM_SUBDIVISION", 98, 108], ["any successful chemotherapy", "TREATMENT", 20, 47], ["the screening", "TEST", 81, 94], ["secretions", "PROBLEM", 98, 108], ["respiratory viruses", "PROBLEM", 113, 132], ["mild infections", "PROBLEM", 141, 156], ["a test", "TEST", 172, 178], ["measles", "PROBLEM", 183, 190], ["mild", "OBSERVATION_MODIFIER", 141, 145], ["infections", "OBSERVATION", 146, 156]]], ["Immunofluorescence enables this to be done.", [["Immunofluorescence", "TEST", 0, 18]]], ["In the normal child with measles, infected cells, including giant cells, are rarely seen after the third day of rash (McQuillin et al, 1976) .", [["cells", "ANATOMY", 43, 48], ["giant cells", "ANATOMY", 60, 71], ["measles, infected", "DISEASE", 25, 42], ["rash", "DISEASE", 112, 116], ["child", "ORGANISM", 14, 19], ["cells", "CELL", 43, 48], ["giant cells", "CELL", 60, 71], ["infected cells", "CELL_TYPE", 34, 48], ["giant cells", "CELL_TYPE", 60, 71], ["child", "SPECIES", 14, 19], ["measles", "PROBLEM", 25, 32], ["infected cells", "PROBLEM", 34, 48], ["giant cells", "PROBLEM", 60, 71], ["rash", "PROBLEM", 112, 116], ["normal", "OBSERVATION", 7, 13], ["infected cells", "OBSERVATION", 34, 48], ["giant cells", "OBSERVATION", 60, 71]]], ["The picture is totally different in the immunosuppressed child with measles.", [["measles", "DISEASE", 68, 75], ["child", "ORGANISM", 57, 62], ["child", "SPECIES", 57, 62], ["measles", "PROBLEM", 68, 75], ["totally different", "OBSERVATION_MODIFIER", 15, 32], ["immunosuppressed", "OBSERVATION", 40, 56]]], ["In these circumstances the secretions are loaded with giant cells which continue to be excreted, usually until the child dies (Pullan et al, 1976) .", [["secretions", "ANATOMY", 27, 37], ["giant cells", "ANATOMY", 54, 65], ["secretions", "ORGANISM_SUBSTANCE", 27, 37], ["giant cells", "CELL", 54, 65], ["giant cells", "CELL_TYPE", 54, 65], ["giant cells", "PROBLEM", 54, 65], ["secretions", "OBSERVATION", 27, 37], ["giant cells", "OBSERVATION", 54, 65]]], ["These virusloaded giant cells are far more numerous and observed for a far longer period than those which occur in the normal child even at the height of his Viruses producing unusual symptoms 295 rash.", [["virusloaded giant cells", "ANATOMY", 6, 29], ["rash", "DISEASE", 197, 201], ["virusloaded giant cells", "CELL", 6, 29], ["child", "ORGANISM", 126, 131], ["virusloaded giant cells", "CELL_TYPE", 6, 29], ["These virusloaded giant cells", "PROBLEM", 0, 29], ["unusual symptoms", "PROBLEM", 176, 192], ["rash", "PROBLEM", 197, 201], ["giant cells", "OBSERVATION", 18, 29], ["more numerous", "OBSERVATION_MODIFIER", 38, 51]]], ["Figure 78 illustrates the appearance of such a giant cell on the twentyfirst day of a measles illness that had become complicated by the development of an interstitial pneumonia.", [["giant cell", "ANATOMY", 47, 57], ["interstitial", "ANATOMY", 155, 167], ["measles illness", "DISEASE", 86, 101], ["interstitial pneumonia", "DISEASE", 155, 177], ["giant cell", "CELL", 47, 57], ["a giant cell", "PROBLEM", 45, 57], ["a measles illness", "PROBLEM", 84, 101], ["an interstitial pneumonia", "PROBLEM", 152, 177], ["giant cell", "OBSERVATION", 47, 57], ["interstitial", "ANATOMY_MODIFIER", 155, 167], ["pneumonia", "OBSERVATION", 168, 177]]], ["Plate 18 illustrates a giant cell in a lung impression smear of a leukaemic child who died with measles pneumonitis.", [["giant cell", "ANATOMY", 23, 33], ["lung", "ANATOMY", 39, 43], ["leukaemic", "ANATOMY", 66, 75], ["leukaemic", "DISEASE", 66, 75], ["measles pneumonitis", "DISEASE", 96, 115], ["giant cell", "CELL", 23, 33], ["lung", "ORGAN", 39, 43], ["leukaemic", "CANCER", 66, 75], ["child", "ORGANISM", 76, 81], ["Plate", "TEST", 0, 5], ["a giant cell", "PROBLEM", 21, 33], ["measles pneumonitis", "PROBLEM", 96, 115], ["giant cell", "OBSERVATION", 23, 33], ["lung", "ANATOMY", 39, 43], ["leukaemic", "OBSERVATION_MODIFIER", 66, 75], ["pneumonitis", "OBSERVATION", 104, 115]]], ["There is every hope that the immunofluorescent techniques will not only simplify the diagnosis of these cases but be a guide to the effect of interferon in the ongoing coded trials.VIRUS INFECTION IN THE IMMUNOSUPPRESSED PATIENT AND ITS MANAGEMENTAs long as immunosuppressive therapy remains an integral part of medical treatment, rapid virus diagnosis must be relied upon as the method of controlling the devastating illnesses caused by relatively innocuous viruses which now prevent the full realization of the improving prognoses in childhood malignancy.FREQUENTLY OCCURRING VIRUSES PRODUCING UNUSUAL SYMPTOMSIn the previous section it was emphasized that ordinary virus infections may, in the immunosuppressed patient, present with unusual clinical features which may make diagnosis difficult.", [["malignancy", "DISEASE", 546, 556], ["infections", "DISEASE", 674, 684], ["interferon", "GENE_OR_GENE_PRODUCT", 142, 152], ["malignancy", "CANCER", 546, 556], ["patient", "ORGANISM", 714, 721], ["interferon", "PROTEIN", 142, 152], ["patient", "SPECIES", 714, 721], ["the immunofluorescent techniques", "TEST", 25, 57], ["interferon", "TREATMENT", 142, 152], ["VIRUS INFECTION", "PROBLEM", 181, 196], ["ITS MANAGEMENTAs", "TREATMENT", 233, 249], ["immunosuppressive therapy", "TREATMENT", 258, 283], ["medical treatment", "TREATMENT", 312, 329], ["rapid virus diagnosis", "PROBLEM", 331, 352], ["the devastating illnesses", "PROBLEM", 402, 427], ["relatively innocuous viruses", "PROBLEM", 438, 466], ["childhood malignancy", "PROBLEM", 536, 556], ["ordinary virus infections", "PROBLEM", 659, 684], ["INFECTION", "OBSERVATION", 187, 196], ["IMMUNOSUPPRESSED", "OBSERVATION_MODIFIER", 204, 220], ["improving", "OBSERVATION_MODIFIER", 513, 522], ["malignancy", "OBSERVATION", 546, 556], ["VIRUSES", "OBSERVATION", 578, 585]]], ["Frequently occurring viruses in normal children may produce unusual symptoms and therefore be difficult to identify; rapid diagnostic methods in these circumstances may be invaluable.", [["children", "ORGANISM", 39, 47], ["children", "SPECIES", 39, 47], ["unusual symptoms", "PROBLEM", 60, 76], ["viruses", "OBSERVATION", 21, 28]]], ["Three of these viruses will serve to illustrate this problem.FREQUENTLY OCCURRING VIRUSES PRODUCING UNUSUAL SYMPTOMSMeasles usually commences with a severe coryza although the rash may not appear for a few days.", [["coryza", "DISEASE", 156, 162], ["rash", "DISEASE", 176, 180], ["these viruses", "PROBLEM", 9, 22], ["a severe coryza", "PROBLEM", 147, 162], ["the rash", "PROBLEM", 172, 180], ["viruses", "OBSERVATION", 15, 22], ["VIRUSES", "OBSERVATION", 82, 89]]], ["It is important to exclude these children from the community at this highly infectious stage.", [["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41], ["infectious", "OBSERVATION", 76, 86]]], ["This can easily be achieved by immunofluorescent methods .", [["immunofluorescent methods", "TEST", 31, 56]]], ["Measles rashes may be modified by prophylactic vaccines and, moreover, be difficult to recognize in the coloured child.", [["Measles rashes", "DISEASE", 0, 14], ["child", "ORGANISM", 113, 118], ["Measles rashes", "PROBLEM", 0, 14], ["prophylactic vaccines", "TREATMENT", 34, 55]]], ["The latter point is of great importance in developing countries where measles can be a devastating illness and in the UK where there has been a substantial increase in the coloured child population.FREQUENTLY OCCURRING VIRUSES PRODUCING UNUSUAL SYMPTOMSInfluenza A is present in the community most winters and frequently reaches epidemic proportions.", [["measles", "DISEASE", 70, 77], ["measles", "ORGANISM", 70, 77], ["a devastating illness", "PROBLEM", 85, 106], ["the coloured child population", "PROBLEM", 168, 197], ["great", "OBSERVATION_MODIFIER", 23, 28], ["substantial", "OBSERVATION_MODIFIER", 144, 155], ["increase", "OBSERVATION_MODIFIER", 156, 164], ["coloured", "OBSERVATION_MODIFIER", 172, 180], ["VIRUSES", "OBSERVATION", 219, 226], ["UNUSUAL", "OBSERVATION_MODIFIER", 237, 244], ["SYMPTOMSInfluenza", "OBSERVATION", 245, 262]]], ["Normally the diagnosis of influenza A is self-evident with a symptomatology which all have experienced.", [["influenza", "DISEASE", 26, 35], ["influenza A", "PROBLEM", 26, 37], ["a symptomatology", "PROBLEM", 59, 75], ["influenza", "OBSERVATION", 26, 35]]], ["The child cannot usually complain in a succinct manner though it is now known that he is frequently infected by the virus.", [["child", "ORGANISM", 4, 9], ["child", "SPECIES", 4, 9], ["the virus", "PROBLEM", 112, 121]]], ["The most frequent form of presentation for influenza A in the young child is a febrile convulsion, a symptom still not considered of viral origin by many physicians because respiratory symptoms and signs are often minimal or absent.", [["respiratory", "ANATOMY", 173, 184], ["influenza A", "DISEASE", 43, 54], ["febrile convulsion", "DISEASE", 79, 97], ["child", "SPECIES", 68, 73], ["influenza", "PROBLEM", 43, 52], ["a febrile convulsion", "PROBLEM", 77, 97], ["a symptom", "PROBLEM", 99, 108], ["respiratory symptoms", "PROBLEM", 173, 193], ["most frequent", "OBSERVATION_MODIFIER", 4, 17]]], ["Immunofluorescence can diagnose influenza A in the cells of these childrens' secretions very readily (Brocklebank et al., 1972) .FREQUENTLY OCCURRING VIRUSES PRODUCING UNUSUAL SYMPTOMSSimilarly, abdominal pain in childhood may be of viral origin.", [["cells", "ANATOMY", 51, 56], ["childrens", "ANATOMY", 66, 75], ["secretions", "ANATOMY", 77, 87], ["abdominal", "ANATOMY", 195, 204], ["abdominal pain", "DISEASE", 195, 209], ["cells", "CELL", 51, 56], ["abdominal", "ORGANISM_SUBDIVISION", 195, 204], ["Immunofluorescence", "TEST", 0, 18], ["influenza", "PROBLEM", 32, 41], ["UNUSUAL SYMPTOMSSimilarly", "PROBLEM", 168, 193], ["abdominal pain", "PROBLEM", 195, 209], ["viral origin", "PROBLEM", 233, 245], ["VIRUSES", "OBSERVATION", 150, 157], ["abdominal", "ANATOMY", 195, 204], ["pain", "OBSERVATION", 205, 209], ["may be of", "UNCERTAINTY", 223, 232], ["viral origin", "OBSERVATION", 233, 245]]], ["The association of this symptom with influenza B infection was originally noted by Kerr et al. (1975) .", [["influenza B infection", "DISEASE", 37, 58], ["influenza B", "ORGANISM", 37, 48], ["this symptom", "PROBLEM", 19, 31], ["influenza B infection", "PROBLEM", 37, 58], ["infection", "OBSERVATION", 49, 58]]], ["In a similar manner to influenza A in febrile 296 Application ofimmunofluorescent technique to clinical virology convulsions, respiratory symptoms may be minimal.", [["respiratory", "ANATOMY", 126, 137], ["influenza A", "DISEASE", 23, 34], ["febrile", "DISEASE", 38, 45], ["convulsions", "DISEASE", 113, 124], ["respiratory symptoms", "DISEASE", 126, 146], ["influenza A in febrile", "PROBLEM", 23, 45], ["Application ofimmunofluorescent technique", "TREATMENT", 50, 91], ["clinical virology convulsions", "PROBLEM", 95, 124], ["respiratory symptoms", "PROBLEM", 126, 146], ["minimal", "OBSERVATION_MODIFIER", 154, 161]]], ["When it is known that influenza B is prevalent rapid immunofluorescence diagnostic techniques could prevent unnecessary appendicectomies.VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYMany viruses are difficult to culture in the laboratory and one example-measles-has been considered already.", [["influenza B", "DISEASE", 22, 33], ["influenza B", "ORGANISM", 22, 33], ["measles", "ORGANISM", 257, 264], ["influenza", "PROBLEM", 22, 31], ["unnecessary appendicectomies", "TREATMENT", 108, 136], ["VIRUSES", "PROBLEM", 137, 144], ["THE LABORATORYMany viruses", "PROBLEM", 171, 197], ["culture", "TEST", 215, 222], ["measles", "PROBLEM", 257, 264]]], ["In measles, rapid immunofluorescent diagnosis is simple and highly sensitive from 2-3 days before the eruption to 2-3 days afterwards; this technique has therefore become the method of choice.VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYParainfluenza virus types 4a and 4b are slow growing and the conditions for the haemadsorption technique, necessary for their screening, variable.", [["measles", "DISEASE", 3, 10], ["rapid immunofluorescent diagnosis", "TEST", 12, 45], ["the eruption", "PROBLEM", 98, 110], ["this technique", "TREATMENT", 135, 149], ["VIRUSES", "PROBLEM", 192, 199], ["slow growing", "PROBLEM", 280, 292], ["the haemadsorption technique", "TEST", 316, 344], ["their screening", "TEST", 360, 375], ["slow", "OBSERVATION_MODIFIER", 280, 284], ["growing", "OBSERVATION_MODIFIER", 285, 292]]], ["Their diagnosis by directly staining virus-infected nasopharyngeal cells by immunofluorescence is easily accomplished, provided suitable reagents are available, and should prove to be the method of choice.VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYSimilarly, coronaviruses probably play an important role in human respiratory infection but their cultivation and identification at this stage can only be considered a research procedure because of the cumbersome and insensitive techniques available.", [["nasopharyngeal cells", "ANATOMY", 52, 72], ["respiratory", "ANATOMY", 319, 330], ["respiratory infection", "DISEASE", 319, 340], ["nasopharyngeal cells", "CELL", 52, 72], ["coronaviruses", "ORGANISM", 264, 277], ["human", "ORGANISM", 313, 318], ["infected nasopharyngeal cells", "CELL_TYPE", 43, 72], ["human", "SPECIES", 313, 318], ["human", "SPECIES", 313, 318], ["directly staining virus", "PROBLEM", 19, 42], ["infected nasopharyngeal cells", "PROBLEM", 43, 72], ["immunofluorescence", "TEST", 76, 94], ["coronaviruses", "PROBLEM", 264, 277], ["human respiratory infection", "PROBLEM", 313, 340], ["their cultivation", "TEST", 345, 362], ["a research procedure", "TREATMENT", 419, 439], ["infected", "OBSERVATION_MODIFIER", 43, 51], ["nasopharyngeal cells", "OBSERVATION", 52, 72], ["respiratory", "ANATOMY", 319, 330], ["infection", "OBSERVATION", 331, 340]]], ["Antisera were prepared against two of these viruses known to be associated with human illness, OC38 and 229E, and used to identify these agents in cells shed from the respiratory tract of human volunteers who had been previously inoculated with them.", [["cells", "ANATOMY", 147, 152], ["respiratory tract", "ANATOMY", 167, 184], ["human illness", "DISEASE", 80, 93], ["Antisera", "ORGANISM_SUBSTANCE", 0, 8], ["human", "ORGANISM", 80, 85], ["cells", "CELL", 147, 152], ["respiratory tract", "ORGANISM_SUBDIVISION", 167, 184], ["human", "ORGANISM", 188, 193], ["volunteers", "ORGANISM", 194, 204], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 188, 193], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 188, 193], ["Antisera", "TREATMENT", 0, 8], ["these viruses", "PROBLEM", 38, 51], ["human illness", "PROBLEM", 80, 93], ["viruses", "OBSERVATION", 44, 51], ["respiratory tract", "ANATOMY", 167, 184]]], ["Figure 79 shows the appearance of a cell infected with OC38 in an NPS.", [["cell", "ANATOMY", 36, 40], ["cell", "CELL", 36, 40], ["Figure", "TEST", 0, 6], ["a cell infected", "PROBLEM", 34, 49], ["an NPS", "TREATMENT", 63, 69], ["cell", "OBSERVATION", 36, 40], ["infected", "OBSERVATION_MODIFIER", 41, 49], ["NPS", "OBSERVATION_MODIFIER", 66, 69]]], ["Virusinfected cells were only found in those volunteers with symptoms (Mclntosh et aL y 1978) .", [["Virusinfected cells", "ANATOMY", 0, 19], ["Virusinfected cells", "CELL", 0, 19], ["volunteers", "ORGANISM", 45, 55], ["Virusinfected cells", "CELL_TYPE", 0, 19], ["Virusinfected cells", "PROBLEM", 0, 19], ["symptoms", "PROBLEM", 61, 69]]], ["These experiments clearly demonstrate that the now routine method of identifying respiratory viruses by immunofluorescence in cells shed into the respiratory tract would be suitable for coronaviruses and is at this stage the only effective method for their rapid diagnosis.VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYThe new group, rotaviruses, is now known to be responsible for 40 per cent of acute diarrhoea in infants and children (Birch et ai, 1977) .VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYThe diagnosis of infection by this virus is usually made at present by electron microscopy, enzyme-linked immunosorbent assay (ELISA) or immunofluorescence.", [["cells", "ANATOMY", 126, 131], ["respiratory tract", "ANATOMY", 146, 163], ["diarrhoea", "DISEASE", 405, 414], ["infection", "DISEASE", 525, 534], ["cells", "CELL", 126, 131], ["respiratory tract", "ORGANISM_SUBDIVISION", 146, 163], ["coronaviruses", "ORGANISM", 186, 199], ["rotaviruses", "ORGANISM", 336, 347], ["infants", "ORGANISM", 418, 425], ["children", "ORGANISM", 430, 438], ["infants", "SPECIES", 418, 425], ["children", "SPECIES", 430, 438], ["respiratory viruses", "PROBLEM", 81, 100], ["immunofluorescence in cells", "PROBLEM", 104, 131], ["coronaviruses", "PROBLEM", 186, 199], ["rotaviruses", "PROBLEM", 336, 347], ["acute diarrhoea", "PROBLEM", 399, 414], ["infection", "PROBLEM", 525, 534], ["this virus", "PROBLEM", 538, 548], ["electron microscopy", "TEST", 579, 598], ["enzyme", "TEST", 600, 606], ["immunosorbent assay", "TEST", 614, 633], ["ELISA", "TEST", 635, 640], ["immunofluorescence", "PROBLEM", 645, 663], ["respiratory viruses", "OBSERVATION", 81, 100], ["respiratory tract", "ANATOMY", 146, 163], ["new", "OBSERVATION_MODIFIER", 325, 328], ["rotaviruses", "OBSERVATION", 336, 347], ["acute", "OBSERVATION_MODIFIER", 399, 404], ["diarrhoea", "OBSERVATION", 405, 414], ["infection", "OBSERVATION", 525, 534]]], ["However, the first method enables the virus to be identified within an hour but an electron microscope is not available to all nor is it particularly suitable for handling large numbers of specimens.", [["specimens", "ANATOMY", 189, 198], ["specimens", "CANCER", 189, 198], ["the virus", "PROBLEM", 34, 43], ["an electron microscope", "TEST", 80, 102]]], ["Although the virus has not as yet been cultured it is known to penetrate tissue culture cells and give one abortive cycle.", [["tissue culture cells", "ANATOMY", 73, 93], ["tissue culture cells", "CELL", 73, 93], ["tissue culture cells", "CELL_TYPE", 73, 93], ["the virus", "PROBLEM", 9, 18], ["tissue culture cells", "TEST", 73, 93], ["virus", "OBSERVATION", 13, 18]]], ["Tissue cultures may be so infected and examined the following day by immunofluorescence.", [["Tissue cultures", "ANATOMY", 0, 15], ["Tissue cultures", "CELL", 0, 15], ["Tissue cultures", "TEST", 0, 15], ["infected", "PROBLEM", 26, 34], ["infected", "OBSERVATION", 26, 34]]], ["The sensitivity of the method may be enhanced by centrifugation of faecal 298 Application ofimmunofluorescence technique to clinical virology supernatant on to the tissue culture cells at low speeds (Banatvala et al., 1975) ; the presence of trypsin has also made the method more sensitive by increasing the number of infective centres in the first cycle (Moosai et al, 1979) .VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYThe diagnosis of hepatitis B can now be made rapidly and effectively by many techniques and immunofluorescence has no part to play at this stage.", [["supernatant", "ANATOMY", 142, 153], ["tissue culture cells", "ANATOMY", 164, 184], ["hepatitis B", "DISEASE", 442, 453], ["tissue culture cells", "CELL", 164, 184], ["trypsin", "GENE_OR_GENE_PRODUCT", 242, 249], ["hepatitis B", "ORGANISM", 442, 453], ["tissue culture cells", "CELL_LINE", 164, 184], ["trypsin", "PROTEIN", 242, 249], ["Application ofimmunofluorescence technique", "TREATMENT", 78, 120], ["clinical virology", "TEST", 124, 141], ["the tissue culture cells", "TEST", 160, 184], ["trypsin", "PROBLEM", 242, 249], ["hepatitis B", "PROBLEM", 442, 453], ["immunofluorescence", "TEST", 517, 535], ["infective", "OBSERVATION", 318, 327], ["hepatitis", "OBSERVATION", 442, 451]]], ["However, though rarely a matter of rapid diagnosis, liver biopsy material can be effectively examined by immunofluorescence (Brzosko et al, 1973) .", [["liver biopsy", "ANATOMY", 52, 64], ["liver biopsy material", "MULTI-TISSUE_STRUCTURE", 52, 73], ["liver biopsy material", "TEST", 52, 73], ["liver", "ANATOMY", 52, 57], ["biopsy", "OBSERVATION", 58, 64]]], ["Until the viruses of hepatitis A, non-A and non-B are more clearly defined it is difficult to see a role for immunofluorescence in their diagnosis.VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYThe examples only serve to illustrate how immunofluorescence may be used to identify viruses for which current culture techniques are inefficient and at the same time provide the clinician with a rapid aetiological diagnosis.PREVENTION OF WARD CROSS-INFECTION WITH VIRUSESFrom personal observations even without planned scientific studies it is well known that if a patient with a respiratory infection is placed next to another patient, the latter will often acquire the infection.", [["respiratory", "ANATOMY", 576, 587], ["hepatitis A", "DISEASE", 21, 32], ["respiratory infection", "DISEASE", 576, 597], ["infection", "DISEASE", 667, 676], ["hepatitis A", "ORGANISM", 21, 32], ["non-A", "CANCER", 34, 39], ["non-B", "CELL", 44, 49], ["patient", "ORGANISM", 561, 568], ["patient", "ORGANISM", 624, 631], ["patient", "SPECIES", 561, 568], ["patient", "SPECIES", 624, 631], ["hepatitis A", "SPECIES", 21, 32], ["hepatitis A", "PROBLEM", 21, 32], ["immunofluorescence", "TEST", 109, 127], ["viruses", "PROBLEM", 280, 287], ["current culture techniques", "TEST", 298, 324], ["WARD CROSS-INFECTION", "PROBLEM", 434, 454], ["scientific studies", "TEST", 515, 533], ["a respiratory infection", "PROBLEM", 574, 597], ["the infection", "PROBLEM", 663, 676], ["viruses", "OBSERVATION", 10, 17], ["hepatitis", "OBSERVATION", 21, 30], ["INFECTION", "OBSERVATION", 445, 454], ["respiratory", "ANATOMY", 576, 587], ["infection", "OBSERVATION", 588, 597], ["infection", "OBSERVATION", 667, 676]]], ["This is especially true for young children who have not had time to develop immunity to the various frequently occurring virus infections.", [["infections", "DISEASE", 127, 137], ["children", "ORGANISM", 34, 42], ["children", "SPECIES", 34, 42], ["virus infections", "PROBLEM", 121, 137]]], ["A defined study was carried out in a number of paediatric wards to obtain information as to which viruses were involved, the severity of these 'cross-infection illnesses' and the chances of acquiring such infections.", [["infection", "DISEASE", 150, 159], ["infections", "DISEASE", 205, 215], ["A defined study", "TEST", 0, 15], ["these 'cross-infection illnesses", "PROBLEM", 137, 169], ["such infections", "PROBLEM", 200, 215], ["infections", "OBSERVATION", 205, 215]]], ["These studies have been fully reported elsewhere and gave valuable information about a number of viruses, namely respiratory syncytial virus, influenza A and the parainfluenza viruses (Ditchburn et al., 1971; Weightman, Downham and Gardner, 1974; Sims et al, 1975) .", [["respiratory syncytial virus", "DISEASE", 113, 140], ["influenza A and the parainfluenza viruses", "DISEASE", 142, 183], ["respiratory syncytial virus", "ORGANISM", 113, 140], ["influenza A", "ORGANISM", 142, 153], ["parainfluenza viruses", "ORGANISM", 162, 183], ["respiratory syncytial virus", "SPECIES", 113, 140], ["parainfluenza", "SPECIES", 162, 175], ["respiratory syncytial virus", "SPECIES", 113, 140], ["These studies", "TEST", 0, 13], ["viruses", "PROBLEM", 97, 104], ["respiratory syncytial virus", "PROBLEM", 113, 140], ["influenza", "PROBLEM", 142, 151], ["the parainfluenza viruses", "PROBLEM", 158, 183], ["respiratory syncytial", "ANATOMY", 113, 134]]], ["For the first time immunofluorescent techniques were used in such studies to define these agents and examine staff and well patients for carriage of virus.", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["immunofluorescent techniques", "TEST", 19, 47], ["such studies", "TEST", 61, 73], ["these agents", "TREATMENT", 84, 96], ["carriage of virus", "PROBLEM", 137, 154]]], ["Table 16 clearly shows the enormity of the problem, over a 4-year period.Prevention of ward cross-infection with viruses 299Respiratory syncytial virus infections were the most severe and one notes with dismay that more than half those acquiring infections had severe lower respiratory tract illnesses which required intensive therapy.", [["lower respiratory tract", "ANATOMY", 268, 291], ["299Respiratory syncytial virus infections", "DISEASE", 121, 162], ["infections", "DISEASE", 246, 256], ["lower respiratory tract illnesses", "DISEASE", 268, 301], ["viruses 299Respiratory syncytial virus", "ORGANISM", 113, 151], ["tract", "ORGANISM_SUBDIVISION", 286, 291], ["299Respiratory syncytial virus", "SPECIES", 121, 151], ["299Respiratory syncytial virus", "SPECIES", 121, 151], ["ward cross-infection", "PROBLEM", 87, 107], ["viruses 299Respiratory syncytial virus infections", "PROBLEM", 113, 162], ["severe lower respiratory tract illnesses", "PROBLEM", 261, 301], ["intensive therapy", "TREATMENT", 317, 334], ["ward cross-infection", "OBSERVATION", 87, 107], ["most severe", "OBSERVATION_MODIFIER", 172, 183], ["severe", "OBSERVATION_MODIFIER", 261, 267], ["lower", "ANATOMY_MODIFIER", 268, 273], ["respiratory tract", "ANATOMY", 274, 291]]], ["The position was in fact far worse as all the severe infections occurred under the age of 1 year and in this age range the child who became infected stood a 70 per cent chance of acquiring a very severe lower respiratory tract infection, usually bronchiolitis.", [["lower respiratory tract", "ANATOMY", 203, 226], ["infections", "DISEASE", 53, 63], ["lower respiratory tract infection", "DISEASE", 203, 236], ["bronchiolitis", "DISEASE", 246, 259], ["child", "ORGANISM", 123, 128], ["lower", "ORGANISM_SUBDIVISION", 203, 208], ["respiratory tract", "ORGANISM_SUBDIVISION", 209, 226], ["child", "SPECIES", 123, 128], ["the severe infections", "PROBLEM", 42, 63], ["a very severe lower respiratory tract infection", "PROBLEM", 189, 236], ["bronchiolitis", "PROBLEM", 246, 259], ["position", "OBSERVATION_MODIFIER", 4, 12], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["infections", "OBSERVATION", 53, 63], ["infected", "OBSERVATION", 140, 148], ["very", "OBSERVATION_MODIFIER", 191, 195], ["severe", "OBSERVATION_MODIFIER", 196, 202], ["lower", "ANATOMY_MODIFIER", 203, 208], ["respiratory tract", "ANATOMY", 209, 226], ["infection", "OBSERVATION", 227, 236], ["bronchiolitis", "OBSERVATION", 246, 259]]], ["Anecdotes may help to emphasize the problem.", [["Anecdotes", "TREATMENT", 0, 9]]], ["An infant aged 3 months, immobile because of a fractured femur, was nursed in a two-bedded cubicle and, during the winter respiratory rush, a child with a rapidly diagnosed respiratory syncytial virus croup was admitted to the free bed, which was the only one available.", [["femur", "ANATOMY", 57, 62], ["respiratory rush", "DISEASE", 122, 138], ["respiratory syncytial virus croup", "DISEASE", 173, 206], ["femur", "ORGAN", 57, 62], ["infant", "SPECIES", 3, 9], ["respiratory syncytial virus", "SPECIES", 173, 200], ["a fractured femur", "PROBLEM", 45, 62], ["a rapidly diagnosed respiratory syncytial virus croup", "PROBLEM", 153, 206], ["fractured", "OBSERVATION", 47, 56], ["femur", "ANATOMY", 57, 62], ["respiratory", "ANATOMY", 173, 184], ["syncytial virus", "OBSERVATION", 185, 200]]], ["Within 5 days the patient with the fractured femur had acquired a proven respiratory syncytial virus bronchiolitis by cross-infection.Influenza AInfluenza A also plays an important role in cross-infection.", [["femur", "ANATOMY", 45, 50], ["respiratory syncytial virus", "DISEASE", 73, 100], ["bronchiolitis", "DISEASE", 101, 114], ["AInfluenza A", "CHEMICAL", 144, 156], ["patient", "ORGANISM", 18, 25], ["femur", "ORGAN", 45, 50], ["Influenza AInfluenza A", "ORGANISM", 134, 156], ["patient", "SPECIES", 18, 25], ["Influenza", "SPECIES", 134, 143], ["the fractured femur", "PROBLEM", 31, 50], ["a proven respiratory syncytial virus bronchiolitis", "PROBLEM", 64, 114], ["Influenza", "PROBLEM", 134, 143], ["fractured", "OBSERVATION", 35, 44], ["femur", "ANATOMY", 45, 50], ["respiratory syncytial virus bronchiolitis", "OBSERVATION", 73, 114]]], ["It would appear from Table 16 that it is relatively unimportant with fewer severe lower respiratory tract infections.", [["lower respiratory tract", "ANATOMY", 82, 105], ["respiratory tract infections", "DISEASE", 88, 116], ["lower", "ORGANISM_SUBDIVISION", 82, 87], ["respiratory tract", "ORGANISM_SUBDIVISION", 88, 105], ["fewer severe lower respiratory tract infections", "PROBLEM", 69, 116], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["lower", "ANATOMY_MODIFIER", 82, 87], ["respiratory tract", "ANATOMY", 88, 105], ["infections", "OBSERVATION", 106, 116]]], ["In fact, the latter illnesses were all pneumonias and a number of these patients died.", [["pneumonias", "DISEASE", 39, 49], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["the latter illnesses", "PROBLEM", 9, 29], ["all pneumonias", "PROBLEM", 35, 49], ["all", "OBSERVATION_MODIFIER", 35, 38], ["pneumonias", "OBSERVATION", 39, 49]]], ["The patients with influenza A infection admitted to hospital are usually older than those admitted with respiratory syncytial virus infection.", [["influenza A infection", "DISEASE", 18, 39], ["respiratory syncytial virus infection", "DISEASE", 104, 141], ["patients", "ORGANISM", 4, 12], ["influenza A", "ORGANISM", 18, 29], ["respiratory syncytial virus", "ORGANISM", 104, 131], ["patients", "SPECIES", 4, 12], ["respiratory syncytial virus", "SPECIES", 104, 131], ["influenza A infection", "PROBLEM", 18, 39], ["respiratory syncytial virus infection", "PROBLEM", 104, 141], ["influenza", "OBSERVATION", 18, 27], ["infection", "OBSERVATION", 30, 39], ["respiratory", "ANATOMY", 104, 115], ["syncytial virus", "OBSERVATION", 116, 131]]], ["The usual reason for admission is a febrile convulsion.", [["febrile convulsion", "DISEASE", 36, 54], ["a febrile convulsion", "PROBLEM", 34, 54]]], ["Frequently by the time they have been admitted to hospital they have recovered from their convulsion and have lost their fever.", [["convulsion", "DISEASE", 90, 100], ["fever", "DISEASE", 121, 126], ["their convulsion", "PROBLEM", 84, 100], ["their fever", "PROBLEM", 115, 126]]], ["Being relatively well at this stage, they run around the ward coughing and secreting virus over patients who can ill afford to acquire infections, such as patients with mucoviscidosis, congenital heart disease or leukaemia or on immunosuppressive therapy.", [["heart", "ANATOMY", 196, 201], ["leukaemia", "ANATOMY", 213, 222], ["infections", "DISEASE", 135, 145], ["mucoviscidosis", "DISEASE", 169, 183], ["congenital heart disease", "DISEASE", 185, 209], ["leukaemia", "DISEASE", 213, 222], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 155, 163], ["heart", "ORGAN", 196, 201], ["leukaemia", "CANCER", 213, 222], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 155, 163], ["the ward coughing", "PROBLEM", 53, 70], ["secreting virus", "PROBLEM", 75, 90], ["infections", "PROBLEM", 135, 145], ["mucoviscidosis", "PROBLEM", 169, 183], ["congenital heart disease", "PROBLEM", 185, 209], ["leukaemia", "PROBLEM", 213, 222], ["immunosuppressive therapy", "TREATMENT", 229, 254], ["infections", "OBSERVATION", 135, 145], ["heart", "ANATOMY", 196, 201], ["disease", "OBSERVATION", 202, 209], ["leukaemia", "OBSERVATION", 213, 222]]], ["It is the latter group of patients who fare badly when acquiring influenza A. Unfortunately, toddlers are not respecters of cubicles, which to them are no barrier.", [["influenza", "DISEASE", 65, 74], ["patients", "ORGANISM", 26, 34], ["cubicles", "CANCER", 124, 132], ["patients", "SPECIES", 26, 34]]], ["It is essential that ward staff realize that febrile convulsions in 50 per cent of cases can be of viral origin and when influenza A is prevalent the percentage of febrile convulsions due to this cause and admitted to hospital rises to very much higher than average (Stokes et ai, 1976) .", [["febrile convulsions", "DISEASE", 45, 64], ["influenza A", "DISEASE", 121, 132], ["convulsions", "DISEASE", 172, 183], ["febrile convulsions", "PROBLEM", 45, 64], ["viral origin", "PROBLEM", 99, 111], ["influenza", "PROBLEM", 121, 130], ["febrile convulsions", "PROBLEM", 164, 183]]], ["They must also realize the serious consequences of cross-infection in debilitated children.", [["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90]]], ["Rapid diagnosis by immunofluorescence has provided a method for identifying influenza A within 3 hours of admission to hospital.", [["influenza A", "DISEASE", 76, 87], ["influenza A", "SPECIES", 76, 87], ["immunofluorescence", "TEST", 19, 37], ["influenza", "PROBLEM", 76, 85]]], ["Now that the risks of influenza A cross-infections are known, every child with a febrile convulsion admitted to hospital when influenza A is prevalent must be examined and also confined to a cubicle until the result of the rapid diagnostic test is available.", [["febrile convulsion", "DISEASE", 81, 99], ["influenza A", "DISEASE", 126, 137], ["cubicle", "CANCER", 191, 198], ["influenza A cross-infections", "PROBLEM", 22, 50], ["a febrile convulsion", "PROBLEM", 79, 99], ["influenza A", "PROBLEM", 126, 137], ["the rapid diagnostic test", "TEST", 219, 244], ["influenza", "OBSERVATION", 22, 31]]], ["It is only in this way that tragic deaths from influenza in debilitated children can be avoided.Influenza AParainfluenza virus is also spread easily and may cause severe lower respiratory tract infection; once again the severest infections are in debilitated children.", [["lower respiratory tract", "ANATOMY", 170, 193], ["deaths", "DISEASE", 35, 41], ["influenza", "DISEASE", 47, 56], ["Influenza AParainfluenza virus", "DISEASE", 96, 126], ["lower respiratory tract infection", "DISEASE", 170, 203], ["infections", "DISEASE", 229, 239], ["children", "ORGANISM", 72, 80], ["Influenza AParainfluenza virus", "ORGANISM", 96, 126], ["tract", "ORGANISM_SUBDIVISION", 188, 193], ["children", "ORGANISM", 259, 267], ["children", "SPECIES", 72, 80], ["Influenza AParainfluenza virus", "SPECIES", 96, 126], ["children", "SPECIES", 259, 267], ["Influenza AParainfluenza virus", "SPECIES", 96, 126], ["tragic deaths", "PROBLEM", 28, 41], ["influenza", "PROBLEM", 47, 56], ["Influenza AParainfluenza virus", "PROBLEM", 96, 126], ["severe lower respiratory tract infection", "PROBLEM", 163, 203], ["the severest infections", "PROBLEM", 216, 239], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["lower", "ANATOMY_MODIFIER", 170, 175], ["respiratory tract", "ANATOMY", 176, 193], ["infection", "OBSERVATION", 194, 203], ["severest", "OBSERVATION_MODIFIER", 220, 228], ["infections", "OBSERVATION", 229, 239]]], ["The toddler will again cause the problems though he is not usually as well on admission as the child following febrile convulsion; the predominant cause of admission with this group of viruses will be croup.VIRUS DIAGNOSIS IN AREAS DISTANT FROM A VIRUS LABORATORYSlides dried and fixed for staining by the fluorescent antibody technique are suitable for transporting over long distances.", [["febrile convulsion", "DISEASE", 111, 129], ["croup", "DISEASE", 201, 206], ["the problems", "PROBLEM", 29, 41], ["febrile convulsion", "PROBLEM", 111, 129], ["viruses", "PROBLEM", 185, 192], ["croup", "PROBLEM", 201, 206], ["A VIRUS LABORATORYSlides", "TREATMENT", 245, 269], ["the fluorescent antibody technique", "TREATMENT", 302, 336], ["VIRUS", "OBSERVATION", 247, 252]]], ["If preparations of secretions, scrapings, biopsies and post-mortem material, etc. are dried and fixed on slides in the usual way they can be sent to a virus laboratory to be diagnosed by immunofluorescence.", [["secretions", "ANATOMY", 19, 29], ["scrapings", "ANATOMY", 31, 40], ["biopsies", "ANATOMY", 42, 50], ["secretions", "ORGANISM_SUBSTANCE", 19, 29], ["scrapings", "TISSUE", 31, 40], ["biopsies", "TISSUE", 42, 50], ["secretions", "PROBLEM", 19, 29], ["scrapings", "TEST", 31, 40], ["biopsies", "TEST", 42, 50], ["post-mortem material", "TEST", 55, 75]]], ["Minimal resources are required at the originating centre where staff can readily be trained in the production of satisfactory slide preparations.VIRUS DIAGNOSIS IN AREAS DISTANT FROM A VIRUS LABORATORYA scheme was initiated some years ago with the Medical Research Council Nutritional Unit in Uganda.", [["A VIRUS LABORATORYA scheme", "TREATMENT", 183, 209], ["resources", "OBSERVATION", 8, 17], ["VIRUS", "OBSERVATION", 185, 190]]], ["A small batch of slides arrived by air within 18 hours and 1 child with pneumonia was shown to have a parainfluenza virus type 3 infection.", [["pneumonia", "DISEASE", 72, 81], ["parainfluenza virus type 3 infection", "DISEASE", 102, 138], ["parainfluenza virus type 3", "ORGANISM", 102, 128], ["parainfluenza virus", "SPECIES", 102, 121], ["A small batch of slides", "PROBLEM", 0, 23], ["pneumonia", "PROBLEM", 72, 81], ["a parainfluenza virus type 3 infection", "PROBLEM", 100, 138], ["small", "OBSERVATION_MODIFIER", 2, 7], ["pneumonia", "OBSERVATION", 72, 81], ["parainfluenza virus", "OBSERVATION", 102, 121], ["infection", "OBSERVATION", 129, 138]]], ["Figure 81 shows how a slide of a specimen which has been well prepared and well fixed can be stained satisfactorily by immunofluorescence after having travelled a long distance.", [["specimen", "ANATOMY", 33, 41]]], ["For obvious reasons this planned investigation came to an abrupt end in Uganda but occasional specimens still arrive from tropical countries for diagnosis, for example 5 out of 8 specimens from children with pneumonia in Kenya proved to be influenza A.VIRUS DIAGNOSIS IN AREAS DISTANT FROM A VIRUS LABORATORYThese successes inspired us to attempt a similar study in an area closer to home without a virus diagnostic service (Downham et ai, 1974) .", [["specimens", "ANATOMY", 94, 103], ["specimens", "ANATOMY", 179, 188], ["pneumonia", "DISEASE", 208, 217], ["influenza", "DISEASE", 240, 249], ["specimens", "CANCER", 94, 103], ["specimens", "CANCER", 179, 188], ["children", "ORGANISM", 194, 202], ["children", "SPECIES", 194, 202], ["occasional specimens", "PROBLEM", 83, 103], ["pneumonia", "PROBLEM", 208, 217], ["influenza", "PROBLEM", 240, 249], ["a similar study", "TEST", 347, 362], ["pneumonia", "OBSERVATION", 208, 217]]], ["West Cumbria, a rural area, has a single hospital admitting all children from that region of the country.", [["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72]]], ["All children admitted with respiratory illness were examined and specimens taken by ward staff and sent to the local pathology laboratory which had no virus facilities.", [["respiratory", "ANATOMY", 27, 38], ["specimens", "ANATOMY", 65, 74], ["respiratory illness", "DISEASE", 27, 46], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["respiratory illness", "PROBLEM", 27, 46], ["respiratory", "ANATOMY", 27, 38], ["illness", "OBSERVATION", 39, 46]]], ["Table 17 shows the results of the study.", [["the study", "TEST", 30, 39]]], ["All the respiratory viruses found in conurbations were also found in West Cumbria causing the same illnesses.", [["respiratory viruses", "DISEASE", 8, 27], ["All the respiratory viruses", "PROBLEM", 0, 27], ["the same illnesses", "PROBLEM", 90, 108], ["respiratory", "ANATOMY", 8, 19], ["viruses", "OBSERVATION", 20, 27]]], ["Specimens were sent by post and always reached Newcastle within 24 hours of dispatch.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9]]], ["This proved very satisfactory for an area which previously had no virus diagnostic service and indeed under the circumstances could still be considered as rapid virus diagnosis.RAPID DIAGNOSIS IN EPIDEMIOLOGYVirus epidemiological studies in the community are difficult and expensive to perform.", [["rapid virus diagnosis", "PROBLEM", 155, 176], ["epidemiological studies", "TEST", 214, 237]]], ["Collection of specimens, their transportation under suitable conditions to the laboratory for virus isolation and the sampling of all illnesses from the most trivial to the most severe in all age groups and both sexes have proved to be the chief stumbling blocks.", [["specimens", "ANATOMY", 14, 23], ["specimens", "CANCER", 14, 23], ["Collection of specimens", "TEST", 0, 23], ["virus isolation", "TREATMENT", 94, 109], ["all illnesses", "PROBLEM", 130, 143], ["most severe", "OBSERVATION_MODIFIER", 173, 184]]], ["To obtain some idea of the virus epidemiology of an area, the total admission of patients to the hospital covering that area can be investigated.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89]]], ["Hospital admissions, however, can only reflect the viruses present in the community as only the most severely ill patients are admitted, but nevertheless much useful information can be obtained.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["the viruses", "PROBLEM", 47, 58], ["viruses", "OBSERVATION", 51, 58]]], ["Many such surveys have been carried out both in Newcastle and in various parts of the country (Report by the Medical Research Council, 1978) ; the most recent report gave valuable information on the occurrence of epidemics of respiratory syncytial virus, influenza A and B and parainfluenza viruses over a 6-year period, the interrelationships of these viruses and the effect of climatic conditions, and admission rates to hospital (Martin, Gardner and McQuillin, 1978) .", [["respiratory syncytial virus", "DISEASE", 226, 253], ["influenza A and B and parainfluenza viruses", "DISEASE", 255, 298], ["respiratory syncytial virus", "ORGANISM", 226, 253], ["influenza A", "ORGANISM", 255, 266], ["B", "GENE_OR_GENE_PRODUCT", 271, 272], ["parainfluenza viruses", "ORGANISM", 277, 298], ["parainfluenza", "SPECIES", 277, 290], ["respiratory syncytial virus", "SPECIES", 226, 253], ["respiratory syncytial virus", "PROBLEM", 226, 253], ["influenza A", "PROBLEM", 255, 266], ["parainfluenza viruses", "PROBLEM", 277, 298], ["these viruses", "PROBLEM", 347, 360], ["respiratory syncytial virus", "OBSERVATION", 226, 253], ["parainfluenza viruses", "OBSERVATION", 277, 298], ["viruses", "OBSERVATION", 353, 360]]], ["The use of immunofluorescence for rapid virus diagnosis made possible the investigation of a greater number of patients and the diagnosis of a wider range of viruses than could be achieved by routine methods.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["immunofluorescence", "TEST", 11, 29], ["rapid virus diagnosis", "TEST", 34, 55], ["a wider range of viruses", "PROBLEM", 141, 165]]], ["The study was based on total hospital admissions and included 2311 identifications by immunofluorescence of respiratory syncytial virus, parainfluenza viruses 1, 2 and 3 and influenza A alone.RAPID DIAGNOSIS IN EPIDEMIOLOGYFurther knowledge of community virus epidemiology might well be obtained by using the immunofluorescence technique of collection and transportation as outlined for specimens coming from a distance.", [["specimens", "ANATOMY", 387, 396], ["respiratory syncytial virus", "DISEASE", 108, 135], ["parainfluenza viruses", "DISEASE", 137, 158], ["respiratory syncytial virus", "ORGANISM", 108, 135], ["parainfluenza viruses 1", "ORGANISM", 137, 160], ["3", "GENE_OR_GENE_PRODUCT", 168, 169], ["respiratory syncytial virus", "SPECIES", 108, 135], ["parainfluenza", "SPECIES", 137, 150], ["respiratory syncytial virus", "SPECIES", 108, 135], ["The study", "TEST", 0, 9], ["immunofluorescence", "TEST", 86, 104], ["respiratory syncytial virus", "PROBLEM", 108, 135], ["parainfluenza viruses", "PROBLEM", 137, 158], ["influenza", "PROBLEM", 174, 183], ["community virus epidemiology", "PROBLEM", 244, 272], ["the immunofluorescence technique", "TEST", 305, 337], ["specimens", "TEST", 387, 396], ["respiratory", "ANATOMY", 108, 119], ["syncytial virus", "OBSERVATION", 120, 135], ["parainfluenza viruses", "OBSERVATION", 137, 158]]], ["The specimens could be prepared in a small side room in the general practitioner's surgery with a nurse or health visitor collecting the specimens.", [["specimens", "ANATOMY", 4, 13], ["specimens", "ANATOMY", 137, 146]]], ["If the general practice is near the hospital the secretion itself, transported on melting ice, could be taken to the laboratory-the time scale here is less critical if isolation of viruses is not attempted and only specific antigen is being identified.RAPID DIAGNOSIS IN EPIDEMIOLOGYA further epidemiological use of the fluorescent antibody technique can be confidently anticipated for assessment of live respiratory vaccines.", [["respiratory", "ANATOMY", 405, 416], ["melting ice", "TREATMENT", 82, 93], ["viruses", "PROBLEM", 181, 188], ["the fluorescent antibody technique", "TREATMENT", 316, 350], ["assessment", "TEST", 386, 396], ["live respiratory vaccines", "TREATMENT", 400, 425], ["viruses", "OBSERVATION", 181, 188]]], ["Great difficulties have been experienced in making a live respiratory syncytial virus vaccine so urgently needed for infant protection.", [["respiratory syncytial virus", "DISEASE", 58, 85], ["respiratory syncytial virus", "ORGANISM", 58, 85], ["Great difficulties", "PROBLEM", 0, 18], ["a live respiratory syncytial virus vaccine", "TREATMENT", 51, 93], ["infant protection", "TREATMENT", 117, 134]]], ["Control of such a vaccine, when produced both in the investigational stage and the practical stage as regards infectivity, spread and length of time of excretion, will prove to be invaluable.RAPID DIAGNOSIS IN EPIDEMIOLOGYOther respiratory vaccines such as influenza A are already available and their control will similarly be simplified by these techniques.RAPID DIAGNOSIS IN EPIDEMIOLOGYThe next few years may see the development of a new class of highly specific monoclonal viral antibodies.", [["monoclonal viral antibodies", "PROTEIN", 466, 493], ["a vaccine", "TREATMENT", 16, 25], ["infectivity", "PROBLEM", 110, 121], ["EPIDEMIOLOGYOther respiratory vaccines", "TREATMENT", 210, 248], ["influenza A", "PROBLEM", 257, 268], ["highly specific monoclonal viral antibodies", "PROBLEM", 450, 493], ["respiratory vaccines", "OBSERVATION", 228, 248], ["monoclonal viral antibodies", "OBSERVATION", 466, 493]]], ["Minor degrees of antigenic variation might be detected directly for viruses in patients' secretions when changes occur in current antigen types.", [["secretions", "ANATOMY", 89, 99], ["patients", "ORGANISM", 79, 87], ["secretions", "ORGANISM_SUBDIVISION", 89, 99], ["patients", "SPECIES", 79, 87], ["antigenic variation", "PROBLEM", 17, 36], ["viruses", "PROBLEM", 68, 75], ["degrees", "OBSERVATION_MODIFIER", 6, 13], ["antigenic variation", "OBSERVATION", 17, 36]]], ["The method might also be adapted to differentiate between vaccine and wild virus strains.", [["wild virus strains", "ORGANISM", 70, 88], ["vaccine", "TREATMENT", 58, 65], ["wild virus strains", "PROBLEM", 70, 88]]], ["The future is alive with many exciting epidemiological developments employing these newer methods.IMMUNOFLUORESCENCE AS A LABORATORY AIDIt has already been stated that wide-scale epidemiological studies on respiratory virus infections would have been almost impossible if every virus needed to be cultured and identified by conventional means.", [["respiratory virus infections", "DISEASE", 206, 234], ["respiratory virus", "ORGANISM", 206, 223], ["respiratory virus", "SPECIES", 206, 223], ["respiratory virus infections", "PROBLEM", 206, 234], ["every virus", "PROBLEM", 272, 283]]], ["Virus culture, however, still takes place mainly when the specimen submitted is unsuitable for immunofluorescence, for example when there are too few cells in the secretion or a throat swab has been submitted instead of a secretion.", [["specimen", "ANATOMY", 58, 66], ["cells", "ANATOMY", 150, 155], ["throat swab", "ANATOMY", 178, 189], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 150, 155], ["Virus culture", "TEST", 0, 13], ["the specimen", "TEST", 54, 66], ["immunofluorescence", "TEST", 95, 113], ["too few cells", "PROBLEM", 142, 155], ["the secretion", "PROBLEM", 159, 172], ["a throat swab", "TEST", 176, 189], ["throat", "ANATOMY", 178, 184]]], ["Under these circumstances, an agent causing a suspicious cytopathic effect can be immediately identified by immunofluorescence by scraping the cells off the culture tube, placing them on to a slide and staining in the usual way.", [["cells", "ANATOMY", 143, 148], ["culture tube", "ANATOMY", 157, 169], ["cells", "CELL", 143, 148], ["tube", "TISSUE", 165, 169], ["an agent", "TREATMENT", 27, 35], ["a suspicious cytopathic effect", "PROBLEM", 44, 74], ["immunofluorescence", "TEST", 108, 126], ["the culture tube", "TREATMENT", 153, 169], ["suspicious", "OBSERVATION_MODIFIER", 46, 56], ["cytopathic", "OBSERVATION", 57, 67], ["culture tube", "OBSERVATION", 157, 169]]], ["This identifies the agent immediately without the necessity for a long and unsatisfactory neutralization test such as for respiratory syncytial virus or for a fastidious haemadsorption inhibition test for the identification of a haemadsorption virus.IMMUNOFLUORESCENCE AS A LABORATORY AIDSince the initial description of immunofluorescence by Coons, Creech and Jones in 1941 the method has evolved from an academic technique of unreliable clinical value to a routine bedside investigation.", [["respiratory syncytial virus", "DISEASE", 122, 149], ["haemadsorption", "DISEASE", 229, 243], ["respiratory syncytial virus", "ORGANISM", 122, 149], ["respiratory syncytial virus", "SPECIES", 122, 149], ["a long and unsatisfactory neutralization test", "TEST", 64, 109], ["respiratory syncytial virus", "PROBLEM", 122, 149], ["a fastidious haemadsorption inhibition test", "TEST", 157, 200], ["a haemadsorption virus", "PROBLEM", 227, 249], ["a routine bedside investigation", "TEST", 457, 488]]]], "PMC5678787": [["IntroductionHuman noroviruses (huNoV) are the most frequent causative agent of acute gastroenteritis worldwide, responsible for over 30% of all cases, subsequently resulting in over 200,000 deaths per annum [1].", [["gastroenteritis", "DISEASE", 85, 100], ["deaths", "DISEASE", 190, 196], ["IntroductionHuman noroviruses", "ORGANISM", 0, 29], ["huNoV", "ORGANISM", 31, 36], ["huNoV", "SPECIES", 31, 36], ["IntroductionHuman noroviruses", "PROBLEM", 0, 29], ["acute gastroenteritis", "PROBLEM", 79, 100], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["gastroenteritis", "OBSERVATION", 85, 100]]], ["Still, no vaccine or specific antiviral therapy is available to counteract huNoV infections.", [["infections", "DISEASE", 81, 91], ["huNoV", "ORGANISM", 75, 80], ["huNoV", "SPECIES", 75, 80], ["vaccine", "TREATMENT", 10, 17], ["specific antiviral therapy", "TREATMENT", 21, 47], ["huNoV infections", "PROBLEM", 75, 91], ["no", "UNCERTAINTY", 7, 9]]], ["Noroviruses are divided into seven different genogroups (GI-GVII) and further subdivided into numerous genotypes [2].", [["Noroviruses", "PROBLEM", 0, 11], ["GI-GVII)", "TREATMENT", 57, 65]]], ["Noroviruses grouped into GI, GII and GIV mainly infect humans but also other species, while GV infects mice.", [["GII", "GENE_OR_GENE_PRODUCT", 29, 32], ["GIV", "GENE_OR_GENE_PRODUCT", 37, 40], ["humans", "ORGANISM", 55, 61], ["GV", "ORGANISM", 92, 94], ["mice", "ORGANISM", 103, 107], ["humans", "SPECIES", 55, 61], ["mice", "SPECIES", 103, 107], ["humans", "SPECIES", 55, 61], ["mice", "SPECIES", 103, 107], ["Noroviruses", "PROBLEM", 0, 11], ["GI", "ANATOMY", 25, 27]]], ["The GII genotype 4 (GII.4) cause the majority of infections with novel outbreak strains emerging every 2\u20133 years, likely in a response to an immunological pressure of herd immunity [3\u20135].IntroductionNoroviruses belong to the Caliciviridae family and have a positive-sense single-stranded RNA genome of approximately 7.5 kilobases (kb) (reviewed in [6]).", [["infections", "DISEASE", 49, 59], ["herd", "ORGANISM_SUBDIVISION", 167, 171], ["Noroviruses", "GENE_OR_GENE_PRODUCT", 199, 210], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 225, 238], ["Caliciviridae family", "PROTEIN", 225, 245], ["positive-sense single-stranded RNA genome", "DNA", 257, 298], ["infections", "PROBLEM", 49, 59], ["novel outbreak strains", "PROBLEM", 65, 87], ["infections", "OBSERVATION", 49, 59]]], ["The huNoV genome contains three open reading frames (ORFs), where ORF1 encodes the non-structural proteins (NS1-7) involved in viral replication, ORF 2 encodes the capsid protein and ORF3 encodes a small structural protein.", [["huNoV", "GENE_OR_GENE_PRODUCT", 4, 9], ["ORF1", "GENE_OR_GENE_PRODUCT", 66, 70], ["NS1-7", "GENE_OR_GENE_PRODUCT", 108, 113], ["ORF 2", "GENE_OR_GENE_PRODUCT", 146, 151], ["ORF3", "GENE_OR_GENE_PRODUCT", 183, 187], ["huNoV genome", "DNA", 4, 16], ["open reading frames", "DNA", 32, 51], ["ORFs", "DNA", 53, 57], ["ORF1", "DNA", 66, 70], ["non-structural proteins", "PROTEIN", 83, 106], ["NS1-7", "PROTEIN", 108, 113], ["ORF 2", "DNA", 146, 151], ["capsid protein", "PROTEIN", 164, 178], ["ORF3", "DNA", 183, 187], ["small structural protein", "PROTEIN", 198, 222], ["the non-structural proteins", "TEST", 79, 106], ["NS1", "TEST", 108, 111], ["viral replication", "TREATMENT", 127, 144], ["the capsid protein", "TEST", 160, 178], ["a small structural protein", "PROBLEM", 196, 222], ["huNoV genome", "OBSERVATION", 4, 16], ["viral replication", "OBSERVATION", 127, 144], ["small", "OBSERVATION_MODIFIER", 198, 203], ["structural protein", "OBSERVATION", 204, 222]]], ["Murine noroviruses (MNV) additionally encode an ORF4 from an alternative reading frame located in ORF2, termed virulence factor 1 (VF1), involved in antagonism of the host innate immune response [7].", [["Murine noroviruses", "ORGANISM", 0, 18], ["MNV", "ORGANISM", 20, 23], ["ORF4", "GENE_OR_GENE_PRODUCT", 48, 52], ["ORF2, termed virulence factor 1", "GENE_OR_GENE_PRODUCT", 98, 129], ["VF1", "GENE_OR_GENE_PRODUCT", 131, 134], ["ORF4", "PROTEIN", 48, 52], ["alternative reading frame", "DNA", 61, 86], ["ORF2", "DNA", 98, 102], ["virulence factor 1", "PROTEIN", 111, 129], ["VF1", "PROTEIN", 131, 134], ["Murine", "SPECIES", 0, 6], ["Murine noroviruses", "SPECIES", 0, 18], ["MNV", "SPECIES", 20, 23], ["Murine noroviruses", "PROBLEM", 0, 18], ["an ORF4", "TREATMENT", 45, 52], ["noroviruses", "OBSERVATION", 7, 18]]], ["The 5\u2019 end of the genome contains a short 5 nucleotide untranslated region (UTR) and the 3\u2019end contains a short UTR and poly-A tail (reviewed in [8]).", [["genome", "CELLULAR_COMPONENT", 18, 24], ["5\u2019 end", "DNA", 4, 10], ["5 nucleotide untranslated region", "DNA", 42, 74], ["UTR", "DNA", 76, 79], ["3\u2019end", "DNA", 89, 94], ["short UTR and poly-A tail", "DNA", 106, 131], ["a short 5 nucleotide untranslated region", "PROBLEM", 34, 74], ["genome", "OBSERVATION", 18, 24], ["short", "OBSERVATION_MODIFIER", 36, 41], ["short", "OBSERVATION_MODIFIER", 106, 111]]], ["The norovirus genome is covalently linked at the 5\u2019end with the viral protein VPg (also termed NS5).", [["norovirus", "ORGANISM", 4, 13], ["VPg", "GENE_OR_GENE_PRODUCT", 78, 81], ["norovirus genome", "DNA", 4, 20], ["5\u2019end", "PROTEIN", 49, 54], ["viral protein VPg", "PROTEIN", 64, 81], ["NS5", "PROTEIN", 95, 98], ["The norovirus genome", "PROBLEM", 0, 20], ["the viral protein VPg", "TREATMENT", 60, 81], ["norovirus genome", "OBSERVATION", 4, 20], ["viral protein VPg", "OBSERVATION", 64, 81]]], ["ORF1 is translated from the full-length genomic RNA, whereas ORF2, ORF3, and ORF4 are mainly translated from a VPg linked subgenomic RNA (reviewed in [8]).IntroductionORF1 encodes a large, approximately 200 kDa, polyprotein that is processed by the viral protease NS6, giving rise to 6 mature nonstructural proteins involved in viral replication and several precursor proteins with potentially additional, yet poorly defined functions (reviewed in [8]).", [["ORF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["ORF2", "GENE_OR_GENE_PRODUCT", 61, 65], ["ORF3", "GENE_OR_GENE_PRODUCT", 67, 71], ["ORF4", "GENE_OR_GENE_PRODUCT", 77, 81], ["NS6", "GENE_OR_GENE_PRODUCT", 264, 267], ["ORF1", "DNA", 0, 4], ["full-length genomic RNA", "RNA", 28, 51], ["ORF2", "DNA", 61, 65], ["ORF3", "DNA", 67, 71], ["ORF4", "DNA", 77, 81], ["VPg linked subgenomic RNA", "RNA", 111, 136], ["IntroductionORF1", "PROTEIN", 155, 171], ["viral protease", "PROTEIN", 249, 263], ["NS6", "PROTEIN", 264, 267], ["6 mature nonstructural proteins", "PROTEIN", 284, 315], ["precursor proteins", "PROTEIN", 358, 376], ["ORF1", "TREATMENT", 0, 4], ["ORF3", "TEST", 67, 71], ["ORF4", "TEST", 77, 81], ["a VPg linked subgenomic RNA", "PROBLEM", 109, 136], ["polyprotein", "TREATMENT", 212, 223], ["the viral protease NS6", "TREATMENT", 245, 267], ["mature nonstructural proteins", "PROBLEM", 286, 315], ["viral replication", "TREATMENT", 328, 345], ["several precursor proteins", "PROBLEM", 350, 376], ["subgenomic RNA", "OBSERVATION", 122, 136], ["large", "OBSERVATION_MODIFIER", 182, 187], ["nonstructural proteins", "OBSERVATION", 293, 315], ["viral replication", "OBSERVATION", 328, 345]]], ["The function of the most N-terminal protein (termed NS1-2 or p48) is unclear. huNoV NS1-2 varies in size (approximately 40\u201348 kDa) and contains an N-terminal disordered region and a C-terminal predicted trans-membrane domain [9].", [["N", "CHEMICAL", 25, 26], ["N", "CHEMICAL", 147, 148], ["C", "CHEMICAL", 182, 183], ["NS1-2", "GENE_OR_GENE_PRODUCT", 52, 57], ["p48", "GENE_OR_GENE_PRODUCT", 61, 64], ["NS1-2", "GENE_OR_GENE_PRODUCT", 84, 89], ["N-terminal protein", "PROTEIN", 25, 43], ["NS1", "PROTEIN", 52, 55], ["p48", "PROTEIN", 61, 64], ["NoV NS1-2", "PROTEIN", 80, 89], ["N-terminal disordered region", "PROTEIN", 147, 175], ["C-terminal predicted trans-membrane domain", "PROTEIN", 182, 224], ["NS1", "TEST", 52, 55], ["huNoV NS1", "TEST", 78, 87], ["an N-terminal disordered region", "PROBLEM", 144, 175], ["NS1", "OBSERVATION", 84, 87], ["size", "OBSERVATION_MODIFIER", 100, 104], ["terminal", "OBSERVATION_MODIFIER", 149, 157], ["disordered", "OBSERVATION", 158, 168], ["terminal", "ANATOMY_MODIFIER", 184, 192]]], ["The central domain further shows homology to the NlpC/p60 superfamily of enzymes, with diverse hydrolase functions [10].", [["NlpC/p60 superfamily", "PROTEIN", 49, 69], ["enzymes", "PROTEIN", 73, 80], ["enzymes", "TEST", 73, 80], ["diverse hydrolase functions", "PROBLEM", 87, 114]]], ["Genogroup I NS1-2 has been shown to localize to the Golgi complex and induce Golgi disassembly, dependent upon the C-terminal hydrophobic region [11].", [["Golgi complex", "ANATOMY", 52, 65], ["Golgi", "ANATOMY", 77, 82], ["C", "CHEMICAL", 115, 116], ["Genogroup I NS1-2", "GENE_OR_GENE_PRODUCT", 0, 17], ["Golgi", "CELLULAR_COMPONENT", 52, 57], ["Golgi", "CELLULAR_COMPONENT", 77, 82], ["Genogroup I NS1-2", "PROTEIN", 0, 17], ["Golgi complex", "PROTEIN", 52, 65], ["C-terminal hydrophobic region", "PROTEIN", 115, 144], ["Golgi disassembly", "PROBLEM", 77, 94], ["the C-terminal hydrophobic region", "TREATMENT", 111, 144]]], ["MNV NS1/2 contains 2 sites cleaved by murine caspase 3 and has been shown to localize to the endoplasmic reticulum (ER) upon transient expression [12,13].", [["endoplasmic reticulum", "ANATOMY", 93, 114], ["ER", "ANATOMY", 116, 118], ["NS1/2", "GENE_OR_GENE_PRODUCT", 4, 9], ["murine", "ORGANISM", 38, 44], ["caspase 3", "GENE_OR_GENE_PRODUCT", 45, 54], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 93, 114], ["ER", "GENE_OR_GENE_PRODUCT", 116, 118], ["MNV NS1/2", "PROTEIN", 0, 9], ["murine caspase 3", "PROTEIN", 38, 54], ["ER", "PROTEIN", 116, 118], ["murine", "SPECIES", 38, 44], ["MNV", "SPECIES", 0, 3], ["endoplasmic reticulum", "ANATOMY", 93, 114]]], ["NS3 (also termed NTPase, 2C-like and p41) has been demonstrated to function as an NTPase in vitro for GI [14].", [["NS3", "GENE_OR_GENE_PRODUCT", 0, 3], ["NTPase", "GENE_OR_GENE_PRODUCT", 17, 23], ["2C", "GENE_OR_GENE_PRODUCT", 25, 27], ["p41", "GENE_OR_GENE_PRODUCT", 37, 40], ["NS3", "PROTEIN", 0, 3], ["NTPase", "PROTEIN", 17, 23], ["2C", "PROTEIN", 25, 27], ["p41", "PROTEIN", 37, 40], ["NTPase", "PROTEIN", 82, 88], ["NS3", "TREATMENT", 0, 3]]], ["NS3 has also been shown to co-localize with double stranded RNA (dsRNA) during MNV infection [15].", [["infection", "DISEASE", 83, 92], ["NS3", "GENE_OR_GENE_PRODUCT", 0, 3], ["MNV", "ORGANISM", 79, 82], ["NS3", "PROTEIN", 0, 3], ["double stranded RNA", "RNA", 44, 63], ["MNV", "SPECIES", 79, 82], ["NS3", "TREATMENT", 0, 3], ["double stranded RNA (dsRNA", "TREATMENT", 44, 70], ["MNV infection", "PROBLEM", 79, 92], ["infection", "OBSERVATION", 83, 92]]], ["NS4 (also called p20, p22 or 3A-like) function remains unclear, although NS4 has been demonstrated to disrupt ER to Golgi trafficking resulting in Golgi disassembly during norovirus replication [16].", [["ER", "ANATOMY", 110, 112], ["Golgi", "ANATOMY", 116, 121], ["Golgi", "ANATOMY", 147, 152], ["NS4", "CHEMICAL", 73, 76], ["NS4", "GENE_OR_GENE_PRODUCT", 0, 3], ["p20", "GENE_OR_GENE_PRODUCT", 17, 20], ["p22", "GENE_OR_GENE_PRODUCT", 22, 25], ["3A", "GENE_OR_GENE_PRODUCT", 29, 31], ["NS4", "GENE_OR_GENE_PRODUCT", 73, 76], ["ER", "GENE_OR_GENE_PRODUCT", 110, 112], ["Golgi", "CELLULAR_COMPONENT", 116, 121], ["Golgi", "CELLULAR_COMPONENT", 147, 152], ["NS4", "PROTEIN", 0, 3], ["p20", "PROTEIN", 17, 20], ["p22", "PROTEIN", 22, 25], ["3A", "PROTEIN", 29, 31], ["NS4", "PROTEIN", 73, 76], ["ER", "PROTEIN", 110, 112], ["Golgi disassembly", "PROBLEM", 147, 164], ["norovirus replication", "TREATMENT", 172, 193]]], ["NS4 has also been shown to inhibit actin cytoskeleton remodeling in an epithelial cell line upon transient expression [17].", [["cytoskeleton", "ANATOMY", 41, 53], ["epithelial cell line", "ANATOMY", 71, 91], ["NS4", "CHEMICAL", 0, 3], ["NS4", "GENE_OR_GENE_PRODUCT", 0, 3], ["actin", "GENE_OR_GENE_PRODUCT", 35, 40], ["cytoskeleton", "CELLULAR_COMPONENT", 41, 53], ["epithelial cell line", "CELL", 71, 91], ["NS4", "PROTEIN", 0, 3], ["actin", "PROTEIN", 35, 40], ["epithelial cell line", "CELL_LINE", 71, 91], ["NS4", "TREATMENT", 0, 3], ["an epithelial cell line", "TREATMENT", 68, 91], ["actin cytoskeleton remodeling", "OBSERVATION", 35, 64], ["epithelial cell line", "OBSERVATION", 71, 91], ["transient", "OBSERVATION_MODIFIER", 97, 106], ["expression", "OBSERVATION_MODIFIER", 107, 117]]], ["Upon MNV infection, NS4 was shown to localize to the replication complex [15], and upon transient expression shown to localize to endosomes [13].", [["endosomes", "ANATOMY", 130, 139], ["MNV infection", "DISEASE", 5, 18], ["MNV", "ORGANISM", 5, 8], ["NS4", "GENE_OR_GENE_PRODUCT", 20, 23], ["endosomes", "CELLULAR_COMPONENT", 130, 139], ["NS4", "PROTEIN", 20, 23], ["replication complex", "PROTEIN", 53, 72], ["MNV", "SPECIES", 5, 8], ["MNV infection", "PROBLEM", 5, 18], ["NS4", "TREATMENT", 20, 23], ["MNV", "OBSERVATION_MODIFIER", 5, 8], ["infection", "OBSERVATION", 9, 18]]], ["NS5 is linked to the 5\u2019 end of the genome and plays an integral role in the initiation of translation through its interaction with eukaryotic initiation factors and likely primes genome and subgenomic RNA synthesis [18].", [["NS5", "GENE_OR_GENE_PRODUCT", 0, 3], ["genome", "CELLULAR_COMPONENT", 35, 41], ["genome", "CELLULAR_COMPONENT", 179, 185], ["NS5", "PROTEIN", 0, 3], ["5\u2019 end", "DNA", 21, 27], ["eukaryotic initiation factors", "PROTEIN", 131, 160], ["subgenomic RNA", "RNA", 190, 204], ["NS5", "TREATMENT", 0, 3], ["eukaryotic initiation factors", "TREATMENT", 131, 160], ["primes genome and subgenomic RNA synthesis", "PROBLEM", 172, 214]]], ["The viral protease NS6 (also called Pro or 3C-like) is a well characterized cysteine protease and responsible for the cleavage and processing of the viral ORF1 polyprotein [12,19].", [["cysteine", "CHEMICAL", 76, 84], ["NS6", "GENE_OR_GENE_PRODUCT", 19, 22], ["3C", "GENE_OR_GENE_PRODUCT", 43, 45], ["cysteine", "AMINO_ACID", 76, 84], ["viral protease", "PROTEIN", 4, 18], ["NS6", "PROTEIN", 19, 22], ["3C", "PROTEIN", 43, 45], ["cysteine protease", "PROTEIN", 76, 93], ["viral ORF1 polyprotein", "PROTEIN", 149, 171], ["The viral protease NS6", "TREATMENT", 0, 22], ["a well characterized cysteine protease", "TREATMENT", 55, 93], ["the cleavage", "PROBLEM", 114, 126], ["the viral ORF1 polyprotein", "TREATMENT", 145, 171]]], ["Lastly, NS7 (also called RdRp) functions as the RNA dependent RNA polymerase in viral replication and transcription of subgenomic RNAs [20,21]).IntroductionMembrane rearrangements play a key role in the establishment of viral replication complexes for positive strand RNA viruses.", [["Membrane", "ANATOMY", 156, 164], ["NS7", "GENE_OR_GENE_PRODUCT", 8, 11], ["RdRp", "GENE_OR_GENE_PRODUCT", 25, 29], ["Membrane", "CELLULAR_COMPONENT", 156, 164], ["NS7", "PROTEIN", 8, 11], ["RdRp", "PROTEIN", 25, 29], ["RNA dependent RNA polymerase", "PROTEIN", 48, 76], ["subgenomic RNAs", "RNA", 119, 134], ["viral replication complexes", "PROTEIN", 220, 247], ["the RNA dependent RNA polymerase", "PROBLEM", 44, 76], ["viral replication", "TREATMENT", 80, 97], ["viral replication complexes", "TREATMENT", 220, 247], ["positive strand RNA viruses", "PROBLEM", 252, 279], ["viral replication", "OBSERVATION", 80, 97], ["RNA viruses", "OBSERVATION", 268, 279]]], ["In principle these membrane alterations can be subdivided into two morphotypes (reviewed in [22,23]).", [["membrane", "ANATOMY", 19, 27], ["membrane", "CELLULAR_COMPONENT", 19, 27], ["membrane alterations", "OBSERVATION", 19, 39]]], ["First, the \u201cinvagination type\u201d consists of single membrane invaginations of a donor membrane which stay connected to the cytoplasm via a pore and are represented by alphaviruses and flaviviruses.", [["membrane invaginations", "ANATOMY", 50, 72], ["donor membrane", "ANATOMY", 78, 92], ["cytoplasm", "ANATOMY", 121, 130], ["pore", "ANATOMY", 137, 141], ["flaviviruses", "DISEASE", 182, 194], ["membrane invaginations", "CELLULAR_COMPONENT", 50, 72], ["donor membrane", "CELLULAR_COMPONENT", 78, 92], ["cytoplasm", "ORGANISM_SUBSTANCE", 121, 130], ["single membrane invaginations", "PROBLEM", 43, 72], ["a donor membrane", "TREATMENT", 76, 92], ["alphaviruses", "PROBLEM", 165, 177], ["flaviviruses", "PROBLEM", 182, 194], ["single", "OBSERVATION_MODIFIER", 43, 49], ["membrane invaginations", "OBSERVATION", 50, 72], ["donor membrane", "OBSERVATION", 78, 92], ["alphaviruses", "OBSERVATION", 165, 177]]], ["Viral replication takes place inside these vesicles and the viral RNA contributes to their morphology [24], with the exception of Brome mosaic virus 1a protein which generates spherules in absence of RNA replication [25].", [["vesicles", "ANATOMY", 43, 51], ["spherules", "ANATOMY", 176, 185], ["vesicles", "CELLULAR_COMPONENT", 43, 51], ["Brome mosaic virus 1a", "ORGANISM", 130, 151], ["viral RNA", "RNA", 60, 69], ["Brome mosaic virus 1a protein", "PROTEIN", 130, 159], ["Brome mosaic virus", "SPECIES", 130, 148], ["Viral replication", "TREATMENT", 0, 17], ["the viral RNA", "PROBLEM", 56, 69], ["Brome mosaic virus 1a protein", "PROBLEM", 130, 159], ["RNA replication", "TREATMENT", 200, 215], ["replication", "OBSERVATION", 6, 17], ["vesicles", "ANATOMY", 43, 51], ["viral RNA", "OBSERVATION", 60, 69], ["spherules", "OBSERVATION_MODIFIER", 176, 185], ["RNA replication", "OBSERVATION", 200, 215]]], ["Second, the \u201cDMV-type\u201d consists of vesicular and tubular membrane rearrangements wrapped by one (single membrane vesicle, SMV), two (double membrane vesicles, DMVs) and multiple membranes (multi membrane vesicles, MMVs), induced by picornaviruses, coronaviruses and hepatitis C virus (HCV).", [["vesicular", "ANATOMY", 35, 44], ["tubular membrane", "ANATOMY", 49, 65], ["membrane vesicle", "ANATOMY", 104, 120], ["SMV", "ANATOMY", 122, 125], ["membrane vesicles", "ANATOMY", 140, 157], ["DMVs", "ANATOMY", 159, 163], ["membranes", "ANATOMY", 178, 187], ["membrane vesicles", "ANATOMY", 195, 212], ["MMVs", "ANATOMY", 214, 218], ["coronaviruses and hepatitis C", "DISEASE", 248, 277], ["vesicular", "MULTI-TISSUE_STRUCTURE", 35, 44], ["tubular membrane", "CELLULAR_COMPONENT", 49, 65], ["membrane vesicle", "CELLULAR_COMPONENT", 104, 120], ["membrane vesicles", "CELLULAR_COMPONENT", 140, 157], ["membranes", "CELLULAR_COMPONENT", 178, 187], ["membrane vesicles", "CELLULAR_COMPONENT", 195, 212], ["MMVs", "CELLULAR_COMPONENT", 214, 218], ["coronaviruses", "ORGANISM", 248, 261], ["hepatitis C virus", "ORGANISM", 266, 283], ["HCV", "ORGANISM", 285, 288], ["SMV", "PROTEIN", 122, 125], ["DMVs", "PROTEIN", 159, 163], ["hepatitis C virus", "SPECIES", 266, 283], ["hepatitis C virus", "SPECIES", 266, 283], ["HCV", "SPECIES", 285, 288], ["vesicular and tubular membrane rearrangements", "PROBLEM", 35, 80], ["two (double membrane vesicles", "PROBLEM", 128, 157], ["DMVs", "PROBLEM", 159, 163], ["multiple membranes (multi membrane vesicles", "PROBLEM", 169, 212], ["MMVs", "PROBLEM", 214, 218], ["picornaviruses", "PROBLEM", 232, 246], ["coronaviruses", "PROBLEM", 248, 261], ["hepatitis C virus (HCV)", "PROBLEM", 266, 289], ["vesicular", "ANATOMY_MODIFIER", 35, 44], ["tubular membrane rearrangements", "OBSERVATION", 49, 80], ["SMV", "ANATOMY", 122, 125], ["multiple", "OBSERVATION_MODIFIER", 169, 177], ["membranes", "OBSERVATION", 178, 187], ["membrane vesicles", "ANATOMY", 195, 212], ["picornaviruses", "OBSERVATION", 232, 246]]], ["Most of these structures have no visible connection to the cytoplasm and the functional significance of the different vesicle subtypes as well as the localization of the RNA synthesis machinery is still a matter of debate.", [["cytoplasm", "ANATOMY", 59, 68], ["vesicle", "ANATOMY", 118, 125], ["cytoplasm", "ORGANISM_SUBSTANCE", 59, 68], ["vesicle", "CELLULAR_COMPONENT", 118, 125], ["visible connection to the cytoplasm", "PROBLEM", 33, 68], ["no", "UNCERTAINTY", 30, 32], ["visible", "OBSERVATION_MODIFIER", 33, 40], ["connection", "OBSERVATION", 41, 51], ["cytoplasm", "OBSERVATION", 59, 68], ["functional", "OBSERVATION_MODIFIER", 77, 87], ["different", "OBSERVATION_MODIFIER", 108, 117], ["vesicle subtypes", "OBSERVATION", 118, 134], ["RNA synthesis", "OBSERVATION", 170, 183]]], ["However, these structures can typically be induced simply by expression of the replicase proteins in absence of RNA replication, exemplified by picornaviruses [26\u201329] and HCV [30\u201332].", [["HCV", "ORGANISM", 171, 174], ["replicase proteins", "PROTEIN", 79, 97], ["HCV", "SPECIES", 171, 174], ["the replicase proteins", "PROBLEM", 75, 97], ["RNA replication", "PROBLEM", 112, 127], ["picornaviruses", "PROBLEM", 144, 158], ["HCV", "TEST", 171, 174], ["RNA replication", "OBSERVATION", 112, 127]]], ["Sole expression of individual nonstructural proteins already induces distinct membrane alterations, which are less complex than those derived from the polyprotein.", [["membrane", "ANATOMY", 78, 86], ["membrane", "CELLULAR_COMPONENT", 78, 86], ["nonstructural proteins", "PROTEIN", 30, 52], ["individual nonstructural proteins", "PROBLEM", 19, 52], ["distinct membrane alterations", "PROBLEM", 69, 98], ["the polyprotein", "TREATMENT", 147, 162], ["nonstructural proteins", "OBSERVATION", 30, 52], ["distinct", "OBSERVATION_MODIFIER", 69, 77], ["membrane alterations", "OBSERVATION", 78, 98], ["less complex", "OBSERVATION_MODIFIER", 110, 122]]], ["Still, such studies have allowed the identification of those viral proteins contributing to the morphogenesis of viral replication sites and the unraveling of some of their functions [26\u201328,30,31,33\u201335].", [["viral proteins", "PROTEIN", 61, 75], ["viral replication sites", "DNA", 113, 136], ["such studies", "TEST", 7, 19], ["those viral proteins", "PROBLEM", 55, 75], ["viral replication sites", "PROBLEM", 113, 136], ["viral replication", "OBSERVATION", 113, 130]]], ["In the case of HCV, virus induced membrane alterations have been identified as efficient drug targets for silibinin [36], direct acting antivirals like NS5A inhibitors [37] and host targeting drugs like cyclophilin inhibitors [38].IntroductionOur understanding of the ultrastructure of huNoV replication organelles is currently scarce, mostly due to the lack of efficient cell culture models [39].", [["membrane", "ANATOMY", 34, 42], ["organelles", "ANATOMY", 304, 314], ["cell culture", "ANATOMY", 372, 384], ["silibinin", "CHEMICAL", 106, 115], ["silibinin", "CHEMICAL", 106, 115], ["HCV", "ORGANISM", 15, 18], ["membrane", "CELLULAR_COMPONENT", 34, 42], ["silibinin", "SIMPLE_CHEMICAL", 106, 115], ["NS5A inhibitors [37]", "SIMPLE_CHEMICAL", 152, 172], ["host targeting drugs", "SIMPLE_CHEMICAL", 177, 197], ["cyclophilin", "GENE_OR_GENE_PRODUCT", 203, 214], ["huNoV", "GENE_OR_GENE_PRODUCT", 286, 291], ["organelles", "CELLULAR_COMPONENT", 304, 314], ["cell", "CELL", 372, 376], ["HCV", "SPECIES", 15, 18], ["HCV", "PROBLEM", 15, 18], ["virus induced membrane alterations", "PROBLEM", 20, 54], ["silibinin", "TREATMENT", 106, 115], ["direct acting antivirals", "TREATMENT", 122, 146], ["NS5A inhibitors", "TREATMENT", 152, 167], ["host targeting drugs", "TREATMENT", 177, 197], ["cyclophilin inhibitors", "TREATMENT", 203, 225], ["efficient cell culture models", "TEST", 362, 391], ["HCV", "OBSERVATION", 15, 18], ["huNoV", "OBSERVATION", 286, 291]]], ["A replicon model has been established in case of GI noroviruses [40], but no ultrastructural analysis is currently available.", [["GI noroviruses", "ORGANISM", 49, 63], ["A replicon model", "TREATMENT", 0, 16], ["GI noroviruses", "PROBLEM", 49, 63], ["ultrastructural analysis", "TEST", 77, 101]]], ["A plasmid driven GII.3 replicon model allows moderate RNA replication levels, but it remains difficult to dissect the contribution of protein expression and bona fide RNA replication in this system [41].", [["plasmid", "ANATOMY", 2, 9], ["GII.3", "GENE_OR_GENE_PRODUCT", 17, 22], ["A plasmid driven GII.3 replicon model", "TREATMENT", 0, 37], ["moderate RNA replication levels", "PROBLEM", 45, 76], ["protein expression", "PROBLEM", 134, 152], ["moderate", "OBSERVATION_MODIFIER", 45, 53], ["RNA replication", "OBSERVATION", 54, 69], ["fide RNA replication", "OBSERVATION", 162, 182]]], ["Recently, tremendous progress has been achieved in cultivating the more clinically relevant GII.4 strains in both B-cells [42] and enteric organoids [43], still neither of these models has yet been proven to allow ultrastructural studies.", [["B-cells", "ANATOMY", 114, 121], ["organoids", "ANATOMY", 139, 148], ["B-cells [42]", "CELL", 114, 126], ["enteric organoids", "CELL", 131, 148], ["B-cells", "CELL_TYPE", 114, 121], ["enteric organoids", "TEST", 131, 148], ["ultrastructural studies", "TEST", 214, 237]]], ["Therefore, most of our knowledge of norovirus induced membrane alterations has been obtained using the MNV model [44].", [["membrane", "ANATOMY", 54, 62], ["norovirus", "DISEASE", 36, 45], ["norovirus", "ORGANISM", 36, 45], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["norovirus induced membrane alterations", "PROBLEM", 36, 74], ["norovirus", "OBSERVATION", 36, 45]]], ["Previous studies showed accumulations of vesicles in the cytoplasm of infected macrophages consisting of single and double membrane vesicles, which have not been further characterized [44].", [["vesicles", "ANATOMY", 41, 49], ["cytoplasm", "ANATOMY", 57, 66], ["macrophages", "ANATOMY", 79, 90], ["membrane vesicles", "ANATOMY", 123, 140], ["vesicles", "CELLULAR_COMPONENT", 41, 49], ["cytoplasm", "ORGANISM_SUBSTANCE", 57, 66], ["macrophages", "CELL", 79, 90], ["membrane vesicles", "CELLULAR_COMPONENT", 123, 140], ["infected macrophages", "CELL_TYPE", 70, 90], ["Previous studies", "TEST", 0, 16], ["accumulations of vesicles", "PROBLEM", 24, 49], ["infected macrophages", "PROBLEM", 70, 90], ["single and double membrane vesicles", "PROBLEM", 105, 140], ["accumulations", "OBSERVATION_MODIFIER", 24, 37], ["vesicles", "OBSERVATION_MODIFIER", 41, 49], ["cytoplasm", "OBSERVATION_MODIFIER", 57, 66], ["infected macrophages", "OBSERVATION", 70, 90], ["single", "OBSERVATION_MODIFIER", 105, 111], ["double membrane vesicles", "OBSERVATION", 116, 140]]], ["In addition, it has been shown that MNV induced vesicle clusters co-localize with all MNV NS proteins and with viral replication intermediates and that these extensive rearrangements of intracellular membranes are mainly derived from the secretory pathway, including ER, Golgi and endosomal membranes [15].", [["vesicle clusters", "ANATOMY", 48, 64], ["intracellular membranes", "ANATOMY", 186, 209], ["ER", "ANATOMY", 267, 269], ["Golgi", "ANATOMY", 271, 276], ["endosomal membranes", "ANATOMY", 281, 300], ["MNV", "ORGANISM", 36, 39], ["vesicle", "CELLULAR_COMPONENT", 48, 55], ["intracellular membranes", "CELLULAR_COMPONENT", 186, 209], ["ER", "GENE_OR_GENE_PRODUCT", 267, 269], ["Golgi", "CELLULAR_COMPONENT", 271, 276], ["endosomal membranes", "CELLULAR_COMPONENT", 281, 300], ["MNV NS proteins", "PROTEIN", 86, 101], ["ER", "PROTEIN", 267, 269], ["MNV", "SPECIES", 36, 39], ["MNV induced vesicle clusters", "PROBLEM", 36, 64], ["all MNV NS proteins", "TREATMENT", 82, 101], ["viral replication intermediates", "PROBLEM", 111, 142], ["these extensive rearrangements of intracellular membranes", "PROBLEM", 152, 209], ["vesicle clusters", "OBSERVATION", 48, 64], ["intracellular membranes", "OBSERVATION", 186, 209], ["endosomal membranes", "OBSERVATION", 281, 300]]], ["Furthermore, the MNV replication organelles seem tightly associated with the cytoskeleton, probably mediated by the main capsid protein [45].", [["organelles", "ANATOMY", 33, 43], ["cytoskeleton", "ANATOMY", 77, 89], ["organelles", "CELLULAR_COMPONENT", 33, 43], ["cytoskeleton", "CELLULAR_COMPONENT", 77, 89], ["capsid protein", "PROTEIN", 121, 135], ["MNV", "SPECIES", 17, 20], ["MNV", "OBSERVATION", 17, 20]]], ["Little is known so far about the contribution of individual nonstructural proteins to virus induced replication vesicles, but it is believed that NS1-2 and NS4 are the main drivers in this process due to their membrane association and comparison to picornavirus proteins (reviewed in [8]).", [["vesicles", "ANATOMY", 112, 120], ["membrane", "ANATOMY", 210, 218], ["vesicles", "CELLULAR_COMPONENT", 112, 120], ["NS1-2", "GENE_OR_GENE_PRODUCT", 146, 151], ["NS4", "GENE_OR_GENE_PRODUCT", 156, 159], ["membrane", "CELLULAR_COMPONENT", 210, 218], ["nonstructural proteins", "PROTEIN", 60, 82], ["NS1", "PROTEIN", 146, 149], ["NS4", "PROTEIN", 156, 159], ["picornavirus proteins", "PROTEIN", 249, 270], ["individual nonstructural proteins", "PROBLEM", 49, 82], ["virus induced replication vesicles", "PROBLEM", 86, 120], ["NS1", "TEST", 146, 149], ["their membrane association", "PROBLEM", 204, 230], ["picornavirus proteins", "PROBLEM", 249, 270]]], ["In addition, NS3 is associated with membranes and recently has been shown to be associated with highly motile vesicular structures [13,46].IntroductionThe current study aimed to investigate membrane alterations induced by clinically highly prevalent GII.4 using a transient expression system in Huh7 cell lines.", [["membranes", "ANATOMY", 36, 45], ["vesicular structures", "ANATOMY", 110, 130], ["membrane", "ANATOMY", 190, 198], ["Huh7 cell lines", "ANATOMY", 295, 310], ["NS3", "GENE_OR_GENE_PRODUCT", 13, 16], ["membranes", "CELLULAR_COMPONENT", 36, 45], ["vesicular structures", "MULTI-TISSUE_STRUCTURE", 110, 130], ["membrane", "CELLULAR_COMPONENT", 190, 198], ["Huh7 cell lines", "CELL", 295, 310], ["NS3", "PROTEIN", 13, 16], ["Huh7 cell lines", "CELL_LINE", 295, 310], ["NS3", "PROBLEM", 13, 16], ["membranes", "PROBLEM", 36, 45], ["The current study", "TEST", 151, 168], ["membrane alterations", "PROBLEM", 190, 210], ["a transient expression system", "TREATMENT", 262, 291], ["Huh7 cell lines", "TREATMENT", 295, 310], ["NS3", "OBSERVATION", 13, 16], ["highly", "OBSERVATION_MODIFIER", 96, 102], ["motile", "OBSERVATION_MODIFIER", 103, 109], ["vesicular structures", "OBSERVATION", 110, 130], ["Huh7 cell lines", "OBSERVATION", 295, 310]]], ["Membrane structures induced by expression of the polyprotein of three important outbreak strains (Den Haag 2006, New Orleans 2009 and Sydney 2012) comprised SMV, DMV and MMV structures.", [["Membrane structures", "ANATOMY", 0, 19], ["MMV structures", "ANATOMY", 170, 184], ["Membrane structures", "CELLULAR_COMPONENT", 0, 19], ["SMV", "MULTI-TISSUE_STRUCTURE", 157, 160], ["MMV structures", "TISSUE", 170, 184], ["SMV", "SPECIES", 157, 160], ["DMV", "SPECIES", 162, 165], ["MMV", "SPECIES", 170, 173], ["Membrane structures", "PROBLEM", 0, 19], ["SMV", "ANATOMY", 157, 160], ["DMV", "ANATOMY", 162, 165], ["MMV structures", "OBSERVATION", 170, 184]]], ["We further observed that SMVs and DMVs were reminiscent of structures found upon MNV infection.", [["SMVs", "ANATOMY", 25, 29], ["MNV infection", "DISEASE", 81, 94], ["SMVs", "GENE_OR_GENE_PRODUCT", 25, 29], ["DMVs", "GENE_OR_GENE_PRODUCT", 34, 38], ["MNV", "ORGANISM", 81, 84], ["SMVs", "PROTEIN", 25, 29], ["DMVs", "PROTEIN", 34, 38], ["MNV", "SPECIES", 81, 84], ["SMVs", "PROBLEM", 25, 29], ["DMVs", "PROBLEM", 34, 38], ["MNV infection", "PROBLEM", 81, 94], ["MNV", "OBSERVATION_MODIFIER", 81, 84], ["infection", "OBSERVATION", 85, 94]]], ["The impact of individual GII.4 NS proteins on intracellular membranes was studied by correlative light and electron microscopy, allowing the localization of each protein within the cellular ultrastructural context.", [["intracellular membranes", "ANATOMY", 46, 69], ["cellular", "ANATOMY", 181, 189], ["GII.4 NS proteins", "GENE_OR_GENE_PRODUCT", 25, 42], ["intracellular membranes", "CELLULAR_COMPONENT", 46, 69], ["cellular", "CELL", 181, 189], ["GII.4 NS proteins", "PROTEIN", 25, 42], ["individual GII.4 NS proteins on intracellular membranes", "TREATMENT", 14, 69], ["electron microscopy", "TEST", 107, 126], ["the localization of each protein", "TEST", 137, 169], ["intracellular membranes", "OBSERVATION", 46, 69], ["cellular ultrastructural context", "OBSERVATION", 181, 213]]], ["GII.4 NS1-2 induced membrane proliferation of the smooth ER, which was strikingly different from MNV NS1/2.", [["membrane", "ANATOMY", 20, 28], ["smooth ER", "ANATOMY", 50, 59], ["NS1-2", "GENE_OR_GENE_PRODUCT", 6, 11], ["membrane", "CELLULAR_COMPONENT", 20, 28], ["ER", "GENE_OR_GENE_PRODUCT", 57, 59], ["GII.4 NS1-2", "PROTEIN", 0, 11], ["smooth ER", "PROTEIN", 50, 59], ["MNV NS1/2", "PROTEIN", 97, 106], ["2 induced", "OBSERVATION_MODIFIER", 10, 19], ["membrane proliferation", "OBSERVATION", 20, 42], ["smooth", "OBSERVATION_MODIFIER", 50, 56]]], ["NS3 was tightly associated with lipid droplets (LDs) and induced convoluted membranes.", [["lipid droplets", "ANATOMY", 32, 46], ["LDs", "ANATOMY", 48, 51], ["convoluted membranes", "ANATOMY", 65, 85], ["NS3", "GENE_OR_GENE_PRODUCT", 0, 3], ["lipid droplets", "SIMPLE_CHEMICAL", 32, 46], ["LDs", "SIMPLE_CHEMICAL", 48, 51], ["convoluted membranes", "CELLULAR_COMPONENT", 65, 85], ["NS3", "PROTEIN", 0, 3], ["NS3", "TREATMENT", 0, 3], ["lipid droplets", "TREATMENT", 32, 46], ["induced convoluted membranes", "PROBLEM", 57, 85], ["lipid droplets", "OBSERVATION", 32, 46], ["convoluted membranes", "OBSERVATION", 65, 85]]], ["However, only NS4 expression was sufficient to induce SMV and DMV formation, much like the ability of HCV NS5A and poliovirus (PV) 3AB to induce DMVs.Expression of MNV ORF1 induces membrane rearrangements comparable to MNV infection ::: ResultsWe aimed to study the determinants of membrane alterations induced by huNoV with a specific focus on clinically relevant GII.4 outbreak strains.", [["SMV", "ANATOMY", 54, 57], ["membrane", "ANATOMY", 181, 189], ["membrane", "ANATOMY", 282, 290], ["MNV infection", "DISEASE", 219, 232], ["huNoV", "CHEMICAL", 314, 319], ["huNoV", "CHEMICAL", 314, 319], ["NS4", "GENE_OR_GENE_PRODUCT", 14, 17], ["SMV", "CANCER", 54, 57], ["DMV", "SIMPLE_CHEMICAL", 62, 65], ["HCV NS5A", "ORGANISM", 102, 110], ["poliovirus (PV) 3AB", "ORGANISM", 115, 134], ["DMVs", "PATHOLOGICAL_FORMATION", 145, 149], ["MNV", "ORGANISM", 164, 167], ["ORF1", "GENE_OR_GENE_PRODUCT", 168, 172], ["membrane", "CELLULAR_COMPONENT", 181, 189], ["MNV", "ORGANISM", 219, 222], ["membrane", "CELLULAR_COMPONENT", 282, 290], ["huNoV", "SIMPLE_CHEMICAL", 314, 319], ["NS4", "PROTEIN", 14, 17], ["HCV NS5A", "PROTEIN", 102, 110], ["poliovirus (PV) 3AB", "PROTEIN", 115, 134], ["DMVs", "PROTEIN", 145, 149], ["MNV ORF1", "DNA", 164, 172], ["SMV", "SPECIES", 54, 57], ["HCV", "SPECIES", 102, 105], ["PV", "SPECIES", 127, 129], ["MNV", "SPECIES", 164, 167], ["MNV", "SPECIES", 219, 222], ["SMV and DMV formation", "PROBLEM", 54, 75], ["HCV NS5A", "TREATMENT", 102, 110], ["poliovirus (PV) 3AB", "TREATMENT", 115, 134], ["DMVs", "PROBLEM", 145, 149], ["membrane rearrangements", "PROBLEM", 181, 204], ["membrane alterations", "PROBLEM", 282, 302], ["4 outbreak strains", "PROBLEM", 369, 387], ["SMV", "ANATOMY", 54, 57], ["infection", "OBSERVATION", 223, 232]]], ["We therefore wanted to exploit expression of ORF1 and of individual NS-proteins to assess the morphology of virus induced membrane alterations in Huh7 cells.", [["membrane", "ANATOMY", 122, 130], ["Huh7 cells", "ANATOMY", 146, 156], ["ORF1", "GENE_OR_GENE_PRODUCT", 45, 49], ["membrane", "CELLULAR_COMPONENT", 122, 130], ["Huh7 cells", "CELL", 146, 156], ["ORF1", "DNA", 45, 49], ["NS-proteins", "PROTEIN", 68, 79], ["Huh7 cells", "CELL_LINE", 146, 156], ["ORF1", "TEST", 45, 49], ["individual NS-proteins", "TEST", 57, 79], ["virus induced membrane alterations in Huh7 cells", "PROBLEM", 108, 156], ["virus", "OBSERVATION", 108, 113], ["membrane alterations", "OBSERVATION", 122, 142], ["Huh7 cells", "OBSERVATION", 146, 156]]], ["We chose Huh7 cells for two reasons: first, Huh7 cells have been shown to support RNA replication of a human GI Norwalk replicon [40] and a plasmid based GII.3 replicon [41], suggesting that they are in principle permissive for huNoV.", [["Huh7 cells", "ANATOMY", 9, 19], ["Huh7 cells", "ANATOMY", 44, 54], ["plasmid", "ANATOMY", 140, 147], ["Huh7 cells", "CELL", 9, 19], ["Huh7 cells", "CELL", 44, 54], ["human", "ORGANISM", 103, 108], ["GI Norwalk replicon", "ORGANISM", 109, 128], ["huNoV", "ORGANISM", 228, 233], ["Huh7 cells", "CELL_LINE", 9, 19], ["Huh7 cells", "CELL_LINE", 44, 54], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["huNoV", "SPECIES", 228, 233], ["Huh7 cells", "TREATMENT", 9, 19], ["Huh7 cells", "TREATMENT", 44, 54], ["a human GI Norwalk replicon", "TREATMENT", 101, 128], ["a plasmid based GII.3 replicon", "TREATMENT", 138, 168]]], ["Second, Huh7 have been used to study membrane alterations for a variety of positive strand RNA viruses, including HCV, hepatitis A virus (HAV), coronaviruses and Dengue virus (reviewed in [22,23]), thereby facilitating the comparison of these structures among different virus groups.Expression of MNV ORF1 induces membrane rearrangements comparable to MNV infection ::: ResultsWe first aimed to evaluate whether structures induced by ORF1 expression indeed resembled those found in infected cells using MNV as a model, ideally using the same cell type as intended for huNoV.", [["Huh7", "ANATOMY", 8, 12], ["membrane", "ANATOMY", 37, 45], ["membrane", "ANATOMY", 314, 322], ["cells", "ANATOMY", 491, 496], ["cell", "ANATOMY", 542, 546], ["HCV, hepatitis A virus (HAV), coronaviruses and Dengue virus", "DISEASE", 114, 174], ["MNV infection", "DISEASE", 352, 365], ["Huh7", "CELL", 8, 12], ["membrane", "CELLULAR_COMPONENT", 37, 45], ["HCV", "ORGANISM", 114, 117], ["hepatitis A virus", "ORGANISM", 119, 136], ["HAV", "ORGANISM", 138, 141], ["coronaviruses", "ORGANISM", 144, 157], ["Dengue virus", "ORGANISM", 162, 174], ["MNV", "ORGANISM", 297, 300], ["ORF1", "GENE_OR_GENE_PRODUCT", 301, 305], ["membrane", "CELLULAR_COMPONENT", 314, 322], ["MNV", "ORGANISM", 352, 355], ["ORF1", "GENE_OR_GENE_PRODUCT", 434, 438], ["cells", "CELL", 491, 496], ["MNV", "ORGANISM", 503, 506], ["cell type", "CELL", 542, 551], ["huNoV", "ORGANISM", 568, 573], ["Huh7", "CELL_LINE", 8, 12], ["MNV ORF1", "DNA", 297, 305], ["ORF1", "DNA", 434, 438], ["infected cells", "CELL_TYPE", 482, 496], ["hepatitis A virus", "SPECIES", 119, 136], ["Dengue virus", "SPECIES", 162, 174], ["HCV", "SPECIES", 114, 117], ["hepatitis A virus", "SPECIES", 119, 136], ["HAV", "SPECIES", 138, 141], ["Dengue virus", "SPECIES", 162, 174], ["MNV", "SPECIES", 297, 300], ["MNV", "SPECIES", 352, 355], ["MNV", "SPECIES", 503, 506], ["huNoV", "SPECIES", 568, 573], ["Huh7", "TREATMENT", 8, 12], ["study membrane alterations", "TEST", 31, 57], ["positive strand RNA viruses", "PROBLEM", 75, 102], ["HCV", "PROBLEM", 114, 117], ["hepatitis A virus (HAV)", "PROBLEM", 119, 142], ["coronaviruses", "PROBLEM", 144, 157], ["Dengue virus", "PROBLEM", 162, 174], ["membrane rearrangements", "PROBLEM", 314, 337], ["infected cells", "PROBLEM", 482, 496], ["strand RNA viruses", "OBSERVATION", 84, 102], ["infection", "OBSERVATION", 356, 365], ["infected cells", "OBSERVATION", 482, 496]]], ["We therefore generated Huh7-CD300lf cells stably expressing the MNV receptor [47,48] and verified that these cells were indeed permissive for MNV infection by demonstrating the presence of NS3 24h after infection (S1A and S1B Fig).", [["Huh7-CD300lf cells", "ANATOMY", 23, 41], ["cells", "ANATOMY", 109, 114], ["MNV infection", "DISEASE", 142, 155], ["infection", "DISEASE", 203, 212], ["Huh7-CD300lf cells", "CELL", 23, 41], ["cells", "CELL", 109, 114], ["MNV", "ORGANISM", 142, 145], ["Huh7", "CELL_LINE", 23, 27], ["CD300lf cells", "CELL_LINE", 28, 41], ["MNV receptor", "PROTEIN", 64, 76], ["NS3", "PROTEIN", 189, 192], ["MNV", "SPECIES", 142, 145], ["Huh7-CD300lf cells", "TREATMENT", 23, 41], ["these cells", "PROBLEM", 103, 114], ["MNV infection", "PROBLEM", 142, 155], ["NS3", "PROBLEM", 189, 192], ["infection", "PROBLEM", 203, 212], ["infection", "OBSERVATION", 146, 155]]], ["In addition, MNV infected Huh7-CD300lf cells produced similar amounts of progeny virus compared to RAW 264.7 cells, albeit with slightly delayed kinetics (S1C Fig).", [["Huh7-CD300lf cells", "ANATOMY", 26, 44], ["RAW 264.7 cells", "ANATOMY", 99, 114], ["MNV", "ORGANISM", 13, 16], ["Huh7-CD300lf cells", "CELL", 26, 44], ["RAW 264.7 cells", "CELL", 99, 114], ["MNV infected Huh7-CD300lf cells", "CELL_LINE", 13, 44], ["RAW 264.7 cells", "CELL_LINE", 99, 114], ["MNV", "SPECIES", 13, 16], ["MNV", "TEST", 13, 16], ["progeny virus", "PROBLEM", 73, 86], ["slightly delayed kinetics", "PROBLEM", 128, 153], ["infected Huh7", "OBSERVATION", 17, 30], ["amounts", "OBSERVATION_MODIFIER", 62, 69], ["progeny virus", "OBSERVATION", 73, 86]]], ["In contrast, Huh7 cells lacking CD300lf failed to amplify the virus inoculum (S1C Fig).", [["Huh7 cells", "ANATOMY", 13, 23], ["Huh7 cells", "CELL", 13, 23], ["CD300lf", "GENE_OR_GENE_PRODUCT", 32, 39], ["Huh7 cells", "CELL_LINE", 13, 23], ["CD300lf", "PROTEIN", 32, 39], ["Huh7 cells", "TREATMENT", 13, 23], ["the virus inoculum", "PROBLEM", 58, 76]]], ["Therefore, ectopic expression of CD300lf rendered Huh7 cells fully permissive for MNV infection and supported the entire MNV replication cycle.", [["Huh7 cells", "ANATOMY", 50, 60], ["infection", "DISEASE", 86, 95], ["CD300lf", "GENE_OR_GENE_PRODUCT", 33, 40], ["Huh7 cells", "CELL", 50, 60], ["MNV", "ORGANISM", 82, 85], ["MNV", "ORGANISM", 121, 124], ["CD300lf", "PROTEIN", 33, 40], ["Huh7 cells", "CELL_LINE", 50, 60], ["MNV", "SPECIES", 82, 85], ["MNV", "SPECIES", 121, 124], ["ectopic expression", "PROBLEM", 11, 29], ["Huh7 cells", "PROBLEM", 50, 60], ["MNV infection", "PROBLEM", 82, 95], ["Huh7 cells", "OBSERVATION", 50, 60], ["infection", "OBSERVATION", 86, 95]]], ["Ultrastructural analysis of MNV infected Huh7-CD300lf revealed two major phenotypes not observed in uninfected cells (Fig 1): (1) Areas containing vesicles with a variety of shapes, sizes and types (Fig 1A).", [["Huh7-CD300lf", "ANATOMY", 41, 53], ["cells", "ANATOMY", 111, 116], ["vesicles", "ANATOMY", 147, 155], ["MNV", "ORGANISM", 28, 31], ["Huh7-CD300lf", "CELL", 41, 53], ["cells", "CELL", 111, 116], ["vesicles", "CELLULAR_COMPONENT", 147, 155], ["MNV infected Huh7-CD300lf", "CELL_LINE", 28, 53], ["uninfected cells", "CELL_TYPE", 100, 116], ["MNV", "SPECIES", 28, 31], ["Ultrastructural analysis", "TEST", 0, 24], ["MNV", "TEST", 28, 31], ["Huh7", "TEST", 41, 45], ["two major phenotypes", "PROBLEM", 63, 83], ["Areas containing vesicles", "PROBLEM", 130, 155], ["uninfected cells", "OBSERVATION", 100, 116], ["vesicles", "ANATOMY_MODIFIER", 147, 155], ["variety", "OBSERVATION_MODIFIER", 163, 170], ["shapes", "OBSERVATION_MODIFIER", 174, 180], ["sizes", "OBSERVATION_MODIFIER", 182, 187]]], ["In addition to previously reported SMVs, more complex structures like DMVs and MMVs were found, often in proximity to lipid droplets (LD).", [["lipid droplets", "ANATOMY", 118, 132], ["SMVs", "GENE_OR_GENE_PRODUCT", 35, 39], ["DMVs", "GENE_OR_GENE_PRODUCT", 70, 74], ["MMVs", "GENE_OR_GENE_PRODUCT", 79, 83], ["lipid droplets", "SIMPLE_CHEMICAL", 118, 132], ["SMVs", "PROTEIN", 35, 39], ["DMVs", "PROTEIN", 70, 74], ["MMVs", "PROTEIN", 79, 83], ["previously reported SMVs", "PROBLEM", 15, 39], ["more complex structures like DMVs", "PROBLEM", 41, 74], ["MMVs", "PROBLEM", 79, 83], ["DMVs", "OBSERVATION", 70, 74], ["lipid droplets", "OBSERVATION", 118, 132]]], ["This phenotype likely resembled an early replication phase described previously [44].", [["early", "OBSERVATION_MODIFIER", 35, 40], ["replication phase", "OBSERVATION", 41, 58]]], ["(2) A massive rearrangement of the entire endomembrane system consisting of complex structures, often associated with virions, and lacking an organized morphology was observed during what was likely a later stage of the replication cycle [44] (Fig 1B).", [["endomembrane system", "ANATOMY", 42, 61], ["virions", "ANATOMY", 118, 125], ["endomembrane", "CELLULAR_COMPONENT", 42, 54], ["A massive rearrangement of the entire endomembrane system", "PROBLEM", 4, 61], ["complex structures", "PROBLEM", 76, 94], ["virions", "PROBLEM", 118, 125], ["massive", "OBSERVATION_MODIFIER", 6, 13], ["rearrangement", "OBSERVATION", 14, 27], ["entire", "ANATOMY_MODIFIER", 35, 41], ["endomembrane system", "ANATOMY", 42, 61], ["complex", "OBSERVATION_MODIFIER", 76, 83], ["virions", "OBSERVATION", 118, 125]]], ["We found similar phenotypes in RAW 264.7 cells (S2 Fig), which have been used in previous studies to characterize the ultrastructure of the MNV replication organelle [15,44], except that these cells lacked LDs (S2 Fig).", [["RAW 264.7 cells", "ANATOMY", 31, 46], ["organelle", "ANATOMY", 156, 165], ["cells", "ANATOMY", 193, 198], ["LDs", "ANATOMY", 206, 209], ["RAW 264.7 cells", "CELL", 31, 46], ["S2 Fig", "CELL", 48, 54], ["MNV", "ORGANISM", 140, 143], ["cells", "CELL", 193, 198], ["LDs", "CELLULAR_COMPONENT", 206, 209], ["RAW 264.7 cells", "CELL_LINE", 31, 46], ["similar phenotypes in RAW", "PROBLEM", 9, 34], ["S2 Fig", "TEST", 48, 54], ["previous studies", "TEST", 81, 97], ["similar phenotypes", "OBSERVATION", 9, 27], ["264.7 cells", "OBSERVATION", 35, 46]]], ["We next analyzed whether similar structures were generated by expression of MNV ORF1.", [["MNV", "ORGANISM", 76, 79], ["ORF1", "GENE_OR_GENE_PRODUCT", 80, 84], ["MNV ORF1", "DNA", 76, 84], ["MNV", "SPECIES", 76, 79]]], ["MNV ORF1 was expressed in Huh7 T7 cells under transcriptional control of the T7 promoter and translational control of an encephalomyocarditis virus internal ribosomal entry site (EMCV IRES), allowing efficient cytoplasmic expression of proteins of interest in the presence of T7 RNA polymerase (Fig 2A and 2B).", [["Huh7 T7 cells", "ANATOMY", 26, 39], ["ribosomal", "ANATOMY", 157, 166], ["cytoplasmic", "ANATOMY", 210, 221], ["MNV", "ORGANISM", 0, 3], ["ORF1", "GENE_OR_GENE_PRODUCT", 4, 8], ["Huh7 T7 cells", "CELL", 26, 39], ["encephalomyocarditis virus", "ORGANISM", 121, 147], ["cytoplasmic", "ORGANISM_SUBSTANCE", 210, 221], ["Fig 2A", "GENE_OR_GENE_PRODUCT", 295, 301], ["2B", "GENE_OR_GENE_PRODUCT", 306, 308], ["MNV ORF1", "DNA", 0, 8], ["Huh7 T7 cells", "CELL_LINE", 26, 39], ["T7 promoter", "DNA", 77, 88], ["encephalomyocarditis virus internal ribosomal entry site", "DNA", 121, 177], ["EMCV IRES", "DNA", 179, 188], ["T7 RNA polymerase", "PROTEIN", 276, 293], ["Fig 2A and 2B", "PROTEIN", 295, 308], ["encephalomyocarditis virus", "SPECIES", 121, 147], ["MNV", "SPECIES", 0, 3], ["encephalomyocarditis virus", "SPECIES", 121, 147], ["EMCV", "SPECIES", 179, 183], ["MNV ORF1", "TEST", 0, 8], ["Huh7 T7 cells", "TREATMENT", 26, 39], ["transcriptional control", "TREATMENT", 46, 69], ["the T7 promoter", "TREATMENT", 73, 88], ["an encephalomyocarditis virus", "PROBLEM", 118, 147], ["T7 RNA polymerase", "PROBLEM", 276, 293], ["T7", "ANATOMY", 77, 79], ["encephalomyocarditis", "OBSERVATION", 121, 141], ["T7", "ANATOMY", 276, 278]]], ["For ultrastructural analysis we used chemical fixation (CF) or high-pressure freezing (HPF) (Fig 2C).", [["ultrastructural analysis", "TEST", 4, 28], ["chemical fixation (CF", "TREATMENT", 37, 58], ["high-pressure freezing", "TREATMENT", 63, 85]]], ["Regardless of the fixation technique, we identified basically the same types of membrane alterations observed in phenotype 1 of MNV infected cells: vesiculated areas with SMVs, DMVs and MMVs, again in close proximity to LDs, whereas phenotype 2 (complex membrane structures lacking organized morphology) was not found upon expression of ORF1.Expression of MNV ORF1 induces membrane rearrangements comparable to MNV infection ::: ResultsWe concluded that expression of ORF1 generates membrane alterations comparable to replication organelles found in MNV infection.", [["membrane", "ANATOMY", 80, 88], ["cells", "ANATOMY", 141, 146], ["SMVs", "ANATOMY", 171, 175], ["DMVs", "ANATOMY", 177, 181], ["MMVs", "ANATOMY", 186, 190], ["LDs", "ANATOMY", 220, 223], ["membrane structures", "ANATOMY", 254, 273], ["membrane", "ANATOMY", 373, 381], ["membrane", "ANATOMY", 483, 491], ["organelles", "ANATOMY", 530, 540], ["MNV infection", "DISEASE", 411, 424], ["MNV infection", "DISEASE", 550, 563], ["membrane", "CELLULAR_COMPONENT", 80, 88], ["MNV", "ORGANISM", 128, 131], ["cells", "CELL", 141, 146], ["SMVs", "GENE_OR_GENE_PRODUCT", 171, 175], ["DMVs", "GENE_OR_GENE_PRODUCT", 177, 181], ["MMVs", "GENE_OR_GENE_PRODUCT", 186, 190], ["LDs", "CELLULAR_COMPONENT", 220, 223], ["phenotype 2", "GENE_OR_GENE_PRODUCT", 233, 244], ["ORF1", "GENE_OR_GENE_PRODUCT", 337, 341], ["MNV", "ORGANISM", 356, 359], ["ORF1", "GENE_OR_GENE_PRODUCT", 360, 364], ["membrane", "CELLULAR_COMPONENT", 373, 381], ["MNV", "ORGANISM", 411, 414], ["ORF1", "GENE_OR_GENE_PRODUCT", 468, 472], ["membrane", "CELLULAR_COMPONENT", 483, 491], ["organelles", "CELLULAR_COMPONENT", 530, 540], ["MNV", "ORGANISM", 550, 553], ["MNV infected cells", "CELL_TYPE", 128, 146], ["SMVs", "PROTEIN", 171, 175], ["DMVs", "PROTEIN", 177, 181], ["MMVs", "PROTEIN", 186, 190], ["ORF1", "DNA", 337, 341], ["MNV ORF1", "DNA", 356, 364], ["ORF1", "DNA", 468, 472], ["MNV", "SPECIES", 128, 131], ["MNV", "SPECIES", 356, 359], ["MNV", "SPECIES", 411, 414], ["MNV", "SPECIES", 550, 553], ["the fixation technique", "TREATMENT", 14, 36], ["membrane alterations", "PROBLEM", 80, 100], ["MNV infected cells", "PROBLEM", 128, 146], ["vesiculated areas", "PROBLEM", 148, 165], ["SMVs", "PROBLEM", 171, 175], ["DMVs", "PROBLEM", 177, 181], ["MMVs", "PROBLEM", 186, 190], ["phenotype 2", "PROBLEM", 233, 244], ["membrane rearrangements", "PROBLEM", 373, 396], ["ORF1 generates membrane alterations", "PROBLEM", 468, 503], ["replication organelles", "PROBLEM", 518, 540], ["MNV infection", "PROBLEM", 550, 563], ["fixation", "OBSERVATION", 18, 26], ["membrane alterations", "OBSERVATION", 80, 100], ["infected cells", "OBSERVATION", 132, 146], ["infection", "OBSERVATION", 415, 424], ["MNV", "OBSERVATION_MODIFIER", 550, 553], ["infection", "OBSERVATION", 554, 563]]], ["Therefore, ORF1 expression seemed a valid model to study the morphology of huNoV induced membrane alterations.Establishment of an ORF1 polyprotein expression model of three GII.4 outbreak strains of HuNoV ::: ResultsWe used ORF1 sequences of three GII.4 strains associated with pandemic outbreaks: a Den Haag 2006b variant (DH) [49], a New Orleans 2009 variant (NO) [50] and a Sydney 2012 variant (Syd) [51].", [["membrane", "ANATOMY", 89, 97], ["NO", "CHEMICAL", 362, 364], ["NO", "CHEMICAL", 362, 364], ["ORF1", "GENE_OR_GENE_PRODUCT", 11, 15], ["huNoV", "GENE_OR_GENE_PRODUCT", 75, 80], ["membrane", "CELLULAR_COMPONENT", 89, 97], ["ORF1", "DNA", 11, 15], ["huNoV", "PROTEIN", 75, 80], ["ORF1 sequences", "DNA", 224, 238], ["HuNoV", "SPECIES", 199, 204], ["Den Haag 2006b variant (DH)", "SPECIES", 300, 327], ["huNoV induced membrane alterations", "PROBLEM", 75, 109], ["an ORF1 polyprotein expression model", "TREATMENT", 127, 163], ["ORF1 sequences", "TEST", 224, 238], ["huNoV", "OBSERVATION", 75, 80], ["membrane alterations", "OBSERVATION", 89, 109]]], ["We first tested the expression of the different ORF1 proteins and their processing to assess the integrity of the polyproteins.", [["ORF1", "GENE_OR_GENE_PRODUCT", 48, 52], ["ORF1 proteins", "PROTEIN", 48, 61], ["polyproteins", "PROTEIN", 114, 126], ["the different ORF1 proteins", "PROBLEM", 34, 61], ["the polyproteins", "PROBLEM", 110, 126], ["polyproteins", "OBSERVATION", 114, 126]]], ["In a coupled in vitro transcription/translation system (S3A Fig) most of NS-proteins remained buried in precursors, which according to their sizes could represent the entire ORF1 and NS4-NS7 (S3A Fig).", [["ORF1", "GENE_OR_GENE_PRODUCT", 174, 178], ["NS4-NS7", "GENE_OR_GENE_PRODUCT", 183, 190], ["NS-proteins", "PROTEIN", 73, 84], ["ORF1", "DNA", 174, 178], ["NS4", "DNA", 183, 186], ["NS7", "DNA", 187, 190], ["NS", "TREATMENT", 73, 75], ["the entire ORF1", "TEST", 163, 178], ["NS4", "TEST", 183, 186], ["buried", "OBSERVATION", 94, 100]]], ["Mature cleavage products were only found for NS1-2 and/or NS3, however the size of these proteins was almost identical.", [["NS1-2", "GENE_OR_GENE_PRODUCT", 45, 50], ["NS3", "GENE_OR_GENE_PRODUCT", 58, 61], ["NS1", "PROTEIN", 45, 48], ["NS3", "PROTEIN", 58, 61], ["Mature cleavage products", "TREATMENT", 0, 24], ["NS1", "TEST", 45, 48], ["NS3", "PROBLEM", 58, 61], ["cleavage products", "OBSERVATION", 7, 24], ["size", "OBSERVATION_MODIFIER", 75, 79], ["proteins", "OBSERVATION", 89, 97]]], ["This result was in line with previous data studying ORF1 in vitro processing of GII.4 [43,52].", [["ORF1", "DNA", 52, 56]]], ["In addition, we assessed polyprotein expression and processing by Western blotting (WB) after transfection of the plasmids encoding the three ORF1 proteins into Huh7 T7 cells.", [["WB", "ANATOMY", 84, 86], ["plasmids", "ANATOMY", 114, 122], ["Huh7 T7 cells", "ANATOMY", 161, 174], ["ORF1", "GENE_OR_GENE_PRODUCT", 142, 146], ["Huh7 T7 cells", "CELL", 161, 174], ["plasmids", "DNA", 114, 122], ["ORF1 proteins", "PROTEIN", 142, 155], ["Huh7 T7 cells", "CELL_LINE", 161, 174], ["polyprotein expression", "TREATMENT", 25, 47], ["transfection of the plasmids", "TREATMENT", 94, 122], ["Huh7 T7", "ANATOMY", 161, 168]]], ["We could detect cleavage products corresponding to NS3, (S3B Fig), NS7 (S3C Fig) and NS1-2, the latter by expressing N-terminal eGFP tagged ORF1 from the NO isolate since we lacked a specific antibody (S3G Fig).", [["NO", "CHEMICAL", 154, 156], ["N", "CHEMICAL", 117, 118], ["NO", "CHEMICAL", 154, 156], ["NS3", "GENE_OR_GENE_PRODUCT", 51, 54], ["NS7", "GENE_OR_GENE_PRODUCT", 67, 70], ["NS1-2", "GENE_OR_GENE_PRODUCT", 85, 90], ["eGFP", "GENE_OR_GENE_PRODUCT", 128, 132], ["ORF1", "GENE_OR_GENE_PRODUCT", 140, 144], ["NO", "GENE_OR_GENE_PRODUCT", 154, 156], ["cleavage products", "PROTEIN", 16, 33], ["NS3", "PROTEIN", 51, 54], ["NS7", "PROTEIN", 67, 70], ["S3C", "PROTEIN", 72, 75], ["NS1", "PROTEIN", 85, 88], ["N-terminal eGFP tagged ORF1", "DNA", 117, 144], ["specific antibody", "PROTEIN", 183, 200], ["S3G Fig", "PROTEIN", 202, 209], ["cleavage products", "PROBLEM", 16, 33], ["NS3", "TEST", 51, 54], ["NS7 (S3C Fig", "TREATMENT", 67, 79], ["NS1", "TREATMENT", 85, 88]]], ["No distinct cleavage products were observed for NS4, NS5 and NS6 (S3D\u2013S3F Fig), indicating that they might be retained in relatively stable precursor proteins, as suggested by in vitro translation.Establishment of an ORF1 polyprotein expression model of three GII.4 outbreak strains of HuNoV ::: ResultsTo investigate membrane alterations resulting from huNoV nonstructural proteins, we expressed the complete ORF1 protein of the three GII.4 isolates in Huh7 T7 cells and performed EM analysis (Fig 3, S4 Fig).", [["membrane", "ANATOMY", 318, 326], ["Huh7 T7 cells", "ANATOMY", 454, 467], ["NS4", "GENE_OR_GENE_PRODUCT", 48, 51], ["NS5", "GENE_OR_GENE_PRODUCT", 53, 56], ["NS6", "GENE_OR_GENE_PRODUCT", 61, 64], ["membrane", "CELLULAR_COMPONENT", 318, 326], ["huNoV nonstructural proteins", "GENE_OR_GENE_PRODUCT", 354, 382], ["ORF1", "GENE_OR_GENE_PRODUCT", 410, 414], ["Huh7 T7 cells", "CELL", 454, 467], ["cleavage products", "PROTEIN", 12, 29], ["NS4", "PROTEIN", 48, 51], ["NS5", "PROTEIN", 53, 56], ["NS6", "PROTEIN", 61, 64], ["S3D", "PROTEIN", 66, 69], ["S3F Fig", "PROTEIN", 70, 77], ["precursor proteins", "PROTEIN", 140, 158], ["huNoV nonstructural proteins", "PROTEIN", 354, 382], ["ORF1 protein", "PROTEIN", 410, 422], ["Huh7 T7 cells", "CELL_LINE", 454, 467], ["HuNoV", "SPECIES", 286, 291], ["distinct cleavage products", "PROBLEM", 3, 29], ["NS4", "TEST", 48, 51], ["NS5", "TREATMENT", 53, 56], ["an ORF1 polyprotein expression model", "TREATMENT", 214, 250], ["membrane alterations", "PROBLEM", 318, 338], ["huNoV nonstructural proteins", "PROBLEM", 354, 382], ["the complete ORF1 protein", "TEST", 397, 422], ["Huh7 T7 cells", "TREATMENT", 454, 467], ["EM analysis", "TEST", 482, 493], ["Fig", "TEST", 495, 498], ["distinct", "OBSERVATION_MODIFIER", 3, 11], ["cleavage products", "OBSERVATION", 12, 29]]], ["As for MNV, the expression of ORF1 polyproteins resulted in the formation of complex vesicular structures for all three GII.4 isolates (Fig 3, S4 Fig), similar to those found in MNV-infected cells (Fig 1, S2 Fig) and irrespective of the fixation technique used.", [["vesicular structures", "ANATOMY", 85, 105], ["cells", "ANATOMY", 191, 196], ["MNV-infected", "DISEASE", 178, 190], ["ORF1", "GENE_OR_GENE_PRODUCT", 30, 34], ["vesicular structures", "MULTI-TISSUE_STRUCTURE", 85, 105], ["MNV", "ORGANISM", 178, 181], ["cells", "CELL", 191, 196], ["ORF1 polyproteins", "PROTEIN", 30, 47], ["MNV-infected cells", "CELL_LINE", 178, 196], ["MNV", "SPECIES", 7, 10], ["MNV", "SPECIES", 178, 181], ["MNV", "PROBLEM", 7, 10], ["ORF1 polyproteins", "PROBLEM", 30, 47], ["complex vesicular structures", "PROBLEM", 77, 105], ["Fig", "TEST", 198, 201], ["the fixation technique", "TREATMENT", 233, 255], ["complex", "OBSERVATION_MODIFIER", 77, 84], ["vesicular", "OBSERVATION", 85, 94], ["infected cells", "OBSERVATION", 182, 196], ["fixation technique", "OBSERVATION", 237, 255]]], ["The average diameter of DMVs was approximately 100\u2013200 nm (Fig 3B), and resembled structures found upon HCV and picornavirus infection [28,31,53\u201356].", [["DMVs", "ANATOMY", 24, 28], ["picornavirus infection", "DISEASE", 112, 134], ["DMVs", "CANCER", 24, 28], ["HCV", "ORGANISM", 104, 107], ["picornavirus", "ORGANISM", 112, 124], ["DMVs", "PROTEIN", 24, 28], ["HCV", "SPECIES", 104, 107], ["DMVs", "TEST", 24, 28], ["HCV", "PROBLEM", 104, 107], ["picornavirus infection", "PROBLEM", 112, 134], ["average", "OBSERVATION_MODIFIER", 4, 11], ["diameter", "OBSERVATION_MODIFIER", 12, 20], ["HCV", "OBSERVATION", 104, 107], ["picornavirus", "OBSERVATION_MODIFIER", 112, 124], ["infection", "OBSERVATION", 125, 134]]], ["Most membrane alterations induced by ORF1 expression in Huh7 cells were again found in close association with LDs, similar to MNV.", [["membrane", "ANATOMY", 5, 13], ["Huh7 cells", "ANATOMY", 56, 66], ["LDs", "ANATOMY", 110, 113], ["membrane", "CELLULAR_COMPONENT", 5, 13], ["ORF1", "GENE_OR_GENE_PRODUCT", 37, 41], ["Huh7 cells", "CELL", 56, 66], ["LDs", "CELLULAR_COMPONENT", 110, 113], ["MNV", "ORGANISM", 126, 129], ["ORF1", "DNA", 37, 41], ["Huh7 cells", "CELL_LINE", 56, 66], ["MNV", "SPECIES", 126, 129], ["Most membrane alterations", "PROBLEM", 0, 25], ["ORF1 expression in Huh7 cells", "PROBLEM", 37, 66]]], ["Overall, no consistent differences were found between ORF1 expression and infection regarding the ratio of SMVs, DMVs and MMVs (Fig 3C).", [["SMVs", "ANATOMY", 107, 111], ["infection", "DISEASE", 74, 83], ["ORF1", "GENE_OR_GENE_PRODUCT", 54, 58], ["SMVs", "GENE_OR_GENE_PRODUCT", 107, 111], ["ORF1", "DNA", 54, 58], ["SMVs", "PROTEIN", 107, 111], ["DMVs", "PROTEIN", 113, 117], ["MMVs", "PROTEIN", 122, 126], ["ORF1 expression", "PROBLEM", 54, 69], ["infection", "PROBLEM", 74, 83], ["SMVs", "PROBLEM", 107, 111], ["DMVs", "PROBLEM", 113, 117], ["MMVs", "TREATMENT", 122, 126], ["no", "UNCERTAINTY", 9, 11], ["infection", "OBSERVATION", 74, 83]]], ["However, high variability in vesicles size was observed among cells of the same condition, likely due to differences in protein abundance, time of infection, cell type, etc. Still, SMVs were by far the most abundant vesicle species in all conditions.Establishment of an ORF1 polyprotein expression model of three GII.4 outbreak strains of HuNoV ::: ResultsIn summary, expression of ORF1 of different GII.4 isolates gave rise to a complex set of membrane alterations independent of RNA replication, but similar to structures found in MNV-infected cells.", [["vesicles", "ANATOMY", 29, 37], ["cells", "ANATOMY", 62, 67], ["cell", "ANATOMY", 158, 162], ["vesicle", "ANATOMY", 216, 223], ["membrane", "ANATOMY", 445, 453], ["cells", "ANATOMY", 546, 551], ["infection", "DISEASE", 147, 156], ["HuNoV", "CHEMICAL", 339, 344], ["vesicles", "CELLULAR_COMPONENT", 29, 37], ["cells", "CELL", 62, 67], ["cell type", "CELL", 158, 167], ["SMVs", "GENE_OR_GENE_PRODUCT", 181, 185], ["vesicle", "CELLULAR_COMPONENT", 216, 223], ["ORF1", "GENE_OR_GENE_PRODUCT", 382, 386], ["membrane", "CELLULAR_COMPONENT", 445, 453], ["MNV", "ORGANISM", 533, 536], ["cells", "CELL", 546, 551], ["SMVs", "PROTEIN", 181, 185], ["ORF1", "DNA", 382, 386], ["MNV-infected cells", "CELL_LINE", 533, 551], ["HuNoV", "SPECIES", 339, 344], ["MNV", "SPECIES", 533, 536], ["high variability in vesicles size", "PROBLEM", 9, 42], ["differences in protein abundance", "PROBLEM", 105, 137], ["infection", "PROBLEM", 147, 156], ["cell type", "PROBLEM", 158, 167], ["SMVs", "PROBLEM", 181, 185], ["an ORF1 polyprotein expression model", "TREATMENT", 267, 303], ["membrane alterations", "PROBLEM", 445, 465], ["RNA replication", "TREATMENT", 481, 496], ["infected cells", "PROBLEM", 537, 551], ["high", "OBSERVATION_MODIFIER", 9, 13], ["variability", "OBSERVATION_MODIFIER", 14, 25], ["vesicles", "OBSERVATION_MODIFIER", 29, 37], ["size", "OBSERVATION_MODIFIER", 38, 42], ["likely due to", "UNCERTAINTY", 91, 104], ["infection", "OBSERVATION", 147, 156], ["cell type", "OBSERVATION", 158, 167], ["vesicle species", "OBSERVATION", 216, 231], ["polyprotein expression", "OBSERVATION", 275, 297], ["RNA replication", "OBSERVATION", 481, 496], ["MNV", "OBSERVATION", 533, 536], ["infected cells", "OBSERVATION", 537, 551]]], ["Altogether our data suggested that norovirus replication organelles might belong to the DMV-morphotype, comparable to those observed for enteroviruses and HCV.Electron Tomography (ET) of cells expressing GII.4 NO ORF1 ::: ResultsWe focused our subsequent analyses on one of the three GII.4 strains (NO), since neither polyprotein processing nor the ultrastructural analysis revealed distinct differences upon the expression of ORF1 among the three strains.Electron Tomography (ET) of cells expressing GII.4 NO ORF1 ::: ResultsTo gain deeper insights into the morphology and biogenesis of ORF1-induced membrane structures we further analyzed tomograms of cells expressing ORF1 of the NO strain fixed by high pressure freezing (S1\u2013S5 Movies, Fig 4A and 4B and S5 Fig), allowing a better preservation of the cell membranes.", [["organelles", "ANATOMY", 57, 67], ["cells", "ANATOMY", 187, 192], ["cells", "ANATOMY", 484, 489], ["membrane structures", "ANATOMY", 601, 620], ["cells", "ANATOMY", 654, 659], ["cell membranes", "ANATOMY", 805, 819], ["enteroviruses", "DISEASE", 137, 150], ["HCV", "DISEASE", 155, 158], ["NO", "CHEMICAL", 210, 212], ["NO", "CHEMICAL", 299, 301], ["NO", "CHEMICAL", 507, 509], ["NO", "CHEMICAL", 683, 685], ["NO", "CHEMICAL", 210, 212], ["NO", "CHEMICAL", 299, 301], ["NO", "CHEMICAL", 507, 509], ["NO", "CHEMICAL", 683, 685], ["norovirus", "ORGANISM", 35, 44], ["organelles", "CELLULAR_COMPONENT", 57, 67], ["DMV", "GENE_OR_GENE_PRODUCT", 88, 91], ["HCV", "ORGANISM", 155, 158], ["cells", "CELL", 187, 192], ["NO", "SIMPLE_CHEMICAL", 299, 301], ["ORF1", "GENE_OR_GENE_PRODUCT", 427, 431], ["cells", "CELL", 484, 489], ["ORF1", "GENE_OR_GENE_PRODUCT", 588, 592], ["membrane structures", "CELLULAR_COMPONENT", 601, 620], ["cells", "CELL", 654, 659], ["ORF1", "GENE_OR_GENE_PRODUCT", 671, 675], ["NO", "GENE_OR_GENE_PRODUCT", 683, 685], ["cell membranes", "CELLULAR_COMPONENT", 805, 819], ["GII.4 NO ORF1", "PROTEIN", 204, 217], ["ORF1", "DNA", 427, 431], ["GII.4 NO ORF1", "PROTEIN", 501, 514], ["ORF1", "DNA", 588, 592], ["ORF1", "DNA", 671, 675], ["HCV", "SPECIES", 155, 158], ["our data", "TEST", 11, 19], ["norovirus replication organelles", "PROBLEM", 35, 67], ["enteroviruses", "PROBLEM", 137, 150], ["HCV", "PROBLEM", 155, 158], ["Electron Tomography", "TEST", 159, 178], ["neither polyprotein processing", "PROBLEM", 310, 340], ["the ultrastructural analysis", "TEST", 345, 373], ["ORF1", "TREATMENT", 427, 431], ["Electron Tomography", "TEST", 456, 475], ["ORF1-induced membrane structures", "TREATMENT", 588, 620], ["ORF1", "TEST", 671, 675], ["strain", "PROBLEM", 686, 692], ["high pressure freezing", "PROBLEM", 702, 724], ["norovirus", "OBSERVATION", 35, 44], ["distinct", "OBSERVATION_MODIFIER", 383, 391], ["NO", "UNCERTAINTY", 683, 685], ["high pressure", "OBSERVATION", 702, 715], ["cell membranes", "OBSERVATION", 805, 819]]], ["Areas appearing as simple accumulations of SMVs, DMVs and MMVs revealed complex structures in close proximity to ER sheets, including clusters of interwoven vesicles delimited by one or several lipid bilayers (S1 and S2 Movies and Fig 4A and 4B).", [["SMVs", "ANATOMY", 43, 47], ["ER sheets", "ANATOMY", 113, 122], ["vesicles", "ANATOMY", 157, 165], ["SMVs", "GENE_OR_GENE_PRODUCT", 43, 47], ["DMVs", "SIMPLE_CHEMICAL", 49, 53], ["ER", "GENE_OR_GENE_PRODUCT", 113, 115], ["vesicles", "CELLULAR_COMPONENT", 157, 165], ["SMVs", "PROTEIN", 43, 47], ["DMVs", "PROTEIN", 49, 53], ["MMVs", "PROTEIN", 58, 62], ["S1", "PROTEIN", 210, 212], ["4B", "PROTEIN", 242, 244], ["simple accumulations of SMVs", "PROBLEM", 19, 47], ["DMVs", "PROBLEM", 49, 53], ["MMVs", "PROBLEM", 58, 62], ["complex structures", "PROBLEM", 72, 90], ["interwoven vesicles", "PROBLEM", 146, 165], ["simple", "OBSERVATION_MODIFIER", 19, 25], ["accumulations", "OBSERVATION_MODIFIER", 26, 39], ["complex", "OBSERVATION_MODIFIER", 72, 79], ["interwoven vesicles", "OBSERVATION", 146, 165]]], ["In addition, we found double membrane vesicles (DMVs) connecting to multivesicular bodies (MVBs) or late endosomes (S1 and S3 Movies and S5A and S5B Fig) and autophagosome-like structures (ALS, S1 and S3 Movies and S5C Fig).Electron Tomography (ET) of cells expressing GII.4 NO ORF1 ::: ResultsSince clusters of SMVs, DMVs and MMVs most closely resembled the organization of the MNV replication sites in infected cells, we rendered these areas to address their 3D organization (Fig 4A and 4B, S4 and S5 Movies).", [["membrane vesicles", "ANATOMY", 29, 46], ["DMVs", "ANATOMY", 48, 52], ["multivesicular bodies", "ANATOMY", 68, 89], ["MVBs", "ANATOMY", 91, 95], ["late endosomes", "ANATOMY", 100, 114], ["autophagosome-like structures", "ANATOMY", 158, 187], ["cells", "ANATOMY", 252, 257], ["SMVs", "ANATOMY", 312, 316], ["DMVs", "ANATOMY", 318, 322], ["cells", "ANATOMY", 413, 418], ["NO", "CHEMICAL", 275, 277], ["NO", "CHEMICAL", 275, 277], ["membrane vesicles", "CELLULAR_COMPONENT", 29, 46], ["multivesicular bodies", "CELLULAR_COMPONENT", 68, 89], ["MVBs", "CELLULAR_COMPONENT", 91, 95], ["late endosomes", "CELLULAR_COMPONENT", 100, 114], ["Movies", "GENE_OR_GENE_PRODUCT", 126, 132], ["S5A", "GENE_OR_GENE_PRODUCT", 137, 140], ["S5B", "GENE_OR_GENE_PRODUCT", 145, 148], ["autophagosome", "CELLULAR_COMPONENT", 158, 171], ["cells", "CELL", 252, 257], ["SMVs", "GENE_OR_GENE_PRODUCT", 312, 316], ["DMVs", "CANCER", 318, 322], ["MMVs", "GENE_OR_GENE_PRODUCT", 327, 331], ["MNV", "ORGANISM", 379, 382], ["cells", "CELL", 413, 418], ["S1", "PROTEIN", 116, 118], ["S3", "PROTEIN", 123, 125], ["Movies", "PROTEIN", 126, 132], ["S5A", "PROTEIN", 137, 140], ["S5B", "PROTEIN", 145, 148], ["autophagosome", "PROTEIN", 158, 171], ["ALS", "PROTEIN", 189, 192], ["S1", "PROTEIN", 194, 196], ["S3", "PROTEIN", 201, 203], ["S5C", "PROTEIN", 215, 218], ["GII.4 NO ORF1", "PROTEIN", 269, 282], ["SMVs", "DNA", 312, 316], ["DMVs", "DNA", 318, 322], ["MMVs", "DNA", 327, 331], ["MNV replication sites", "DNA", 379, 400], ["infected cells", "CELL_TYPE", 404, 418], ["double membrane vesicles (DMVs)", "PROBLEM", 22, 53], ["late endosomes", "PROBLEM", 100, 114], ["S5A", "TEST", 137, 140], ["autophagosome", "TEST", 158, 171], ["Electron Tomography", "TEST", 224, 243], ["SMVs", "PROBLEM", 312, 316], ["DMVs", "PROBLEM", 318, 322], ["MMVs", "PROBLEM", 327, 331], ["infected cells", "PROBLEM", 404, 418], ["double", "OBSERVATION_MODIFIER", 22, 28], ["membrane vesicles", "OBSERVATION", 29, 46], ["multivesicular", "ANATOMY_MODIFIER", 68, 82], ["bodies", "ANATOMY_MODIFIER", 83, 89], ["late", "OBSERVATION_MODIFIER", 100, 104], ["endosomes", "OBSERVATION_MODIFIER", 105, 114], ["S1", "ANATOMY_MODIFIER", 116, 118], ["MNV replication", "OBSERVATION", 379, 394], ["infected cells", "OBSERVATION", 404, 418]]], ["SMVs (white), DMVs (yellow) and MMVs (blue) all appeared rather vesicular than tubular, were tightly attached to each other and mostly found adjacent to ER cisternae.", [["SMVs", "ANATOMY", 0, 4], ["vesicular", "ANATOMY", 64, 73], ["tubular", "ANATOMY", 79, 86], ["ER cisternae", "ANATOMY", 153, 165], ["SMVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["DMVs", "GENE_OR_GENE_PRODUCT", 14, 18], ["MMVs", "GENE_OR_GENE_PRODUCT", 32, 36], ["tubular", "TISSUE", 79, 86], ["ER", "GENE_OR_GENE_PRODUCT", 153, 155], ["cisternae", "CELLULAR_COMPONENT", 156, 165], ["SMVs (white), DMVs (yellow) and MMVs (blue", "PROBLEM", 0, 42], ["white", "OBSERVATION_MODIFIER", 6, 11], ["vesicular", "OBSERVATION_MODIFIER", 64, 73], ["cisternae", "ANATOMY_MODIFIER", 156, 165]]], ["In some serial slices, the membrane of a DMV was found still in continuation with the ER (Fig 4A, panel 2).", [["slices", "ANATOMY", 15, 21], ["membrane", "ANATOMY", 27, 35], ["membrane", "CELLULAR_COMPONENT", 27, 35], ["ER", "GENE_OR_GENE_PRODUCT", 86, 88], ["ER", "PROTEIN", 86, 88], ["some serial slices", "TEST", 3, 21], ["a DMV", "PROBLEM", 39, 44], ["panel", "TEST", 98, 103]]], ["MMVs were mainly generated by enwrapping of SMVs with tubular structures, most likely elongated or collapsed SMVs, appearing as multilamellar vesicles in cross-sections (Fig 4B, panel 2).", [["MMVs", "ANATOMY", 0, 4], ["SMVs", "ANATOMY", 44, 48], ["tubular structures", "ANATOMY", 54, 72], ["SMVs", "ANATOMY", 109, 113], ["multilamellar vesicles", "ANATOMY", 128, 150], ["MMVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["SMVs", "GENE_OR_GENE_PRODUCT", 44, 48], ["tubular structures", "TISSUE", 54, 72], ["SMVs", "PATHOLOGICAL_FORMATION", 109, 113], ["multilamellar vesicles", "CELLULAR_COMPONENT", 128, 150], ["MMVs", "PROTEIN", 0, 4], ["SMVs", "PROTEIN", 44, 48], ["MMVs", "PROBLEM", 0, 4], ["tubular structures", "PROBLEM", 54, 72], ["collapsed SMVs", "PROBLEM", 99, 113], ["panel", "TEST", 178, 183], ["tubular", "ANATOMY_MODIFIER", 54, 61], ["most likely", "UNCERTAINTY", 74, 85], ["elongated", "OBSERVATION_MODIFIER", 86, 95], ["collapsed", "OBSERVATION_MODIFIER", 99, 108], ["SMVs", "OBSERVATION", 109, 113], ["multilamellar vesicles", "OBSERVATION", 128, 150]]], ["Alternatively MMVs were originated as SMVs or DMVs engulfing pre-existing DMVs (Fig 4B, panel 3, 4).", [["MMVs", "ANATOMY", 14, 18], ["MMVs", "GENE_OR_GENE_PRODUCT", 14, 18], ["MMVs", "PROTEIN", 14, 18], ["MMVs", "PROBLEM", 14, 18], ["SMVs", "PROBLEM", 38, 42], ["DMVs", "PROBLEM", 46, 50], ["panel", "TEST", 88, 93]]], ["Overall, the morphology and complexity of the membrane alterations, as well as their biogenesis, appeared very reminiscent of later stages of the enterovirus replication sites [53\u201356].Electron Tomography (ET) of cells expressing GII.4 NO ORF1 ::: ResultsAltogether, the ET analysis revealed complex interwoven vesicular structures adjacent to the ER, with one or several membrane bilayers, appearing as SMVs, DMVs and MMVs.", [["membrane", "ANATOMY", 46, 54], ["cells", "ANATOMY", 212, 217], ["vesicular structures", "ANATOMY", 310, 330], ["ER", "ANATOMY", 347, 349], ["membrane bilayers", "ANATOMY", 371, 388], ["enterovirus", "DISEASE", 146, 157], ["NO", "CHEMICAL", 235, 237], ["NO", "CHEMICAL", 235, 237], ["membrane", "CELLULAR_COMPONENT", 46, 54], ["enterovirus", "ORGANISM", 146, 157], ["cells", "CELL", 212, 217], ["vesicular structures", "MULTI-TISSUE_STRUCTURE", 310, 330], ["ER", "GENE_OR_GENE_PRODUCT", 347, 349], ["membrane bilayers", "CELLULAR_COMPONENT", 371, 388], ["SMVs", "GENE_OR_GENE_PRODUCT", 403, 407], ["MMVs", "PATHOLOGICAL_FORMATION", 418, 422], ["enterovirus replication sites", "DNA", 146, 175], ["GII.4 NO ORF1", "PROTEIN", 229, 242], ["ER", "PROTEIN", 347, 349], ["SMVs", "PROTEIN", 403, 407], ["DMVs", "PROTEIN", 409, 413], ["MMVs", "PROTEIN", 418, 422], ["the membrane alterations", "PROBLEM", 42, 66], ["the enterovirus replication sites", "PROBLEM", 142, 175], ["Electron Tomography", "TEST", 184, 203], ["the ET analysis", "TEST", 266, 281], ["complex interwoven vesicular structures", "PROBLEM", 291, 330], ["several membrane bilayers", "PROBLEM", 363, 388], ["SMVs", "PROBLEM", 403, 407], ["DMVs", "PROBLEM", 409, 413], ["MMVs", "PROBLEM", 418, 422], ["morphology", "OBSERVATION_MODIFIER", 13, 23], ["complexity", "OBSERVATION_MODIFIER", 28, 38], ["membrane alterations", "OBSERVATION", 46, 66], ["enterovirus replication", "OBSERVATION", 146, 169], ["complex", "OBSERVATION_MODIFIER", 291, 298], ["interwoven", "OBSERVATION_MODIFIER", 299, 309], ["vesicular structures", "OBSERVATION", 310, 330], ["several", "OBSERVATION_MODIFIER", 363, 370], ["membrane bilayers", "OBSERVATION", 371, 388]]], ["MMVs were likely generated by enwrapping of SMVs with elongated SMVs, very similar to the mechanism proposed for enteroviruses.The N-terminal protein GII.4 NS1-2 localizes at the ER and induces tubular ER protrusions ::: ResultsLittle is known so far about the contribution of individual norovirus NS proteins to the biogenesis of the viral replication complex.", [["SMVs", "ANATOMY", 44, 48], ["SMVs", "ANATOMY", 64, 68], ["ER", "ANATOMY", 179, 181], ["tubular ER", "ANATOMY", 194, 204], ["enteroviruses", "DISEASE", 113, 126], ["MMVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["SMVs", "GENE_OR_GENE_PRODUCT", 44, 48], ["SMVs", "GENE_OR_GENE_PRODUCT", 64, 68], ["enteroviruses", "ORGANISM", 113, 126], ["NS1-2", "GENE_OR_GENE_PRODUCT", 156, 161], ["ER", "GENE_OR_GENE_PRODUCT", 179, 181], ["ER", "GENE_OR_GENE_PRODUCT", 202, 204], ["MMVs", "PROTEIN", 0, 4], ["SMVs", "PROTEIN", 44, 48], ["N-terminal protein GII.4 NS1-2", "PROTEIN", 131, 161], ["ER", "PROTEIN", 179, 181], ["norovirus NS proteins", "PROTEIN", 288, 309], ["viral replication complex", "PROTEIN", 335, 360], ["SMVs", "PROBLEM", 44, 48], ["elongated SMVs", "PROBLEM", 54, 68], ["enteroviruses", "PROBLEM", 113, 126], ["The N-terminal protein GII", "TEST", 127, 153], ["NS1", "TEST", 156, 159], ["individual norovirus NS proteins", "TREATMENT", 277, 309], ["the viral replication complex", "TREATMENT", 331, 360], ["elongated", "OBSERVATION_MODIFIER", 54, 63], ["SMVs", "OBSERVATION", 64, 68], ["enteroviruses", "OBSERVATION", 113, 126], ["tubular", "ANATOMY_MODIFIER", 194, 201], ["protrusions", "OBSERVATION_MODIFIER", 205, 216], ["norovirus", "OBSERVATION", 288, 297], ["viral replication", "OBSERVATION", 335, 352]]], ["We therefore fused NS1-2, NS3 and NS4, known to be associated with membranes [13], N-terminally with eGFP, to study their propensity to induce membrane alterations by correlative light and electron microscopy (CLEM).", [["membranes", "ANATOMY", 67, 76], ["membrane", "ANATOMY", 143, 151], ["NS1-2", "GENE_OR_GENE_PRODUCT", 19, 24], ["NS3", "GENE_OR_GENE_PRODUCT", 26, 29], ["NS4", "GENE_OR_GENE_PRODUCT", 34, 37], ["eGFP", "GENE_OR_GENE_PRODUCT", 101, 105], ["membrane", "CELLULAR_COMPONENT", 143, 151], ["NS1", "PROTEIN", 19, 22], ["NS3", "PROTEIN", 26, 29], ["NS4", "PROTEIN", 34, 37], ["N-terminally", "PROTEIN", 83, 95], ["eGFP", "PROTEIN", 101, 105], ["NS1", "TEST", 19, 22], ["NS3", "TREATMENT", 26, 29], ["NS4", "TREATMENT", 34, 37], ["membrane alterations", "PROBLEM", 143, 163], ["electron microscopy", "TEST", 189, 208]]], ["We first confirmed by WB the expression of stable fusion proteins and the absence of free eGFP (S6A and S6B Fig).The N-terminal protein GII.4 NS1-2 localizes at the ER and induces tubular ER protrusions ::: ResultsThe N-terminal protein of norovirus ORF1 is thought to induce membrane rearrangements and is considered to be involved in replication complex formation (reviewed in [8]).", [["ER", "ANATOMY", 165, 167], ["tubular ER", "ANATOMY", 180, 190], ["membrane", "ANATOMY", 276, 284], ["eGFP", "GENE_OR_GENE_PRODUCT", 90, 94], ["S6A", "GENE_OR_GENE_PRODUCT", 96, 99], ["S6B", "GENE_OR_GENE_PRODUCT", 104, 107], ["NS1-2", "GENE_OR_GENE_PRODUCT", 142, 147], ["ER", "GENE_OR_GENE_PRODUCT", 165, 167], ["ER", "GENE_OR_GENE_PRODUCT", 188, 190], ["norovirus ORF1", "ORGANISM", 240, 254], ["membrane", "CELLULAR_COMPONENT", 276, 284], ["fusion proteins", "PROTEIN", 50, 65], ["eGFP", "PROTEIN", 90, 94], ["S6A", "PROTEIN", 96, 99], ["S6B", "PROTEIN", 104, 107], ["N-terminal protein GII.4 NS1-2", "PROTEIN", 117, 147], ["ER", "PROTEIN", 165, 167], ["N-terminal protein", "PROTEIN", 218, 236], ["norovirus ORF1", "DNA", 240, 254], ["stable fusion proteins", "PROBLEM", 43, 65], ["free eGFP", "TEST", 85, 94], ["The N-terminal protein GII", "TEST", 113, 139], ["NS1", "TEST", 142, 145], ["The N-terminal protein of norovirus ORF1", "PROBLEM", 214, 254], ["membrane rearrangements", "PROBLEM", 276, 299], ["stable", "OBSERVATION_MODIFIER", 43, 49], ["fusion", "OBSERVATION", 50, 56], ["tubular", "ANATOMY_MODIFIER", 180, 187], ["protrusions", "OBSERVATION_MODIFIER", 191, 202], ["norovirus ORF1", "OBSERVATION", 240, 254], ["membrane rearrangements", "OBSERVATION", 276, 299]]], ["First, we examined the localization of eGFP-NS1-2 with respect to subcellular markers by immunofluorescence (Fig 5A).", [["subcellular", "ANATOMY", 66, 77], ["eGFP-NS1-2", "GENE_OR_GENE_PRODUCT", 39, 49], ["eGFP", "PROTEIN", 39, 43], ["NS1", "PROTEIN", 44, 47], ["subcellular markers", "PROTEIN", 66, 85], ["eGFP", "TEST", 39, 43], ["subcellular markers", "TEST", 66, 85]]], ["Interestingly, eGFP-NS1-2 had a very peculiar filamentous subcellular distribution in most cells (Fig 5A).", [["subcellular", "ANATOMY", 58, 69], ["cells", "ANATOMY", 91, 96], ["eGFP-NS1-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["cells", "CELL", 91, 96], ["Fig 5A", "CELL", 98, 104], ["eGFP", "PROTEIN", 15, 19], ["NS1", "PROTEIN", 20, 23], ["eGFP", "TEST", 15, 19], ["NS1", "TEST", 20, 23], ["a very peculiar filamentous subcellular distribution", "PROBLEM", 30, 82], ["very", "OBSERVATION_MODIFIER", 32, 36], ["peculiar", "OBSERVATION_MODIFIER", 37, 45], ["filamentous", "OBSERVATION_MODIFIER", 46, 57], ["subcellular distribution", "OBSERVATION", 58, 82], ["most cells", "OBSERVATION_MODIFIER", 86, 96]]], ["A minority of cells showed a focal distribution of NS1-2 or an intermediate phenotype (Fig 5A, white and yellow asterisk, respectively).", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["NS1-2", "GENE_OR_GENE_PRODUCT", 51, 56], ["NS1", "PROTEIN", 51, 54], ["A minority of cells", "PROBLEM", 0, 19], ["a focal distribution of NS1", "PROBLEM", 27, 54], ["an intermediate phenotype", "PROBLEM", 60, 85], ["white and yellow asterisk", "PROBLEM", 95, 120], ["focal", "OBSERVATION_MODIFIER", 29, 34], ["distribution", "OBSERVATION_MODIFIER", 35, 47], ["NS1", "OBSERVATION", 51, 54], ["intermediate phenotype", "OBSERVATION", 63, 85]]], ["Since the filamentous localization was observed for N-terminally HA-tagged NS1-2, an artifact caused by eGFP fusion can be excluded (Fig 5C).", [["filamentous", "ANATOMY", 10, 21], ["N", "CHEMICAL", 52, 53], ["NS1-2", "GENE_OR_GENE_PRODUCT", 75, 80], ["eGFP", "GENE_OR_GENE_PRODUCT", 104, 108], ["N-terminally HA", "PROTEIN", 52, 67], ["NS1", "PROTEIN", 75, 78], ["eGFP fusion", "DNA", 104, 115], ["the filamentous localization", "TEST", 6, 34], ["an artifact", "PROBLEM", 82, 93], ["eGFP fusion", "TREATMENT", 104, 115], ["artifact", "OBSERVATION", 85, 93], ["eGFP fusion", "OBSERVATION", 104, 115]]], ["We found a significant co-localization of NS1-2 with a marker of the ER, judged by Pearson correlation values above 0.5 (Fig 5A and 5B).", [["NS1-2", "GENE_OR_GENE_PRODUCT", 42, 47], ["ER", "GENE_OR_GENE_PRODUCT", 69, 71], ["NS1", "PROTEIN", 42, 45], ["ER", "PROTEIN", 69, 71], ["NS1", "TEST", 42, 45], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["co-localization", "OBSERVATION", 23, 38], ["NS1", "OBSERVATION", 42, 45]]], ["Next, we used CLEM to determine the ultrastructural morphology of NS1-2-GFP positive structures (Fig 5D).", [["NS1-2", "GENE_OR_GENE_PRODUCT", 66, 71], ["GFP", "GENE_OR_GENE_PRODUCT", 72, 75], ["NS1", "PROTEIN", 66, 69], ["GFP", "PROTEIN", 72, 75], ["NS1", "TEST", 66, 69]]], ["Here, regions with strong eGFP fluorescence, indicating high NS1-2 expression, were represented by a network of tubular membrane protrusions.", [["tubular membrane", "ANATOMY", 112, 128], ["eGFP", "GENE_OR_GENE_PRODUCT", 26, 30], ["NS1-2", "GENE_OR_GENE_PRODUCT", 61, 66], ["tubular membrane", "CELLULAR_COMPONENT", 112, 128], ["NS1", "PROTEIN", 61, 64], ["strong eGFP fluorescence", "PROBLEM", 19, 43], ["high NS1-2 expression", "PROBLEM", 56, 77], ["tubular membrane protrusions", "PROBLEM", 112, 140], ["strong", "OBSERVATION_MODIFIER", 19, 25], ["eGFP fluorescence", "OBSERVATION", 26, 43], ["high NS1", "OBSERVATION", 56, 64], ["tubular membrane protrusions", "OBSERVATION", 112, 140]]], ["The absence of ribosomes associated with these structures, and the general co-localization of NS1-2 with an ER marker indicated that these membrane protrusions originated from the smooth ER.", [["ribosomes", "ANATOMY", 15, 24], ["membrane protrusions", "ANATOMY", 139, 159], ["smooth ER", "ANATOMY", 180, 189], ["ribosomes", "CELLULAR_COMPONENT", 15, 24], ["NS1-2", "GENE_OR_GENE_PRODUCT", 94, 99], ["ER", "GENE_OR_GENE_PRODUCT", 108, 110], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["ER", "GENE_OR_GENE_PRODUCT", 187, 189], ["NS1", "PROTEIN", 94, 97], ["ER", "PROTEIN", 108, 110], ["smooth ER", "PROTEIN", 180, 189], ["NS1", "TEST", 94, 97], ["an ER marker", "TEST", 105, 117], ["these membrane protrusions", "PROBLEM", 133, 159], ["membrane protrusions", "OBSERVATION", 139, 159], ["smooth", "OBSERVATION_MODIFIER", 180, 186]]], ["It is interesting to note that similar tubular structures can be induced by overexpression of ER-shaping proteins such as REEP1 and CLIMP-63 through direct interaction with microtubules [57].", [["tubular structures", "ANATOMY", 39, 57], ["microtubules", "ANATOMY", 173, 185], ["tubular structures", "TISSUE", 39, 57], ["ER", "GENE_OR_GENE_PRODUCT", 94, 96], ["REEP1", "GENE_OR_GENE_PRODUCT", 122, 127], ["CLIMP-63", "GENE_OR_GENE_PRODUCT", 132, 140], ["microtubules", "CELLULAR_COMPONENT", 173, 185], ["ER", "PROTEIN", 94, 96], ["REEP1", "PROTEIN", 122, 127], ["CLIMP-63", "PROTEIN", 132, 140], ["microtubules", "PROTEIN", 173, 185], ["similar tubular structures", "PROBLEM", 31, 57], ["REEP1", "TEST", 122, 127], ["CLIMP", "TEST", 132, 137], ["tubular", "OBSERVATION", 39, 46]]], ["However, we found no indication for a co-localization of NS1-2 induced ER-tubules with microtubules or intermediate filaments (S6C and S6D Fig).", [["ER-tubules", "ANATOMY", 71, 81], ["microtubules", "ANATOMY", 87, 99], ["filaments", "ANATOMY", 116, 125], ["NS1-2", "GENE_OR_GENE_PRODUCT", 57, 62], ["ER", "GENE_OR_GENE_PRODUCT", 71, 73], ["tubules", "TISSUE", 74, 81], ["microtubules", "CELLULAR_COMPONENT", 87, 99], ["intermediate filaments", "CELLULAR_COMPONENT", 103, 125], ["NS1", "PROTEIN", 57, 60], ["ER", "PROTEIN", 71, 73], ["microtubules", "PROTEIN", 87, 99], ["S6C", "PROTEIN", 127, 130], ["NS1", "TEST", 57, 60], ["no indication for", "UNCERTAINTY", 18, 35], ["intermediate filaments", "OBSERVATION", 103, 125]]], ["In addition we analyzed co-localization of eGFP-NS1-2 and NS3 upon expression of eGFP-ORF1 (S6E and S6F Fig) to assess the impact of the polyprotein on eGFP-NS1-2 localization.", [["eGFP-NS1-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["NS3", "GENE_OR_GENE_PRODUCT", 58, 61], ["eGFP-ORF1", "GENE_OR_GENE_PRODUCT", 81, 90], ["eGFP", "GENE_OR_GENE_PRODUCT", 152, 156], ["NS1-2", "GENE_OR_GENE_PRODUCT", 157, 162], ["eGFP", "PROTEIN", 43, 47], ["NS1", "PROTEIN", 48, 51], ["NS3", "PROTEIN", 58, 61], ["eGFP", "DNA", 81, 85], ["ORF1", "DNA", 86, 90], ["S6E", "DNA", 92, 95], ["eGFP", "DNA", 152, 156], ["NS1", "PROTEIN", 157, 160], ["eGFP", "TEST", 43, 47], ["NS1", "TEST", 48, 51], ["NS3", "PROBLEM", 58, 61], ["eGFP", "TEST", 81, 85], ["ORF1", "TEST", 86, 90], ["eGFP", "TEST", 152, 156]]], ["Interestingly, we found a variety of phenotypes in various cells, ranging from a focal distribution of both proteins (upper panel) to the filamentous localization of NS1-2 observed upon individual expression (lowest panel).", [["cells", "ANATOMY", 59, 64], ["filamentous", "ANATOMY", 138, 149], ["cells", "CELL", 59, 64], ["NS1-2", "GENE_OR_GENE_PRODUCT", 166, 171], ["NS1", "PROTEIN", 166, 169], ["phenotypes in various cells", "PROBLEM", 37, 64], ["NS1", "TEST", 166, 169], ["variety", "OBSERVATION_MODIFIER", 26, 33], ["various cells", "OBSERVATION", 51, 64], ["focal", "OBSERVATION_MODIFIER", 81, 86], ["distribution", "OBSERVATION_MODIFIER", 87, 99]]], ["This result indicated a mutual impact of the NS proteins on their subcellular localization, retaining significant co-localization in all cases (S6F Fig), as reported for MNV [15].", [["subcellular", "ANATOMY", 66, 77], ["NS proteins", "PROTEIN", 45, 56], ["the NS proteins", "TREATMENT", 41, 56], ["their subcellular localization", "TEST", 60, 90], ["significant", "OBSERVATION_MODIFIER", 102, 113], ["co-localization", "OBSERVATION", 114, 129]]], ["Since the distribution of GII.4 NS1-2 was very different from the pattern reported for NS1/2 of MNV [13], we further analyzed eGFP-NS1/2 of MNV by CLEM (S7 Fig).", [["GII.4", "ORGANISM", 26, 31], ["NS1-2", "GENE_OR_GENE_PRODUCT", 32, 37], ["NS1/2", "GENE_OR_GENE_PRODUCT", 87, 92], ["MNV", "ORGANISM", 96, 99], ["eGFP", "GENE_OR_GENE_PRODUCT", 126, 130], ["MNV", "ORGANISM", 140, 143], ["GII.4 NS1-2", "PROTEIN", 26, 37], ["NS1", "PROTEIN", 87, 90], ["eGFP", "PROTEIN", 126, 130], ["NS1", "PROTEIN", 131, 134], ["CLEM", "PROTEIN", 147, 151], ["MNV", "SPECIES", 96, 99], ["MNV", "SPECIES", 140, 143], ["GII.4 NS1", "TEST", 26, 35], ["NS1", "TEST", 87, 90], ["MNV", "TEST", 96, 99], ["eGFP", "TEST", 126, 130], ["NS1", "TEST", 131, 134], ["MNV", "TEST", 140, 143], ["CLEM", "TEST", 147, 151]]], ["Interestingly and in concordance with literature, NS1/2 of MNV was widely distributed throughout the cell and co-localized with the ER (S7B Fig).", [["cell", "ANATOMY", 101, 105], ["NS1/2", "GENE_OR_GENE_PRODUCT", 50, 55], ["MNV", "ORGANISM", 59, 62], ["cell", "CELL", 101, 105], ["ER", "GENE_OR_GENE_PRODUCT", 132, 134], ["NS1", "PROTEIN", 50, 53], ["MNV", "PROTEIN", 59, 62], ["ER", "PROTEIN", 132, 134], ["S7B Fig", "PROTEIN", 136, 143], ["MNV", "SPECIES", 59, 62], ["NS1", "TEST", 50, 53], ["MNV", "PROBLEM", 59, 62], ["widely", "OBSERVATION_MODIFIER", 67, 73], ["distributed", "OBSERVATION_MODIFIER", 74, 85], ["cell", "OBSERVATION_MODIFIER", 101, 105]]], ["However, we found no indications for specific membrane structures induced by MNV NS1/2 (S7C Fig) comparable to those found for GII.4 NO.", [["membrane structures", "ANATOMY", 46, 65], ["NO", "CHEMICAL", 133, 135], ["NO", "CHEMICAL", 133, 135], ["membrane", "CELLULAR_COMPONENT", 46, 54], ["NO", "SIMPLE_CHEMICAL", 133, 135], ["MNV NS1", "PROTEIN", 77, 84], ["specific membrane structures", "PROBLEM", 37, 65], ["MNV NS1", "TEST", 77, 84], ["GII", "PROBLEM", 127, 130], ["no indications for", "UNCERTAINTY", 18, 36]]], ["The MNV NS1/2 signal could be often correlated with membranes surrounding LDs (S7C Fig), which may represent the ring like structures described in a previous study [13].The N-terminal protein GII.4 NS1-2 localizes at the ER and induces tubular ER protrusions ::: ResultsTaken together, eGFP-NS1-2 of GII.4 induced tubular protrusions of membranes likely derived from smooth ER in a focused, mainly perinuclear area.", [["membranes", "ANATOMY", 52, 61], ["LDs", "ANATOMY", 74, 77], ["ring like structures", "ANATOMY", 113, 133], ["ER", "ANATOMY", 221, 223], ["tubular ER", "ANATOMY", 236, 246], ["tubular", "ANATOMY", 314, 321], ["membranes", "ANATOMY", 337, 346], ["smooth ER", "ANATOMY", 367, 376], ["perinuclear area", "ANATOMY", 398, 414], ["2", "GENE_OR_GENE_PRODUCT", 12, 13], ["membranes", "CELLULAR_COMPONENT", 52, 61], ["LDs", "CELLULAR_COMPONENT", 74, 77], ["NS1-2", "GENE_OR_GENE_PRODUCT", 198, 203], ["ER", "GENE_OR_GENE_PRODUCT", 221, 223], ["ER", "GENE_OR_GENE_PRODUCT", 244, 246], ["eGFP-NS1-2", "GENE_OR_GENE_PRODUCT", 286, 296], ["GII", "GENE_OR_GENE_PRODUCT", 300, 303], ["tubular", "TISSUE", 314, 321], ["membranes", "CELLULAR_COMPONENT", 337, 346], ["ER", "GENE_OR_GENE_PRODUCT", 374, 376], ["perinuclear area", "CELLULAR_COMPONENT", 398, 414], ["NS1", "PROTEIN", 8, 11], ["N-terminal protein GII.4 NS1-2", "PROTEIN", 173, 203], ["ER", "PROTEIN", 221, 223], ["eGFP", "PROTEIN", 286, 290], ["NS1", "PROTEIN", 291, 294], ["smooth ER", "PROTEIN", 367, 376], ["The MNV NS1/2 signal", "TEST", 0, 20], ["the ring like structures", "PROBLEM", 109, 133], ["a previous study", "TEST", 147, 163], ["The N-terminal protein GII", "TEST", 169, 195], ["NS1", "TEST", 198, 201], ["eGFP", "TEST", 286, 290], ["NS1", "TEST", 291, 294], ["GII", "PROBLEM", 300, 303], ["4 induced tubular protrusions of membranes", "PROBLEM", 304, 346], ["LDs", "OBSERVATION_MODIFIER", 74, 77], ["may represent", "UNCERTAINTY", 95, 108], ["ring", "OBSERVATION_MODIFIER", 113, 117], ["tubular", "ANATOMY_MODIFIER", 236, 243], ["protrusions", "OBSERVATION_MODIFIER", 247, 258], ["tubular", "ANATOMY_MODIFIER", 314, 321], ["protrusions", "OBSERVATION", 322, 333], ["membranes", "OBSERVATION", 337, 346], ["smooth", "OBSERVATION_MODIFIER", 367, 373], ["mainly", "OBSERVATION_MODIFIER", 391, 397], ["perinuclear", "OBSERVATION_MODIFIER", 398, 409]]], ["This is in contrast to MNV NS1/2, which is widely distributed on the ER.", [["ER", "ANATOMY", 69, 71], ["MNV", "ORGANISM", 23, 26], ["NS1/2", "GENE_OR_GENE_PRODUCT", 27, 32], ["ER", "GENE_OR_GENE_PRODUCT", 69, 71], ["NS1", "PROTEIN", 27, 30], ["ER", "PROTEIN", 69, 71], ["widely", "OBSERVATION_MODIFIER", 43, 49], ["distributed", "OBSERVATION_MODIFIER", 50, 61]]], ["This suggests that NS1-2 of GII.4 probably does not directly induce the vesicular membrane rearrangements observed upon ORF1 expression, but rather may contribute to the proliferation of membranes engaged in replication complex formation.", [["vesicular membrane", "ANATOMY", 72, 90], ["membranes", "ANATOMY", 187, 196], ["NS1-2", "GENE_OR_GENE_PRODUCT", 19, 24], ["GII", "GENE_OR_GENE_PRODUCT", 28, 31], ["vesicular membrane", "CELLULAR_COMPONENT", 72, 90], ["ORF1", "GENE_OR_GENE_PRODUCT", 120, 124], ["membranes", "CELLULAR_COMPONENT", 187, 196], ["NS1", "PROTEIN", 19, 22], ["ORF1", "DNA", 120, 124], ["NS1", "TEST", 19, 22], ["GII", "PROBLEM", 28, 31], ["the vesicular membrane rearrangements", "PROBLEM", 68, 105], ["the proliferation of membranes", "PROBLEM", 166, 196], ["NS1", "OBSERVATION", 19, 22], ["probably does not", "UNCERTAINTY", 34, 51], ["vesicular membrane rearrangements", "OBSERVATION", 72, 105], ["may contribute to", "UNCERTAINTY", 148, 165], ["proliferation", "OBSERVATION", 170, 183]]], ["Our results further illustrate differences in the subcellular localization and possible functions of NS1-2 proteins from different norovirus genogroups.GII.4 NS3 is associated with membranes surrounding LD membranes, the Golgi and rough ER ::: ResultsWe next analyzed the co-localization of eGFP-NS3 of GII.4 NO with different markers of subcellular compartments (Fig 6A).", [["subcellular", "ANATOMY", 50, 61], ["membranes", "ANATOMY", 181, 190], ["LD membranes", "ANATOMY", 203, 215], ["Golgi", "ANATOMY", 221, 226], ["subcellular compartments", "ANATOMY", 338, 362], ["NO", "CHEMICAL", 309, 311], ["NO", "CHEMICAL", 309, 311], ["NS1-2", "GENE_OR_GENE_PRODUCT", 101, 106], ["GII.4 NS3", "ORGANISM", 152, 161], ["membranes", "CELLULAR_COMPONENT", 181, 190], ["LD membranes", "CELLULAR_COMPONENT", 203, 215], ["Golgi", "CELLULAR_COMPONENT", 221, 226], ["ER", "GENE_OR_GENE_PRODUCT", 237, 239], ["eGFP", "GENE_OR_GENE_PRODUCT", 291, 295], ["GII.4", "ORGANISM", 303, 308], ["NO", "GENE_OR_GENE_PRODUCT", 309, 311], ["NS1-2 proteins", "PROTEIN", 101, 115], ["GII.4 NS3", "PROTEIN", 152, 161], ["ER", "PROTEIN", 237, 239], ["eGFP", "PROTEIN", 291, 295], ["NS3", "PROTEIN", 296, 299], ["the subcellular localization", "TEST", 46, 74], ["NS1", "TEST", 101, 104], ["different norovirus genogroups", "PROBLEM", 121, 151], ["eGFP", "TEST", 291, 295], ["GII.4", "PROBLEM", 303, 308], ["norovirus genogroups", "OBSERVATION", 131, 151], ["LD membranes", "OBSERVATION", 203, 215], ["subcellular", "ANATOMY_MODIFIER", 338, 349], ["compartments", "ANATOMY_MODIFIER", 350, 362]]], ["We observed a distinct, rather dot-like staining pattern for NS3 (Fig 6A and 6B), which was similar to the pattern described for MNV NS3 [13].", [["NS3 (Fig 6A", "GENE_OR_GENE_PRODUCT", 61, 72], ["NS3", "PROTEIN", 61, 64], ["6B", "PROTEIN", 77, 79], ["MNV", "SPECIES", 129, 132], ["a distinct, rather dot-like staining pattern", "PROBLEM", 12, 56], ["NS3 (Fig 6A", "TEST", 61, 72], ["distinct", "OBSERVATION_MODIFIER", 14, 22]]], ["NS3 significantly co-localized with markers of the Golgi apparatus, rough ER and LDs (Fig 6A and 6C).", [["Golgi apparatus", "ANATOMY", 51, 66], ["ER", "ANATOMY", 74, 76], ["LDs", "ANATOMY", 81, 84], ["NS3", "GENE_OR_GENE_PRODUCT", 0, 3], ["Golgi apparatus", "CELLULAR_COMPONENT", 51, 66], ["ER", "GENE_OR_GENE_PRODUCT", 74, 76], ["LDs", "CELLULAR_COMPONENT", 81, 84], ["NS3", "PROTEIN", 0, 3], ["ER", "PROTEIN", 74, 76], ["LDs", "PROTEIN", 81, 84], ["Fig 6A and 6C", "PROTEIN", 86, 99], ["NS3", "PROBLEM", 0, 3]]], ["We also characterized the subcellular localization of NS3 upon expression of ORF1 (S8A\u2013S8C Fig).", [["subcellular", "ANATOMY", 26, 37], ["NS3", "GENE_OR_GENE_PRODUCT", 54, 57], ["ORF1", "GENE_OR_GENE_PRODUCT", 77, 81], ["NS3", "PROTEIN", 54, 57], ["ORF1", "DNA", 77, 81], ["S8A", "DNA", 83, 86], ["ORF1", "TEST", 77, 81], ["NS3", "OBSERVATION", 54, 57]]], ["Again we found some co-localization of NS3 with ER and LDs (S8A and S8C Fig), albeit to a lesser extent as in case of individually expressed NS3.", [["ER", "ANATOMY", 48, 50], ["LDs", "ANATOMY", 55, 58], ["NS3", "GENE_OR_GENE_PRODUCT", 39, 42], ["ER", "GENE_OR_GENE_PRODUCT", 48, 50], ["LDs", "GENE_OR_GENE_PRODUCT", 55, 58], ["NS3", "GENE_OR_GENE_PRODUCT", 141, 144], ["NS3", "PROTEIN", 39, 42], ["ER", "PROTEIN", 48, 50], ["LDs", "PROTEIN", 55, 58], ["S8A", "PROTEIN", 60, 63], ["S8C Fig", "PROTEIN", 68, 75], ["NS3", "PROTEIN", 141, 144], ["NS3", "PROBLEM", 39, 42], ["LDs", "TEST", 55, 58], ["S8A", "TEST", 60, 63], ["NS3", "OBSERVATION", 39, 42], ["LDs", "OBSERVATION_MODIFIER", 55, 58], ["lesser extent", "OBSERVATION_MODIFIER", 90, 103], ["NS3", "OBSERVATION", 141, 144]]], ["In contrast, very little co-localization with several other markers of membranous intracellular organelles was observed, including Golgi apparatus (S8C Fig), suggesting again a mutual impact of the NS proteins on their subcellular localization.", [["intracellular organelles", "ANATOMY", 82, 106], ["Golgi apparatus", "ANATOMY", 131, 146], ["subcellular", "ANATOMY", 219, 230], ["membranous", "CELLULAR_COMPONENT", 71, 81], ["intracellular organelles", "CELLULAR_COMPONENT", 82, 106], ["Golgi apparatus", "CELLULAR_COMPONENT", 131, 146], ["NS proteins", "PROTEIN", 198, 209], ["membranous intracellular organelles", "PROBLEM", 71, 106], ["Golgi apparatus", "TEST", 131, 146], ["the NS proteins", "TREATMENT", 194, 209], ["little", "OBSERVATION_MODIFIER", 18, 24], ["co-localization", "OBSERVATION", 25, 40], ["membranous", "OBSERVATION_MODIFIER", 71, 81], ["intracellular organelles", "OBSERVATION", 82, 106]]], ["The tight association of GII.4 NS3 with LDs was also validated in CLEM experiments (Fig 6B).", [["GII.4 NS3", "GENE_OR_GENE_PRODUCT", 25, 34], ["LDs", "GENE_OR_GENE_PRODUCT", 40, 43], ["GII", "PROTEIN", 25, 28], ["NS3", "PROTEIN", 31, 34], ["GII.4 NS3", "TREATMENT", 25, 34], ["LDs", "TREATMENT", 40, 43], ["tight", "OBSERVATION_MODIFIER", 4, 9]]], ["Donut like structures of NS3 observed in IF were indeed NS3-studded membrane layers surrounding LDs (area 1).", [["membrane layers", "ANATOMY", 68, 83], ["LDs", "ANATOMY", 96, 99], ["NS3", "GENE_OR_GENE_PRODUCT", 25, 28], ["IF", "GENE_OR_GENE_PRODUCT", 41, 43], ["membrane layers", "CELLULAR_COMPONENT", 68, 83], ["NS3", "PROTEIN", 25, 28], ["IF", "PROTEIN", 41, 43], ["NS3", "PROTEIN", 56, 59], ["NS3", "PROBLEM", 25, 28], ["NS3", "PROBLEM", 56, 59], ["NS3", "OBSERVATION", 25, 28], ["NS3", "OBSERVATION", 56, 59], ["layers", "OBSERVATION_MODIFIER", 77, 83], ["LDs", "OBSERVATION_MODIFIER", 96, 99]]], ["Interestingly, large foci with strong NS3 but weak LD signal were found to represent highly ordered membrane proliferations and were often observed in close proximity to one or more LDs (area 2, 3).", [["foci", "ANATOMY", 21, 25], ["membrane proliferations", "ANATOMY", 100, 123], ["LDs", "ANATOMY", 182, 185], ["membrane", "CELLULAR_COMPONENT", 100, 108], ["NS3", "PROTEIN", 38, 41], ["large foci", "PROBLEM", 15, 25], ["strong NS3", "PROBLEM", 31, 41], ["weak LD signal", "PROBLEM", 46, 60], ["highly ordered membrane proliferations", "PROBLEM", 85, 123], ["large", "OBSERVATION_MODIFIER", 15, 20], ["foci", "OBSERVATION", 21, 25], ["strong", "OBSERVATION_MODIFIER", 31, 37], ["NS3", "OBSERVATION", 38, 41], ["weak", "OBSERVATION_MODIFIER", 46, 50], ["membrane proliferations", "OBSERVATION", 100, 123]]], ["Such convoluted membranes were similar to previously described OSER (organized smooth ER) membranes with cubic symmetry (reviewed in [58,59]).", [["convoluted membranes", "ANATOMY", 5, 25], ["smooth ER) membranes", "ANATOMY", 79, 99], ["convoluted membranes", "MULTI-TISSUE_STRUCTURE", 5, 25], ["smooth ER", "GENE_OR_GENE_PRODUCT", 79, 88], ["membranes", "CELLULAR_COMPONENT", 90, 99], ["OSER", "PROTEIN", 63, 67], ["ER", "PROTEIN", 86, 88], ["Such convoluted membranes", "PROBLEM", 0, 25]]], ["However, we did not observe these structures upon ORF1 expression (Fig 3).", [["ORF1", "GENE_OR_GENE_PRODUCT", 50, 54], ["ORF1", "DNA", 50, 54], ["ORF1 expression", "TEST", 50, 65]]], ["Overall, our findings indicate that GII.4 NS3 was found on different membrane compartments of the secretory pathway and was closely associated to intracellular lipid storage compartments.GII.4 NS4 is capable of inducing the formation of DMVs as well as other types of membrane alterations ::: ResultsThe fluorescence pattern of eGFP-NS3 and -NS4 was quite similar, revealing a dot like pattern with donut like and filled structures (Fig 7A) located mainly in the perinuclear area.", [["membrane compartments", "ANATOMY", 69, 90], ["intracellular", "ANATOMY", 146, 159], ["membrane", "ANATOMY", 268, 276], ["perinuclear area", "ANATOMY", 463, 479], ["NS3", "GENE_OR_GENE_PRODUCT", 42, 45], ["membrane compartments", "CELLULAR_COMPONENT", 69, 90], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 146, 159], ["lipid", "SIMPLE_CHEMICAL", 160, 165], ["DMVs", "GENE_OR_GENE_PRODUCT", 237, 241], ["membrane", "CELLULAR_COMPONENT", 268, 276], ["eGFP-NS3", "GENE_OR_GENE_PRODUCT", 328, 336], ["-NS4", "GENE_OR_GENE_PRODUCT", 341, 345], ["perinuclear area", "CELLULAR_COMPONENT", 463, 479], ["NS3", "PROTEIN", 42, 45], ["GII.4 NS4", "PROTEIN", 187, 196], ["DMVs", "PROTEIN", 237, 241], ["eGFP", "PROTEIN", 328, 332], ["NS3", "PROTEIN", 333, 336], ["NS4", "PROTEIN", 342, 345], ["GII", "PROBLEM", 36, 39], ["NS3", "TREATMENT", 42, 45], ["DMVs", "PROBLEM", 237, 241], ["The fluorescence pattern", "TEST", 300, 324], ["eGFP", "TEST", 328, 332], ["NS3", "TEST", 333, 336], ["a dot like pattern", "PROBLEM", 375, 393], ["GII", "OBSERVATION", 36, 39], ["lipid storage", "OBSERVATION", 160, 173], ["perinuclear", "ANATOMY_MODIFIER", 463, 474], ["area", "ANATOMY_MODIFIER", 475, 479]]], ["Still, the eGFP-NS4 signal tended to accumulate in larger clusters compared to the majority of eGFP-NS3 (Fig 7A and 7B), but also co-localized with markers of ER, Golgi apparatus and LDs (Fig 7A and 7B).", [["ER", "ANATOMY", 159, 161], ["Golgi apparatus", "ANATOMY", 163, 178], ["LDs", "ANATOMY", 183, 186], ["eGFP", "GENE_OR_GENE_PRODUCT", 11, 15], ["NS4", "GENE_OR_GENE_PRODUCT", 16, 19], ["eGFP-NS3 (Fig 7A", "GENE_OR_GENE_PRODUCT", 95, 111], ["7B", "GENE_OR_GENE_PRODUCT", 116, 118], ["ER", "GENE_OR_GENE_PRODUCT", 159, 161], ["Golgi apparatus", "CELLULAR_COMPONENT", 163, 178], ["LDs", "CELLULAR_COMPONENT", 183, 186], ["eGFP", "PROTEIN", 11, 15], ["NS4", "PROTEIN", 16, 19], ["eGFP", "PROTEIN", 95, 99], ["NS3", "PROTEIN", 100, 103], ["7B", "PROTEIN", 116, 118], ["ER", "PROTEIN", 159, 161], ["the eGFP", "TEST", 7, 15], ["NS4 signal", "PROBLEM", 16, 26], ["eGFP", "TEST", 95, 99], ["NS3", "TEST", 100, 103], ["Golgi apparatus", "TEST", 163, 178], ["LDs", "TEST", 183, 186], ["larger", "OBSERVATION_MODIFIER", 51, 57], ["clusters", "OBSERVATION_MODIFIER", 58, 66]]], ["CLEM analysis identified several interesting types of membrane alterations in areas with strong eGFP signal, in agreement with the idea that NS4 is a key driver in the formation of the norovirus replication compartment.", [["membrane", "ANATOMY", 54, 62], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["eGFP", "GENE_OR_GENE_PRODUCT", 96, 100], ["NS4", "GENE_OR_GENE_PRODUCT", 141, 144], ["norovirus", "ORGANISM", 185, 194], ["eGFP", "PROTEIN", 96, 100], ["NS4", "PROTEIN", 141, 144], ["CLEM analysis", "TEST", 0, 13], ["membrane alterations in areas", "PROBLEM", 54, 83], ["several", "OBSERVATION_MODIFIER", 25, 32], ["membrane alterations", "OBSERVATION", 54, 74], ["strong", "OBSERVATION_MODIFIER", 89, 95], ["eGFP", "OBSERVATION", 96, 100], ["norovirus replication", "OBSERVATION", 185, 206]]], ["Donut like structures were found to be membranes tightly associated with LDs (Fig 7B, area 2), similar to those found for NS3 (Fig 6B).", [["membranes", "ANATOMY", 39, 48], ["LDs", "ANATOMY", 73, 76], ["membranes", "CELLULAR_COMPONENT", 39, 48], ["LDs", "CELLULAR_COMPONENT", 73, 76], ["NS3", "PROTEIN", 122, 125], ["Fig 6B", "PROTEIN", 127, 133], ["Donut like structures", "PROBLEM", 0, 21], ["LDs (Fig 7B", "PROBLEM", 73, 84], ["NS3 (Fig 6B", "TREATMENT", 122, 133]]], ["In addition, large eGFP-NS4 positive foci found in close proximity to LDs consisted of vesicle clusters composed of DMVs and SMVs (Fig 7B, area 3, 4; 7C, area 5).", [["foci", "ANATOMY", 37, 41], ["LDs", "ANATOMY", 70, 73], ["vesicle clusters", "ANATOMY", 87, 103], ["eGFP", "GENE_OR_GENE_PRODUCT", 19, 23], ["NS4", "GENE_OR_GENE_PRODUCT", 24, 27], ["LDs", "CELLULAR_COMPONENT", 70, 73], ["NS4", "PROTEIN", 24, 27], ["DMVs", "PROTEIN", 116, 120], ["SMVs", "PROTEIN", 125, 129], ["large eGFP", "TEST", 13, 23], ["NS4 positive foci", "PROBLEM", 24, 41], ["vesicle clusters", "PROBLEM", 87, 103], ["DMVs", "PROBLEM", 116, 120], ["SMVs", "PROBLEM", 125, 129], ["large", "OBSERVATION_MODIFIER", 13, 18], ["eGFP", "OBSERVATION", 19, 23], ["foci", "OBSERVATION", 37, 41], ["vesicle clusters", "OBSERVATION", 87, 103], ["DMVs", "OBSERVATION", 116, 120]]], ["The size and morphology of NS4 induced DMVs was very similar to those observed upon expression of the polyprotein (Fig 7D compared to Fig 3B), but their abundance was apparently lower.", [["NS4", "GENE_OR_GENE_PRODUCT", 27, 30], ["DMVs", "PATHOLOGICAL_FORMATION", 39, 43], ["NS4", "PROTEIN", 27, 30], ["DMVs", "PROTEIN", 39, 43], ["NS4 induced DMVs", "PROBLEM", 27, 43], ["the polyprotein (Fig", "TREATMENT", 98, 118], ["size", "OBSERVATION_MODIFIER", 4, 8], ["morphology", "OBSERVATION_MODIFIER", 13, 23], ["NS4 induced DMVs", "OBSERVATION", 27, 43], ["lower", "OBSERVATION_MODIFIER", 178, 183]]], ["In contrast, SMVs were much more abundant and heterogeneous in size, with a diameter ranging from 50 nm to 300 nm, although more than ~80% had a diameter <100 nm (Fig 7E).", [["SMVs", "ANATOMY", 13, 17], ["SMVs", "GENE_OR_GENE_PRODUCT", 13, 17], ["SMVs", "PROTEIN", 13, 17], ["abundant", "OBSERVATION_MODIFIER", 33, 41], ["heterogeneous", "OBSERVATION_MODIFIER", 46, 59], ["size", "OBSERVATION_MODIFIER", 63, 67], ["diameter", "OBSERVATION_MODIFIER", 76, 84], ["ranging", "OBSERVATION_MODIFIER", 85, 92], ["50 nm", "OBSERVATION_MODIFIER", 98, 103], ["300 nm", "OBSERVATION_MODIFIER", 107, 113]]], ["These data suggested that NS4 on its own was capable of inducing vesicle accumulations reminiscent of vesicle clusters of the GII.4 replication compartment.", [["vesicle", "ANATOMY", 65, 72], ["vesicle clusters", "ANATOMY", 102, 118], ["NS4", "CHEMICAL", 26, 29], ["NS4", "GENE_OR_GENE_PRODUCT", 26, 29], ["vesicle", "CELLULAR_COMPONENT", 65, 72], ["vesicle clusters", "CELLULAR_COMPONENT", 102, 118], ["NS4", "PROTEIN", 26, 29], ["These data", "TEST", 0, 10], ["NS4", "PROBLEM", 26, 29], ["vesicle accumulations", "PROBLEM", 65, 86], ["vesicle accumulations", "OBSERVATION", 65, 86], ["vesicle clusters", "OBSERVATION", 102, 118], ["GII.4 replication", "OBSERVATION", 126, 143]]], ["Finally, similarly to NS3, highly fluorescent clusters of NS4 within the cells corresponded to regions forming regularly shaped membrane lattices (Fig 7C, areas 6 and 7).", [["cells", "ANATOMY", 73, 78], ["membrane lattices", "ANATOMY", 128, 145], ["NS3", "GENE_OR_GENE_PRODUCT", 22, 25], ["NS4", "GENE_OR_GENE_PRODUCT", 58, 61], ["cells", "CELL", 73, 78], ["NS3", "PROTEIN", 22, 25], ["NS4", "PROTEIN", 58, 61], ["highly fluorescent clusters of NS4 within the cells", "PROBLEM", 27, 78], ["highly", "OBSERVATION_MODIFIER", 27, 33], ["fluorescent clusters", "OBSERVATION", 34, 54], ["regularly", "OBSERVATION_MODIFIER", 111, 120], ["shaped", "OBSERVATION_MODIFIER", 121, 127], ["membrane lattices", "OBSERVATION", 128, 145]]], ["However, NS4 expression resulted in membranes aligned predominantly in tubules with hexagonal symmetry (Fig 7C, area 6).", [["membranes", "ANATOMY", 36, 45], ["tubules", "ANATOMY", 71, 78], ["NS4", "GENE_OR_GENE_PRODUCT", 9, 12], ["membranes", "CELLULAR_COMPONENT", 36, 45], ["tubules", "TISSUE", 71, 78], ["NS4", "PROTEIN", 9, 12], ["membranes", "PROBLEM", 36, 45], ["membranes aligned", "OBSERVATION", 36, 53], ["predominantly", "OBSERVATION_MODIFIER", 54, 67], ["hexagonal symmetry", "OBSERVATION", 84, 102]]], ["This hexagonal symmetry appeared very similar to the arrangement observed upon overexpression of the hydroxy-methylglutaryl (HMG)-CoA reductase [60], although regions with cubic symmetry were also observed (Fig 7C, area 7).", [["hydroxy-methylglutaryl", "CHEMICAL", 101, 123], ["hydroxy-methylglutaryl", "CHEMICAL", 101, 123], ["HMG)-CoA", "CHEMICAL", 125, 133], ["hydroxy-methylglutaryl", "SIMPLE_CHEMICAL", 101, 123], ["HMG)-CoA reductase", "GENE_OR_GENE_PRODUCT", 125, 143], ["hydroxy-methylglutaryl (HMG)-CoA reductase", "PROTEIN", 101, 143], ["the hydroxy-methylglutaryl (HMG", "TREATMENT", 97, 128], ["CoA reductase", "TEST", 130, 143], ["cubic symmetry", "PROBLEM", 172, 186], ["very", "OBSERVATION_MODIFIER", 33, 37], ["similar", "OBSERVATION", 38, 45], ["CoA", "ANATOMY", 130, 133], ["cubic symmetry", "OBSERVATION", 172, 186]]], ["Furthermore, NS4 induced crystalline membrane structures were found in proximity to vesicle clusters (Fig 7C, area 1), suggesting that their formation might be concentration dependent and a consequence of very high local concentrations of NS4.GII.4 NS4 is capable of inducing the formation of DMVs as well as other types of membrane alterations ::: ResultsIn essence, our results indicated that NS4 was a key factor in the biogenesis of GII.4 induced membrane alterations.", [["membrane structures", "ANATOMY", 37, 56], ["vesicle clusters", "ANATOMY", 84, 100], ["membrane", "ANATOMY", 324, 332], ["membrane", "ANATOMY", 451, 459], ["NS4", "CHEMICAL", 13, 16], ["NS4", "GENE_OR_GENE_PRODUCT", 13, 16], ["vesicle clusters", "CELLULAR_COMPONENT", 84, 100], ["NS4", "GENE_OR_GENE_PRODUCT", 239, 242], ["DMVs", "GENE_OR_GENE_PRODUCT", 293, 297], ["membrane", "CELLULAR_COMPONENT", 324, 332], ["NS4", "GENE_OR_GENE_PRODUCT", 395, 398], ["GII", "GENE_OR_GENE_PRODUCT", 437, 440], ["membrane", "CELLULAR_COMPONENT", 451, 459], ["NS4", "PROTEIN", 13, 16], ["NS4", "PROTEIN", 239, 242], ["DMVs", "PROTEIN", 293, 297], ["NS4", "PROTEIN", 395, 398], ["NS4 induced crystalline membrane structures", "PROBLEM", 13, 56], ["concentration dependent", "PROBLEM", 160, 183], ["DMVs", "PROBLEM", 293, 297], ["membrane alterations", "PROBLEM", 324, 344], ["4 induced membrane alterations", "PROBLEM", 441, 471], ["crystalline membrane", "OBSERVATION", 25, 45], ["vesicle clusters", "OBSERVATION", 84, 100], ["membrane alterations", "OBSERVATION", 451, 471]]], ["Specifically, the sole expression of NS4 was sufficient to induce several different types of membrane structures, including SMVs, DMVs, as well as geometric membrane lattices not found in infected cells.Structural predictions of GII.4 NS proteins NS1-2, NS3 and NS4 and functional analysis of point mutations in the active center of the putative hydrolase domain of NS1-2 ::: ResultsOur results obtained from individual expression of eGFP-NS1-2, NS3 and NS4 of GII.4 strain NO revealed that they were indeed associated with membranes.", [["membrane structures", "ANATOMY", 93, 112], ["SMVs", "ANATOMY", 124, 128], ["membrane", "ANATOMY", 157, 165], ["cells", "ANATOMY", 197, 202], ["membranes", "ANATOMY", 524, 533], ["NO", "CHEMICAL", 474, 476], ["NO", "CHEMICAL", 474, 476], ["NS4", "GENE_OR_GENE_PRODUCT", 37, 40], ["membrane structures", "CELLULAR_COMPONENT", 93, 112], ["SMVs", "GENE_OR_GENE_PRODUCT", 124, 128], ["DMVs", "GENE_OR_GENE_PRODUCT", 130, 134], ["cells", "CELL", 197, 202], ["NS1-2", "GENE_OR_GENE_PRODUCT", 247, 252], ["NS3", "GENE_OR_GENE_PRODUCT", 254, 257], ["NS1-2", "GENE_OR_GENE_PRODUCT", 366, 371], ["eGFP-NS1-2", "GENE_OR_GENE_PRODUCT", 434, 444], ["NS3", "GENE_OR_GENE_PRODUCT", 446, 449], ["NO", "SIMPLE_CHEMICAL", 474, 476], ["membranes", "CELLULAR_COMPONENT", 524, 533], ["NS4", "PROTEIN", 37, 40], ["SMVs", "PROTEIN", 124, 128], ["DMVs", "PROTEIN", 130, 134], ["infected cells", "CELL_TYPE", 188, 202], ["GII.4 NS proteins", "PROTEIN", 229, 246], ["NS1", "PROTEIN", 247, 250], ["NS3", "PROTEIN", 254, 257], ["NS4", "PROTEIN", 262, 265], ["putative hydrolase domain", "PROTEIN", 337, 362], ["NS1", "PROTEIN", 366, 369], ["eGFP", "PROTEIN", 434, 438], ["NS1", "PROTEIN", 439, 442], ["NS3", "PROTEIN", 446, 449], ["NS4", "PROTEIN", 454, 457], ["GII", "PROTEIN", 461, 464], ["membrane structures", "PROBLEM", 93, 112], ["SMVs", "PROBLEM", 124, 128], ["DMVs", "PROBLEM", 130, 134], ["geometric membrane lattices", "PROBLEM", 147, 174], ["infected cells", "PROBLEM", 188, 202], ["GII.4 NS proteins", "TREATMENT", 229, 246], ["NS1", "TEST", 247, 250], ["NS3", "TREATMENT", 254, 257], ["NS4", "TREATMENT", 262, 265], ["functional analysis", "TEST", 270, 289], ["point mutations", "PROBLEM", 293, 308], ["NS1", "TEST", 366, 369], ["eGFP", "TEST", 434, 438], ["NS1", "TEST", 439, 442], ["NS3", "TREATMENT", 446, 449], ["GII", "PROBLEM", 461, 464], ["membranes", "PROBLEM", 524, 533], ["membrane structures", "OBSERVATION", 93, 112], ["infected cells", "OBSERVATION", 188, 202]]], ["Since the functions of all three proteins, in particular NS1-2 and NS4, are widely enigmatic, we next aimed to generate structural models based on secondary structure analysis and homology searches, allowing for the development of hypotheses accessible to experimental validation.", [["NS1-2", "GENE_OR_GENE_PRODUCT", 57, 62], ["NS4", "GENE_OR_GENE_PRODUCT", 67, 70], ["NS1", "PROTEIN", 57, 60], ["NS4", "PROTEIN", 67, 70], ["all three proteins", "TEST", 23, 41], ["NS1", "TEST", 57, 60], ["secondary structure analysis", "TEST", 147, 175], ["widely", "OBSERVATION_MODIFIER", 76, 82], ["enigmatic", "OBSERVATION_MODIFIER", 83, 92]]], ["There are no close homologs of known structures for these three proteins, but advanced search methods unambiguously detect distant homologs (20% sequence identity) for parts of both NS1-2 and NS3.", [["NS1-2", "GENE_OR_GENE_PRODUCT", 182, 187], ["NS3", "GENE_OR_GENE_PRODUCT", 192, 195], ["NS1", "PROTEIN", 182, 185], ["NS3", "PROTEIN", 192, 195], ["these three proteins", "PROBLEM", 52, 72], ["NS1", "TEST", 182, 185], ["NS3", "PROBLEM", 192, 195], ["no", "UNCERTAINTY", 10, 12]]], ["These together with secondary structure predictions show that the 334-residue NS1-2 can be described as a three-partite protein with an unstructured N-terminus (residues 1\u2013110) followed by a papain-like thiol hydrolase domain (residues ca 120\u2013230) that is related to a family of phospholipases and acyltransferases [61], and finally a hydrophobic domain (residues ca 250\u2013310) with one or possibly two transmembrane helices.", [["thiol", "CHEMICAL", 203, 208], ["N", "CHEMICAL", 149, 150], ["thiol", "CHEMICAL", 203, 208], ["NS1-2", "GENE_OR_GENE_PRODUCT", 78, 83], ["NS1", "PROTEIN", 78, 81], ["partite protein", "PROTEIN", 112, 127], ["N-terminus", "PROTEIN", 149, 159], ["residues 1\u2013110", "PROTEIN", 161, 175], ["papain-like thiol hydrolase domain", "PROTEIN", 191, 225], ["residues ca 120\u2013230", "PROTEIN", 227, 246], ["phospholipases", "PROTEIN", 279, 293], ["hydrophobic domain", "PROTEIN", 335, 353], ["residues ca 250\u2013310", "PROTEIN", 355, 374], ["transmembrane helices", "PROTEIN", 401, 422], ["secondary structure predictions", "PROBLEM", 20, 51], ["residue NS1", "TEST", 70, 81], ["a papain-like thiol hydrolase domain", "TREATMENT", 189, 225], ["residues ca", "TEST", 227, 238], ["a hydrophobic domain (residues ca", "TEST", 333, 366], ["transmembrane helices", "OBSERVATION", 401, 422]]], ["We can thus draw two possible topologies for membrane association of NS1-2 (Fig 8A).", [["membrane", "ANATOMY", 45, 53], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["NS1-2", "GENE_OR_GENE_PRODUCT", 69, 74], ["Fig 8A", "GENE_OR_GENE_PRODUCT", 76, 82], ["NS1", "PROTEIN", 69, 72], ["Fig 8A", "PROTEIN", 76, 82], ["NS1", "TEST", 69, 72]]], ["Interestingly, the catalytic cysteine and histidine of the putative thiol hydrolase are both present in NS1-2 as C205 and H139.", [["cysteine", "CHEMICAL", 29, 37], ["histidine", "CHEMICAL", 42, 51], ["thiol", "CHEMICAL", 68, 73], ["cysteine", "CHEMICAL", 29, 37], ["histidine", "CHEMICAL", 42, 51], ["thiol", "CHEMICAL", 68, 73], ["cysteine", "AMINO_ACID", 29, 37], ["histidine", "AMINO_ACID", 42, 51], ["NS1-2", "GENE_OR_GENE_PRODUCT", 104, 109], ["putative thiol hydrolase", "PROTEIN", 59, 83], ["NS1", "PROTEIN", 104, 107], ["C205", "PROTEIN", 113, 117], ["H139", "PROTEIN", 122, 126], ["the catalytic cysteine", "TREATMENT", 15, 37], ["the putative thiol hydrolase", "TREATMENT", 55, 83], ["NS1", "TEST", 104, 107], ["thiol hydrolase", "OBSERVATION", 68, 83]]], ["The 366-residue NS3 is a distant homolog of AAA ATPases with an extra 50 residues at the N-terminus comprising a hydrophobic helix that could be transmembrane.", [["transmembrane", "ANATOMY", 145, 158], ["N", "CHEMICAL", 89, 90], ["AAA ATPases", "GENE_OR_GENE_PRODUCT", 44, 55], ["transmembrane", "CELLULAR_COMPONENT", 145, 158], ["366-residue NS3", "PROTEIN", 4, 19], ["AAA ATPases", "PROTEIN", 44, 55], ["N-terminus", "PROTEIN", 89, 99], ["hydrophobic helix", "PROTEIN", 113, 130], ["AAA ATPases", "TREATMENT", 44, 55], ["a hydrophobic helix", "PROBLEM", 111, 130], ["AAA", "OBSERVATION", 44, 47]]], ["Again, we have two possibilities for NS3 membrane association.", [["membrane", "ANATOMY", 41, 49], ["NS3", "GENE_OR_GENE_PRODUCT", 37, 40], ["NS3", "PROTEIN", 37, 40], ["NS3 membrane association", "TREATMENT", 37, 61], ["NS3 membrane", "OBSERVATION", 37, 49]]], ["Finally, we could find no homolog of known structure for the 179-residue NS4, but secondary structure predictions show that its approximately 140 N-terminal residues are highly structured and end in an amphipathic helix connecting to a natively unfolded C-terminus (Fig 8A).Structural predictions of GII.4 NS proteins NS1-2, NS3 and NS4 and functional analysis of point mutations in the active center of the putative hydrolase domain of NS1-2 ::: ResultsBased on these predictions we finally aimed to gain some evidence for the putative hydrolase domain and its importance for membrane protrusions induced by NS1-2 of GII.4.", [["membrane", "ANATOMY", 577, 585], ["N", "CHEMICAL", 146, 147], ["NS4", "GENE_OR_GENE_PRODUCT", 73, 76], ["NS1-2", "GENE_OR_GENE_PRODUCT", 318, 323], ["NS3", "GENE_OR_GENE_PRODUCT", 325, 328], ["NS1-2", "GENE_OR_GENE_PRODUCT", 437, 442], ["membrane", "CELLULAR_COMPONENT", 577, 585], ["NS1-2", "GENE_OR_GENE_PRODUCT", 609, 614], ["GII", "GENE_OR_GENE_PRODUCT", 618, 621], ["179-residue NS4", "PROTEIN", 61, 76], ["140 N-terminal residues", "PROTEIN", 142, 165], ["amphipathic helix", "PROTEIN", 202, 219], ["natively unfolded C-terminus", "PROTEIN", 236, 264], ["Fig 8A", "PROTEIN", 266, 272], ["GII.4 NS proteins", "PROTEIN", 300, 317], ["NS1", "PROTEIN", 318, 321], ["NS3", "PROTEIN", 325, 328], ["NS4", "PROTEIN", 333, 336], ["putative hydrolase domain", "PROTEIN", 408, 433], ["NS1", "PROTEIN", 437, 440], ["putative hydrolase domain", "PROTEIN", 528, 553], ["NS1", "PROTEIN", 609, 612], ["GII", "PROTEIN", 618, 621], ["the 179-residue NS4", "PROBLEM", 57, 76], ["secondary structure predictions", "PROBLEM", 82, 113], ["terminal residues", "PROBLEM", 148, 165], ["an amphipathic helix", "TREATMENT", 199, 219], ["GII.4 NS proteins", "TREATMENT", 300, 317], ["NS1", "TEST", 318, 321], ["NS3", "TREATMENT", 325, 328], ["NS4", "TREATMENT", 333, 336], ["functional analysis", "TEST", 341, 360], ["point mutations", "PROBLEM", 364, 379], ["NS1", "TEST", 437, 440], ["these predictions", "TEST", 463, 480], ["the putative hydrolase domain", "PROBLEM", 524, 553], ["membrane protrusions", "PROBLEM", 577, 597], ["NS1", "TEST", 609, 612], ["GII", "PROBLEM", 618, 621], ["terminal residues", "OBSERVATION", 148, 165], ["amphipathic helix", "OBSERVATION", 202, 219], ["unfolded", "OBSERVATION_MODIFIER", 245, 253]]], ["To this end we generated mutants of the highly conserved proposed catalytic residues H139 and C205 in the context of eGFP-NS1-2.", [["C205", "AMINO_ACID", 94, 98], ["eGFP-NS1-2", "GENE_OR_GENE_PRODUCT", 117, 127], ["catalytic residues", "PROTEIN", 66, 84], ["C205", "PROTEIN", 94, 98], ["eGFP", "PROTEIN", 117, 121], ["NS1", "PROTEIN", 122, 125], ["eGFP", "TEST", 117, 121], ["NS1", "TEST", 122, 125], ["catalytic residues", "OBSERVATION", 66, 84]]], ["Since these residues are invariant in all norovirus genogroups, we used MNV as a surrogate model to study their functional importance for norovirus replication.", [["MNV", "ORGANISM", 72, 75], ["norovirus", "ORGANISM", 138, 147], ["MNV", "SPECIES", 72, 75], ["norovirus", "SPECIES", 138, 147], ["these residues", "PROBLEM", 6, 20], ["all norovirus genogroups", "PROBLEM", 38, 62], ["norovirus replication", "TREATMENT", 138, 159], ["invariant", "OBSERVATION_MODIFIER", 25, 34], ["norovirus", "OBSERVATION", 42, 51]]], ["Interestingly, both NS1-2 mutants affected the abundance of the filamentous phenotype (Fig 8B\u20138D), arguing for a contribution of the putative hydrolase domain to the generation of tubular ER protrusions.", [["tubular ER", "ANATOMY", 180, 190], ["NS1-2", "GENE_OR_GENE_PRODUCT", 20, 25], ["ER", "GENE_OR_GENE_PRODUCT", 188, 190], ["NS1", "PROTEIN", 20, 23], ["hydrolase domain", "PROTEIN", 142, 158], ["NS1", "TEST", 20, 23], ["the putative hydrolase domain", "PROBLEM", 129, 158], ["tubular ER protrusions", "PROBLEM", 180, 202], ["NS1", "OBSERVATION", 20, 23], ["abundance", "OBSERVATION_MODIFIER", 47, 56], ["filamentous phenotype", "OBSERVATION", 64, 85], ["tubular ER protrusions", "OBSERVATION", 180, 202]]], ["Albeit mutations H139A and C205A both resulted in an increased abundance of the intermediate phenotype, or a focal distribution of eGFP-NS1-2, all variants still remained localized to the ER (Fig 8E).", [["eGFP-NS1-2", "GENE_OR_GENE_PRODUCT", 131, 141], ["ER", "GENE_OR_GENE_PRODUCT", 188, 190], ["eGFP", "DNA", 131, 135], ["NS1", "PROTEIN", 136, 139], ["ER", "PROTEIN", 188, 190], ["the intermediate phenotype", "PROBLEM", 76, 102], ["eGFP", "TEST", 131, 135], ["NS1", "TEST", 136, 139], ["all variants", "PROBLEM", 143, 155], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["abundance", "OBSERVATION", 63, 72], ["intermediate phenotype", "OBSERVATION", 80, 102], ["focal", "OBSERVATION_MODIFIER", 109, 114]]], ["Importantly, both residues were indeed essential for norovirus replication, as mutations at the corresponding positions H150A and C216A of MNV NS1-2 abrogated the production of infectious virus (Fig 8F).Structural predictions of GII.4 NS proteins NS1-2, NS3 and NS4 and functional analysis of point mutations in the active center of the putative hydrolase domain of NS1-2 ::: ResultsIn summary, our analysis of individually expressed NS1-2, NS3 and NS4 suggest that these proteins, in particular NS4, were the main drivers of replication complex formation for GII.4.", [["norovirus", "ORGANISM", 53, 62], ["NS1-2", "GENE_OR_GENE_PRODUCT", 143, 148], ["infectious virus", "ORGANISM", 177, 193], ["NS1-2", "GENE_OR_GENE_PRODUCT", 247, 252], ["NS3", "GENE_OR_GENE_PRODUCT", 254, 257], ["NS1-2", "GENE_OR_GENE_PRODUCT", 366, 371], ["NS1-2", "GENE_OR_GENE_PRODUCT", 434, 439], ["NS3", "GENE_OR_GENE_PRODUCT", 441, 444], ["NS4", "GENE_OR_GENE_PRODUCT", 449, 452], ["NS4", "GENE_OR_GENE_PRODUCT", 496, 499], ["MNV NS1-2", "DNA", 139, 148], ["GII.4 NS proteins", "PROTEIN", 229, 246], ["NS1", "PROTEIN", 247, 250], ["NS3", "PROTEIN", 254, 257], ["NS4", "PROTEIN", 262, 265], ["putative hydrolase domain", "PROTEIN", 337, 362], ["NS1", "PROTEIN", 366, 369], ["NS1", "PROTEIN", 434, 437], ["NS3", "PROTEIN", 441, 444], ["NS4", "PROTEIN", 449, 452], ["NS4", "PROTEIN", 496, 499], ["replication complex", "PROTEIN", 526, 545], ["norovirus replication", "TREATMENT", 53, 74], ["MNV NS1", "TEST", 139, 146], ["infectious virus", "PROBLEM", 177, 193], ["GII.4 NS proteins", "TREATMENT", 229, 246], ["NS1", "TEST", 247, 250], ["NS3", "TREATMENT", 254, 257], ["NS4", "TREATMENT", 262, 265], ["functional analysis", "TEST", 270, 289], ["point mutations", "PROBLEM", 293, 308], ["NS1", "TEST", 366, 369], ["our analysis", "TEST", 395, 407], ["NS1", "TEST", 434, 437], ["NS3", "PROBLEM", 441, 444], ["these proteins", "PROBLEM", 466, 480], ["GII", "PROBLEM", 560, 563], ["infectious virus", "OBSERVATION", 177, 193]]], ["The structural models proposing their membrane topology will allow more in depth studies of their precise functions.", [["membrane", "ANATOMY", 38, 46], ["membrane", "CELLULAR_COMPONENT", 38, 46], ["their membrane topology", "TREATMENT", 32, 55], ["depth studies", "TEST", 75, 88]]], ["Our data further suggest a role of the predicted hydrolase domain in the membrane shaping activity of NS1-2, but not to the general localization to the ER.DiscussionIn this study, we analyzed membrane alterations induced by ORF1 expression of clinically relevant GII.4 isolates and by the individually expressed NS-proteins.", [["membrane", "ANATOMY", 73, 81], ["ER", "ANATOMY", 152, 154], ["membrane", "ANATOMY", 192, 200], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["NS1-2", "GENE_OR_GENE_PRODUCT", 102, 107], ["ER", "GENE_OR_GENE_PRODUCT", 152, 154], ["membrane", "CELLULAR_COMPONENT", 192, 200], ["hydrolase domain", "PROTEIN", 49, 65], ["NS1", "PROTEIN", 102, 105], ["ER", "PROTEIN", 152, 154], ["ORF1", "DNA", 224, 228], ["NS-proteins", "PROTEIN", 312, 323], ["the predicted hydrolase domain", "PROBLEM", 35, 65], ["this study", "TEST", 168, 178], ["membrane alterations", "PROBLEM", 192, 212]]], ["ORF1 expression generated vesicle accumulations comparable to those observed in MNV infected cells, mainly consisting of SMVs, DMVs and MMVs.", [["vesicle", "ANATOMY", 26, 33], ["cells", "ANATOMY", 93, 98], ["SMVs", "ANATOMY", 121, 125], ["ORF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["vesicle", "CELLULAR_COMPONENT", 26, 33], ["MNV", "ORGANISM", 80, 83], ["cells", "CELL", 93, 98], ["SMVs", "GENE_OR_GENE_PRODUCT", 121, 125], ["DMVs", "GENE_OR_GENE_PRODUCT", 127, 131], ["MMVs", "GENE_OR_GENE_PRODUCT", 136, 140], ["ORF1", "DNA", 0, 4], ["MNV infected cells", "CELL_LINE", 80, 98], ["SMVs", "PROTEIN", 121, 125], ["DMVs", "PROTEIN", 127, 131], ["MMVs", "CELL_TYPE", 136, 140], ["MNV", "SPECIES", 80, 83], ["ORF1 expression generated vesicle accumulations", "PROBLEM", 0, 47], ["MNV infected cells", "PROBLEM", 80, 98], ["SMVs", "PROBLEM", 121, 125], ["DMVs", "PROBLEM", 127, 131], ["MMVs", "PROBLEM", 136, 140], ["vesicle accumulations", "OBSERVATION", 26, 47], ["infected cells", "OBSERVATION", 84, 98]]], ["Therefore, norovirus-induced membrane alterations can be generated in the absence of active RNA synthesis, and are reminiscent of picornaviruses and HCV [28,31,53\u201356].", [["membrane", "ANATOMY", 29, 37], ["norovirus", "DISEASE", 11, 20], ["norovirus", "ORGANISM", 11, 20], ["membrane", "CELLULAR_COMPONENT", 29, 37], ["picornaviruses", "ORGANISM", 130, 144], ["HCV", "ORGANISM", 149, 152], ["HCV", "SPECIES", 149, 152], ["norovirus", "PROBLEM", 11, 20], ["induced membrane alterations", "PROBLEM", 21, 49], ["active RNA synthesis", "PROBLEM", 85, 105], ["picornaviruses", "PROBLEM", 130, 144], ["HCV", "PROBLEM", 149, 152], ["norovirus", "OBSERVATION", 11, 20], ["membrane alterations", "OBSERVATION", 29, 49], ["active", "OBSERVATION_MODIFIER", 85, 91], ["RNA synthesis", "OBSERVATION", 92, 105], ["picornaviruses", "OBSERVATION", 130, 144]]], ["Our data indicate that NS1-2, NS3 and NS4 are the main drivers in the formation of GII.4 replication organelles.", [["organelles", "ANATOMY", 101, 111], ["NS1-2", "GENE_OR_GENE_PRODUCT", 23, 28], ["NS3", "GENE_OR_GENE_PRODUCT", 30, 33], ["NS4", "GENE_OR_GENE_PRODUCT", 38, 41], ["organelles", "CELLULAR_COMPONENT", 101, 111], ["NS1", "PROTEIN", 23, 26], ["NS3", "PROTEIN", 30, 33], ["NS4", "PROTEIN", 38, 41], ["Our data", "TEST", 0, 8], ["NS1", "TEST", 23, 26], ["NS3", "PROBLEM", 30, 33], ["NS4", "TREATMENT", 38, 41], ["NS1", "OBSERVATION", 23, 26], ["main", "OBSERVATION_MODIFIER", 50, 54], ["GII.4 replication", "OBSERVATION", 83, 100]]], ["However, only NS4 generated SMVs and DMVs similar to those observed upon ORF1 expression and MNV infection.", [["MNV infection", "DISEASE", 93, 106], ["NS4", "GENE_OR_GENE_PRODUCT", 14, 17], ["SMVs", "GENE_OR_GENE_PRODUCT", 28, 32], ["DMVs", "GENE_OR_GENE_PRODUCT", 37, 41], ["ORF1", "GENE_OR_GENE_PRODUCT", 73, 77], ["MNV", "ORGANISM", 93, 96], ["NS4", "PROTEIN", 14, 17], ["ORF1", "DNA", 73, 77], ["MNV", "SPECIES", 93, 96], ["DMVs", "PROBLEM", 37, 41], ["ORF1 expression", "PROBLEM", 73, 88], ["MNV infection", "PROBLEM", 93, 106], ["MNV", "OBSERVATION_MODIFIER", 93, 96], ["infection", "OBSERVATION", 97, 106]]], ["These data provide the first experimental evidence for the hypothesis that NS4 might be the key factor in the morphogenesis of norovirus replication organelles (reviewed in [8]).DiscussionPrevious studies on the ultrastructure of MNV replication organelles in RAW 264.7 cells reported on the appearance of vesiculated areas consisting of SMVs and DMVs at 12h post infection, progressing to a complete destruction of ER and Golgi at later time points, coinciding with the accumulation of virions [44].", [["organelles", "ANATOMY", 149, 159], ["organelles", "ANATOMY", 246, 256], ["RAW 264.7 cells", "ANATOMY", 260, 275], ["SMVs", "ANATOMY", 338, 342], ["ER", "ANATOMY", 416, 418], ["Golgi", "ANATOMY", 423, 428], ["infection", "DISEASE", 364, 373], ["NS4", "GENE_OR_GENE_PRODUCT", 75, 78], ["norovirus", "ORGANISM", 127, 136], ["organelles", "CELLULAR_COMPONENT", 149, 159], ["MNV", "ORGANISM", 230, 233], ["organelles", "CELLULAR_COMPONENT", 246, 256], ["RAW 264.7 cells", "CELL", 260, 275], ["SMVs", "GENE_OR_GENE_PRODUCT", 338, 342], ["ER", "GENE_OR_GENE_PRODUCT", 416, 418], ["Golgi", "CELLULAR_COMPONENT", 423, 428], ["NS4", "PROTEIN", 75, 78], ["RAW 264.7 cells", "CELL_LINE", 260, 275], ["ER", "PROTEIN", 416, 418], ["MNV", "SPECIES", 230, 233], ["the hypothesis", "PROBLEM", 55, 69], ["norovirus replication organelles", "PROBLEM", 127, 159], ["DiscussionPrevious studies", "TEST", 178, 204], ["vesiculated areas", "PROBLEM", 306, 323], ["SMVs", "PROBLEM", 338, 342], ["DMVs", "PROBLEM", 347, 351], ["infection", "PROBLEM", 364, 373], ["a complete destruction of ER", "PROBLEM", 390, 418], ["the accumulation of virions", "PROBLEM", 467, 494], ["norovirus", "OBSERVATION", 127, 136], ["264.7 cells", "OBSERVATION", 264, 275], ["infection", "OBSERVATION", 364, 373], ["destruction", "OBSERVATION", 401, 412]]], ["We found in principle the same two phenotypes upon MNV infection of Huh7-CD300lf cells and in RAW 264.7 cells.", [["Huh7-CD300lf cells", "ANATOMY", 68, 86], ["RAW 264.7 cells", "ANATOMY", 94, 109], ["infection", "DISEASE", 55, 64], ["MNV", "ORGANISM", 51, 54], ["Huh7-CD300lf cells", "CELL", 68, 86], ["RAW 264.7 cells", "CELL", 94, 109], ["Huh7-CD300lf cells", "CELL_LINE", 68, 86], ["RAW 264.7 cells", "CELL_LINE", 94, 109], ["MNV", "SPECIES", 51, 54], ["MNV infection", "PROBLEM", 51, 64], ["Huh7-CD300lf cells", "TEST", 68, 86], ["MNV", "OBSERVATION_MODIFIER", 51, 54], ["infection", "OBSERVATION", 55, 64], ["Huh7", "ANATOMY", 68, 72], ["264.7 cells", "OBSERVATION", 98, 109]]], ["ORF1 expression induced structures very similar to the phenotype lacking virions, likely corresponding to an early/intermediate infection stage, but did not progress into the complex endomembrane system observed concomitantly to intracellular virions appearance.", [["virions", "ANATOMY", 73, 80], ["endomembrane system", "ANATOMY", 183, 202], ["intracellular", "ANATOMY", 229, 242], ["infection", "DISEASE", 128, 137], ["ORF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 229, 242], ["ORF1", "DNA", 0, 4], ["ORF1 expression induced structures", "PROBLEM", 0, 34], ["the phenotype lacking virions", "PROBLEM", 51, 80], ["an early/intermediate infection stage", "PROBLEM", 106, 143], ["virions", "OBSERVATION", 73, 80], ["intermediate", "OBSERVATION_MODIFIER", 115, 127], ["infection", "OBSERVATION", 128, 137], ["endomembrane system", "OBSERVATION", 183, 202], ["intracellular virions", "OBSERVATION", 229, 250]]], ["Progression to the late stages found in infection might require the presence of the structural proteins or resemble cytopathic effects induced by infection, but not by ORF1 expression.", [["infection", "DISEASE", 40, 49], ["infection", "DISEASE", 146, 155], ["ORF1", "GENE_OR_GENE_PRODUCT", 168, 172], ["structural proteins", "PROTEIN", 84, 103], ["ORF1", "DNA", 168, 172], ["the late stages", "PROBLEM", 15, 30], ["infection", "PROBLEM", 40, 49], ["the structural proteins", "PROBLEM", 80, 103], ["cytopathic effects", "PROBLEM", 116, 134], ["infection", "PROBLEM", 146, 155], ["late stages", "OBSERVATION_MODIFIER", 19, 30], ["infection", "OBSERVATION", 40, 49], ["cytopathic", "OBSERVATION_MODIFIER", 116, 126], ["infection", "OBSERVATION", 146, 155]]], ["Interestingly, we found no obvious difference in the membrane rearrangements induced by ORF1 or MNV compared to any of the three GII.4 isolates included in this study, arguing for similar mechanisms driving these processes in various norovirus genogroups and validating MNV as a useful surrogate model to study particular aspects of general norovirus biology.", [["membrane", "ANATOMY", 53, 61], ["norovirus", "DISEASE", 341, 350], ["membrane", "CELLULAR_COMPONENT", 53, 61], ["ORF1", "GENE_OR_GENE_PRODUCT", 88, 92], ["MNV", "ORGANISM", 270, 273], ["norovirus", "ORGANISM", 341, 350], ["ORF1", "DNA", 88, 92], ["MNV", "SPECIES", 270, 273], ["the membrane rearrangements", "PROBLEM", 49, 76], ["this study", "TEST", 156, 166], ["no obvious", "UNCERTAINTY", 24, 34], ["membrane rearrangements", "OBSERVATION", 53, 76]]], ["Still, our data obtained upon GII.4 ORF1 expression will ultimately require validation in a cell culture model with bona fide RNA replication, such as the recently established enteric organoid cultures [43] or infection of B cells [42].", [["cell culture", "ANATOMY", 92, 104], ["organoid cultures", "ANATOMY", 184, 201], ["B cells", "ANATOMY", 223, 230], ["infection", "DISEASE", 210, 219], ["ORF1", "GENE_OR_GENE_PRODUCT", 36, 40], ["cell", "CELL", 92, 96], ["organoid cultures", "CELL", 184, 201], ["B cells", "CELL", 223, 230], ["ORF1", "DNA", 36, 40], ["enteric organoid cultures", "CELL_LINE", 176, 201], ["B cells", "CELL_TYPE", 223, 230], ["validation", "TREATMENT", 76, 86], ["a cell culture model", "TREATMENT", 90, 110], ["bona fide RNA replication", "TREATMENT", 116, 141], ["enteric organoid cultures", "TEST", 176, 201], ["infection of B cells", "PROBLEM", 210, 230], ["fide RNA replication", "OBSERVATION", 121, 141]]], ["The same holds true for the functional significance of the LD association we found for GII.4 NS3 and NS4.", [["GII.4 NS3", "GENE_OR_GENE_PRODUCT", 87, 96], ["NS4", "GENE_OR_GENE_PRODUCT", 101, 104], ["GII", "PROTEIN", 87, 90], ["NS3", "PROTEIN", 93, 96], ["NS4", "PROTEIN", 101, 104], ["GII.4 NS3", "TREATMENT", 87, 96], ["NS4", "TREATMENT", 101, 104]]], ["While LDs are clearly not essential for MNV replication, since they are not detectable in RAW 264.7 cells, we found them close to all virus induced membrane alterations in Huh7 cells, both, upon expression of ORF1 and upon MNV infection.", [["LDs", "ANATOMY", 6, 9], ["RAW 264.7 cells", "ANATOMY", 90, 105], ["membrane", "ANATOMY", 148, 156], ["Huh7 cells", "ANATOMY", 172, 182], ["MNV infection", "DISEASE", 223, 236], ["LDs", "GENE_OR_GENE_PRODUCT", 6, 9], ["MNV", "ORGANISM", 40, 43], ["RAW 264.7 cells", "CELL", 90, 105], ["membrane", "CELLULAR_COMPONENT", 148, 156], ["Huh7 cells", "CELL", 172, 182], ["ORF1", "GENE_OR_GENE_PRODUCT", 209, 213], ["MNV", "ORGANISM", 223, 226], ["RAW 264.7 cells", "CELL_LINE", 90, 105], ["Huh7 cells", "CELL_LINE", 172, 182], ["ORF1", "DNA", 209, 213], ["MNV", "SPECIES", 40, 43], ["MNV", "SPECIES", 223, 226], ["MNV replication", "PROBLEM", 40, 55], ["all virus induced membrane alterations in Huh7 cells", "PROBLEM", 130, 182], ["ORF1", "TREATMENT", 209, 213], ["MNV infection", "PROBLEM", 223, 236], ["membrane alterations", "OBSERVATION", 148, 168], ["Huh7 cells", "OBSERVATION", 172, 182], ["MNV", "OBSERVATION_MODIFIER", 223, 226], ["infection", "OBSERVATION", 227, 236]]], ["Whether this is co-incidence due to high LD abundance in Huh7 cells or whether LDs have a functional significance in GII.4 replication remains to be determined.", [["Huh7 cells", "ANATOMY", 57, 67], ["LDs", "ANATOMY", 79, 82], ["Huh7 cells", "CELL", 57, 67], ["LDs", "CELLULAR_COMPONENT", 79, 82], ["GII.4", "ORGANISM", 117, 122], ["Huh7 cells", "CELL_LINE", 57, 67], ["high LD abundance in Huh7 cells", "PROBLEM", 36, 67], ["LDs", "PROBLEM", 79, 82], ["GII.4 replication", "TREATMENT", 117, 134], ["Huh7 cells", "OBSERVATION", 57, 67]]], ["At this point we have not been able to detect membrane alterations that could unequivocally be assigned to norovirus infection by EM in norovirus infected enteroid cultures (S. Boulant, personal communication), likely due to the yet limited efficiency of this model and the high percentage of infected cells required for a thorough EM analysis.", [["membrane", "ANATOMY", 46, 54], ["enteroid cultures", "ANATOMY", 155, 172], ["cells", "ANATOMY", 302, 307], ["norovirus infection", "DISEASE", 107, 126], ["norovirus infected enteroid", "DISEASE", 136, 163], ["membrane", "CELLULAR_COMPONENT", 46, 54], ["norovirus", "ORGANISM", 107, 116], ["norovirus", "ORGANISM", 136, 145], ["enteroid cultures", "CELL", 155, 172], ["cells", "CELL", 302, 307], ["norovirus infected enteroid cultures", "CELL_LINE", 136, 172], ["infected cells", "CELL_TYPE", 293, 307], ["membrane alterations", "PROBLEM", 46, 66], ["norovirus infection", "PROBLEM", 107, 126], ["norovirus infected enteroid cultures", "PROBLEM", 136, 172], ["this model", "PROBLEM", 255, 265], ["infected cells", "PROBLEM", 293, 307], ["a thorough EM analysis", "TEST", 321, 343], ["infected cells", "OBSERVATION", 293, 307]]], ["However, further optimization of culture conditions will hopefully allow such studies in the future, as well as the establishment of a reverse genetics model for GII.4 isolates.DiscussionOur ultrastructural analysis does not allow drawing firm conclusions on the origin and biogenesis of GII.4 induced SMVs, since we did not observe such vesicles directly connected to cellular membranes.", [["SMVs", "ANATOMY", 302, 306], ["vesicles", "ANATOMY", 338, 346], ["cellular membranes", "ANATOMY", 369, 387], ["SMVs", "PATHOLOGICAL_FORMATION", 302, 306], ["vesicles", "CELLULAR_COMPONENT", 338, 346], ["cellular membranes", "CELLULAR_COMPONENT", 369, 387], ["culture conditions", "TEST", 33, 51], ["such studies", "TEST", 73, 85], ["GII", "PROBLEM", 162, 165], ["ultrastructural analysis", "TEST", 191, 215], ["GII", "PROBLEM", 288, 291], ["4 induced SMVs", "PROBLEM", 292, 306], ["such vesicles", "PROBLEM", 333, 346], ["cellular membranes", "OBSERVATION", 369, 387]]], ["In contrast to PV, we could not find evidence for an interconnected tubular network [55].", [["tubular network", "ANATOMY", 68, 83], ["tubular network", "MULTI-TISSUE_STRUCTURE", 68, 83], ["an interconnected tubular network", "PROBLEM", 50, 83], ["tubular network", "OBSERVATION", 68, 83]]], ["Most of our evidence points to membranes of the ER as the origin of SMVs, similar to MNV [15], due to the co-localization of NS1-2 and NS3 with ER membranes when expressed in the context of ORF1.", [["membranes", "ANATOMY", 31, 40], ["ER", "ANATOMY", 48, 50], ["SMVs", "ANATOMY", 68, 72], ["ER membranes", "ANATOMY", 144, 156], ["membranes", "CELLULAR_COMPONENT", 31, 40], ["ER", "GENE_OR_GENE_PRODUCT", 48, 50], ["SMVs", "GENE_OR_GENE_PRODUCT", 68, 72], ["NS1-2", "GENE_OR_GENE_PRODUCT", 125, 130], ["NS3", "GENE_OR_GENE_PRODUCT", 135, 138], ["ER", "GENE_OR_GENE_PRODUCT", 144, 146], ["ORF1", "GENE_OR_GENE_PRODUCT", 190, 194], ["ER", "PROTEIN", 48, 50], ["SMVs", "PROTEIN", 68, 72], ["NS1", "PROTEIN", 125, 128], ["NS3", "PROTEIN", 135, 138], ["ER", "PROTEIN", 144, 146], ["ORF1", "DNA", 190, 194], ["MNV", "TEST", 85, 88], ["NS1", "TEST", 125, 128], ["NS3", "PROBLEM", 135, 138], ["ER membranes", "PROBLEM", 144, 156], ["NS1", "OBSERVATION", 125, 128]]], ["Furthermore, our tomograms reveal a close proximity of the induced vesicles to ER membranes.", [["vesicles", "ANATOMY", 67, 75], ["ER membranes", "ANATOMY", 79, 91], ["vesicles", "CELLULAR_COMPONENT", 67, 75], ["ER", "GENE_OR_GENE_PRODUCT", 79, 81], ["membranes", "CELLULAR_COMPONENT", 82, 91], ["ER", "PROTEIN", 79, 81], ["our tomograms", "TEST", 13, 26], ["vesicles", "OBSERVATION", 67, 75]]], ["Finally, individually expressed NS1-2, NS3 and NS4 all at least in part co-localize to and rearrange ER membranes.", [["ER membranes", "ANATOMY", 101, 113], ["NS1-2", "GENE_OR_GENE_PRODUCT", 32, 37], ["NS3", "GENE_OR_GENE_PRODUCT", 39, 42], ["NS4", "GENE_OR_GENE_PRODUCT", 47, 50], ["ER", "GENE_OR_GENE_PRODUCT", 101, 103], ["membranes", "CELLULAR_COMPONENT", 104, 113], ["NS1", "PROTEIN", 32, 35], ["NS3", "PROTEIN", 39, 42], ["NS4", "PROTEIN", 47, 50], ["ER", "PROTEIN", 101, 103], ["NS1", "TEST", 32, 35], ["NS3", "TREATMENT", 39, 42], ["NS4", "TREATMENT", 47, 50]]], ["Therefore, huNoV, like many other viruses, may hijack this cell organelle to generate its replication organelles (reviewed in [62]).", [["cell organelle", "ANATOMY", 59, 73], ["organelles", "ANATOMY", 102, 112], ["huNoV", "CHEMICAL", 11, 16], ["huNoV", "GENE_OR_GENE_PRODUCT", 11, 16], ["cell", "CELL", 59, 63], ["organelles", "CELLULAR_COMPONENT", 102, 112], ["huNoV", "PROTEIN", 11, 16], ["huNoV", "PROBLEM", 11, 16], ["huNoV", "OBSERVATION", 11, 16], ["viruses", "OBSERVATION", 34, 41]]], ["Regarding DMVs and MMVs, we were able to identify intermediate structures.", [["DMVs", "SIMPLE_CHEMICAL", 10, 14], ["DMVs", "PROTEIN", 10, 14], ["MMVs", "PROTEIN", 19, 23], ["DMVs", "PROBLEM", 10, 14], ["MMVs", "TREATMENT", 19, 23]]], ["Many vesicles appearing as DMVs in a single plane were in fact MMVs in stato nascendi, generated by enwrapping vesicles with collapsed, elongated SMVs or ER cisternae.", [["vesicles", "ANATOMY", 5, 13], ["vesicles", "ANATOMY", 111, 119], ["SMVs", "ANATOMY", 146, 150], ["ER cisternae", "ANATOMY", 154, 166], ["vesicles", "CELLULAR_COMPONENT", 5, 13], ["stato nascendi", "CELL", 71, 85], ["vesicles", "CELLULAR_COMPONENT", 111, 119], ["SMVs", "GENE_OR_GENE_PRODUCT", 146, 150], ["ER", "GENE_OR_GENE_PRODUCT", 154, 156], ["cisternae", "CELLULAR_COMPONENT", 157, 166], ["MMVs", "PROTEIN", 63, 67], ["SMVs", "PROTEIN", 146, 150], ["stato nascendi", "SPECIES", 71, 85], ["Many vesicles", "PROBLEM", 0, 13], ["DMVs", "PROBLEM", 27, 31], ["vesicles", "OBSERVATION", 5, 13], ["collapsed", "OBSERVATION", 125, 134], ["elongated", "OBSERVATION_MODIFIER", 136, 145], ["SMVs", "OBSERVATION_MODIFIER", 146, 150], ["cisternae", "ANATOMY_MODIFIER", 157, 166]]], ["DMVs might originate as well from collapsing SMVs.", [["SMVs", "DISEASE", 45, 49], ["DMVs", "SIMPLE_CHEMICAL", 0, 4], ["SMVs", "PATHOLOGICAL_FORMATION", 45, 49], ["DMVs", "PROTEIN", 0, 4], ["DMVs", "PROBLEM", 0, 4], ["collapsing SMVs", "PROBLEM", 34, 49], ["collapsing", "OBSERVATION_MODIFIER", 34, 44], ["SMVs", "OBSERVATION", 45, 49]]], ["This indeed closely resembles the mechanisms demonstrated for picornaviruses [55,56].", [["picornaviruses", "PROBLEM", 62, 76]]], ["Finally, our tomograms also showed a variety of complex structures (e.g. MVBs, ALS) that might be linked to the biogenesis of these vesicles, however these structures are currently difficult to interpret regarding their functional significance.", [["MVBs", "ANATOMY", 73, 77], ["vesicles", "ANATOMY", 132, 140], ["ALS", "DISEASE", 79, 82], ["MVBs", "CELLULAR_COMPONENT", 73, 77], ["vesicles", "CELLULAR_COMPONENT", 132, 140], ["our tomograms", "TEST", 9, 22], ["variety", "OBSERVATION_MODIFIER", 37, 44], ["complex", "OBSERVATION_MODIFIER", 48, 55], ["vesicles", "ANATOMY", 132, 140]]], ["Overall, our data suggest that norovirus induced membrane alterations are very closely related to picornavirus replication organelles with respect to both morphology and biogenesis.", [["membrane", "ANATOMY", 49, 57], ["organelles", "ANATOMY", 123, 133], ["norovirus", "DISEASE", 31, 40], ["norovirus", "ORGANISM", 31, 40], ["membrane", "CELLULAR_COMPONENT", 49, 57], ["organelles", "CELLULAR_COMPONENT", 123, 133], ["our data", "TEST", 9, 17], ["norovirus induced membrane alterations", "PROBLEM", 31, 69], ["picornavirus replication organelles", "PROBLEM", 98, 133], ["norovirus", "OBSERVATION", 31, 40], ["picornavirus replication", "OBSERVATION", 98, 122]]], ["The relatively low abundance of DMVs and MMVs further argues for a non-essential role in norovirus infection, again in line with reports on picornaviruses, where replication most likely occurs on single membrane structures, whereas the appearance of DMVs is associated with later stages of infection [55,56].DiscussionExpression of the individual nonstructural proteins fused to eGFP and subsequent analysis by CLEM revealed striking phenotypes for NS1-2, NS3 and NS4, which are very poorly understood regarding specific functions in viral RNA replication and topology (Fig 8A).", [["membrane structures", "ANATOMY", 203, 222], ["norovirus infection", "DISEASE", 89, 108], ["infection", "DISEASE", 290, 299], ["DMVs", "GENE_OR_GENE_PRODUCT", 32, 36], ["MMVs", "GENE_OR_GENE_PRODUCT", 41, 45], ["norovirus", "ORGANISM", 89, 98], ["picornaviruses", "ORGANISM", 140, 154], ["membrane structures", "CELLULAR_COMPONENT", 203, 222], ["DMVs", "GENE_OR_GENE_PRODUCT", 250, 254], ["eGFP", "GENE_OR_GENE_PRODUCT", 379, 383], ["NS1-2", "GENE_OR_GENE_PRODUCT", 449, 454], ["NS3", "GENE_OR_GENE_PRODUCT", 456, 459], ["NS4", "GENE_OR_GENE_PRODUCT", 464, 467], ["DMVs", "PROTEIN", 32, 36], ["MMVs", "PROTEIN", 41, 45], ["nonstructural proteins", "PROTEIN", 347, 369], ["eGFP", "DNA", 379, 383], ["CLEM", "PROTEIN", 411, 415], ["NS1", "PROTEIN", 449, 452], ["NS3", "PROTEIN", 456, 459], ["NS4", "PROTEIN", 464, 467], ["norovirus", "SPECIES", 89, 98], ["DMVs", "PROBLEM", 32, 36], ["MMVs", "TREATMENT", 41, 45], ["norovirus infection", "PROBLEM", 89, 108], ["picornaviruses", "PROBLEM", 140, 154], ["DMVs", "PROBLEM", 250, 254], ["infection", "PROBLEM", 290, 299], ["the individual nonstructural proteins", "PROBLEM", 332, 369], ["eGFP", "TEST", 379, 383], ["subsequent analysis", "TEST", 388, 407], ["CLEM", "TEST", 411, 415], ["striking phenotypes", "PROBLEM", 425, 444], ["NS1", "TEST", 449, 452], ["NS3", "PROBLEM", 456, 459], ["NS4", "TREATMENT", 464, 467], ["viral RNA replication", "TREATMENT", 534, 555], ["relatively", "OBSERVATION_MODIFIER", 4, 14], ["low abundance", "OBSERVATION_MODIFIER", 15, 28], ["norovirus", "OBSERVATION_MODIFIER", 89, 98], ["infection", "OBSERVATION", 99, 108], ["picornaviruses", "OBSERVATION", 140, 154], ["most likely", "UNCERTAINTY", 174, 185], ["infection", "OBSERVATION", 290, 299], ["viral RNA", "OBSERVATION", 534, 543]]], ["The sequence of NS1-2 is highly divergent between different norovirus genogroups with no specific function assigned thus far.", [["NS1-2", "GENE_OR_GENE_PRODUCT", 16, 21], ["NS1", "PROTEIN", 16, 19], ["NS1", "TEST", 16, 19], ["different norovirus genogroups", "PROBLEM", 50, 80], ["norovirus", "OBSERVATION", 60, 69]]], ["Bioinformatic analysis proposed an unstructured N-terminal region, which was confirmed biochemically [9], a central domain with potential hydrolase function [10] and a C-terminal transmembrane domain [9,63].", [["N", "CHEMICAL", 48, 49], ["C", "CHEMICAL", 168, 169], ["N-terminal region", "DNA", 48, 65], ["hydrolase", "PROTEIN", 138, 147], ["C-terminal transmembrane domain", "PROTEIN", 168, 199], ["Bioinformatic analysis", "TEST", 0, 22], ["potential hydrolase function", "PROBLEM", 128, 156], ["a C-terminal transmembrane domain", "PROBLEM", 166, 199], ["terminal", "ANATOMY_MODIFIER", 50, 58]]], ["Norwalk virus NS1-2 was shown to disrupt the Golgi apparatus [11], whereas MNV NS1-2 mainly localizes to the ER [13].", [["Golgi apparatus", "ANATOMY", 45, 60], ["Norwalk virus", "ORGANISM", 0, 13], ["NS1-2", "GENE_OR_GENE_PRODUCT", 14, 19], ["Golgi", "CELLULAR_COMPONENT", 45, 50], ["NS1-2", "GENE_OR_GENE_PRODUCT", 79, 84], ["ER", "GENE_OR_GENE_PRODUCT", 109, 111], ["NS1", "PROTEIN", 14, 17], ["MNV NS1-2", "PROTEIN", 75, 84], ["ER", "PROTEIN", 109, 111], ["Norwalk virus NS1", "SPECIES", 0, 17], ["Norwalk virus NS1", "TEST", 0, 17], ["NS1", "TEST", 79, 82]]], ["Our data now show a very peculiar filamentous localization of GII.4 NS1-2 which could be identified as tubular protrusions of the smooth ER when analyzed by CLEM.", [["filamentous", "ANATOMY", 34, 45], ["tubular", "ANATOMY", 103, 110], ["smooth ER", "ANATOMY", 130, 139], ["NS1-2", "GENE_OR_GENE_PRODUCT", 68, 73], ["tubular", "TISSUE", 103, 110], ["ER", "GENE_OR_GENE_PRODUCT", 137, 139], ["GII", "PROTEIN", 62, 65], ["NS1", "PROTEIN", 68, 71], ["ER", "PROTEIN", 137, 139], ["Our data", "TEST", 0, 8], ["a very peculiar filamentous localization of GII", "PROBLEM", 18, 65], ["very", "OBSERVATION_MODIFIER", 20, 24], ["peculiar", "OBSERVATION_MODIFIER", 25, 33], ["filamentous", "OBSERVATION", 34, 45], ["GII", "OBSERVATION", 62, 65], ["tubular", "OBSERVATION_MODIFIER", 103, 110], ["protrusions", "OBSERVATION", 111, 122], ["smooth", "OBSERVATION_MODIFIER", 130, 136]]], ["Similar structures have been observed upon overexpression of cellular ER remodeling proteins such as REEP1 and CLIMP-63 through direct interaction with microtubules [57], which appear to be the driving force in protruding the tubules.", [["cellular", "ANATOMY", 61, 69], ["microtubules", "ANATOMY", 152, 164], ["tubules", "ANATOMY", 226, 233], ["cellular", "CELL", 61, 69], ["ER", "GENE_OR_GENE_PRODUCT", 70, 72], ["REEP1", "GENE_OR_GENE_PRODUCT", 101, 106], ["CLIMP-63", "GENE_OR_GENE_PRODUCT", 111, 119], ["tubules", "TISSUE", 226, 233], ["cellular ER remodeling proteins", "PROTEIN", 61, 92], ["REEP1", "PROTEIN", 101, 106], ["CLIMP-63", "PROTEIN", 111, 119], ["cellular ER remodeling proteins", "PROBLEM", 61, 92], ["REEP1", "TEST", 101, 106], ["CLIMP", "TEST", 111, 116], ["overexpression", "OBSERVATION_MODIFIER", 43, 57], ["cellular", "OBSERVATION_MODIFIER", 61, 69]]], ["In the case of NS1-2, we found no co-localization with microtubules or intermediate filaments, therefore it is currently not clear how the ER-tubules are expanded.", [["microtubules", "ANATOMY", 55, 67], ["filaments", "ANATOMY", 84, 93], ["ER-tubules", "ANATOMY", 139, 149], ["NS1-2", "GENE_OR_GENE_PRODUCT", 15, 20], ["microtubules", "CELLULAR_COMPONENT", 55, 67], ["intermediate filaments", "CELLULAR_COMPONENT", 71, 93], ["ER", "GENE_OR_GENE_PRODUCT", 139, 141], ["tubules", "TISSUE", 142, 149], ["NS1", "PROTEIN", 15, 18], ["microtubules", "PROTEIN", 55, 67], ["ER", "PROTEIN", 139, 141], ["NS1", "TEST", 15, 18], ["microtubules or intermediate filaments", "PROBLEM", 55, 93], ["no", "UNCERTAINTY", 31, 33], ["intermediate filaments", "OBSERVATION", 71, 93], ["expanded", "OBSERVATION_MODIFIER", 154, 162]]], ["Since mutations in the active site of the putative hydrolase domain severely affected the formation of the tubular ER-protrusions, it is tempting to speculate about a role of this predicted enzymatic function in the membrane shaping activity of NS1-2.", [["tubular ER", "ANATOMY", 107, 117], ["membrane", "ANATOMY", 216, 224], ["tubular", "CELLULAR_COMPONENT", 107, 114], ["ER", "GENE_OR_GENE_PRODUCT", 115, 117], ["membrane", "CELLULAR_COMPONENT", 216, 224], ["NS1-2", "GENE_OR_GENE_PRODUCT", 245, 250], ["putative hydrolase domain", "PROTEIN", 42, 67], ["ER", "PROTEIN", 115, 117], ["NS1", "PROTEIN", 245, 248], ["mutations", "PROBLEM", 6, 15], ["NS1", "TEST", 245, 248], ["tubular", "OBSERVATION_MODIFIER", 107, 114], ["protrusions", "OBSERVATION_MODIFIER", 118, 129]]], ["However, the functional significance of the ability of GII.4 NS1-2 to form filamentous ER tubules still remains unclear, since MNV NS1/2 is devoid of this property.", [["filamentous ER tubules", "ANATOMY", 75, 97], ["GII.4", "ORGANISM", 55, 60], ["NS1-2", "GENE_OR_GENE_PRODUCT", 61, 66], ["ER", "GENE_OR_GENE_PRODUCT", 87, 89], ["MNV NS1", "ORGANISM", 127, 134], ["GII.4 NS1-2", "PROTEIN", 55, 66], ["MNV NS1/2", "PROTEIN", 127, 136], ["GII.4 NS1", "TREATMENT", 55, 64], ["filamentous ER tubules", "PROBLEM", 75, 97]]], ["Overall these data are suggestive for the presence of an enzymatic activity residing in NS1-2, but they clearly provide no formal proof, which will require the demonstration of such activity in a purified protein.", [["NS1-2", "GENE_OR_GENE_PRODUCT", 88, 93], ["NS1", "PROTEIN", 88, 91], ["purified protein", "PROTEIN", 196, 212], ["an enzymatic activity", "PROBLEM", 54, 75], ["suggestive for", "UNCERTAINTY", 23, 37], ["enzymatic activity", "OBSERVATION", 57, 75]]], ["Interestingly, a recent study identified an interaction of the variable, unstructured N-terminus of MNV NS1/2 with the host proteins VAPA and VAPB, critical for viral replication [64].", [["MNV", "ORGANISM", 100, 103], ["NS1/2", "GENE_OR_GENE_PRODUCT", 104, 109], ["VAPA", "GENE_OR_GENE_PRODUCT", 133, 137], ["VAPB", "GENE_OR_GENE_PRODUCT", 142, 146], ["N-terminus", "PROTEIN", 86, 96], ["MNV NS1/2", "PROTEIN", 100, 109], ["host proteins", "PROTEIN", 119, 132], ["VAPA", "PROTEIN", 133, 137], ["VAPB", "PROTEIN", 142, 146], ["a recent study", "TEST", 15, 29], ["the host proteins VAPA", "TREATMENT", 115, 137], ["VAPB", "TREATMENT", 142, 146], ["viral replication", "TREATMENT", 161, 178]]], ["VAPA has already been observed to complex with Norwalk NS1-2 [65], presumably via a different, yet to be defined region.", [["VAPA", "CHEMICAL", 0, 4], ["VAPA", "GENE_OR_GENE_PRODUCT", 0, 4], ["VAPA", "PROTEIN", 0, 4], ["NS1", "PROTEIN", 55, 58], ["Norwalk NS1", "TEST", 47, 58]]], ["More strikingly, VAPA and VAPB have been implicated in the biogenesis of the HCV replication compartment via interaction with NS5A (reviewed in [23]).", [["VAPA", "CHEMICAL", 17, 21], ["VAPB", "CHEMICAL", 26, 30], ["VAPA", "GENE_OR_GENE_PRODUCT", 17, 21], ["VAPB", "GENE_OR_GENE_PRODUCT", 26, 30], ["NS5A", "GENE_OR_GENE_PRODUCT", 126, 130], ["VAPA", "PROTEIN", 17, 21], ["VAPB", "PROTEIN", 26, 30], ["NS5A", "PROTEIN", 126, 130], ["HCV", "SPECIES", 77, 80], ["NS5A", "TREATMENT", 126, 130], ["HCV", "OBSERVATION", 77, 80]]], ["Therefore, VAPA and VAPB interactions might contribute to the function of NS1-2 in the formation of the norovirus replication organelle, or even be a common host factor of many DMV-type positive strand RNA viruses.DiscussionOverall, our data provide a first step to define a role for GII.4 NS1-2 in the biogenesis of the huNoV replication compartment in proliferating membranes of the smooth ER, thereby generating the material that could be transformed into vesicle clusters by other NS-proteins and suggesting a role of the predicted hydrolase function in this process.DiscussionOur study demonstrates that NS3 and NS4 both had the ability to create organized ER structures known as convoluted membranes, tubulo-reticular structures, crystalloid ER or cubic membranes, which have been found in a variety of viral infections and upon overexpression of ER membrane shaping proteins (reviewed in [58,59]).", [["organelle", "ANATOMY", 126, 135], ["membranes", "ANATOMY", 368, 377], ["smooth ER", "ANATOMY", 385, 394], ["vesicle clusters", "ANATOMY", 459, 475], ["ER structures", "ANATOMY", 662, 675], ["convoluted membranes", "ANATOMY", 685, 705], ["tubulo-reticular structures", "ANATOMY", 707, 734], ["crystalloid ER", "ANATOMY", 736, 750], ["cubic membranes", "ANATOMY", 754, 769], ["ER membrane", "ANATOMY", 853, 864], ["viral infections", "DISEASE", 809, 825], ["VAPA", "GENE_OR_GENE_PRODUCT", 11, 15], ["VAPB", "GENE_OR_GENE_PRODUCT", 20, 24], ["NS1-2", "GENE_OR_GENE_PRODUCT", 74, 79], ["norovirus", "ORGANISM", 104, 113], ["organelle", "CELLULAR_COMPONENT", 126, 135], ["NS1-2", "GENE_OR_GENE_PRODUCT", 290, 295], ["huNoV", "GENE_OR_GENE_PRODUCT", 321, 326], ["membranes", "CELLULAR_COMPONENT", 368, 377], ["ER", "GENE_OR_GENE_PRODUCT", 392, 394], ["vesicle", "CELLULAR_COMPONENT", 459, 466], ["NS3", "GENE_OR_GENE_PRODUCT", 609, 612], ["NS4", "GENE_OR_GENE_PRODUCT", 617, 620], ["ER", "GENE_OR_GENE_PRODUCT", 662, 664], ["convoluted membranes", "CELLULAR_COMPONENT", 685, 705], ["reticular structures", "CELLULAR_COMPONENT", 714, 734], ["ER", "GENE_OR_GENE_PRODUCT", 748, 750], ["cubic membranes", "CELLULAR_COMPONENT", 754, 769], ["ER", "GENE_OR_GENE_PRODUCT", 853, 855], ["membrane", "CELLULAR_COMPONENT", 856, 864], ["NS1", "PROTEIN", 74, 77], ["NS1", "PROTEIN", 290, 293], ["smooth ER", "PROTEIN", 385, 394], ["NS-proteins", "PROTEIN", 485, 496], ["hydrolase", "PROTEIN", 536, 545], ["NS3", "PROTEIN", 609, 612], ["NS4", "PROTEIN", 617, 620], ["ER", "PROTEIN", 662, 664], ["crystalloid ER", "PROTEIN", 736, 750], ["ER", "PROTEIN", 853, 855], ["VAPA", "TREATMENT", 11, 15], ["NS1", "PROBLEM", 74, 77], ["the norovirus replication organelle", "PROBLEM", 100, 135], ["many DMV", "PROBLEM", 172, 180], ["type positive strand RNA viruses", "PROBLEM", 181, 213], ["GII", "PROBLEM", 284, 287], ["NS1", "TREATMENT", 290, 293], ["the predicted hydrolase function", "PROBLEM", 522, 554], ["DiscussionOur study", "TEST", 571, 590], ["NS3", "TREATMENT", 609, 612], ["convoluted membranes", "PROBLEM", 685, 705], ["tubulo-reticular structures", "PROBLEM", 707, 734], ["crystalloid ER or cubic membranes", "PROBLEM", 736, 769], ["viral infections", "PROBLEM", 809, 825], ["ER membrane shaping proteins", "PROBLEM", 853, 881], ["norovirus", "OBSERVATION", 104, 113], ["strand RNA viruses", "OBSERVATION", 195, 213], ["huNoV replication", "OBSERVATION", 321, 338], ["proliferating membranes", "OBSERVATION", 354, 377], ["smooth", "OBSERVATION_MODIFIER", 385, 391], ["NS3", "OBSERVATION", 609, 612], ["convoluted membranes", "OBSERVATION", 685, 705], ["reticular", "ANATOMY_MODIFIER", 714, 723], ["crystalloid", "OBSERVATION_MODIFIER", 736, 747], ["cubic membranes", "OBSERVATION", 754, 769], ["variety", "OBSERVATION_MODIFIER", 798, 805], ["viral", "OBSERVATION_MODIFIER", 809, 814], ["infections", "OBSERVATION", 815, 825]]], ["Interestingly, similar structures have been found upon expression of HAV 2C and 2BC, with the former regarded as the functional counterpart of norovirus NS3 in picornaviruses [34].", [["HAV 2C", "ORGANISM", 69, 75], ["2BC", "GENE_OR_GENE_PRODUCT", 80, 83], ["norovirus NS3", "ORGANISM", 143, 156], ["HAV 2C", "PROTEIN", 69, 75], ["2BC", "PROTEIN", 80, 83], ["norovirus NS3", "PROTEIN", 143, 156], ["HAV 2C", "SPECIES", 69, 75], ["HAV 2C", "TREATMENT", 69, 75], ["2BC", "TREATMENT", 80, 83], ["norovirus NS3 in picornaviruses", "PROBLEM", 143, 174]]], ["These structures clearly resemble OSER membranes with cubic (NS3) and hexagonal (NS4) symmetry.", [["OSER membranes", "ANATOMY", 34, 48], ["OSER membranes", "CELLULAR_COMPONENT", 34, 48], ["NS3", "PROTEIN", 61, 64], ["NS4", "PROTEIN", 81, 84], ["cubic (NS3) and hexagonal (NS4) symmetry", "TREATMENT", 54, 94], ["OSER membranes", "OBSERVATION", 34, 48]]], ["It has been reported that OSER structures can be generated through weak protein-protein interactions, which can even be triggered by overexpression of GFP tagged to cytochrome b(5), with the GFP moiety providing the homotypic interactions [66].", [["GFP", "GENE_OR_GENE_PRODUCT", 151, 154], ["cytochrome b(5)", "GENE_OR_GENE_PRODUCT", 165, 180], ["GFP", "GENE_OR_GENE_PRODUCT", 191, 194], ["OSER", "PROTEIN", 26, 30], ["GFP", "PROTEIN", 151, 154], ["cytochrome b", "PROTEIN", 165, 177], ["GFP moiety", "PROTEIN", 191, 201], ["OSER structures", "PROBLEM", 26, 41], ["weak protein-protein interactions", "PROBLEM", 67, 100], ["GFP", "TEST", 151, 154], ["the GFP moiety", "PROBLEM", 187, 201]]], ["Therefore, we currently cannot exclude that the fusion of NS3 and NS4 with eGFP, required for CLEM, also contributed to this phenotype.", [["NS3", "GENE_OR_GENE_PRODUCT", 58, 61], ["NS4", "GENE_OR_GENE_PRODUCT", 66, 69], ["eGFP", "GENE_OR_GENE_PRODUCT", 75, 79], ["CLEM", "GENE_OR_GENE_PRODUCT", 94, 98], ["NS3", "PROTEIN", 58, 61], ["NS4", "PROTEIN", 66, 69], ["eGFP", "PROTEIN", 75, 79], ["CLEM", "PROTEIN", 94, 98], ["the fusion of NS3", "TREATMENT", 44, 61], ["eGFP", "TEST", 75, 79], ["CLEM", "PROBLEM", 94, 98], ["this phenotype", "PROBLEM", 120, 134]]], ["However, it seems unlikely that these structures are essential for viral replication, since they have not been observed so far in either MNV infected cells or upon ORF1 overexpression [15,44].", [["cells", "ANATOMY", 150, 155], ["cells", "CELL", 150, 155], ["ORF1", "GENE_OR_GENE_PRODUCT", 164, 168], ["MNV infected cells", "CELL_LINE", 137, 155], ["ORF1", "DNA", 164, 168], ["MNV", "SPECIES", 137, 140], ["viral replication", "PROBLEM", 67, 84], ["MNV infected cells", "PROBLEM", 137, 155], ["ORF1 overexpression", "TEST", 164, 183], ["seems unlikely", "UNCERTAINTY", 12, 26]]], ["Therefore, the ability of NS3 and NS4 to induce cubic membranes might point to an intrinsic property, probably weak homotypic interactions, and seems to be linked to strong overexpression of single NS proteins.", [["cubic membranes", "ANATOMY", 48, 63], ["NS3", "GENE_OR_GENE_PRODUCT", 26, 29], ["NS4", "GENE_OR_GENE_PRODUCT", 34, 37], ["membranes", "CELLULAR_COMPONENT", 54, 63], ["single NS proteins", "GENE_OR_GENE_PRODUCT", 191, 209], ["NS3", "PROTEIN", 26, 29], ["NS4", "PROTEIN", 34, 37], ["NS proteins", "PROTEIN", 198, 209], ["NS3", "TREATMENT", 26, 29], ["NS4", "TREATMENT", 34, 37], ["cubic membranes", "PROBLEM", 48, 63], ["weak homotypic interactions", "PROBLEM", 111, 138], ["single NS proteins", "TREATMENT", 191, 209], ["intrinsic property", "OBSERVATION", 82, 100], ["probably", "UNCERTAINTY", 102, 110], ["weak", "OBSERVATION_MODIFIER", 111, 115], ["homotypic", "OBSERVATION", 116, 125]]], ["Upon ORF1 expression and virus infection, such structures might be prevented due to the interactions among NS-proteins and by lower local concentrations of individual NS-proteins.", [["infection", "DISEASE", 31, 40], ["ORF1", "GENE_OR_GENE_PRODUCT", 5, 9], ["ORF1", "DNA", 5, 9], ["NS-proteins", "PROTEIN", 107, 118], ["NS-proteins", "PROTEIN", 167, 178], ["virus infection", "PROBLEM", 25, 40], ["NS-proteins", "TREATMENT", 107, 118], ["virus", "OBSERVATION_MODIFIER", 25, 30], ["infection", "OBSERVATION", 31, 40]]], ["Also in the case of HAV, cubic membranes were only found upon 2C/2BC overexpression [34] but not in HAV infected cells [28].DiscussionThe strong association of NS3 with ER membranes surrounding LDs as well as its potential to induce convoluted membranes suggests an active function in the formation of GII.4 replication organelles, which clearly requires more detailed studies beyond the scope of this manuscript.", [["cubic membranes", "ANATOMY", 25, 40], ["cells", "ANATOMY", 113, 118], ["ER membranes", "ANATOMY", 169, 181], ["LDs", "ANATOMY", 194, 197], ["convoluted membranes", "ANATOMY", 233, 253], ["organelles", "ANATOMY", 320, 330], ["HAV infected", "DISEASE", 100, 112], ["HAV", "ORGANISM", 20, 23], ["2BC", "GENE_OR_GENE_PRODUCT", 65, 68], ["HAV", "ORGANISM", 100, 103], ["cells", "CELL", 113, 118], ["NS3", "GENE_OR_GENE_PRODUCT", 160, 163], ["ER", "GENE_OR_GENE_PRODUCT", 169, 171], ["membranes", "CELLULAR_COMPONENT", 172, 181], ["LDs", "CELLULAR_COMPONENT", 194, 197], ["membranes", "CELLULAR_COMPONENT", 244, 253], ["organelles", "CELLULAR_COMPONENT", 320, 330], ["2BC", "PROTEIN", 65, 68], ["HAV infected cells", "CELL_TYPE", 100, 118], ["NS3", "PROTEIN", 160, 163], ["ER", "PROTEIN", 169, 171], ["HAV", "SPECIES", 20, 23], ["HAV", "SPECIES", 100, 103], ["HAV", "PROBLEM", 20, 23], ["cubic membranes", "PROBLEM", 25, 40], ["HAV infected cells", "PROBLEM", 100, 118], ["NS3 with ER membranes surrounding LDs", "TREATMENT", 160, 197], ["convoluted membranes", "PROBLEM", 233, 253], ["GII", "PROBLEM", 302, 305], ["4 replication organelles", "PROBLEM", 306, 330], ["detailed studies", "TEST", 360, 376], ["active", "OBSERVATION_MODIFIER", 266, 272], ["function", "OBSERVATION", 273, 281], ["replication organelles", "OBSERVATION", 308, 330]]], ["A similar localization pattern was previously found for MNV NS3 in Vero cells, but not tested for LD localization at that point [13].", [["Vero cells", "ANATOMY", 67, 77], ["MNV NS3", "ORGANISM", 56, 63], ["Vero cells", "CELL", 67, 77], ["MNV NS3", "PROTEIN", 56, 63], ["Vero cells", "CELL_LINE", 67, 77], ["MNV", "SPECIES", 56, 59], ["A similar localization pattern", "PROBLEM", 0, 30], ["MNV NS3 in Vero cells", "PROBLEM", 56, 77], ["LD localization", "TEST", 98, 113], ["Vero cells", "OBSERVATION", 67, 77]]], ["Interestingly, NS1-2 co-localized to NS3 on LDs in most cells upon expression of ORF1, whereas this LD association was never found upon sole expression of GII.4 NS1-2.", [["LDs", "ANATOMY", 44, 47], ["cells", "ANATOMY", 56, 61], ["NS1-2", "GENE_OR_GENE_PRODUCT", 15, 20], ["NS3", "GENE_OR_GENE_PRODUCT", 37, 40], ["LDs", "GENE_OR_GENE_PRODUCT", 44, 47], ["cells", "CELL", 56, 61], ["ORF1", "GENE_OR_GENE_PRODUCT", 81, 85], ["GII", "GENE_OR_GENE_PRODUCT", 155, 158], ["NS1", "PROTEIN", 15, 18], ["NS3", "PROTEIN", 37, 40], ["ORF1", "DNA", 81, 85], ["NS1", "PROTEIN", 161, 164], ["NS1", "TEST", 15, 18], ["NS3", "OBSERVATION", 37, 40], ["most cells", "OBSERVATION_MODIFIER", 51, 61]]], ["This result argues for an additional role of NS3 in recruiting NS1-2 upon formation of the viral replication organelle, probably involving direct interactions.", [["organelle", "ANATOMY", 109, 118], ["NS3", "GENE_OR_GENE_PRODUCT", 45, 48], ["NS1-2", "GENE_OR_GENE_PRODUCT", 63, 68], ["organelle", "CELLULAR_COMPONENT", 109, 118], ["NS3", "PROTEIN", 45, 48], ["NS1", "PROTEIN", 63, 66], ["NS3", "TREATMENT", 45, 48], ["NS1", "TREATMENT", 63, 66], ["the viral replication organelle", "PROBLEM", 87, 118], ["viral replication", "OBSERVATION", 91, 108]]], ["The recently observed localization of MNV NS3 with microtubules and cholesterol rich lipids when transiently expressed in Vero cells [45,46] further argues for a function of NS3 in shaping the replication organelle.", [["microtubules", "ANATOMY", 51, 63], ["Vero cells", "ANATOMY", 122, 132], ["organelle", "ANATOMY", 205, 214], ["cholesterol", "CHEMICAL", 68, 79], ["cholesterol", "CHEMICAL", 68, 79], ["MNV NS3", "ORGANISM", 38, 45], ["microtubules", "CELLULAR_COMPONENT", 51, 63], ["cholesterol", "SIMPLE_CHEMICAL", 68, 79], ["rich lipids", "CELLULAR_COMPONENT", 80, 91], ["Vero cells", "CELL", 122, 132], ["NS3", "GENE_OR_GENE_PRODUCT", 174, 177], ["organelle", "CELLULAR_COMPONENT", 205, 214], ["MNV NS3", "PROTEIN", 38, 45], ["microtubules", "PROTEIN", 51, 63], ["Vero cells", "CELL_LINE", 122, 132], ["NS3", "PROTEIN", 174, 177], ["MNV", "SPECIES", 38, 41], ["MNV NS3", "TREATMENT", 38, 45], ["microtubules and cholesterol rich lipids", "TREATMENT", 51, 91], ["Vero cells", "PROBLEM", 122, 132], ["NS3", "TREATMENT", 174, 177]]], ["Whether or not the NTPase activity, which has been demonstrated for the NS3 protein of GI.1 [14], is important for localization and membrane activity of NS3 remains to be determined.", [["membrane", "ANATOMY", 132, 140], ["NTPase", "GENE_OR_GENE_PRODUCT", 19, 25], ["GI.1 [14]", "GENE_OR_GENE_PRODUCT", 87, 96], ["membrane", "CELLULAR_COMPONENT", 132, 140], ["NS3", "GENE_OR_GENE_PRODUCT", 153, 156], ["NTPase", "PROTEIN", 19, 25], ["NS3 protein", "PROTEIN", 72, 83], ["NS3", "PROTEIN", 153, 156], ["the NTPase activity", "TEST", 15, 34], ["the NS3 protein", "TEST", 68, 83], ["NS3", "TREATMENT", 153, 156]]], ["However, the most obvious putative function of NS3 in RNA replication is a supposed helicase activity, suggested by conserved SF3 helicase motifs [67].", [["NS3", "GENE_OR_GENE_PRODUCT", 47, 50], ["SF3", "GENE_OR_GENE_PRODUCT", 126, 129], ["NS3", "PROTEIN", 47, 50], ["SF3 helicase motifs", "PROTEIN", 126, 145], ["NS3 in RNA replication", "TREATMENT", 47, 69]]], ["Still to date, only the related 2C protein from the picornavirus Enterovirus 71 has been shown to function as an ATP dependent helicase [68].DiscussionNS4 is by far the most enigmatic among the norovirus NS proteins and little is currently known about its structure or function.", [["ATP", "CHEMICAL", 113, 116], ["ATP", "CHEMICAL", 113, 116], ["2C", "GENE_OR_GENE_PRODUCT", 32, 34], ["picornavirus Enterovirus 71", "ORGANISM", 52, 79], ["ATP", "SIMPLE_CHEMICAL", 113, 116], ["2C protein", "PROTEIN", 32, 42], ["ATP dependent helicase", "PROTEIN", 113, 135], ["norovirus NS proteins", "PROTEIN", 194, 215], ["picornavirus Enterovirus 71", "SPECIES", 52, 79], ["the picornavirus Enterovirus", "PROBLEM", 48, 76], ["an ATP dependent helicase", "PROBLEM", 110, 135], ["the norovirus NS proteins", "TREATMENT", 190, 215], ["norovirus", "OBSERVATION", 194, 203]]], ["Here, we provide the first direct experimental evidence suggesting that NS4 indeed might be the central organizer of the norovirus replication complex.", [["NS4", "GENE_OR_GENE_PRODUCT", 72, 75], ["norovirus", "ORGANISM", 121, 130], ["NS4", "PROTEIN", 72, 75], ["norovirus replication complex", "PROTEIN", 121, 150], ["NS4", "TREATMENT", 72, 75], ["central", "ANATOMY_MODIFIER", 96, 103], ["norovirus replication", "OBSERVATION", 121, 142]]], ["In contrast to HCV, where all NS proteins can induce the formation of vesicular structures [31], NS4 was, in our hands, the only GII.4 protein capable of vesicle formation upon individual expression.", [["vesicular structures", "ANATOMY", 70, 90], ["vesicle", "ANATOMY", 154, 161], ["HCV", "ORGANISM", 15, 18], ["NS4", "GENE_OR_GENE_PRODUCT", 97, 100], ["vesicle", "CELLULAR_COMPONENT", 154, 161], ["NS proteins", "PROTEIN", 30, 41], ["NS4", "PROTEIN", 97, 100], ["HCV", "SPECIES", 15, 18], ["HCV", "PROBLEM", 15, 18], ["all NS proteins", "TREATMENT", 26, 41], ["vesicle formation", "PROBLEM", 154, 171], ["HCV", "OBSERVATION", 15, 18], ["vesicular", "ANATOMY_MODIFIER", 70, 79], ["hands", "ANATOMY", 113, 118], ["vesicle formation", "OBSERVATION", 154, 171]]], ["In addition, SMVs and DMVs were found, similar to MNV infection and ORF1 expression, albeit with differing abundance.", [["infection", "DISEASE", 54, 63], ["SMVs", "GENE_OR_GENE_PRODUCT", 13, 17], ["DMVs", "GENE_OR_GENE_PRODUCT", 22, 26], ["MNV", "ORGANISM", 50, 53], ["ORF1", "GENE_OR_GENE_PRODUCT", 68, 72], ["SMVs", "PROTEIN", 13, 17], ["DMVs", "PROTEIN", 22, 26], ["ORF1", "DNA", 68, 72], ["MNV", "SPECIES", 50, 53], ["SMVs", "PROBLEM", 13, 17], ["DMVs", "PROBLEM", 22, 26], ["MNV infection", "PROBLEM", 50, 63], ["ORF1 expression", "PROBLEM", 68, 83], ["MNV", "OBSERVATION_MODIFIER", 50, 53], ["infection", "OBSERVATION", 54, 63], ["ORF1 expression", "OBSERVATION", 68, 83]]], ["Altogether, these data suggest that NS4 may be the key driver in the formation of norovirus induced replication vesicles, requiring auxiliary functions of NS1-2 and NS3 to finally shape the replication organelles.", [["vesicles", "ANATOMY", 112, 120], ["organelles", "ANATOMY", 202, 212], ["norovirus", "DISEASE", 82, 91], ["NS4", "GENE_OR_GENE_PRODUCT", 36, 39], ["norovirus", "ORGANISM", 82, 91], ["vesicles", "CELLULAR_COMPONENT", 112, 120], ["NS1-2", "GENE_OR_GENE_PRODUCT", 155, 160], ["NS3", "GENE_OR_GENE_PRODUCT", 165, 168], ["organelles", "CELLULAR_COMPONENT", 202, 212], ["NS4", "PROTEIN", 36, 39], ["NS1", "PROTEIN", 155, 158], ["NS3", "PROTEIN", 165, 168], ["norovirus induced replication vesicles", "PROBLEM", 82, 120], ["NS1", "TREATMENT", 155, 158], ["NS3", "TREATMENT", 165, 168], ["norovirus", "OBSERVATION", 82, 91], ["replication vesicles", "OBSERVATION", 100, 120], ["replication organelles", "OBSERVATION", 190, 212]]], ["This is reminiscent of HCV, where the complexity of the so called membranous web is only found upon expression of a polyprotein precursor encoding NS3 to NS5B, arguing for a concerted action engaging several NS-proteins [31,33].", [["membranous web", "ANATOMY", 66, 80], ["HCV", "ORGANISM", 23, 26], ["membranous", "GENE_OR_GENE_PRODUCT", 66, 76], ["NS3", "GENE_OR_GENE_PRODUCT", 147, 150], ["NS5B", "GENE_OR_GENE_PRODUCT", 154, 158], ["polyprotein precursor", "PROTEIN", 116, 137], ["NS3", "PROTEIN", 147, 150], ["NS5B", "PROTEIN", 154, 158], ["NS-proteins", "PROTEIN", 208, 219], ["HCV", "SPECIES", 23, 26], ["HCV", "PROBLEM", 23, 26], ["a polyprotein precursor encoding NS3", "TREATMENT", 114, 150], ["NS5B", "TREATMENT", 154, 158], ["HCV", "OBSERVATION", 23, 26]]], ["In the case of picornaviruses, 2BC [27], 2BC/3A [26], 2C [34,69] and 3AB [35] have been found to generate distinct membrane alterations upon individual expression, with 2BC/3A and 3AB generating DMVs.", [["membrane", "ANATOMY", 115, 123], ["picornaviruses", "ORGANISM", 15, 29], ["2C [34,69]", "SIMPLE_CHEMICAL", 54, 64], ["3AB [35]", "SIMPLE_CHEMICAL", 69, 77], ["membrane", "CELLULAR_COMPONENT", 115, 123], ["3AB", "SIMPLE_CHEMICAL", 180, 183], ["DMVs", "GENE_OR_GENE_PRODUCT", 195, 199], ["2BC", "PROTEIN", 169, 172], ["3AB", "PROTEIN", 180, 183], ["DMVs", "PROTEIN", 195, 199], ["picornaviruses", "PROBLEM", 15, 29], ["2BC", "TEST", 31, 34], ["2BC", "TEST", 41, 44], ["2C", "TEST", 54, 56], ["3AB", "TEST", 69, 72], ["distinct membrane alterations", "PROBLEM", 106, 135], ["2BC", "TEST", 169, 172], ["3AB generating DMVs", "PROBLEM", 180, 199], ["distinct membrane", "OBSERVATION", 106, 123]]], ["However the ultrastructure of the replication organelles is far more complex upon infection also in case of picornaviruses [55].", [["organelles", "ANATOMY", 46, 56], ["infection", "DISEASE", 82, 91], ["organelles", "CELLULAR_COMPONENT", 46, 56], ["the replication organelles", "PROBLEM", 30, 56], ["infection", "PROBLEM", 82, 91], ["picornaviruses", "PROBLEM", 108, 122], ["more complex", "OBSERVATION_MODIFIER", 64, 76], ["infection", "OBSERVATION", 82, 91]]], ["Still, it is interesting to note that the unrelated proteins NS5A of HCV and 3A of PV are capable of inducing DMVs and share a similar structural organization.", [["NS5A", "GENE_OR_GENE_PRODUCT", 61, 65], ["HCV", "ORGANISM", 69, 72], ["PV", "GENE_OR_GENE_PRODUCT", 83, 85], ["DMVs", "GENE_OR_GENE_PRODUCT", 110, 114], ["NS5A", "PROTEIN", 61, 65], ["HCV and 3A", "PROTEIN", 69, 79], ["PV", "PROTEIN", 83, 85], ["DMVs", "PROTEIN", 110, 114], ["HCV", "SPECIES", 69, 72], ["PV", "SPECIES", 83, 85], ["HCV", "PROBLEM", 69, 72], ["inducing DMVs", "PROBLEM", 101, 114], ["a similar structural organization", "PROBLEM", 125, 158], ["NS5A", "OBSERVATION", 61, 65], ["structural organization", "OBSERVATION", 135, 158]]], ["Specifically, both contain a unique structured region lacking enzymatic functions, which has been resolved for HCV NS5A [70] and PV 3A [71], an intrinsically unfolded region engaged in recruitment of host factors [72\u201374] and a membrane attachment region.", [["membrane", "ANATOMY", 227, 235], ["membrane", "CELLULAR_COMPONENT", 227, 235], ["intrinsically unfolded region", "PROTEIN", 144, 173], ["host factors", "PROTEIN", 200, 212], ["membrane attachment region", "PROTEIN", 227, 253], ["HCV", "SPECIES", 111, 114], ["HCV NS5A", "TREATMENT", 111, 119], ["an intrinsically unfolded region", "PROBLEM", 141, 173], ["a membrane attachment region", "PROBLEM", 225, 253], ["enzymatic functions", "OBSERVATION", 62, 81], ["unfolded", "OBSERVATION", 158, 166], ["recruitment", "OBSERVATION_MODIFIER", 185, 196]]], ["Our current prediction for the organization of NS4, albeit highly speculative at this point, is strikingly similar regarding subdomain organization and functions (Fig 8A).", [["NS4", "GENE_OR_GENE_PRODUCT", 47, 50], ["NS4", "PROTEIN", 47, 50], ["NS4", "TREATMENT", 47, 50]]], ["This model will provide a valuable starting point for further in depth studies regarding the function of norovirus NS4.DiscussionAnother important aspect that needs to be addressed in future studies is the function of NS4 as part of various stable polyprotein cleavage intermediates.", [["norovirus", "ORGANISM", 105, 114], ["NS4", "GENE_OR_GENE_PRODUCT", 115, 118], ["NS4", "GENE_OR_GENE_PRODUCT", 218, 221], ["norovirus NS4", "PROTEIN", 105, 118], ["NS4", "PROTEIN", 218, 221], ["depth studies", "TEST", 65, 78], ["norovirus", "PROBLEM", 105, 114], ["NS4", "TREATMENT", 218, 221], ["various stable polyprotein cleavage intermediates", "TREATMENT", 233, 282], ["norovirus", "OBSERVATION", 105, 114]]], ["Our study, including three different GII.4 strains suggests a delayed cleavage of the NS4-NS7 precursor, based on in vitro translation.", [["NS4", "GENE_OR_GENE_PRODUCT", 86, 89], ["NS4", "PROTEIN", 86, 89], ["NS7 precursor", "PROTEIN", 90, 103], ["Our study", "TEST", 0, 9], ["4 strains", "PROBLEM", 41, 50], ["a delayed cleavage", "PROBLEM", 60, 78]]], ["However, a far more detailed analysis of polyprotein cleavage kinetics using a different GII.4 strain suggests a number of cleavage intermediates with NS4, including NS4-NS7, NS4-NS6 and NS4-NS5 [52], which might serve specific functions in the norovirus replication cycle.", [["norovirus", "DISEASE", 245, 254], ["NS4", "GENE_OR_GENE_PRODUCT", 151, 154], ["NS4-NS7", "GENE_OR_GENE_PRODUCT", 166, 173], ["NS4-NS6", "GENE_OR_GENE_PRODUCT", 175, 182], ["NS4-NS5", "GENE_OR_GENE_PRODUCT", 187, 194], ["norovirus", "ORGANISM", 245, 254], ["NS4", "PROTEIN", 151, 154], ["NS4", "PROTEIN", 166, 169], ["NS7", "PROTEIN", 170, 173], ["NS4", "PROTEIN", 175, 178], ["NS6", "PROTEIN", 179, 182], ["NS4", "PROTEIN", 187, 190], ["NS5", "PROTEIN", 191, 194], ["polyprotein cleavage kinetics", "TREATMENT", 41, 70], ["a different GII", "TREATMENT", 77, 92], ["NS4", "TREATMENT", 151, 154], ["NS4", "TREATMENT", 166, 169], ["NS7", "TREATMENT", 170, 173], ["NS4", "TREATMENT", 175, 178], ["NS6", "TREATMENT", 179, 182], ["NS4", "TREATMENT", 187, 190], ["NS5", "TREATMENT", 191, 194], ["norovirus replication", "OBSERVATION", 245, 266]]], ["It is particularly tempting to speculate that delayed cleavage of NS4-NS7 might avoid diffusion of the replicase components, since NS4 seems the only protein associated with membranes in this precursor protein.DiscussionOur model of the putative membrane organization of NS1-2, NS3 and NS4 (Fig 8A) is still highly speculative and contains several uncertainties regarding transmembrane topology.", [["membranes", "ANATOMY", 174, 183], ["membrane", "ANATOMY", 246, 254], ["transmembrane", "ANATOMY", 372, 385], ["NS4-NS7", "GENE_OR_GENE_PRODUCT", 66, 73], ["NS4", "GENE_OR_GENE_PRODUCT", 131, 134], ["membranes", "CELLULAR_COMPONENT", 174, 183], ["membrane", "CELLULAR_COMPONENT", 246, 254], ["NS1-2", "GENE_OR_GENE_PRODUCT", 271, 276], ["NS3", "GENE_OR_GENE_PRODUCT", 278, 281], ["NS4 (Fig 8A", "GENE_OR_GENE_PRODUCT", 286, 297], ["transmembrane", "CELLULAR_COMPONENT", 372, 385], ["NS4", "PROTEIN", 66, 69], ["NS7", "PROTEIN", 70, 73], ["replicase components", "PROTEIN", 103, 123], ["NS4", "PROTEIN", 131, 134], ["precursor protein", "PROTEIN", 192, 209], ["NS1", "PROTEIN", 271, 274], ["NS3", "PROTEIN", 278, 281], ["NS4", "PROTEIN", 286, 289], ["Fig 8A", "PROTEIN", 291, 297], ["NS4", "TREATMENT", 66, 69], ["NS7", "TREATMENT", 70, 73], ["diffusion of the replicase components", "PROBLEM", 86, 123], ["NS1", "TEST", 271, 274], ["NS3", "TREATMENT", 278, 281], ["NS4", "TEST", 286, 289], ["transmembrane topology", "TREATMENT", 372, 394]]], ["While our predictions are in favor of one transmembrane domain for both, the NS1-2 and NS3 proteins, this topology would require a post-cleavage membrane insertion to keep the cleavage site accessible to NS6.", [["membrane", "ANATOMY", 145, 153], ["NS1-2", "GENE_OR_GENE_PRODUCT", 77, 82], ["NS3", "GENE_OR_GENE_PRODUCT", 87, 90], ["membrane", "CELLULAR_COMPONENT", 145, 153], ["NS6", "GENE_OR_GENE_PRODUCT", 204, 207], ["transmembrane domain", "PROTEIN", 42, 62], ["NS1-2 and NS3 proteins", "PROTEIN", 77, 99], ["NS6", "PROTEIN", 204, 207], ["the NS1", "TEST", 73, 80], ["NS3 proteins", "TREATMENT", 87, 99], ["a post-cleavage membrane insertion", "TREATMENT", 129, 163], ["the cleavage site", "PROBLEM", 172, 189]]], ["Alternatively, and still in line with the predictions, NS1-2 could span the membrane twice and NS3 may harbor an amphipathic alpha helix tethering the protein to membranes, thereby keeping the NS6 cleavage site in the cytoplasm.", [["membrane", "ANATOMY", 76, 84], ["membranes", "ANATOMY", 162, 171], ["cytoplasm", "ANATOMY", 218, 227], ["NS1-2", "GENE_OR_GENE_PRODUCT", 55, 60], ["membrane", "CELLULAR_COMPONENT", 76, 84], ["NS3", "GENE_OR_GENE_PRODUCT", 95, 98], ["membranes", "CELLULAR_COMPONENT", 162, 171], ["NS6", "GENE_OR_GENE_PRODUCT", 193, 196], ["cytoplasm", "ORGANISM_SUBSTANCE", 218, 227], ["NS1", "PROTEIN", 55, 58], ["NS3", "PROTEIN", 95, 98], ["amphipathic alpha helix", "PROTEIN", 113, 136], ["NS6", "PROTEIN", 193, 196], ["NS1", "TREATMENT", 55, 58], ["NS3", "TREATMENT", 95, 98], ["an amphipathic alpha helix", "PROBLEM", 110, 136], ["the NS6 cleavage site", "TREATMENT", 189, 210], ["amphipathic alpha helix", "OBSERVATION", 113, 136], ["cleavage site", "OBSERVATION", 197, 210], ["cytoplasm", "OBSERVATION_MODIFIER", 218, 227]]], ["Regardless, the transmembrane topology of NS1-2 and NS3 can be experimentally addressed in future studies using our expression model and, for example, testing the accessibility of N- and C-termini to proteases in cell lysates.DiscussionIn summary, our study reveals a first insight into the organization of the putative GII.4 replication organelle and the contribution of individual NS proteins to its biogenesis using a protein expression model.", [["transmembrane", "ANATOMY", 16, 29], ["cell lysates", "ANATOMY", 213, 225], ["organelle", "ANATOMY", 338, 347], ["N", "CHEMICAL", 180, 181], ["C", "CHEMICAL", 187, 188], ["transmembrane", "CELLULAR_COMPONENT", 16, 29], ["NS1-2", "GENE_OR_GENE_PRODUCT", 42, 47], ["NS3", "GENE_OR_GENE_PRODUCT", 52, 55], ["cell lysates", "CELL", 213, 225], ["GII", "GENE_OR_GENE_PRODUCT", 320, 323], ["organelle", "CELLULAR_COMPONENT", 338, 347], ["NS1", "PROTEIN", 42, 45], ["NS3", "PROTEIN", 52, 55], ["N- and C-termini", "PROTEIN", 180, 196], ["proteases", "PROTEIN", 200, 209], ["putative GII", "PROTEIN", 311, 323], ["NS proteins", "PROTEIN", 383, 394], ["the transmembrane topology", "TEST", 12, 38], ["NS1", "TEST", 42, 45], ["NS3", "TREATMENT", 52, 55], ["N", "TEST", 180, 181], ["cell lysates", "PROBLEM", 213, 225], ["our study", "TEST", 248, 257], ["individual NS proteins", "TREATMENT", 372, 394], ["a protein expression model", "TREATMENT", 419, 445], ["cell lysates", "OBSERVATION", 213, 225]]], ["In the case of HCV, comparable expression models have been invaluable to study formation and structure of the viral replication organelles as they allow mechanistic studies using replication deficient mutants or inhibitors interfering with replication.", [["organelles", "ANATOMY", 128, 138], ["HCV", "ORGANISM", 15, 18], ["HCV", "SPECIES", 15, 18], ["HCV", "PROBLEM", 15, 18], ["study formation", "TEST", 73, 88], ["the viral replication organelles", "PROBLEM", 106, 138], ["mechanistic studies", "TEST", 153, 172], ["replication deficient mutants", "TREATMENT", 179, 208], ["inhibitors", "TREATMENT", 212, 222], ["HCV", "OBSERVATION", 15, 18], ["viral replication", "OBSERVATION", 110, 127]]], ["Thereby, the contribution of viral NS-proteins could be clearly defined [31,33] in addition to the importance of host factors like PI4KA [75,76].", [["PI4KA", "GENE_OR_GENE_PRODUCT", 131, 136], ["viral NS-proteins", "PROTEIN", 29, 46], ["host factors", "PROTEIN", 113, 125], ["PI4KA", "PROTEIN", 131, 136], ["viral NS-proteins", "TREATMENT", 29, 46]]], ["Only expression models allowed us to identify viral membrane alterations as targets of direct antiviral agents (NS5A inhibitors [37]) and host targeting drugs including PI4KA inhibitors [75] and cyclophilin inhibitors [38].", [["membrane", "ANATOMY", 52, 60], ["PI4KA inhibitors [75]", "SIMPLE_CHEMICAL", 169, 190], ["cyclophilin", "GENE_OR_GENE_PRODUCT", 195, 206], ["viral membrane alterations", "PROBLEM", 46, 72], ["direct antiviral agents (NS5A inhibitors", "TREATMENT", 87, 127], ["host targeting drugs", "TREATMENT", 138, 158], ["PI4KA inhibitors", "TREATMENT", 169, 185], ["cyclophilin inhibitors", "TREATMENT", 195, 217]]], ["Similar approaches might help to identify novel strategies to develop drugs targeting norovirus replication in future studies.", [["norovirus", "DISEASE", 86, 95], ["norovirus", "ORGANISM", 86, 95], ["norovirus", "SPECIES", 86, 95], ["drugs", "TREATMENT", 70, 75], ["norovirus replication", "TREATMENT", 86, 107]]], ["Furthermore, our study lays the groundwork for an in-depth analysis of the functions of NS1-2 and NS4 in replication complex formation.Cell lines and viruses ::: Material and methodsAll cell lines were cultured in Dulbecco\u2019s Modified Eagle Medium (DMEM; Life Technologies, Darmstadt, Germany) supplemented with 10% fetal bovine serum, non-essential amino acids (Life Technologies, Darmstadt, Germany), 100U/ml penicillin and 100ng/ml streptomycin (Life Technologies) and cultivated at 37\u00b0C and 5% CO2.", [["Cell lines", "ANATOMY", 135, 145], ["cell lines", "ANATOMY", 186, 196], ["fetal bovine serum", "ANATOMY", 315, 333], ["amino acids", "CHEMICAL", 349, 360], ["penicillin", "CHEMICAL", 410, 420], ["streptomycin", "CHEMICAL", 434, 446], ["CO2", "CHEMICAL", 497, 500], ["amino acids", "CHEMICAL", 349, 360], ["penicillin", "CHEMICAL", 410, 420], ["streptomycin", "CHEMICAL", 434, 446], ["CO2", "CHEMICAL", 497, 500], ["NS1-2", "GENE_OR_GENE_PRODUCT", 88, 93], ["NS4", "GENE_OR_GENE_PRODUCT", 98, 101], ["Cell lines", "CELL", 135, 145], ["cell lines", "CELL", 186, 196], ["bovine", "ORGANISM", 321, 327], ["serum", "ORGANISM_SUBSTANCE", 328, 333], ["amino acids", "AMINO_ACID", 349, 360], ["penicillin", "SIMPLE_CHEMICAL", 410, 420], ["streptomycin", "SIMPLE_CHEMICAL", 434, 446], ["CO2", "SIMPLE_CHEMICAL", 497, 500], ["NS1", "PROTEIN", 88, 91], ["NS4", "PROTEIN", 98, 101], ["cell lines", "CELL_LINE", 186, 196], ["bovine", "SPECIES", 321, 327], ["bovine", "SPECIES", 321, 327], ["our study", "TEST", 13, 22], ["an in-depth analysis", "TEST", 47, 67], ["NS1", "TEST", 88, 91], ["All cell lines", "TREATMENT", 182, 196], ["Modified Eagle Medium (DMEM", "TREATMENT", 225, 252], ["Life Technologies", "TREATMENT", 254, 271], ["10% fetal bovine serum", "TREATMENT", 311, 333], ["non-essential amino acids", "TREATMENT", 335, 360], ["Darmstadt", "TREATMENT", 381, 390], ["penicillin", "TREATMENT", 410, 420], ["streptomycin", "TREATMENT", 434, 446], ["viruses", "OBSERVATION", 150, 157], ["cell lines", "OBSERVATION", 186, 196]]], ["The human hepatoma cell line Huh7 (maintained in our laboratory), stably expressing T7 RNA polymerase under blasticidine selection (5 \u03bcg/ml, Invitrogen, Germany) [74], was used for transient expression of plasmids encoding GII.4 NoV proteins that were analyzed by immunofluorescence and Western blot assays.", [["hepatoma cell line Huh7", "ANATOMY", 10, 33], ["plasmids", "ANATOMY", 205, 213], ["blasticidine", "CHEMICAL", 108, 120], ["blasticidine", "CHEMICAL", 108, 120], ["human", "ORGANISM", 4, 9], ["hepatoma cell line Huh7", "CELL", 10, 33], ["GII.4 NoV", "ORGANISM", 223, 232], ["human hepatoma cell line Huh7", "CELL_LINE", 4, 33], ["T7 RNA polymerase", "PROTEIN", 84, 101], ["plasmids", "DNA", 205, 213], ["GII.4 NoV proteins", "PROTEIN", 223, 241], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["GII.4 NoV", "SPECIES", 223, 232], ["The human hepatoma cell line Huh7", "TREATMENT", 0, 33], ["blasticidine selection", "TREATMENT", 108, 130], ["plasmids", "TREATMENT", 205, 213], ["blot assays", "TEST", 295, 306], ["hepatoma", "ANATOMY", 10, 18], ["cell line", "OBSERVATION", 19, 28], ["Huh7", "OBSERVATION", 29, 33]]], ["Huh7 cells expressing the MNV receptor CD300lf were generated by transduction with a lentiviral vector encoding the murine CD300lf cDNA [47] (generous gift from R.C. Orchard and H.W. Virgin).", [["Huh7 cells", "ANATOMY", 0, 10], ["Huh7 cells", "CELL", 0, 10], ["MNV", "ORGANISM", 26, 29], ["CD300lf", "GENE_OR_GENE_PRODUCT", 39, 46], ["lentiviral", "ORGANISM", 85, 95], ["murine", "ORGANISM", 116, 122], ["CD300lf", "GENE_OR_GENE_PRODUCT", 123, 130], ["Huh7 cells", "CELL_LINE", 0, 10], ["MNV receptor CD300lf", "PROTEIN", 26, 46], ["murine CD300lf cDNA", "DNA", 116, 135], ["murine", "SPECIES", 116, 122], ["Huh7 cells", "TREATMENT", 0, 10], ["the MNV receptor CD300lf", "TREATMENT", 22, 46], ["a lentiviral vector", "TREATMENT", 83, 102]]], ["Cells were selected by puromycin to obtain a stable culture of Huh7 cells with CD300lf expression.", [["Cells", "ANATOMY", 0, 5], ["Huh7 cells", "ANATOMY", 63, 73], ["puromycin", "CHEMICAL", 23, 32], ["puromycin", "CHEMICAL", 23, 32], ["Cells", "CELL", 0, 5], ["puromycin", "SIMPLE_CHEMICAL", 23, 32], ["Huh7 cells", "CELL", 63, 73], ["CD300lf", "GENE_OR_GENE_PRODUCT", 79, 86], ["Huh7 cells", "CELL_LINE", 63, 73], ["CD300lf", "PROTEIN", 79, 86], ["puromycin", "TREATMENT", 23, 32], ["Huh7 cells", "PROBLEM", 63, 73], ["Huh7 cells", "OBSERVATION", 63, 73]]], ["The murine macrophage cell line RAW 264.7 was obtained from ATCC (Middlesex, UK) and used for infection with MNV.", [["macrophage cell line RAW 264.7", "ANATOMY", 11, 41], ["ATCC", "ANATOMY", 60, 64], ["RAW 264.7", "CHEMICAL", 32, 41], ["infection", "DISEASE", 94, 103], ["murine", "ORGANISM", 4, 10], ["macrophage cell line RAW 264.7", "CELL", 11, 41], ["ATCC", "CELL", 60, 64], ["MNV", "ORGANISM", 109, 112], ["murine macrophage cell line", "CELL_LINE", 4, 31], ["RAW 264.7", "CELL_LINE", 32, 41], ["murine", "SPECIES", 4, 10], ["ATCC", "SPECIES", 60, 64], ["MNV", "SPECIES", 109, 112], ["The murine macrophage cell line RAW", "TEST", 0, 35], ["ATCC", "TEST", 60, 64], ["infection", "PROBLEM", 94, 103], ["macrophage cell line", "OBSERVATION", 11, 31], ["infection", "OBSERVATION", 94, 103]]], ["MNV-CW1 [44] was used at a multiplicity of infection of 1 and analyzed 24 h after infection, unless otherwise stated.", [["MNV-CW1 [44]", "CHEMICAL", 0, 12], ["infection", "DISEASE", 43, 52], ["infection", "DISEASE", 82, 91], ["MNV", "ORGANISM", 0, 3], ["MNV", "TEST", 0, 3], ["CW1", "TEST", 4, 7], ["infection", "PROBLEM", 43, 52], ["infection", "PROBLEM", 82, 91], ["infection", "OBSERVATION", 43, 52], ["infection", "OBSERVATION", 82, 91]]], ["HEK293T-cells (Birke Bartosch, Lyon) were used for production of MNV virus stocks upon transfection of plasmid pMNV-CW1 (generous gift from H.W. Virgin).Plasmid constructs ::: Material and methodsThe genomes representing consensus sequences of respective patient isolates of three GII.4 strains including a Den Haag 2006b variant (DH) (GenBank accession no. AB447456), a New Orleans 2009 variant (NO) (GenBank accession no JQ613573) and a Sydney 2012 variant (Syd) (GenBank accession no JX459908) were used in this study.", [["HEK293T-cells", "ANATOMY", 0, 13], ["AB447456", "CHEMICAL", 358, 366], ["NO", "CHEMICAL", 397, 399], ["AB447456", "CHEMICAL", 358, 366], ["NO", "CHEMICAL", 397, 399], ["HEK293T-cells", "CELL", 0, 13], ["Birke Bartosch", "CELL", 15, 29], ["MNV", "ORGANISM", 65, 68], ["pMNV-CW1", "GENE_OR_GENE_PRODUCT", 111, 119], ["patient", "ORGANISM", 255, 262], ["AB447456", "SIMPLE_CHEMICAL", 358, 366], ["HEK293T-cells", "CELL_LINE", 0, 13], ["plasmid pMNV", "DNA", 103, 115], ["CW1", "DNA", 116, 119], ["Plasmid constructs", "DNA", 153, 171], ["consensus sequences", "DNA", 221, 240], ["patient", "SPECIES", 255, 262], ["MNV virus", "SPECIES", 65, 74], ["HEK293T", "TEST", 0, 7], ["Birke Bartosch", "TREATMENT", 15, 29], ["MNV virus stocks", "TREATMENT", 65, 81], ["plasmid pMNV", "TREATMENT", 103, 115], ["this study", "TEST", 510, 520]]], ["Coding sequences corresponding to ORF1 of the three isolates were synthesized with protein sequences identical to the GenBank entries in vector pBMH by Biomatik (Cambridge, Canada).", [["ORF1", "DNA", 34, 38], ["protein sequences", "DNA", 83, 100], ["GenBank entries", "DNA", 118, 133], ["Coding sequences", "TEST", 0, 16], ["ORF1", "TEST", 34, 38], ["protein sequences", "TEST", 83, 100]]], ["Full length ORF1 of NO, Saga, Sydney, MNV were amplified by PCR from the pBMH construct.", [["NO", "CHEMICAL", 20, 22], ["NO", "GENE_OR_GENE_PRODUCT", 20, 22], ["MNV", "GENE_OR_GENE_PRODUCT", 38, 41], ["ORF1", "DNA", 12, 16], ["pBMH construct", "DNA", 73, 87], ["NO", "UNCERTAINTY", 20, 22]]], ["Restriction sites NcoI and PacI were used to insert fragments into a basic pTM1-2, AgeI and PacI was used for insertion into basic pTM 1\u20133.Plasmid constructs ::: Material and methodsTo generate pTM vectors allowing expression of N-terminally HA- or eGFP tagged individual norovirus nonstructural proteins, respective coding sequences were amplified using primers given in Table 1 and cloned into pTM-HA or pTM-eGFP, respectively using the indicated restriction sites.Plasmid constructs ::: Material and methodsAll PCR amplifications for cloning were performed with Phusion Flash High-Fidelity PCR Master Mix according to the manufacturer\u2019s instructions (Thermo Fisher Scientific, Germany).", [["fragments", "ANATOMY", 52, 61], ["NcoI", "GENE_OR_GENE_PRODUCT", 18, 22], ["PacI", "GENE_OR_GENE_PRODUCT", 27, 31], ["pTM1-2", "GENE_OR_GENE_PRODUCT", 75, 81], ["AgeI", "GENE_OR_GENE_PRODUCT", 83, 87], ["PacI", "GENE_OR_GENE_PRODUCT", 92, 96], ["pTM", "GENE_OR_GENE_PRODUCT", 194, 197], ["HA", "GENE_OR_GENE_PRODUCT", 242, 244], ["eGFP", "GENE_OR_GENE_PRODUCT", 249, 253], ["pTM-HA", "GENE_OR_GENE_PRODUCT", 396, 402], ["pTM-eGFP", "GENE_OR_GENE_PRODUCT", 406, 414], ["PacI", "DNA", 27, 31], ["basic pTM1-2", "DNA", 69, 81], ["AgeI", "DNA", 83, 87], ["PacI", "DNA", 92, 96], ["basic pTM 1\u20133", "DNA", 125, 138], ["Plasmid constructs", "DNA", 139, 157], ["pTM vectors", "DNA", 194, 205], ["N-terminally HA", "PROTEIN", 229, 244], ["eGFP", "PROTEIN", 249, 253], ["norovirus nonstructural proteins", "PROTEIN", 272, 304], ["pTM", "DNA", 396, 399], ["HA", "DNA", 400, 402], ["pTM", "DNA", 406, 409], ["eGFP", "DNA", 410, 414], ["restriction sites", "DNA", 449, 466], ["Plasmid constructs", "DNA", 467, 485], ["PCR amplifications", "DNA", 514, 532], ["Restriction sites NcoI", "TREATMENT", 0, 22], ["PacI", "TREATMENT", 27, 31], ["PacI", "TREATMENT", 92, 96], ["pTM vectors", "TREATMENT", 194, 205], ["N-terminally HA", "PROBLEM", 229, 244], ["eGFP tagged individual norovirus nonstructural proteins", "PROBLEM", 249, 304], ["respective coding sequences", "TEST", 306, 333], ["HA", "PROBLEM", 400, 402], ["All PCR amplifications", "TREATMENT", 510, 532], ["Phusion Flash", "TREATMENT", 565, 578]]], ["PCR products were separated by agarose gel electrophoresis and purified with NucleoSpin Gel and PCR Clean-up kits purchased from Macherey-Nagel (Germany).", [["agarose", "SIMPLE_CHEMICAL", 31, 38], ["PCR products", "TREATMENT", 0, 12], ["agarose gel electrophoresis", "TEST", 31, 58], ["NucleoSpin Gel", "TREATMENT", 77, 91], ["PCR", "TEST", 96, 99]]], ["Restriction digests were performed according to the instructions of the manufacturer (New England Biolabs).", [["Biolabs", "GENE_OR_GENE_PRODUCT", 98, 105], ["Restriction digests", "TREATMENT", 0, 19]]], ["All parts of plasmid sequences amplified by PCR were analyzed by Sanger-sequencing to verify sequence fidelity and the correct reading frame (GATC Biotech, Konstanz, Germany).Production of infectious MNV virus stocks ::: Material and methodsMNV stocks were obtained by transfecting plasmid pMNV-CW1 (generous gift from Herbert W. Virgin) into 293T cells, as described [77].", [["293T cells", "ANATOMY", 343, 353], ["MNV virus", "ORGANISM", 200, 209], ["MNV", "ORGANISM", 241, 244], ["293T cells", "CELL", 343, 353], ["plasmid sequences", "DNA", 13, 30], ["reading frame", "DNA", 127, 140], ["pMNV", "PROTEIN", 290, 294], ["CW1", "DNA", 295, 298], ["293T cells", "CELL_LINE", 343, 353], ["MNV virus", "SPECIES", 200, 209], ["MNV", "SPECIES", 241, 244], ["plasmid sequences", "TEST", 13, 30], ["PCR", "TEST", 44, 47], ["methodsMNV stocks", "TEST", 234, 251], ["infectious", "OBSERVATION_MODIFIER", 189, 199], ["MNV stocks", "OBSERVATION", 241, 251]]], ["293T cells were seeded in 10 cm tissue culture dish (Corning, Durham, NC, USA) at a density of 3x105 cells/ml in 15.5 ml of complete DMEM.", [["293T cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 101, 106], ["293T cells", "CELL", 0, 10], ["3x105 cells", "CELL", 95, 106], ["293T cells", "CELL_LINE", 0, 10], ["10 cm tissue", "OBSERVATION_MODIFIER", 26, 38]]], ["After 24 hours, cells were transfected with 15 \u03bcg of pMNV-CW1 plasmid DNA using TransIT-LT1 Transfection Reagent (Mirrus Bio LLC, Madison, WI, USA) following the instructions of the manufacturer.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["pMNV", "PROTEIN", 53, 57], ["CW1 plasmid DNA", "DNA", 58, 73], ["pMNV", "TREATMENT", 53, 57], ["CW1 plasmid DNA", "TREATMENT", 58, 73], ["TransIT", "TEST", 80, 87], ["the manufacturer", "TREATMENT", 178, 194]]], ["Virus stocks were obtained by harvesting the cells in their culture medium and twice freezing at -80\u00b0C and then thawing at 37\u00b0C. Lysates were then centrifuged at 2500 x g for 5 minutes and clarified virus stocks were stored at -80\u00b0C. To determine virus titers, RAW 264.7 cells were seeded in 96 well tissue culture plates (Corning, Durham, NC, USA) at a density of 2x104 cells per well.", [["cells", "ANATOMY", 45, 50], ["Lysates", "ANATOMY", 129, 136], ["RAW 264.7 cells", "ANATOMY", 261, 276], ["cells", "ANATOMY", 371, 376], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 45, 50], ["C", "SIMPLE_CHEMICAL", 101, 102], ["Lysates", "ORGANISM_SUBSTANCE", 129, 136], ["RAW 264.7 cells", "CELL", 261, 276], ["cells", "CELL", 371, 376], ["RAW 264.7 cells", "CELL_LINE", 261, 276], ["2x104 cells", "CELL_LINE", 365, 376], ["Virus stocks", "TREATMENT", 0, 12], ["Lysates", "TREATMENT", 129, 136], ["virus stocks", "TREATMENT", 199, 211], ["virus titers", "TEST", 247, 259], ["a density of 2x104 cells", "TREATMENT", 352, 376]]], ["After 24 hours, wells were infected in quadruplicate with serial dilutions of virus stocks diluted in DMEM medium.", [["serial dilutions of virus stocks", "TREATMENT", 58, 90], ["infected", "OBSERVATION", 27, 35]]], ["Assays were harvested 72 hours post infection by aspirating supernatant, washing with PBS and staining with 50 \u03bcl of a 1.25% (w/v) crystal violet solution (Merck, Darmstadt, Germany) in a 25% (v/v) ethanol solution for 10 minutes at room temperature.", [["supernatant", "ANATOMY", 60, 71], ["infection", "DISEASE", 36, 45], ["ethanol", "CHEMICAL", 198, 205], ["ethanol", "CHEMICAL", 198, 205], ["ethanol", "SIMPLE_CHEMICAL", 198, 205], ["Assays", "TEST", 0, 6], ["infection", "PROBLEM", 36, 45], ["aspirating supernatant", "PROBLEM", 49, 71], ["PBS", "TREATMENT", 86, 89], ["staining", "TEST", 94, 102], ["w/v) crystal violet solution", "TREATMENT", 126, 154], ["Merck, Darmstadt, Germany)", "TREATMENT", 156, 182], ["ethanol solution", "TREATMENT", 198, 214], ["infection", "OBSERVATION", 36, 45]]], ["The wells were washed twice with distilled water and scored as positively infected or negative.", [["negative", "OBSERVATION", 86, 94]]], ["The TCID50/ml was then calculated using the Spaerman-K\u00e4rber method [78,79].Immunofluorescence (IF) microscopy ::: Material and methodsFor the transient expression of norovirus eGFP or HA-tagged proteins, Huh7 T7 cells were transfected with LT1 transfection agent (Mirus Bio LLC, Madison, WI, USA) according to the manufacturer's instructions.", [["Huh7 T7 cells", "ANATOMY", 204, 217], ["norovirus", "ORGANISM", 166, 175], ["eGFP", "GENE_OR_GENE_PRODUCT", 176, 180], ["Huh7 T7 cells", "CELL", 204, 217], ["norovirus eGFP", "PROTEIN", 166, 180], ["HA", "PROTEIN", 184, 186], ["tagged proteins", "PROTEIN", 187, 202], ["Huh7 T7 cells", "CELL_LINE", 204, 217], ["norovirus", "SPECIES", 166, 175], ["The TCID50/ml", "TREATMENT", 0, 13], ["methods", "TREATMENT", 127, 134], ["norovirus eGFP", "PROBLEM", 166, 180], ["HA", "PROBLEM", 184, 186], ["tagged proteins", "PROBLEM", 187, 202], ["Huh7 T7 cells", "TREATMENT", 204, 217], ["LT1 transfection agent", "TREATMENT", 240, 262], ["norovirus", "OBSERVATION", 166, 175]]], ["Cells were processed for IF as described in [76].", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["IF", "GENE_OR_GENE_PRODUCT", 25, 27], ["IF", "PROTEIN", 25, 27]]], ["Briefly, cells were fixed in 4% paraformaldehyde (PFA) for 20 min and permeabilized with 0.5% Triton X-100 (PBS) for 15 min for co-localization analysis of eGFP-tagged proteins with subcellular markers.", [["cells", "ANATOMY", 9, 14], ["subcellular", "ANATOMY", 182, 193], ["Triton X-100", "CHEMICAL", 94, 106], ["paraformaldehyde", "CHEMICAL", 32, 48], ["PFA", "CHEMICAL", 50, 53], ["Triton X-100", "CHEMICAL", 94, 106], ["cells", "CELL", 9, 14], ["paraformaldehyde", "SIMPLE_CHEMICAL", 32, 48], ["PFA", "SIMPLE_CHEMICAL", 50, 53], ["Triton X-100", "SIMPLE_CHEMICAL", 94, 106], ["eGFP", "GENE_OR_GENE_PRODUCT", 156, 160], ["eGFP", "PROTEIN", 156, 160], ["tagged proteins", "PROTEIN", 161, 176], ["subcellular markers", "PROTEIN", 182, 201], ["0.5% Triton", "TREATMENT", 89, 100], ["co-localization analysis", "TEST", 128, 152], ["eGFP", "TEST", 156, 160], ["subcellular markers", "TEST", 182, 201]]], ["Primary antibodies were incubated in 3% bovine serum albumin (BSA) for 1 h at room temperature (RT).", [["serum", "ANATOMY", 47, 52], ["BSA", "CHEMICAL", 62, 65], ["bovine", "ORGANISM", 40, 46], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["albumin", "SIMPLE_CHEMICAL", 53, 60], ["BSA", "SIMPLE_CHEMICAL", 62, 65], ["antibodies", "PROTEIN", 8, 18], ["bovine", "SPECIES", 40, 46], ["bovine", "SPECIES", 40, 46], ["Primary antibodies", "TEST", 0, 18], ["3% bovine serum albumin", "TREATMENT", 37, 60]]], ["NS3 was detected with an in-house created rabbit polyclonal serum, animals were immunized with NS3 expressed and purified from E. coli by Davids Biotechnology, Regensburg, Germany.", [["serum", "ANATOMY", 60, 65], ["NS3", "GENE_OR_GENE_PRODUCT", 0, 3], ["rabbit", "ORGANISM", 42, 48], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["animals", "ORGANISM", 67, 74], ["NS3", "ORGANISM", 95, 98], ["E. coli", "ORGANISM", 127, 134], ["NS3", "PROTEIN", 0, 3], ["NS3", "PROTEIN", 95, 98], ["rabbit", "SPECIES", 42, 48], ["E. coli", "SPECIES", 127, 134], ["rabbit", "SPECIES", 42, 48], ["E. coli", "SPECIES", 127, 134], ["NS3", "TREATMENT", 0, 3], ["NS3", "TREATMENT", 95, 98], ["E. coli", "PROBLEM", 127, 134], ["E. coli", "OBSERVATION_MODIFIER", 127, 134]]], ["Antibodies detecting NS4/p20 and NS6 of GII.4 were a generous gift from Stefan Taube [80].", [["NS4", "GENE_OR_GENE_PRODUCT", 21, 24], ["p20", "GENE_OR_GENE_PRODUCT", 25, 28], ["NS6", "GENE_OR_GENE_PRODUCT", 33, 36], ["NS4", "PROTEIN", 21, 24], ["p20", "PROTEIN", 25, 28], ["NS6", "PROTEIN", 33, 36], ["Antibodies", "TEST", 0, 10]]], ["Anti NS5/VPg (strain SAB60) and anti NS7 (NO-strain) sera were raised in rabbits (Eurogentech) based on purified proteins expressed in E. coli. \u03b1NS3MNV PAB was kindly provided by Prof. Dr. Ian Goodfellow, Cambridge University, UK, and was obtained by immunization of rabbits with GV MNV and GI sequences [81].", [["sera", "ANATOMY", 53, 57], ["NO", "CHEMICAL", 42, 44], ["NS5", "GENE_OR_GENE_PRODUCT", 5, 8], ["VPg", "GENE_OR_GENE_PRODUCT", 9, 12], ["NS7", "GENE_OR_GENE_PRODUCT", 37, 40], ["sera", "ORGANISM_SUBSTANCE", 53, 57], ["rabbits", "ORGANISM", 73, 80], ["E. coli", "ORGANISM", 135, 142], ["rabbits", "ORGANISM", 267, 274], ["Anti NS5", "PROTEIN", 0, 8], ["VPg", "PROTEIN", 9, 12], ["purified proteins", "PROTEIN", 104, 121], ["rabbits", "SPECIES", 73, 80], ["E. coli", "SPECIES", 135, 142], ["rabbits", "SPECIES", 267, 274], ["rabbits", "SPECIES", 73, 80], ["E. coli", "SPECIES", 135, 142], ["rabbits", "SPECIES", 267, 274], ["Anti NS5", "TREATMENT", 0, 8], ["VPg (strain SAB60", "TREATMENT", 9, 26], ["anti NS7", "TREATMENT", 32, 40], ["sera", "TREATMENT", 53, 57], ["purified proteins", "PROBLEM", 104, 121], ["E. coli", "PROBLEM", 135, 142], ["NS3MNV PAB", "TREATMENT", 145, 155], ["GI sequences", "TEST", 291, 303], ["E. coli", "OBSERVATION", 135, 142], ["PAB", "OBSERVATION", 152, 155]]], ["Subcellular compartments and dsRNA were labeled by the following commercially available antibodies: SEC31A/ COPII Vesicles: BD Bioscience / 612351 (Becton Dickinson GmbH, NJ USA); Golgi Apparatus: Anti-Golgin 97 (ab84340, Abcam); autophagosome: p62/ SQSTM1 (M162-3, MBL Life science).", [["Subcellular compartments", "ANATOMY", 0, 24], ["SEC31A", "GENE_OR_GENE_PRODUCT", 100, 106], ["COPII", "GENE_OR_GENE_PRODUCT", 108, 113], ["Anti-Golgin 97", "GENE_OR_GENE_PRODUCT", 197, 211], ["ab84340", "GENE_OR_GENE_PRODUCT", 213, 220], ["Abcam", "GENE_OR_GENE_PRODUCT", 222, 227], ["autophagosome", "CELLULAR_COMPONENT", 230, 243], ["p62", "GENE_OR_GENE_PRODUCT", 245, 248], ["antibodies", "PROTEIN", 88, 98], ["SEC31A", "PROTEIN", 100, 106], ["COPII", "PROTEIN", 108, 113], ["Anti-Golgin 97", "PROTEIN", 197, 211], ["ab84340", "PROTEIN", 213, 220], ["Abcam", "PROTEIN", 222, 227], ["p62", "PROTEIN", 245, 248], ["SQSTM1", "PROTEIN", 250, 256], ["M162", "PROTEIN", 258, 262], ["MBL", "PROTEIN", 266, 269], ["Subcellular compartments and dsRNA", "PROBLEM", 0, 34], ["Anti-Golgin", "TEST", 197, 208], ["Abcam", "TEST", 222, 227], ["SQSTM1", "TEST", 250, 256], ["M162", "TEST", 258, 262], ["compartments", "ANATOMY_MODIFIER", 12, 24], ["dsRNA", "ANATOMY", 29, 34]]], ["Mitochondria were labeled with MitoTracker Deep Red (M22426) and LDs were stained with HCS LipidTox Red Neutral Lipid Stain (Thermo Fisher Scientific Waltham, Massachusetts, USA).", [["Mitochondria", "ANATOMY", 0, 12], ["LDs", "ANATOMY", 65, 68], ["Mitochondria", "CELLULAR_COMPONENT", 0, 12], ["MitoTracker", "SIMPLE_CHEMICAL", 31, 42], ["LDs", "CELLULAR_COMPONENT", 65, 68], ["Mitochondria", "TEST", 0, 12], ["LDs", "TEST", 65, 68], ["HCS", "TEST", 87, 90], ["Red Neutral Lipid Stain", "TEST", 100, 123]]], ["ER was stained with a polyclonal anti-PDI antibody (ab31811; Abcam, Cambridge, UK) unless otherwise stated.", [["ER", "GENE_OR_GENE_PRODUCT", 0, 2], ["Abcam", "GENE_OR_GENE_PRODUCT", 61, 66], ["UK", "GENE_OR_GENE_PRODUCT", 79, 81], ["ER", "PROTEIN", 0, 2], ["polyclonal anti-PDI antibody", "PROTEIN", 22, 50], ["ab31811", "PROTEIN", 52, 59], ["Abcam", "PROTEIN", 61, 66], ["a polyclonal anti-PDI antibody", "TEST", 20, 50]]], ["In case co-staining did not allow the use of this antibody, a mouse monoclonal antibody against Climp-63 (mainly rough ER, ALX-804-604, Enzo) or reticulon 3 (RTN3 sc-374599, Santa Cruz Biotechnology) was used.", [["Climp-63", "CHEMICAL", 96, 104], ["ALX-804-604", "CHEMICAL", 123, 134], ["RTN3 sc-374599", "CHEMICAL", 158, 172], ["mouse", "ORGANISM", 62, 67], ["Climp-63", "GENE_OR_GENE_PRODUCT", 96, 104], ["ER", "GENE_OR_GENE_PRODUCT", 119, 121], ["ALX-804-604", "GENE_OR_GENE_PRODUCT", 123, 134], ["Enzo", "GENE_OR_GENE_PRODUCT", 136, 140], ["reticulon 3", "GENE_OR_GENE_PRODUCT", 145, 156], ["mouse monoclonal antibody", "PROTEIN", 62, 87], ["Climp-63", "PROTEIN", 96, 104], ["ER", "PROTEIN", 119, 121], ["reticulon 3", "PROTEIN", 145, 156], ["Santa Cruz Biotechnology", "PROTEIN", 174, 198], ["mouse", "SPECIES", 62, 67], ["mouse", "SPECIES", 62, 67], ["this antibody", "TEST", 45, 58], ["a mouse monoclonal antibody", "TEST", 60, 87], ["Climp", "TEST", 96, 101], ["ALX-", "TEST", 123, 127], ["reticulon", "TEST", 145, 154]]], ["The lysosome was marked with anti LBPA1 antibody (Clone 6C4, Sigma-Aldrich, Germany).", [["lysosome", "ANATOMY", 4, 12], ["lysosome", "CELLULAR_COMPONENT", 4, 12], ["anti LBPA1 antibody", "PROTEIN", 29, 48], ["Clone 6C4", "PROTEIN", 50, 59], ["anti LBPA1 antibody", "TREATMENT", 29, 48], ["lysosome", "OBSERVATION", 4, 12], ["marked", "OBSERVATION_MODIFIER", 17, 23]]], ["All primary antibodies were utilized in a 1:50 dilution.", [["primary antibodies", "PROTEIN", 4, 22]]], ["Alexa 488 or 647-conjugated secondary antibodies (Invitrogen, Molecular Probes) were incubated in 3% BSA for 45 min at RT with a dilution of 1:1000.", [["BSA", "CHEMICAL", 101, 104], ["Alexa 488", "CHEMICAL", 0, 9], ["Alexa 488", "SIMPLE_CHEMICAL", 0, 9], ["BSA", "SIMPLE_CHEMICAL", 101, 104], ["Alexa 488 or 647-conjugated secondary antibodies", "PROTEIN", 0, 48], ["Invitrogen, Molecular Probes", "PROTEIN", 50, 78], ["Alexa", "TEST", 0, 5]]], ["Nuclei were stained using 4,6-diamidino-2-phenylindole (DAPI) for 1 min at a dilution of 1:4000 after incubation with secondary antibodies.", [["Nuclei", "ANATOMY", 0, 6], ["4,6-diamidino-2-phenylindole", "CHEMICAL", 26, 54], ["DAPI", "CHEMICAL", 56, 60], ["4,6-diamidino-2-phenylindole", "CHEMICAL", 26, 54], ["DAPI", "CHEMICAL", 56, 60], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["4,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 26, 54], ["DAPI", "SIMPLE_CHEMICAL", 56, 60], ["secondary antibodies", "PROTEIN", 118, 138], ["diamidino", "TREATMENT", 30, 39], ["secondary antibodies", "PROBLEM", 118, 138], ["secondary antibodies", "OBSERVATION", 118, 138]]], ["Cells were mounted with Fluoromount G (Southern Biotechnology Associates, Birmingham, AL, USA).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["Confocal microscopy was conducted on a Leica SP5 AOBS Point Scanning Confocal Microscope (Leica Microsystems).", [["Confocal microscopy", "TEST", 0, 19], ["a Leica", "TEST", 37, 44]]], ["Confocal microscopy was conducted on a Leica SP5 and on Leica SP8 AOBS Point Scanning Confocal Microscopes (Leica Microsystems).", [["Leica SP5", "DNA", 39, 48], ["Confocal microscopy", "TEST", 0, 19], ["a Leica SP5", "TEST", 37, 48], ["Leica", "TEST", 56, 61]]], ["Image analysis was performed using the ImageJ software package Fiji (http://fiji.sc/wiki/index.php/Fiji) [82] and the Coloc 2 plugin was used to calculate the Pearson's correlation coefficient.", [["Image analysis", "TEST", 0, 14], ["the Coloc 2 plugin", "TREATMENT", 114, 132]]], ["A Pearson's correlation coefficient higher than 0.5 indicates a strong colocalization.Conventional preparation of cells for electron microscopy (EM) ::: Material and methodsCells grown on glass coverslips were subjected to chemical fixation and subsequent epon embedding.", [["cells", "ANATOMY", 114, 119], ["Cells", "ANATOMY", 173, 178], ["cells", "CELL", 114, 119], ["Cells", "CELL", 173, 178], ["A Pearson's correlation coefficient", "TEST", 0, 35], ["electron microscopy", "TEST", 124, 143], ["glass coverslips", "TREATMENT", 188, 204], ["chemical fixation", "TREATMENT", 223, 240], ["subsequent epon embedding", "TREATMENT", 245, 270], ["strong", "OBSERVATION_MODIFIER", 64, 70], ["colocalization", "OBSERVATION", 71, 85], ["glass coverslips", "OBSERVATION", 188, 204], ["chemical fixation", "OBSERVATION", 223, 240], ["epon embedding", "OBSERVATION", 256, 270]]], ["For overexpression of norovirus proteins, Huh7-Lunet T7 cells were transfected with TransIT-LT1 (Mirus, Madison USA) transfection reagent according to manufacturer\u2019s instructions and fixed 24 hours post transfection.", [["Huh7-Lunet T7 cells", "ANATOMY", 42, 61], ["norovirus", "ORGANISM", 22, 31], ["Huh7-Lunet T7 cells", "CELL", 42, 61], ["Madison USA", "ORGANISM", 104, 115], ["norovirus proteins", "PROTEIN", 22, 40], ["Huh7-Lunet T7 cells", "CELL_LINE", 42, 61], ["LT1", "DNA", 92, 95], ["norovirus proteins", "PROBLEM", 22, 40], ["Huh7", "TEST", 42, 46], ["Lunet T7 cells", "TREATMENT", 47, 61], ["TransIT", "TEST", 84, 91], ["transfection reagent", "TREATMENT", 117, 137], ["norovirus", "OBSERVATION", 22, 31], ["T7", "ANATOMY", 53, 55]]], ["RAW 264.7 (ATCC, UK) were used for infection with MNV-CW1 [83].", [["RAW 264.7", "ANATOMY", 0, 9], ["ATCC", "ANATOMY", 11, 15], ["RAW 264.7", "CHEMICAL", 0, 9], ["infection", "DISEASE", 35, 44], ["RAW 264.7 (ATCC, UK", "CELL", 0, 19], ["MNV", "ORGANISM", 50, 53], ["RAW 264.7", "CELL_LINE", 0, 9], ["ATCC", "SPECIES", 11, 15], ["MNV-CW1", "SPECIES", 50, 57], ["infection", "PROBLEM", 35, 44], ["MNV", "TEST", 50, 53]]], ["For chemical fixation, cells were washed 3 times with 1x PBS and fixed for 30 min with pre-warmed 2.5% glutaraldehyde in 50 mM sodium cacodylate buffer (pH 7.2) containing 1 M KCl, 0.1 M MgCl2, 0.1 M CaCl2 and 2% sucrose.", [["cells", "ANATOMY", 23, 28], ["glutaraldehyde", "CHEMICAL", 103, 117], ["sodium cacodylate", "CHEMICAL", 127, 144], ["KCl", "CHEMICAL", 176, 179], ["MgCl2", "CHEMICAL", 187, 192], ["CaCl2", "CHEMICAL", 200, 205], ["sucrose", "CHEMICAL", 213, 220], ["glutaraldehyde", "CHEMICAL", 103, 117], ["sodium cacodylate", "CHEMICAL", 127, 144], ["KCl", "CHEMICAL", 176, 179], ["MgCl2", "CHEMICAL", 187, 192], ["CaCl2", "CHEMICAL", 200, 205], ["sucrose", "CHEMICAL", 213, 220], ["cells", "CELL", 23, 28], ["glutaraldehyde", "SIMPLE_CHEMICAL", 103, 117], ["MgCl2", "SIMPLE_CHEMICAL", 187, 192], ["CaCl2", "SIMPLE_CHEMICAL", 200, 205], ["sucrose", "SIMPLE_CHEMICAL", 213, 220], ["chemical fixation", "TREATMENT", 4, 21], ["1x PBS", "TREATMENT", 54, 60], ["pre-warmed 2.5% glutaraldehyde", "TREATMENT", 87, 117], ["50 mM sodium cacodylate buffer", "TREATMENT", 121, 151], ["pH", "TEST", 153, 155], ["1 M KCl", "TREATMENT", 172, 179], ["CaCl2", "TREATMENT", 200, 205], ["2% sucrose", "TREATMENT", 210, 220], ["fixation", "OBSERVATION", 13, 21]]], ["Cells were washed thoroughly 5 times with 50 mM cacodylate buffer and post-fixed on ice in the dark with 2% OsO4 in 50 mM cacodylate buffer for 40 min.", [["Cells", "ANATOMY", 0, 5], ["OsO4", "CHEMICAL", 108, 112], ["cacodylate", "CHEMICAL", 48, 58], ["OsO4", "CHEMICAL", 108, 112], ["cacodylate", "CHEMICAL", 122, 132], ["Cells", "CELL", 0, 5], ["OsO4", "SIMPLE_CHEMICAL", 108, 112], ["50 mM cacodylate buffer", "TREATMENT", 42, 65], ["ice", "TREATMENT", 84, 87], ["2% OsO4 in 50 mM cacodylate buffer", "TREATMENT", 105, 139]]], ["Cells were washed with H2O overnight, treated with 0.5% uranyl acetate in H2O for 30 min, rinsed thoroughly with H2O and dehydrated in a graded ethanol series at RT (40%, 50%, 60%, 70% and 80%) for 5 min each and 95% and 100% for 20 min each.", [["Cells", "ANATOMY", 0, 5], ["H2O", "CHEMICAL", 23, 26], ["uranyl acetate", "CHEMICAL", 56, 70], ["H2O", "CHEMICAL", 74, 77], ["H2O", "CHEMICAL", 113, 116], ["ethanol", "CHEMICAL", 144, 151], ["H2O", "CHEMICAL", 23, 26], ["uranyl acetate", "CHEMICAL", 56, 70], ["H2O", "CHEMICAL", 74, 77], ["H2O", "CHEMICAL", 113, 116], ["ethanol", "CHEMICAL", 144, 151], ["Cells", "CELL", 0, 5], ["uranyl acetate", "SIMPLE_CHEMICAL", 56, 70], ["H2O", "SIMPLE_CHEMICAL", 74, 77], ["H2O", "SIMPLE_CHEMICAL", 113, 116], ["ethanol", "SIMPLE_CHEMICAL", 144, 151], ["H2O", "TREATMENT", 23, 26], ["0.5% uranyl acetate in H2O", "TREATMENT", 51, 77], ["a graded ethanol series", "TREATMENT", 135, 158]]], ["Cells were immersed in 100% propilene oxid and immediately embedded in an Araldite-Epon mixture (Araldite 502/Embed 812 Kit; Electron Microscopy Sciences).", [["Cells", "ANATOMY", 0, 5], ["propilene oxid", "CHEMICAL", 28, 42], ["propilene oxid", "CHEMICAL", 28, 42], ["Epon", "CHEMICAL", 83, 87], ["Cells", "CELL", 0, 5], ["propilene oxid", "SIMPLE_CHEMICAL", 28, 42], ["Araldite", "SIMPLE_CHEMICAL", 74, 82], ["Cells", "TEST", 0, 5], ["propilene oxid", "TREATMENT", 28, 42], ["an Araldite-Epon mixture", "TREATMENT", 71, 95]]], ["After polymerization at 60\u00b0C for 2 days, coverslips were removed and the embedded cell monolayers were sectioned using a Leica Ultracut UCT microtome and a diamond knife.", [["cell monolayers", "ANATOMY", 82, 97], ["cell monolayers", "CELL", 82, 97], ["polymerization", "TREATMENT", 6, 20], ["coverslips", "TREATMENT", 41, 51], ["the embedded cell monolayers", "TREATMENT", 69, 97], ["a Leica Ultracut UCT microtome", "TREATMENT", 119, 149], ["a diamond knife", "TREATMENT", 154, 169], ["cell monolayers", "OBSERVATION", 82, 97]]], ["Sections with a thickness of 70 nm were counter-stained with 3% uranyl acetate in 70% methanol for 5 min and 2% lead citrate in H2O for 2 min, and examined with the transmission electron microscope Philips CM120 TEM (Biotwin, 120 kV).Correlative light-electron microscopy (CLEM) ::: Material and methodsHuh7-T7 cells seeded on glass-bottom dishes containing a photoetched gridded coverslip (MatTek) were transiently transfected with expression plasmids coding for GFP-fused norovirus proteins.", [["Huh7-T7 cells", "ANATOMY", 303, 316], ["plasmids", "ANATOMY", 444, 452], ["uranyl acetate", "CHEMICAL", 64, 78], ["methanol", "CHEMICAL", 86, 94], ["citrate", "CHEMICAL", 117, 124], ["H2O", "CHEMICAL", 128, 131], ["uranyl acetate", "CHEMICAL", 64, 78], ["methanol", "CHEMICAL", 86, 94], ["citrate", "CHEMICAL", 117, 124], ["H2O", "CHEMICAL", 128, 131], ["uranyl acetate", "SIMPLE_CHEMICAL", 64, 78], ["methanol", "SIMPLE_CHEMICAL", 86, 94], ["citrate", "SIMPLE_CHEMICAL", 117, 124], ["Huh7-T7 cells", "CELL", 303, 316], ["GFP", "GENE_OR_GENE_PRODUCT", 464, 467], ["norovirus", "ORGANISM", 474, 483], ["Huh7-T7 cells", "CELL_LINE", 303, 316], ["MatTek", "DNA", 391, 397], ["expression plasmids", "DNA", 433, 452], ["GFP", "PROTEIN", 464, 467], ["norovirus proteins", "PROTEIN", 474, 492], ["3% uranyl acetate", "TREATMENT", 61, 78], ["2% lead citrate in H2O", "TREATMENT", 109, 131], ["Biotwin", "TEST", 217, 224], ["Correlative light-electron microscopy", "TEST", 234, 271], ["Material", "TEST", 283, 291], ["methodsHuh7-T7 cells", "TREATMENT", 296, 316], ["glass-bottom dishes", "TREATMENT", 327, 346], ["a photoetched gridded coverslip (MatTek", "TREATMENT", 358, 397], ["expression plasmids", "TREATMENT", 433, 452], ["GFP", "TEST", 464, 467], ["fused norovirus proteins", "PROBLEM", 468, 492], ["T7", "ANATOMY", 308, 310], ["norovirus", "OBSERVATION", 474, 483]]], ["After 24 h cells were washed twice with PBS, fixed for 30 min at room temperature with PBS containing 4% paraformaldehyde and 0.2% glutaraldehyde and stained with DAPI and far-red LipidTOX neutral lipid stain (Thermofisher) according to the manufacturer's instructions.", [["cells", "ANATOMY", 11, 16], ["glutaraldehyde", "CHEMICAL", 131, 145], ["paraformaldehyde", "CHEMICAL", 105, 121], ["glutaraldehyde", "CHEMICAL", 131, 145], ["DAPI", "CHEMICAL", 163, 167], ["cells", "CELL", 11, 16], ["paraformaldehyde", "SIMPLE_CHEMICAL", 105, 121], ["glutaraldehyde", "SIMPLE_CHEMICAL", 131, 145], ["DAPI", "SIMPLE_CHEMICAL", 163, 167], ["LipidTOX", "SIMPLE_CHEMICAL", 180, 188], ["PBS", "TREATMENT", 40, 43], ["PBS", "TEST", 87, 90], ["4% paraformaldehyde", "TREATMENT", 102, 121], ["DAPI", "TREATMENT", 163, 167], ["far-red LipidTOX neutral lipid stain", "TREATMENT", 172, 208]]], ["Samples were analyzed on a Nikon TE2000 Ultraview ERS spinning disc (PerkinElmer).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["disc", "ANATOMY", 63, 67]]], ["Z-stacks of GFP-positive cells were collected and the positions of the cells of interest were recorded using transmitted light with a differential interference contrast configuration.", [["GFP-positive cells", "ANATOMY", 12, 30], ["cells", "ANATOMY", 71, 76], ["GFP", "GENE_OR_GENE_PRODUCT", 12, 15], ["cells", "CELL", 25, 30], ["cells", "CELL", 71, 76], ["GFP-positive cells", "CELL_LINE", 12, 30], ["Z-stacks of GFP", "TEST", 0, 15], ["positive cells", "PROBLEM", 16, 30], ["positive cells", "OBSERVATION", 16, 30]]], ["Cells were then fixed in EM fixative and embedded in Epon/araldite resin, as described above.Correlative light-electron microscopy (CLEM) ::: Material and methodsSeventy nm ultrathin sections were prepared and examined with a Jeol JEM-1400 transmission electron microscope (Jeol Ltd., Tokyo, Japan).", [["Cells", "ANATOMY", 0, 5], ["sections", "ANATOMY", 183, 191], ["Epon", "CHEMICAL", 53, 57], ["Cells", "CELL", 0, 5], ["araldite resin", "SIMPLE_CHEMICAL", 58, 72], ["EM fixative", "TREATMENT", 25, 36], ["Epon/araldite resin", "TREATMENT", 53, 72], ["Correlative light-electron microscopy", "TEST", 93, 130]]], ["Landmark correspondence plugin from Fiji imageJ distribution was used to correlate the light microscopy and the electron microscopy datasets.", [["the light microscopy", "TEST", 83, 103], ["the electron microscopy datasets", "TEST", 108, 140]]], ["Briefly, a single optical section displaying a LDs distribution that matched the one observed in the electron microscopy micrograph was extracted from the z-stack and the corresponding LDs on the two images were used as landmark to calculate the transformation.High pressure freezing and freeze substitution (HPF-FS) ::: Material and methodsCells were seeded onto 3 mm sapphire discs (M. Wohlwend GmbH, Sennwald, Switzerland) that had been carbon coated to improve cell adhesion.", [["LDs", "ANATOMY", 47, 50], ["Cells", "ANATOMY", 341, 346], ["cell", "ANATOMY", 465, 469], ["carbon", "CHEMICAL", 440, 446], ["LDs", "CELLULAR_COMPONENT", 185, 188], ["Cells", "CELL", 341, 346], ["cell", "CELL", 465, 469], ["a single optical section", "TREATMENT", 9, 33], ["a LDs distribution", "PROBLEM", 45, 63], ["the electron microscopy micrograph", "TEST", 97, 131], ["the two images", "TEST", 192, 206], ["High pressure freezing", "TREATMENT", 261, 283], ["freeze substitution", "TREATMENT", 288, 307], ["Cells", "TEST", 341, 346], ["carbon coated", "TREATMENT", 440, 453], ["pressure freezing", "OBSERVATION", 266, 283], ["cell adhesion", "OBSERVATION", 465, 478]]], ["One day after transfection or infection cells (Huh7-Lunet T7 and RAW 264.7, respectively) were frozen after immersion in 1-hexadecene (Merck, Hohenbrunn, Germany) using a high-pressure freezer (M. Wohlwend GmbH).", [["cells", "ANATOMY", 40, 45], ["Huh7", "ANATOMY", 47, 51], ["RAW 264.7", "ANATOMY", 65, 74], ["infection", "DISEASE", 30, 39], ["1-hexadecene", "CHEMICAL", 121, 133], ["1-hexadecene", "CHEMICAL", 121, 133], ["cells", "CELL", 40, 45], ["Huh7-Lunet T7", "CELL", 47, 60], ["RAW 264.7", "CELL", 65, 74], ["1-hexadecene", "SIMPLE_CHEMICAL", 121, 133], ["Merck", "SIMPLE_CHEMICAL", 135, 140], ["infection cells", "CELL_TYPE", 30, 45], ["Huh7", "CELL_LINE", 47, 51], ["Lunet T7", "CELL_LINE", 52, 60], ["RAW 264.7", "CELL_LINE", 65, 74], ["infection cells", "PROBLEM", 30, 45], ["Huh7", "TEST", 47, 51], ["a high-pressure freezer", "TREATMENT", 169, 192], ["infection cells", "OBSERVATION", 30, 45]]], ["Frozen discs were stored in liquid nitrogen until further processing.", [["discs", "ANATOMY", 7, 12], ["nitrogen", "CHEMICAL", 35, 43], ["Frozen discs", "TREATMENT", 0, 12], ["liquid nitrogen", "TREATMENT", 28, 43]]], ["Freeze substitution was done in acetone containing 0.2% (w/v) OsO4, 0.1% (w/v) UA, and 5% (v/v) water by slowly warming the samples from \u221290\u00b0C to 0\u00b0C during a period of 20 h [84].", [["samples", "ANATOMY", 124, 131], ["acetone", "CHEMICAL", 32, 39], ["UA", "CHEMICAL", 79, 81], ["acetone", "CHEMICAL", 32, 39], ["OsO4", "CHEMICAL", 62, 66], ["acetone", "SIMPLE_CHEMICAL", 32, 39], ["UA", "SIMPLE_CHEMICAL", 79, 81], ["Freeze substitution", "TREATMENT", 0, 19], ["acetone containing", "TREATMENT", 32, 50], ["w/v) OsO4", "TREATMENT", 57, 66], ["UA", "TEST", 79, 81]]], ["Samples were kept at 0\u00b0C and at room temperature for 30 min each, washed with acetone, and embedded in four-step epon series (Fluka, Buchs, Switzerland) using 1 h-incubation in 25%, 50% and 75% epon dissolved in acetone and overnight incubation in 100% epon.", [["Samples", "ANATOMY", 0, 7], ["acetone", "CHEMICAL", 78, 85], ["acetone", "CHEMICAL", 212, 219], ["acetone", "CHEMICAL", 78, 85], ["acetone", "CHEMICAL", 212, 219], ["acetone", "SIMPLE_CHEMICAL", 78, 85], ["acetone", "SIMPLE_CHEMICAL", 212, 219], ["Samples", "TEST", 0, 7], ["acetone", "TREATMENT", 78, 85], ["acetone", "TREATMENT", 212, 219]]], ["Epon was exchanged, polymerized for 3 d at 60\u00b0C and sapphire discs were removed by immersion in liquid nitrogen.", [["Epon", "CHEMICAL", 0, 4], ["nitrogen", "CHEMICAL", 103, 111], ["C", "SIMPLE_CHEMICAL", 46, 47], ["C and sapphire discs", "TREATMENT", 46, 66], ["liquid nitrogen", "TREATMENT", 96, 111]]], ["Seventy or 250 nm thick sections for were examined by conventional transmission EM or electron tomography, respectively.Electron tomography (ET) ::: Material and methodsSections of 250 nm thickness were collected on palladium-copper slot grids (Science Services, Munich, Germany) coated with Formvar (Plano, Wetzlar, Germany).", [["sections", "ANATOMY", 24, 32], ["palladium-copper", "CHEMICAL", 216, 232], ["palladium", "CHEMICAL", 216, 225], ["copper", "CHEMICAL", 226, 232], ["electron tomography", "TEST", 86, 105], ["Electron tomography", "TEST", 120, 139], ["methodsSections", "TEST", 162, 177], ["nm thickness", "TEST", 185, 197]]], ["Protein A-gold (10 nm) was added to both sides of the sections as fiducial markers.", [["sections", "ANATOMY", 54, 62], ["Protein", "TEST", 0, 7], ["fiducial markers", "TEST", 66, 82]]], ["Single axis tilt series were acquired with a FEI TECNAI F30 microscope operated at 300 kV and equipped with a 4k FEI Eagle camera over a \u221265\u00b0 to 65\u00b0 tilt range (increment 1\u00b0) and at an average defocus of \u22120.2 \u03bcm.", [["4k FEI Eagle camera", "DNA", 110, 129], ["Single axis tilt series", "TEST", 0, 23]]], ["Reconstruction of the tomograms and rendering of their 3D surface was performed by using the IMOD software package (version 4.9)[85] (bio3d.colorado.edu/imod).Western blot (WB) ::: Material and methodsFor Western blotting, the cells in a 6-well plate well were lysed and denatured in 150 \u03bcL of 6\u00d7 Laemmli buffer by heating to 95\u00b0C for 5 minutes, and loaded onto an 12% polyacrylamide-SDS gel.", [["3D surface", "ANATOMY", 55, 65], ["cells", "ANATOMY", 227, 232], ["polyacrylamide", "CHEMICAL", 369, 383], ["cells", "CELL", 227, 232], ["the tomograms", "TEST", 18, 31], ["Western blotting", "TEST", 205, 221], ["the cells", "TREATMENT", 223, 232], ["a 6-well plate", "TREATMENT", 236, 250], ["Laemmli buffer", "TREATMENT", 297, 311], ["an 12% polyacrylamide", "TREATMENT", 362, 383], ["SDS gel", "TREATMENT", 384, 391]]], ["After resolution by SDS-PAGE, proteins were transferred to a polyvinylidene difluoride (PVDF) membrane, with the exception of NS7, which was transferred to a nitrocellulose membrane (Amersham Protran 0.45 NC, GE Healthcare Life Science).", [["membrane", "ANATOMY", 173, 181], ["polyvinylidene difluoride", "CHEMICAL", 61, 86], ["PVDF", "CHEMICAL", 88, 92], ["nitrocellulose", "CHEMICAL", 158, 172], ["NS7", "SIMPLE_CHEMICAL", 126, 129], ["membrane", "CELLULAR_COMPONENT", 173, 181], ["NS7", "PROTEIN", 126, 129], ["a polyvinylidene difluoride (PVDF) membrane", "TREATMENT", 59, 102], ["NS7", "TREATMENT", 126, 129], ["a nitrocellulose membrane", "TREATMENT", 156, 181], ["Amersham Protran", "TREATMENT", 183, 199]]], ["NS proteins were detected using NS-protein specific polyclonal rabbit antibodies described in IF section in a 1:1000 dilution. \u03b2-actin was detected by monoclonal mouse antibody (A5441), Sigma-Aldrich.", [["rabbit", "ORGANISM", 63, 69], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 127, 134], ["mouse", "ORGANISM", 162, 167], ["Sigma-Aldrich", "ORGANISM", 186, 199], ["NS proteins", "PROTEIN", 0, 11], ["NS-protein specific polyclonal rabbit antibodies", "PROTEIN", 32, 80], ["\u03b2-actin", "PROTEIN", 127, 134], ["monoclonal mouse antibody", "PROTEIN", 151, 176], ["A5441", "PROTEIN", 178, 183], ["rabbit", "SPECIES", 63, 69], ["mouse", "SPECIES", 162, 167], ["rabbit", "SPECIES", 63, 69], ["mouse", "SPECIES", 162, 167], ["NS proteins", "TREATMENT", 0, 11], ["NS-protein specific polyclonal rabbit antibodies", "TREATMENT", 32, 80], ["\u03b2-actin", "TEST", 127, 134], ["monoclonal mouse antibody", "TEST", 151, 176]]], ["Primary antibodies were detected using \u03b1rabbit/ \u03b1mouse horseradish peroxidase (HRP)-coupled secondary antibodies (Sigma-Aldrich) and imaging was done with the ChemoCam 6.0 ECL system (INTAS Science Imaging, Goettingen, Germany).Coupled in vitro transcription-translation assay ::: Material and methodspTM based constructs were phenol/chloroform purified and reconstituted in RNase-free double-distilled H2O to a concentration of 1 \u03bcg/\u03bcL.", [["phenol/chloroform", "CHEMICAL", 327, 344], ["H2O", "CHEMICAL", 403, 406], ["phenol", "CHEMICAL", 327, 333], ["chloroform", "CHEMICAL", 334, 344], ["H2O", "CHEMICAL", 403, 406], ["\u03b1rabbit", "GENE_OR_GENE_PRODUCT", 39, 46], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 55, 77], ["HRP", "SIMPLE_CHEMICAL", 79, 82], ["phenol", "SIMPLE_CHEMICAL", 327, 333], ["chloroform", "SIMPLE_CHEMICAL", 334, 344], ["RNase", "GENE_OR_GENE_PRODUCT", 375, 380], ["\u03b1rabbit", "PROTEIN", 39, 46], ["\u03b1mouse horseradish peroxidase (HRP)-coupled secondary antibodies", "PROTEIN", 48, 112], ["RNase", "PROTEIN", 375, 380], ["horseradish", "SPECIES", 55, 66], ["Primary antibodies", "TEST", 0, 18], ["\u03b1rabbit/ \u03b1mouse horseradish peroxidase", "TREATMENT", 39, 77], ["secondary antibodies", "PROBLEM", 92, 112], ["imaging", "TEST", 133, 140], ["the ChemoCam", "TEST", 155, 167], ["Imaging", "TEST", 198, 205], ["Material and methodspTM based constructs", "TREATMENT", 281, 321], ["phenol/chloroform", "TREATMENT", 327, 344], ["RNase", "TEST", 375, 380]]], ["0.5 \u03bcg of the plasmid preparation were then mixed with 10 \u03bcL of the L1170 T7 TNT-kit (Promega, Madison, USA) and 1\u03bcL of 35S Methionine 10 mCi/ml.", [["plasmid", "ANATOMY", 14, 21], ["35S Methionine", "CHEMICAL", 120, 134], ["Methionine", "CHEMICAL", 124, 134], ["Promega", "ORGANISM", 86, 93], ["Madison", "ORGANISM", 95, 102], ["35S Methionine", "SIMPLE_CHEMICAL", 120, 134], ["the plasmid preparation", "TREATMENT", 10, 33], ["35S Methionine", "TREATMENT", 120, 134]]], ["The reaction mixture was then incubated at 30\u00b0C for 90 min.", [["The reaction mixture", "TREATMENT", 0, 20]]], ["Afterwards, the reaction was suspended in 2x laemmli buffer, and denatured at 95\u00b0C for 5 min before being loaded onto a 12% SDS gel for electrophoresis.", [["the reaction", "PROBLEM", 12, 24], ["a 12% SDS gel", "TREATMENT", 118, 131], ["electrophoresis", "PROBLEM", 136, 151]]], ["Radiolabeled proteins were visualized by autoradiography using a phospho-imager (BioRad, Munich, Germany).Generation of Huh7 cells expressing the MNV receptor CD300lf ::: Material and methodsStable cell lines expressing the MNV receptor CD300lf [47,48], were created by lentiviral transduction.", [["Huh7 cells", "ANATOMY", 120, 130], ["cell lines", "ANATOMY", 198, 208], ["Huh7 cells", "CELL", 120, 130], ["MNV", "ORGANISM", 146, 149], ["cell lines", "CELL", 198, 208], ["MNV", "ORGANISM", 224, 227], ["CD300lf", "GENE_OR_GENE_PRODUCT", 237, 244], ["lentiviral", "ORGANISM", 270, 280], ["Huh7 cells", "CELL_LINE", 120, 130], ["MNV receptor", "PROTEIN", 146, 158], ["CD300lf", "PROTEIN", 159, 166], ["MNV receptor", "PROTEIN", 224, 236], ["CD300lf", "PROTEIN", 237, 244], ["Radiolabeled proteins", "TEST", 0, 21], ["autoradiography", "TEST", 41, 56], ["a phospho-imager", "TEST", 63, 79], ["Huh7 cells", "PROBLEM", 120, 130], ["Huh7 cells", "OBSERVATION", 120, 130], ["Stable", "OBSERVATION_MODIFIER", 191, 197], ["cell lines", "OBSERVATION", 198, 208]]], ["The lentiviral vectors were created by co-transfecting 293T cells with a gag-pol plasmid (pCMV\u22068.31), the retroviral vector containing the CD300lf sequence (gift from Dr. Herbert Virgin, Washington University at St. Louis, St. Louis, MO, USA), and an envelope plasmid (pMD.G) mixed in a 3:3:1 ratio, respectively, as described elsewhere [86].", [["293T cells", "ANATOMY", 55, 65], ["plasmid", "ANATOMY", 260, 267], ["lentiviral", "ORGANISM", 4, 14], ["293T cells", "CELL", 55, 65], ["gag-pol", "GENE_OR_GENE_PRODUCT", 73, 80], ["retroviral", "ORGANISM", 106, 116], ["293T cells", "CELL_LINE", 55, 65], ["gag-pol plasmid", "DNA", 73, 88], ["pCMV\u22068.31", "DNA", 90, 99], ["CD300lf sequence", "DNA", 139, 155], ["envelope plasmid", "DNA", 251, 267], ["pMD.G", "DNA", 269, 274], ["The lentiviral vectors", "TREATMENT", 0, 22], ["a gag", "TEST", 71, 76], ["the retroviral vector", "TREATMENT", 102, 123], ["an envelope plasmid", "TREATMENT", 248, 267], ["lentiviral vectors", "OBSERVATION", 4, 22]]], ["Huh7 cells were seeded at a density of 1x105 cells per well in 6-well plates and transduced with 1 ml of lentivirus suspension mixed with 1 ml of fresh DMEM medium for 12 hours.", [["Huh7 cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 45, 50], ["Huh7 cells", "CELL", 0, 10], ["cells", "CELL", 45, 50], ["lentivirus", "ORGANISM", 105, 115], ["Huh7 cells", "CELL_LINE", 0, 10], ["1x105 cells", "CELL_LINE", 39, 50], ["lentivirus", "SPECIES", 105, 115], ["Huh7 cells", "TREATMENT", 0, 10], ["a density of 1x105 cells", "TREATMENT", 26, 50], ["lentivirus suspension", "TREATMENT", 105, 126], ["fresh DMEM medium", "TREATMENT", 146, 163]]], ["Media was aspirated and replaced with 1:1 lentivirus suspension and 1 ml of fresh DMEM two more times at 12 hour intervals.", [["lentivirus", "ORGANISM", 42, 52], ["lentivirus", "SPECIES", 42, 52], ["1:1 lentivirus suspension", "TREATMENT", 38, 63], ["fresh DMEM", "TREATMENT", 76, 86], ["aspirated", "OBSERVATION", 10, 19]]], ["After 36 hours, the media was changed and 2 ml of fresh DMEM containing 2 \u03bcg/ml puromycin selection was added and selective pressure was maintained during passaging.Modelling of the structure of NS1-2, NS3 and NS4 ::: Material and methodsWe used resources of the MPI bioinformatics Toolkit [87] to define domains in NS1-2, NS3 and NS4.", [["DMEM", "CHEMICAL", 56, 60], ["puromycin", "CHEMICAL", 80, 89], ["puromycin", "CHEMICAL", 80, 89], ["puromycin", "SIMPLE_CHEMICAL", 80, 89], ["NS1-2", "GENE_OR_GENE_PRODUCT", 195, 200], ["NS3", "GENE_OR_GENE_PRODUCT", 202, 205], ["NS1-2", "GENE_OR_GENE_PRODUCT", 316, 321], ["NS3", "GENE_OR_GENE_PRODUCT", 323, 326], ["NS4", "GENE_OR_GENE_PRODUCT", 331, 334], ["NS1", "PROTEIN", 195, 198], ["NS3", "PROTEIN", 202, 205], ["NS4", "PROTEIN", 210, 213], ["NS1", "PROTEIN", 316, 319], ["NS3", "PROTEIN", 323, 326], ["NS4", "PROTEIN", 331, 334], ["the media", "TREATMENT", 16, 25], ["fresh DMEM", "TREATMENT", 50, 60], ["2 \u03bcg/ml puromycin selection", "TREATMENT", 72, 99], ["selective pressure", "TREATMENT", 114, 132], ["NS1", "TEST", 195, 198], ["NS1", "TEST", 316, 319], ["NS3", "TREATMENT", 323, 326], ["NS4", "TREATMENT", 331, 334], ["NS1", "OBSERVATION", 195, 198]]], ["HHPRED was used to find domains with homologs of known structure and Quick2D to identify structured and non-structured regions and putative transmembrane helices [88,89].", [["transmembrane", "ANATOMY", 140, 153], ["HHPRED", "PROTEIN", 0, 6], ["Quick2D", "PROTEIN", 69, 76], ["non-structured regions", "PROTEIN", 104, 126], ["transmembrane helices", "PROTEIN", 140, 161], ["putative transmembrane helices", "TEST", 131, 161]]], ["Transmembrane helices were further sought with Polyphobius.", [["Transmembrane helices", "PROBLEM", 0, 21], ["Polyphobius", "PROBLEM", 47, 58]]], ["For putative membrane-peripheral and transmembrane helices, ideal alpha-helices were generated with the \u201cfab\u201d function of PyMOL, as were intervening loops.", [["membrane", "ANATOMY", 13, 21], ["transmembrane helices", "ANATOMY", 37, 58], ["membrane-peripheral", "CELLULAR_COMPONENT", 13, 32], ["transmembrane helices", "CELLULAR_COMPONENT", 37, 58], ["PyMOL", "GENE_OR_GENE_PRODUCT", 122, 127], ["putative membrane-peripheral and transmembrane helices", "PROTEIN", 4, 58], ["alpha-helices", "PROTEIN", 66, 79], ["PyMOL", "PROTEIN", 122, 127], ["putative membrane-peripheral and transmembrane helices", "TREATMENT", 4, 58], ["peripheral", "ANATOMY_MODIFIER", 22, 32], ["loops", "OBSERVATION_MODIFIER", 149, 154]]], ["The NS1-2 central domain (residues 119 to 213) was homology modelled with SwissModel [90] from Protein Data Bank entry 4DPZ [61].", [["NS1-2", "GENE_OR_GENE_PRODUCT", 4, 9], ["NS1-2 central domain", "PROTEIN", 4, 24], ["residues 119 to 213", "PROTEIN", 26, 45], ["The NS1", "TEST", 0, 7]]], ["The non-structured N-terminus and helical C-terminus were then generated with PyMOL 1.8.2.0 [91].", [["N", "CHEMICAL", 19, 20], ["C", "CHEMICAL", 42, 43], ["non-structured N-terminus", "PROTEIN", 4, 29], ["helical C-terminus", "PROTEIN", 34, 52], ["helical C-terminus", "TEST", 34, 52], ["PyMOL", "TEST", 78, 83], ["terminus", "ANATOMY_MODIFIER", 21, 29]]], ["The three parts were assembled in PyMOL with the PyMOL sculpting function.", [["PyMOL", "GENE_OR_GENE_PRODUCT", 34, 39]]], ["NS3 was modelled with I-Tasser [92] and NS4 was modelled with RaptorX [93], with default parameters.", [["NS3", "PROTEIN", 0, 3], ["NS4", "PROTEIN", 40, 43], ["NS3", "TREATMENT", 0, 3], ["NS4", "TREATMENT", 40, 43], ["RaptorX", "TEST", 62, 69], ["default parameters", "TEST", 81, 99]]], ["A membrane model was generated with the Charmm-GUI webserver [94] with a lipid composition similar to the endoplasmic reticulum (Phosphatidylcholine 60%; Phosphatidylethanolamine 25%; Phosphatidylinositol 15%)[95].", [["membrane", "ANATOMY", 2, 10], ["endoplasmic reticulum", "ANATOMY", 106, 127], ["Phosphatidylcholine", "CHEMICAL", 129, 148], ["Phosphatidylethanolamine", "CHEMICAL", 154, 178], ["Phosphatidylinositol", "CHEMICAL", 184, 204], ["Phosphatidylcholine", "CHEMICAL", 129, 148], ["Phosphatidylethanolamine", "CHEMICAL", 154, 178], ["Phosphatidylinositol", "CHEMICAL", 184, 204], ["membrane", "CELLULAR_COMPONENT", 2, 10], ["lipid", "SIMPLE_CHEMICAL", 73, 78], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 106, 127], ["Phosphatidylcholine", "SIMPLE_CHEMICAL", 129, 148], ["Phosphatidylethanolamine", "SIMPLE_CHEMICAL", 154, 178], ["Phosphatidylinositol", "SIMPLE_CHEMICAL", 184, 204], ["A membrane model", "TEST", 0, 16], ["a lipid composition", "TREATMENT", 71, 90], ["the endoplasmic reticulum (Phosphatidylcholine", "TREATMENT", 102, 148], ["Phosphatidylethanolamine", "TREATMENT", 154, 178], ["Phosphatidylinositol", "TREATMENT", 184, 204]]], ["The positions of the transmembrane/peripheral helices relative to this membrane were adjusted with PyMOL.", [["transmembrane", "ANATOMY", 21, 34], ["membrane", "ANATOMY", 71, 79], ["transmembrane", "CELLULAR_COMPONENT", 21, 34], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["transmembrane/peripheral helices", "PROTEIN", 21, 53], ["the transmembrane/peripheral helices", "TREATMENT", 17, 53], ["this membrane", "TREATMENT", 66, 79], ["PyMOL", "TREATMENT", 99, 104], ["peripheral", "ANATOMY_MODIFIER", 35, 45]]], ["The structures were then minimized with secondary structure restraints with the Phenix geometry minimization function [96].Statistical analyses ::: Material and methodsGeneral statistical analyses as indicated in the corresponding figures were performed using Graphpad Prism Software.", [["secondary structure restraints", "TREATMENT", 40, 70], ["General statistical analyses", "TEST", 168, 196]]]], "PMC4808031": [["INTRODUCTIONNasopharyngeal carcinoma (NPC) is an epithelial malignancy of the head and neck.", [["INTRODUCTIONNasopharyngeal carcinoma", "ANATOMY", 0, 36], ["NPC", "ANATOMY", 38, 41], ["epithelial malignancy", "ANATOMY", 49, 70], ["head", "ANATOMY", 78, 82], ["neck", "ANATOMY", 87, 91], ["INTRODUCTIONNasopharyngeal carcinoma", "DISEASE", 0, 36], ["NPC", "DISEASE", 38, 41], ["malignancy of the head and neck", "DISEASE", 60, 91], ["INTRODUCTIONNasopharyngeal carcinoma", "CANCER", 0, 36], ["NPC", "CANCER", 38, 41], ["epithelial malignancy", "CANCER", 49, 70], ["head", "ORGANISM_SUBDIVISION", 78, 82], ["neck", "ORGAN", 87, 91], ["INTRODUCTIONNasopharyngeal carcinoma", "PROBLEM", 0, 36], ["an epithelial malignancy of the head and neck", "PROBLEM", 46, 91], ["carcinoma", "OBSERVATION", 27, 36], ["epithelial", "ANATOMY_MODIFIER", 49, 59], ["malignancy", "OBSERVATION", 60, 70], ["head", "ANATOMY", 78, 82], ["neck", "ANATOMY", 87, 91]]], ["The incidence of NPC is higher in Southeast Asia and Africa but lower among Caucasians in North America and Europe.", [["NPC", "ANATOMY", 17, 20], ["NPC", "DISEASE", 17, 20], ["NPC", "CANCER", 17, 20], ["NPC", "PROBLEM", 17, 20], ["NPC", "OBSERVATION", 17, 20], ["higher", "OBSERVATION_MODIFIER", 24, 30]]], ["NPC is a complex disease caused by an interaction among Epstein-Barr virus infection, environmental risk factors and host genes in a multi-step process of carcinogenesis [2].", [["NPC", "ANATOMY", 0, 3], ["NPC", "DISEASE", 0, 3], ["Epstein-Barr virus infection", "DISEASE", 56, 84], ["carcinogenesis", "DISEASE", 155, 169], ["NPC", "CANCER", 0, 3], ["Epstein-Barr virus", "ORGANISM", 56, 74], ["environmental risk factors", "PROTEIN", 86, 112], ["host genes", "DNA", 117, 127], ["Epstein-Barr virus", "SPECIES", 56, 74], ["NPC", "PROBLEM", 0, 3], ["a complex disease", "PROBLEM", 7, 24], ["Barr virus infection", "PROBLEM", 64, 84], ["environmental risk factors", "PROBLEM", 86, 112], ["Barr virus", "OBSERVATION", 64, 74]]], ["The identification of susceptibility genes contributing to NPC may help clarify the pathogenesis of carcinogenesis and improve the prevention and treatment of this malignancy.INTRODUCTIONThe human 5p15.33 locus contains two well-known genes, the telomerase reverse transcriptase (TERT) and the cleft lip and palate transmembrane 1-like (CLPTM1L) genes, which have been implicated in carcinogenesis.", [["NPC", "ANATOMY", 59, 62], ["cleft lip", "ANATOMY", 294, 303], ["NPC", "DISEASE", 59, 62], ["carcinogenesis", "DISEASE", 100, 114], ["malignancy", "DISEASE", 164, 174], ["carcinogenesis", "DISEASE", 383, 397], ["NPC", "CANCER", 59, 62], ["malignancy", "CANCER", 164, 174], ["human", "ORGANISM", 191, 196], ["5p15.33", "GENE_OR_GENE_PRODUCT", 197, 204], ["telomerase reverse transcriptase", "GENE_OR_GENE_PRODUCT", 246, 278], ["TERT", "GENE_OR_GENE_PRODUCT", 280, 284], ["lip", "ORGAN", 300, 303], ["palate transmembrane 1", "GENE_OR_GENE_PRODUCT", 308, 330], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 337, 344], ["susceptibility genes", "DNA", 22, 42], ["human 5p15.33 locus", "DNA", 191, 210], ["telomerase reverse transcriptase", "PROTEIN", 246, 278], ["TERT", "PROTEIN", 280, 284], ["cleft lip and palate transmembrane 1-like (CLPTM1L) genes", "DNA", 294, 351], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 191, 196], ["susceptibility genes", "PROBLEM", 22, 42], ["NPC", "TREATMENT", 59, 62], ["carcinogenesis", "PROBLEM", 100, 114], ["treatment", "TREATMENT", 146, 155], ["this malignancy", "PROBLEM", 159, 174], ["the cleft lip and palate transmembrane", "TEST", 290, 328], ["susceptibility genes", "OBSERVATION", 22, 42], ["carcinogenesis", "OBSERVATION", 100, 114], ["malignancy", "OBSERVATION", 164, 174], ["cleft lip", "ANATOMY", 294, 303], ["palate", "ANATOMY", 308, 314], ["carcinogenesis", "OBSERVATION", 383, 397]]], ["TERT, as the rate-limiting catalytic subunit of the telomerase enzyme, plays an essential role in the maintenance of telomere DNA length, chromosomal stability, and cellular immortality [3].", [["telomere", "ANATOMY", 117, 125], ["chromosomal", "ANATOMY", 138, 149], ["cellular", "ANATOMY", 165, 173], ["TERT", "GENE_OR_GENE_PRODUCT", 0, 4], ["telomerase", "GENE_OR_GENE_PRODUCT", 52, 62], ["telomere DNA", "CELLULAR_COMPONENT", 117, 129], ["chromosomal", "CELLULAR_COMPONENT", 138, 149], ["cellular", "CELL", 165, 173], ["TERT", "PROTEIN", 0, 4], ["catalytic subunit", "PROTEIN", 27, 44], ["telomerase enzyme", "PROTEIN", 52, 69], ["the rate", "TEST", 9, 17], ["the telomerase enzyme", "TEST", 48, 69], ["telomere DNA length", "TREATMENT", 117, 136], ["chromosomal stability", "PROBLEM", 138, 159], ["stability", "OBSERVATION_MODIFIER", 150, 159]]], ["TERT is expressed in the vast majority of human malignant celllines and tumors but not in the corresponding benign tissues [4].", [["malignant celllines", "ANATOMY", 48, 67], ["tumors", "ANATOMY", 72, 78], ["benign tissues", "ANATOMY", 108, 122], ["malignant celllines", "DISEASE", 48, 67], ["tumors", "DISEASE", 72, 78], ["TERT", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 42, 47], ["malignant celllines", "CANCER", 48, 67], ["tumors", "CANCER", 72, 78], ["benign tissues", "TISSUE", 108, 122], ["TERT", "PROTEIN", 0, 4], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["human malignant celllines", "PROBLEM", 42, 67], ["tumors", "PROBLEM", 72, 78], ["tumors", "OBSERVATION", 72, 78], ["benign", "OBSERVATION_MODIFIER", 108, 114]]], ["With regard to NPC, elevated telomerase activity and TERT expression levels were detected in tumor tissues compared with normal nasopharyngeal epithelium and tissues [5, 6].", [["NPC", "ANATOMY", 15, 18], ["tumor tissues", "ANATOMY", 93, 106], ["nasopharyngeal epithelium", "ANATOMY", 128, 153], ["tissues", "ANATOMY", 158, 165], ["tumor", "DISEASE", 93, 98], ["NPC", "CANCER", 15, 18], ["telomerase", "GENE_OR_GENE_PRODUCT", 29, 39], ["TERT", "GENE_OR_GENE_PRODUCT", 53, 57], ["tumor tissues", "TISSUE", 93, 106], ["nasopharyngeal epithelium", "TISSUE", 128, 153], ["tissues", "TISSUE", 158, 165], ["NPC", "PROTEIN", 15, 18], ["telomerase", "PROTEIN", 29, 39], ["TERT", "PROTEIN", 53, 57], ["NPC", "TREATMENT", 15, 18], ["elevated telomerase activity", "PROBLEM", 20, 48], ["TERT expression levels", "PROBLEM", 53, 75], ["elevated", "OBSERVATION_MODIFIER", 20, 28], ["telomerase activity", "OBSERVATION", 29, 48], ["tumor tissues", "OBSERVATION", 93, 106], ["nasopharyngeal epithelium", "ANATOMY", 128, 153]]], ["Furthermore, for the clinicopathological features in NPC patients, the telomerase activity was observed more frequently in advanced clinical stage and lymph node metastasis [7, 8].", [["NPC", "ANATOMY", 53, 56], ["lymph node", "ANATOMY", 151, 161], ["NPC", "DISEASE", 53, 56], ["NPC", "CANCER", 53, 56], ["patients", "ORGANISM", 57, 65], ["telomerase", "GENE_OR_GENE_PRODUCT", 71, 81], ["lymph node", "MULTI-TISSUE_STRUCTURE", 151, 161], ["telomerase", "PROTEIN", 71, 81], ["patients", "SPECIES", 57, 65], ["the telomerase activity", "PROBLEM", 67, 90], ["lymph node metastasis", "PROBLEM", 151, 172], ["lymph node metastasis", "OBSERVATION", 151, 172]]], ["The other gene in this region, CLPTM1L, which is named for its similarity to a gene implicated in the susceptibility to cleft lip palate, was identified through screening for cisplatin-resistance-related genes.", [["cleft lip palate", "ANATOMY", 120, 136], ["cleft lip palate", "DISEASE", 120, 136], ["cisplatin", "CHEMICAL", 175, 184], ["cisplatin", "CHEMICAL", 175, 184], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 31, 38], ["lip", "ORGAN", 126, 129], ["palate", "ORGAN", 130, 136], ["cisplatin", "SIMPLE_CHEMICAL", 175, 184], ["CLPTM1L", "DNA", 31, 38], ["cisplatin-resistance-related genes", "DNA", 175, 209], ["the susceptibility to cleft lip palate", "PROBLEM", 98, 136], ["screening", "TEST", 161, 170], ["cisplatin", "TREATMENT", 175, 184], ["lip palate", "ANATOMY", 126, 136]]], ["Although the function of this gene is less known, it was found to be upregulated in cisplatin-resistant ovarian tumor cell lines and to induce apoptosis in cisplatin-sensitive cells [9].", [["ovarian tumor cell lines", "ANATOMY", 104, 128], ["cells", "ANATOMY", 176, 181], ["cisplatin", "CHEMICAL", 84, 93], ["ovarian tumor", "DISEASE", 104, 117], ["cisplatin", "CHEMICAL", 156, 165], ["cisplatin", "CHEMICAL", 84, 93], ["cisplatin", "CHEMICAL", 156, 165], ["cisplatin", "SIMPLE_CHEMICAL", 84, 93], ["ovarian tumor cell lines", "CELL", 104, 128], ["cisplatin", "SIMPLE_CHEMICAL", 156, 165], ["cells", "CELL", 176, 181], ["cisplatin-resistant ovarian tumor cell lines", "CELL_LINE", 84, 128], ["cisplatin-sensitive cells", "CELL_LINE", 156, 181], ["cisplatin", "TREATMENT", 84, 93], ["resistant ovarian tumor cell lines", "PROBLEM", 94, 128], ["apoptosis", "PROBLEM", 143, 152], ["cisplatin", "TEST", 156, 165], ["sensitive cells", "PROBLEM", 166, 181], ["ovarian", "ANATOMY", 104, 111], ["tumor cell lines", "OBSERVATION", 112, 128]]], ["On the basis of the above functional relevance of the TERT and CLPTM1L genes in the pathogenesis of cancers, we hypothesize that TERT and CLPTM1L may be excellent biological candidate susceptibility genes for cancers.INTRODUCTIONSingle nucleotide polymorphisms (SNPs) in the TERT-CLPTM1L locus on chromosome 5p15.33 have been linked to a spectrum of cancers.", [["cancers", "ANATOMY", 100, 107], ["cancers", "ANATOMY", 209, 216], ["chromosome 5p15.33", "ANATOMY", 297, 315], ["cancers", "ANATOMY", 350, 357], ["cancers", "DISEASE", 100, 107], ["cancers", "DISEASE", 209, 216], ["cancers", "DISEASE", 350, 357], ["TERT", "GENE_OR_GENE_PRODUCT", 54, 58], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 63, 70], ["cancers", "CANCER", 100, 107], ["TERT", "GENE_OR_GENE_PRODUCT", 129, 133], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 138, 145], ["cancers", "CANCER", 209, 216], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 275, 287], ["chromosome 5p15.33", "CELLULAR_COMPONENT", 297, 315], ["cancers", "CANCER", 350, 357], ["TERT and CLPTM1L genes", "DNA", 54, 76], ["TERT", "PROTEIN", 129, 133], ["CLPTM1L", "DNA", 138, 145], ["susceptibility genes", "DNA", 184, 204], ["INTRODUCTIONSingle nucleotide polymorphisms", "DNA", 217, 260], ["SNPs", "DNA", 262, 266], ["TERT-CLPTM1L locus", "DNA", 275, 293], ["chromosome 5p15.33", "DNA", 297, 315], ["the TERT and CLPTM1L genes", "PROBLEM", 50, 76], ["cancers", "PROBLEM", 100, 107], ["TERT and CLPTM1L", "PROBLEM", 129, 145], ["cancers", "PROBLEM", 209, 216], ["INTRODUCTIONSingle nucleotide polymorphisms (SNPs)", "TREATMENT", 217, 267], ["cancers", "PROBLEM", 350, 357], ["cancers", "OBSERVATION", 100, 107], ["cancers", "OBSERVATION", 350, 357]]], ["Multiple independent genome-wide association studies (GWAS) have shown that SNPs in the TERT-CLPTM1L locus were significantly associated with the risk of many different types of cancer, including basal cell carcinoma, glioma, lung, cervical, prostate, bladder, pancreatic, chronic lymphocytic leukemia, and testicular germ cell cancers [10\u201317].", [["cancer", "ANATOMY", 178, 184], ["basal cell carcinoma", "ANATOMY", 196, 216], ["glioma", "ANATOMY", 218, 224], ["lung", "ANATOMY", 226, 230], ["cervical", "ANATOMY", 232, 240], ["prostate", "ANATOMY", 242, 250], ["bladder", "ANATOMY", 252, 259], ["pancreatic", "ANATOMY", 261, 271], ["chronic lymphocytic leukemia", "ANATOMY", 273, 301], ["testicular germ cell cancers", "ANATOMY", 307, 335], ["cancer", "DISEASE", 178, 184], ["basal cell carcinoma", "DISEASE", 196, 216], ["glioma", "DISEASE", 218, 224], ["lung, cervical, prostate, bladder, pancreatic, chronic lymphocytic leukemia", "DISEASE", 226, 301], ["testicular germ cell cancers", "DISEASE", 307, 335], ["TERT-", "GENE_OR_GENE_PRODUCT", 88, 93], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 93, 100], ["cancer", "CANCER", 178, 184], ["basal cell carcinoma", "CANCER", 196, 216], ["glioma", "CANCER", 218, 224], ["lung", "ORGAN", 226, 230], ["cervical", "ORGAN", 232, 240], ["prostate", "CANCER", 242, 250], ["bladder", "ORGAN", 252, 259], ["pancreatic", "CANCER", 261, 271], ["chronic lymphocytic leukemia", "CANCER", 273, 301], ["testicular germ cell cancers", "CANCER", 307, 335], ["TERT-CLPTM1L locus", "DNA", 88, 106], ["SNPs", "PROBLEM", 76, 80], ["cancer", "PROBLEM", 178, 184], ["basal cell carcinoma", "PROBLEM", 196, 216], ["glioma", "PROBLEM", 218, 224], ["lung, cervical, prostate, bladder", "PROBLEM", 226, 259], ["pancreatic, chronic lymphocytic leukemia", "PROBLEM", 261, 301], ["testicular germ cell cancers", "PROBLEM", 307, 335], ["cancer", "OBSERVATION", 178, 184], ["basal cell carcinoma", "OBSERVATION", 196, 216], ["glioma", "OBSERVATION", 218, 224], ["lung", "ANATOMY", 226, 230], ["cervical", "ANATOMY", 232, 240], ["prostate", "ANATOMY", 242, 250], ["bladder", "ANATOMY", 252, 259], ["pancreatic", "ANATOMY", 261, 271], ["chronic", "OBSERVATION_MODIFIER", 273, 280], ["lymphocytic leukemia", "OBSERVATION", 281, 301], ["testicular", "ANATOMY", 307, 317], ["germ cell cancers", "OBSERVATION", 318, 335]]], ["Association studies on candidate gene strategy also reported that polymorphisms in the TERT-CLPTM1L locus were associated with serous ovarian, breast, endometrial, lung, and colorectal cancers [18\u201320].", [["serous ovarian", "ANATOMY", 127, 141], ["breast", "ANATOMY", 143, 149], ["endometrial", "ANATOMY", 151, 162], ["lung", "ANATOMY", 164, 168], ["colorectal cancers", "ANATOMY", 174, 192], ["serous ovarian, breast, endometrial, lung, and colorectal cancers", "DISEASE", 127, 192], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 87, 99], ["serous ovarian", "CANCER", 127, 141], ["breast", "CANCER", 143, 149], ["endometrial", "CANCER", 151, 162], ["lung", "ORGAN", 164, 168], ["colorectal cancers", "CANCER", 174, 192], ["TERT-CLPTM1L locus", "DNA", 87, 105], ["Association studies", "TEST", 0, 19], ["polymorphisms in the TERT-CLPTM1L locus", "PROBLEM", 66, 105], ["serous ovarian, breast, endometrial, lung, and colorectal cancers", "PROBLEM", 127, 192], ["associated with", "UNCERTAINTY", 111, 126], ["serous ovarian", "OBSERVATION", 127, 141], ["breast", "ANATOMY", 143, 149], ["endometrial", "ANATOMY", 151, 162], ["lung", "ANATOMY", 164, 168], ["colorectal", "ANATOMY", 174, 184], ["cancers", "OBSERVATION", 185, 192]]], ["The roles of the polymorphism in the TERT-CLPTM1L locus in NPC, however, have not been fully investigated.", [["NPC", "ANATOMY", 59, 62], ["NPC", "DISEASE", 59, 62], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 37, 49], ["NPC", "CANCER", 59, 62], ["TERT-CLPTM1L locus", "DNA", 37, 55], ["the polymorphism", "PROBLEM", 13, 29], ["polymorphism", "OBSERVATION_MODIFIER", 17, 29], ["NPC", "ANATOMY", 59, 62]]], ["In the present study, we examined whether the polymorphism in the TERT-CLPTM1L locus have any bearing on the risk or severity of NPC in Chinese populations.Genetic association between polymorphisms in the TERT-CLPTM1L locus and NPC ::: RESULTSAmong the 26 tag SNPs chosen first, four SNPs were eliminated because of low frequency (rs2853691), poor genotyping reliability (rs2736118), or departure from Hardy-Weinberg equilibrium (P < 0.05) (rs2853668 and rs10073340).", [["NPC", "ANATOMY", 129, 132], ["NPC", "ANATOMY", 228, 231], ["NPC", "DISEASE", 129, 132], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 66, 78], ["NPC", "CANCER", 129, 132], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 205, 217], ["NPC", "CANCER", 228, 231], ["TERT-CLPTM1L locus", "DNA", 66, 84], ["TERT-CLPTM1L locus", "DNA", 205, 223], ["NPC", "DNA", 228, 231], ["26 tag SNPs", "DNA", 253, 264], ["the present study", "TEST", 3, 20], ["the polymorphism in the TERT-CLPTM1L locus", "PROBLEM", 42, 84], ["NPC", "PROBLEM", 129, 132], ["Genetic association between polymorphisms", "PROBLEM", 156, 197], ["RESULTSAmong the 26 tag SNPs", "TREATMENT", 236, 264], ["four SNPs", "TREATMENT", 279, 288], ["low frequency", "PROBLEM", 316, 329], ["NPC", "OBSERVATION", 129, 132], ["NPC", "ANATOMY", 228, 231], ["low frequency", "OBSERVATION_MODIFIER", 316, 329]]], ["We therefore selected the remaining 22 SNPs for the subsequent analyses.Genetic association between polymorphisms in the TERT-CLPTM1L locus and NPC ::: RESULTSThe genotyping results for the 22 SNPs are shown in Table 1 and Figure 1.", [["NPC", "ANATOMY", 144, 147], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 121, 133], ["NPC", "CANCER", 144, 147], ["TERT-CLPTM1L locus", "DNA", 121, 139], ["NPC", "PROTEIN", 144, 147], ["the subsequent analyses", "TEST", 48, 71], ["RESULTSThe genotyping", "TEST", 152, 173], ["the 22 SNPs", "TEST", 186, 197], ["NPC", "ANATOMY", 144, 147]]], ["On the basis of logistic regression analysis with adjustment for age, sex, smoking status, alcohol use, and family history, significant associations with the susceptibility to NPC were observed with the 12 SNPs in the Guangxi population (Table 1).", [["NPC", "ANATOMY", 176, 179], ["smoking", "CHEMICAL", 75, 82], ["alcohol", "CHEMICAL", 91, 98], ["NPC", "DISEASE", 176, 179], ["alcohol", "CHEMICAL", 91, 98], ["NPC", "CANCER", 176, 179], ["logistic regression analysis", "TEST", 16, 44], ["the susceptibility to NPC", "PROBLEM", 154, 179]]], ["After multiple corrections, four SNPs (rs2736098, rs2735845, rs402710, and rs401681) were significantly associated with NPC risk (P < 0.0029 after SNP SpD correction, Meff Li value = 17, Table 1).", [["NPC", "ANATOMY", 120, 123], ["NPC", "DISEASE", 120, 123], ["SNP", "CHEMICAL", 147, 150], ["NPC", "CANCER", 120, 123], ["four SNPs", "TEST", 28, 37], ["rs", "TEST", 61, 63], ["NPC risk", "PROBLEM", 120, 128], ["SNP SpD correction", "TREATMENT", 147, 165], ["Meff Li value", "TEST", 167, 180]]], ["We also investigated the association between the 22 SNPs and the severity of NPC (as measured by TNM staging system) in the Guangxi population.", [["NPC", "ANATOMY", 77, 80], ["NPC", "DISEASE", 77, 80], ["NPC", "CANCER", 77, 80], ["the 22 SNPs", "TREATMENT", 45, 56], ["NPC", "PROBLEM", 77, 80], ["TNM staging system", "TEST", 97, 115], ["NPC", "ANATOMY", 77, 80], ["Guangxi", "ANATOMY", 124, 131]]], ["After multiple corrections, no association was observed between the 22 SNPs and the severity of NPC (Table S8).Genetic association between polymorphisms in the TERT-CLPTM1L locus and NPC ::: RESULTSTo confirm the initial associations of these four SNPs with NPC, the Guangdong population, composed of 997 patients and 972 controls, was also genotyped.", [["NPC", "ANATOMY", 96, 99], ["NPC", "ANATOMY", 183, 186], ["NPC", "ANATOMY", 258, 261], ["NPC", "DISEASE", 96, 99], ["NPC", "DISEASE", 258, 261], ["NPC", "CANCER", 96, 99], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 160, 172], ["NPC", "CANCER", 183, 186], ["NPC", "CANCER", 258, 261], ["patients", "ORGANISM", 305, 313], ["NPC", "PROTEIN", 96, 99], ["TERT-CLPTM1L locus", "DNA", 160, 178], ["NPC", "PROTEIN", 183, 186], ["patients", "SPECIES", 305, 313], ["NPC", "PROBLEM", 96, 99], ["NPC", "TREATMENT", 258, 261], ["NPC", "ANATOMY", 183, 186]]], ["The observed genotype frequencies for the four polymorphisms conformed to Hardy-Weinberg equilibrium in the Guangdong population (all P > 0.05, data not shown).", [["The observed genotype frequencies", "TREATMENT", 0, 33], ["the four polymorphisms", "PROBLEM", 38, 60]]], ["There was no association between the rs2736098 and rs402710 polymorphisms and the risk of NPC in the Guangdong population (data not shown).", [["NPC", "ANATOMY", 90, 93], ["NPC", "DISEASE", 90, 93], ["rs2736098", "GENE_OR_GENE_PRODUCT", 37, 46], ["rs402710", "GENE_OR_GENE_PRODUCT", 51, 59], ["NPC", "CANCER", 90, 93], ["rs2736098 and rs402710 polymorphisms", "DNA", 37, 73], ["NPC", "PROBLEM", 90, 93], ["no association between", "UNCERTAINTY", 10, 32]]], ["However, the rs2735845 and rs401681 polymorphisms were significantly associated with risk of NPC in the Guangdong population (Table 2).", [["NPC", "ANATOMY", 93, 96], ["NPC", "DISEASE", 93, 96], ["rs2735845", "GENE_OR_GENE_PRODUCT", 13, 22], ["rs401681", "GENE_OR_GENE_PRODUCT", 27, 35], ["NPC", "CANCER", 93, 96], ["rs2735845 and rs401681 polymorphisms", "DNA", 13, 49], ["NPC", "PROBLEM", 93, 96]]], ["For the 2735845 polymorphism, the G allele presented significant association with increased risk of NPC in the additive model (OR = 1.19, 95% CI = 1.04\u20131.37, P = 0.011).", [["NPC", "ANATOMY", 100, 103], ["NPC", "DISEASE", 100, 103], ["G", "GENE_OR_GENE_PRODUCT", 34, 35], ["NPC", "CANCER", 100, 103], ["G allele", "DNA", 34, 42], ["NPC", "PROBLEM", 100, 103], ["CI", "TEST", 142, 144], ["P", "TEST", 158, 159], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["NPC", "OBSERVATION", 100, 103]]], ["For the rs401681 polymorphism, the T allele presented significant association with decreased risk of NPC in the additive model (OR = 0.85, 95% CI = 0.74\u20130.99, P = 0.034).", [["NPC", "ANATOMY", 101, 104], ["NPC", "DISEASE", 101, 104], ["rs401681", "GENE_OR_GENE_PRODUCT", 8, 16], ["NPC", "CANCER", 101, 104], ["rs401681", "DNA", 8, 16], ["T allele", "DNA", 35, 43], ["CI", "TEST", 143, 145], ["P", "TEST", 159, 160], ["significant", "OBSERVATION_MODIFIER", 54, 65]]], ["When the Guangxi and Guangdong populations were combined, stronger associations were observed between both the rs2735845 and rs401681 polymorphisms and NPC risk in the additive model (for rs2735845: adjusted OR = 1.23, 95% CI = 1.12\u20131.35, P = 4.64 \u00d7 10\u22125; for rs401681: adjusted OR = 0.81, 95% CI = 0.74\u20130.90, P = 1.00 \u00d7 10\u22124) (Table 2).", [["NPC", "ANATOMY", 152, 155], ["rs2735845", "GENE_OR_GENE_PRODUCT", 111, 120], ["rs401681", "GENE_OR_GENE_PRODUCT", 125, 133], ["NPC", "CANCER", 152, 155], ["NPC risk", "PROBLEM", 152, 160], ["CI", "TEST", 223, 225], ["P", "TEST", 239, 240], ["rs", "TEST", 260, 262], ["CI", "TEST", 294, 296], ["P", "TEST", 310, 311]]], ["The effects of rs2735845 and rs401681 were maintained when corrected for each other by logistic regression (OR = 1.15, 95% CI = 1.03\u20131.29, P = 0.012 and OR = 0.88, 95% CI = 0.78\u20130.99, P = 0.03, respectively).", [["rs2735845", "GENE_OR_GENE_PRODUCT", 15, 24], ["rs401681", "GENE_OR_GENE_PRODUCT", 29, 37], ["CI", "TEST", 123, 125], ["P", "TEST", 139, 140], ["OR", "TEST", 153, 155], ["CI", "TEST", 168, 170], ["P", "TEST", 184, 185]]], ["No association more significant than that of rs2735845 and rs401681 was identified through imputation of other polymorphisms in the TERT-CLPTM1L locus based on HapMap CHB data (data not shown).", [["rs2735845", "GENE_OR_GENE_PRODUCT", 45, 54], ["rs401681", "GENE_OR_GENE_PRODUCT", 59, 67], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 132, 144], ["TERT-CLPTM1L locus", "DNA", 132, 150], ["other polymorphisms", "PROBLEM", 105, 124], ["the TERT-CLPTM1L locus", "TREATMENT", 128, 150], ["HapMap CHB data", "TEST", 160, 175], ["more significant", "OBSERVATION_MODIFIER", 15, 31]]], ["Furthermore, the correlation between rs2735845 and rs401681 is not strong (D\u2019 = 0.91, r2 = 0.24 in HapMap CHB samples, D\u2019 = 0.89, r2 = 0.24 in our control data; Figure 1).", [["rs2735845", "GENE_OR_GENE_PRODUCT", 37, 46], ["rs401681", "GENE_OR_GENE_PRODUCT", 51, 59], ["D", "TEST", 75, 76], ["r2", "TEST", 86, 88], ["HapMap CHB samples", "TEST", 99, 117], ["D", "TEST", 119, 120], ["r2", "TEST", 130, 132]]], ["Taken together, these data strongly suggest that rs2735845 and rs401681 are independently associated with NPC.Genetic association between polymorphisms in the TERT-CLPTM1L locus and NPC ::: RESULTSThe associations between the rs2735845 and rs401681 polymorphisms and the susceptibility to NPC in both the Guangxi and Guangdong populations were further examined with stratification by age, sex, smoking status, smoking level, drinking status and family of history.", [["NPC", "ANATOMY", 106, 109], ["NPC", "ANATOMY", 182, 185], ["NPC", "ANATOMY", 289, 292], ["NPC", "DISEASE", 106, 109], ["NPC", "DISEASE", 289, 292], ["smoking", "CHEMICAL", 410, 417], ["rs2735845", "GENE_OR_GENE_PRODUCT", 49, 58], ["rs401681", "GENE_OR_GENE_PRODUCT", 63, 71], ["NPC", "CANCER", 106, 109], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 159, 171], ["NPC", "CANCER", 182, 185], ["rs2735845", "GENE_OR_GENE_PRODUCT", 226, 235], ["rs401681", "GENE_OR_GENE_PRODUCT", 240, 248], ["NPC", "CANCER", 289, 292], ["TERT-CLPTM1L locus", "DNA", 159, 177], ["NPC", "PROTEIN", 182, 185], ["rs2735845 and rs401681 polymorphisms", "DNA", 226, 262], ["NPC", "PROBLEM", 106, 109], ["the susceptibility to NPC", "PROBLEM", 267, 292], ["Guangdong populations", "TREATMENT", 317, 338], ["NPC", "ANATOMY", 182, 185]]], ["For the rs401681 polymorphism, although the susceptibility to NPC seemed to be more pronounced in some subgroups, these differences could be attributed to chance (all P > 0.05, test for homogeneity; data not shown).", [["NPC", "ANATOMY", 62, 65], ["NPC", "DISEASE", 62, 65], ["rs401681", "GENE_OR_GENE_PRODUCT", 8, 16], ["NPC", "CANCER", 62, 65], ["rs401681", "DNA", 8, 16], ["the susceptibility to NPC", "PROBLEM", 40, 65], ["more pronounced", "OBSERVATION_MODIFIER", 79, 94]]], ["For the rs2735845 polymorphism, the general pattern of results was similar (data not shown).Effects of the rs2735845 and rs401681 polymorphisms on TERT and CLPTM1L mRNA expression ::: RESULTSWe evaluated the association between genotypes of the rs2735845 and rs401681 polymorphisms and TERT and CLPTM1L mRNA levels in 12 fetal mesenchymal stem cells (fMSCs).", [["fetal mesenchymal stem cells", "ANATOMY", 321, 349], ["fMSCs", "ANATOMY", 351, 356], ["rs2735845", "GENE_OR_GENE_PRODUCT", 8, 17], ["rs2735845", "GENE_OR_GENE_PRODUCT", 107, 116], ["rs401681", "GENE_OR_GENE_PRODUCT", 121, 129], ["TERT", "GENE_OR_GENE_PRODUCT", 147, 151], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 156, 163], ["rs2735845", "GENE_OR_GENE_PRODUCT", 245, 254], ["rs401681", "GENE_OR_GENE_PRODUCT", 259, 267], ["TERT", "GENE_OR_GENE_PRODUCT", 286, 290], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 295, 302], ["fetal mesenchymal stem cells", "CELL", 321, 349], ["fMSCs", "CELL", 351, 356], ["rs2735845 polymorphism", "DNA", 8, 30], ["CLPTM1L mRNA", "RNA", 156, 168], ["CLPTM1L mRNA", "RNA", 295, 307], ["fetal mesenchymal stem cells", "CELL_TYPE", 321, 349], ["fMSCs", "CELL_TYPE", 351, 356], ["genotypes", "TEST", 228, 237], ["polymorphisms", "TEST", 268, 281], ["TERT", "TEST", 286, 290], ["CLPTM1L mRNA levels", "TEST", 295, 314], ["fMSCs", "TEST", 351, 356], ["mesenchymal stem cells", "OBSERVATION", 327, 349]]], ["As shown in Figure 2, the relative CLPTM1L mRNA level from fMSCs with rs2735845 G allele (GG + CG genotypes) was significantly higher than that from fMSCs with CC genotype (t test; P = 0.02).", [["fMSCs", "ANATOMY", 59, 64], ["fMSCs", "ANATOMY", 149, 154], ["CC", "CHEMICAL", 160, 162], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 35, 42], ["rs2735845 G allele", "GENE_OR_GENE_PRODUCT", 70, 88], ["fMSCs", "PATHOLOGICAL_FORMATION", 149, 154], ["CLPTM1L mRNA", "RNA", 35, 47], ["fMSCs", "CELL_TYPE", 59, 64], ["rs2735845 G allele", "DNA", 70, 88], ["the relative CLPTM1L mRNA level", "TEST", 22, 53], ["fMSCs", "TEST", 59, 64], ["G allele", "TEST", 80, 88], ["GG + CG genotypes", "TEST", 90, 107], ["CC genotype", "TEST", 160, 171], ["t test", "TEST", 173, 179], ["P", "TEST", 181, 182]]], ["However, there was no association between CLPTM1L mRNA level and rs401681 genotypes in fMSCs (data not shown).Greater TERT and CLPTM1L expression in NPC tissues compared with that in non-cancerous nasopharyngeal tissues ::: RESULTSWe investigated the protein expression of TERT and CLPTM1L in NPC tissues and non-cancerous nasopharyngeal tissues by immunohistochemical (IHC) assay (Figure 3 and Table S1 in Supplementary Materials).", [["fMSCs", "ANATOMY", 87, 92], ["NPC tissues", "ANATOMY", 149, 160], ["non-cancerous nasopharyngeal tissues", "ANATOMY", 183, 219], ["NPC tissues", "ANATOMY", 293, 304], ["non-cancerous nasopharyngeal tissues", "ANATOMY", 309, 345], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 42, 49], ["rs401681", "GENE_OR_GENE_PRODUCT", 65, 73], ["fMSCs", "PATHOLOGICAL_FORMATION", 87, 92], ["TERT", "GENE_OR_GENE_PRODUCT", 118, 122], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 127, 134], ["NPC tissues", "TISSUE", 149, 160], ["non-cancerous nasopharyngeal tissues", "TISSUE", 183, 219], ["TERT", "GENE_OR_GENE_PRODUCT", 273, 277], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 282, 289], ["NPC tissues", "TISSUE", 293, 304], ["non-cancerous nasopharyngeal tissues", "TISSUE", 309, 345], ["CLPTM1L mRNA", "RNA", 42, 54], ["fMSCs", "CELL_TYPE", 87, 92], ["TERT", "PROTEIN", 118, 122], ["CLPTM1L", "PROTEIN", 127, 134], ["TERT", "PROTEIN", 273, 277], ["CLPTM1L", "PROTEIN", 282, 289], ["association between CLPTM1L mRNA level", "PROBLEM", 22, 60], ["genotypes", "TEST", 74, 83], ["fMSCs", "TEST", 87, 92], ["Greater TERT and CLPTM1L expression in NPC tissues", "PROBLEM", 110, 160], ["TERT and CLPTM1L in NPC tissues", "PROBLEM", 273, 304], ["non-cancerous nasopharyngeal tissues", "PROBLEM", 309, 345], ["immunohistochemical (IHC) assay", "TEST", 349, 380], ["Figure", "TEST", 382, 388], ["no association between", "UNCERTAINTY", 19, 41], ["CLPTM1L expression", "OBSERVATION", 127, 145], ["NPC tissues", "OBSERVATION", 149, 160], ["nasopharyngeal tissues", "ANATOMY", 197, 219], ["NPC tissues", "ANATOMY", 293, 304], ["non-cancerous", "OBSERVATION_MODIFIER", 309, 322], ["nasopharyngeal tissues", "ANATOMY", 323, 345]]], ["Significantly higher expression of TERT was observed in the NPC tissues compared to that in the non-cancer nasopharyngeal tissues (P < 0.001).", [["NPC tissues", "ANATOMY", 60, 71], ["non-cancer nasopharyngeal tissues", "ANATOMY", 96, 129], ["non-cancer", "DISEASE", 96, 106], ["TERT", "GENE_OR_GENE_PRODUCT", 35, 39], ["NPC tissues", "TISSUE", 60, 71], ["nasopharyngeal tissues", "TISSUE", 107, 129], ["TERT", "PROTEIN", 35, 39], ["Significantly higher expression of TERT", "PROBLEM", 0, 39], ["the NPC tissues", "PROBLEM", 56, 71], ["higher", "OBSERVATION_MODIFIER", 14, 20], ["expression", "OBSERVATION_MODIFIER", 21, 31], ["TERT", "OBSERVATION", 35, 39], ["NPC tissues", "ANATOMY", 60, 71], ["non-cancer", "OBSERVATION", 96, 106], ["nasopharyngeal tissues", "ANATOMY", 107, 129]]], ["There was also significantly higher expression of CLPTM1L in the NPC tissues compared to that in the non-cancer nasopharyngeal tissues (P < 0.001).", [["NPC tissues", "ANATOMY", 65, 76], ["non-cancer nasopharyngeal tissues", "ANATOMY", 101, 134], ["non-cancer", "DISEASE", 101, 111], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 50, 57], ["NPC tissues", "TISSUE", 65, 76], ["nasopharyngeal tissues", "TISSUE", 112, 134], ["CLPTM1L", "PROTEIN", 50, 57], ["CLPTM1L in the NPC tissues", "PROBLEM", 50, 76], ["significantly", "OBSERVATION_MODIFIER", 15, 28], ["higher", "OBSERVATION_MODIFIER", 29, 35], ["expression", "OBSERVATION_MODIFIER", 36, 46], ["CLPTM1L", "OBSERVATION", 50, 57], ["NPC tissues", "ANATOMY", 65, 76], ["non-cancer", "OBSERVATION", 101, 111], ["nasopharyngeal tissues", "ANATOMY", 112, 134]]], ["However, there was no association between the genotypes of the rs2735845 and rs401681 polymorphisms and the expression of TERT and CLPTM1L in NPC tissues and non-cancerous nasopharyngeal tissues.DISCUSSIONIn this study, we investigated the associations of 26 tag SNPs in the TERT-CLPTM1L locus on 5p15.33 with the risk of occurrence and progression of NPC in populations in southern China.", [["NPC tissues", "ANATOMY", 142, 153], ["non-cancerous nasopharyngeal tissues", "ANATOMY", 158, 194], ["NPC", "ANATOMY", 352, 355], ["NPC", "DISEASE", 352, 355], ["rs2735845", "GENE_OR_GENE_PRODUCT", 63, 72], ["rs401681", "GENE_OR_GENE_PRODUCT", 77, 85], ["TERT", "GENE_OR_GENE_PRODUCT", 122, 126], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 131, 138], ["NPC tissues", "TISSUE", 142, 153], ["non-cancerous nasopharyngeal tissues", "TISSUE", 158, 194], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 275, 287], ["NPC", "CANCER", 352, 355], ["TERT", "PROTEIN", 122, 126], ["CLPTM1L", "PROTEIN", 131, 138], ["TERT-CLPTM1L locus", "DNA", 275, 293], ["the genotypes", "TEST", 42, 55], ["TERT and CLPTM1L in NPC tissues", "PROBLEM", 122, 153], ["non-cancerous nasopharyngeal tissues", "PROBLEM", 158, 194], ["this study", "TEST", 208, 218], ["26 tag SNPs", "TREATMENT", 256, 267], ["NPC", "PROBLEM", 352, 355], ["NPC tissues", "ANATOMY", 142, 153], ["non-cancerous", "OBSERVATION", 158, 171], ["nasopharyngeal tissues", "ANATOMY", 172, 194], ["progression", "OBSERVATION_MODIFIER", 337, 348], ["NPC", "OBSERVATION", 352, 355]]], ["We found that two SNPs, rs2735845 and rs401681, were significantly associated with the onset of NPC in two independent populations.", [["NPC", "ANATOMY", 96, 99], ["NPC", "DISEASE", 96, 99], ["rs2735845", "GENE_OR_GENE_PRODUCT", 24, 33], ["rs401681", "GENE_OR_GENE_PRODUCT", 38, 46], ["NPC", "CANCER", 96, 99], ["two SNPs", "TEST", 14, 22], ["NPC", "PROBLEM", 96, 99], ["two", "OBSERVATION_MODIFIER", 14, 17], ["SNPs", "OBSERVATION_MODIFIER", 18, 22], ["NPC", "OBSERVATION", 96, 99], ["two independent", "OBSERVATION_MODIFIER", 103, 118], ["populations", "OBSERVATION_MODIFIER", 119, 130]]], ["Functional analysis showed that the rs2735845 G allele was associated with higher CLPTM1L mRNA levels when compared with the C allele.", [["rs2735845", "GENE_OR_GENE_PRODUCT", 36, 45], ["G", "GENE_OR_GENE_PRODUCT", 46, 47], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 82, 89], ["C", "GENE_OR_GENE_PRODUCT", 125, 126], ["rs2735845", "DNA", 36, 45], ["G allele", "DNA", 46, 54], ["CLPTM1L mRNA", "RNA", 82, 94], ["C allele", "DNA", 125, 133], ["Functional analysis", "TEST", 0, 19], ["higher CLPTM1L mRNA levels", "PROBLEM", 75, 101]]], ["In addition, we also found that the expression of TERT and CLPTM1L was higher in the NPC tissues compared to the non-cancer nasopharyngeal tissues.", [["NPC tissues", "ANATOMY", 85, 96], ["non-cancer nasopharyngeal tissues", "ANATOMY", 113, 146], ["non-cancer", "DISEASE", 113, 123], ["TERT", "GENE_OR_GENE_PRODUCT", 50, 54], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 59, 66], ["NPC tissues", "TISSUE", 85, 96], ["non-cancer nasopharyngeal tissues", "TISSUE", 113, 146], ["TERT", "PROTEIN", 50, 54], ["CLPTM1L", "PROTEIN", 59, 66], ["TERT and CLPTM1L", "PROBLEM", 50, 66], ["the non-cancer nasopharyngeal tissues", "PROBLEM", 109, 146], ["TERT", "OBSERVATION", 50, 54], ["higher", "OBSERVATION_MODIFIER", 71, 77], ["NPC tissues", "ANATOMY", 85, 96], ["non-cancer", "OBSERVATION", 113, 123], ["nasopharyngeal tissues", "ANATOMY", 124, 146]]], ["Our data, together with recent evidence for an association of the polymorphisms in the TERT-CLPTM1L locus with the risk of lung and colorectal cancer [19, 20], suggest that the polymorphisms at this locus are potent genetic risk factors for the onset of NPC.DISCUSSIONThe genetic associations observed in this study are biologically plausible.", [["lung", "ANATOMY", 123, 127], ["colorectal cancer", "ANATOMY", 132, 149], ["NPC", "ANATOMY", 254, 257], ["lung and colorectal cancer", "DISEASE", 123, 149], ["NPC", "DISEASE", 254, 257], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 87, 99], ["lung", "ORGAN", 123, 127], ["colorectal cancer", "CANCER", 132, 149], ["locus", "CELLULAR_COMPONENT", 199, 204], ["NPC", "CANCER", 254, 257], ["TERT-CLPTM1L locus", "DNA", 87, 105], ["Our data", "TEST", 0, 8], ["the polymorphisms in the TERT-CLPTM1L locus", "PROBLEM", 62, 105], ["lung and colorectal cancer", "PROBLEM", 123, 149], ["the polymorphisms", "PROBLEM", 173, 190], ["NPC", "PROBLEM", 254, 257], ["this study", "TEST", 305, 315], ["polymorphisms", "OBSERVATION", 66, 79], ["lung", "ANATOMY", 123, 127], ["colorectal", "ANATOMY", 132, 142], ["cancer", "OBSERVATION", 143, 149]]], ["There are two genes within the 5p15.33 TERT-CLPTM1L locus through which the association might plausibly be mediated: TERT and CLPTM1L.", [["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 39, 51], ["TERT", "GENE_OR_GENE_PRODUCT", 117, 121], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 126, 133], ["5p15.33 TERT-CLPTM1L locus", "DNA", 31, 57], ["TERT", "PROTEIN", 117, 121], ["CLPTM1L", "PROTEIN", 126, 133], ["TERT", "OBSERVATION", 117, 121]]], ["TERT translates the catalytic protein subunit of the telomerase complex, which elongates the telomere in cells.", [["telomere", "ANATOMY", 93, 101], ["cells", "ANATOMY", 105, 110], ["TERT", "GENE_OR_GENE_PRODUCT", 0, 4], ["telomerase", "GENE_OR_GENE_PRODUCT", 53, 63], ["telomere", "CELLULAR_COMPONENT", 93, 101], ["cells", "CELL", 105, 110], ["TERT", "PROTEIN", 0, 4], ["catalytic protein subunit", "PROTEIN", 20, 45], ["telomerase complex", "PROTEIN", 53, 71], ["telomere", "OBSERVATION_MODIFIER", 93, 101]]], ["Telomere-driven genome instability is a widespread cause of genome instability in cancer and is thought to be the crucial event in the development of tumorigenesis [3].", [["Telomere", "ANATOMY", 0, 8], ["cancer", "ANATOMY", 82, 88], ["genome instability", "DISEASE", 60, 78], ["cancer", "DISEASE", 82, 88], ["Telomere", "CELLULAR_COMPONENT", 0, 8], ["genome", "CELLULAR_COMPONENT", 16, 22], ["cancer", "CANCER", 82, 88], ["Telomere-driven genome instability", "PROBLEM", 0, 34], ["genome instability in cancer", "PROBLEM", 60, 88], ["genome instability", "OBSERVATION", 16, 34], ["widespread", "OBSERVATION_MODIFIER", 40, 50], ["genome instability", "OBSERVATION", 60, 78], ["cancer", "OBSERVATION", 82, 88], ["thought to be", "UNCERTAINTY", 96, 109], ["tumorigenesis", "OBSERVATION", 150, 163]]], ["It has been shown that small hairpin RNA can direct against TERT to inhibit cell viability by regulating telomerase activity and its related protein expression in NPC cells [21].", [["cell", "ANATOMY", 76, 80], ["NPC cells", "ANATOMY", 163, 172], ["TERT", "GENE_OR_GENE_PRODUCT", 60, 64], ["cell", "CELL", 76, 80], ["telomerase", "GENE_OR_GENE_PRODUCT", 105, 115], ["NPC cells", "CELL", 163, 172], ["small hairpin RNA", "RNA", 23, 40], ["TERT", "PROTEIN", 60, 64], ["telomerase", "PROTEIN", 105, 115], ["NPC cells", "CELL_TYPE", 163, 172], ["small hairpin RNA", "PROBLEM", 23, 40], ["TERT to inhibit cell viability", "PROBLEM", 60, 90], ["telomerase activity", "TEST", 105, 124], ["its related protein expression in NPC cells", "PROBLEM", 129, 172], ["small", "OBSERVATION_MODIFIER", 23, 28], ["hairpin RNA", "OBSERVATION", 29, 40], ["cell viability", "OBSERVATION", 76, 90]]], ["Moreover, overexpression of TERT has been detected in a variety of cancer cells, including NPC [6].", [["cancer cells", "ANATOMY", 67, 79], ["NPC", "ANATOMY", 91, 94], ["cancer", "DISEASE", 67, 73], ["NPC", "DISEASE", 91, 94], ["TERT", "GENE_OR_GENE_PRODUCT", 28, 32], ["cancer cells", "CELL", 67, 79], ["NPC [6]", "CELL", 91, 98], ["TERT", "PROTEIN", 28, 32], ["cancer cells", "CELL_TYPE", 67, 79], ["overexpression of TERT", "PROBLEM", 10, 32], ["cancer cells", "PROBLEM", 67, 79]]], ["In this study, we also found that the expression of TERT was higher in the NPC tissues compared to the non-cancer nasopharyngeal tissues.", [["NPC tissues", "ANATOMY", 75, 86], ["non-cancer nasopharyngeal tissues", "ANATOMY", 103, 136], ["non-cancer", "DISEASE", 103, 113], ["TERT", "GENE_OR_GENE_PRODUCT", 52, 56], ["NPC tissues", "TISSUE", 75, 86], ["non-cancer nasopharyngeal tissues", "TISSUE", 103, 136], ["TERT", "PROTEIN", 52, 56], ["this study", "TEST", 3, 13], ["the expression of TERT", "PROBLEM", 34, 56], ["the non-cancer nasopharyngeal tissues", "PROBLEM", 99, 136], ["TERT", "OBSERVATION", 52, 56], ["higher", "OBSERVATION_MODIFIER", 61, 67], ["NPC tissues", "ANATOMY", 75, 86], ["non-cancer", "OBSERVATION", 103, 113], ["nasopharyngeal tissues", "ANATOMY", 114, 136]]], ["Our results, together with those of the earlier studies, suggest that TERT plays an important role in NPC carcinogenesis.", [["NPC", "ANATOMY", 102, 105], ["carcinogenesis", "DISEASE", 106, 120], ["TERT", "GENE_OR_GENE_PRODUCT", 70, 74], ["NPC", "CANCER", 102, 105], ["TERT", "PROTEIN", 70, 74], ["the earlier studies", "TEST", 36, 55], ["NPC carcinogenesis", "PROBLEM", 102, 120]]], ["CLPTM1L encodes a predicted transmembrane protein, which plays an important role in carcinogenesis.", [["transmembrane", "ANATOMY", 28, 41], ["carcinogenesis", "DISEASE", 84, 98], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 0, 7], ["transmembrane", "CELLULAR_COMPONENT", 28, 41], ["CLPTM1L", "PROTEIN", 0, 7], ["transmembrane protein", "PROTEIN", 28, 49], ["a predicted transmembrane protein", "PROBLEM", 16, 49], ["carcinogenesis", "OBSERVATION", 84, 98]]], ["CLPTM1L is upregulated in a cisplatin-resistant ovary cancer cell line and might be involved in the apoptotic response of cells under genotoxic stress caused by cisplatin [9].", [["ovary cancer cell line", "ANATOMY", 48, 70], ["cells", "ANATOMY", 122, 127], ["cisplatin", "CHEMICAL", 28, 37], ["ovary cancer", "DISEASE", 48, 60], ["cisplatin", "CHEMICAL", 161, 170], ["cisplatin", "CHEMICAL", 28, 37], ["cisplatin", "CHEMICAL", 161, 170], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 0, 7], ["cisplatin", "SIMPLE_CHEMICAL", 28, 37], ["ovary cancer cell line", "CELL", 48, 70], ["cells", "CELL", 122, 127], ["cisplatin", "SIMPLE_CHEMICAL", 161, 170], ["CLPTM1L", "PROTEIN", 0, 7], ["cisplatin-resistant ovary cancer cell line", "CELL_LINE", 28, 70], ["a cisplatin-resistant ovary cancer cell line", "TREATMENT", 26, 70], ["genotoxic stress", "PROBLEM", 134, 150], ["cisplatin", "TREATMENT", 161, 170], ["upregulated", "OBSERVATION_MODIFIER", 11, 22], ["resistant", "OBSERVATION_MODIFIER", 38, 47], ["ovary", "ANATOMY", 48, 53], ["cancer cell line", "OBSERVATION", 54, 70], ["genotoxic stress", "OBSERVATION", 134, 150]]], ["CLPTM1L has been reported in the cellular response to genotoxic stress and cisplatin resistance [9].", [["cellular", "ANATOMY", 33, 41], ["CLPTM1L", "CHEMICAL", 0, 7], ["cisplatin", "CHEMICAL", 75, 84], ["cisplatin", "CHEMICAL", 75, 84], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 0, 7], ["cellular", "CELL", 33, 41], ["cisplatin", "SIMPLE_CHEMICAL", 75, 84], ["CLPTM1L", "PROTEIN", 0, 7], ["genotoxic stress", "PROBLEM", 54, 70], ["cisplatin resistance", "TREATMENT", 75, 95], ["genotoxic stress", "OBSERVATION", 54, 70], ["cisplatin resistance", "OBSERVATION", 75, 95]]], ["In addition, over-expression of CLPTM1L has been observed in lung tumors [22].", [["lung tumors", "ANATOMY", 61, 72], ["lung tumors", "DISEASE", 61, 72], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 32, 39], ["lung tumors", "CANCER", 61, 72], ["CLPTM1L", "PROTEIN", 32, 39], ["CLPTM1L", "TREATMENT", 32, 39], ["lung tumors", "PROBLEM", 61, 72], ["lung", "ANATOMY", 61, 65], ["tumors", "OBSERVATION", 66, 72]]], ["In this study, we found that the expression of CLPTM1L was higher in the NPC tissues compared to the non-cancer nasopharyngeal tissues, suggesting that the CLPTM1Lhas been implicated in NPC carcinogenesis.DISCUSSIONChromosome 5p15.33 is one of the strongest and most consistent association signals for cancer risk [23].", [["NPC tissues", "ANATOMY", 73, 84], ["non-cancer nasopharyngeal tissues", "ANATOMY", 101, 134], ["NPC carcinogenesis.", "ANATOMY", 186, 205], ["cancer", "ANATOMY", 302, 308], ["non-cancer", "DISEASE", 101, 111], ["cancer", "DISEASE", 302, 308], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 47, 54], ["NPC tissues", "TISSUE", 73, 84], ["non-cancer nasopharyngeal tissues", "TISSUE", 101, 134], ["CLPTM1Lhas", "GENE_OR_GENE_PRODUCT", 156, 166], ["NPC", "CANCER", 186, 189], ["cancer", "CANCER", 302, 308], ["CLPTM1L", "PROTEIN", 47, 54], ["CLPTM1Lhas", "PROTEIN", 156, 166], ["this study", "TEST", 3, 13], ["the expression of CLPTM1L", "PROBLEM", 29, 54], ["the non-cancer nasopharyngeal tissues", "PROBLEM", 97, 134], ["cancer risk", "PROBLEM", 302, 313], ["higher", "OBSERVATION_MODIFIER", 59, 65], ["NPC tissues", "ANATOMY", 73, 84], ["non-cancer", "OBSERVATION", 101, 111], ["nasopharyngeal tissues", "ANATOMY", 112, 134]]], ["Both GWAS and candidate gene association studies have identified common variants in 5p15.33 that reproducibly associate with several types of cancer.", [["cancer", "ANATOMY", 142, 148], ["cancer", "DISEASE", 142, 148], ["cancer", "CANCER", 142, 148], ["gene association studies", "TEST", 24, 48], ["cancer", "PROBLEM", 142, 148], ["cancer", "OBSERVATION", 142, 148]]], ["In 2008, McKay et al. carried out a GWAS of lung cancer, and two independent polymorphisms, rs402710 and rs2736100, were detected [12].", [["lung cancer", "ANATOMY", 44, 55], ["lung cancer", "DISEASE", 44, 55], ["lung cancer", "CANCER", 44, 55], ["rs2736100", "GENE_OR_GENE_PRODUCT", 105, 114], ["lung cancer", "PROBLEM", 44, 55], ["lung", "ANATOMY", 44, 48], ["cancer", "OBSERVATION", 49, 55]]], ["Another GWAS of lung cancer identified another associated polymorphism: rs401681 [11].", [["lung cancer", "ANATOMY", 16, 27], ["lung cancer", "DISEASE", 16, 27], ["lung cancer", "CANCER", 16, 27], ["lung cancer", "PROBLEM", 16, 27], ["lung", "ANATOMY", 16, 20], ["cancer", "OBSERVATION", 21, 27]]], ["Subsequently, Rafnar et al. found that the rs401681 polymorphism was associated with the risk of basal cell, lung, urinary bladder, prostate and cervical cancers and cutaneous melanoma, and rs2736098, a synonymous coding SNP in exon 2 of the TERT gene, was associated with the risk of basal cell, lung, urinary bladder, and prostate cancers [10, 24].", [["basal cell", "ANATOMY", 97, 107], ["lung", "ANATOMY", 109, 113], ["urinary bladder", "ANATOMY", 115, 130], ["prostate", "ANATOMY", 132, 140], ["cervical cancers", "ANATOMY", 145, 161], ["cutaneous melanoma", "ANATOMY", 166, 184], ["basal cell", "ANATOMY", 285, 295], ["lung", "ANATOMY", 297, 301], ["urinary bladder", "ANATOMY", 303, 318], ["prostate cancers", "ANATOMY", 324, 340], ["basal cell, lung, urinary bladder, prostate and cervical cancers", "DISEASE", 97, 161], ["cutaneous melanoma", "DISEASE", 166, 184], ["basal cell, lung, urinary bladder, and prostate cancers", "DISEASE", 285, 340], ["rs401681", "GENE_OR_GENE_PRODUCT", 43, 51], ["basal cell", "CELL", 97, 107], ["lung", "ORGAN", 109, 113], ["urinary bladder", "CANCER", 115, 130], ["prostate", "CANCER", 132, 140], ["cervical cancers", "CANCER", 145, 161], ["cutaneous melanoma", "CANCER", 166, 184], ["rs2736098", "GENE_OR_GENE_PRODUCT", 190, 199], ["TERT", "GENE_OR_GENE_PRODUCT", 242, 246], ["basal cell", "CELL", 285, 295], ["lung", "ORGAN", 297, 301], ["urinary bladder", "CANCER", 303, 318], ["prostate cancers", "CANCER", 324, 340], ["rs401681", "DNA", 43, 51], ["exon 2", "DNA", 228, 234], ["TERT gene", "DNA", 242, 251], ["basal cell, lung, urinary bladder", "PROBLEM", 97, 130], ["prostate and cervical cancers", "PROBLEM", 132, 161], ["cutaneous melanoma", "PROBLEM", 166, 184], ["a synonymous coding SNP", "TREATMENT", 201, 224], ["basal cell, lung, urinary bladder", "PROBLEM", 285, 318], ["prostate cancers", "PROBLEM", 324, 340], ["basal cell", "OBSERVATION", 97, 107], ["lung", "ANATOMY", 109, 113], ["urinary bladder", "ANATOMY", 115, 130], ["prostate", "ANATOMY", 132, 140], ["cervical", "ANATOMY", 145, 153], ["cancers", "OBSERVATION", 154, 161], ["cutaneous", "ANATOMY", 166, 175], ["melanoma", "OBSERVATION", 176, 184], ["basal cell", "OBSERVATION", 285, 295], ["lung", "ANATOMY", 297, 301], ["urinary bladder", "ANATOMY", 303, 318], ["prostate", "ANATOMY", 324, 332], ["cancers", "OBSERVATION", 333, 340]]], ["Additionally, a meta-analysis of two GWAS of glioma demonstrated that the rs2736100 polymorphism was associated with the risk of glioma [16].", [["glioma", "ANATOMY", 45, 51], ["glioma", "ANATOMY", 129, 135], ["glioma", "DISEASE", 45, 51], ["glioma", "DISEASE", 129, 135], ["glioma", "CANCER", 45, 51], ["rs2736100", "GENE_OR_GENE_PRODUCT", 74, 83], ["glioma", "CANCER", 129, 135], ["rs2736100 polymorphism", "DNA", 74, 96], ["a meta-analysis", "TEST", 14, 29], ["two GWAS of glioma", "PROBLEM", 33, 51], ["the rs2736100 polymorphism", "PROBLEM", 70, 96], ["glioma", "PROBLEM", 129, 135], ["glioma", "OBSERVATION", 45, 51], ["glioma", "OBSERVATION", 129, 135]]], ["Petersen et al. conducted a GWAS of pancreatic cancer, and rs401681 was one of the most significantly associated polymorphisms [14].", [["pancreatic cancer", "ANATOMY", 36, 53], ["pancreatic cancer", "DISEASE", 36, 53], ["pancreatic cancer", "CANCER", 36, 53], ["rs401681", "GENE_OR_GENE_PRODUCT", 59, 67], ["pancreatic cancer", "PROBLEM", 36, 53], ["pancreatic", "ANATOMY", 36, 46], ["cancer", "OBSERVATION", 47, 53]]], ["GWAS of a testicular germ cell tumor identified two independently associated polymorphisms in the TERT-CLPTM1L locus, rs4635969 and rs2736100 [15].", [["testicular germ cell tumor", "ANATOMY", 10, 36], ["testicular germ cell tumor", "DISEASE", 10, 36], ["testicular germ cell tumor", "CANCER", 10, 36], ["TERT", "GENE_OR_GENE_PRODUCT", 98, 102], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 103, 110], ["TERT-CLPTM1L locus", "DNA", 98, 116], ["a testicular germ cell tumor", "PROBLEM", 8, 36], ["testicular", "ANATOMY", 10, 20], ["germ cell tumor", "OBSERVATION", 21, 36], ["polymorphisms", "OBSERVATION_MODIFIER", 77, 90]]], ["Association studies of candidate gene strategies also reported that SNPs in TERT were associated with serous ovarian, breast, and endometrial cancers [25\u201327].", [["serous ovarian", "ANATOMY", 102, 116], ["breast", "ANATOMY", 118, 124], ["endometrial cancers", "ANATOMY", 130, 149], ["serous ovarian, breast, and endometrial cancers", "DISEASE", 102, 149], ["TERT", "GENE_OR_GENE_PRODUCT", 76, 80], ["serous ovarian", "CANCER", 102, 116], ["breast", "CANCER", 118, 124], ["endometrial cancers", "CANCER", 130, 149], ["TERT", "DNA", 76, 80], ["Association studies", "TEST", 0, 19], ["gene strategies", "TREATMENT", 33, 48], ["SNPs in TERT", "PROBLEM", 68, 80], ["serous ovarian, breast", "PROBLEM", 102, 124], ["endometrial cancers", "PROBLEM", 130, 149], ["ovarian", "ANATOMY", 109, 116], ["breast", "ANATOMY", 118, 124], ["endometrial", "ANATOMY", 130, 141], ["cancers", "OBSERVATION", 142, 149]]], ["With regard to NPC, Fachiroh et al. and Ko et al. have reported that certain polymorphisms in the TERT gene were associated with NPC risk in Thailand [28, 29].", [["NPC", "ANATOMY", 15, 18], ["NPC", "ANATOMY", 129, 132], ["NPC", "DISEASE", 15, 18], ["NPC", "DISEASE", 129, 132], ["NPC", "CANCER", 15, 18], ["TERT", "GENE_OR_GENE_PRODUCT", 98, 102], ["NPC", "CANCER", 129, 132], ["NPC", "PROTEIN", 15, 18], ["TERT gene", "DNA", 98, 107], ["NPC", "PROBLEM", 15, 18], ["NPC", "ANATOMY", 15, 18]]], ["In this study, we found that two independent SNPs, rs2735845 and rs401681, were significantly associated with the risk of NPC.", [["NPC", "ANATOMY", 122, 125], ["NPC", "DISEASE", 122, 125], ["rs2735845", "GENE_OR_GENE_PRODUCT", 51, 60], ["rs401681", "GENE_OR_GENE_PRODUCT", 65, 73], ["NPC", "CANCER", 122, 125], ["this study", "TEST", 3, 13], ["NPC", "PROBLEM", 122, 125], ["NPC", "OBSERVATION", 122, 125]]], ["Our results, together with those of the earlier studies, suggest that the TERT-CLPTM1L locus may be a susceptibility region for NPC.DISCUSSIONThe molecular mechanism by which the rs401681 and rs2735845 polymorphisms confer cancer risk is not well characterized.", [["NPC", "ANATOMY", 128, 131], ["cancer", "ANATOMY", 223, 229], ["NPC", "DISEASE", 128, 131], ["cancer", "DISEASE", 223, 229], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 74, 86], ["NPC", "CANCER", 128, 131], ["rs401681", "GENE_OR_GENE_PRODUCT", 179, 187], ["rs2735845", "GENE_OR_GENE_PRODUCT", 192, 201], ["cancer", "CANCER", 223, 229], ["TERT-CLPTM1L locus", "DNA", 74, 92], ["rs401681 and rs2735845 polymorphisms", "DNA", 179, 215], ["the earlier studies", "TEST", 36, 55], ["the TERT-CLPTM1L locus", "PROBLEM", 70, 92], ["NPC", "PROBLEM", 128, 131], ["polymorphisms confer cancer risk", "PROBLEM", 202, 234], ["cancer", "OBSERVATION", 223, 229], ["well characterized", "OBSERVATION_MODIFIER", 242, 260]]], ["The rs2735845 polymorphism, which resides in the intergenic region, was never reported before.", [["rs2735845", "GENE_OR_GENE_PRODUCT", 4, 13], ["rs2735845 polymorphism", "DNA", 4, 26], ["intergenic region", "DNA", 49, 66], ["rs2735845", "OBSERVATION_MODIFIER", 4, 13], ["polymorphism", "OBSERVATION", 14, 26], ["intergenic", "ANATOMY_MODIFIER", 49, 59], ["region", "ANATOMY_MODIFIER", 60, 66]]], ["The rs401681 polymorphism, which resides in an LD block that contains the CLPTM1L gene and the 5\u2032 end of the TERT gene, is one of the most extensively studied polymorphisms in the TERT-CLPTM1L locus.", [["rs401681", "GENE_OR_GENE_PRODUCT", 4, 12], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 74, 81], ["TERT", "GENE_OR_GENE_PRODUCT", 109, 113], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 180, 192], ["rs401681 polymorphism", "DNA", 4, 25], ["LD block", "DNA", 47, 55], ["CLPTM1L gene", "DNA", 74, 86], ["5\u2032 end", "DNA", 95, 101], ["TERT gene", "DNA", 109, 118], ["TERT-CLPTM1L locus", "DNA", 180, 198], ["an LD block", "PROBLEM", 44, 55], ["LD block", "OBSERVATION", 47, 55], ["TERT gene", "OBSERVATION", 109, 118], ["TERT-CLPTM1L locus", "OBSERVATION", 180, 198]]], ["Rafnar et al. reported that the rs401681 polymorphism may lead to an increase in the gradual shortening of telomeres over time, but the effect may only become apparent after a certain age [10].", [["telomeres", "ANATOMY", 107, 116], ["rs401681", "GENE_OR_GENE_PRODUCT", 32, 40], ["telomeres", "CELLULAR_COMPONENT", 107, 116], ["rs401681", "DNA", 32, 40], ["the rs401681 polymorphism", "PROBLEM", 28, 53], ["an increase", "PROBLEM", 66, 77], ["the gradual shortening of telomeres", "PROBLEM", 81, 116], ["increase", "OBSERVATION_MODIFIER", 69, 77], ["gradual", "OBSERVATION_MODIFIER", 85, 92], ["shortening", "OBSERVATION_MODIFIER", 93, 103]]], ["In this study, we did not find any association between rs401681 genotypes and TERT and CLPTM1L mRNA levels.", [["rs401681", "GENE_OR_GENE_PRODUCT", 55, 63], ["TERT", "GENE_OR_GENE_PRODUCT", 78, 82], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 87, 94], ["CLPTM1L mRNA", "RNA", 87, 99], ["this study", "TEST", 3, 13], ["genotypes", "TEST", 64, 73], ["TERT", "TEST", 78, 82], ["CLPTM1L mRNA levels", "TEST", 87, 106]]], ["We found that the CLPTM1L mRNA levels transcribed by the rs2735845 G allele were higher than those transcribed by the CC genotype in fMSCs.", [["fMSCs", "ANATOMY", 133, 138], ["CC", "CHEMICAL", 118, 120], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 18, 25], ["rs2735845", "GENE_OR_GENE_PRODUCT", 57, 66], ["G", "GENE_OR_GENE_PRODUCT", 67, 68], ["fMSCs", "CELL", 133, 138], ["CLPTM1L mRNA", "RNA", 18, 30], ["G allele", "DNA", 67, 75], ["fMSCs", "CELL_TYPE", 133, 138], ["the CLPTM1L mRNA levels", "PROBLEM", 14, 37], ["G allele", "PROBLEM", 67, 75], ["higher", "OBSERVATION_MODIFIER", 81, 87]]], ["However, the difference in the induction of the reporter gene expression between the rs2735845 two alleles is not statistically significant (data not shown).", [["rs2735845", "GENE_OR_GENE_PRODUCT", 85, 94], ["reporter gene", "DNA", 48, 61], ["rs2735845 two alleles", "DNA", 85, 106]]], ["Further studies are warranted to elucidate the molecular mechanism of these two polymorphisms.DISCUSSIONWhen reviewing the results of this study, several potential limits should be kept in mind.", [["Further studies", "TEST", 0, 15], ["this study", "TEST", 134, 144]]], ["First, in this hospital-based study, our patients were enrolled from hospitals, and the controls were selected from the community population; thus, inherent selection bias cannot be completely excluded.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["based study", "TEST", 24, 35], ["inherent selection bias", "PROBLEM", 148, 171], ["cannot be completely excluded", "UNCERTAINTY", 172, 201]]], ["However, through further adjustment and stratification in the data analyses, the potential confounding effect might have been minimized.", [["the data analyses", "TEST", 58, 75]]], ["Second, a tag SNP approach has been shown to improve the power of the study for common genetic variants; however, the modest effects from rare genetic variants may remain undetected.", [["SNP", "CHEMICAL", 14, 17], ["a tag SNP approach", "TREATMENT", 8, 26], ["the study", "TEST", 66, 75], ["common genetic variants", "PROBLEM", 80, 103], ["the modest effects from rare genetic variants", "PROBLEM", 114, 159], ["modest", "OBSERVATION_MODIFIER", 118, 124], ["genetic variants", "OBSERVATION", 143, 159]]], ["Deep re-sequencing of the TERT-CLPTM1L locus may provide further help to uncover additional associated variants and to facilitate selection of potential causal variants for further functional studies.DISCUSSIONIn conclusion, our study shows an association between the genetic variations in the TERT-CLPTM1L locus and the risk of occurrence of NPC in two Chinese subpopulations.", [["NPC", "ANATOMY", 343, 346], ["NPC", "DISEASE", 343, 346], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 26, 38], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 294, 306], ["NPC", "CANCER", 343, 346], ["TERT-CLPTM1L locus", "DNA", 26, 44], ["TERT-CLPTM1L locus", "DNA", 294, 312], ["Deep re-sequencing", "TEST", 0, 18], ["the TERT-CLPTM1L locus", "TREATMENT", 22, 44], ["additional associated variants", "PROBLEM", 81, 111], ["potential causal variants", "PROBLEM", 143, 168], ["further functional studies", "TEST", 173, 199], ["our study", "TEST", 225, 234], ["NPC", "PROBLEM", 343, 346], ["NPC", "OBSERVATION", 343, 346]]], ["These findings may provide support for the importance of the TERT-CLPTM1L locus in the pathogenesis of NPC.", [["NPC", "ANATOMY", 103, 106], ["NPC", "DISEASE", 103, 106], ["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 61, 73], ["NPC", "CANCER", 103, 106], ["TERT-CLPTM1L locus", "DNA", 61, 79], ["the TERT-CLPTM1L locus", "TREATMENT", 57, 79], ["NPC", "PROBLEM", 103, 106], ["NPC", "ANATOMY", 103, 106]]], ["If confirmed by other studies, knowledge of genetic factors contributing to the pathogenesis of the NPC as presented here may have implications for the screening and treatment of this disorder.Study population ::: MATERIALS AND METHODSThis study consisted of two populations of patients with NPC and controls residing in Guangxi and Guangdong provinces, both of which are located in southern China (see Supplementary Materials, Table S2).", [["NPC", "ANATOMY", 100, 103], ["NPC", "ANATOMY", 292, 295], ["NPC", "DISEASE", 100, 103], ["NPC", "DISEASE", 292, 295], ["NPC", "CANCER", 100, 103], ["patients", "ORGANISM", 278, 286], ["NPC", "CANCER", 292, 295], ["patients", "SPECIES", 278, 286], ["other studies", "TEST", 16, 29], ["genetic factors", "PROBLEM", 44, 59], ["the NPC", "PROBLEM", 96, 103], ["the screening", "TEST", 148, 161], ["treatment", "TREATMENT", 166, 175], ["this disorder", "PROBLEM", 179, 192], ["METHODSThis study", "TEST", 228, 245], ["NPC", "TREATMENT", 292, 295]]], ["The Guangxi population, which was used for the 1st stage scanning analysis, consisted of 855 patients with NPC and 1036 controls.", [["NPC", "ANATOMY", 107, 110], ["NPC", "DISEASE", 107, 110], ["patients", "ORGANISM", 93, 101], ["NPC", "CANCER", 107, 110], ["patients", "SPECIES", 93, 101], ["the 1st stage scanning analysis", "TEST", 43, 74], ["NPC", "TREATMENT", 107, 110]]], ["The diagnosis of patients, the inclusion and exclusion criteria for patients and controls, and the definition of smokers and drinkers were described in detail in our previous studies [30].", [["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 68, 76], ["smokers", "ORGANISM", 113, 120], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 68, 76], ["exclusion criteria", "TEST", 45, 63]]], ["Briefly, the patients with NPC were newly diagnosed and pathologically confirmed, and they were consecutively recruited at the Guangxi Cancer Hospital (Nanning, China) between September 2003 and January 2008.", [["NPC", "ANATOMY", 27, 30], ["NPC", "DISEASE", 27, 30], ["Cancer", "DISEASE", 135, 141], ["patients", "ORGANISM", 13, 21], ["NPC", "CANCER", 27, 30], ["patients", "SPECIES", 13, 21], ["NPC", "PROBLEM", 27, 30]]], ["The response rate for case patients was 95%.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35]]], ["Patients who received chemotherapy or radiotherapy before surgery or had another type of cancer were excluded from this study.", [["cancer", "ANATOMY", 89, 95], ["cancer", "DISEASE", 89, 95], ["Patients", "ORGANISM", 0, 8], ["cancer", "CANCER", 89, 95], ["Patients", "SPECIES", 0, 8], ["chemotherapy", "TREATMENT", 22, 34], ["radiotherapy", "TREATMENT", 38, 50], ["surgery", "TREATMENT", 58, 65], ["cancer", "PROBLEM", 89, 95], ["this study", "TEST", 115, 125], ["cancer", "OBSERVATION", 89, 95]]], ["The controls were randomly selected from a community cancer screening program for early detection of cancer conducted in the same regions during the same time period in which the NPC patients were collected.", [["cancer", "ANATOMY", 53, 59], ["cancer", "ANATOMY", 101, 107], ["NPC", "ANATOMY", 179, 182], ["cancer", "DISEASE", 53, 59], ["cancer", "DISEASE", 101, 107], ["NPC", "DISEASE", 179, 182], ["cancer", "CANCER", 53, 59], ["cancer", "CANCER", 101, 107], ["NPC", "CANCER", 179, 182], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["a community cancer screening program", "TREATMENT", 41, 77], ["cancer", "PROBLEM", 101, 107], ["cancer", "OBSERVATION", 101, 107]]], ["The response rate for control subjects was 91%.", [["The response rate", "TEST", 0, 17]]], ["The selection criteria for the controls included no individual history of cancer.", [["cancer", "ANATOMY", 74, 80], ["cancer", "DISEASE", 74, 80], ["cancer", "CANCER", 74, 80], ["The selection criteria", "TEST", 0, 22], ["cancer", "PROBLEM", 74, 80], ["cancer", "OBSERVATION", 74, 80]]], ["The Guangdong population, which was used for the 2nd stage replication analysis, consisted of 997 patients and 972 controls.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["The Guangdong population", "TREATMENT", 0, 24], ["the 2nd stage replication analysis", "TEST", 45, 79]]], ["The diagnosis of patients and the inclusion and exclusion criteria for patients and controls were described in detail previously [31].", [["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 71, 79]]], ["Briefly, the patients with NPC were newly diagnosed and pathologically confirmed, and they were consecutively recruited from Sun Yat-sen University Cancer Center (SYSUCC, Guangzhou, China) between October 2005 and October 2007.", [["NPC", "ANATOMY", 27, 30], ["NPC", "DISEASE", 27, 30], ["Cancer", "DISEASE", 148, 154], ["patients", "ORGANISM", 13, 21], ["NPC", "CANCER", 27, 30], ["patients", "SPECIES", 13, 21], ["NPC", "PROBLEM", 27, 30]]], ["Only the patients who were self-reported as Guangdong Chinese and who lived in Guangdong province were recruited.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["During the same period, healthy controls were recruited from physical examination centers of several large comprehensive hospitals in the local communities of Guangdong.", [["physical examination", "TEST", 61, 81], ["large", "OBSERVATION_MODIFIER", 101, 106]]], ["The selection criteria for the controls included no individual history of cancer.", [["cancer", "ANATOMY", 74, 80], ["cancer", "DISEASE", 74, 80], ["cancer", "CANCER", 74, 80], ["The selection criteria", "TEST", 0, 22], ["cancer", "PROBLEM", 74, 80], ["cancer", "OBSERVATION", 74, 80]]], ["The response rate for cases and control was 90%.", [["The response rate", "TEST", 0, 17]]], ["For both populations, tumor staging was performed according to the tumor-node-metastasis (TNM) classification of the 1997 American Joint Committee on Cancer (AJCC) system.", [["tumor", "ANATOMY", 22, 27], ["tumor-node", "ANATOMY", 67, 77], ["Cancer", "ANATOMY", 150, 156], ["tumor", "DISEASE", 22, 27], ["tumor", "DISEASE", 67, 72], ["Cancer", "DISEASE", 150, 156], ["AJCC", "DISEASE", 158, 162], ["tumor", "CANCER", 22, 27], ["tumor", "CANCER", 67, 72], ["Joint Committee on Cancer", "CANCER", 131, 156], ["tumor staging", "TEST", 22, 35], ["metastasis", "PROBLEM", 78, 88], ["Cancer (AJCC) system", "TREATMENT", 150, 170], ["tumor", "OBSERVATION", 22, 27], ["tumor", "OBSERVATION", 67, 72], ["node", "ANATOMY", 73, 77], ["metastasis", "OBSERVATION", 78, 88], ["Joint", "ANATOMY", 131, 136], ["Cancer", "OBSERVATION", 150, 156]]], ["All TNM classifications were determined by senior pathologists of the hospital on the basis of the postoperative histopathologic examination.Study population ::: MATERIALS AND METHODSOf the patients with NPC in the Guangxi population, 41 patients who had undergone resection before receiving any further treatment at Guangxi Cancer Hospital were selected, and primary NPC biopsies were collected from them (see Supplementary Materials, Table S3).", [["NPC", "ANATOMY", 204, 207], ["primary NPC biopsies", "ANATOMY", 360, 380], ["NPC", "DISEASE", 204, 207], ["Cancer", "DISEASE", 325, 331], ["patients", "ORGANISM", 190, 198], ["NPC", "CANCER", 204, 207], ["patients", "ORGANISM", 238, 246], ["NPC biopsies", "CANCER", 368, 380], ["patients", "SPECIES", 190, 198], ["patients", "SPECIES", 238, 246], ["the postoperative histopathologic examination", "TEST", 95, 140], ["NPC", "TREATMENT", 204, 207], ["resection", "TREATMENT", 265, 274], ["any further treatment", "TREATMENT", 292, 313], ["primary NPC biopsies", "TEST", 360, 380], ["resection", "OBSERVATION", 265, 274]]], ["All 41 tumor tissues were poorly differentiated squamous cell carcinoma (SCC).", [["tumor tissues", "ANATOMY", 7, 20], ["squamous cell carcinoma", "ANATOMY", 48, 71], ["SCC", "ANATOMY", 73, 76], ["tumor", "DISEASE", 7, 12], ["squamous cell carcinoma", "DISEASE", 48, 71], ["SCC", "DISEASE", 73, 76], ["tumor tissues", "TISSUE", 7, 20], ["squamous cell carcinoma", "CANCER", 48, 71], ["SCC", "CANCER", 73, 76], ["All 41 tumor tissues", "PROBLEM", 0, 20], ["poorly differentiated squamous cell carcinoma", "PROBLEM", 26, 71], ["tumor tissues", "OBSERVATION", 7, 20], ["poorly differentiated", "OBSERVATION_MODIFIER", 26, 47], ["squamous cell carcinoma", "OBSERVATION", 48, 71]]], ["Histological non-cancerous nasopharyngeal epithelium tissues were collected from 13 of the 1036 control subjects in the Guangxi population (see Supplementary Materials, Table S3).", [["non-cancerous nasopharyngeal epithelium tissues", "ANATOMY", 13, 60], ["non-cancerous nasopharyngeal epithelium tissues", "TISSUE", 13, 60], ["Histological non-cancerous nasopharyngeal epithelium tissues", "PROBLEM", 0, 60], ["non-cancerous", "OBSERVATION_MODIFIER", 13, 26], ["nasopharyngeal", "ANATOMY", 27, 41], ["epithelium tissues", "OBSERVATION", 42, 60]]], ["All of the tissues were fixed in paraformaldehyde, embedded in paraffin wax, and prepared for IHC staining.Study population ::: MATERIALS AND METHODSFor TERT and CLPTM1L expression assays, human umbilical cord (UC) was obtained from a group of 12 normal full-term-delivery women.", [["tissues", "ANATOMY", 11, 18], ["umbilical cord", "ANATOMY", 195, 209], ["UC", "ANATOMY", 211, 213], ["paraformaldehyde", "CHEMICAL", 33, 49], ["tissues", "TISSUE", 11, 18], ["paraformaldehyde", "SIMPLE_CHEMICAL", 33, 49], ["TERT", "GENE_OR_GENE_PRODUCT", 153, 157], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 162, 169], ["human", "ORGANISM", 189, 194], ["umbilical cord", "MULTI-TISSUE_STRUCTURE", 195, 209], ["UC", "PATHOLOGICAL_FORMATION", 211, 213], ["women", "ORGANISM", 273, 278], ["TERT", "PROTEIN", 153, 157], ["CLPTM1L", "PROTEIN", 162, 169], ["human", "SPECIES", 189, 194], ["women", "SPECIES", 273, 278], ["human", "SPECIES", 189, 194], ["paraformaldehyde", "TREATMENT", 33, 49], ["IHC staining", "PROBLEM", 94, 106], ["METHODSFor TERT", "TREATMENT", 142, 157], ["CLPTM1L expression assays", "TEST", 162, 187], ["tissues", "ANATOMY", 11, 18], ["fixed", "OBSERVATION_MODIFIER", 24, 29], ["paraffin wax", "OBSERVATION", 63, 75], ["umbilical cord", "ANATOMY", 195, 209]]], ["At recruitment, informed consent was obtained from all participants, and personal information about demographic factors and medical history and tobacco and alcohol use was collected via structured questionnaire.", [["alcohol", "CHEMICAL", 156, 163], ["alcohol", "CHEMICAL", 156, 163], ["tobacco", "ORGANISM", 144, 151], ["alcohol", "SIMPLE_CHEMICAL", 156, 163], ["participants", "SPECIES", 55, 67], ["tobacco", "SPECIES", 144, 151]]], ["This study was performed with the approval of the Ethical Committee of Beijing Institute of Radiation Medicine and conducted according to the principles expressed in the Declaration of Helsinki.Selection of SNPs ::: MATERIALS AND METHODSUsing the tagger program implemented in Haploview 4.1 [32], tag SNPs across the 115-kb of TERT-CLPTM1L locus on 5p15.33 (chr5:1,301,873\u20131,417,242) were selected on the basis of linkage disequilibrium (LD) patterns observed in the population of Han Chinese in Beijing, China (CHB), and genotyped as part of the International HapMap Project (data Rel 24/phase II, http://www.hapmap.org) (see Supplementary Materials, Figure S1).", [["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 327, 339], ["tag SNPs", "DNA", 297, 305], ["TERT-CLPTM1L locus", "DNA", 327, 345], ["This study", "TEST", 0, 10], ["Radiation Medicine", "TREATMENT", 92, 110], ["the tagger program", "TREATMENT", 243, 261], ["tag SNPs", "TEST", 297, 305], ["TERT-CLPTM1L locus", "TEST", 327, 345], ["linkage disequilibrium (LD) patterns", "PROBLEM", 414, 450], ["China (CHB)", "TREATMENT", 505, 516]]], ["Two well-studied functional SNPs in the TERT gene (rs2853669 and rs2735940) and six SNPs (rs2736100, rs2736098, rs4975616, rs402710, rs401681, rs31489) reported in the GWAS studied were directly included as tag SNPs using the forced inclusion option [10\u201312, 33, 34].", [["TERT", "GENE_OR_GENE_PRODUCT", 40, 44], ["rs2853669", "GENE_OR_GENE_PRODUCT", 51, 60], ["TERT gene", "DNA", 40, 49], ["rs2853669", "DNA", 51, 60], ["rs2735940", "DNA", 65, 74], ["rs2736100", "DNA", 90, 99], ["rs402710", "DNA", 123, 131], ["rs31489", "DNA", 143, 150], ["tag SNPs", "DNA", 207, 215], ["six SNPs", "TEST", 80, 88], ["rs", "TEST", 90, 92], ["the forced inclusion option", "TREATMENT", 222, 249]]], ["In addition, 18 additional tag SNPs (rs3803309, rs4983540, rs3809454, rs3803304, rs2494738, rs2494743, rs2494750, rs4983559, rs2498806, rs10139525, rs8010024 and rs2582519) were selected with a pairwise r2 of > 0.80 and a minor allele frequency of \u2265 0.01 on the basis of HapMap CHB data.", [["rs2494738", "GENE_OR_GENE_PRODUCT", 81, 90], ["rs2494743", "GENE_OR_GENE_PRODUCT", 92, 101], ["rs2494750", "GENE_OR_GENE_PRODUCT", 103, 112], ["rs4983559", "GENE_OR_GENE_PRODUCT", 114, 123], ["rs2498806", "GENE_OR_GENE_PRODUCT", 125, 134], ["rs10139525", "GENE_OR_GENE_PRODUCT", 136, 146], ["rs2582519", "GENE_OR_GENE_PRODUCT", 162, 171], ["tag SNPs", "DNA", 27, 35], ["a pairwise r2", "TEST", 192, 205], ["HapMap CHB data", "TEST", 271, 286]]], ["Overall, 26 tag SNPs in the TERT-CLPTM1L locus were selected for further genotyping (see Supplementary Materials, Table S4).Genotype analysis ::: MATERIALS AND METHODSIn the stage I association study, 15 SNPs were genotyped using the MassArray System (Sequenom) with primers (see Supplementary Materials, Table S6) that were described previously [35].", [["TERT-CLPTM1L", "GENE_OR_GENE_PRODUCT", 28, 40], ["TERT-CLPTM1L locus", "DNA", 28, 46], ["26 tag SNPs", "TREATMENT", 9, 20], ["the TERT-CLPTM1L locus", "TREATMENT", 24, 46], ["further genotyping", "TEST", 65, 83], ["Genotype analysis", "TEST", 124, 141], ["association study", "TEST", 182, 199], ["the MassArray System", "TEST", 230, 250], ["primers", "TEST", 267, 274], ["26 tag", "OBSERVATION_MODIFIER", 9, 15]]], ["All 15 SNPs had genotyping call rates of 95% or better.", [["genotyping call rates", "TEST", 16, 37]]], ["Nine SNPs were genotyped using the SNPstream ultra-high throughput genotyping system (Beckman Coulter, Fullerton, CA) according to the manufacturer's instructions, as described previously [36].", [["Nine SNPs", "TREATMENT", 0, 9], ["the SNPstream ultra-high throughput genotyping system", "TREATMENT", 31, 84]]], ["The primer sequences are listed in Table S6 in Supplementary Materials 1.", [["primer sequences", "DNA", 4, 20], ["The primer sequences", "TEST", 0, 20]]], ["The s2736118 polymorphism was eliminated because of poor genotyping reliability.", [["The s2736118 polymorphism", "TEST", 0, 25], ["poor genotyping reliability", "PROBLEM", 52, 79]]], ["The remaining eight SNPs had genotyping call rates of 95% or better.", [["genotyping call rates", "TEST", 29, 50]]], ["The rs2736100 polymorphism was genotyped by TaqMan MGB assay (Applied Biosystems, USA) according to the manufacturer's protocol, as described previously [30].", [["rs2736100", "GENE_OR_GENE_PRODUCT", 4, 13], ["rs2736100 polymorphism", "DNA", 4, 26], ["TaqMan MGB assay", "TEST", 44, 60], ["the manufacturer's protocol", "TREATMENT", 100, 127]]], ["The primer and TaqMan probes used for the rs2736100 polymorphism were as follows: 5\u2032-AGACGGGGAACAAAGGAGGA-3\u2032 (forward primer), 5\u2032-AGTTCTATCTCAGGCATCTTGACACC-3\u2032 (reverse primer), 5\u2032-FAM-CAAAGCTAAAGAAACAC-MGB-3\u2032, 5\u2032-HEX-CAAAGCTACAGAAACA-MGB-3\u2032.", [["rs2736100", "GENE_OR_GENE_PRODUCT", 42, 51], ["TaqMan probes", "DNA", 15, 28], ["reverse primer", "DNA", 161, 175], ["5\u2032-HEX-CAAAGCTACAGAAACA", "DNA", 211, 234], ["MGB-3\u2032", "DNA", 235, 241], ["The primer", "TREATMENT", 0, 10], ["TaqMan probes", "TEST", 15, 28], ["the rs2736100 polymorphism", "TEST", 38, 64], ["AGACGGGGAACAAAGGAGGA", "TEST", 85, 105], ["5\u2032-AGTTCTATCTCAGGCATCTTGACACC", "TEST", 127, 156], ["5\u2032-FAM-CAAAGCTAAAGAAACAC", "TEST", 178, 202], ["MGB", "TEST", 203, 206], ["5\u2032-HEX-CAAAGCTACAGAAACA", "TEST", 211, 234], ["MGB", "TEST", 235, 238]]], ["The rs2853669 polymorphism was genotyped using polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [["rs2853669", "GENE_OR_GENE_PRODUCT", 4, 13], ["rs2853669 polymorphism", "DNA", 4, 26], ["RFLP", "DNA", 125, 129], ["polymerase chain reaction", "PROBLEM", 47, 72], ["based restriction fragment length polymorphism", "PROBLEM", 73, 119], ["PCR-RFLP) analysis", "TEST", 121, 139], ["fragment", "OBSERVATION_MODIFIER", 91, 99], ["length", "OBSERVATION_MODIFIER", 100, 106]]], ["The primers and the restriction enzymes used are listed in Table S7 in Supplementary Materials 1.", [["restriction enzymes", "PROTEIN", 20, 39], ["The primers", "TREATMENT", 0, 11], ["the restriction enzymes", "TEST", 16, 39]]], ["The PCR conditions were identical to those used for the SNP discovery described previously [37].Genotype analysis ::: MATERIALS AND METHODSIn the stage II association study, four SNPs (rs2736098, rs2735845, rs401710, and rs401681) were further genotyped in the Guangdong population.", [["SNP", "CHEMICAL", 56, 59], ["rs401681", "GENE_OR_GENE_PRODUCT", 221, 229], ["The PCR conditions", "TEST", 0, 18], ["Genotype analysis", "TEST", 96, 113], ["four SNPs", "TEST", 174, 183]]], ["The genotyping data of the rs401710 and rs401681 polymorphisms were collected from Human610-Quad data published in Bei et al.'s study [31].", [["rs401710", "GENE_OR_GENE_PRODUCT", 27, 35], ["rs401681", "GENE_OR_GENE_PRODUCT", 40, 48], ["Human", "ORGANISM", 83, 88], ["rs401710 and rs401681 polymorphisms", "DNA", 27, 62], ["Human", "SPECIES", 83, 88], ["The genotyping data", "TEST", 0, 19], ["polymorphisms", "TEST", 49, 62], ["Quad data", "TEST", 92, 101], ["Bei et al.'s study", "TEST", 115, 133]]], ["The rs2735845 and rs2736098 polymorphisms were genotyped by PCR-RFLP analysis (Table S6 in Supplementary Materials).", [["rs2735845", "GENE_OR_GENE_PRODUCT", 4, 13], ["rs2736098", "GENE_OR_GENE_PRODUCT", 18, 27], ["rs2735845 and rs2736098 polymorphisms", "DNA", 4, 41], ["polymorphisms", "TEST", 28, 41], ["PCR", "TEST", 60, 63], ["RFLP analysis", "TEST", 64, 77]]], ["The PCR conditions were identical to those for the rs2853669 polymorphism.Genotype analysis ::: MATERIALS AND METHODSGenotyping was performed in a blind manner such that the performers did not know the subjects' patient or control status.", [["rs2853669", "GENE_OR_GENE_PRODUCT", 51, 60], ["patient", "ORGANISM", 212, 219], ["rs2853669 polymorphism", "DNA", 51, 73], ["patient", "SPECIES", 212, 219], ["The PCR conditions", "TEST", 0, 18], ["Genotype analysis", "TEST", 74, 91]]], ["For quality control, a 15% masked, random sample of patients and controls was tested twice by different people, and all results exhibited 100% concordance.", [["patients", "ORGANISM", 52, 60], ["people", "ORGANISM", 104, 110], ["patients", "SPECIES", 52, 60], ["people", "SPECIES", 104, 110]]], ["We also designed PCR-RFLP assays to validate two random SNPs to compare with the results of the Sequneom and SNPstream methods, respectively, in 5% of the patient/control samples; the reproducibility was 98.8%.", [["samples", "ANATOMY", 171, 178], ["patient", "ORGANISM", 155, 162], ["patient", "SPECIES", 155, 162], ["PCR", "TEST", 17, 20], ["RFLP assays", "TEST", 21, 32], ["the reproducibility", "TEST", 180, 199]]], ["In addition, genotypes identified by PCR-RFLP were confirmed by DNA sequencing.Isolation and expansion of fMSCs from UC ::: MATERIALS AND METHODSUC (n = 12) was obtained from normal full-term-delivery women.", [["fMSCs", "ANATOMY", 106, 111], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["fMSCs", "CELL", 106, 111], ["UC", "PATHOLOGICAL_FORMATION", 117, 119], ["women", "ORGANISM", 201, 206], ["RFLP", "DNA", 41, 45], ["fMSCs", "CELL_TYPE", 106, 111], ["women", "SPECIES", 201, 206], ["genotypes", "PROBLEM", 13, 22], ["PCR", "TEST", 37, 40], ["RFLP", "TEST", 41, 45], ["DNA sequencing", "TEST", 64, 78], ["expansion", "OBSERVATION_MODIFIER", 93, 102]]], ["Briefly, after disinfection with 75% ethanol, the fresh UC was transferred to PBS where excess blood on the surface was removed.", [["blood", "ANATOMY", 95, 100], ["surface", "ANATOMY", 108, 115], ["ethanol", "CHEMICAL", 37, 44], ["UC", "CHEMICAL", 56, 58], ["ethanol", "CHEMICAL", 37, 44], ["ethanol", "SIMPLE_CHEMICAL", 37, 44], ["UC", "PATHOLOGICAL_FORMATION", 56, 58], ["blood", "ORGANISM_SUBSTANCE", 95, 100], ["surface", "CELLULAR_COMPONENT", 108, 115], ["disinfection", "TREATMENT", 15, 27], ["excess blood on the surface", "PROBLEM", 88, 115], ["UC", "OBSERVATION", 56, 58]]], ["After removal of blood vessels, 2 cm of UC was sliced into very small pieces followed by treatment with 0.1% collagenase II (Gibco, USA), containing antibiotic solution (100 U/mL penicillin and 100 \u03bcg/mL streptomycin; CSPC, China) in Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) (Gibco) overnight at 37\u00b0C. The cells were cultured in DMEM/F12 supplemented with 10% fetal bovine serum (Hyclone, China) in 5% CO2 in a 37\u00b0C incubator for 3\u20134 days to allow cells to adhere.", [["blood vessels", "ANATOMY", 17, 30], ["cells", "ANATOMY", 313, 318], ["fetal bovine serum", "ANATOMY", 367, 385], ["cells", "ANATOMY", 455, 460], ["penicillin", "CHEMICAL", 179, 189], ["streptomycin", "CHEMICAL", 204, 216], ["CO2", "CHEMICAL", 409, 412], ["penicillin", "CHEMICAL", 179, 189], ["streptomycin", "CHEMICAL", 204, 216], ["CO2", "CHEMICAL", 409, 412], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 17, 30], ["UC", "PATHOLOGICAL_FORMATION", 40, 42], ["penicillin", "SIMPLE_CHEMICAL", 179, 189], ["streptomycin", "SIMPLE_CHEMICAL", 204, 216], ["cells", "CELL", 313, 318], ["bovine", "ORGANISM", 373, 379], ["serum", "ORGANISM_SUBSTANCE", 380, 385], ["Hyclone", "ORGANISM_SUBSTANCE", 387, 394], ["CO2", "SIMPLE_CHEMICAL", 409, 412], ["cells", "CELL", 455, 460], ["bovine", "SPECIES", 373, 379], ["bovine", "SPECIES", 373, 379], ["removal of blood vessels", "TREATMENT", 6, 30], ["2 cm of UC", "TREATMENT", 32, 42], ["treatment", "TREATMENT", 89, 98], ["0.1% collagenase II", "TREATMENT", 104, 123], ["antibiotic solution", "TREATMENT", 149, 168], ["penicillin", "TREATMENT", 179, 189], ["streptomycin", "TREATMENT", 204, 216], ["CSPC", "TREATMENT", 218, 222], ["Dulbecco's Modified Eagle Medium/F12 (DMEM/F12", "TREATMENT", 234, 280], ["a 37\u00b0C incubator", "TREATMENT", 416, 432], ["blood vessels", "ANATOMY", 17, 30], ["UC", "OBSERVATION", 40, 42], ["very", "OBSERVATION_MODIFIER", 59, 63], ["small pieces", "OBSERVATION", 64, 76]]], ["The adherent cells formed colonies and grew rapidly, exhibiting spindle-shaped morphology.", [["cells", "ANATOMY", 13, 18], ["colonies", "ANATOMY", 26, 34], ["spindle", "ANATOMY", 64, 71], ["cells", "CELL", 13, 18], ["adherent cells", "CELL_TYPE", 4, 18], ["adherent cells", "OBSERVATION", 4, 18], ["formed colonies", "OBSERVATION", 19, 34], ["rapidly", "OBSERVATION_MODIFIER", 44, 51], ["spindle", "OBSERVATION_MODIFIER", 64, 71], ["shaped", "OBSERVATION_MODIFIER", 72, 78], ["morphology", "OBSERVATION_MODIFIER", 79, 89]]], ["The medium was replaced every three days.", [["medium", "OBSERVATION_MODIFIER", 4, 10]]], ["When the cells reached to 60\u201380% confluence, they were harvested with trypsin-EDTA solution (Neuronbc, China) and subcultured at a density of 3\u20136\u00d7103 cells/cm2 [38].", [["cells", "ANATOMY", 9, 14], ["cells", "ANATOMY", 150, 155], ["trypsin-EDTA", "CHEMICAL", 70, 82], ["trypsin-EDTA", "CHEMICAL", 70, 82], ["cells", "CELL", 9, 14], ["trypsin-", "SIMPLE_CHEMICAL", 70, 78], ["EDTA", "SIMPLE_CHEMICAL", 78, 82], ["cells", "CELL", 150, 155], ["trypsin-EDTA solution", "TREATMENT", 70, 91]]], ["Amplification of pluripotent stem cell markers, such as Oct-4 and Rex-1, was used to demonstrate primitive properties of the cultured cells, as described previously [39].Real-time analysis of TERT and CLPTM1L messenger RNA (mRNA) expression ::: MATERIALS AND METHODSTotal RNA was extracted from 12 fetal MSCs using Trizol reagent (Invitrogen, USA) according to the manufacturer's protocol.", [["pluripotent stem cell", "ANATOMY", 17, 38], ["cells", "ANATOMY", 134, 139], ["fetal MSCs", "ANATOMY", 298, 308], ["pluripotent stem cell", "CELL", 17, 38], ["Oct-4", "GENE_OR_GENE_PRODUCT", 56, 61], ["Rex-1", "GENE_OR_GENE_PRODUCT", 66, 71], ["cells", "CELL", 134, 139], ["TERT", "GENE_OR_GENE_PRODUCT", 192, 196], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 201, 208], ["fetal MSCs", "CELL", 298, 308], ["pluripotent stem cell markers", "PROTEIN", 17, 46], ["Oct-4", "PROTEIN", 56, 61], ["Rex", "PROTEIN", 66, 69], ["cultured cells", "CELL_LINE", 125, 139], ["TERT and CLPTM1L messenger RNA", "RNA", 192, 222], ["mRNA", "RNA", 224, 228], ["METHODSTotal RNA", "RNA", 259, 275], ["fetal MSCs", "CELL_TYPE", 298, 308], ["pluripotent stem cell markers", "TEST", 17, 46], ["Oct", "TEST", 56, 59], ["TERT", "PROBLEM", 192, 196], ["METHODSTotal RNA", "TREATMENT", 259, 275], ["Trizol reagent", "TREATMENT", 315, 329], ["the manufacturer's protocol", "TREATMENT", 361, 388], ["pluripotent stem cell markers", "OBSERVATION", 17, 46], ["primitive", "OBSERVATION", 97, 106], ["cultured cells", "OBSERVATION", 125, 139], ["METHODSTotal RNA", "OBSERVATION", 259, 275]]], ["Reverse transcription was performed using a reverse transcriptase system (Promega, USA) according to the manufacturer's instructions.", [["reverse transcriptase", "PROTEIN", 44, 65], ["a reverse transcriptase system", "TREATMENT", 42, 72]]], ["Quantitative real-time PCR for CLPTM1L and full-length TERT, with GAPDH as an internal reference gene, was performed using the Bio-Rad IQ5 (Bio-Rad, USA) based on the SYBR-Green method.", [["CLPTM1L", "GENE_OR_GENE_PRODUCT", 31, 38], ["TERT", "GENE_OR_GENE_PRODUCT", 55, 59], ["GAPDH", "GENE_OR_GENE_PRODUCT", 66, 71], ["SYBR", "GENE_OR_GENE_PRODUCT", 167, 171], ["CLPTM1L", "PROTEIN", 31, 38], ["TERT", "DNA", 55, 59], ["GAPDH", "PROTEIN", 66, 71], ["internal reference gene", "DNA", 78, 101], ["Rad IQ5", "PROTEIN", 131, 138], ["Bio-Rad, USA", "DNA", 140, 152], ["Quantitative real-time PCR", "TEST", 0, 26], ["CLPTM1L", "TEST", 31, 38], ["GAPDH", "PROBLEM", 66, 71], ["the SYBR", "TEST", 163, 171]]], ["The primers used for TERT were 5\u2032-TGTACTTTGTCAAGGTGGATGTG-3\u2032 and 5\u2032-GTAAGGCTGGAGGTCTGTCAA-3\u2032 [40], those used for CLPTM1L were 5\u2032-TAAGAGCTGGTACTCCTGGT-3\u2032 and 5\u2032-GTCATCAATGAAGGTGTTGA-3\u2032, and those used for GAPDH were 5\u2032-CATGAGAAGTATGACAACAGCCT-3\u2032 and 5\u2032-ACTCCTTCCACGATACCAAAGT-3\u2032.", [["TERT", "GENE_OR_GENE_PRODUCT", 21, 25], ["GAPDH", "GENE_OR_GENE_PRODUCT", 205, 210], ["TERT", "DNA", 21, 25], ["The primers", "TREATMENT", 0, 11], ["TERT", "TEST", 21, 25], ["TGTACTTTGTCAAGGTGGATGTG", "TEST", 34, 57], ["GTAAGGCTGGAGGTCTGTCAA", "TEST", 68, 89], ["CLPTM1L", "TEST", 114, 121], ["TAAGAGCTGGTACTCCTGGT", "TEST", 130, 150], ["GTCATCAATGAAGGTGTTGA", "TEST", 161, 181], ["GAPDH", "TEST", 205, 210], ["CATGAGAAGTATGACAACAGCCT", "TEST", 219, 242]]], ["All reactions performed in a 15-\u03bcL reaction volume containing 7.5 \u03bcL of 2X SYBR Green Master mix (Bio-Rad, USA), 1 \u03bcL of each primer pair (6 \u03bcmol/L), and 1 \u03bcL of cDNA templates.", [["cDNA templates", "DNA", 162, 176], ["All reactions", "PROBLEM", 0, 13], ["volume", "TEST", 44, 50], ["cDNA templates", "TREATMENT", 162, 176]]], ["The data were analyzed using the 2\u2212\u0394\u0394Ct method [41].", [["The data", "TEST", 0, 8]]], ["All analyses were performed in a blinded fashion with the laboratory persons unaware of the genotyping data.IHC staining analysis ::: MATERIALS AND METHODSNPC tissues (n = 41) and non-tumor nasopharyngeal tissues (n = 13), which had been fixed with paraformaldehyde and embedded in paraffin wax, were analyzed for protein expression of TERT and CLPTM1L.", [["METHODSNPC tissues", "ANATOMY", 148, 166], ["non-tumor nasopharyngeal tissues", "ANATOMY", 180, 212], ["paraformaldehyde", "CHEMICAL", 249, 265], ["METHODSNPC tissues", "TISSUE", 148, 166], ["non-tumor nasopharyngeal tissues", "TISSUE", 180, 212], ["paraformaldehyde", "SIMPLE_CHEMICAL", 249, 265], ["TERT", "GENE_OR_GENE_PRODUCT", 336, 340], ["CLPTM1L", "GENE_OR_GENE_PRODUCT", 345, 352], ["TERT", "PROTEIN", 336, 340], ["CLPTM1L", "PROTEIN", 345, 352], ["persons", "SPECIES", 69, 76], ["All analyses", "TEST", 0, 12], ["the genotyping data", "TEST", 88, 107], ["IHC staining analysis", "TEST", 108, 129], ["METHODSNPC tissues", "TEST", 148, 166], ["non-tumor nasopharyngeal tissues", "PROBLEM", 180, 212], ["paraformaldehyde", "TREATMENT", 249, 265], ["embedded in paraffin wax", "TREATMENT", 270, 294], ["TERT and CLPTM1L", "TREATMENT", 336, 352], ["nasopharyngeal tissues", "ANATOMY", 190, 212]]], ["The IHC assay was performed as previously described [42].", [["The IHC assay", "TEST", 0, 13]]], ["Briefly, two slides of each biopsy were stained with hematoxylin-eosin for routine histological evaluation.", [["hematoxylin", "CHEMICAL", 53, 64], ["eosin", "CHEMICAL", 65, 70], ["hematoxylin-eosin", "SIMPLE_CHEMICAL", 53, 70], ["each biopsy", "TEST", 23, 34], ["hematoxylin", "TREATMENT", 53, 64], ["routine histological evaluation", "TEST", 75, 106]]], ["The slides were washed in xylene to remove the paraffin and then rehydrated through serial dilutions of alcohol, followed by washings with a solution of PBS (pH 7.2).", [["alcohol", "CHEMICAL", 104, 111], ["xylene", "CHEMICAL", 26, 32], ["paraffin", "CHEMICAL", 47, 55], ["alcohol", "CHEMICAL", 104, 111], ["xylene", "SIMPLE_CHEMICAL", 26, 32], ["alcohol", "SIMPLE_CHEMICAL", 104, 111], ["xylene", "TREATMENT", 26, 32], ["the paraffin", "TREATMENT", 43, 55], ["serial dilutions of alcohol", "TREATMENT", 84, 111], ["a solution of PBS", "TREATMENT", 139, 156], ["pH", "TEST", 158, 160]]], ["All subsequent washes were buffered via the same protocol.", [["All subsequent washes", "TREATMENT", 0, 21], ["washes", "OBSERVATION", 15, 21]]], ["The slides were then incubated with 3% H2O2 for 10 min to reduce non-specific staining.", [["H2O2", "CHEMICAL", 39, 43], ["H2O2", "CHEMICAL", 39, 43], ["H2O2", "SIMPLE_CHEMICAL", 39, 43], ["3% H2O2", "TREATMENT", 36, 43], ["non-specific staining", "PROBLEM", 65, 86], ["non-specific", "OBSERVATION_MODIFIER", 65, 77], ["staining", "OBSERVATION", 78, 86]]], ["The treated sections were then placed in a citrate buffer (pH 6.0) and heated in a pressure cooker for two minutes.", [["sections", "ANATOMY", 12, 20], ["citrate", "CHEMICAL", 43, 50], ["citrate", "CHEMICAL", 43, 50], ["citrate", "SIMPLE_CHEMICAL", 43, 50], ["The treated sections", "TREATMENT", 0, 20], ["a citrate buffer", "TREATMENT", 41, 57], ["pH", "TEST", 59, 61]]], ["The samples were then incubated with a polyclonal anti-human CLPTM1L antibody (Sigma Aldrich, HPA014791) or a monoclonal rabbit anti-human TERT antibody (Lifespan, LS-C49516) overnight at 4\u00b0C. The conventional streptavidin peroxidase method (MaxVision\u2122 HRP-Polymer IHC Kit; Maxim Co., China) was performed for signal development, and the cells were counter-stained with hematoxylin.", [["samples", "ANATOMY", 4, 11], ["cells", "ANATOMY", 338, 343], ["HPA014791", "CHEMICAL", 94, 103], ["hematoxylin", "CHEMICAL", 370, 381], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 79, 92], ["HPA014791", "SIMPLE_CHEMICAL", 94, 103], ["rabbit", "ORGANISM", 121, 127], ["TERT", "GENE_OR_GENE_PRODUCT", 139, 143], ["streptavidin peroxidase", "SIMPLE_CHEMICAL", 210, 233], ["cells", "CELL", 338, 343], ["hematoxylin", "SIMPLE_CHEMICAL", 370, 381], ["polyclonal anti-human CLPTM1L antibody", "PROTEIN", 39, 77], ["monoclonal rabbit anti-human TERT antibody", "PROTEIN", 110, 152], ["streptavidin peroxidase", "PROTEIN", 210, 233], ["rabbit", "SPECIES", 121, 127], ["rabbit", "SPECIES", 121, 127], ["The samples", "TEST", 0, 11], ["a polyclonal anti-human CLPTM1L antibody", "TEST", 37, 77], ["a monoclonal rabbit anti-human TERT antibody", "TREATMENT", 108, 152], ["LS", "TEST", 164, 166], ["The conventional streptavidin peroxidase method", "TREATMENT", 193, 240], ["MaxVision", "TEST", 242, 251], ["HRP", "TEST", 253, 256], ["hematoxylin", "TREATMENT", 370, 381]]], ["The slides were mounted with gum for examination and capture by the Olympus BX51 microscopic/Digital Camera System for study comparison.", [["examination", "TEST", 37, 48], ["the Olympus", "TEST", 64, 75], ["study comparison", "TEST", 119, 135]]], ["IHC signals were scored as previously described [42].", [["IHC signals", "TEST", 0, 11]]], ["Slides were scored by two pathologists (Wu JH and Wang AC) who did not have knowledge of the genotype results of rs2735845 and rs401681 polymorphisms or of the patient outcomes.Statistical analysis ::: MATERIALS AND METHODSGenotype and allele frequencies for polymorphisms were determined by gene counting.", [["rs2735845", "GENE_OR_GENE_PRODUCT", 113, 122], ["rs401681", "GENE_OR_GENE_PRODUCT", 127, 135], ["patient", "ORGANISM", 160, 167], ["patient", "SPECIES", 160, 167], ["METHODSGenotype and allele frequencies", "TREATMENT", 216, 254], ["polymorphisms", "PROBLEM", 259, 272], ["gene counting", "TEST", 292, 305]]], ["The fitness according to the Hardy-Weinberg equilibrium was tested using the \u03c72 test.", [["the \u03c72 test", "TEST", 73, 84]]], ["Associations between polymorphisms and risk of NPC were estimated by use of logistic regression analyses.", [["NPC", "ANATOMY", 47, 50], ["NPC", "DISEASE", 47, 50], ["NPC", "CANCER", 47, 50], ["NPC", "PROBLEM", 47, 50], ["logistic regression analyses", "TEST", 76, 104], ["NPC", "OBSERVATION", 47, 50]]], ["Odds ratios (ORs) and 95% confidence intervals (CIs) were used to measure the strength of association.", [["CIs", "TEST", 48, 51]]], ["To correct for multiple testing, we used spectral decomposition (SpD) of matrices of LD between SNPs, which adjusts for multiple testing while taking into account LD among the tested SNPs [43].", [["multiple testing", "TEST", 15, 31], ["spectral decomposition (SpD) of matrices of LD between SNPs", "TREATMENT", 41, 100], ["multiple testing", "TEST", 120, 136]]], ["This method showed that P values of 0.0029 and below can be considered statistically significant after correction for multiple testing.", [["This method", "TEST", 0, 11], ["P values", "TEST", 24, 32], ["multiple testing", "TEST", 118, 134]]], ["These analyses were performed using SPSS software (version 17.0, SPSS Inc., Chicago, IL, USA).", [["These analyses", "TEST", 0, 14], ["SPSS software", "TEST", 36, 49], ["version", "TEST", 51, 58], ["SPSS Inc.", "TEST", 65, 74]]], ["The pairwise LD calculation (Lewontin's D and r2) and haplotype block construction were performed using the program Haploview 4.2 [32].", [["The pairwise LD calculation", "TEST", 0, 27], ["Lewontin's D and r2)", "TREATMENT", 29, 49], ["haplotype block construction", "TREATMENT", 54, 82]]], ["The haplotype analysis was performed using PLINK software (version 1.07) (http://pngu.mgh.harvard.edu/purcell/plink/) [44].", [["The haplotype analysis", "TEST", 0, 22]]]]}